@prefix schema: <http://schema.org/> .
@prefix adms: <http://www.w3.org/ns/adms#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix org: <http://www.w3.org/ns/org#> .
@prefix xls2rdf: <https://xls2rdf.sparna.fr/vocabulary#> .
@prefix this: <http://www.limics.org/remiames_ontology/thesaurus_interactions#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix skosthes: <http://purl.org/iso25964/skos-thes#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix adm: <http://www.limics.org/remiames_ontology/administrations#> .
@prefix qb: <http://purl.org/linked-data/cube#> .
@prefix r: <http://www.limics.org/remiames_ontology#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix doap: <http://usefulinc.com/ns/doap#> .
@prefix sh: <http://www.w3.org/ns/shacl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix dcat: <http://www.w3.org/ns/dcat#> .
@prefix euvoc: <http://publications.europa.eu/ontology/euvoc#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix foaf: <http://xmlns.com/foaf/0.1/> .
@prefix dc: <http://purl.org/dc/elements/1.1/> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix skosxl: <http://www.w3.org/2008/05/skos-xl#> .

<http://www.limics.org/remiames_ontology/thesaurus_interactions> a owl:Ontology;
  owl:imports <http://www.limics.org/remiames_ontology>, <http://www.limics.org/remiames_ontology/classes_et_groupes_substances>,
    <http://www.limics.org/remiames_ontology/administrations> .

this:IAM_10454-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> LIDOCAINE"@fr;
  dct:identifier "IAM_10454";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630710;
  r:natureDuRisque "Avec la lidocaïne utilisée par voie IV : augmentation des concentrations plasmatiques de lidocaïne avec possibilité d'effets indésirables neurologiques et cardiaques (diminution de la clairance hépatique de la lidocaïne)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement contrôle des concentrations plasmatiques de lidocaïne pendant l'association et après l'arrêt du bêta-bloquant. Adaptation si besoin de la posologie de la lidocaïne."@fr;
  rdfs:comment "De nombreuses publications, souvent anciennes, évoquent une diminution de la clairance de la lidocaïne lorsque les bêta-bloquants sont pris conjointement, vraisemblablement en raison de la diminution du flux sanguin hépatique. De fait, ces publications ne"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630719, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630710 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630711 .

_:807f36cf91fe4e8caa53aadeff92477630711 rdf:first _:807f36cf91fe4e8caa53aadeff92477630712;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630713 .

_:807f36cf91fe4e8caa53aadeff92477630712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff92477630713 rdf:first _:807f36cf91fe4e8caa53aadeff92477630714;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630715 .

_:807f36cf91fe4e8caa53aadeff92477630714 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10523 .

_:807f36cf91fe4e8caa53aadeff92477630715 rdf:first _:807f36cf91fe4e8caa53aadeff92477630716;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630716 a owl:Restriction;
  owl:onProperty r:patient;
  owl:someValuesFrom _:807f36cf91fe4e8caa53aadeff92477630717 .

_:807f36cf91fe4e8caa53aadeff92477630717 a owl:Restriction;
  owl:onProperty r:diabete;
  owl:hasValue r:Oui .

_:807f36cf91fe4e8caa53aadeff92477630719 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10454-XXX a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> LIDOCAINE"@fr;
  dct:identifier "IAM_10454";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630721;
  r:natureDuRisque "Avec la lidocaïne utilisée par voie IV : augmentation des concentrations plasmatiques de lidocaïne avec possibilité d'effets indésirables neurologiques et cardiaques (diminution de la clairance hépatique de la lidocaïne)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement contrôle des concentrations plasmatiques de lidocaïne pendant l'association et après l'arrêt du bêta-bloquant. Adaptation si besoin de la posologie de la lidocaïne."@fr;
  rdfs:comment "De nombreuses publications, souvent anciennes, évoquent une diminution de la clairance de la lidocaïne lorsque les bêta-bloquants sont pris conjointement, vraisemblablement en raison de la diminution du flux sanguin hépatique. De fait, ces publications ne"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630736, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630721 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630722 .

_:807f36cf91fe4e8caa53aadeff92477630722 rdf:first _:807f36cf91fe4e8caa53aadeff92477630723;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630724 .

_:807f36cf91fe4e8caa53aadeff92477630723 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff92477630724 rdf:first _:807f36cf91fe4e8caa53aadeff92477630725;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630726 .

_:807f36cf91fe4e8caa53aadeff92477630725 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10523 .

_:807f36cf91fe4e8caa53aadeff92477630726 rdf:first _:807f36cf91fe4e8caa53aadeff92477630727;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630727 a owl:Restriction;
  owl:onProperty r:patient;
  owl:someValuesFrom _:807f36cf91fe4e8caa53aadeff92477630728 .

_:807f36cf91fe4e8caa53aadeff92477630728 a owl:Class;
  owl:unionOf _:807f36cf91fe4e8caa53aadeff92477630729 .

_:807f36cf91fe4e8caa53aadeff92477630729 rdf:first _:807f36cf91fe4e8caa53aadeff92477630730;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630731 .

_:807f36cf91fe4e8caa53aadeff92477630730 a owl:Restriction;
  owl:onProperty r:diabete;
  owl:hasValue r:Inconnu .

_:807f36cf91fe4e8caa53aadeff92477630731 rdf:first _:807f36cf91fe4e8caa53aadeff92477630732;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630733 .

_:807f36cf91fe4e8caa53aadeff92477630732 a owl:Restriction;
  owl:onProperty r:diabete;
  owl:hasValue r:Oui .

_:807f36cf91fe4e8caa53aadeff92477630733 rdf:first _:807f36cf91fe4e8caa53aadeff92477630734;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630734 a owl:Restriction;
  owl:onProperty r:diabete;
  owl:hasValue r:Possible .

_:807f36cf91fe4e8caa53aadeff92477630736 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10443-1 a owl:Class;
  rdfs:label "BENZODIAZÉPINES ET APPARENTÉS <-> CLOZAPINE"@fr;
  dct:identifier "IAM_10443";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630738;
  r:natureDuRisque "Risque accru de collapsus avec arrêt respiratoire et / ou cardiaque."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630746, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630738 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630739 .

_:807f36cf91fe4e8caa53aadeff92477630739 rdf:first _:807f36cf91fe4e8caa53aadeff92477630740;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630741 .

_:807f36cf91fe4e8caa53aadeff92477630740 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10049 .

_:807f36cf91fe4e8caa53aadeff92477630741 rdf:first _:807f36cf91fe4e8caa53aadeff92477630742;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630743 .

_:807f36cf91fe4e8caa53aadeff92477630742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10220 .

_:807f36cf91fe4e8caa53aadeff92477630743 rdf:first _:807f36cf91fe4e8caa53aadeff92477630744;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:minQualifiedCardinality "2"^^xsd:nonNegativeInteger;
  owl:onClass adm:Administration_GS_IAM_10220 .

_:807f36cf91fe4e8caa53aadeff92477630746 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10444-1 a owl:Class;
  rdfs:label "BENZODIAZÉPINES ET APPARENTÉS <-> MORPHINIQUES"@fr;
  dct:identifier "IAM_10444";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630748;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630754, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630748 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630749 .

_:807f36cf91fe4e8caa53aadeff92477630749 rdf:first _:807f36cf91fe4e8caa53aadeff92477630750;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630751 .

_:807f36cf91fe4e8caa53aadeff92477630750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10049 .

_:807f36cf91fe4e8caa53aadeff92477630751 rdf:first _:807f36cf91fe4e8caa53aadeff92477630752;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10109 .

_:807f36cf91fe4e8caa53aadeff92477630754 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10445-1 a owl:Class;
  rdfs:label "BÊTA-2 MIMÉTIQUES <-> HALOTHANE"@fr;
  dct:identifier "IAM_10445";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630756;
  r:natureDuRisque "En cas d'intervention obstétricale, majoration de l'inertie utérine avec risque hémorragique ; par ailleurs, troubles du rythme ventriculaires graves, par augmentation de la réactivité cardiaque."@fr;
  r:conduiteATenir "Interrompre le traitement par bêta-2 mimétiques si l'anesthésie doit se faire sous halothane."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630762, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630756 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630757 .

_:807f36cf91fe4e8caa53aadeff92477630757 rdf:first _:807f36cf91fe4e8caa53aadeff92477630758;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630759 .

_:807f36cf91fe4e8caa53aadeff92477630758 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10052 .

_:807f36cf91fe4e8caa53aadeff92477630759 rdf:first _:807f36cf91fe4e8caa53aadeff92477630760;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10427 .

_:807f36cf91fe4e8caa53aadeff92477630762 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10446-1 a owl:Class;
  rdfs:label "BÊTA-2 MIMÉTIQUES <-> INSULINE"@fr;
  dct:identifier "IAM_10446";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630764;
  r:natureDuRisque "Elévation de la glycémie par le bêta-2 mimétique."@fr;
  r:conduiteATenir "Renforcer la surveillance sanguine et urinaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630770, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630764 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630765 .

_:807f36cf91fe4e8caa53aadeff92477630765 rdf:first _:807f36cf91fe4e8caa53aadeff92477630766;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630767 .

_:807f36cf91fe4e8caa53aadeff92477630766 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10052 .

_:807f36cf91fe4e8caa53aadeff92477630767 rdf:first _:807f36cf91fe4e8caa53aadeff92477630768;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10105 .

_:807f36cf91fe4e8caa53aadeff92477630770 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10447-1 a owl:Class;
  rdfs:label "BÊTA-2 MIMÉTIQUES <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10447";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630772;
  r:natureDuRisque "Elévation de la glycémie par le bêta-2 mimétique."@fr;
  r:conduiteATenir "Renforcer la surveillance sanguine et urinaire. Passer éventuellement à l'insuline, le cas échéant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630778, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630772 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630773 .

_:807f36cf91fe4e8caa53aadeff92477630773 rdf:first _:807f36cf91fe4e8caa53aadeff92477630774;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630775 .

_:807f36cf91fe4e8caa53aadeff92477630774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10052 .

_:807f36cf91fe4e8caa53aadeff92477630775 rdf:first _:807f36cf91fe4e8caa53aadeff92477630776;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477630778 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10448-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> DIHYDROPYRIDINES"@fr;
  dct:identifier "IAM_10448";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630780;
  r:natureDuRisque "Hypotension, défaillance cardiaque chez les patients en insuffisance cardiaque latente ou non contrôlée (addition des effets inotropes négatifs). Le bêta-bloquant peut par ailleurs minimiser la réaction sympathique réflexe mise en jeu en cas de répercussi"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630786, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630780 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630781 .

_:807f36cf91fe4e8caa53aadeff92477630781 rdf:first _:807f36cf91fe4e8caa53aadeff92477630782;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630783 .

_:807f36cf91fe4e8caa53aadeff92477630782 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff92477630783 rdf:first _:807f36cf91fe4e8caa53aadeff92477630784;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10062 .

_:807f36cf91fe4e8caa53aadeff92477630786 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10449-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10449";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630788;
  r:natureDuRisque "Troubles de l'automatisme (bradycardie excessive, arrêt sinusal), troubles de la conduction sino-auriculaire et auriculo-ventriculaire et défaillance cardiaque."@fr;
  r:conduiteATenir "Une telle association ne doit se faire que sous surveillance clinique et ECG étroite, en particulier chez le sujet âgé ou en début de traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630794, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630788 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630789 .

_:807f36cf91fe4e8caa53aadeff92477630789 rdf:first _:807f36cf91fe4e8caa53aadeff92477630790;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630791 .

_:807f36cf91fe4e8caa53aadeff92477630790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff92477630791 rdf:first _:807f36cf91fe4e8caa53aadeff92477630792;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477630794 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10450-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> DIPYRIDAMOLE"@fr;
  dct:identifier "IAM_10450";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630796;
  r:natureDuRisque "Avec le dipyridamole par voie injectable : majoration de l'effet antihypertenseur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630802, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630796 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630797 .

_:807f36cf91fe4e8caa53aadeff92477630797 rdf:first _:807f36cf91fe4e8caa53aadeff92477630798;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630799 .

_:807f36cf91fe4e8caa53aadeff92477630798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff92477630799 rdf:first _:807f36cf91fe4e8caa53aadeff92477630800;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10297 .

_:807f36cf91fe4e8caa53aadeff92477630802 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10451-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> GLINIDES"@fr;
  dct:identifier "IAM_10451";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630804;
  r:natureDuRisque "Tous les bêta-bloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer, surtout en début de traitement, l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630810, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630804 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630805 .

_:807f36cf91fe4e8caa53aadeff92477630805 rdf:first _:807f36cf91fe4e8caa53aadeff92477630806;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630807 .

_:807f36cf91fe4e8caa53aadeff92477630806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff92477630807 rdf:first _:807f36cf91fe4e8caa53aadeff92477630808;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10078 .

_:807f36cf91fe4e8caa53aadeff92477630810 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10394-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10394";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630812;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'atorvastatine par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630818, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630812 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630813 .

_:807f36cf91fe4e8caa53aadeff92477630813 rdf:first _:807f36cf91fe4e8caa53aadeff92477630814;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630815 .

_:807f36cf91fe4e8caa53aadeff92477630814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477630815 rdf:first _:807f36cf91fe4e8caa53aadeff92477630816;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477630818 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10453-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> INSULINE"@fr;
  dct:identifier "IAM_10453";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630820;
  r:natureDuRisque "Tous les bêtabloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer, surtout en début de traitement, l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630826, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630820 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630821 .

_:807f36cf91fe4e8caa53aadeff92477630821 rdf:first _:807f36cf91fe4e8caa53aadeff92477630822;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630823 .

_:807f36cf91fe4e8caa53aadeff92477630822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff92477630823 rdf:first _:807f36cf91fe4e8caa53aadeff92477630824;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:807f36cf91fe4e8caa53aadeff92477630826 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10440-1 a owl:Class;
  rdfs:label "BÉDAQUILINE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10440";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630828;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de bédaquiline par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630834, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630828 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630829 .

_:807f36cf91fe4e8caa53aadeff92477630829 rdf:first _:807f36cf91fe4e8caa53aadeff92477630830;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630831 .

_:807f36cf91fe4e8caa53aadeff92477630830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10105 .

_:807f36cf91fe4e8caa53aadeff92477630831 rdf:first _:807f36cf91fe4e8caa53aadeff92477630832;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477630834 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10455-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10455";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630836;
  r:natureDuRisque "Troubles de la contractilité, de l'automatisme et de la conduction (suppression des mécanismes sympathiques compensateurs)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630842, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630836 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630837 .

_:807f36cf91fe4e8caa53aadeff92477630837 rdf:first _:807f36cf91fe4e8caa53aadeff92477630838;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630839 .

_:807f36cf91fe4e8caa53aadeff92477630838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff92477630839 rdf:first _:807f36cf91fe4e8caa53aadeff92477630840;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477630842 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10456-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10456";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630844;
  r:natureDuRisque "Tous les bêta-bloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer, surtout en début de traitement, l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630850, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630844 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630845 .

_:807f36cf91fe4e8caa53aadeff92477630845 rdf:first _:807f36cf91fe4e8caa53aadeff92477630846;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630847 .

_:807f36cf91fe4e8caa53aadeff92477630846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff92477630847 rdf:first _:807f36cf91fe4e8caa53aadeff92477630848;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477630850 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10457-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10457";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630852;
  r:natureDuRisque "Troubles de l'automatisme (bradycardie excessive, arrêt sinusal), trouble de la conduction sino-auriculaire et auriculo-ventriculaire et défaillance cardiaque."@fr;
  r:conduiteATenir "Une telle association ne doit se faire que sous surveillance clinique et ECG étroite, en particulier chez le sujet âgé ou en début de traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630858, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630852 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630853 .

_:807f36cf91fe4e8caa53aadeff92477630853 rdf:first _:807f36cf91fe4e8caa53aadeff92477630854;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630855 .

_:807f36cf91fe4e8caa53aadeff92477630854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff92477630855 rdf:first _:807f36cf91fe4e8caa53aadeff92477630856;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477630858 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10458-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> DIGOXINE"@fr;
  dct:identifier "IAM_10458";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630860;
  r:natureDuRisque "Troubles de l’automatisme (bradycardie, arrêt sinusal) et troubles de la conduction sino-auriculaire et auriculo-ventriculaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630866, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630860 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630861 .

_:807f36cf91fe4e8caa53aadeff92477630861 rdf:first _:807f36cf91fe4e8caa53aadeff92477630862;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630863 .

_:807f36cf91fe4e8caa53aadeff92477630862 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477630863 rdf:first _:807f36cf91fe4e8caa53aadeff92477630864;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477630866 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10459-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> DIHYDROPYRIDINES"@fr;
  dct:identifier "IAM_10459";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630868;
  r:natureDuRisque "Hypotension, défaillance cardiaque chez les malades en insuffisance cardiaque latente ou non contrôlée (effet inotrope négatif in vitro des dihydropyridines plus ou moins marqué et susceptibles de s'additionner aux effets inotropes négatifs des bêta-bloqu"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630874, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630868 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630869 .

_:807f36cf91fe4e8caa53aadeff92477630869 rdf:first _:807f36cf91fe4e8caa53aadeff92477630870;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630871 .

_:807f36cf91fe4e8caa53aadeff92477630870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477630871 rdf:first _:807f36cf91fe4e8caa53aadeff92477630872;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10062 .

_:807f36cf91fe4e8caa53aadeff92477630874 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10460-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10460";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630876;
  r:natureDuRisque "Effet inotrope négatif avec risque de décompensation de l’insuffisance cardiaque, troubles de l'automatisme (bradycardie, arrêt sinusal) et troubles de la conduction sino-auriculaire et auriculo-ventriculaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630882, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630876 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630877 .

_:807f36cf91fe4e8caa53aadeff92477630877 rdf:first _:807f36cf91fe4e8caa53aadeff92477630878;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630879 .

_:807f36cf91fe4e8caa53aadeff92477630878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477630879 rdf:first _:807f36cf91fe4e8caa53aadeff92477630880;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477630882 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10461-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> GLINIDES"@fr;
  dct:identifier "IAM_10461";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630884;
  r:chapeau """A l’heure actuelle, 4 bêta-bloquants ont l'indication \"insuffisance cardiaque\" : le carvédilol, le bisoprolol, le métoprolol et le névibolol.
Les interactions médicamenteuses des bêta-bloquants, lorsqu’ils sont prescrits dans l’insuffisance cardiaque, pe"""@fr;
  r:natureDuRisque "Tous les bêtabloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer, surtout en début de traitement, l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630890, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630884 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630885 .

_:807f36cf91fe4e8caa53aadeff92477630885 rdf:first _:807f36cf91fe4e8caa53aadeff92477630886;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630887 .

_:807f36cf91fe4e8caa53aadeff92477630886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477630887 rdf:first _:807f36cf91fe4e8caa53aadeff92477630888;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10078 .

_:807f36cf91fe4e8caa53aadeff92477630890 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10462-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> INSULINE"@fr;
  dct:identifier "IAM_10462";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630892;
  r:natureDuRisque "Tous les bêtabloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer, surtout en début de traitement, l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630898, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630892 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630893 .

_:807f36cf91fe4e8caa53aadeff92477630893 rdf:first _:807f36cf91fe4e8caa53aadeff92477630894;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630895 .

_:807f36cf91fe4e8caa53aadeff92477630894 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477630895 rdf:first _:807f36cf91fe4e8caa53aadeff92477630896;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:807f36cf91fe4e8caa53aadeff92477630898 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10463-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> LIDOCAINE"@fr;
  dct:identifier "IAM_10463";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630900;
  r:natureDuRisque "Effet inotrope négatif avec risque de décompensation cardiaque."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630906, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630900 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630901 .

_:807f36cf91fe4e8caa53aadeff92477630901 rdf:first _:807f36cf91fe4e8caa53aadeff92477630902;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630903 .

_:807f36cf91fe4e8caa53aadeff92477630902 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477630903 rdf:first _:807f36cf91fe4e8caa53aadeff92477630904;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10523 .

_:807f36cf91fe4e8caa53aadeff92477630906 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10452-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> GLIPTINES"@fr;
  dct:identifier "IAM_10452";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630908;
  r:natureDuRisque "Tous les bêtabloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer, surtout en début de traitement, l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630914, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630908 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630909 .

_:807f36cf91fe4e8caa53aadeff92477630909 rdf:first _:807f36cf91fe4e8caa53aadeff92477630910;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630911 .

_:807f36cf91fe4e8caa53aadeff92477630910 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff92477630911 rdf:first _:807f36cf91fe4e8caa53aadeff92477630912;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10079 .

_:807f36cf91fe4e8caa53aadeff92477630914 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10430-1 a owl:Class;
  rdfs:label "AZITHROMYCINE <-> DIGOXINE"@fr;
  dct:identifier "IAM_10430";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630916;
  r:natureDuRisque "Augmentation de la digoxinémie par augmentation de son absorption."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la digoxinémie pendant le traitement par l'azithromycine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630922, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630916 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630917 .

_:807f36cf91fe4e8caa53aadeff92477630917 rdf:first _:807f36cf91fe4e8caa53aadeff92477630918;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630919 .

_:807f36cf91fe4e8caa53aadeff92477630918 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477630919 rdf:first _:807f36cf91fe4e8caa53aadeff92477630920;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477630922 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10521-1 a owl:Class;
  rdfs:label "CAFEINE <-> CIPROFLOXACINE"@fr;
  dct:identifier "IAM_10521";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630924;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de caféine, par diminution de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630930, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630924 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630925 .

_:807f36cf91fe4e8caa53aadeff92477630925 rdf:first _:807f36cf91fe4e8caa53aadeff92477630926;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630927 .

_:807f36cf91fe4e8caa53aadeff92477630926 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477630927 rdf:first _:807f36cf91fe4e8caa53aadeff92477630928;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:807f36cf91fe4e8caa53aadeff92477630930 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10396-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_10396";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630932;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’inhibiteur de l’HMG-CoA reductase)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630938, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630932 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630933 .

_:807f36cf91fe4e8caa53aadeff92477630933 rdf:first _:807f36cf91fe4e8caa53aadeff92477630934;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630935 .

_:807f36cf91fe4e8caa53aadeff92477630934 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477630935 rdf:first _:807f36cf91fe4e8caa53aadeff92477630936;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477630938 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10397-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> RANOLAZINE"@fr;
  dct:identifier "IAM_10397";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630940;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse par inhibition du métabolisme de l'atorvastatine par la ranolazine."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d’hypocholestérolémiant ou une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630946, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630940 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630941 .

_:807f36cf91fe4e8caa53aadeff92477630941 rdf:first _:807f36cf91fe4e8caa53aadeff92477630942;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630943 .

_:807f36cf91fe4e8caa53aadeff92477630942 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477630943 rdf:first _:807f36cf91fe4e8caa53aadeff92477630944;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:807f36cf91fe4e8caa53aadeff92477630946 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10398-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10398";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630948;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques d'atorvastatine, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630954, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630948 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630949 .

_:807f36cf91fe4e8caa53aadeff92477630949 rdf:first _:807f36cf91fe4e8caa53aadeff92477630950;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630951 .

_:807f36cf91fe4e8caa53aadeff92477630950 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477630951 rdf:first _:807f36cf91fe4e8caa53aadeff92477630952;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477630954 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10399-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> ROXITHROMYCINE"@fr;
  dct:identifier "IAM_10399";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630956;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d’hypocholestérolémiant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630962, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630956 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630957 .

_:807f36cf91fe4e8caa53aadeff92477630957 rdf:first _:807f36cf91fe4e8caa53aadeff92477630958;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630959 .

_:807f36cf91fe4e8caa53aadeff92477630958 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477630959 rdf:first _:807f36cf91fe4e8caa53aadeff92477630960;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10817 .

_:807f36cf91fe4e8caa53aadeff92477630962 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10400-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10400";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630964;
  r:natureDuRisque "Risque majoré d’effets indésirables (dose-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’hypocholestérolémiant)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630970, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630964 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630965 .

_:807f36cf91fe4e8caa53aadeff92477630965 rdf:first _:807f36cf91fe4e8caa53aadeff92477630966;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630967 .

_:807f36cf91fe4e8caa53aadeff92477630966 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477630967 rdf:first _:807f36cf91fe4e8caa53aadeff92477630968;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477630970 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10401-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> TELAPREVIR"@fr;
  dct:identifier "IAM_10401";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630972;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l'atorvastatine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630978, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630972 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630973 .

_:807f36cf91fe4e8caa53aadeff92477630973 rdf:first _:807f36cf91fe4e8caa53aadeff92477630974;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630975 .

_:807f36cf91fe4e8caa53aadeff92477630974 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477630975 rdf:first _:807f36cf91fe4e8caa53aadeff92477630976;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477630978 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10402-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_10402";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630980;
  r:natureDuRisque "Risque majoré d’effets indésirables (dose-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’hypocholestérolémiant)."@fr;
  rdfs:comment """La télithromycine est un inhibiteur du CYP3A4. Par conséquent, son administration est contre-indiquée avec des médicaments qui sont métabolisés par le CYP3A4 et qui ont un index thérapeutique étroit. 
L’association de la télithromycine avec la simvastatin"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630986, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630980 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630981 .

_:807f36cf91fe4e8caa53aadeff92477630981 rdf:first _:807f36cf91fe4e8caa53aadeff92477630982;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630983 .

_:807f36cf91fe4e8caa53aadeff92477630982 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477630983 rdf:first _:807f36cf91fe4e8caa53aadeff92477630984;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477630986 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10412-1 a owl:Class;
  rdfs:label "AUTRES CORTICOÏDES, NOTAMMENT INHALÉS <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10412";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630988;
  r:natureDuRisque """En cas d’utilisation prolongée par voie orale ou inhalée : 
augmentation des concentrations plasmatiques du corticoïde par diminution de son métabolisme hépatique par le voriconazole, avec risque d’apparition d’un syndrome cushingoïde voire d’une insuffis"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477630994, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630988 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630989 .

_:807f36cf91fe4e8caa53aadeff92477630989 rdf:first _:807f36cf91fe4e8caa53aadeff92477630990;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630991 .

_:807f36cf91fe4e8caa53aadeff92477630990 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10047 .

_:807f36cf91fe4e8caa53aadeff92477630991 rdf:first _:807f36cf91fe4e8caa53aadeff92477630992;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477630992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477630994 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10442-1 a owl:Class;
  rdfs:label "BENZODIAZÉPINES ET APPARENTÉS <-> BUPRENORPHINE"@fr;
  dct:identifier "IAM_10442";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477630996;
  r:natureDuRisque "Avec la buprénorphine utilisée en traitement de substitution : risque majoré de dépression respiratoire, pouvant être fatale."@fr;
  r:conduiteATenir "Evaluer attentivement le rapport bénéfice/risque de cette association. Informer le patient de la nécessité de respecter les doses prescrites."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631002, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477630996 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477630997 .

_:807f36cf91fe4e8caa53aadeff92477630997 rdf:first _:807f36cf91fe4e8caa53aadeff92477630998;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477630999 .

_:807f36cf91fe4e8caa53aadeff92477630998 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10049 .

_:807f36cf91fe4e8caa53aadeff92477630999 rdf:first _:807f36cf91fe4e8caa53aadeff92477631000;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10139 .

_:807f36cf91fe4e8caa53aadeff92477631002 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10429-1 a owl:Class;
  rdfs:label "AZITHROMYCINE <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10429";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631004;
  r:natureDuRisque "Risque d'augmentation des concentrations sanguines de ciclosporine et de la créatininémie."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de la ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après l'arrêt du macrolide."@fr;
  rdfs:comment """En 2001, une publication évoquant une interaction entre azithromycine et ciclosporine n’avait pas été prise en compte car aucune autre observation n'allait dans ce sens.
Depuis, huit nouvelles observations ont été évaluées. Six d’entre elles sont bien doc"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631010, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631004 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631005 .

_:807f36cf91fe4e8caa53aadeff92477631005 rdf:first _:807f36cf91fe4e8caa53aadeff92477631006;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631007 .

_:807f36cf91fe4e8caa53aadeff92477631006 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477631007 rdf:first _:807f36cf91fe4e8caa53aadeff92477631008;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477631010 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10441-1 a owl:Class;
  rdfs:label "BÉLATACEPT <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10441";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631012;
  r:natureDuRisque "Risque de maladie vaccinale généralisée, éventuellement mortelle."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631018, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631012 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631013 .

_:807f36cf91fe4e8caa53aadeff92477631013 rdf:first _:807f36cf91fe4e8caa53aadeff92477631014;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631015 .

_:807f36cf91fe4e8caa53aadeff92477631014 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477631015 rdf:first _:807f36cf91fe4e8caa53aadeff92477631016;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10106 .

_:807f36cf91fe4e8caa53aadeff92477631018 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10431-1 a owl:Class;
  rdfs:label "AZITHROMYCINE <-> IVABRADINE"@fr;
  dct:identifier "IAM_10431";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631020;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaires, notamment de torsades de pointes. De plus, augmentation des concentrations plasmatiques de l’ivabradine par diminution de son métabolisme par l’azithromycine."@fr;
  r:conduiteATenir "Surveillance clinique et ECG pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631026, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631020 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631021 .

_:807f36cf91fe4e8caa53aadeff92477631021 rdf:first _:807f36cf91fe4e8caa53aadeff92477631022;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631023 .

_:807f36cf91fe4e8caa53aadeff92477631022 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477631023 rdf:first _:807f36cf91fe4e8caa53aadeff92477631024;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:807f36cf91fe4e8caa53aadeff92477631026 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10432-1 a owl:Class;
  rdfs:label "AZITHROMYCINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10432";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631028;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d’hypocholestérolémiant ou une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631034, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631028 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631029 .

_:807f36cf91fe4e8caa53aadeff92477631029 rdf:first _:807f36cf91fe4e8caa53aadeff92477631030;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631031 .

_:807f36cf91fe4e8caa53aadeff92477631030 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477631031 rdf:first _:807f36cf91fe4e8caa53aadeff92477631032;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477631034 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10433-1 a owl:Class;
  rdfs:label "AZITHROMYCINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10433";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631036;
  r:natureDuRisque """Risque majoré de troubles du rythme ventriculaire, notamment de
torsades de pointes."""@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631042, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631036 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631037 .

_:807f36cf91fe4e8caa53aadeff92477631037 rdf:first _:807f36cf91fe4e8caa53aadeff92477631038;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631039 .

_:807f36cf91fe4e8caa53aadeff92477631038 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477631039 rdf:first _:807f36cf91fe4e8caa53aadeff92477631040;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477631042 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10434-1 a owl:Class;
  rdfs:label "AZTREONAM <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_10434";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631044;
  r:natureDuRisque "Risque de survenue de crises convulsives, par diminution des concentrations plasmatiques de l'acide valproïque."@fr;
  r:conduiteATenir "Surveillance clinique, dosages plasmatiques et adaptation éventuelle de la posologie de l'anticonvulsivant pendant le traitement par l'anti-infectieux et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631050, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631044 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631045 .

_:807f36cf91fe4e8caa53aadeff92477631045 rdf:first _:807f36cf91fe4e8caa53aadeff92477631046;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631047 .

_:807f36cf91fe4e8caa53aadeff92477631046 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477631047 rdf:first _:807f36cf91fe4e8caa53aadeff92477631048;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10101 .

_:807f36cf91fe4e8caa53aadeff92477631050 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10435-1 a owl:Class;
  rdfs:label "BACLOFENE <-> LEVODOPA"@fr;
  dct:identifier "IAM_10435";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631052;
  r:natureDuRisque "Risque d’aggravation du syndrome parkinsonien ou d’effets indésirables centraux (hallucinations visuelles, état confusionnel, céphalées)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631058, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631052 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631053 .

_:807f36cf91fe4e8caa53aadeff92477631053 rdf:first _:807f36cf91fe4e8caa53aadeff92477631054;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631055 .

_:807f36cf91fe4e8caa53aadeff92477631054 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10102 .

_:807f36cf91fe4e8caa53aadeff92477631055 rdf:first _:807f36cf91fe4e8caa53aadeff92477631056;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:807f36cf91fe4e8caa53aadeff92477631058 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10436-1 a owl:Class;
  rdfs:label "BARBITURIQUES <-> BENZODIAZÉPINES ET APPARENTÉS"@fr;
  dct:identifier "IAM_10436";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631060;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631066, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631060 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631061 .

_:807f36cf91fe4e8caa53aadeff92477631061 rdf:first _:807f36cf91fe4e8caa53aadeff92477631062;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631063 .

_:807f36cf91fe4e8caa53aadeff92477631062 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477631063 rdf:first _:807f36cf91fe4e8caa53aadeff92477631064;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10049 .

_:807f36cf91fe4e8caa53aadeff92477631066 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10437-1 a owl:Class;
  rdfs:label "BARBITURIQUES <-> MORPHINIQUES"@fr;
  dct:identifier "IAM_10437";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631068;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631074, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631068 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631069 .

_:807f36cf91fe4e8caa53aadeff92477631069 rdf:first _:807f36cf91fe4e8caa53aadeff92477631070;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631071 .

_:807f36cf91fe4e8caa53aadeff92477631070 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477631071 rdf:first _:807f36cf91fe4e8caa53aadeff92477631072;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10109 .

_:807f36cf91fe4e8caa53aadeff92477631074 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10438-1 a owl:Class;
  rdfs:label "BÉDAQUILINE <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10438";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631076;
  r:natureDuRisque "Diminution des concentrations plasmatiques de bédaquiline par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631082, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631076 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631077 .

_:807f36cf91fe4e8caa53aadeff92477631077 rdf:first _:807f36cf91fe4e8caa53aadeff92477631078;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631079 .

_:807f36cf91fe4e8caa53aadeff92477631078 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477631079 rdf:first _:807f36cf91fe4e8caa53aadeff92477631080;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10105 .

_:807f36cf91fe4e8caa53aadeff92477631082 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10439-1 a owl:Class;
  rdfs:label "BÉDAQUILINE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10439";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631084;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de bédaquiline par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  r:conduiteATenir "Si l’association est nécessaire, une surveillance ECG plus fréquente et une surveillance des transaminases sont recommandées."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631090, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631084 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631085 .

_:807f36cf91fe4e8caa53aadeff92477631085 rdf:first _:807f36cf91fe4e8caa53aadeff92477631086;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631087 .

_:807f36cf91fe4e8caa53aadeff92477631086 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477631087 rdf:first _:807f36cf91fe4e8caa53aadeff92477631088;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10105 .

_:807f36cf91fe4e8caa53aadeff92477631090 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10466-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10466";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631092;
  r:natureDuRisque "Tous les bêta-bloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le malade et renforcer, surtout au début du traitement, l'autosurveillance sanguine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631098, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631092 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631093 .

_:807f36cf91fe4e8caa53aadeff92477631093 rdf:first _:807f36cf91fe4e8caa53aadeff92477631094;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631095 .

_:807f36cf91fe4e8caa53aadeff92477631094 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477631095 rdf:first _:807f36cf91fe4e8caa53aadeff92477631096;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477631098 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10428-1 a owl:Class;
  rdfs:label "AVANAFIL <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_10428";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631100;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'avanafil, avec risque d’hypotension."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631106, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631100 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631101 .

_:807f36cf91fe4e8caa53aadeff92477631101 rdf:first _:807f36cf91fe4e8caa53aadeff92477631102;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631103 .

_:807f36cf91fe4e8caa53aadeff92477631102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477631103 rdf:first _:807f36cf91fe4e8caa53aadeff92477631104;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477631106 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10499-1 a owl:Class;
  rdfs:label "BUPROPION <-> DESIPRAMINE"@fr;
  dct:identifier "IAM_10499";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631108;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la désipramine par diminution de son métabolisme hépatique par le bupropion."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la désipramine pendant le traitement par le bupropion."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631114, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631108 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631109 .

_:807f36cf91fe4e8caa53aadeff92477631109 rdf:first _:807f36cf91fe4e8caa53aadeff92477631110;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631111 .

_:807f36cf91fe4e8caa53aadeff92477631110 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477631111 rdf:first _:807f36cf91fe4e8caa53aadeff92477631112;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10268 .

_:807f36cf91fe4e8caa53aadeff92477631114 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10464-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> NEUROLEPTIQUES"@fr;
  dct:identifier "IAM_10464";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631116;
  r:natureDuRisque "Effet vasodilatateur et risque d'hypotension, notamment orthostatique (effet additif)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631122, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631116 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631117 .

_:807f36cf91fe4e8caa53aadeff92477631117 rdf:first _:807f36cf91fe4e8caa53aadeff92477631118;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631119 .

_:807f36cf91fe4e8caa53aadeff92477631118 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477631119 rdf:first _:807f36cf91fe4e8caa53aadeff92477631120;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10124 .

_:807f36cf91fe4e8caa53aadeff92477631122 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10408-1 a owl:Class;
  rdfs:label "AUTRES BRADYCARDISANTS <-> BRADYCARDISANTS"@fr;
  dct:identifier "IAM_10408";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631124;
  r:natureDuRisque "Risque de bradycardie excessive (addition des effets)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631126, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631124 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10051 .

_:807f36cf91fe4e8caa53aadeff92477631126 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10491-1 a owl:Class;
  rdfs:label "BRADYCARDISANTS <-> FINGOLIMOD"@fr;
  dct:identifier "IAM_10491";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631128;
  r:natureDuRisque "Potentialisation des effets bradycardisants pouvant avoir des conséquences fatales. Les bêta-bloquants sont d’autant plus à risque qu’ils empêchent les mécanismes de compensation adrénergique."@fr;
  r:conduiteATenir "Surveillance clinique et ECG continu pendant les 24 heures suivant la première dose."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631134, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631128 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631129 .

_:807f36cf91fe4e8caa53aadeff92477631129 rdf:first _:807f36cf91fe4e8caa53aadeff92477631130;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631131 .

_:807f36cf91fe4e8caa53aadeff92477631130 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10051 .

_:807f36cf91fe4e8caa53aadeff92477631131 rdf:first _:807f36cf91fe4e8caa53aadeff92477631132;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631132 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10379 .

_:807f36cf91fe4e8caa53aadeff92477631134 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10492-1 a owl:Class;
  rdfs:label "BRADYCARDISANTS <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10492";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631136;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631142, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631136 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631137 .

_:807f36cf91fe4e8caa53aadeff92477631137 rdf:first _:807f36cf91fe4e8caa53aadeff92477631138;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631139 .

_:807f36cf91fe4e8caa53aadeff92477631138 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10051 .

_:807f36cf91fe4e8caa53aadeff92477631139 rdf:first _:807f36cf91fe4e8caa53aadeff92477631140;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631140 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477631142 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10493-1 a owl:Class;
  rdfs:label "BRENTUXIMAB <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10493";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631144;
  r:natureDuRisque "Augmentation des concentrations du métabolite actif du brentuximab, avec risque de neutropénie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631150, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631144 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631145 .

_:807f36cf91fe4e8caa53aadeff92477631145 rdf:first _:807f36cf91fe4e8caa53aadeff92477631146;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631147 .

_:807f36cf91fe4e8caa53aadeff92477631146 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477631147 rdf:first _:807f36cf91fe4e8caa53aadeff92477631148;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631148 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10133 .

_:807f36cf91fe4e8caa53aadeff92477631150 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10494-1 a owl:Class;
  rdfs:label "BUPRENORPHINE <-> FOSAMPRENAVIR"@fr;
  dct:identifier "IAM_10494";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631152;
  r:natureDuRisque "Risque de majoration ou de diminution des effets de la A prendre en compte buprénorphine, à la fois par inhibition et accélération de son métabolisme par l’inhibiteur de protéases."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631158, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631152 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631153 .

_:807f36cf91fe4e8caa53aadeff92477631153 rdf:first _:807f36cf91fe4e8caa53aadeff92477631154;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631155 .

_:807f36cf91fe4e8caa53aadeff92477631154 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10139 .

_:807f36cf91fe4e8caa53aadeff92477631155 rdf:first _:807f36cf91fe4e8caa53aadeff92477631156;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631156 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10400 .

_:807f36cf91fe4e8caa53aadeff92477631158 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10495-1 a owl:Class;
  rdfs:label "BUPRENORPHINE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10495";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631160;
  r:natureDuRisque "Risque de majoration ou de diminution des effets de la buprénorphine, à la fois par inhibition et accélération de son métabolisme par l’inhibiteur de protéases."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631166, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631160 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631161 .

_:807f36cf91fe4e8caa53aadeff92477631161 rdf:first _:807f36cf91fe4e8caa53aadeff92477631162;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631163 .

_:807f36cf91fe4e8caa53aadeff92477631162 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477631163 rdf:first _:807f36cf91fe4e8caa53aadeff92477631164;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631164 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10139 .

_:807f36cf91fe4e8caa53aadeff92477631166 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10496-1 a owl:Class;
  rdfs:label "BUPRENORPHINE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10496";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631168;
  r:natureDuRisque "Augmentation des concentrations de buprénorphine par diminution de son métabolisme hépatique, avec risque de majoration de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la buprénorphine pendant le traitement par l'inhibiteur et, le cas échéant, après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631174, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631168 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631169 .

_:807f36cf91fe4e8caa53aadeff92477631169 rdf:first _:807f36cf91fe4e8caa53aadeff92477631170;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631171 .

_:807f36cf91fe4e8caa53aadeff92477631170 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10139 .

_:807f36cf91fe4e8caa53aadeff92477631171 rdf:first _:807f36cf91fe4e8caa53aadeff92477631172;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631172 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477631174 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10497-1 a owl:Class;
  rdfs:label "BUPRENORPHINE <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10497";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631176;
  r:natureDuRisque "Augmentation des concentrations de buprénorphine par diminution de son métabolisme hépatique, avec risque de majoration de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la buprénorphine pendant le traitement par l'inhibiteur et, le cas échéant, après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631182, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631176 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631177 .

_:807f36cf91fe4e8caa53aadeff92477631177 rdf:first _:807f36cf91fe4e8caa53aadeff92477631178;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631179 .

_:807f36cf91fe4e8caa53aadeff92477631178 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10139 .

_:807f36cf91fe4e8caa53aadeff92477631179 rdf:first _:807f36cf91fe4e8caa53aadeff92477631180;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631180 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477631182 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10489-1 a owl:Class;
  rdfs:label "BOSENTAN <-> PROGESTATIFS NON CONTRACEPTIFS, ASSOCIÉS OU NON À UN ESTROGÈNE"@fr;
  dct:identifier "IAM_10489";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631184;
  r:natureDuRisque "Risque de diminution de l’efficacité du progestatif."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du traitement hormonal pendant l’administration du bosentan et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631190, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631184 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631185 .

_:807f36cf91fe4e8caa53aadeff92477631185 rdf:first _:807f36cf91fe4e8caa53aadeff92477631186;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631187 .

_:807f36cf91fe4e8caa53aadeff92477631186 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10135 .

_:807f36cf91fe4e8caa53aadeff92477631187 rdf:first _:807f36cf91fe4e8caa53aadeff92477631188;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631188 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff92477631190 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10498-1 a owl:Class;
  rdfs:label "BUPROPION <-> CLOMIPRAMINE"@fr;
  dct:identifier "IAM_10498";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631192;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la clomipramine par diminution de son métabolisme hépatique par le bupropion."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la clomipramine pendant le traitement par le bupropion."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631198, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631192 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631193 .

_:807f36cf91fe4e8caa53aadeff92477631193 rdf:first _:807f36cf91fe4e8caa53aadeff92477631194;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631195 .

_:807f36cf91fe4e8caa53aadeff92477631194 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477631195 rdf:first _:807f36cf91fe4e8caa53aadeff92477631196;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631196 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10212 .

_:807f36cf91fe4e8caa53aadeff92477631198 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10488-1 a owl:Class;
  rdfs:label "BOSENTAN <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10488";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631200;
  r:natureDuRisque "Risque de diminution de l'efficacité du contraceptif hormonal par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive fiable, additionnelle ou alternative, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631206, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631200 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631201 .

_:807f36cf91fe4e8caa53aadeff92477631201 rdf:first _:807f36cf91fe4e8caa53aadeff92477631202;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631203 .

_:807f36cf91fe4e8caa53aadeff92477631202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:807f36cf91fe4e8caa53aadeff92477631203 rdf:first _:807f36cf91fe4e8caa53aadeff92477631204;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631204 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff92477631206 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10511-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10511";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631208;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la buspirone par diminution de son métabolisme hépatique, avec majoration importante de la sédation."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631214, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631208 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631209 .

_:807f36cf91fe4e8caa53aadeff92477631209 rdf:first _:807f36cf91fe4e8caa53aadeff92477631210;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631211 .

_:807f36cf91fe4e8caa53aadeff92477631210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff92477631211 rdf:first _:807f36cf91fe4e8caa53aadeff92477631212;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631212 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477631214 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10512-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10512";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631216;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la buspirone par diminution de son métabolisme hépatique, avec majoration importante de la sédation."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631222, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631216 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631217 .

_:807f36cf91fe4e8caa53aadeff92477631217 rdf:first _:807f36cf91fe4e8caa53aadeff92477631218;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631219 .

_:807f36cf91fe4e8caa53aadeff92477631218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff92477631219 rdf:first _:807f36cf91fe4e8caa53aadeff92477631220;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631220 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477631222 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10513-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_10513";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631224;
  r:natureDuRisque "Risque de majoration des effets indésirables de la buspirone par diminution de son métabolisme par le pamplemousse."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631230, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631224 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631225 .

_:807f36cf91fe4e8caa53aadeff92477631225 rdf:first _:807f36cf91fe4e8caa53aadeff92477631226;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631227 .

_:807f36cf91fe4e8caa53aadeff92477631226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477631227 rdf:first _:807f36cf91fe4e8caa53aadeff92477631228;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631228 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff92477631230 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10514-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10514";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631232;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la buspirone par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la buspirone pendant le traitement par rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631238, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631232 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631233 .

_:807f36cf91fe4e8caa53aadeff92477631233 rdf:first _:807f36cf91fe4e8caa53aadeff92477631234;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631235 .

_:807f36cf91fe4e8caa53aadeff92477631234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff92477631235 rdf:first _:807f36cf91fe4e8caa53aadeff92477631236;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631236 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477631238 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10515-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10515";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631240;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la buspirone par diminution de son métabolisme hépatique par le vérapamil, avec augmentation de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la buspirone si nécessaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631246, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631240 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631241 .

_:807f36cf91fe4e8caa53aadeff92477631241 rdf:first _:807f36cf91fe4e8caa53aadeff92477631242;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631243 .

_:807f36cf91fe4e8caa53aadeff92477631242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff92477631243 rdf:first _:807f36cf91fe4e8caa53aadeff92477631244;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631244 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477631246 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10516-1 a owl:Class;
  rdfs:label "BUSULFAN <-> DEFERASIROX"@fr;
  dct:identifier "IAM_10516";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631248;
  r:natureDuRisque "Risque d’augmentation de la toxicité du busulfan par diminution de sa clairance par le déférasirox."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631254, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631248 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631249 .

_:807f36cf91fe4e8caa53aadeff92477631249 rdf:first _:807f36cf91fe4e8caa53aadeff92477631250;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631251 .

_:807f36cf91fe4e8caa53aadeff92477631250 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10142 .

_:807f36cf91fe4e8caa53aadeff92477631251 rdf:first _:807f36cf91fe4e8caa53aadeff92477631252;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631252 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:807f36cf91fe4e8caa53aadeff92477631254 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10517-1 a owl:Class;
  rdfs:label "BUSULFAN <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10517";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631256;
  r:natureDuRisque "Avec le busulfan à fortes doses : doublement des concentrations de busulfan par l’itraconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631262, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631256 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631257 .

_:807f36cf91fe4e8caa53aadeff92477631257 rdf:first _:807f36cf91fe4e8caa53aadeff92477631258;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631259 .

_:807f36cf91fe4e8caa53aadeff92477631258 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10142 .

_:807f36cf91fe4e8caa53aadeff92477631259 rdf:first _:807f36cf91fe4e8caa53aadeff92477631260;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631260 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477631262 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10518-1 a owl:Class;
  rdfs:label "BUSULFAN <-> METRONIDAZOLE"@fr;
  dct:identifier "IAM_10518";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631264;
  r:natureDuRisque "Avec le busulfan à fortes doses : doublement des concentrations de busulfan par le métronidazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631270, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631264 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631265 .

_:807f36cf91fe4e8caa53aadeff92477631265 rdf:first _:807f36cf91fe4e8caa53aadeff92477631266;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631267 .

_:807f36cf91fe4e8caa53aadeff92477631266 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10142 .

_:807f36cf91fe4e8caa53aadeff92477631267 rdf:first _:807f36cf91fe4e8caa53aadeff92477631268;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631268 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10580 .

_:807f36cf91fe4e8caa53aadeff92477631270 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10519-1 a owl:Class;
  rdfs:label "CABAZITAXEL <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10519";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631272;
  r:natureDuRisque "Diminution des concentrations du cytotoxique par augmentation de son métabolisme par l’inducteur, avec risque de moindre efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631278, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631272 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631273 .

_:807f36cf91fe4e8caa53aadeff92477631273 rdf:first _:807f36cf91fe4e8caa53aadeff92477631274;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631275 .

_:807f36cf91fe4e8caa53aadeff92477631274 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477631275 rdf:first _:807f36cf91fe4e8caa53aadeff92477631276;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477631278 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10714-1 a owl:Class;
  rdfs:label "DACLATASVIR <-> DEXAMETHASONE"@fr;
  dct:identifier "IAM_10714";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631280;
  r:natureDuRisque "Avec la dexaméthasone à usage systémique, risque de diminution significative des concentrations plasmatiques de daclatasvir par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631286, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631280 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631281 .

_:807f36cf91fe4e8caa53aadeff92477631281 rdf:first _:807f36cf91fe4e8caa53aadeff92477631282;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631283 .

_:807f36cf91fe4e8caa53aadeff92477631282 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10243 .

_:807f36cf91fe4e8caa53aadeff92477631283 rdf:first _:807f36cf91fe4e8caa53aadeff92477631284;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477631286 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10501-1 a owl:Class;
  rdfs:label "BUPROPION <-> IMAO-B"@fr;
  dct:identifier "IAM_10501";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631288;
  r:natureDuRisque "Risque de crises hypertensives."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631294, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631288 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631289 .

_:807f36cf91fe4e8caa53aadeff92477631289 rdf:first _:807f36cf91fe4e8caa53aadeff92477631290;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631291 .

_:807f36cf91fe4e8caa53aadeff92477631290 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477631291 rdf:first _:807f36cf91fe4e8caa53aadeff92477631292;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477631294 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10477-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10477";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631296;
  r:natureDuRisque "En dehors de l’association éthinylestradiol (0,035mg)/noréthistérone (1mg), risque de diminution de l'efficacité contraceptive par augmentation du métabolisme hépatique du contraceptif hormonal par le bocéprévir"@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive fiable, additionnelle ou alternative, pendant la durée de l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631302, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631296 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631297 .

_:807f36cf91fe4e8caa53aadeff92477631297 rdf:first _:807f36cf91fe4e8caa53aadeff92477631298;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631299 .

_:807f36cf91fe4e8caa53aadeff92477631298 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:807f36cf91fe4e8caa53aadeff92477631299 rdf:first _:807f36cf91fe4e8caa53aadeff92477631300;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff92477631302 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10393-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10393";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631304;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l'atorvastatine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631310, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631304 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631305 .

_:807f36cf91fe4e8caa53aadeff92477631305 rdf:first _:807f36cf91fe4e8caa53aadeff92477631306;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631307 .

_:807f36cf91fe4e8caa53aadeff92477631306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477631307 rdf:first _:807f36cf91fe4e8caa53aadeff92477631308;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477631310 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10467-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10467";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631312;
  r:natureDuRisque "Effet inotrope négatif avec risque de décompensation de l’insuffisance cardiaque, troubles de l'automatisme (bradycardie, arrêt sinusal) et troubles de la conduction sino-auriculaire et auriculo-ventriculaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631318, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631312 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631313 .

_:807f36cf91fe4e8caa53aadeff92477631313 rdf:first _:807f36cf91fe4e8caa53aadeff92477631314;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631315 .

_:807f36cf91fe4e8caa53aadeff92477631314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477631315 rdf:first _:807f36cf91fe4e8caa53aadeff92477631316;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477631318 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10468-1 a owl:Class;
  rdfs:label "BISPHOSPHONATES <-> CALCIUM"@fr;
  dct:identifier "IAM_10468";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631320;
  r:natureDuRisque "Pour les sels de calcium administrés par voie orale : diminution de l'absorption digestive des bisphosphonates."@fr;
  r:conduiteATenir "Prendre les sels de calcium et antiacides à distance des bisphosphonates (de 30 minutes au minimum à plus de 2 heures, si possible, selon le bisphosphonate)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631326, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631320 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631321 .

_:807f36cf91fe4e8caa53aadeff92477631321 rdf:first _:807f36cf91fe4e8caa53aadeff92477631322;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631323 .

_:807f36cf91fe4e8caa53aadeff92477631322 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10050 .

_:807f36cf91fe4e8caa53aadeff92477631323 rdf:first _:807f36cf91fe4e8caa53aadeff92477631324;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477631326 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10469-1 a owl:Class;
  rdfs:label "BISPHOSPHONATES <-> FER"@fr;
  dct:identifier "IAM_10469";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631328;
  r:natureDuRisque "Pour les sels de fer administrés par voie orale : diminution de l'absorption digestive des bisphosphonates."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance des bisphosphonates (de 30 minutes au minimum à plus de 2 heures, si possible, selon le bisphosphonate)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631334, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631328 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631329 .

_:807f36cf91fe4e8caa53aadeff92477631329 rdf:first _:807f36cf91fe4e8caa53aadeff92477631330;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631331 .

_:807f36cf91fe4e8caa53aadeff92477631330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10050 .

_:807f36cf91fe4e8caa53aadeff92477631331 rdf:first _:807f36cf91fe4e8caa53aadeff92477631332;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477631334 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10470-1 a owl:Class;
  rdfs:label "BLEOMYCINE <-> BRENTUXIMAB"@fr;
  dct:identifier "IAM_10470";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631336;
  r:natureDuRisque "Risque de majoration de la toxicité pulmonaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631342, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631336 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631337 .

_:807f36cf91fe4e8caa53aadeff92477631337 rdf:first _:807f36cf91fe4e8caa53aadeff92477631338;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631339 .

_:807f36cf91fe4e8caa53aadeff92477631338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10123 .

_:807f36cf91fe4e8caa53aadeff92477631339 rdf:first _:807f36cf91fe4e8caa53aadeff92477631340;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10133 .

_:807f36cf91fe4e8caa53aadeff92477631342 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10471-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> DROSPIRENONE"@fr;
  dct:identifier "IAM_10471";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631344;
  r:natureDuRisque "Augmentation de plus du double des concentrations de drospérinone en association avec le bocéprévir."@fr;
  r:conduiteATenir "Préférer une contraception avec un autre progestatif, a fortiori en cas d’hyperkaliémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631350, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631344 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631345 .

_:807f36cf91fe4e8caa53aadeff92477631345 rdf:first _:807f36cf91fe4e8caa53aadeff92477631346;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631347 .

_:807f36cf91fe4e8caa53aadeff92477631346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff92477631347 rdf:first _:807f36cf91fe4e8caa53aadeff92477631348;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10313 .

_:807f36cf91fe4e8caa53aadeff92477631350 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10472-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> ESTROGÈNES NON CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10472";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631352;
  r:natureDuRisque "Diminution de l'efficacité de l'estrogène."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du traitement hormonal pendant l'administration du bocéprévir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631358, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631352 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631353 .

_:807f36cf91fe4e8caa53aadeff92477631353 rdf:first _:807f36cf91fe4e8caa53aadeff92477631354;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631355 .

_:807f36cf91fe4e8caa53aadeff92477631354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10072 .

_:807f36cf91fe4e8caa53aadeff92477631355 rdf:first _:807f36cf91fe4e8caa53aadeff92477631356;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff92477631358 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10473-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> ESTROPROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10473";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631360;
  r:natureDuRisque "En dehors de l’association éthinylestradiol (0,035mg)/noréthistérone (1mg), risque de diminution de l'efficacité contraceptive par augmentation du métabolisme hépatique du contraceptif hormonal par le bocéprévir"@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive fiable, additionnelle ou alternative, pendant la durée de l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631366, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631360 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631361 .

_:807f36cf91fe4e8caa53aadeff92477631361 rdf:first _:807f36cf91fe4e8caa53aadeff92477631362;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631363 .

_:807f36cf91fe4e8caa53aadeff92477631362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477631363 rdf:first _:807f36cf91fe4e8caa53aadeff92477631364;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff92477631366 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10474-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10474";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631368;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur (notable pour la ciclosporine, extrêmement importante pour le tacrolimus)."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de sa posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631374, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631368 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631369 .

_:807f36cf91fe4e8caa53aadeff92477631369 rdf:first _:807f36cf91fe4e8caa53aadeff92477631370;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631371 .

_:807f36cf91fe4e8caa53aadeff92477631370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477631371 rdf:first _:807f36cf91fe4e8caa53aadeff92477631372;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff92477631374 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10490-1 a owl:Class;
  rdfs:label "BOSENTAN <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10490";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631376;
  r:natureDuRisque "Risque de diminution, importante pour la rifampicine, des concentrations plasmatiques de bosentan."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631382, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631376 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631377 .

_:807f36cf91fe4e8caa53aadeff92477631377 rdf:first _:807f36cf91fe4e8caa53aadeff92477631378;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631379 .

_:807f36cf91fe4e8caa53aadeff92477631378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff92477631379 rdf:first _:807f36cf91fe4e8caa53aadeff92477631380;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477631382 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10476-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> METHADONE"@fr;
  dct:identifier "IAM_10476";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631384;
  r:natureDuRisque "Diminution des concentrations plasmatiques de méthadone, avec risque d'apparition d'un syndrome de sevrage, par augmentation de son métabolisme hépatique par le bocéprévir."@fr;
  r:conduiteATenir "Surveillance clinique régulière et adaptation éventuelle de la posologie de méthadone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631390, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631384 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631385 .

_:807f36cf91fe4e8caa53aadeff92477631385 rdf:first _:807f36cf91fe4e8caa53aadeff92477631386;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631387 .

_:807f36cf91fe4e8caa53aadeff92477631386 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff92477631387 rdf:first _:807f36cf91fe4e8caa53aadeff92477631388;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff92477631390 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10465-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10465";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631392;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631398, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631392 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631393 .

_:807f36cf91fe4e8caa53aadeff92477631393 rdf:first _:807f36cf91fe4e8caa53aadeff92477631394;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631395 .

_:807f36cf91fe4e8caa53aadeff92477631394 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477631395 rdf:first _:807f36cf91fe4e8caa53aadeff92477631396;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477631398 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10478-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10478";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631400;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de bocéprévir."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631406, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631400 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631401 .

_:807f36cf91fe4e8caa53aadeff92477631401 rdf:first _:807f36cf91fe4e8caa53aadeff92477631402;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631403 .

_:807f36cf91fe4e8caa53aadeff92477631402 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff92477631403 rdf:first _:807f36cf91fe4e8caa53aadeff92477631404;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477631406 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10479-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10479";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631408;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse par diminution du métabolisme de la simvastatine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631414, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631408 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631409 .

_:807f36cf91fe4e8caa53aadeff92477631409 rdf:first _:807f36cf91fe4e8caa53aadeff92477631410;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631411 .

_:807f36cf91fe4e8caa53aadeff92477631410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff92477631411 rdf:first _:807f36cf91fe4e8caa53aadeff92477631412;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477631414 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10480-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_10480";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631416;
  r:natureDuRisque "Risque de diminution de l'efficacité du ténofovir alafénamide par diminution de son activité intracellulaire par le bocéprevir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631422, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631416 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631417 .

_:807f36cf91fe4e8caa53aadeff92477631417 rdf:first _:807f36cf91fe4e8caa53aadeff92477631418;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631419 .

_:807f36cf91fe4e8caa53aadeff92477631418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff92477631419 rdf:first _:807f36cf91fe4e8caa53aadeff92477631420;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff92477631422 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10481-1 a owl:Class;
  rdfs:label "BORTEZOMIB <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10481";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631424;
  r:natureDuRisque "Diminution des concentrations du cytotoxique par augmentation de son métabolisme par l’inducteur, avec risque de moindre efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631430, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631424 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631425 .

_:807f36cf91fe4e8caa53aadeff92477631425 rdf:first _:807f36cf91fe4e8caa53aadeff92477631426;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631427 .

_:807f36cf91fe4e8caa53aadeff92477631426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477631427 rdf:first _:807f36cf91fe4e8caa53aadeff92477631428;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477631430 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10482-1 a owl:Class;
  rdfs:label "BORTEZOMIB <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10482";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631432;
  r:natureDuRisque "Risque de majoration des effets indésirables, notamment neurologiques, du bortezomib par diminution de son métabolisme."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du bortezomib pendant la durée du traitement par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631438, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631432 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631433 .

_:807f36cf91fe4e8caa53aadeff92477631433 rdf:first _:807f36cf91fe4e8caa53aadeff92477631434;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631435 .

_:807f36cf91fe4e8caa53aadeff92477631434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477631435 rdf:first _:807f36cf91fe4e8caa53aadeff92477631436;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477631438 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10483-1 a owl:Class;
  rdfs:label "BOSENTAN <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10483";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631440;
  r:natureDuRisque "Diminution importante des concentrations sanguines de la ciclosporine et augmentation des concentrations plasmatiques de bosentan."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631446, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631440 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631441 .

_:807f36cf91fe4e8caa53aadeff92477631441 rdf:first _:807f36cf91fe4e8caa53aadeff92477631442;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631443 .

_:807f36cf91fe4e8caa53aadeff92477631442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff92477631443 rdf:first _:807f36cf91fe4e8caa53aadeff92477631444;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477631446 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10484-1 a owl:Class;
  rdfs:label "BOSENTAN <-> CYPROTERONE"@fr;
  dct:identifier "IAM_10484";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631448;
  r:natureDuRisque "Risque de diminution de l'efficacité de la cyprotérone."@fr;
  r:conduiteATenir """Dans ses indications comme anti-androgène, surveillance clinique et si possible adaptation de la posologie de la cyprotérone pendant l'administration avec le bosentan et après son arrêt.

Dans son utilisation comme contraceptif hormonal, utiliser une méth"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631454, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631448 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631449 .

_:807f36cf91fe4e8caa53aadeff92477631449 rdf:first _:807f36cf91fe4e8caa53aadeff92477631450;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631451 .

_:807f36cf91fe4e8caa53aadeff92477631450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff92477631451 rdf:first _:807f36cf91fe4e8caa53aadeff92477631452;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff92477631454 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10485-1 a owl:Class;
  rdfs:label "BOSENTAN <-> ESTROPROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10485";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631456;
  r:natureDuRisque "Risque de diminution de l'efficacité contraceptive par augmentation du métabolisme hépatique du contraceptif hormonal."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive fiable, additionnelle ou alternative, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631462, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631456 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631457 .

_:807f36cf91fe4e8caa53aadeff92477631457 rdf:first _:807f36cf91fe4e8caa53aadeff92477631458;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631459 .

_:807f36cf91fe4e8caa53aadeff92477631458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477631459 rdf:first _:807f36cf91fe4e8caa53aadeff92477631460;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff92477631462 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10486-1 a owl:Class;
  rdfs:label "BOSENTAN <-> GLIBENCLAMIDE"@fr;
  dct:identifier "IAM_10486";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631464;
  r:natureDuRisque "Risque de moindre efficacité du glibenclamide par diminution de ses concentrations plasmatiques, en raison de l'effet inducteur du bosentan. Par ailleurs, des cas d'hépatotoxicité ont été rapportés lors de l'association."@fr;
  r:conduiteATenir "Surveillance de la glycémie, adaptation du traitement si besoin, et surveillance des constantes biologiques hépatiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631470, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631464 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631465 .

_:807f36cf91fe4e8caa53aadeff92477631465 rdf:first _:807f36cf91fe4e8caa53aadeff92477631466;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631467 .

_:807f36cf91fe4e8caa53aadeff92477631466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff92477631467 rdf:first _:807f36cf91fe4e8caa53aadeff92477631468;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10414 .

_:807f36cf91fe4e8caa53aadeff92477631470 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10487-1 a owl:Class;
  rdfs:label "BOSENTAN <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10487";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631472;
  r:natureDuRisque "Risque majoré des effets indésirables du bosentan, notamment d’atteintes hépatiques, par diminution de son métabolisme par l'inhibiteur."@fr;
  r:conduiteATenir "Surveillance clinique et biologique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631478, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631472 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631473 .

_:807f36cf91fe4e8caa53aadeff92477631473 rdf:first _:807f36cf91fe4e8caa53aadeff92477631474;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631475 .

_:807f36cf91fe4e8caa53aadeff92477631474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477631475 rdf:first _:807f36cf91fe4e8caa53aadeff92477631476;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff92477631478 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10475-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10475";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631480;
  r:natureDuRisque "Diminution des concentrations du bocéprévir et du lopinavir (ou darunavir ou fosamprénavir), avec risque d’échec thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631486, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631480 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631481 .

_:807f36cf91fe4e8caa53aadeff92477631481 rdf:first _:807f36cf91fe4e8caa53aadeff92477631482;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631483 .

_:807f36cf91fe4e8caa53aadeff92477631482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477631483 rdf:first _:807f36cf91fe4e8caa53aadeff92477631484;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff92477631486 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10321-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CEFTRIAXONE"@fr;
  dct:identifier "IAM_10321";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631488;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la céphalosporine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631494, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631488 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631489 .

_:807f36cf91fe4e8caa53aadeff92477631489 rdf:first _:807f36cf91fe4e8caa53aadeff92477631490;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631491 .

_:807f36cf91fe4e8caa53aadeff92477631490 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477631491 rdf:first _:807f36cf91fe4e8caa53aadeff92477631492;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10172 .

_:807f36cf91fe4e8caa53aadeff92477631494 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10311-1 a owl:Class;
  rdfs:label "ANTI-TNF ALPHA <-> CANAKINUMAB"@fr;
  dct:identifier "IAM_10311";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631496;
  r:natureDuRisque "Risque de majoration des infections graves."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631502, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631496 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631497 .

_:807f36cf91fe4e8caa53aadeff92477631497 rdf:first _:807f36cf91fe4e8caa53aadeff92477631498;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631499 .

_:807f36cf91fe4e8caa53aadeff92477631498 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10021 .

_:807f36cf91fe4e8caa53aadeff92477631499 rdf:first _:807f36cf91fe4e8caa53aadeff92477631500;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477631502 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10312-1 a owl:Class;
  rdfs:label "ANTI-TNF ALPHA <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10312";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631504;
  r:natureDuRisque "Risque de maladie vaccinale généralisée éventuellement mortelle."@fr;
  r:conduiteATenir "Et pendant les 3 mois suivant l'arrêt du traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631510, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631504 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631505 .

_:807f36cf91fe4e8caa53aadeff92477631505 rdf:first _:807f36cf91fe4e8caa53aadeff92477631506;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631507 .

_:807f36cf91fe4e8caa53aadeff92477631506 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10021 .

_:807f36cf91fe4e8caa53aadeff92477631507 rdf:first _:807f36cf91fe4e8caa53aadeff92477631508;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477631510 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10313-1 a owl:Class;
  rdfs:label "ANTITUSSIFS MORPHINE-LIKE <-> METHADONE"@fr;
  dct:identifier "IAM_10313";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631512;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631518, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631512 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631513 .

_:807f36cf91fe4e8caa53aadeff92477631513 rdf:first _:807f36cf91fe4e8caa53aadeff92477631514;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631515 .

_:807f36cf91fe4e8caa53aadeff92477631514 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10044 .

_:807f36cf91fe4e8caa53aadeff92477631515 rdf:first _:807f36cf91fe4e8caa53aadeff92477631516;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff92477631518 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10314-1 a owl:Class;
  rdfs:label "ANTITUSSIFS MORPHINIQUES VRAIS <-> METHADONE"@fr;
  dct:identifier "IAM_10314";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631520;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631526, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631520 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631521 .

_:807f36cf91fe4e8caa53aadeff92477631521 rdf:first _:807f36cf91fe4e8caa53aadeff92477631522;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631523 .

_:807f36cf91fe4e8caa53aadeff92477631522 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10045 .

_:807f36cf91fe4e8caa53aadeff92477631523 rdf:first _:807f36cf91fe4e8caa53aadeff92477631524;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff92477631526 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10315-1 a owl:Class;
  rdfs:label "ANTITUSSIFS MORPHINIQUES VRAIS <-> MORPHINIQUES AGONISTES-ANTAGONISTES"@fr;
  dct:identifier "IAM_10315";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631528;
  r:natureDuRisque "Diminution de l'effet antalgique ou antitussif du morphinique, par blocage compétitif des récepteurs, avec risque d'apparition d'un syndrome de sevrage."@fr;
  rdfs:comment "L’association d’agonistes-antagonistes morphiniques (buprénorphine, nalbuphine, pentazocine) avec des analgésiques morphiniques agonistes a été contre-indiquée jusqu'à présent, et ce, quel que soit leur niveau (palier II ou III de la classification de l'O"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631534, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631528 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631529 .

_:807f36cf91fe4e8caa53aadeff92477631529 rdf:first _:807f36cf91fe4e8caa53aadeff92477631530;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631531 .

_:807f36cf91fe4e8caa53aadeff92477631530 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10045 .

_:807f36cf91fe4e8caa53aadeff92477631531 rdf:first _:807f36cf91fe4e8caa53aadeff92477631532;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10110 .

_:807f36cf91fe4e8caa53aadeff92477631534 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10076-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10076";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631536;
  r:natureDuRisque "Variations possibles de l'effet anticoagulant, avec augmentation en cas d'intoxication aiguë ou diminution en cas d'alcoolisme chronique (métabolisme augmenté)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631542, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631536 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631537 .

_:807f36cf91fe4e8caa53aadeff92477631537 rdf:first _:807f36cf91fe4e8caa53aadeff92477631538;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631539 .

_:807f36cf91fe4e8caa53aadeff92477631538 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477631539 rdf:first _:807f36cf91fe4e8caa53aadeff92477631540;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:807f36cf91fe4e8caa53aadeff92477631542 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10316-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> APREPITANT"@fr;
  dct:identifier "IAM_10316";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631544;
  r:natureDuRisque "Risque de diminution de l’effet de l’antivitamine K par augmentation de son métabolisme hépatique par l’aprépitant."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation de la posologie de l’antivitamine K pendant et après l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631550, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631544 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631545 .

_:807f36cf91fe4e8caa53aadeff92477631545 rdf:first _:807f36cf91fe4e8caa53aadeff92477631546;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631547 .

_:807f36cf91fe4e8caa53aadeff92477631546 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477631547 rdf:first _:807f36cf91fe4e8caa53aadeff92477631548;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff92477631550 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10317-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> BOSENTAN"@fr;
  dct:identifier "IAM_10317";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631552;
  r:natureDuRisque "Diminution de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631558, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631552 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631553 .

_:807f36cf91fe4e8caa53aadeff92477631553 rdf:first _:807f36cf91fe4e8caa53aadeff92477631554;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631555 .

_:807f36cf91fe4e8caa53aadeff92477631554 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477631555 rdf:first _:807f36cf91fe4e8caa53aadeff92477631556;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff92477631558 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10318-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CEFAMANDOLE"@fr;
  dct:identifier "IAM_10318";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631560;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la céphalosporine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631566, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631560 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631561 .

_:807f36cf91fe4e8caa53aadeff92477631561 rdf:first _:807f36cf91fe4e8caa53aadeff92477631562;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631563 .

_:807f36cf91fe4e8caa53aadeff92477631562 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477631563 rdf:first _:807f36cf91fe4e8caa53aadeff92477631564;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10169 .

_:807f36cf91fe4e8caa53aadeff92477631566 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10395-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_10395";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631568;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'hypolipémiant, avec risque de survenue d'effets indésirables, notamment musculaires."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631574, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631568 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631569 .

_:807f36cf91fe4e8caa53aadeff92477631569 rdf:first _:807f36cf91fe4e8caa53aadeff92477631570;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631571 .

_:807f36cf91fe4e8caa53aadeff92477631570 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477631571 rdf:first _:807f36cf91fe4e8caa53aadeff92477631572;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477631574 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10320-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CEFOTETAN"@fr;
  dct:identifier "IAM_10320";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631576;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la céphalosporine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631582, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631576 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631577 .

_:807f36cf91fe4e8caa53aadeff92477631577 rdf:first _:807f36cf91fe4e8caa53aadeff92477631578;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631579 .

_:807f36cf91fe4e8caa53aadeff92477631578 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477631579 rdf:first _:807f36cf91fe4e8caa53aadeff92477631580;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10171 .

_:807f36cf91fe4e8caa53aadeff92477631582 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10308-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_10308";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631584;
  r:natureDuRisque "Risque de diminution de l’effet de l’ulipristal, par diminution de son absorption."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631590, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631584 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631585 .

_:807f36cf91fe4e8caa53aadeff92477631585 rdf:first _:807f36cf91fe4e8caa53aadeff92477631586;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631587 .

_:807f36cf91fe4e8caa53aadeff92477631586 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477631587 rdf:first _:807f36cf91fe4e8caa53aadeff92477631588;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477631590 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10322-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10322";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631592;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation de l'effet de l'antivitamine K et du risque hémorragique (diminution de son métabolisme hépatique)."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la cimétidine et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631598, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631592 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631593 .

_:807f36cf91fe4e8caa53aadeff92477631593 rdf:first _:807f36cf91fe4e8caa53aadeff92477631594;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631595 .

_:807f36cf91fe4e8caa53aadeff92477631594 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477631595 rdf:first _:807f36cf91fe4e8caa53aadeff92477631596;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477631598 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10323-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CLINDAMYCINE"@fr;
  dct:identifier "IAM_10323";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631600;
  r:natureDuRisque "Augmentation de l’effet de l’antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation éventuelle de la posologie de l’antivitamine K pendant le traitement par clindamycine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631606, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631600 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631601 .

_:807f36cf91fe4e8caa53aadeff92477631601 rdf:first _:807f36cf91fe4e8caa53aadeff92477631602;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631603 .

_:807f36cf91fe4e8caa53aadeff92477631602 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477631603 rdf:first _:807f36cf91fe4e8caa53aadeff92477631604;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10209 .

_:807f36cf91fe4e8caa53aadeff92477631606 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10324-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> COLCHICINE"@fr;
  dct:identifier "IAM_10324";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631608;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la colchicine et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631614, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631608 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631609 .

_:807f36cf91fe4e8caa53aadeff92477631609 rdf:first _:807f36cf91fe4e8caa53aadeff92477631610;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631611 .

_:807f36cf91fe4e8caa53aadeff92477631610 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477631611 rdf:first _:807f36cf91fe4e8caa53aadeff92477631612;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477631614 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10325-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CYCLINES"@fr;
  dct:identifier "IAM_10325";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631616;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la cycline et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631622, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631616 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631617 .

_:807f36cf91fe4e8caa53aadeff92477631617 rdf:first _:807f36cf91fe4e8caa53aadeff92477631618;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631619 .

_:807f36cf91fe4e8caa53aadeff92477631618 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477631619 rdf:first _:807f36cf91fe4e8caa53aadeff92477631620;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:807f36cf91fe4e8caa53aadeff92477631622 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10326-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CYTOTOXIQUES"@fr;
  dct:identifier "IAM_10326";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631624;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation du risque thrombotique et hémorragique au cours des affections tumorales. De surcroit, possible interaction entre les AVK et la chimiothérapie."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631630, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631624 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631625 .

_:807f36cf91fe4e8caa53aadeff92477631625 rdf:first _:807f36cf91fe4e8caa53aadeff92477631626;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631627 .

_:807f36cf91fe4e8caa53aadeff92477631626 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477631627 rdf:first _:807f36cf91fe4e8caa53aadeff92477631628;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10060 .

_:807f36cf91fe4e8caa53aadeff92477631630 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10327-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> DANAZOL"@fr;
  dct:identifier "IAM_10327";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631632;
  r:natureDuRisque "Augmentation du risque hémorragique par effet direct sur la coagulation et/ou les systèmes fibrinolytiques."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation de la posologie de l’antivitamine K pendant le traitement par le danazol et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631638, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631632 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631633 .

_:807f36cf91fe4e8caa53aadeff92477631633 rdf:first _:807f36cf91fe4e8caa53aadeff92477631634;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631635 .

_:807f36cf91fe4e8caa53aadeff92477631634 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477631635 rdf:first _:807f36cf91fe4e8caa53aadeff92477631636;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:807f36cf91fe4e8caa53aadeff92477631638 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10328-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> DEFERASIROX"@fr;
  dct:identifier "IAM_10328";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631640;
  r:natureDuRisque "Majoration du risque ulcérogène et hémorragique digestif."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631646, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631640 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631641 .

_:807f36cf91fe4e8caa53aadeff92477631641 rdf:first _:807f36cf91fe4e8caa53aadeff92477631642;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631643 .

_:807f36cf91fe4e8caa53aadeff92477631642 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477631643 rdf:first _:807f36cf91fe4e8caa53aadeff92477631644;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:807f36cf91fe4e8caa53aadeff92477631646 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10329-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> DISULFIRAME"@fr;
  dct:identifier "IAM_10329";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631648;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation de la posologie de l'antivitamine K pendant le traitement par le disulfirame et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631654, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631648 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631649 .

_:807f36cf91fe4e8caa53aadeff92477631649 rdf:first _:807f36cf91fe4e8caa53aadeff92477631650;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631651 .

_:807f36cf91fe4e8caa53aadeff92477631650 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477631651 rdf:first _:807f36cf91fe4e8caa53aadeff92477631652;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10299 .

_:807f36cf91fe4e8caa53aadeff92477631654 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10330-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> DRONEDARONE"@fr;
  dct:identifier "IAM_10330";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631656;
  r:natureDuRisque "Augmentation de l’effet de l’antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation éventuelle de la posologie de l’antivitamine K pendant le traitement par la dronédarone et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631662, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631656 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631657 .

_:807f36cf91fe4e8caa53aadeff92477631657 rdf:first _:807f36cf91fe4e8caa53aadeff92477631658;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631659 .

_:807f36cf91fe4e8caa53aadeff92477631658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477631659 rdf:first _:807f36cf91fe4e8caa53aadeff92477631660;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477631662 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10319-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CEFOPERAZONE"@fr;
  dct:identifier "IAM_10319";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631664;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la céphalosporine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631670, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631664 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631665 .

_:807f36cf91fe4e8caa53aadeff92477631665 rdf:first _:807f36cf91fe4e8caa53aadeff92477631666;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631667 .

_:807f36cf91fe4e8caa53aadeff92477631666 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477631667 rdf:first _:807f36cf91fe4e8caa53aadeff92477631668;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631668 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10170 .

_:807f36cf91fe4e8caa53aadeff92477631670 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11222-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_11222";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631672;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631678, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631672 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631673 .

_:807f36cf91fe4e8caa53aadeff92477631673 rdf:first _:807f36cf91fe4e8caa53aadeff92477631674;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631675 .

_:807f36cf91fe4e8caa53aadeff92477631674 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477631675 rdf:first _:807f36cf91fe4e8caa53aadeff92477631676;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631676 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:807f36cf91fe4e8caa53aadeff92477631678 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11080-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_11080";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631680;
  r:natureDuRisque "Augmentation des concentrations sanguines de l’immunosuppresseur (diminution de son métabolisme hépatique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631686, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631680 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631681 .

_:807f36cf91fe4e8caa53aadeff92477631681 rdf:first _:807f36cf91fe4e8caa53aadeff92477631682;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631683 .

_:807f36cf91fe4e8caa53aadeff92477631682 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477631683 rdf:first _:807f36cf91fe4e8caa53aadeff92477631684;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631684 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477631686 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11082-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_11082";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631688;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation éventuelle de la posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631694, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631688 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631689 .

_:807f36cf91fe4e8caa53aadeff92477631689 rdf:first _:807f36cf91fe4e8caa53aadeff92477631690;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631691 .

_:807f36cf91fe4e8caa53aadeff92477631690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477631691 rdf:first _:807f36cf91fe4e8caa53aadeff92477631692;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631692 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477631694 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11083-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_11083";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631696;
  r:natureDuRisque "Risque de maladie vaccinale généralisée éventuellement mortelle."@fr;
  r:conduiteATenir "Et pendant les 3 mois suivant l'arrêt du traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631702, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631696 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631697 .

_:807f36cf91fe4e8caa53aadeff92477631697 rdf:first _:807f36cf91fe4e8caa53aadeff92477631698;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631699 .

_:807f36cf91fe4e8caa53aadeff92477631698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477631699 rdf:first _:807f36cf91fe4e8caa53aadeff92477631700;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631700 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477631702 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11084-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> VÉMURAFÉNIB"@fr;
  dct:identifier "IAM_11084";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631704;
  r:natureDuRisque "Risque de diminution des concentrations des immunosuppresseurs, avec pour conséquence un risque d’inefficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631710, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631704 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631705 .

_:807f36cf91fe4e8caa53aadeff92477631705 rdf:first _:807f36cf91fe4e8caa53aadeff92477631706;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631707 .

_:807f36cf91fe4e8caa53aadeff92477631706 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477631707 rdf:first _:807f36cf91fe4e8caa53aadeff92477631708;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631708 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10978 .

_:807f36cf91fe4e8caa53aadeff92477631710 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11085-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11085";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631712;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique par le voriconazole."@fr;
  r:conduiteATenir """Association déconseillée
- avec l'évérolimus, le sirolimus, et le temsirolimus.

Précaution d'emploi
- avec la ciclosporine et le tacrolimus :
dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de la p"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631718, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631712 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631713 .

_:807f36cf91fe4e8caa53aadeff92477631713 rdf:first _:807f36cf91fe4e8caa53aadeff92477631714;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631715 .

_:807f36cf91fe4e8caa53aadeff92477631714 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477631715 rdf:first _:807f36cf91fe4e8caa53aadeff92477631716;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631716 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477631718 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11086-1 a owl:Class;
  rdfs:label "INDINAVIR <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_11086";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631720;
  r:natureDuRisque "Risque de baisse de l'efficacité de l'indinavir."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631726, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631720 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631721 .

_:807f36cf91fe4e8caa53aadeff92477631721 rdf:first _:807f36cf91fe4e8caa53aadeff92477631722;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631723 .

_:807f36cf91fe4e8caa53aadeff92477631722 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10455 .

_:807f36cf91fe4e8caa53aadeff92477631723 rdf:first _:807f36cf91fe4e8caa53aadeff92477631724;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631724 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:807f36cf91fe4e8caa53aadeff92477631726 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11088-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> IRINOTECAN"@fr;
  dct:identifier "IAM_11088";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631728;
  r:natureDuRisque """Diminution probable des concentrations plasmatiques du métabolite actif de l'irinotécan, avec risque d'échec du traitement
cytotoxique."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631734, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631728 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631729 .

_:807f36cf91fe4e8caa53aadeff92477631729 rdf:first _:807f36cf91fe4e8caa53aadeff92477631730;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631731 .

_:807f36cf91fe4e8caa53aadeff92477631730 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477631731 rdf:first _:807f36cf91fe4e8caa53aadeff92477631732;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631732 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10486 .

_:807f36cf91fe4e8caa53aadeff92477631734 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11089-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> ISAVUCONAZOLE"@fr;
  dct:identifier "IAM_11089";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631736;
  r:natureDuRisque "Diminution des concentrations plasmatiques d’isavuconazole par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631742, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631736 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631737 .

_:807f36cf91fe4e8caa53aadeff92477631737 rdf:first _:807f36cf91fe4e8caa53aadeff92477631738;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631739 .

_:807f36cf91fe4e8caa53aadeff92477631738 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477631739 rdf:first _:807f36cf91fe4e8caa53aadeff92477631740;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631740 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10487 .

_:807f36cf91fe4e8caa53aadeff92477631742 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11090-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_11090";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631744;
  r:natureDuRisque "Diminution des concentrations plasmatiques d’itraconazole, avec risque de perte d’efficacité, par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631750, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631744 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631745 .

_:807f36cf91fe4e8caa53aadeff92477631745 rdf:first _:807f36cf91fe4e8caa53aadeff92477631746;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631747 .

_:807f36cf91fe4e8caa53aadeff92477631746 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477631747 rdf:first _:807f36cf91fe4e8caa53aadeff92477631748;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631748 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477631750 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10310-1 a owl:Class;
  rdfs:label "ANTISPASMODIQUES URINAIRES <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10310";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631752;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Risque de majoration des effets indésirables."@fr;
  r:conduiteATenir """Contre-indication :
- avec la darifénacine
- avec la fésotérodine et la solifénacine, en cas d'insuffisance rénale ou hépatique, modérée à sévère.

Association déconseillée : 
- avec la toltérodine

Précaution d'emploi:
- avec la fésotérodine ou la solifé"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631758, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631752 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631753 .

_:807f36cf91fe4e8caa53aadeff92477631753 rdf:first _:807f36cf91fe4e8caa53aadeff92477631754;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631755 .

_:807f36cf91fe4e8caa53aadeff92477631754 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10041 .

_:807f36cf91fe4e8caa53aadeff92477631755 rdf:first _:807f36cf91fe4e8caa53aadeff92477631756;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631756 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477631758 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11092-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> LURASIDONE"@fr;
  dct:identifier "IAM_11092";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631760;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la lurasidone par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631766, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631760 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631761 .

_:807f36cf91fe4e8caa53aadeff92477631761 rdf:first _:807f36cf91fe4e8caa53aadeff92477631762;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631763 .

_:807f36cf91fe4e8caa53aadeff92477631762 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477631763 rdf:first _:807f36cf91fe4e8caa53aadeff92477631764;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631764 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10542 .

_:807f36cf91fe4e8caa53aadeff92477631766 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10309-1 a owl:Class;
  rdfs:label "ANTISEPTIQUES MERCURIELS <-> POVIDONE IODÉE"@fr;
  dct:identifier "IAM_10309";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631768;
  r:natureDuRisque """Erythèmes, phlyctènes, voire nécrose cutanéo-muqueuse 
(formation d'un complexe caustique en cas d'utilisation
concomitante d'antiseptiques iodés et mercuriels). L'interaction
dépend de la stabilité de l'organo-mercuriel au niveau cutané et de la sensibil"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631774, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631768 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631769 .

_:807f36cf91fe4e8caa53aadeff92477631769 rdf:first _:807f36cf91fe4e8caa53aadeff92477631770;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631771 .

_:807f36cf91fe4e8caa53aadeff92477631770 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477631771 rdf:first _:807f36cf91fe4e8caa53aadeff92477631772;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631772 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10745 .

_:807f36cf91fe4e8caa53aadeff92477631774 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11224-1 a owl:Class;
  rdfs:label "LAMIVUDINE <-> ZALCITABINE"@fr;
  dct:identifier "IAM_11224";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631776;
  r:natureDuRisque "Risque de diminution de l'efficacité de chaque antiviral par antagoniste compétitif de la réaction de phosphorylation à l'origine des métabolites actifs."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631782, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631776 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631777 .

_:807f36cf91fe4e8caa53aadeff92477631777 rdf:first _:807f36cf91fe4e8caa53aadeff92477631778;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631779 .

_:807f36cf91fe4e8caa53aadeff92477631778 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10506 .

_:807f36cf91fe4e8caa53aadeff92477631779 rdf:first _:807f36cf91fe4e8caa53aadeff92477631780;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631780 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11002 .

_:807f36cf91fe4e8caa53aadeff92477631782 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11225-1 a owl:Class;
  rdfs:label "LAMOTRIGINE <-> OXCARBAZEPINE"@fr;
  dct:identifier "IAM_11225";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631784;
  r:natureDuRisque "Diminution des concentrations de la lamotrigine avec risque de moindre efficacité, par augmentation de son métabolisme hépatique par l'oxcarbazépine."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques, avec adaptation de la posologie de la lamotrigine si besoin."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631790, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631784 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631785 .

_:807f36cf91fe4e8caa53aadeff92477631785 rdf:first _:807f36cf91fe4e8caa53aadeff92477631786;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631787 .

_:807f36cf91fe4e8caa53aadeff92477631786 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:807f36cf91fe4e8caa53aadeff92477631787 rdf:first _:807f36cf91fe4e8caa53aadeff92477631788;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631788 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10674 .

_:807f36cf91fe4e8caa53aadeff92477631790 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11226-1 a owl:Class;
  rdfs:label "LAMOTRIGINE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11226";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631792;
  r:natureDuRisque "Risque majoré de réactions cutanées graves (syndrome de Lyell). Par ailleurs, augmentation des concentrations plasmatiques de lamotrigine (diminution de son métabolisme hépatique par le valproate de sodium)."@fr;
  r:conduiteATenir "Si l'association s'avère nécessaire, surveillance clinique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631798, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631792 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631793 .

_:807f36cf91fe4e8caa53aadeff92477631793 rdf:first _:807f36cf91fe4e8caa53aadeff92477631794;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631795 .

_:807f36cf91fe4e8caa53aadeff92477631794 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477631795 rdf:first _:807f36cf91fe4e8caa53aadeff92477631796;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631796 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:807f36cf91fe4e8caa53aadeff92477631798 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11227-1 a owl:Class;
  rdfs:label "LANSOPRAZOLE <-> TACROLIMUS"@fr;
  dct:identifier "IAM_11227";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631800;
  r:natureDuRisque "Augmentation des concentrations sanguines du tacrolimus."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines du tacrolimus, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631806, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631800 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631801 .

_:807f36cf91fe4e8caa53aadeff92477631801 rdf:first _:807f36cf91fe4e8caa53aadeff92477631802;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631803 .

_:807f36cf91fe4e8caa53aadeff92477631802 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10509 .

_:807f36cf91fe4e8caa53aadeff92477631803 rdf:first _:807f36cf91fe4e8caa53aadeff92477631804;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631804 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477631806 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11228-1 a owl:Class;
  rdfs:label "LÉDIPASVIR <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11228";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631808;
  r:natureDuRisque "Risque de diminution importante des concentrations plasmatiques du lédipasvir par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631814, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631808 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631809 .

_:807f36cf91fe4e8caa53aadeff92477631809 rdf:first _:807f36cf91fe4e8caa53aadeff92477631810;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631811 .

_:807f36cf91fe4e8caa53aadeff92477631810 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:807f36cf91fe4e8caa53aadeff92477631811 rdf:first _:807f36cf91fe4e8caa53aadeff92477631812;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631812 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477631814 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10304-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10304";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631816;
  r:natureDuRisque "Risque d’inefficacité du traitement antisécrétoire par augmentation de son métabolisme par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631822, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631816 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631817 .

_:807f36cf91fe4e8caa53aadeff92477631817 rdf:first _:807f36cf91fe4e8caa53aadeff92477631818;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631819 .

_:807f36cf91fe4e8caa53aadeff92477631818 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477631819 rdf:first _:807f36cf91fe4e8caa53aadeff92477631820;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631820 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477631822 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10305-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> MYCOPHENOLATE MOFETIL"@fr;
  dct:identifier "IAM_10305";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631824;
  r:natureDuRisque "Diminution des concentrations de l’acide mycophénolique d’environ un tiers, avec risque potentiel de baisse d’efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631830, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631824 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631825 .

_:807f36cf91fe4e8caa53aadeff92477631825 rdf:first _:807f36cf91fe4e8caa53aadeff92477631826;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631827 .

_:807f36cf91fe4e8caa53aadeff92477631826 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477631827 rdf:first _:807f36cf91fe4e8caa53aadeff92477631828;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631828 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10609 .

_:807f36cf91fe4e8caa53aadeff92477631830 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10306-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_10306";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631832;
  r:natureDuRisque "Diminution de l'absorption de l'azolé antifongique, par augmentation du pH intragastrique par l'antisécrétoire."@fr;
  r:conduiteATenir """Association déconseillée:
- uniquement avec la forme suspension buvable de posaconazole."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631838, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631832 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631833 .

_:807f36cf91fe4e8caa53aadeff92477631833 rdf:first _:807f36cf91fe4e8caa53aadeff92477631834;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631835 .

_:807f36cf91fe4e8caa53aadeff92477631834 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477631835 rdf:first _:807f36cf91fe4e8caa53aadeff92477631836;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631836 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477631838 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10307-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> RILPIVIRINE"@fr;
  dct:identifier "IAM_10307";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631840;
  r:natureDuRisque "Diminution des concentrations plasmatiques de rilpivirine par l’inhibiteur de la pompe à protons (absorption diminuée en raison de l’augmentation du pH gastrique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631846, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631840 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631841 .

_:807f36cf91fe4e8caa53aadeff92477631841 rdf:first _:807f36cf91fe4e8caa53aadeff92477631842;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631843 .

_:807f36cf91fe4e8caa53aadeff92477631842 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477631843 rdf:first _:807f36cf91fe4e8caa53aadeff92477631844;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631844 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10803 .

_:807f36cf91fe4e8caa53aadeff92477631846 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10333-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> FIBRATES"@fr;
  dct:identifier "IAM_10333";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631848;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par le fibrate et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631854, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631848 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631849 .

_:807f36cf91fe4e8caa53aadeff92477631849 rdf:first _:807f36cf91fe4e8caa53aadeff92477631850;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631851 .

_:807f36cf91fe4e8caa53aadeff92477631850 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477631851 rdf:first _:807f36cf91fe4e8caa53aadeff92477631852;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631852 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10074 .

_:807f36cf91fe4e8caa53aadeff92477631854 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11091-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> IVACAFTOR"@fr;
  dct:identifier "IAM_11091";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631856;
  r:natureDuRisque "Diminution importante des concentrations de l’ivacaftor, avec risque de perte d’efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631862, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631856 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631857 .

_:807f36cf91fe4e8caa53aadeff92477631857 rdf:first _:807f36cf91fe4e8caa53aadeff92477631858;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631859 .

_:807f36cf91fe4e8caa53aadeff92477631858 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477631859 rdf:first _:807f36cf91fe4e8caa53aadeff92477631860;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631860 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10498 .

_:807f36cf91fe4e8caa53aadeff92477631862 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10382-1 a owl:Class;
  rdfs:label "ATAZANAVIR <-> EFAVIRENZ"@fr;
  dct:identifier "IAM_10382";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631864;
  r:natureDuRisque "Risque de baisse de l’efficacité de l’atazanavir par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Si l’association s’avère nécessaire, adaptation posologique de l’atazanavir avec surveillance clinique et biologique régulière, notamment en début d’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631870, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631864 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631865 .

_:807f36cf91fe4e8caa53aadeff92477631865 rdf:first _:807f36cf91fe4e8caa53aadeff92477631866;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631867 .

_:807f36cf91fe4e8caa53aadeff92477631866 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:807f36cf91fe4e8caa53aadeff92477631867 rdf:first _:807f36cf91fe4e8caa53aadeff92477631868;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631868 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477631870 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10331-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> ECONAZOLE"@fr;
  dct:identifier "IAM_10331";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631872;
  r:natureDuRisque "Quelle que soit la voie d'administration de l'éconazole : augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par éconazole et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631878, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631872 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631873 .

_:807f36cf91fe4e8caa53aadeff92477631873 rdf:first _:807f36cf91fe4e8caa53aadeff92477631874;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631875 .

_:807f36cf91fe4e8caa53aadeff92477631874 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477631875 rdf:first _:807f36cf91fe4e8caa53aadeff92477631876;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631876 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10317 .

_:807f36cf91fe4e8caa53aadeff92477631878 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10372-1 a owl:Class;
  rdfs:label "APREPITANT <-> CYPROTERONE"@fr;
  dct:identifier "IAM_10372";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631880;
  r:natureDuRisque "Risque de diminution des concentrations de la cyprotérone avec risque de moindre efficacité contraceptive."@fr;
  r:conduiteATenir """Dans son utilisation comme contraceptif hormonal : 
Utiliser une méthode de contraception fiable, additionnelle ou alternative, pendant la durée de l'association."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631886, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631880 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631881 .

_:807f36cf91fe4e8caa53aadeff92477631881 rdf:first _:807f36cf91fe4e8caa53aadeff92477631882;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631883 .

_:807f36cf91fe4e8caa53aadeff92477631882 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff92477631883 rdf:first _:807f36cf91fe4e8caa53aadeff92477631884;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631884 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff92477631886 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10373-1 a owl:Class;
  rdfs:label "APREPITANT <-> ESTROPROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10373";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631888;
  r:natureDuRisque "Diminution des concentrations de l’estroprogestatif ou du progestatif, avec risque de moindre efficacité contraceptive."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631894, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631888 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631889 .

_:807f36cf91fe4e8caa53aadeff92477631889 rdf:first _:807f36cf91fe4e8caa53aadeff92477631890;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631891 .

_:807f36cf91fe4e8caa53aadeff92477631890 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477631891 rdf:first _:807f36cf91fe4e8caa53aadeff92477631892;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631892 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff92477631894 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10374-1 a owl:Class;
  rdfs:label "APREPITANT <-> IFOSFAMIDE"@fr;
  dct:identifier "IAM_10374";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631896;
  r:natureDuRisque "Risque d’augmentation de la neurotoxicité de l’ifosfamide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631902, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631896 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631897 .

_:807f36cf91fe4e8caa53aadeff92477631897 rdf:first _:807f36cf91fe4e8caa53aadeff92477631898;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631899 .

_:807f36cf91fe4e8caa53aadeff92477631898 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff92477631899 rdf:first _:807f36cf91fe4e8caa53aadeff92477631900;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631900 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10445 .

_:807f36cf91fe4e8caa53aadeff92477631902 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10375-1 a owl:Class;
  rdfs:label "APREPITANT <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10375";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631904;
  r:natureDuRisque "Augmentation des concentrations d’aprépitant par diminution de son métabolisme hépatique par l’itraconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631910, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631904 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631905 .

_:807f36cf91fe4e8caa53aadeff92477631905 rdf:first _:807f36cf91fe4e8caa53aadeff92477631906;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631907 .

_:807f36cf91fe4e8caa53aadeff92477631906 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff92477631907 rdf:first _:807f36cf91fe4e8caa53aadeff92477631908;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631908 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477631910 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10376-1 a owl:Class;
  rdfs:label "APREPITANT <-> PIMOZIDE"@fr;
  dct:identifier "IAM_10376";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631912;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631918, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631912 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631913 .

_:807f36cf91fe4e8caa53aadeff92477631913 rdf:first _:807f36cf91fe4e8caa53aadeff92477631914;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631915 .

_:807f36cf91fe4e8caa53aadeff92477631914 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff92477631915 rdf:first _:807f36cf91fe4e8caa53aadeff92477631916;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631916 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477631918 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10377-1 a owl:Class;
  rdfs:label "APREPITANT <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10377";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631920;
  r:natureDuRisque "(Sauf stérilet), diminution des concentrations du progestatif, avec risque de moindre efficacité contraceptive."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631926, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631920 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631921 .

_:807f36cf91fe4e8caa53aadeff92477631921 rdf:first _:807f36cf91fe4e8caa53aadeff92477631922;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631923 .

_:807f36cf91fe4e8caa53aadeff92477631922 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:807f36cf91fe4e8caa53aadeff92477631923 rdf:first _:807f36cf91fe4e8caa53aadeff92477631924;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631924 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff92477631926 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10378-1 a owl:Class;
  rdfs:label "APREPITANT <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10378";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631928;
  r:natureDuRisque "Diminution très importante des concentrations d'aprépitant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631934, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631928 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631929 .

_:807f36cf91fe4e8caa53aadeff92477631929 rdf:first _:807f36cf91fe4e8caa53aadeff92477631930;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631931 .

_:807f36cf91fe4e8caa53aadeff92477631930 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff92477631931 rdf:first _:807f36cf91fe4e8caa53aadeff92477631932;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631932 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477631934 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10379-1 a owl:Class;
  rdfs:label "ARIPIPRAZOLE <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10379";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631936;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’aripiprazole."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l’aripiprazole pendant l’association et 1 à 2 semaines après l’arrêt de l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631942, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631936 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631937 .

_:807f36cf91fe4e8caa53aadeff92477631937 rdf:first _:807f36cf91fe4e8caa53aadeff92477631938;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631939 .

_:807f36cf91fe4e8caa53aadeff92477631938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477631939 rdf:first _:807f36cf91fe4e8caa53aadeff92477631940;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631940 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477631942 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10370-1 a owl:Class;
  rdfs:label "APIXABAN <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10370";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631944;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’apixaban par la rifampicine, avec risque de diminution de l’effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631950, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631944 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631945 .

_:807f36cf91fe4e8caa53aadeff92477631945 rdf:first _:807f36cf91fe4e8caa53aadeff92477631946;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631947 .

_:807f36cf91fe4e8caa53aadeff92477631946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10078 .

_:807f36cf91fe4e8caa53aadeff92477631947 rdf:first _:807f36cf91fe4e8caa53aadeff92477631948;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631948 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477631950 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10381-1 a owl:Class;
  rdfs:label "ATAZANAVIR <-> CLARITHROMYCINE"@fr;
  dct:identifier "IAM_10381";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631952;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de clarithromycine et inhibition de la formation de son métabolite actif."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631958, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631952 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631953 .

_:807f36cf91fe4e8caa53aadeff92477631953 rdf:first _:807f36cf91fe4e8caa53aadeff92477631954;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631955 .

_:807f36cf91fe4e8caa53aadeff92477631954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:807f36cf91fe4e8caa53aadeff92477631955 rdf:first _:807f36cf91fe4e8caa53aadeff92477631956;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631956 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477631958 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10369-1 a owl:Class;
  rdfs:label "APIXABAN <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10369";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631960;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l’apixaban par l'inhibiteur, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631966, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631960 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631961 .

_:807f36cf91fe4e8caa53aadeff92477631961 rdf:first _:807f36cf91fe4e8caa53aadeff92477631962;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631963 .

_:807f36cf91fe4e8caa53aadeff92477631962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477631963 rdf:first _:807f36cf91fe4e8caa53aadeff92477631964;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631964 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10078 .

_:807f36cf91fe4e8caa53aadeff92477631966 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10383-1 a owl:Class;
  rdfs:label "ATAZANAVIR <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_10383";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631968;
  r:natureDuRisque "Risque de baisse de l’efficacité de l’atazanavir par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Si l’association s’avère nécessaire, adaptation posologique de l’atazanavir avec surveillance clinique et biologique régulière, notamment en début d’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631974, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631968 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631969 .

_:807f36cf91fe4e8caa53aadeff92477631969 rdf:first _:807f36cf91fe4e8caa53aadeff92477631970;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631971 .

_:807f36cf91fe4e8caa53aadeff92477631970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:807f36cf91fe4e8caa53aadeff92477631971 rdf:first _:807f36cf91fe4e8caa53aadeff92477631972;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631972 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:807f36cf91fe4e8caa53aadeff92477631974 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10384-1 a owl:Class;
  rdfs:label "ATAZANAVIR <-> TENOFOVIR DISOPROXIL"@fr;
  dct:identifier "IAM_10384";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631976;
  r:natureDuRisque "Diminution d’environ un tiers de l’exposition à l’atazanavir chez le patient en cas d’association au ténofovir, comparativement au sujet sain recevant la même association."@fr;
  r:conduiteATenir "Ne pas administrer l’atazanavir avec le ténofovir sans ritonavir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631982, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631976 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631977 .

_:807f36cf91fe4e8caa53aadeff92477631977 rdf:first _:807f36cf91fe4e8caa53aadeff92477631978;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631979 .

_:807f36cf91fe4e8caa53aadeff92477631978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:807f36cf91fe4e8caa53aadeff92477631979 rdf:first _:807f36cf91fe4e8caa53aadeff92477631980;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631980 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10896 .

_:807f36cf91fe4e8caa53aadeff92477631982 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10385-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> AZITHROMYCINE"@fr;
  dct:identifier "IAM_10385";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631984;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d’hypocholestérolémiant ou une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631990, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631984 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631985 .

_:807f36cf91fe4e8caa53aadeff92477631985 rdf:first _:807f36cf91fe4e8caa53aadeff92477631986;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631987 .

_:807f36cf91fe4e8caa53aadeff92477631986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477631987 rdf:first _:807f36cf91fe4e8caa53aadeff92477631988;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631988 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477631990 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10386-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> BOCEPREVIR"@fr;
  dct:identifier "IAM_10386";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477631992;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'atorvastatine."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 20mg/jour d'atorvastatine. Si l'objectif thérapeutique n'est pas atteint à cette posologie, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477631998, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477631992 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477631993 .

_:807f36cf91fe4e8caa53aadeff92477631993 rdf:first _:807f36cf91fe4e8caa53aadeff92477631994;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477631995 .

_:807f36cf91fe4e8caa53aadeff92477631994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477631995 rdf:first _:807f36cf91fe4e8caa53aadeff92477631996;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477631996 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff92477631998 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10387-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10387";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632000;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme de l'hypocholestérolémiant)."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 10mg/jour d'atorvastatine. Si l'objectif thérapeutique n'est pas atteint à cette posologie, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632006, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632000 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632001 .

_:807f36cf91fe4e8caa53aadeff92477632001 rdf:first _:807f36cf91fe4e8caa53aadeff92477632002;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632003 .

_:807f36cf91fe4e8caa53aadeff92477632002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477632003 rdf:first _:807f36cf91fe4e8caa53aadeff92477632004;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632004 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477632006 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10388-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> CLARITHROMYCINE"@fr;
  dct:identifier "IAM_10388";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632008;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholesterolémiant."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d'hypocholestérolémiant. Si l'objectif thérapeutique n'est pas atteint, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632014, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632008 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632009 .

_:807f36cf91fe4e8caa53aadeff92477632009 rdf:first _:807f36cf91fe4e8caa53aadeff92477632010;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632011 .

_:807f36cf91fe4e8caa53aadeff92477632010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477632011 rdf:first _:807f36cf91fe4e8caa53aadeff92477632012;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632012 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632014 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10389-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10389";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632016;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d’hypocholestérolémiant ou une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632022, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632016 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632017 .

_:807f36cf91fe4e8caa53aadeff92477632017 rdf:first _:807f36cf91fe4e8caa53aadeff92477632018;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632019 .

_:807f36cf91fe4e8caa53aadeff92477632018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477632019 rdf:first _:807f36cf91fe4e8caa53aadeff92477632020;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632020 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477632022 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10390-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10390";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632024;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholesterolémiant."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d'hypocholestérolémiant. Si l'objectif thérapeutique n'est pas atteint, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632030, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632024 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632025 .

_:807f36cf91fe4e8caa53aadeff92477632025 rdf:first _:807f36cf91fe4e8caa53aadeff92477632026;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632027 .

_:807f36cf91fe4e8caa53aadeff92477632026 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477632027 rdf:first _:807f36cf91fe4e8caa53aadeff92477632028;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632028 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477632030 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10391-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10391";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632032;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l'atorvastatine)."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d'atorvastatine. Si l'objectif thérapeutique n'est pas atteint, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632038, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632032 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632033 .

_:807f36cf91fe4e8caa53aadeff92477632033 rdf:first _:807f36cf91fe4e8caa53aadeff92477632034;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632035 .

_:807f36cf91fe4e8caa53aadeff92477632034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477632035 rdf:first _:807f36cf91fe4e8caa53aadeff92477632036;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632036 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477632038 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10392-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10392";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632040;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l'atorvastatine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632046, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632040 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632041 .

_:807f36cf91fe4e8caa53aadeff92477632041 rdf:first _:807f36cf91fe4e8caa53aadeff92477632042;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632043 .

_:807f36cf91fe4e8caa53aadeff92477632042 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477632043 rdf:first _:807f36cf91fe4e8caa53aadeff92477632044;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632044 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477632046 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10380-1 a owl:Class;
  rdfs:label "ATAZANAVIR <-> BUPRENORPHINE"@fr;
  dct:identifier "IAM_10380";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632048;
  r:natureDuRisque "Risque de majoration ou de diminution des effets de la buprénorphine, à la fois par inhibition et accélération de son métabolisme par l’inhibiteur de protéases."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632054, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632048 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632049 .

_:807f36cf91fe4e8caa53aadeff92477632049 rdf:first _:807f36cf91fe4e8caa53aadeff92477632050;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632051 .

_:807f36cf91fe4e8caa53aadeff92477632050 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:807f36cf91fe4e8caa53aadeff92477632051 rdf:first _:807f36cf91fe4e8caa53aadeff92477632052;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632052 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10139 .

_:807f36cf91fe4e8caa53aadeff92477632054 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10358-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> ROPINIROLE"@fr;
  dct:identifier "IAM_10358";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632056;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation éventuelle de la posologie de l’antivitamine K pendant le traitement par ropinirole et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632062, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632056 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632057 .

_:807f36cf91fe4e8caa53aadeff92477632057 rdf:first _:807f36cf91fe4e8caa53aadeff92477632058;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632059 .

_:807f36cf91fe4e8caa53aadeff92477632058 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632059 rdf:first _:807f36cf91fe4e8caa53aadeff92477632060;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632060 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10813 .

_:807f36cf91fe4e8caa53aadeff92477632062 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10522-1 a owl:Class;
  rdfs:label "CAFEINE <-> DIPYRIDAMOLE"@fr;
  dct:identifier "IAM_10522";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632064;
  r:natureDuRisque "Avec le dipyridamole par voie injectable : réduction de l’effet vasodilatateur du dipyridamole par la caféine."@fr;
  r:conduiteATenir "Interrompre un traitement à base de caféine au moins 5 jours avant une imagerie myocardique avec le dipyridamole et éviter la consommation de café, thé, chocolat ou cola dans les 24 heures qui précèdent le test."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632070, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632064 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632065 .

_:807f36cf91fe4e8caa53aadeff92477632065 rdf:first _:807f36cf91fe4e8caa53aadeff92477632066;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632067 .

_:807f36cf91fe4e8caa53aadeff92477632066 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477632067 rdf:first _:807f36cf91fe4e8caa53aadeff92477632068;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632068 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10297 .

_:807f36cf91fe4e8caa53aadeff92477632070 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10334-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10334";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632072;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par le fluconazole et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632078, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632072 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632073 .

_:807f36cf91fe4e8caa53aadeff92477632073 rdf:first _:807f36cf91fe4e8caa53aadeff92477632074;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632075 .

_:807f36cf91fe4e8caa53aadeff92477632074 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632075 rdf:first _:807f36cf91fe4e8caa53aadeff92477632076;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632076 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477632078 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10335-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> FLUOROQUINOLONES"@fr;
  dct:identifier "IAM_10335";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632080;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la fluoroquinolone et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632086, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632080 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632081 .

_:807f36cf91fe4e8caa53aadeff92477632081 rdf:first _:807f36cf91fe4e8caa53aadeff92477632082;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632083 .

_:807f36cf91fe4e8caa53aadeff92477632082 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632083 rdf:first _:807f36cf91fe4e8caa53aadeff92477632084;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632084 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff92477632086 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10336-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> FLUOROURACILE (ET, PAR EXTRAPOLATION, AUTRES FLUOROPYRIMIDINES)"@fr;
  dct:identifier "IAM_10336";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632088;
  r:natureDuRisque "Augmentation importante de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Si elle ne peut être évitée, contrôle plus fréquent de l'INR. Adaptation de la posologie de l'antivitamine K pendant le traitement par le cytotoxique et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632094, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632088 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632089 .

_:807f36cf91fe4e8caa53aadeff92477632089 rdf:first _:807f36cf91fe4e8caa53aadeff92477632090;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632091 .

_:807f36cf91fe4e8caa53aadeff92477632090 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632091 rdf:first _:807f36cf91fe4e8caa53aadeff92477632092;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632092 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10076 .

_:807f36cf91fe4e8caa53aadeff92477632094 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10337-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> GLUCOSAMINE"@fr;
  dct:identifier "IAM_10337";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632096;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adapation éventuelle de la posologie de l’antivitamine K."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632102, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632096 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632097 .

_:807f36cf91fe4e8caa53aadeff92477632097 rdf:first _:807f36cf91fe4e8caa53aadeff92477632098;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632099 .

_:807f36cf91fe4e8caa53aadeff92477632098 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632099 rdf:first _:807f36cf91fe4e8caa53aadeff92477632100;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632100 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10418 .

_:807f36cf91fe4e8caa53aadeff92477632102 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10339-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> HÉPARINES NON FRACTIONNÉES (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10339";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632104;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Lors du relais de l'héparine par l'antivitamine K, renforcer la surveillance clinique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632110, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632104 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632105 .

_:807f36cf91fe4e8caa53aadeff92477632105 rdf:first _:807f36cf91fe4e8caa53aadeff92477632106;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632107 .

_:807f36cf91fe4e8caa53aadeff92477632106 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632107 rdf:first _:807f36cf91fe4e8caa53aadeff92477632108;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632108 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10091 .

_:807f36cf91fe4e8caa53aadeff92477632110 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10338-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> GRISEOFULVINE"@fr;
  dct:identifier "IAM_10338";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632112;
  r:natureDuRisque "Diminution de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique par la griséofulvine."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la griséofulvine et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632118, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632112 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632113 .

_:807f36cf91fe4e8caa53aadeff92477632113 rdf:first _:807f36cf91fe4e8caa53aadeff92477632114;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632115 .

_:807f36cf91fe4e8caa53aadeff92477632114 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632115 rdf:first _:807f36cf91fe4e8caa53aadeff92477632116;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632116 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10422 .

_:807f36cf91fe4e8caa53aadeff92477632118 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10340-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> IMATINIB"@fr;
  dct:identifier "IAM_10340";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632120;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite et mesure fréquente de l'INR."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632126, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632120 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632121 .

_:807f36cf91fe4e8caa53aadeff92477632121 rdf:first _:807f36cf91fe4e8caa53aadeff92477632122;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632123 .

_:807f36cf91fe4e8caa53aadeff92477632122 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632123 rdf:first _:807f36cf91fe4e8caa53aadeff92477632124;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632124 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10448 .

_:807f36cf91fe4e8caa53aadeff92477632126 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10341-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10341";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632128;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632134, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632128 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632129 .

_:807f36cf91fe4e8caa53aadeff92477632129 rdf:first _:807f36cf91fe4e8caa53aadeff92477632130;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632131 .

_:807f36cf91fe4e8caa53aadeff92477632130 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632131 rdf:first _:807f36cf91fe4e8caa53aadeff92477632132;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632132 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff92477632134 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10371-1 a owl:Class;
  rdfs:label "APOMORPHINE <-> ONDANSETRON"@fr;
  dct:identifier "IAM_10371";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632136;
  r:natureDuRisque "Des hypotensions sévères et des pertes de connaissance ont été rapportées lors de l’association d’ondansetron avec l’apomorphine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632142, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632136 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632137 .

_:807f36cf91fe4e8caa53aadeff92477632137 rdf:first _:807f36cf91fe4e8caa53aadeff92477632138;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632139 .

_:807f36cf91fe4e8caa53aadeff92477632138 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10079 .

_:807f36cf91fe4e8caa53aadeff92477632139 rdf:first _:807f36cf91fe4e8caa53aadeff92477632140;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632140 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10665 .

_:807f36cf91fe4e8caa53aadeff92477632142 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10357-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10357";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632144;
  r:natureDuRisque "Diminution de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la rifampicine et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632150, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632144 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632145 .

_:807f36cf91fe4e8caa53aadeff92477632145 rdf:first _:807f36cf91fe4e8caa53aadeff92477632146;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632147 .

_:807f36cf91fe4e8caa53aadeff92477632146 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632147 rdf:first _:807f36cf91fe4e8caa53aadeff92477632148;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632148 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477632150 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10332-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> EFAVIRENZ"@fr;
  dct:identifier "IAM_10332";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632152;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Diminution de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632158, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632152 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632153 .

_:807f36cf91fe4e8caa53aadeff92477632153 rdf:first _:807f36cf91fe4e8caa53aadeff92477632154;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632155 .

_:807f36cf91fe4e8caa53aadeff92477632154 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632155 rdf:first _:807f36cf91fe4e8caa53aadeff92477632156;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632156 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477632158 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10359-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> SUCRALFATE"@fr;
  dct:identifier "IAM_10359";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632160;
  r:natureDuRisque "Diminution de l'absorption digestive de l'antivitamine K."@fr;
  r:conduiteATenir "Prendre le sucralfate à distance de l'antivitamine K (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632166, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632160 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632161 .

_:807f36cf91fe4e8caa53aadeff92477632161 rdf:first _:807f36cf91fe4e8caa53aadeff92477632162;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632163 .

_:807f36cf91fe4e8caa53aadeff92477632162 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632163 rdf:first _:807f36cf91fe4e8caa53aadeff92477632164;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632164 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10864 .

_:807f36cf91fe4e8caa53aadeff92477632166 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10360-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> SULFAFURAZOL"@fr;
  dct:identifier "IAM_10360";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632168;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement anti-infectieux et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632174, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632168 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632169 .

_:807f36cf91fe4e8caa53aadeff92477632169 rdf:first _:807f36cf91fe4e8caa53aadeff92477632170;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632171 .

_:807f36cf91fe4e8caa53aadeff92477632170 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632171 rdf:first _:807f36cf91fe4e8caa53aadeff92477632172;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632172 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10868 .

_:807f36cf91fe4e8caa53aadeff92477632174 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10361-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> SULFAMETHIZOL"@fr;
  dct:identifier "IAM_10361";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632176;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement anti-infectieux et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632182, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632176 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632177 .

_:807f36cf91fe4e8caa53aadeff92477632177 rdf:first _:807f36cf91fe4e8caa53aadeff92477632178;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632179 .

_:807f36cf91fe4e8caa53aadeff92477632178 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632179 rdf:first _:807f36cf91fe4e8caa53aadeff92477632180;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632180 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10870 .

_:807f36cf91fe4e8caa53aadeff92477632182 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10362-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> SULFAMETHOXAZOLE"@fr;
  dct:identifier "IAM_10362";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632184;
  r:natureDuRisque "Augmentation importante de l’effet de l’antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, contrôle plus fréquent de l’INR et adaptation de la posologie de l’antivitamine K pendant le traitement par cotrimoxazole et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632190, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632184 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632185 .

_:807f36cf91fe4e8caa53aadeff92477632185 rdf:first _:807f36cf91fe4e8caa53aadeff92477632186;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632187 .

_:807f36cf91fe4e8caa53aadeff92477632186 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632187 rdf:first _:807f36cf91fe4e8caa53aadeff92477632188;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632188 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10871 .

_:807f36cf91fe4e8caa53aadeff92477632190 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10363-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> TAMOXIFENE"@fr;
  dct:identifier "IAM_10363";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632192;
  r:natureDuRisque "Risque d'augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632198, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632192 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632193 .

_:807f36cf91fe4e8caa53aadeff92477632193 rdf:first _:807f36cf91fe4e8caa53aadeff92477632194;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632195 .

_:807f36cf91fe4e8caa53aadeff92477632194 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632195 rdf:first _:807f36cf91fe4e8caa53aadeff92477632196;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632196 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:807f36cf91fe4e8caa53aadeff92477632198 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10364-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> THROMBOLYTIQUES"@fr;
  dct:identifier "IAM_10364";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632200;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632206, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632200 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632201 .

_:807f36cf91fe4e8caa53aadeff92477632201 rdf:first _:807f36cf91fe4e8caa53aadeff92477632202;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632203 .

_:807f36cf91fe4e8caa53aadeff92477632202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632203 rdf:first _:807f36cf91fe4e8caa53aadeff92477632204;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632204 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10151 .

_:807f36cf91fe4e8caa53aadeff92477632206 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10365-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> TIBOLONE"@fr;
  dct:identifier "IAM_10365";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632208;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la tibolone et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632214, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632208 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632209 .

_:807f36cf91fe4e8caa53aadeff92477632209 rdf:first _:807f36cf91fe4e8caa53aadeff92477632210;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632211 .

_:807f36cf91fe4e8caa53aadeff92477632210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632211 rdf:first _:807f36cf91fe4e8caa53aadeff92477632212;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632212 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10925 .

_:807f36cf91fe4e8caa53aadeff92477632214 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10366-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> TRAMADOL"@fr;
  dct:identifier "IAM_10366";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632216;
  r:natureDuRisque "Risque d’augmentation de l’effet de l’antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation éventuelle de la posologie de l’antivitamine K pendant le traitement par le tramadol et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632222, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632216 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632217 .

_:807f36cf91fe4e8caa53aadeff92477632217 rdf:first _:807f36cf91fe4e8caa53aadeff92477632218;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632219 .

_:807f36cf91fe4e8caa53aadeff92477632218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632219 rdf:first _:807f36cf91fe4e8caa53aadeff92477632220;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632220 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:807f36cf91fe4e8caa53aadeff92477632222 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10367-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10367";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632224;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par voriconazole et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632230, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632224 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632225 .

_:807f36cf91fe4e8caa53aadeff92477632225 rdf:first _:807f36cf91fe4e8caa53aadeff92477632226;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632227 .

_:807f36cf91fe4e8caa53aadeff92477632226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632227 rdf:first _:807f36cf91fe4e8caa53aadeff92477632228;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632228 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477632230 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10368-1 a owl:Class;
  rdfs:label "APIXABAN <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10368";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632232;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'apixaban par le fluconazole, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632238, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632232 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632233 .

_:807f36cf91fe4e8caa53aadeff92477632233 rdf:first _:807f36cf91fe4e8caa53aadeff92477632234;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632235 .

_:807f36cf91fe4e8caa53aadeff92477632234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10078 .

_:807f36cf91fe4e8caa53aadeff92477632235 rdf:first _:807f36cf91fe4e8caa53aadeff92477632236;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632236 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477632238 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10342-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10342";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632240;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Variation de l'effet de l'antivitamine K, le plus souvent dans le sens d'une diminution."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant la durée du traitement."@fr;
  rdfs:comment """Il existe une interaction au niveau \"précaution d'emploi\" évoquant une modification de l'effet de l'anticoagulant oral, « le plus souvent dans le sens d’une diminution ». 
Il existe en effet une disproportion importante entre les cas rapportés : un seul c"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632246, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632240 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632241 .

_:807f36cf91fe4e8caa53aadeff92477632241 rdf:first _:807f36cf91fe4e8caa53aadeff92477632242;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632243 .

_:807f36cf91fe4e8caa53aadeff92477632242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477632243 rdf:first _:807f36cf91fe4e8caa53aadeff92477632244;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632244 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477632246 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10641-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> GLIMEPIRIDE"@fr;
  dct:identifier "IAM_10641";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632248;
  r:natureDuRisque "Risque d'hypoglycémie par augmentation de l’absorption et des concentrations plasmatiques de l’antidiabétique."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide hypoglycémiant pendant le traitement par la clarithromycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632254, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632248 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632249 .

_:807f36cf91fe4e8caa53aadeff92477632249 rdf:first _:807f36cf91fe4e8caa53aadeff92477632250;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632251 .

_:807f36cf91fe4e8caa53aadeff92477632250 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632251 rdf:first _:807f36cf91fe4e8caa53aadeff92477632252;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632252 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10416 .

_:807f36cf91fe4e8caa53aadeff92477632254 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10632-1 a owl:Class;
  rdfs:label "CIPROFLOXACINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10632";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632256;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage, par diminution de son métabolisme hépatique par la ciprofloxacine."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632262, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632256 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632257 .

_:807f36cf91fe4e8caa53aadeff92477632257 rdf:first _:807f36cf91fe4e8caa53aadeff92477632258;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632259 .

_:807f36cf91fe4e8caa53aadeff92477632258 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477632259 rdf:first _:807f36cf91fe4e8caa53aadeff92477632260;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632260 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:807f36cf91fe4e8caa53aadeff92477632262 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10633-1 a owl:Class;
  rdfs:label "CLADRIBINE <-> LAMIVUDINE"@fr;
  dct:identifier "IAM_10633";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632264;
  r:natureDuRisque "Risque de diminution de l’efficacité de la cladribine par la lamivudine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632270, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632264 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632265 .

_:807f36cf91fe4e8caa53aadeff92477632265 rdf:first _:807f36cf91fe4e8caa53aadeff92477632266;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632267 .

_:807f36cf91fe4e8caa53aadeff92477632266 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10205 .

_:807f36cf91fe4e8caa53aadeff92477632267 rdf:first _:807f36cf91fe4e8caa53aadeff92477632268;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632268 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10506 .

_:807f36cf91fe4e8caa53aadeff92477632270 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10656-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_10656";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632272;
  r:natureDuRisque "Risque de majoration de la toxicité de l'antimitotique par diminution de son métabolisme hépatique par la clarithromycine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique étroite. Eventuellement, utiliser un autre antibiotique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632278, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632272 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632273 .

_:807f36cf91fe4e8caa53aadeff92477632273 rdf:first _:807f36cf91fe4e8caa53aadeff92477632274;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632275 .

_:807f36cf91fe4e8caa53aadeff92477632274 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:807f36cf91fe4e8caa53aadeff92477632275 rdf:first _:807f36cf91fe4e8caa53aadeff92477632276;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632278 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10645-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> LUMEFANTRINE"@fr;
  dct:identifier "IAM_10645";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632280;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre le torsadogène associé. Si l'association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632286, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632280 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632281 .

_:807f36cf91fe4e8caa53aadeff92477632281 rdf:first _:807f36cf91fe4e8caa53aadeff92477632282;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632283 .

_:807f36cf91fe4e8caa53aadeff92477632282 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632283 rdf:first _:807f36cf91fe4e8caa53aadeff92477632284;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10541 .

_:807f36cf91fe4e8caa53aadeff92477632286 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10634-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> DEXAMETHASONE"@fr;
  dct:identifier "IAM_10634";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632288;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632294, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632288 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632289 .

_:807f36cf91fe4e8caa53aadeff92477632289 rdf:first _:807f36cf91fe4e8caa53aadeff92477632290;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632291 .

_:807f36cf91fe4e8caa53aadeff92477632290 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632291 rdf:first _:807f36cf91fe4e8caa53aadeff92477632292;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477632294 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10635-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> DIGOXINE"@fr;
  dct:identifier "IAM_10635";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632296;
  r:natureDuRisque "Augmentation de la digoxinémie par augmentation de son absorption."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la digoxinémie pendant le traitement par la clarithromycine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632302, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632296 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632297 .

_:807f36cf91fe4e8caa53aadeff92477632297 rdf:first _:807f36cf91fe4e8caa53aadeff92477632298;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632299 .

_:807f36cf91fe4e8caa53aadeff92477632298 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632299 rdf:first _:807f36cf91fe4e8caa53aadeff92477632300;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477632302 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10636-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> EBASTINE"@fr;
  dct:identifier "IAM_10636";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632304;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire chez les sujets prédisposés (syndrome du QT long congénital)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632310, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632304 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632305 .

_:807f36cf91fe4e8caa53aadeff92477632305 rdf:first _:807f36cf91fe4e8caa53aadeff92477632306;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632307 .

_:807f36cf91fe4e8caa53aadeff92477632306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632307 rdf:first _:807f36cf91fe4e8caa53aadeff92477632308;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10316 .

_:807f36cf91fe4e8caa53aadeff92477632310 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10637-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> ÉRIBULINE"@fr;
  dct:identifier "IAM_10637";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632312;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’éribuline par la clarithromycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632318, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632312 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632313 .

_:807f36cf91fe4e8caa53aadeff92477632313 rdf:first _:807f36cf91fe4e8caa53aadeff92477632314;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632315 .

_:807f36cf91fe4e8caa53aadeff92477632314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632315 rdf:first _:807f36cf91fe4e8caa53aadeff92477632316;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10335 .

_:807f36cf91fe4e8caa53aadeff92477632318 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10638-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> ETRAVIRINE"@fr;
  dct:identifier "IAM_10638";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632320;
  r:natureDuRisque "Dans le traitement des infections à Mycobacterium avium complex, risque de diminution de l’efficacité de la clarithromycine par augmentation de son métabolisme hépatique par l’étravirine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632326, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632320 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632321 .

_:807f36cf91fe4e8caa53aadeff92477632321 rdf:first _:807f36cf91fe4e8caa53aadeff92477632322;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632323 .

_:807f36cf91fe4e8caa53aadeff92477632322 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632323 rdf:first _:807f36cf91fe4e8caa53aadeff92477632324;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10360 .

_:807f36cf91fe4e8caa53aadeff92477632326 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10607-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_10607";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632328;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du ténofovir alafénamide par augmentation de son absorption."@fr;
  r:conduiteATenir "En cas de co-administration avec la ciclosporine, la dose de ténofovir alafénamide doit être limitée à 10 mg par jour."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632334, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632328 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632329 .

_:807f36cf91fe4e8caa53aadeff92477632329 rdf:first _:807f36cf91fe4e8caa53aadeff92477632330;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632331 .

_:807f36cf91fe4e8caa53aadeff92477632330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477632331 rdf:first _:807f36cf91fe4e8caa53aadeff92477632332;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff92477632334 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10640-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> GLIBENCLAMIDE"@fr;
  dct:identifier "IAM_10640";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632336;
  r:natureDuRisque "Risque d'hypoglycémie par augmentation de l’absorption et des concentrations plasmatiques de l’antidiabétique."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide hypoglycémiant pendant le traitement par la clarithromycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632342, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632336 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632337 .

_:807f36cf91fe4e8caa53aadeff92477632337 rdf:first _:807f36cf91fe4e8caa53aadeff92477632338;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632339 .

_:807f36cf91fe4e8caa53aadeff92477632338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632339 rdf:first _:807f36cf91fe4e8caa53aadeff92477632340;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10414 .

_:807f36cf91fe4e8caa53aadeff92477632342 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10629-1 a owl:Class;
  rdfs:label "CIPROFLOXACINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10629";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632344;
  r:natureDuRisque """Variation, éventuellement importante, des concentrations de
phénytoïne en cas de traitement par la ciprofloxacine."""@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques de l’anticonvulsivant pendant le traitement par ciprofloxacine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632350, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632344 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632345 .

_:807f36cf91fe4e8caa53aadeff92477632345 rdf:first _:807f36cf91fe4e8caa53aadeff92477632346;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632347 .

_:807f36cf91fe4e8caa53aadeff92477632346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477632347 rdf:first _:807f36cf91fe4e8caa53aadeff92477632348;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:807f36cf91fe4e8caa53aadeff92477632350 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10642-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10642";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632352;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation éventuelle de la posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632358, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632352 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632353 .

_:807f36cf91fe4e8caa53aadeff92477632353 rdf:first _:807f36cf91fe4e8caa53aadeff92477632354;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632355 .

_:807f36cf91fe4e8caa53aadeff92477632354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477632355 rdf:first _:807f36cf91fe4e8caa53aadeff92477632356;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632358 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10643-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10643";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632360;
  r:natureDuRisque "Augmentation des concentrations de la clarithromycine et de son métabolite actif par diminution de son métabolisme hépatique par l'inhibiteur de protéases."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632366, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632360 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632361 .

_:807f36cf91fe4e8caa53aadeff92477632361 rdf:first _:807f36cf91fe4e8caa53aadeff92477632362;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632363 .

_:807f36cf91fe4e8caa53aadeff92477632362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477632363 rdf:first _:807f36cf91fe4e8caa53aadeff92477632364;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632366 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10644-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> LINEZOLIDE"@fr;
  dct:identifier "IAM_10644";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632368;
  r:natureDuRisque "Risque de majoration des effets indésirables du linézolide par la clarithromycine, par augmentation de son absorption."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632374, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632368 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632369 .

_:807f36cf91fe4e8caa53aadeff92477632369 rdf:first _:807f36cf91fe4e8caa53aadeff92477632370;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632371 .

_:807f36cf91fe4e8caa53aadeff92477632370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632371 rdf:first _:807f36cf91fe4e8caa53aadeff92477632372;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10526 .

_:807f36cf91fe4e8caa53aadeff92477632374 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10646-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> MIZOLASTINE"@fr;
  dct:identifier "IAM_10646";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632376;
  r:natureDuRisque "Risque de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632382, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632376 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632377 .

_:807f36cf91fe4e8caa53aadeff92477632377 rdf:first _:807f36cf91fe4e8caa53aadeff92477632378;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632379 .

_:807f36cf91fe4e8caa53aadeff92477632378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632379 rdf:first _:807f36cf91fe4e8caa53aadeff92477632380;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10597 .

_:807f36cf91fe4e8caa53aadeff92477632382 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10647-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> PRAVASTATINE"@fr;
  dct:identifier "IAM_10647";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632384;
  r:natureDuRisque "Augmentation de la concentration plasmatique de la pravastatine par la clarithromycine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique pendant le traitement par l'antibiotique."@fr;
  rdfs:comment "La clarithromycine et l’érythromycine sont des inhibiteurs puissants du CYP3A4 et de la P-gp intestinale, transporteur qui intervient dans l’efflux de nombreux médicaments au niveau de la lumière intestinale et qui limite donc leur absorption digestive. L"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632390, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632384 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632385 .

_:807f36cf91fe4e8caa53aadeff92477632385 rdf:first _:807f36cf91fe4e8caa53aadeff92477632386;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632387 .

_:807f36cf91fe4e8caa53aadeff92477632386 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632387 rdf:first _:807f36cf91fe4e8caa53aadeff92477632388;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10748 .

_:807f36cf91fe4e8caa53aadeff92477632390 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10648-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> REPAGLINIDE"@fr;
  dct:identifier "IAM_10648";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632392;
  r:natureDuRisque "Risque d'hypoglycémie par augmentation des concentrations plasmatiques du répaglinide."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie de l'hypoglycémiant pendant le traitement par la clarithromycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632398, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632392 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632393 .

_:807f36cf91fe4e8caa53aadeff92477632393 rdf:first _:807f36cf91fe4e8caa53aadeff92477632394;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632395 .

_:807f36cf91fe4e8caa53aadeff92477632394 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632395 rdf:first _:807f36cf91fe4e8caa53aadeff92477632396;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:807f36cf91fe4e8caa53aadeff92477632398 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10649-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> RIFABUTINE"@fr;
  dct:identifier "IAM_10649";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632400;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la rifabutine (uvéites) par augmentation de ses concentrations et de celle de son métabolite actif par la clarithromycine. De plus, augmentation du métabolisme de la clarithromycine par la rifabutine, avec"@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632406, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632400 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632401 .

_:807f36cf91fe4e8caa53aadeff92477632401 rdf:first _:807f36cf91fe4e8caa53aadeff92477632402;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632403 .

_:807f36cf91fe4e8caa53aadeff92477632402 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632403 rdf:first _:807f36cf91fe4e8caa53aadeff92477632404;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff92477632406 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10650-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10650";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632408;
  r:natureDuRisque "Diminution des concentrations plasmatiques et risque de baisse de l'efficacité de la clarithromycine, notamment chez le patient HIV, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632414, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632408 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632409 .

_:807f36cf91fe4e8caa53aadeff92477632409 rdf:first _:807f36cf91fe4e8caa53aadeff92477632410;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632411 .

_:807f36cf91fe4e8caa53aadeff92477632410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632411 rdf:first _:807f36cf91fe4e8caa53aadeff92477632412;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477632414 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10651-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10651";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632416;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632422, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632416 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632417 .

_:807f36cf91fe4e8caa53aadeff92477632417 rdf:first _:807f36cf91fe4e8caa53aadeff92477632418;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632419 .

_:807f36cf91fe4e8caa53aadeff92477632418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632419 rdf:first _:807f36cf91fe4e8caa53aadeff92477632420;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477632422 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10639-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> FIDAXOMICINE"@fr;
  dct:identifier "IAM_10639";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632424;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632430, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632424 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632425 .

_:807f36cf91fe4e8caa53aadeff92477632425 rdf:first _:807f36cf91fe4e8caa53aadeff92477632426;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632427 .

_:807f36cf91fe4e8caa53aadeff92477632426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632427 rdf:first _:807f36cf91fe4e8caa53aadeff92477632428;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:807f36cf91fe4e8caa53aadeff92477632430 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10619-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10619";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632432;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation des concentrations plasmatiques de phénytoïne avec possibilité d'apparition des signes habituels de surdosage."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite, dosage des concentrations plasmatiques de phénytoïne et adaptation éventuelle de sa posologie pendant le traitement par la cimétidine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632438, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632432 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632433 .

_:807f36cf91fe4e8caa53aadeff92477632433 rdf:first _:807f36cf91fe4e8caa53aadeff92477632434;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632435 .

_:807f36cf91fe4e8caa53aadeff92477632434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477632435 rdf:first _:807f36cf91fe4e8caa53aadeff92477632436;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477632438 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10520-1 a owl:Class;
  rdfs:label "CABAZITAXEL <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10520";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632440;
  r:natureDuRisque "Risque de majoration des effets indésirables dose-dépendants du cabazitaxel par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du cabazitaxel pendant le traitement par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632446, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632440 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632441 .

_:807f36cf91fe4e8caa53aadeff92477632441 rdf:first _:807f36cf91fe4e8caa53aadeff92477632442;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632443 .

_:807f36cf91fe4e8caa53aadeff92477632442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477632443 rdf:first _:807f36cf91fe4e8caa53aadeff92477632444;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477632446 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10609-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> TICLOPIDINE"@fr;
  dct:identifier "IAM_10609";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632448;
  r:natureDuRisque "Diminution des concentrations sanguines de ciclosporine."@fr;
  r:conduiteATenir "Augmentation de la posologie de la ciclosporine sous contrôle des concentrations sanguines. Réduction de la posologie en cas d'arrêt de la ticlopidine."@fr;
  rdfs:comment """L'essentiel des publications repose sur des cas isolés, trois d'entre eux comportant la notion d'une réintroduction positive. 
Dans une étude chez 20 patients transplantés cardiaques recevant de la ticlopidine, les ciclosporinémies n'ont en moyenne pas va"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632454, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632448 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632449 .

_:807f36cf91fe4e8caa53aadeff92477632449 rdf:first _:807f36cf91fe4e8caa53aadeff92477632450;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632451 .

_:807f36cf91fe4e8caa53aadeff92477632450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477632451 rdf:first _:807f36cf91fe4e8caa53aadeff92477632452;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10928 .

_:807f36cf91fe4e8caa53aadeff92477632454 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10610-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> TRIMETHOPRIME"@fr;
  dct:identifier "IAM_10610";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632456;
  r:natureDuRisque """Avec le triméthoprime (seul ou associé) par voie orale : augmentation de la créatininémie avec diminution possible des concentrations sanguines de ciclosporine.

Avec le trimethoprime (seul ou associé) par voie IV : la diminution des concentrations sangui"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632462, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632456 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632457 .

_:807f36cf91fe4e8caa53aadeff92477632457 rdf:first _:807f36cf91fe4e8caa53aadeff92477632458;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632459 .

_:807f36cf91fe4e8caa53aadeff92477632458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477632459 rdf:first _:807f36cf91fe4e8caa53aadeff92477632460;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10955 .

_:807f36cf91fe4e8caa53aadeff92477632462 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10611-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10611";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632464;
  r:natureDuRisque "Augmentation des concentrations sanguines de la ciclosporine (diminution de son métabolisme hépatique), et majoration du risque de gingivopathies."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de la ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632470, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632464 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632465 .

_:807f36cf91fe4e8caa53aadeff92477632465 rdf:first _:807f36cf91fe4e8caa53aadeff92477632466;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632467 .

_:807f36cf91fe4e8caa53aadeff92477632466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477632467 rdf:first _:807f36cf91fe4e8caa53aadeff92477632468;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477632470 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10612-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> DIAZEPAM"@fr;
  dct:identifier "IAM_10612";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632472;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : risque accru de somnolence."@fr;
  r:conduiteATenir "Avertir les patients de l'augmentation du risque en cas de conduite automobile ou d'utilisation de machines."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632478, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632472 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632473 .

_:807f36cf91fe4e8caa53aadeff92477632473 rdf:first _:807f36cf91fe4e8caa53aadeff92477632474;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632475 .

_:807f36cf91fe4e8caa53aadeff92477632474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477632475 rdf:first _:807f36cf91fe4e8caa53aadeff92477632476;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10280 .

_:807f36cf91fe4e8caa53aadeff92477632478 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10613-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> LIDOCAINE"@fr;
  dct:identifier "IAM_10613";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632480;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation des concentrations plasmatiques de lidocaïne avec risque d'effets indésirables neurologiques et cardiaques (inhibition du métabolisme hépatique de la lidocaïne)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement des concentrations plasmatiques de la lidocaïne ; s'il y a lieu, adaptation de la posologie de la lidocaïne pendant le traitement par la cimétidine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632486, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632480 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632481 .

_:807f36cf91fe4e8caa53aadeff92477632481 rdf:first _:807f36cf91fe4e8caa53aadeff92477632482;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632483 .

_:807f36cf91fe4e8caa53aadeff92477632482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477632483 rdf:first _:807f36cf91fe4e8caa53aadeff92477632484;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10523 .

_:807f36cf91fe4e8caa53aadeff92477632486 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10614-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> LOMUSTINE"@fr;
  dct:identifier "IAM_10614";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632488;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : toxicité médullaire accrue (inhibition du métabolisme de la lomustine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632494, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632488 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632489 .

_:807f36cf91fe4e8caa53aadeff92477632489 rdf:first _:807f36cf91fe4e8caa53aadeff92477632490;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632491 .

_:807f36cf91fe4e8caa53aadeff92477632490 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477632491 rdf:first _:807f36cf91fe4e8caa53aadeff92477632492;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10534 .

_:807f36cf91fe4e8caa53aadeff92477632494 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10615-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> METHADONE"@fr;
  dct:identifier "IAM_10615";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632496;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de méthadone avec surdosage et risque majoré d’allongement de l’intervalle QT et de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique renforcée ; si besoin, adaptation de la posologie de la méthadone pendant le traitement par la cimétidine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632502, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632496 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632497 .

_:807f36cf91fe4e8caa53aadeff92477632497 rdf:first _:807f36cf91fe4e8caa53aadeff92477632498;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632499 .

_:807f36cf91fe4e8caa53aadeff92477632498 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477632499 rdf:first _:807f36cf91fe4e8caa53aadeff92477632500;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff92477632502 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10616-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> METOPROLOL"@fr;
  dct:identifier "IAM_10616";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632504;
  r:natureDuRisque "Avec le métoprolol utilisé dans l'insuffisance cardiaque, et la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation des concentrations du métoprolol, pouvant être préjudiciables dans le cas du traitement de l'insuffisance cardi"@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du métoprolol pendant le traitement par la cimétidine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632510, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632504 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632505 .

_:807f36cf91fe4e8caa53aadeff92477632505 rdf:first _:807f36cf91fe4e8caa53aadeff92477632506;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632507 .

_:807f36cf91fe4e8caa53aadeff92477632506 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477632507 rdf:first _:807f36cf91fe4e8caa53aadeff92477632508;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477632510 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10631-1 a owl:Class;
  rdfs:label "CIPROFLOXACINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10631";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632512;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Surveillance clinique et électrocardiographique pendant
l'association."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632518, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632512 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632513 .

_:807f36cf91fe4e8caa53aadeff92477632513 rdf:first _:807f36cf91fe4e8caa53aadeff92477632514;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632515 .

_:807f36cf91fe4e8caa53aadeff92477632514 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477632515 rdf:first _:807f36cf91fe4e8caa53aadeff92477632516;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:807f36cf91fe4e8caa53aadeff92477632518 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10618-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> NIFEDIPINE"@fr;
  dct:identifier "IAM_10618";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632520;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation de l'effet hypotenseur de la nifédipine par inhibition de son métabolisme hépatique par la cimétidine."@fr;
  r:conduiteATenir "Surveillance clinique accrue : adapter la posologie de la nifédipine pendant le tratiement par la cimétidine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632526, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632520 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632521 .

_:807f36cf91fe4e8caa53aadeff92477632521 rdf:first _:807f36cf91fe4e8caa53aadeff92477632522;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632523 .

_:807f36cf91fe4e8caa53aadeff92477632522 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477632523 rdf:first _:807f36cf91fe4e8caa53aadeff92477632524;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10633 .

_:807f36cf91fe4e8caa53aadeff92477632526 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10630-1 a owl:Class;
  rdfs:label "CIPROFLOXACINE <-> ROPINIROLE"@fr;
  dct:identifier "IAM_10630";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632528;
  r:natureDuRisque "Augmentation des concentrations de ropinirole avec risque de surdosage, par diminution de son métabolisme hépatique par la ciprofloxacine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie du ropinirole pendant le traitement par la ciprofloxacine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632534, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632528 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632529 .

_:807f36cf91fe4e8caa53aadeff92477632529 rdf:first _:807f36cf91fe4e8caa53aadeff92477632530;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632531 .

_:807f36cf91fe4e8caa53aadeff92477632530 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:807f36cf91fe4e8caa53aadeff92477632531 rdf:first _:807f36cf91fe4e8caa53aadeff92477632532;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10813 .

_:807f36cf91fe4e8caa53aadeff92477632534 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10620-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10620";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632536;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation de la théophyllinémie avec risque de surdosage (diminution du métabolisme de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie. S'il y a lieu, adaptation de la théophylline pendant le traitement par la cimétidine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632542, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632536 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632537 .

_:807f36cf91fe4e8caa53aadeff92477632537 rdf:first _:807f36cf91fe4e8caa53aadeff92477632538;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632539 .

_:807f36cf91fe4e8caa53aadeff92477632538 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477632539 rdf:first _:807f36cf91fe4e8caa53aadeff92477632540;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477632542 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10621-1 a owl:Class;
  rdfs:label "CINACALCET <-> DEXTROMETHORPHANE"@fr;
  dct:identifier "IAM_10621";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632544;
  r:natureDuRisque "Augmentation très importante des concentrations plasmatiques de dextrométhorphane avec risque de surdosage, par diminution de son métabolisme hépatique par le cinacalcet."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632550, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632544 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632545 .

_:807f36cf91fe4e8caa53aadeff92477632545 rdf:first _:807f36cf91fe4e8caa53aadeff92477632546;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632547 .

_:807f36cf91fe4e8caa53aadeff92477632546 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10197 .

_:807f36cf91fe4e8caa53aadeff92477632547 rdf:first _:807f36cf91fe4e8caa53aadeff92477632548;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10278 .

_:807f36cf91fe4e8caa53aadeff92477632550 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10622-1 a owl:Class;
  rdfs:label "CINACALCET <-> FLECAINIDE"@fr;
  dct:identifier "IAM_10622";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632552;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de flécaïnide avec risque de surdosage, par diminution de son métabolisme hépatique par le cinacalcet."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du flécaïnide pendant le traitement par cinacalcet."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632558, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632552 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632553 .

_:807f36cf91fe4e8caa53aadeff92477632553 rdf:first _:807f36cf91fe4e8caa53aadeff92477632554;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632555 .

_:807f36cf91fe4e8caa53aadeff92477632554 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10197 .

_:807f36cf91fe4e8caa53aadeff92477632555 rdf:first _:807f36cf91fe4e8caa53aadeff92477632556;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:807f36cf91fe4e8caa53aadeff92477632558 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10624-1 a owl:Class;
  rdfs:label "CINACALCET <-> METOPROLOL"@fr;
  dct:identifier "IAM_10624";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632560;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de métroprolol avec risque de surdosage, par diminution de son métabolisme hépatique par le cinacalcet."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du métroprolol pendant le traitement par cinacalcet."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632566, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632560 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632561 .

_:807f36cf91fe4e8caa53aadeff92477632561 rdf:first _:807f36cf91fe4e8caa53aadeff92477632562;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632563 .

_:807f36cf91fe4e8caa53aadeff92477632562 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10197 .

_:807f36cf91fe4e8caa53aadeff92477632563 rdf:first _:807f36cf91fe4e8caa53aadeff92477632564;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477632566 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10623-1 a owl:Class;
  rdfs:label "CINACALCET <-> MEQUITAZINE"@fr;
  dct:identifier "IAM_10623";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632568;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méquitazine, par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632574, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632568 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632569 .

_:807f36cf91fe4e8caa53aadeff92477632569 rdf:first _:807f36cf91fe4e8caa53aadeff92477632570;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632571 .

_:807f36cf91fe4e8caa53aadeff92477632570 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10197 .

_:807f36cf91fe4e8caa53aadeff92477632571 rdf:first _:807f36cf91fe4e8caa53aadeff92477632572;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10561 .

_:807f36cf91fe4e8caa53aadeff92477632574 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10625-1 a owl:Class;
  rdfs:label "CINACALCET <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10625";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632576;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de propafénone avec risque de surdosage, par diminution de son métabolisme hépatique par le cinacalcet."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie de la propafénone pendant le traitement par cinacalcet."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632582, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632576 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632577 .

_:807f36cf91fe4e8caa53aadeff92477632577 rdf:first _:807f36cf91fe4e8caa53aadeff92477632578;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632579 .

_:807f36cf91fe4e8caa53aadeff92477632578 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10197 .

_:807f36cf91fe4e8caa53aadeff92477632579 rdf:first _:807f36cf91fe4e8caa53aadeff92477632580;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477632582 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10626-1 a owl:Class;
  rdfs:label "CINACALCET <-> VORTIOXÉTINE"@fr;
  dct:identifier "IAM_10626";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632584;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la vortioxétine par diminution importante de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la vortioxétine pendant le traitement par le cinacalcet et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632590, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632584 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632585 .

_:807f36cf91fe4e8caa53aadeff92477632585 rdf:first _:807f36cf91fe4e8caa53aadeff92477632586;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632587 .

_:807f36cf91fe4e8caa53aadeff92477632586 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10197 .

_:807f36cf91fe4e8caa53aadeff92477632587 rdf:first _:807f36cf91fe4e8caa53aadeff92477632588;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10999 .

_:807f36cf91fe4e8caa53aadeff92477632590 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10627-1 a owl:Class;
  rdfs:label "CIPROFLOXACINE <-> CLOZAPINE"@fr;
  dct:identifier "IAM_10627";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632592;
  r:natureDuRisque "Augmentation des concentrations de clozapine avec risque de surdosage, par diminution de son métabolisme hépatique par la ciprofloxacine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de la clozapine pendant le traitement par la ciprofloxacine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632598, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632592 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632593 .

_:807f36cf91fe4e8caa53aadeff92477632593 rdf:first _:807f36cf91fe4e8caa53aadeff92477632594;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632595 .

_:807f36cf91fe4e8caa53aadeff92477632594 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:807f36cf91fe4e8caa53aadeff92477632595 rdf:first _:807f36cf91fe4e8caa53aadeff92477632596;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10220 .

_:807f36cf91fe4e8caa53aadeff92477632598 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10628-1 a owl:Class;
  rdfs:label "CIPROFLOXACINE <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10628";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632600;
  r:natureDuRisque "Augmentation de la toxicité du méthotrexate par inhibition de sa sécrétion tubulaire rénale par la ciprofloxacine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632606, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632600 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632601 .

_:807f36cf91fe4e8caa53aadeff92477632601 rdf:first _:807f36cf91fe4e8caa53aadeff92477632602;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632603 .

_:807f36cf91fe4e8caa53aadeff92477632602 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:807f36cf91fe4e8caa53aadeff92477632603 rdf:first _:807f36cf91fe4e8caa53aadeff92477632604;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477632606 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10654-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10654";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632608;
  r:natureDuRisque "Risque d'augmentation de la théophyllinémie, particulièrement chez l'enfant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632614, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632608 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632609 .

_:807f36cf91fe4e8caa53aadeff92477632609 rdf:first _:807f36cf91fe4e8caa53aadeff92477632610;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632611 .

_:807f36cf91fe4e8caa53aadeff92477632610 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477632611 rdf:first _:807f36cf91fe4e8caa53aadeff92477632612;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632614 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10617-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> MOCLOBEMIDE"@fr;
  dct:identifier "IAM_10617";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632616;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation des concentrations du moclobémide, par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique avec adaptation éventuelle de la posologie de moclobémide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632622, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632616 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632617 .

_:807f36cf91fe4e8caa53aadeff92477632617 rdf:first _:807f36cf91fe4e8caa53aadeff92477632618;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632619 .

_:807f36cf91fe4e8caa53aadeff92477632618 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477632619 rdf:first _:807f36cf91fe4e8caa53aadeff92477632620;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10598 .

_:807f36cf91fe4e8caa53aadeff92477632622 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10703-1 a owl:Class;
  rdfs:label "CYTOTOXIQUES <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10703";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632624;
  r:natureDuRisque "Risque de survenue de convulsions par diminution de l'absorption digestive de la seule phénytoïne par le cytotoxique, ou bien risque de majoration de la toxicité ou de perte d'efficacité du cytotoxique par augmentation de son métabolisme hépatique par la"@fr;
  rdfs:comment "Deux niveaux de contrainte distincts avaient été retenus entre les cytotoxiques et la phénytoïne, selon que l'anticonvulsivant était administré antérieurement à la chimiothérapie (conduisant alors à une précaution d’emploi) ou qu'il aurait pu être donné à"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632630, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632624 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632625 .

_:807f36cf91fe4e8caa53aadeff92477632625 rdf:first _:807f36cf91fe4e8caa53aadeff92477632626;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632627 .

_:807f36cf91fe4e8caa53aadeff92477632626 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10060 .

_:807f36cf91fe4e8caa53aadeff92477632627 rdf:first _:807f36cf91fe4e8caa53aadeff92477632628;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477632630 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10652-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10652";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632632;
  r:natureDuRisque """Risque majoré de troubles du rythme ventriculaire, notamment de
torsades de pointes."""@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632638, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632632 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632633 .

_:807f36cf91fe4e8caa53aadeff92477632633 rdf:first _:807f36cf91fe4e8caa53aadeff92477632634;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632635 .

_:807f36cf91fe4e8caa53aadeff92477632634 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477632635 rdf:first _:807f36cf91fe4e8caa53aadeff92477632636;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632638 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10693-1 a owl:Class;
  rdfs:label "CYCLINES <-> VITAMINE A"@fr;
  dct:identifier "IAM_10693";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632640;
  r:natureDuRisque "En cas d'apport de 10,000 UI/j et plus : risque d’hypertension intracrânienne."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632646, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632640 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632641 .

_:807f36cf91fe4e8caa53aadeff92477632641 rdf:first _:807f36cf91fe4e8caa53aadeff92477632642;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632643 .

_:807f36cf91fe4e8caa53aadeff92477632642 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:807f36cf91fe4e8caa53aadeff92477632643 rdf:first _:807f36cf91fe4e8caa53aadeff92477632644;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10997 .

_:807f36cf91fe4e8caa53aadeff92477632646 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10694-1 a owl:Class;
  rdfs:label "CYCLINES <-> ZINC"@fr;
  dct:identifier "IAM_10694";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632648;
  r:natureDuRisque "Diminution de l'absorption digestive des cyclines."@fr;
  r:conduiteATenir "Prendre les sels de zinc à distance des cyclines (plus de 2 heures si possible)."@fr;
  rdfs:comment """Le zinc est utilisé dans le traitement de l’acné inflammatoire macrokystique et/ou nodulaire ainsi que dans le traitement des acrodermatites entéropathiques. Comme le fer et le calcium, il peut chélater les tétracyclines et diminuer leur efficacité. 
Cett"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632654, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632648 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632649 .

_:807f36cf91fe4e8caa53aadeff92477632649 rdf:first _:807f36cf91fe4e8caa53aadeff92477632650;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632651 .

_:807f36cf91fe4e8caa53aadeff92477632650 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:807f36cf91fe4e8caa53aadeff92477632651 rdf:first _:807f36cf91fe4e8caa53aadeff92477632652;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11005 .

_:807f36cf91fe4e8caa53aadeff92477632654 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10695-1 a owl:Class;
  rdfs:label "CYCLOPHOSPHAMIDE <-> PENTOSTATINE"@fr;
  dct:identifier "IAM_10695";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632656;
  r:natureDuRisque "Majoration du risque de toxicité pulmonaire pouvant être fatale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632662, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632656 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632657 .

_:807f36cf91fe4e8caa53aadeff92477632657 rdf:first _:807f36cf91fe4e8caa53aadeff92477632658;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632659 .

_:807f36cf91fe4e8caa53aadeff92477632658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10235 .

_:807f36cf91fe4e8caa53aadeff92477632659 rdf:first _:807f36cf91fe4e8caa53aadeff92477632660;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10704 .

_:807f36cf91fe4e8caa53aadeff92477632662 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10696-1 a owl:Class;
  rdfs:label "CYPROHEPTADINE <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_10696";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632664;
  r:natureDuRisque "Risque de diminution de l'efficacité de l'antidépresseur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632670, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632664 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632665 .

_:807f36cf91fe4e8caa53aadeff92477632665 rdf:first _:807f36cf91fe4e8caa53aadeff92477632666;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632667 .

_:807f36cf91fe4e8caa53aadeff92477632666 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477632667 rdf:first _:807f36cf91fe4e8caa53aadeff92477632668;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632668 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10237 .

_:807f36cf91fe4e8caa53aadeff92477632670 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10697-1 a owl:Class;
  rdfs:label "CYPROTERONE <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10697";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632672;
  r:natureDuRisque "Risque de diminution de l'efficacité de la cyprotérone."@fr;
  r:conduiteATenir """Association déconseillée:
- dans son utilisation comme contraceptif hormonal: utiliser de préférence une autre méthode de contraception en particulier de type mécanique, pendant la durée de l'association et un cycle suivant.

Précaution d'emploi
- dans se"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632678, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632672 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632673 .

_:807f36cf91fe4e8caa53aadeff92477632673 rdf:first _:807f36cf91fe4e8caa53aadeff92477632674;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632675 .

_:807f36cf91fe4e8caa53aadeff92477632674 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477632675 rdf:first _:807f36cf91fe4e8caa53aadeff92477632676;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632676 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff92477632678 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10698-1 a owl:Class;
  rdfs:label "CYPROTERONE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10698";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632680;
  r:natureDuRisque "Risque de diminution de l'efficacité de la cyprotérone."@fr;
  r:conduiteATenir """Association déconseillée
- dans son utilisation comme contraceptif hormonal: utiliser de préférence une autre méthode de contraception en particulier de type mécanique, pendant la durée de l'association et un cycle suivant.

Précaution d'emploi
- dans ses"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632686, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632680 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632681 .

_:807f36cf91fe4e8caa53aadeff92477632681 rdf:first _:807f36cf91fe4e8caa53aadeff92477632682;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632683 .

_:807f36cf91fe4e8caa53aadeff92477632682 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477632683 rdf:first _:807f36cf91fe4e8caa53aadeff92477632684;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632684 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff92477632686 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10699-1 a owl:Class;
  rdfs:label "CYPROTERONE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10699";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632688;
  r:natureDuRisque "Risque de diminution de l'efficacité de la cyprotérone, par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632694, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632688 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632689 .

_:807f36cf91fe4e8caa53aadeff92477632689 rdf:first _:807f36cf91fe4e8caa53aadeff92477632690;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632691 .

_:807f36cf91fe4e8caa53aadeff92477632690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff92477632691 rdf:first _:807f36cf91fe4e8caa53aadeff92477632692;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632692 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477632694 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10700-1 a owl:Class;
  rdfs:label "CYPROTERONE <-> PÉRAMPANEL"@fr;
  dct:identifier "IAM_10700";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632696;
  r:natureDuRisque "Pour des doses de pérampanel > ou = à 12 mg/jour, risque de diminution de l'efficacité de la cyprotérone."@fr;
  r:conduiteATenir "Dans son utilisation comme contraceptif hormonal: utiliser de préférence une autre méthode de contraception en particulier de type mécanique, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632702, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632696 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632697 .

_:807f36cf91fe4e8caa53aadeff92477632697 rdf:first _:807f36cf91fe4e8caa53aadeff92477632698;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632699 .

_:807f36cf91fe4e8caa53aadeff92477632698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff92477632699 rdf:first _:807f36cf91fe4e8caa53aadeff92477632700;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632700 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10706 .

_:807f36cf91fe4e8caa53aadeff92477632702 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10691-1 a owl:Class;
  rdfs:label "CYCLINES <-> RÉTINOÏDES"@fr;
  dct:identifier "IAM_10691";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632704;
  r:natureDuRisque "Risque d'hypertension intracrânienne."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632710, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632704 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632705 .

_:807f36cf91fe4e8caa53aadeff92477632705 rdf:first _:807f36cf91fe4e8caa53aadeff92477632706;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632707 .

_:807f36cf91fe4e8caa53aadeff92477632706 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:807f36cf91fe4e8caa53aadeff92477632707 rdf:first _:807f36cf91fe4e8caa53aadeff92477632708;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632708 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff92477632710 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10702-1 a owl:Class;
  rdfs:label "CYTOTOXIQUES <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10702";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632712;
  r:natureDuRisque "Immunodépression excessive avec risque de syndrome lympho-prolifératif."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632718, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632712 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632713 .

_:807f36cf91fe4e8caa53aadeff92477632713 rdf:first _:807f36cf91fe4e8caa53aadeff92477632714;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632715 .

_:807f36cf91fe4e8caa53aadeff92477632714 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10060 .

_:807f36cf91fe4e8caa53aadeff92477632715 rdf:first _:807f36cf91fe4e8caa53aadeff92477632716;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632716 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477632718 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10690-1 a owl:Class;
  rdfs:label "CYCLINES <-> FER"@fr;
  dct:identifier "IAM_10690";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632720;
  r:natureDuRisque "Avec les cyclines utilisées par voie orale : diminution de l'absorption digestive des cyclines (formation de complexes)."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance des cyclines (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632726, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632720 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632721 .

_:807f36cf91fe4e8caa53aadeff92477632721 rdf:first _:807f36cf91fe4e8caa53aadeff92477632722;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632723 .

_:807f36cf91fe4e8caa53aadeff92477632722 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:807f36cf91fe4e8caa53aadeff92477632723 rdf:first _:807f36cf91fe4e8caa53aadeff92477632724;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632724 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477632726 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10704-1 a owl:Class;
  rdfs:label "CYTOTOXIQUES <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10704";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632728;
  r:natureDuRisque "Risque de maladie vaccinale généralisée éventuellement mortelle."@fr;
  r:conduiteATenir """- Et pendant les 6 mois suivant l'arrêt de la chimiothérapie.

- Et, à l'exception de l'hydroxycarbamide dans son indication chez le patient drépanocytaire."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632734, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632728 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632729 .

_:807f36cf91fe4e8caa53aadeff92477632729 rdf:first _:807f36cf91fe4e8caa53aadeff92477632730;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632731 .

_:807f36cf91fe4e8caa53aadeff92477632730 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10060 .

_:807f36cf91fe4e8caa53aadeff92477632731 rdf:first _:807f36cf91fe4e8caa53aadeff92477632732;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632732 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477632734 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10705-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> DRONEDARONE"@fr;
  dct:identifier "IAM_10705";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632736;
  r:natureDuRisque "Doublement des concentrations plasmatiques de dabigatran, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632742, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632736 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632737 .

_:807f36cf91fe4e8caa53aadeff92477632737 rdf:first _:807f36cf91fe4e8caa53aadeff92477632738;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632739 .

_:807f36cf91fe4e8caa53aadeff92477632738 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff92477632739 rdf:first _:807f36cf91fe4e8caa53aadeff92477632740;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632740 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477632742 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10706-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10706";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632744;
  r:natureDuRisque "Augmentation de plus du double des concentrations plasmatiques de dabigatran, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632750, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632744 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632745 .

_:807f36cf91fe4e8caa53aadeff92477632745 rdf:first _:807f36cf91fe4e8caa53aadeff92477632746;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632747 .

_:807f36cf91fe4e8caa53aadeff92477632746 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff92477632747 rdf:first _:807f36cf91fe4e8caa53aadeff92477632748;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632748 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477632750 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10707-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10707";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632752;
  r:natureDuRisque "Augmentation de plus du double des concentrations plasmatiques de dabigatran, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632758, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632752 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632753 .

_:807f36cf91fe4e8caa53aadeff92477632753 rdf:first _:807f36cf91fe4e8caa53aadeff92477632754;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632755 .

_:807f36cf91fe4e8caa53aadeff92477632754 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff92477632755 rdf:first _:807f36cf91fe4e8caa53aadeff92477632756;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632756 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477632758 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10708-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> QUINIDINE"@fr;
  dct:identifier "IAM_10708";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632760;
  r:natureDuRisque """Augmentation des concentrations plasmatiques de dabigatran,
avec majoration du risque de saignement."""@fr;
  r:conduiteATenir "Dans l'indication post-chirurgicale : surveillance clinique et adaptation de la posologie du dabigatran à 150 mg/j en une prise."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632766, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632760 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632761 .

_:807f36cf91fe4e8caa53aadeff92477632761 rdf:first _:807f36cf91fe4e8caa53aadeff92477632762;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632763 .

_:807f36cf91fe4e8caa53aadeff92477632762 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff92477632763 rdf:first _:807f36cf91fe4e8caa53aadeff92477632764;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632764 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477632766 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10709-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10709";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632768;
  r:natureDuRisque "Diminution des concentrations plasmatiques de dabigatran, avec risque de diminution de l'effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632774, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632768 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632769 .

_:807f36cf91fe4e8caa53aadeff92477632769 rdf:first _:807f36cf91fe4e8caa53aadeff92477632770;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632771 .

_:807f36cf91fe4e8caa53aadeff92477632770 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff92477632771 rdf:first _:807f36cf91fe4e8caa53aadeff92477632772;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632772 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477632774 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10710-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10710";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632776;
  r:natureDuRisque "Risque d'augmentation des concentrations plasmatiques de dabigatran."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632782, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632776 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632777 .

_:807f36cf91fe4e8caa53aadeff92477632777 rdf:first _:807f36cf91fe4e8caa53aadeff92477632778;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632779 .

_:807f36cf91fe4e8caa53aadeff92477632778 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff92477632779 rdf:first _:807f36cf91fe4e8caa53aadeff92477632780;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632780 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477632782 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10711-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> TICAGRELOR"@fr;
  dct:identifier "IAM_10711";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632784;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de dabigatran, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632790, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632784 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632785 .

_:807f36cf91fe4e8caa53aadeff92477632785 rdf:first _:807f36cf91fe4e8caa53aadeff92477632786;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632787 .

_:807f36cf91fe4e8caa53aadeff92477632786 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff92477632787 rdf:first _:807f36cf91fe4e8caa53aadeff92477632788;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632788 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477632790 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10712-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10712";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632792;
  r:natureDuRisque """Augmentation des concentrations plasmatiques de dabigatran,
avec majoration du risque de saignement."""@fr;
  r:conduiteATenir """Dans l'indication post-chirurgicale : surveillance clinique et adaptation de la posologie du dabigatran à 150 mg/j en une prise, voire 75 mg/j en cas d'insuffisance rénale modérée.

Dans l'indication fibrillation auriculaire : surveillance clinique et ada"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632798, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632792 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632793 .

_:807f36cf91fe4e8caa53aadeff92477632793 rdf:first _:807f36cf91fe4e8caa53aadeff92477632794;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632795 .

_:807f36cf91fe4e8caa53aadeff92477632794 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff92477632795 rdf:first _:807f36cf91fe4e8caa53aadeff92477632796;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632796 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477632798 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10001-1 a owl:Class;
  rdfs:label "ABATACEPT <-> ANTI-TNF ALPHA"@fr;
  dct:identifier "IAM_10001";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632800;
  r:natureDuRisque "Majoration de l’immunodépression."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632806, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632800 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632801 .

_:807f36cf91fe4e8caa53aadeff92477632801 rdf:first _:807f36cf91fe4e8caa53aadeff92477632802;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632803 .

_:807f36cf91fe4e8caa53aadeff92477632802 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10021 .

_:807f36cf91fe4e8caa53aadeff92477632803 rdf:first _:807f36cf91fe4e8caa53aadeff92477632804;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632804 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477632806 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10701-1 a owl:Class;
  rdfs:label "CYPROTERONE <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_10701";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632808;
  r:natureDuRisque """Dans l'indication contraception d'urgence de l'ulipristal :
Antagonisme des effets de l’ulipristal en cas de reprise d’un contraceptif hormonal moins de 5 jours après la prise de la contraception d’urgence.

Dans l’indication fibrome de l'ulipristal :
Ant"""@fr;
  r:conduiteATenir """Association déconseillée 
Dans l'utilisation à visée contraceptive de la cyprotérone

- Dans l'indication contraception d'urgence de l'ulipristal
Dans le cas où la (re)prise d’une contraception hormonale est envisagée, utiliser une contraception additionn"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632814, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632808 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632809 .

_:807f36cf91fe4e8caa53aadeff92477632809 rdf:first _:807f36cf91fe4e8caa53aadeff92477632810;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632811 .

_:807f36cf91fe4e8caa53aadeff92477632810 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff92477632811 rdf:first _:807f36cf91fe4e8caa53aadeff92477632812;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632812 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477632814 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10666-1 a owl:Class;
  rdfs:label "CLOZAPINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10666";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632816;
  r:natureDuRisque "Risque d'inefficacité du traitement antipsychotique (diminution des concentrations plasmatiques de clozapine par augmentation de son métabolisme hépatique)."@fr;
  r:conduiteATenir "Surveillance clinique et augmentation éventuelle de la posologie de la clozapine durant le traitement par la phénytoïne."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632822, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632816 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632817 .

_:807f36cf91fe4e8caa53aadeff92477632817 rdf:first _:807f36cf91fe4e8caa53aadeff92477632818;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632819 .

_:807f36cf91fe4e8caa53aadeff92477632818 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477632819 rdf:first _:807f36cf91fe4e8caa53aadeff92477632820;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632820 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10220 .

_:807f36cf91fe4e8caa53aadeff92477632822 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10606-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> SULFINPYRAZONE"@fr;
  dct:identifier "IAM_10606";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632824;
  r:natureDuRisque "Diminution des concentrations sanguines de ciclosporine par augmentation de son métabolisme par la sulfinpyrazone."@fr;
  r:conduiteATenir "Contrôle des concentrations sanguines de ciclosporine et adaptation éventuelle de sa posologie pendant le traitement par sulfinpyrazone et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632830, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632824 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632825 .

_:807f36cf91fe4e8caa53aadeff92477632825 rdf:first _:807f36cf91fe4e8caa53aadeff92477632826;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632827 .

_:807f36cf91fe4e8caa53aadeff92477632826 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477632827 rdf:first _:807f36cf91fe4e8caa53aadeff92477632828;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632828 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10873 .

_:807f36cf91fe4e8caa53aadeff92477632830 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10655-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_10655";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632832;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632838, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632832 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632833 .

_:807f36cf91fe4e8caa53aadeff92477632833 rdf:first _:807f36cf91fe4e8caa53aadeff92477632834;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632835 .

_:807f36cf91fe4e8caa53aadeff92477632834 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632835 rdf:first _:807f36cf91fe4e8caa53aadeff92477632836;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632836 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:807f36cf91fe4e8caa53aadeff92477632838 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10657-1 a owl:Class;
  rdfs:label "CLINDAMYCINE <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10657";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632840;
  r:natureDuRisque "Diminution des concentrations sanguines de l'immunosuppresseur, avec risque de perte de l'activité immunosuppressive."@fr;
  r:conduiteATenir "Contrôle renforcé des dosages sanguins de tacrolimus et augmentation éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632846, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632840 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632841 .

_:807f36cf91fe4e8caa53aadeff92477632841 rdf:first _:807f36cf91fe4e8caa53aadeff92477632842;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632843 .

_:807f36cf91fe4e8caa53aadeff92477632842 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10209 .

_:807f36cf91fe4e8caa53aadeff92477632843 rdf:first _:807f36cf91fe4e8caa53aadeff92477632844;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632844 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477632846 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10658-1 a owl:Class;
  rdfs:label "CLOBAZAM <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10658";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632848;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de ces anticonvulsivants, avec risque de surdosage, par inhibition de leur métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique, dosage plasmatique, lorsque cela est possible, de l'anticonvulsivant associé au stiripentol et éventuelle adaptation posologique de l'anticonvulsivant associé."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632854, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632848 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632849 .

_:807f36cf91fe4e8caa53aadeff92477632849 rdf:first _:807f36cf91fe4e8caa53aadeff92477632850;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632851 .

_:807f36cf91fe4e8caa53aadeff92477632850 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10210 .

_:807f36cf91fe4e8caa53aadeff92477632851 rdf:first _:807f36cf91fe4e8caa53aadeff92477632852;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632852 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477632854 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10659-1 a owl:Class;
  rdfs:label "CLONIDINE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10659";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632856;
  r:natureDuRisque "Troubles de l'automatisme (troubles de la conduction auriculo-ventriculaire par addition des effets négatifs sur la conduction)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632862, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632856 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632857 .

_:807f36cf91fe4e8caa53aadeff92477632857 rdf:first _:807f36cf91fe4e8caa53aadeff92477632858;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632859 .

_:807f36cf91fe4e8caa53aadeff92477632858 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10214 .

_:807f36cf91fe4e8caa53aadeff92477632859 rdf:first _:807f36cf91fe4e8caa53aadeff92477632860;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632860 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477632862 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10660-1 a owl:Class;
  rdfs:label "CLONIDINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10660";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632864;
  r:natureDuRisque "Troubles de l'automatisme (troubles de la conduction auriculo-ventriculaire par addition des effets négatifs sur la conduction)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632870, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632864 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632865 .

_:807f36cf91fe4e8caa53aadeff92477632865 rdf:first _:807f36cf91fe4e8caa53aadeff92477632866;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632867 .

_:807f36cf91fe4e8caa53aadeff92477632866 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10214 .

_:807f36cf91fe4e8caa53aadeff92477632867 rdf:first _:807f36cf91fe4e8caa53aadeff92477632868;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632868 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477632870 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10661-1 a owl:Class;
  rdfs:label "CLONIDINE <-> YOHIMBINE"@fr;
  dct:identifier "IAM_10661";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632872;
  r:natureDuRisque "Inhibition possible de l’activité antihypertensive par antagonisme au niveau des récepteurs."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632878, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632872 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632873 .

_:807f36cf91fe4e8caa53aadeff92477632873 rdf:first _:807f36cf91fe4e8caa53aadeff92477632874;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632875 .

_:807f36cf91fe4e8caa53aadeff92477632874 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10214 .

_:807f36cf91fe4e8caa53aadeff92477632875 rdf:first _:807f36cf91fe4e8caa53aadeff92477632876;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632876 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11001 .

_:807f36cf91fe4e8caa53aadeff92477632878 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10662-1 a owl:Class;
  rdfs:label "CLOPIDOGREL <-> PACLITAXEL"@fr;
  dct:identifier "IAM_10662";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632880;
  r:natureDuRisque "Augmentation des concentrations du paclitaxel par le clopidogrel, avec risque de majoration des effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632886, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632880 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632881 .

_:807f36cf91fe4e8caa53aadeff92477632881 rdf:first _:807f36cf91fe4e8caa53aadeff92477632882;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632883 .

_:807f36cf91fe4e8caa53aadeff92477632882 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10216 .

_:807f36cf91fe4e8caa53aadeff92477632883 rdf:first _:807f36cf91fe4e8caa53aadeff92477632884;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632884 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10685 .

_:807f36cf91fe4e8caa53aadeff92477632886 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10663-1 a owl:Class;
  rdfs:label "CLOPIDOGREL <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10663";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632888;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne avec signes de surdosage (inhibition du métabolisme de la phénytoïne)."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques de phénytoïne."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632894, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632888 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632889 .

_:807f36cf91fe4e8caa53aadeff92477632889 rdf:first _:807f36cf91fe4e8caa53aadeff92477632890;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632891 .

_:807f36cf91fe4e8caa53aadeff92477632890 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477632891 rdf:first _:807f36cf91fe4e8caa53aadeff92477632892;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632892 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10216 .

_:807f36cf91fe4e8caa53aadeff92477632894 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10692-1 a owl:Class;
  rdfs:label "CYCLINES <-> STRONTIUM"@fr;
  dct:identifier "IAM_10692";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632896;
  r:natureDuRisque "Diminution de l'absorption digestive du strontium."@fr;
  r:conduiteATenir "Prendre le strontium à distance des cyclines (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632902, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632896 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632897 .

_:807f36cf91fe4e8caa53aadeff92477632897 rdf:first _:807f36cf91fe4e8caa53aadeff92477632898;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632899 .

_:807f36cf91fe4e8caa53aadeff92477632898 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:807f36cf91fe4e8caa53aadeff92477632899 rdf:first _:807f36cf91fe4e8caa53aadeff92477632900;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632900 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10863 .

_:807f36cf91fe4e8caa53aadeff92477632902 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10665-1 a owl:Class;
  rdfs:label "CLOZAPINE <-> FLUVOXAMINE"@fr;
  dct:identifier "IAM_10665";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632904;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de clozapine avec signes de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique accrue ; si besoin, adaptation de la posologie de la clozapine pendant le traitement par la fluvoxamine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632910, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632904 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632905 .

_:807f36cf91fe4e8caa53aadeff92477632905 rdf:first _:807f36cf91fe4e8caa53aadeff92477632906;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632907 .

_:807f36cf91fe4e8caa53aadeff92477632906 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10220 .

_:807f36cf91fe4e8caa53aadeff92477632907 rdf:first _:807f36cf91fe4e8caa53aadeff92477632908;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632908 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477632910 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10653-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10653";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632912;
  r:natureDuRisque "Risque d'hypoglycémie par augmentation des concentrations plasmatiques de l’antidiabétique."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide hypoglycémiant pendant le traitement par la clarithromycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632918, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632912 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632913 .

_:807f36cf91fe4e8caa53aadeff92477632913 rdf:first _:807f36cf91fe4e8caa53aadeff92477632914;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632915 .

_:807f36cf91fe4e8caa53aadeff92477632914 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477632915 rdf:first _:807f36cf91fe4e8caa53aadeff92477632916;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632916 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477632918 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10667-1 a owl:Class;
  rdfs:label "CLOZAPINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10667";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632920;
  r:natureDuRisque "Risque d'inefficacité du traitement antipsychotique (diminution des concentrations plasmatiques de clozapine par augmentation de son métabolisme hépatique)."@fr;
  r:conduiteATenir "Surveillance clinique et augmentation éventuelle de la posologie de la clozapine durant le traitement par la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632926, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632920 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632921 .

_:807f36cf91fe4e8caa53aadeff92477632921 rdf:first _:807f36cf91fe4e8caa53aadeff92477632922;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632923 .

_:807f36cf91fe4e8caa53aadeff92477632922 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10220 .

_:807f36cf91fe4e8caa53aadeff92477632923 rdf:first _:807f36cf91fe4e8caa53aadeff92477632924;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632924 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477632926 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10675-1 a owl:Class;
  rdfs:label "COBICISTAT <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_10675";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632928;
  r:natureDuRisque "Majoration de la neurotoxicité de l’antimitotique par diminution de son métabolisme hépatique par le cobicistat."@fr;
  r:conduiteATenir "Surveillance clinique étroite et adaptation éventuelle de la posologie de l’antimitotique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632934, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632928 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632929 .

_:807f36cf91fe4e8caa53aadeff92477632929 rdf:first _:807f36cf91fe4e8caa53aadeff92477632930;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632931 .

_:807f36cf91fe4e8caa53aadeff92477632930 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:807f36cf91fe4e8caa53aadeff92477632931 rdf:first _:807f36cf91fe4e8caa53aadeff92477632932;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632932 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477632934 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10668-1 a owl:Class;
  rdfs:label "COBICISTAT <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10668";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632936;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques du cobicistat ou de l’inhibiteur du CYP3A4."@fr;
  r:conduiteATenir "Pour connaître les risques et les niveaux de contrainte de chaque interaction, il convient de se reporter aux AMM specifiques à chaque spécialité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632942, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632936 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632937 .

_:807f36cf91fe4e8caa53aadeff92477632937 rdf:first _:807f36cf91fe4e8caa53aadeff92477632938;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632939 .

_:807f36cf91fe4e8caa53aadeff92477632938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477632939 rdf:first _:807f36cf91fe4e8caa53aadeff92477632940;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632940 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477632942 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10669-1 a owl:Class;
  rdfs:label "COBICISTAT <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10669";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632944;
  r:natureDuRisque "Risque d’augmentation des concentrations d’itraconazole par le cobicistat."@fr;
  r:conduiteATenir "Surveillance clinique lors de l’association. L’administration de doses élevées d’itraconazole (>200 mg par jour) n’est pas recommandée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632950, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632944 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632945 .

_:807f36cf91fe4e8caa53aadeff92477632945 rdf:first _:807f36cf91fe4e8caa53aadeff92477632946;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632947 .

_:807f36cf91fe4e8caa53aadeff92477632946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477632947 rdf:first _:807f36cf91fe4e8caa53aadeff92477632948;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632948 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477632950 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10670-1 a owl:Class;
  rdfs:label "COBICISTAT <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10670";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632952;
  r:natureDuRisque "Risque de diminution de l’efficacité du cobicistat par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632958, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632952 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632953 .

_:807f36cf91fe4e8caa53aadeff92477632953 rdf:first _:807f36cf91fe4e8caa53aadeff92477632954;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632955 .

_:807f36cf91fe4e8caa53aadeff92477632954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477632955 rdf:first _:807f36cf91fe4e8caa53aadeff92477632956;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632956 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477632958 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10671-1 a owl:Class;
  rdfs:label "COBICISTAT <-> QUINIDINE"@fr;
  dct:identifier "IAM_10671";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632960;
  r:natureDuRisque "Risque de majoration des effets indésirables de la quinidine par diminution de son métabolisme par le cobicistat."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632966, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632960 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632961 .

_:807f36cf91fe4e8caa53aadeff92477632961 rdf:first _:807f36cf91fe4e8caa53aadeff92477632962;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632963 .

_:807f36cf91fe4e8caa53aadeff92477632962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477632963 rdf:first _:807f36cf91fe4e8caa53aadeff92477632964;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632964 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477632966 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10672-1 a owl:Class;
  rdfs:label "COBICISTAT <-> RIFABUTINE"@fr;
  dct:identifier "IAM_10672";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632968;
  r:natureDuRisque "Augmentation très importante du métabolite de la rifabutine, avec risque de majoration de sa toxicité (uvéites, neutropénies). Par ailleurs, possible diminution des concentrations de cobicistat."@fr;
  r:conduiteATenir "Adaptation de la posologie de la rifabutine (en principe, réduction des doses de moitié)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632974, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632968 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632969 .

_:807f36cf91fe4e8caa53aadeff92477632969 rdf:first _:807f36cf91fe4e8caa53aadeff92477632970;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632971 .

_:807f36cf91fe4e8caa53aadeff92477632970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477632971 rdf:first _:807f36cf91fe4e8caa53aadeff92477632972;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632972 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff92477632974 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10687-1 a owl:Class;
  rdfs:label "CURARES <-> LINCOSANIDES"@fr;
  dct:identifier "IAM_10687";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632976;
  r:chapeau """Certaines substances peuvent modifier l'intensité et/ou la durée de l'effet des curares non dépolarisants. 
Les médicaments susceptibles de potentialiser l'action des curares non dépolarisants sont :
- les anesthésiques volatils tels que isoflurane, enflu"""@fr;
  r:natureDuRisque "Potentialisation des curares lorque l'antibiotique est administré par voie parentérale et/ou péritonéale avant, pendant ou après l'agent curarisant."@fr;
  r:conduiteATenir "Surveiller le degré de curarisation en fin d'anesthésie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632982, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632976 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632977 .

_:807f36cf91fe4e8caa53aadeff92477632977 rdf:first _:807f36cf91fe4e8caa53aadeff92477632978;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632979 .

_:807f36cf91fe4e8caa53aadeff92477632978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10057 .

_:807f36cf91fe4e8caa53aadeff92477632979 rdf:first _:807f36cf91fe4e8caa53aadeff92477632980;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632980 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10106 .

_:807f36cf91fe4e8caa53aadeff92477632982 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10688-1 a owl:Class;
  rdfs:label "CURARES <-> POLYMYXINE B"@fr;
  dct:identifier "IAM_10688";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632984;
  r:natureDuRisque "Potentialisation des curares lorque l'antibiotique est administré par voie parentérale et/ou péritonéale avant, pendant ou après l'agent curarisant."@fr;
  r:conduiteATenir "Surveiller le degré de curarisation en fin d'anesthésie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632990, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632984 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632985 .

_:807f36cf91fe4e8caa53aadeff92477632985 rdf:first _:807f36cf91fe4e8caa53aadeff92477632986;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632987 .

_:807f36cf91fe4e8caa53aadeff92477632986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10057 .

_:807f36cf91fe4e8caa53aadeff92477632987 rdf:first _:807f36cf91fe4e8caa53aadeff92477632988;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632988 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10739 .

_:807f36cf91fe4e8caa53aadeff92477632990 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10689-1 a owl:Class;
  rdfs:label "CURARES NON DÉPOLARISANTS <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10689";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477632992;
  r:natureDuRisque "Avec les glucocorticoïdes par voie IV : risque de myopathie sévère, réversible après un délai éventuellement long (plusieurs mois)."@fr;
  rdfs:comment """Une interaction entre l'hydrocortisone et les curares non dépolarisants a été retenue en raison de l’existence de plusieurs cas de myopathie aiguë avec l’utilisation de corticoïdes injectables.
La Myopathie Aiguë de Réanimation (MAR) est une atteinte musc"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477632998, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477632992 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477632993 .

_:807f36cf91fe4e8caa53aadeff92477632993 rdf:first _:807f36cf91fe4e8caa53aadeff92477632994;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477632995 .

_:807f36cf91fe4e8caa53aadeff92477632994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10058 .

_:807f36cf91fe4e8caa53aadeff92477632995 rdf:first _:807f36cf91fe4e8caa53aadeff92477632996;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477632996 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477632998 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10664-1 a owl:Class;
  rdfs:label "CLOPIDOGREL <-> REPAGLINIDE"@fr;
  dct:identifier "IAM_10664";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633000;
  r:natureDuRisque "Augmentation des concentrations du répaglinide par le clopidogrel, avec risque de majoration des effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633006, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633000 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633001 .

_:807f36cf91fe4e8caa53aadeff92477633001 rdf:first _:807f36cf91fe4e8caa53aadeff92477633002;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633003 .

_:807f36cf91fe4e8caa53aadeff92477633002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10216 .

_:807f36cf91fe4e8caa53aadeff92477633003 rdf:first _:807f36cf91fe4e8caa53aadeff92477633004;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633004 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:807f36cf91fe4e8caa53aadeff92477633006 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10558-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> PAROXETINE"@fr;
  dct:identifier "IAM_10558";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633008;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques de carbamazépine et réduction éventuelle de la posologie de la carbamazépine pendant le traitement par l'antidépresseur sérotoninergique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633014, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633008 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633009 .

_:807f36cf91fe4e8caa53aadeff92477633009 rdf:first _:807f36cf91fe4e8caa53aadeff92477633010;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633011 .

_:807f36cf91fe4e8caa53aadeff92477633010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633011 rdf:first _:807f36cf91fe4e8caa53aadeff92477633012;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633012 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:807f36cf91fe4e8caa53aadeff92477633014 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10547-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10547";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633016;
  r:natureDuRisque "Pour des doses de fluconazole >= 200 mg par jour : augmentation possible des effets indésirables de la carbamazépine."@fr;
  r:conduiteATenir "Adapter la posologie de carbamazépine, pendant et après l’arrêt du traitement antifongique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633022, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633016 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633017 .

_:807f36cf91fe4e8caa53aadeff92477633017 rdf:first _:807f36cf91fe4e8caa53aadeff92477633018;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633019 .

_:807f36cf91fe4e8caa53aadeff92477633018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633019 rdf:first _:807f36cf91fe4e8caa53aadeff92477633020;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633020 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477633022 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10548-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> FLUOXETINE"@fr;
  dct:identifier "IAM_10548";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633024;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques de carbamazépine et réduction éventuelle de la posologie de la carbamazépine pendant le traitement par l'antidépresseur sérotoninergique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633030, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633024 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633025 .

_:807f36cf91fe4e8caa53aadeff92477633025 rdf:first _:807f36cf91fe4e8caa53aadeff92477633026;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633027 .

_:807f36cf91fe4e8caa53aadeff92477633026 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633027 rdf:first _:807f36cf91fe4e8caa53aadeff92477633028;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633028 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:807f36cf91fe4e8caa53aadeff92477633030 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10549-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> FLUVOXAMINE"@fr;
  dct:identifier "IAM_10549";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633032;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques de carbamazépine et réduction éventuelle de la posologie de la carbamazépine pendant le traitement par l'antidépresseur sérotoninergique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633038, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633032 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633033 .

_:807f36cf91fe4e8caa53aadeff92477633033 rdf:first _:807f36cf91fe4e8caa53aadeff92477633034;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633035 .

_:807f36cf91fe4e8caa53aadeff92477633034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633035 rdf:first _:807f36cf91fe4e8caa53aadeff92477633036;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633036 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477633038 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10550-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> ISONIAZIDE"@fr;
  dct:identifier "IAM_10550";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633040;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage par inhibition de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633046, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633040 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633041 .

_:807f36cf91fe4e8caa53aadeff92477633041 rdf:first _:807f36cf91fe4e8caa53aadeff92477633042;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633043 .

_:807f36cf91fe4e8caa53aadeff92477633042 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633043 rdf:first _:807f36cf91fe4e8caa53aadeff92477633044;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633044 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:807f36cf91fe4e8caa53aadeff92477633046 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10551-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> JOSAMYCINE"@fr;
  dct:identifier "IAM_10551";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633048;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage, par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, dosage plasmatique et réduction éventuelle de la posologie de la carbamazépine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633054, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633048 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633049 .

_:807f36cf91fe4e8caa53aadeff92477633049 rdf:first _:807f36cf91fe4e8caa53aadeff92477633050;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633051 .

_:807f36cf91fe4e8caa53aadeff92477633050 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633051 rdf:first _:807f36cf91fe4e8caa53aadeff92477633052;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633052 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477633054 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10552-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> LAMOTRIGINE"@fr;
  dct:identifier "IAM_10552";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633056;
  r:natureDuRisque "Risque d'augmentation des effets neurologiques (vertiges, ataxie, diplopie) de la carbamazépine lors de l'introduction de la lamotrigine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de la carbamazépine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633062, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633056 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633057 .

_:807f36cf91fe4e8caa53aadeff92477633057 rdf:first _:807f36cf91fe4e8caa53aadeff92477633058;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633059 .

_:807f36cf91fe4e8caa53aadeff92477633058 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633059 rdf:first _:807f36cf91fe4e8caa53aadeff92477633060;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633060 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:807f36cf91fe4e8caa53aadeff92477633062 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10553-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> LITHIUM"@fr;
  dct:identifier "IAM_10553";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633064;
  r:natureDuRisque "Risque de neurotoxicité se manifestant par des troubles cérébelleux, confusion, somnolence, ataxie. Ces troubles sont réversibles à l'arrêt du traitement par le lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633070, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633064 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633065 .

_:807f36cf91fe4e8caa53aadeff92477633065 rdf:first _:807f36cf91fe4e8caa53aadeff92477633066;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633067 .

_:807f36cf91fe4e8caa53aadeff92477633066 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633067 rdf:first _:807f36cf91fe4e8caa53aadeff92477633068;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633068 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477633070 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10554-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10554";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633072;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques et de l'efficacité de la carbamazepine."@fr;
  rdfs:comment "Bien qu'une étude d'interaction rigoureuse, menée sur des volontaires sains, n'ait pas mis en évidence de modification des paramètres pharmacocinétiques de la carbamazépine lorsque celle-ci était administrée conjointement au millepertuis, une association"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633078, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633072 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633073 .

_:807f36cf91fe4e8caa53aadeff92477633073 rdf:first _:807f36cf91fe4e8caa53aadeff92477633074;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633075 .

_:807f36cf91fe4e8caa53aadeff92477633074 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633075 rdf:first _:807f36cf91fe4e8caa53aadeff92477633076;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633076 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477633078 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10555-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_10555";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633080;
  r:natureDuRisque "Diminution des concentrations plasmatiques du nintédanib par diminution de son absorption par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633086, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633080 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633081 .

_:807f36cf91fe4e8caa53aadeff92477633081 rdf:first _:807f36cf91fe4e8caa53aadeff92477633082;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633083 .

_:807f36cf91fe4e8caa53aadeff92477633082 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633083 rdf:first _:807f36cf91fe4e8caa53aadeff92477633084;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633084 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477633086 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10608-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> TERBINAFINE"@fr;
  dct:identifier "IAM_10608";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633088;
  r:natureDuRisque "Diminution des concentrations sanguines de ciclosporine."@fr;
  r:conduiteATenir "Contrôle des concentrations sanguines de ciclosporine et adaptation éventuelle de sa posologie pendant le traitement par terbinafine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633094, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633088 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633089 .

_:807f36cf91fe4e8caa53aadeff92477633089 rdf:first _:807f36cf91fe4e8caa53aadeff92477633090;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633091 .

_:807f36cf91fe4e8caa53aadeff92477633090 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477633091 rdf:first _:807f36cf91fe4e8caa53aadeff92477633092;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633092 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:807f36cf91fe4e8caa53aadeff92477633094 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10557-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_10557";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633096;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine, avec risque de surdosage, par inhibition de son métabolisme par le pamplemousse."@fr;
  rdfs:comment "Outre l’existence de 3 trois cas cliniques suggérant un risque de surdosage en carbamazépine lors de l’ingestion de jus de pamplemousse, une étude pharmacocinétique chez 10 patients a confirmé une augmentation des concentrations de carbamazépine après ing"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633102, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633096 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633097 .

_:807f36cf91fe4e8caa53aadeff92477633097 rdf:first _:807f36cf91fe4e8caa53aadeff92477633098;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633099 .

_:807f36cf91fe4e8caa53aadeff92477633098 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477633099 rdf:first _:807f36cf91fe4e8caa53aadeff92477633100;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633100 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633102 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10544-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10544";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633104;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine, avec signes de surdosage, par inhibition de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633110, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633104 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633105 .

_:807f36cf91fe4e8caa53aadeff92477633105 rdf:first _:807f36cf91fe4e8caa53aadeff92477633106;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633107 .

_:807f36cf91fe4e8caa53aadeff92477633106 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633107 rdf:first _:807f36cf91fe4e8caa53aadeff92477633108;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633108 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477633110 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10559-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE)"@fr;
  dct:identifier "IAM_10559";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633112;
  r:natureDuRisque "Diminution progressive des concentrations plasmatiques de carbamazépine et de son métabolite actif sans modification apparente de l'efficacité anticomitiale."@fr;
  r:conduiteATenir "Prudence quant à l'interprétation des concentrations plasmatiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633118, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633112 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633113 .

_:807f36cf91fe4e8caa53aadeff92477633113 rdf:first _:807f36cf91fe4e8caa53aadeff92477633114;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633115 .

_:807f36cf91fe4e8caa53aadeff92477633114 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477633115 rdf:first _:807f36cf91fe4e8caa53aadeff92477633116;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633116 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633118 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10560-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10560";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633120;
  r:natureDuRisque "Réduction réciproque des concentrations plasmatiques (augmentation du métabolisme sans modification apparente de l'efficacité anticomitiale)."@fr;
  r:conduiteATenir "Prudence dans l'interprétation des concentrations plasmatiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633126, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633120 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633121 .

_:807f36cf91fe4e8caa53aadeff92477633121 rdf:first _:807f36cf91fe4e8caa53aadeff92477633122;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633123 .

_:807f36cf91fe4e8caa53aadeff92477633122 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477633123 rdf:first _:807f36cf91fe4e8caa53aadeff92477633124;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633124 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633126 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10561-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10561";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633128;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de la carbamazépine par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques et adaptation de la posologie de la carbamazépine pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633134, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633128 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633129 .

_:807f36cf91fe4e8caa53aadeff92477633129 rdf:first _:807f36cf91fe4e8caa53aadeff92477633130;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633131 .

_:807f36cf91fe4e8caa53aadeff92477633130 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633131 rdf:first _:807f36cf91fe4e8caa53aadeff92477633132;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633132 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477633134 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10562-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> RISPERIDONE"@fr;
  dct:identifier "IAM_10562";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633136;
  r:natureDuRisque "Risque de diminution de la fraction active de la rispéridone et de son efficacité thérapeutique par augmentation de son métabolisme hépatique par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique, et si besoin, adaptation posologique de la rispéridone."@fr;
  rdfs:comment """La rispéridone est majoritairement métabolisée par le CYP2D6 en 9-OH-rispéridone, métabolite actif. La fraction pharmacologiquement active de la rispéridone est ainsi constituée par la molécule mère et son métabolite hydroxylé.
Dans un cas isolé non publi"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633142, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633136 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633137 .

_:807f36cf91fe4e8caa53aadeff92477633137 rdf:first _:807f36cf91fe4e8caa53aadeff92477633138;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633139 .

_:807f36cf91fe4e8caa53aadeff92477633138 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633139 rdf:first _:807f36cf91fe4e8caa53aadeff92477633140;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633140 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10805 .

_:807f36cf91fe4e8caa53aadeff92477633142 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10563-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10563";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633144;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques de simvastatine, par augmentation de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633150, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633144 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633145 .

_:807f36cf91fe4e8caa53aadeff92477633145 rdf:first _:807f36cf91fe4e8caa53aadeff92477633146;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633147 .

_:807f36cf91fe4e8caa53aadeff92477633146 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633147 rdf:first _:807f36cf91fe4e8caa53aadeff92477633148;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633148 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477633150 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10564-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> TOPIRAMATE"@fr;
  dct:identifier "IAM_10564";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633152;
  r:natureDuRisque "Diminution des concentrations du topiramate avec risque de moindre efficacité, par augmentation de son métabolisme hépatique par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique, et si besoin, adaptation posologique du topiramate pendant le traitement par la carbamazépine et après son arrêt."@fr;
  rdfs:comment "Les concentrations du topiramate ont diminué de moitié environ en association avec la carbamazépine, tant chez des patients que des volontaires sains. En revanche, le profil pharmacocinétique de la carbamazépine n’est pas modifié par le topiramate."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633158, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633152 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633153 .

_:807f36cf91fe4e8caa53aadeff92477633153 rdf:first _:807f36cf91fe4e8caa53aadeff92477633154;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633155 .

_:807f36cf91fe4e8caa53aadeff92477633154 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633155 rdf:first _:807f36cf91fe4e8caa53aadeff92477633156;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633156 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10941 .

_:807f36cf91fe4e8caa53aadeff92477633158 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10565-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_10565";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633160;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du métabolite actif de la carbamazépine avec signes de surdosage. De plus, diminution des concentrations plasmatiques d'acide valproïque par augmentation de son métabolisme hépatique par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique, dosages plasmatiques et adaptation de la posologie des deux anticonvulsivants."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633166, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633160 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633161 .

_:807f36cf91fe4e8caa53aadeff92477633161 rdf:first _:807f36cf91fe4e8caa53aadeff92477633162;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633163 .

_:807f36cf91fe4e8caa53aadeff92477633162 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477633163 rdf:first _:807f36cf91fe4e8caa53aadeff92477633164;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633164 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633166 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10566-1 a owl:Class;
  rdfs:label "CARMUSTINE <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10566";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633168;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : toxicité médullaire accrue (inhibition du métabolisme de la carmustine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633174, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633168 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633169 .

_:807f36cf91fe4e8caa53aadeff92477633169 rdf:first _:807f36cf91fe4e8caa53aadeff92477633170;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633171 .

_:807f36cf91fe4e8caa53aadeff92477633170 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477633171 rdf:first _:807f36cf91fe4e8caa53aadeff92477633172;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633172 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477633174 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10567-1 a owl:Class;
  rdfs:label "CARVEDILOL <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10567";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633176;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation des concentrations du carvédilol, pouvant être préjudiciables dans le cas du traitement de l'insuffisance cardiaque, par diminution de son métabolisme hépatique par la"@fr;
  r:conduiteATenir "Utiliser un autre antisécrétoire gastrique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633182, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633176 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633177 .

_:807f36cf91fe4e8caa53aadeff92477633177 rdf:first _:807f36cf91fe4e8caa53aadeff92477633178;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633179 .

_:807f36cf91fe4e8caa53aadeff92477633178 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10163 .

_:807f36cf91fe4e8caa53aadeff92477633179 rdf:first _:807f36cf91fe4e8caa53aadeff92477633180;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633180 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477633182 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10556-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> OLANZAPINE"@fr;
  dct:identifier "IAM_10556";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633184;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de l'olanzapine et de son efficacité thérapeutique, par augmentation de son métabolisme hépatique par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique, et si besoin, adaptation posologique de l'olanzapine."@fr;
  rdfs:comment """Plusieurs publications chez des volontaires sains ou des patients montrent que les concentrations plasmatiques de l’olanzapine sont diminuées de plus de la moitié lors de son association avec la carbamazépine, inducteur puissant des CYP3A4 et CYP1A2. 
L’o"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633190, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633184 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633185 .

_:807f36cf91fe4e8caa53aadeff92477633185 rdf:first _:807f36cf91fe4e8caa53aadeff92477633186;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633187 .

_:807f36cf91fe4e8caa53aadeff92477633186 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633187 rdf:first _:807f36cf91fe4e8caa53aadeff92477633188;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633188 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10658 .

_:807f36cf91fe4e8caa53aadeff92477633190 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10534-1 a owl:Class;
  rdfs:label "CALCIUM <-> HORMONES THYROÏDIENNES"@fr;
  dct:identifier "IAM_10534";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633192;
  r:natureDuRisque "Diminution de l’absorption des hormones thyroïdiennes."@fr;
  r:conduiteATenir "Prendre les sels de calcium à distance des hormones thyroïdiennes (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633198, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633192 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633193 .

_:807f36cf91fe4e8caa53aadeff92477633193 rdf:first _:807f36cf91fe4e8caa53aadeff92477633194;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633195 .

_:807f36cf91fe4e8caa53aadeff92477633194 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477633195 rdf:first _:807f36cf91fe4e8caa53aadeff92477633196;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633196 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477633198 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10523-1 a owl:Class;
  rdfs:label "CAFEINE <-> ENOXACINE"@fr;
  dct:identifier "IAM_10523";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633200;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de caféine, pouvant entraîner excitations et hallucinations, par diminution de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633206, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633200 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633201 .

_:807f36cf91fe4e8caa53aadeff92477633201 rdf:first _:807f36cf91fe4e8caa53aadeff92477633202;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633203 .

_:807f36cf91fe4e8caa53aadeff92477633202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477633203 rdf:first _:807f36cf91fe4e8caa53aadeff92477633204;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633204 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10323 .

_:807f36cf91fe4e8caa53aadeff92477633206 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10524-1 a owl:Class;
  rdfs:label "CAFEINE <-> LITHIUM"@fr;
  dct:identifier "IAM_10524";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633208;
  r:natureDuRisque "En cas d’arrêt brutal de la consommation de café ou de médicaments contenant de la caféine, risque d’augmentation de la lithémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633214, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633208 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633209 .

_:807f36cf91fe4e8caa53aadeff92477633209 rdf:first _:807f36cf91fe4e8caa53aadeff92477633210;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633211 .

_:807f36cf91fe4e8caa53aadeff92477633210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477633211 rdf:first _:807f36cf91fe4e8caa53aadeff92477633212;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633212 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477633214 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10525-1 a owl:Class;
  rdfs:label "CAFEINE <-> MEXILETINE"@fr;
  dct:identifier "IAM_10525";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633216;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de caféine, par inhibition de son métabolisme hépatique par la méxilétine."@fr;
  rdfs:comment "La caféine est métabolisée par le CYP1A2 et des cas d’intoxication par inhibition de son métabolisme ont été antérieurement décrits avec l’idrocilamide ou la ciprofloxacine. Pour cette dernière, déjà retenue au niveau \"à prendre en compte\", la diminution"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633222, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633216 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633217 .

_:807f36cf91fe4e8caa53aadeff92477633217 rdf:first _:807f36cf91fe4e8caa53aadeff92477633218;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633219 .

_:807f36cf91fe4e8caa53aadeff92477633218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477633219 rdf:first _:807f36cf91fe4e8caa53aadeff92477633220;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633220 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10582 .

_:807f36cf91fe4e8caa53aadeff92477633222 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10526-1 a owl:Class;
  rdfs:label "CAFEINE <-> NORFLOXACINE"@fr;
  dct:identifier "IAM_10526";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633224;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de caféine, par diminution du métabolisme hépatique de la caféine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633230, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633224 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633225 .

_:807f36cf91fe4e8caa53aadeff92477633225 rdf:first _:807f36cf91fe4e8caa53aadeff92477633226;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633227 .

_:807f36cf91fe4e8caa53aadeff92477633226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477633227 rdf:first _:807f36cf91fe4e8caa53aadeff92477633228;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633228 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10650 .

_:807f36cf91fe4e8caa53aadeff92477633230 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10527-1 a owl:Class;
  rdfs:label "CAFEINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10527";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633232;
  r:natureDuRisque "Augmentation possible des concentrations plasmatiques de la caféine, avec risque de surdosage, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de caféine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633238, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633232 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633233 .

_:807f36cf91fe4e8caa53aadeff92477633233 rdf:first _:807f36cf91fe4e8caa53aadeff92477633234;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633235 .

_:807f36cf91fe4e8caa53aadeff92477633234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477633235 rdf:first _:807f36cf91fe4e8caa53aadeff92477633236;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633236 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477633238 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10528-1 a owl:Class;
  rdfs:label "CALCITONINE <-> LITHIUM"@fr;
  dct:identifier "IAM_10528";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633240;
  r:natureDuRisque "Risque de baisse de l’efficacité du lithium par augmentation de son élimination rénale par la calcitonine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633246, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633240 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633241 .

_:807f36cf91fe4e8caa53aadeff92477633241 rdf:first _:807f36cf91fe4e8caa53aadeff92477633242;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633243 .

_:807f36cf91fe4e8caa53aadeff92477633242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10148 .

_:807f36cf91fe4e8caa53aadeff92477633243 rdf:first _:807f36cf91fe4e8caa53aadeff92477633244;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633244 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477633246 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10529-1 a owl:Class;
  rdfs:label "CALCIUM <-> CYCLINES"@fr;
  dct:identifier "IAM_10529";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633248;
  r:natureDuRisque "Diminution de l'absorption digestive des cyclines."@fr;
  r:conduiteATenir "Prendre les sels de calcium à distance des cyclines (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633254, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633248 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633249 .

_:807f36cf91fe4e8caa53aadeff92477633249 rdf:first _:807f36cf91fe4e8caa53aadeff92477633250;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633251 .

_:807f36cf91fe4e8caa53aadeff92477633250 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:807f36cf91fe4e8caa53aadeff92477633251 rdf:first _:807f36cf91fe4e8caa53aadeff92477633252;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633252 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477633254 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10530-1 a owl:Class;
  rdfs:label "CALCIUM <-> DIGOXINE"@fr;
  dct:identifier "IAM_10530";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633256;
  r:natureDuRisque "Risque de troubles du rythme graves, voire mortels avec les sels de calcium administrés par voie IV."@fr;
  r:conduiteATenir """Contre-indication :
- avec les sels de calcium IV, hormis supplémentation parentérale.

Précaution d'emploi :
- avec les sels de calcium par voie orale.
Surveillance clinique et, s'il y a lieu, contrôle de l'ECG et de la calcémie."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633262, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633256 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633257 .

_:807f36cf91fe4e8caa53aadeff92477633257 rdf:first _:807f36cf91fe4e8caa53aadeff92477633258;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633259 .

_:807f36cf91fe4e8caa53aadeff92477633258 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477633259 rdf:first _:807f36cf91fe4e8caa53aadeff92477633260;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633260 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477633262 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10531-1 a owl:Class;
  rdfs:label "CALCIUM <-> DIURÉTIQUES THIAZIDIQUES ET APPARENTÉS"@fr;
  dct:identifier "IAM_10531";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633264;
  r:natureDuRisque "Risque d'hypercalcémie par diminution de l'élimination urinaire du calcium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633270, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633264 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633265 .

_:807f36cf91fe4e8caa53aadeff92477633265 rdf:first _:807f36cf91fe4e8caa53aadeff92477633266;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633267 .

_:807f36cf91fe4e8caa53aadeff92477633266 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633267 rdf:first _:807f36cf91fe4e8caa53aadeff92477633268;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633268 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477633270 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10546-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> FELBAMATE"@fr;
  dct:identifier "IAM_10546";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633272;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du métabolite actif de la carbamazépine. De plus, diminution des concentrations plasmatiques de felbamate par augmentation de son métabolisme hépatique par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique, dosages plasmatiques et adaptation éventuelle des posologies des deux anticonvulsivants."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633278, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633272 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633273 .

_:807f36cf91fe4e8caa53aadeff92477633273 rdf:first _:807f36cf91fe4e8caa53aadeff92477633274;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633275 .

_:807f36cf91fe4e8caa53aadeff92477633274 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633275 rdf:first _:807f36cf91fe4e8caa53aadeff92477633276;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10369 .

_:807f36cf91fe4e8caa53aadeff92477633278 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10533-1 a owl:Class;
  rdfs:label "CALCIUM <-> FER"@fr;
  dct:identifier "IAM_10533";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633280;
  r:natureDuRisque "Avec les sels de fer par voie orale : diminution de l'absorption digestive des sels de fer."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance des repas et en l'absence de calcium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633286, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633280 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633281 .

_:807f36cf91fe4e8caa53aadeff92477633281 rdf:first _:807f36cf91fe4e8caa53aadeff92477633282;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633283 .

_:807f36cf91fe4e8caa53aadeff92477633282 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477633283 rdf:first _:807f36cf91fe4e8caa53aadeff92477633284;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477633286 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10545-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> ETHOSUXIMIDE"@fr;
  dct:identifier "IAM_10545";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633288;
  r:natureDuRisque "Diminution des concentrations plasmatiques d'éthosuximide."@fr;
  r:conduiteATenir "Surveillance clinique, dosage plasmatique de l'éthosuximide et augmentation éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633294, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633288 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633289 .

_:807f36cf91fe4e8caa53aadeff92477633289 rdf:first _:807f36cf91fe4e8caa53aadeff92477633290;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633291 .

_:807f36cf91fe4e8caa53aadeff92477633290 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633291 rdf:first _:807f36cf91fe4e8caa53aadeff92477633292;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10352 .

_:807f36cf91fe4e8caa53aadeff92477633294 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10535-1 a owl:Class;
  rdfs:label "CALCIUM <-> STRONTIUM"@fr;
  dct:identifier "IAM_10535";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633296;
  r:natureDuRisque "Avec les sels de calcium administrés par voie orale : diminution de l'absorption digestive du strontium."@fr;
  r:conduiteATenir "Prendre le strontium à distance des sels de calcium (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633302, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633296 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633297 .

_:807f36cf91fe4e8caa53aadeff92477633297 rdf:first _:807f36cf91fe4e8caa53aadeff92477633298;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633299 .

_:807f36cf91fe4e8caa53aadeff92477633298 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477633299 rdf:first _:807f36cf91fe4e8caa53aadeff92477633300;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10863 .

_:807f36cf91fe4e8caa53aadeff92477633302 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10536-1 a owl:Class;
  rdfs:label "CALCIUM <-> ZINC"@fr;
  dct:identifier "IAM_10536";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633304;
  r:natureDuRisque "Diminution de l’absorption digestive du zinc par le calcium."@fr;
  r:conduiteATenir "Prendre les sels de calcium à distance du zinc (plus de 2 heures si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633310, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633304 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633305 .

_:807f36cf91fe4e8caa53aadeff92477633305 rdf:first _:807f36cf91fe4e8caa53aadeff92477633306;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633307 .

_:807f36cf91fe4e8caa53aadeff92477633306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477633307 rdf:first _:807f36cf91fe4e8caa53aadeff92477633308;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11005 .

_:807f36cf91fe4e8caa53aadeff92477633310 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10537-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10537";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633312;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : en début de traitement, augmentation des concentrations plasmatiques de carbamazépine par inhibition de son métabolisme hépatique par la cimétidine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de la carbamazépine, spécialement pendant les premiers jours de traitement par la cimétidine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633318, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633312 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633313 .

_:807f36cf91fe4e8caa53aadeff92477633313 rdf:first _:807f36cf91fe4e8caa53aadeff92477633314;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633315 .

_:807f36cf91fe4e8caa53aadeff92477633314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633315 rdf:first _:807f36cf91fe4e8caa53aadeff92477633316;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477633318 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10538-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> CLARITHROMYCINE"@fr;
  dct:identifier "IAM_10538";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633320;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de la carbamazépine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633326, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633320 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633321 .

_:807f36cf91fe4e8caa53aadeff92477633321 rdf:first _:807f36cf91fe4e8caa53aadeff92477633322;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633323 .

_:807f36cf91fe4e8caa53aadeff92477633322 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633323 rdf:first _:807f36cf91fe4e8caa53aadeff92477633324;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477633326 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10539-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> CLONAZEPAM"@fr;
  dct:identifier "IAM_10539";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633328;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du métabolite actif de la carbamazépine. De plus, diminution des concentrations plasmatiques du clonazépam par augmentation de son métabolisme hépatique par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique, dosages plasmatiques et adaptation éventuelle des posologies des deux anticonvulsivants."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633334, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633328 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633329 .

_:807f36cf91fe4e8caa53aadeff92477633329 rdf:first _:807f36cf91fe4e8caa53aadeff92477633330;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633331 .

_:807f36cf91fe4e8caa53aadeff92477633330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633331 rdf:first _:807f36cf91fe4e8caa53aadeff92477633332;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10213 .

_:807f36cf91fe4e8caa53aadeff92477633334 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10540-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> CLOZAPINE"@fr;
  dct:identifier "IAM_10540";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633336;
  r:natureDuRisque "Risque de majoration des effets hématologiques graves."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633342, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633336 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633337 .

_:807f36cf91fe4e8caa53aadeff92477633337 rdf:first _:807f36cf91fe4e8caa53aadeff92477633338;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633339 .

_:807f36cf91fe4e8caa53aadeff92477633338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633339 rdf:first _:807f36cf91fe4e8caa53aadeff92477633340;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10220 .

_:807f36cf91fe4e8caa53aadeff92477633342 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10541-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> DANAZOL"@fr;
  dct:identifier "IAM_10541";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633344;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine, avec signes de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de la carbamazépine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633350, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633344 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633345 .

_:807f36cf91fe4e8caa53aadeff92477633345 rdf:first _:807f36cf91fe4e8caa53aadeff92477633346;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633347 .

_:807f36cf91fe4e8caa53aadeff92477633346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633347 rdf:first _:807f36cf91fe4e8caa53aadeff92477633348;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:807f36cf91fe4e8caa53aadeff92477633350 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10542-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> DIGOXINE"@fr;
  dct:identifier "IAM_10542";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633352;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine et diminution de la digoxinémie."@fr;
  r:conduiteATenir "Prudence dans l'interprétation des concentrations plasmatiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633358, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633352 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633353 .

_:807f36cf91fe4e8caa53aadeff92477633353 rdf:first _:807f36cf91fe4e8caa53aadeff92477633354;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633355 .

_:807f36cf91fe4e8caa53aadeff92477633354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633355 rdf:first _:807f36cf91fe4e8caa53aadeff92477633356;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477633358 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10543-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> DIURÉTIQUES HYPOKALIÉMIANTS"@fr;
  dct:identifier "IAM_10543";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633360;
  r:natureDuRisque "Risque d'hyponatrémie symptomatique."@fr;
  r:conduiteATenir "Surveillance clinique et biologique. Si possible, utiliser une autre classe de diurétiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633366, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633360 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633361 .

_:807f36cf91fe4e8caa53aadeff92477633361 rdf:first _:807f36cf91fe4e8caa53aadeff92477633362;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633363 .

_:807f36cf91fe4e8caa53aadeff92477633362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10065 .

_:807f36cf91fe4e8caa53aadeff92477633363 rdf:first _:807f36cf91fe4e8caa53aadeff92477633364;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477633366 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10570-1 a owl:Class;
  rdfs:label "CATIORESINE SULFO SODIQUE <-> SORBITOL"@fr;
  dct:identifier "IAM_10570";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633368;
  r:natureDuRisque "Avec la résine administrée par voie orale et rectale : risque de nécrose colique, éventuellement fatale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633374, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633368 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633369 .

_:807f36cf91fe4e8caa53aadeff92477633369 rdf:first _:807f36cf91fe4e8caa53aadeff92477633370;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633371 .

_:807f36cf91fe4e8caa53aadeff92477633370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10167 .

_:807f36cf91fe4e8caa53aadeff92477633371 rdf:first _:807f36cf91fe4e8caa53aadeff92477633372;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10853 .

_:807f36cf91fe4e8caa53aadeff92477633374 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10532-1 a owl:Class;
  rdfs:label "CALCIUM <-> ESTRAMUSTINE"@fr;
  dct:identifier "IAM_10532";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633376;
  r:natureDuRisque "Diminution de l'absorption digestive de l'estramustine."@fr;
  r:conduiteATenir "Prendre les sels de calcium à distance de l'estramustine (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633382, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633376 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633377 .

_:807f36cf91fe4e8caa53aadeff92477633377 rdf:first _:807f36cf91fe4e8caa53aadeff92477633378;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633379 .

_:807f36cf91fe4e8caa53aadeff92477633378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477633379 rdf:first _:807f36cf91fe4e8caa53aadeff92477633380;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10345 .

_:807f36cf91fe4e8caa53aadeff92477633382 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10595-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> NIFEDIPINE"@fr;
  dct:identifier "IAM_10595";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633384;
  r:natureDuRisque "Risque d'addition d'effets indésirables à type de gingivopathies."@fr;
  r:conduiteATenir "Utiliser une autre dihydropyridine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633390, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633384 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633385 .

_:807f36cf91fe4e8caa53aadeff92477633385 rdf:first _:807f36cf91fe4e8caa53aadeff92477633386;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633387 .

_:807f36cf91fe4e8caa53aadeff92477633386 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477633387 rdf:first _:807f36cf91fe4e8caa53aadeff92477633388;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10633 .

_:807f36cf91fe4e8caa53aadeff92477633390 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10568-1 a owl:Class;
  rdfs:label "CARVEDILOL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10568";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633392;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques du carvédilol, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique régulière et adaptation de la posologie du carvédilol pendant le traitement par la rifampicine. A l'arrêt de la rifampicine, risque de remontée importante des concentrations plasmatiques de carvédilol imposant une réduction posologiq"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633398, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633392 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633393 .

_:807f36cf91fe4e8caa53aadeff92477633393 rdf:first _:807f36cf91fe4e8caa53aadeff92477633394;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633395 .

_:807f36cf91fe4e8caa53aadeff92477633394 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10163 .

_:807f36cf91fe4e8caa53aadeff92477633395 rdf:first _:807f36cf91fe4e8caa53aadeff92477633396;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477633398 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11038-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> INHIBITEURS DE LA CATÉCHOL-O-MÉTHYLTRANSFÉRASE (COMT)"@fr;
  dct:identifier "IAM_11038";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633400;
  r:natureDuRisque "Potentialisation des effets pharmacologiques, et notamment vasopresseurs, des catécholamines par inhibition conjuguée de leur métabolisme."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633406, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633400 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633401 .

_:807f36cf91fe4e8caa53aadeff92477633401 rdf:first _:807f36cf91fe4e8caa53aadeff92477633402;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633403 .

_:807f36cf91fe4e8caa53aadeff92477633402 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477633403 rdf:first _:807f36cf91fe4e8caa53aadeff92477633404;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10097 .

_:807f36cf91fe4e8caa53aadeff92477633406 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11039-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_11039";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633408;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  r:conduiteATenir "Respecter un délai de deux semaines entre l'arrêt de l'IMAO et le début du traitement par l'antidépresseur sérotoninergique, et d'au moins une semaine entre l'arrêt de l'antidépresseur sérotoninergique (sauf pour la fluoxétine : cinq semaines) et le début"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633414, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633408 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633409 .

_:807f36cf91fe4e8caa53aadeff92477633409 rdf:first _:807f36cf91fe4e8caa53aadeff92477633410;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633411 .

_:807f36cf91fe4e8caa53aadeff92477633410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477633411 rdf:first _:807f36cf91fe4e8caa53aadeff92477633412;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477633414 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11040-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> MÉDICAMENTS MIXTES ADRÉNERGIQUES-SÉROTONINERGIQUES"@fr;
  dct:identifier "IAM_11040";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633416;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  r:conduiteATenir "Respecter un délai de deux semaines entre l'arrêt de l'IMAO et le début de l'autre traitement, et d'au moins une semaine entre l'arrêt de l'autre traitement et le début de l'IMAO."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633422, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633416 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633417 .

_:807f36cf91fe4e8caa53aadeff92477633417 rdf:first _:807f36cf91fe4e8caa53aadeff92477633418;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633419 .

_:807f36cf91fe4e8caa53aadeff92477633418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477633419 rdf:first _:807f36cf91fe4e8caa53aadeff92477633420;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10116 .

_:807f36cf91fe4e8caa53aadeff92477633422 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11041-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> MIDODRINE"@fr;
  dct:identifier "IAM_11041";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633424;
  r:natureDuRisque "Crises hypertensives (inhibition du métabolisme des amines pressives). Du fait de la durée d'action des IMAO, cette interaction est encore possible 15 jours après l'arrêt de l'IMAO."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633430, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633424 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633425 .

_:807f36cf91fe4e8caa53aadeff92477633425 rdf:first _:807f36cf91fe4e8caa53aadeff92477633426;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633427 .

_:807f36cf91fe4e8caa53aadeff92477633426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477633427 rdf:first _:807f36cf91fe4e8caa53aadeff92477633428;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10587 .

_:807f36cf91fe4e8caa53aadeff92477633430 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10589-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> JOSAMYCINE"@fr;
  dct:identifier "IAM_10589";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633432;
  r:natureDuRisque "Risque d'augmentation des concentrations sanguines de ciclosporine et de la créatininémie."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de la ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après l'arrêt du macrolide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633438, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633432 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633433 .

_:807f36cf91fe4e8caa53aadeff92477633433 rdf:first _:807f36cf91fe4e8caa53aadeff92477633434;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633435 .

_:807f36cf91fe4e8caa53aadeff92477633434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477633435 rdf:first _:807f36cf91fe4e8caa53aadeff92477633436;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477633438 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10590-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> LERCANIDIPINE"@fr;
  dct:identifier "IAM_10590";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633440;
  r:natureDuRisque "Augmentation modérée des concentrations sanguines de l'immunosuppresseur et augmentation plus notable des concentrations de lercanidipine."@fr;
  r:conduiteATenir "Décaler les prises des deux médicaments. Dosage des concentrations sanguines de l'immunosuppresseur, et adaptation si nécessaire de sa posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633446, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633440 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633441 .

_:807f36cf91fe4e8caa53aadeff92477633441 rdf:first _:807f36cf91fe4e8caa53aadeff92477633442;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633443 .

_:807f36cf91fe4e8caa53aadeff92477633442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477633443 rdf:first _:807f36cf91fe4e8caa53aadeff92477633444;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10514 .

_:807f36cf91fe4e8caa53aadeff92477633446 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10591-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10591";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633448;
  r:natureDuRisque "Augmentation de la toxicité du méthotrexate et de la ciclosporine avec augmentation de la créatininémie : diminution réciproque des clairances des deux médicaments."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de ciclosporine et de méthotrexate. Adaptation posologique si nécessaire pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633454, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633448 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633449 .

_:807f36cf91fe4e8caa53aadeff92477633449 rdf:first _:807f36cf91fe4e8caa53aadeff92477633450;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633451 .

_:807f36cf91fe4e8caa53aadeff92477633450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477633451 rdf:first _:807f36cf91fe4e8caa53aadeff92477633452;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477633454 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10592-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> METHYLPREDNISOLONE"@fr;
  dct:identifier "IAM_10592";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633456;
  r:natureDuRisque "Avec la méthylprednisolone administrée par voie IV : augmentation possible des concentrations sanguines de ciclosporine et de la créatininémie. Mécanisme invoqué : diminution de l'élimination hépatique de la ciclosporine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633462, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633456 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633457 .

_:807f36cf91fe4e8caa53aadeff92477633457 rdf:first _:807f36cf91fe4e8caa53aadeff92477633458;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633459 .

_:807f36cf91fe4e8caa53aadeff92477633458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477633459 rdf:first _:807f36cf91fe4e8caa53aadeff92477633460;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10576 .

_:807f36cf91fe4e8caa53aadeff92477633462 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11037-1 a owl:Class;
  rdfs:label "IFOSFAMIDE <-> VÉMURAFÉNIB"@fr;
  dct:identifier "IAM_11037";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633464;
  r:natureDuRisque "Risque de diminution des concentrations de l'ifosfamide, avec augmentation de son métabolite actif et toxicité majorée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633470, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633464 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633465 .

_:807f36cf91fe4e8caa53aadeff92477633465 rdf:first _:807f36cf91fe4e8caa53aadeff92477633466;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633467 .

_:807f36cf91fe4e8caa53aadeff92477633466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10445 .

_:807f36cf91fe4e8caa53aadeff92477633467 rdf:first _:807f36cf91fe4e8caa53aadeff92477633468;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10978 .

_:807f36cf91fe4e8caa53aadeff92477633470 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10594-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> MODAFINIL"@fr;
  dct:identifier "IAM_10594";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633472;
  r:natureDuRisque "Risque de diminution des concentrations sanguines et de l'efficacité de l'immunosuppresseur."@fr;
  rdfs:comment "L’existence d’un seul cas de baisse des concentrations plasmatiques de ciclosporine, lors de l’association à du modafinil, s’explique vraisemblablement par l'indication restreinte du modafinil et son usage limité. Dans la mesure où toute suspicion d’induc"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633478, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633472 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633473 .

_:807f36cf91fe4e8caa53aadeff92477633473 rdf:first _:807f36cf91fe4e8caa53aadeff92477633474;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633475 .

_:807f36cf91fe4e8caa53aadeff92477633474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477633475 rdf:first _:807f36cf91fe4e8caa53aadeff92477633476;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10599 .

_:807f36cf91fe4e8caa53aadeff92477633478 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11036-1 a owl:Class;
  rdfs:label "IFOSFAMIDE <-> PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE)"@fr;
  dct:identifier "IAM_11036";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633480;
  r:natureDuRisque "Risque de majoration de la neurotoxicité de l'ifosfamide par augmentation de son métabolisme hépatique par le phénobarbital."@fr;
  rdfs:comment """L'association entre les cytotoxiques et la phénytoïne, qui faisait l'objet d'un double niveau de contrainte, a été harmonisée en une seule association déconseillée. 
Cette modification s'applique de la même façon à l'interaction entre le phénobarbital et"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633486, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633480 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633481 .

_:807f36cf91fe4e8caa53aadeff92477633481 rdf:first _:807f36cf91fe4e8caa53aadeff92477633482;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633483 .

_:807f36cf91fe4e8caa53aadeff92477633482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477633483 rdf:first _:807f36cf91fe4e8caa53aadeff92477633484;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10445 .

_:807f36cf91fe4e8caa53aadeff92477633486 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10596-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_10596";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633488;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par la ciclosporine."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633494, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633488 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633489 .

_:807f36cf91fe4e8caa53aadeff92477633489 rdf:first _:807f36cf91fe4e8caa53aadeff92477633490;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633491 .

_:807f36cf91fe4e8caa53aadeff92477633490 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477633491 rdf:first _:807f36cf91fe4e8caa53aadeff92477633492;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477633494 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10597-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> ORLISTAT"@fr;
  dct:identifier "IAM_10597";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633496;
  r:natureDuRisque "Diminution des concentrations sanguines de ciclosporine par diminution de son absorption intestinale, avec risque de perte de l'activité immunosuppressive."@fr;
  r:conduiteATenir "Prendre l'orlistat à distance de la ciclosporine (au moins 3 heures). Contrôle renforcé des dosages sanguins de ciclosporine, notamment en début d’association, et lors d’augmentation éventuelle de la posologie de l’orlistat."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633502, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633496 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633497 .

_:807f36cf91fe4e8caa53aadeff92477633497 rdf:first _:807f36cf91fe4e8caa53aadeff92477633498;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633499 .

_:807f36cf91fe4e8caa53aadeff92477633498 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477633499 rdf:first _:807f36cf91fe4e8caa53aadeff92477633500;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477633502 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10598-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> PITAVASTATINE"@fr;
  dct:identifier "IAM_10598";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633504;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, ou de néphrotoxicité, par diminution du métabolisme de la pitavastatine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633510, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633504 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633505 .

_:807f36cf91fe4e8caa53aadeff92477633505 rdf:first _:807f36cf91fe4e8caa53aadeff92477633506;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633507 .

_:807f36cf91fe4e8caa53aadeff92477633506 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477633507 rdf:first _:807f36cf91fe4e8caa53aadeff92477633508;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10735 .

_:807f36cf91fe4e8caa53aadeff92477633510 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10599-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> POTASSIUM"@fr;
  dct:identifier "IAM_10599";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633512;
  r:natureDuRisque "Hyperkaliémie essentiellement létale, surtout lors d'une insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Eviter cette association sauf s'il existe une hypokaliémie préalable."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633518, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633512 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633513 .

_:807f36cf91fe4e8caa53aadeff92477633513 rdf:first _:807f36cf91fe4e8caa53aadeff92477633514;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633515 .

_:807f36cf91fe4e8caa53aadeff92477633514 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477633515 rdf:first _:807f36cf91fe4e8caa53aadeff92477633516;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10742 .

_:807f36cf91fe4e8caa53aadeff92477633518 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10600-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> PREDNISOLONE"@fr;
  dct:identifier "IAM_10600";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633520;
  r:natureDuRisque "Augmentation des effets de la prednisolone : aspect cushingoïde, réduction de la tolérance aux glucides (diminution de la clairance de la prednisolone)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633526, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633520 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633521 .

_:807f36cf91fe4e8caa53aadeff92477633521 rdf:first _:807f36cf91fe4e8caa53aadeff92477633522;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633523 .

_:807f36cf91fe4e8caa53aadeff92477633522 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477633523 rdf:first _:807f36cf91fe4e8caa53aadeff92477633524;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10752 .

_:807f36cf91fe4e8caa53aadeff92477633526 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10601-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> REPAGLINIDE"@fr;
  dct:identifier "IAM_10601";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633528;
  r:natureDuRisque "Augmentation de plus du double des concentrations du répaglinide par augmentation de son absorption."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633534, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633528 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633529 .

_:807f36cf91fe4e8caa53aadeff92477633529 rdf:first _:807f36cf91fe4e8caa53aadeff92477633530;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633531 .

_:807f36cf91fe4e8caa53aadeff92477633530 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477633531 rdf:first _:807f36cf91fe4e8caa53aadeff92477633532;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:807f36cf91fe4e8caa53aadeff92477633534 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10602-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> ROSUVASTATINE"@fr;
  dct:identifier "IAM_10602";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633536;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, ou de néphrotoxicité, par diminution du métabolisme de la rosuvastatine."@fr;
  rdfs:comment "La ciclosporine entraîne un doublement des concentrations de l'hypolipémiant. La rosuvastatine ayant une marge thérapeutique étroite et exposant à un risque musculaire et rénal imprévisible, cette association est contre-indiquée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633542, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633536 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633537 .

_:807f36cf91fe4e8caa53aadeff92477633537 rdf:first _:807f36cf91fe4e8caa53aadeff92477633538;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633539 .

_:807f36cf91fe4e8caa53aadeff92477633538 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477633539 rdf:first _:807f36cf91fe4e8caa53aadeff92477633540;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10814 .

_:807f36cf91fe4e8caa53aadeff92477633542 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10603-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> ROXITHROMYCINE"@fr;
  dct:identifier "IAM_10603";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633544;
  r:natureDuRisque "Risque d'augmentation des concentrations sanguines de ciclosporine et de la créatininémie."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de la ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après l'arrêt du macrolide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633550, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633544 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633545 .

_:807f36cf91fe4e8caa53aadeff92477633545 rdf:first _:807f36cf91fe4e8caa53aadeff92477633546;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633547 .

_:807f36cf91fe4e8caa53aadeff92477633546 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477633547 rdf:first _:807f36cf91fe4e8caa53aadeff92477633548;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10817 .

_:807f36cf91fe4e8caa53aadeff92477633550 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10604-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10604";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633552;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse par diminution du métabolisme de la simvastatine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633558, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633552 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633553 .

_:807f36cf91fe4e8caa53aadeff92477633553 rdf:first _:807f36cf91fe4e8caa53aadeff92477633554;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633555 .

_:807f36cf91fe4e8caa53aadeff92477633554 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477633555 rdf:first _:807f36cf91fe4e8caa53aadeff92477633556;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477633558 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10605-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> SIROLIMUS"@fr;
  dct:identifier "IAM_10605";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633560;
  r:natureDuRisque "Augmentation des concentrations sanguines de sirolimus par la ciclosporine. La néphrotoxicité de la ciclosporine est également augmentée lors de l’association."@fr;
  r:conduiteATenir "Il est recommandé d’administrer le sirolimus 4 heures après la ciclosporine. Contrôle de la fonction rénale, pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633566, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633560 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633561 .

_:807f36cf91fe4e8caa53aadeff92477633561 rdf:first _:807f36cf91fe4e8caa53aadeff92477633562;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633563 .

_:807f36cf91fe4e8caa53aadeff92477633562 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477633563 rdf:first _:807f36cf91fe4e8caa53aadeff92477633564;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10839 .

_:807f36cf91fe4e8caa53aadeff92477633566 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10593-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> MIDECAMYCINE"@fr;
  dct:identifier "IAM_10593";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633568;
  r:natureDuRisque "Risque d'augmentation des concentrations sanguines de ciclosporine et de la créatininémie."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de la ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après l'arrêt du macrolide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633574, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633568 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633569 .

_:807f36cf91fe4e8caa53aadeff92477633569 rdf:first _:807f36cf91fe4e8caa53aadeff92477633570;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633571 .

_:807f36cf91fe4e8caa53aadeff92477633570 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477633571 rdf:first _:807f36cf91fe4e8caa53aadeff92477633572;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10586 .

_:807f36cf91fe4e8caa53aadeff92477633574 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11289-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> ÉRIBULINE"@fr;
  dct:identifier "IAM_11289";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633576;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques d’éribuline par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633582, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633576 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633577 .

_:807f36cf91fe4e8caa53aadeff92477633577 rdf:first _:807f36cf91fe4e8caa53aadeff92477633578;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633579 .

_:807f36cf91fe4e8caa53aadeff92477633578 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10335 .

_:807f36cf91fe4e8caa53aadeff92477633579 rdf:first _:807f36cf91fe4e8caa53aadeff92477633580;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477633582 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10302-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> LÉDIPASVIR"@fr;
  dct:identifier "IAM_10302";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633584;
  r:natureDuRisque "Diminution des concentrations du lédipasvir en cas d’administration de l’inhibiteur de la pompe à protons avant le lédipasvir."@fr;
  r:conduiteATenir "Il est recommandé de prendre l'’inhibiteur de la pompe à protons et le lédipasvir simultanément."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633590, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633584 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633585 .

_:807f36cf91fe4e8caa53aadeff92477633585 rdf:first _:807f36cf91fe4e8caa53aadeff92477633586;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633587 .

_:807f36cf91fe4e8caa53aadeff92477633586 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477633587 rdf:first _:807f36cf91fe4e8caa53aadeff92477633588;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:807f36cf91fe4e8caa53aadeff92477633590 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10571-1 a owl:Class;
  rdfs:label "CHLORDIAZEPOXIDE <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10571";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633592;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : risque accru de somnolence."@fr;
  r:conduiteATenir "Avertir les patients de l'augmentation du risque en cas de conduite automobile ou d'utilisation de machines."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633598, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633592 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633593 .

_:807f36cf91fe4e8caa53aadeff92477633593 rdf:first _:807f36cf91fe4e8caa53aadeff92477633594;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633595 .

_:807f36cf91fe4e8caa53aadeff92477633594 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10182 .

_:807f36cf91fe4e8caa53aadeff92477633595 rdf:first _:807f36cf91fe4e8caa53aadeff92477633596;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477633598 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10572-1 a owl:Class;
  rdfs:label "CHLOROQUINE <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10572";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633600;
  r:natureDuRisque "Risque d'augmentation des concentrations sanguines de ciclosporine et de la créatininémie."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après l'arrêt de la chloroquine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633606, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633600 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633601 .

_:807f36cf91fe4e8caa53aadeff92477633601 rdf:first _:807f36cf91fe4e8caa53aadeff92477633602;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633603 .

_:807f36cf91fe4e8caa53aadeff92477633602 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10184 .

_:807f36cf91fe4e8caa53aadeff92477633603 rdf:first _:807f36cf91fe4e8caa53aadeff92477633604;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477633606 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10573-1 a owl:Class;
  rdfs:label "CHLOROQUINE <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10573";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633608;
  r:natureDuRisque "Ralentissement de l’élimination de la chloroquine et risque de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633614, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633608 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633609 .

_:807f36cf91fe4e8caa53aadeff92477633609 rdf:first _:807f36cf91fe4e8caa53aadeff92477633610;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633611 .

_:807f36cf91fe4e8caa53aadeff92477633610 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10184 .

_:807f36cf91fe4e8caa53aadeff92477633611 rdf:first _:807f36cf91fe4e8caa53aadeff92477633612;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477633614 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10574-1 a owl:Class;
  rdfs:label "CHLOROQUINE <-> HORMONES THYROÏDIENNES"@fr;
  dct:identifier "IAM_10574";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633616;
  r:natureDuRisque "Risque d’hypothyroïdie clinique chez les patients substitués par hormones thyroïdiennes."@fr;
  r:conduiteATenir "Surveillance des concentrations sériques de T3 et de T4 et adaptation, si besoin, de la posologie de l'hormone thyroïdienne pendant le traitement par l’antipaludique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633622, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633616 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633617 .

_:807f36cf91fe4e8caa53aadeff92477633617 rdf:first _:807f36cf91fe4e8caa53aadeff92477633618;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633619 .

_:807f36cf91fe4e8caa53aadeff92477633618 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477633619 rdf:first _:807f36cf91fe4e8caa53aadeff92477633620;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10184 .

_:807f36cf91fe4e8caa53aadeff92477633622 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10575-1 a owl:Class;
  rdfs:label "CHLORPROMAZINE <-> INSULINE"@fr;
  dct:identifier "IAM_10575";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633624;
  r:natureDuRisque "A fortes posologies (100 mg par jour de chlorpromazine) : élévation de la glycémie (diminution de la libération de l'insuline)."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer l'autosurveillance glycémique. Adapter éventuellement la posologie de l'insuline pendant le traitement par le neuroleptique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633630, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633624 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633625 .

_:807f36cf91fe4e8caa53aadeff92477633625 rdf:first _:807f36cf91fe4e8caa53aadeff92477633626;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633627 .

_:807f36cf91fe4e8caa53aadeff92477633626 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10186 .

_:807f36cf91fe4e8caa53aadeff92477633627 rdf:first _:807f36cf91fe4e8caa53aadeff92477633628;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:807f36cf91fe4e8caa53aadeff92477633630 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10576-1 a owl:Class;
  rdfs:label "CHLORPROMAZINE <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10576";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633632;
  r:natureDuRisque "A fortes posologies (100 mg par jour de chlorpromazine) : élévation de la glycémie (diminution de la libération de l'insuline)."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer l'autosurveillance glycémique. Adapter éventuellement la posologie du neuroleptique pendant le traitement et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633638, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633632 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633633 .

_:807f36cf91fe4e8caa53aadeff92477633633 rdf:first _:807f36cf91fe4e8caa53aadeff92477633634;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633635 .

_:807f36cf91fe4e8caa53aadeff92477633634 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477633635 rdf:first _:807f36cf91fe4e8caa53aadeff92477633636;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10186 .

_:807f36cf91fe4e8caa53aadeff92477633638 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10888-1 a owl:Class;
  rdfs:label "ERGOTAMINE <-> TRICLABENDAZOLE"@fr;
  dct:identifier "IAM_10888";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633640;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l’alcaloïde de l’ergot de seigle)."@fr;
  r:conduiteATenir "Respecter un délai de 24 heures entre l’arrêt du triclabendazole et l’ergotamine, et inversement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633646, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633640 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633641 .

_:807f36cf91fe4e8caa53aadeff92477633641 rdf:first _:807f36cf91fe4e8caa53aadeff92477633642;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633643 .

_:807f36cf91fe4e8caa53aadeff92477633642 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:807f36cf91fe4e8caa53aadeff92477633643 rdf:first _:807f36cf91fe4e8caa53aadeff92477633644;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10953 .

_:807f36cf91fe4e8caa53aadeff92477633646 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11461-1 a owl:Class;
  rdfs:label "VERAPAMIL <-> ÉRIBULINE"@fr;
  dct:identifier "IAM_11461";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633648;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’éribuline par le vérapamil."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633654, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633648 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633649 .

_:807f36cf91fe4e8caa53aadeff92477633649 rdf:first _:807f36cf91fe4e8caa53aadeff92477633650;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633651 .

_:807f36cf91fe4e8caa53aadeff92477633650 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10335 .

_:807f36cf91fe4e8caa53aadeff92477633651 rdf:first _:807f36cf91fe4e8caa53aadeff92477633652;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477633654 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10077-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> IMAO IRRÉVERSIBLES"@fr;
  dct:identifier "IAM_10077";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633656;
  r:natureDuRisque "Majoration des effets hypertenseurs et/ou hyperthermiques de la tyramine présente dans certaines boissons alcoolisées (chianti, certaines bières, etc)."@fr;
  r:conduiteATenir "Eviter la prise de boissons alcoolisées et de médicaments contenant de l'alcool."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633662, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633656 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633657 .

_:807f36cf91fe4e8caa53aadeff92477633657 rdf:first _:807f36cf91fe4e8caa53aadeff92477633658;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633659 .

_:807f36cf91fe4e8caa53aadeff92477633658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477633659 rdf:first _:807f36cf91fe4e8caa53aadeff92477633660;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:807f36cf91fe4e8caa53aadeff92477633662 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11124-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> ÉRIBULINE"@fr;
  dct:identifier "IAM_11124";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633664;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’éribuline par le ritonavir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633670, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633664 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633665 .

_:807f36cf91fe4e8caa53aadeff92477633665 rdf:first _:807f36cf91fe4e8caa53aadeff92477633666;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633667 .

_:807f36cf91fe4e8caa53aadeff92477633666 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477633667 rdf:first _:807f36cf91fe4e8caa53aadeff92477633668;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633668 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10335 .

_:807f36cf91fe4e8caa53aadeff92477633670 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10569-1 a owl:Class;
  rdfs:label "CATIORESINE SULFO CALCIQUE <-> SORBITOL"@fr;
  dct:identifier "IAM_10569";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633672;
  r:natureDuRisque "Avec la résine administrée par voie orale et rectale : risque de nécrose colique, éventuellement fatale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633678, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633672 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633673 .

_:807f36cf91fe4e8caa53aadeff92477633673 rdf:first _:807f36cf91fe4e8caa53aadeff92477633674;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633675 .

_:807f36cf91fe4e8caa53aadeff92477633674 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10166 .

_:807f36cf91fe4e8caa53aadeff92477633675 rdf:first _:807f36cf91fe4e8caa53aadeff92477633676;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633676 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10853 .

_:807f36cf91fe4e8caa53aadeff92477633678 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10893-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> LUMEFANTRINE"@fr;
  dct:identifier "IAM_10893";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633680;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre le torsadogène associé. Si l'association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633686, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633680 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633681 .

_:807f36cf91fe4e8caa53aadeff92477633681 rdf:first _:807f36cf91fe4e8caa53aadeff92477633682;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633683 .

_:807f36cf91fe4e8caa53aadeff92477633682 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477633683 rdf:first _:807f36cf91fe4e8caa53aadeff92477633684;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633684 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10541 .

_:807f36cf91fe4e8caa53aadeff92477633686 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10901-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_10901";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633688;
  r:natureDuRisque "Risque de majoration de la toxicité de l'antimitotique par diminution de son métabolisme hépatique par l' érythromycine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique étroite. Eventuellement, utiliser un autre antibiotique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633694, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633688 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633689 .

_:807f36cf91fe4e8caa53aadeff92477633689 rdf:first _:807f36cf91fe4e8caa53aadeff92477633690;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633691 .

_:807f36cf91fe4e8caa53aadeff92477633690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:807f36cf91fe4e8caa53aadeff92477633691 rdf:first _:807f36cf91fe4e8caa53aadeff92477633692;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633692 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477633694 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10889-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> FIDAXOMICINE"@fr;
  dct:identifier "IAM_10889";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633696;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633702, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633696 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633697 .

_:807f36cf91fe4e8caa53aadeff92477633697 rdf:first _:807f36cf91fe4e8caa53aadeff92477633698;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633699 .

_:807f36cf91fe4e8caa53aadeff92477633698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477633699 rdf:first _:807f36cf91fe4e8caa53aadeff92477633700;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633700 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:807f36cf91fe4e8caa53aadeff92477633702 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10890-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> GLIBENCLAMIDE"@fr;
  dct:identifier "IAM_10890";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633704;
  r:natureDuRisque "Risque d'hypoglycémie par augmentation de l’absorption et des concentrations plasmatiques de l’antidiabétique."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide hypoglycémiant pendant le traitement par l’érythromycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633710, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633704 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633705 .

_:807f36cf91fe4e8caa53aadeff92477633705 rdf:first _:807f36cf91fe4e8caa53aadeff92477633706;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633707 .

_:807f36cf91fe4e8caa53aadeff92477633706 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477633707 rdf:first _:807f36cf91fe4e8caa53aadeff92477633708;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633708 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10414 .

_:807f36cf91fe4e8caa53aadeff92477633710 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10421-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS MÉDICAMENTS HYPONATRÉMIANTS <-> HYPONATRÉMIANTS"@fr;
  dct:identifier "IAM_10421";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633712;
  r:natureDuRisque "Majoration du risque d’hyponatrémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633714, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10087 .

_:807f36cf91fe4e8caa53aadeff92477633714 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11031-1 a owl:Class;
  rdfs:label "IBRUTINIB <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11031";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633716;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’ibrutinib par diminution de son métabolisme hépatique par le vérapamil."@fr;
  r:conduiteATenir "Surveiller clinique étroite et réduction de la dose d’ibrutinib à 140 mg par jour pendant la durée de l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633722, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633716 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633717 .

_:807f36cf91fe4e8caa53aadeff92477633717 rdf:first _:807f36cf91fe4e8caa53aadeff92477633718;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633719 .

_:807f36cf91fe4e8caa53aadeff92477633718 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10441 .

_:807f36cf91fe4e8caa53aadeff92477633719 rdf:first _:807f36cf91fe4e8caa53aadeff92477633720;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477633722 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11032-1 a owl:Class;
  rdfs:label "IDÉLALISIB <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11032";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633724;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’idélalisib par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633730, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633724 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633725 .

_:807f36cf91fe4e8caa53aadeff92477633725 rdf:first _:807f36cf91fe4e8caa53aadeff92477633726;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633727 .

_:807f36cf91fe4e8caa53aadeff92477633726 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477633727 rdf:first _:807f36cf91fe4e8caa53aadeff92477633728;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10444 .

_:807f36cf91fe4e8caa53aadeff92477633730 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11033-1 a owl:Class;
  rdfs:label "IDÉLALISIB <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11033";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633732;
  r:natureDuRisque "Risque de diminution importante des concentrations plasmatiques d’idélalisib par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633738, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633732 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633733 .

_:807f36cf91fe4e8caa53aadeff92477633733 rdf:first _:807f36cf91fe4e8caa53aadeff92477633734;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633735 .

_:807f36cf91fe4e8caa53aadeff92477633734 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10444 .

_:807f36cf91fe4e8caa53aadeff92477633735 rdf:first _:807f36cf91fe4e8caa53aadeff92477633736;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477633738 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11034-1 a owl:Class;
  rdfs:label "IDÉLALISIB <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11034";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633740;
  r:natureDuRisque "Diminution des concentrations plasmatiques d’idélalisib par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633746, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633740 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633741 .

_:807f36cf91fe4e8caa53aadeff92477633741 rdf:first _:807f36cf91fe4e8caa53aadeff92477633742;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633743 .

_:807f36cf91fe4e8caa53aadeff92477633742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10444 .

_:807f36cf91fe4e8caa53aadeff92477633743 rdf:first _:807f36cf91fe4e8caa53aadeff92477633744;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477633746 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11035-1 a owl:Class;
  rdfs:label "IDÉLALISIB <-> SUBSTRATS À RISQUE DU CYP3A4"@fr;
  dct:identifier "IAM_11035";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633748;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du substrat par diminution de son métabolisme hépatique par l’idelalisib."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633754, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633748 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633749 .

_:807f36cf91fe4e8caa53aadeff92477633749 rdf:first _:807f36cf91fe4e8caa53aadeff92477633750;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633751 .

_:807f36cf91fe4e8caa53aadeff92477633750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10145 .

_:807f36cf91fe4e8caa53aadeff92477633751 rdf:first _:807f36cf91fe4e8caa53aadeff92477633752;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10444 .

_:807f36cf91fe4e8caa53aadeff92477633754 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11087-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> ÉRIBULINE"@fr;
  dct:identifier "IAM_11087";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633756;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques d’éribuline par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633762, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633756 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633757 .

_:807f36cf91fe4e8caa53aadeff92477633757 rdf:first _:807f36cf91fe4e8caa53aadeff92477633758;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633759 .

_:807f36cf91fe4e8caa53aadeff92477633758 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477633759 rdf:first _:807f36cf91fe4e8caa53aadeff92477633760;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10335 .

_:807f36cf91fe4e8caa53aadeff92477633762 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10138-1 a owl:Class;
  rdfs:label "AMIODARONE <-> OLAPARIB"@fr;
  dct:identifier "IAM_10138";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633764;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’olaparib par l' amiodarone"@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, limiter la dose d’olaparib à 200 mg 2 fois par jour avec l’amiodarone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633770, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633764 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633765 .

_:807f36cf91fe4e8caa53aadeff92477633765 rdf:first _:807f36cf91fe4e8caa53aadeff92477633766;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633767 .

_:807f36cf91fe4e8caa53aadeff92477633766 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633767 rdf:first _:807f36cf91fe4e8caa53aadeff92477633768;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10659 .

_:807f36cf91fe4e8caa53aadeff92477633770 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10127-1 a owl:Class;
  rdfs:label "AMIODARONE <-> DABIGATRAN"@fr;
  dct:identifier "IAM_10127";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633772;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de dabigatran, avec majoration du risque de saignement."@fr;
  r:conduiteATenir "Dans l'indication post-chirurgicale : surveillance clinique et adaptation de la posologie du dabigatran si nécessaire, sans excéder 150 mg/j."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633778, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633772 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633773 .

_:807f36cf91fe4e8caa53aadeff92477633773 rdf:first _:807f36cf91fe4e8caa53aadeff92477633774;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633775 .

_:807f36cf91fe4e8caa53aadeff92477633774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633775 rdf:first _:807f36cf91fe4e8caa53aadeff92477633776;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff92477633778 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10128-1 a owl:Class;
  rdfs:label "AMIODARONE <-> DACLATASVIR"@fr;
  dct:identifier "IAM_10128";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633780;
  r:natureDuRisque """Uniquement lors de la bithérapie daclatasvir/sofosbuvir :
Survenue de bradycardie éventuellement brutale, pouvant avoir des conséquences fatales."""@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique et ECG étroite, en particulier pendant les premières semaines de traitement par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633786, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633780 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633781 .

_:807f36cf91fe4e8caa53aadeff92477633781 rdf:first _:807f36cf91fe4e8caa53aadeff92477633782;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633783 .

_:807f36cf91fe4e8caa53aadeff92477633782 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633783 rdf:first _:807f36cf91fe4e8caa53aadeff92477633784;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10243 .

_:807f36cf91fe4e8caa53aadeff92477633786 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10129-1 a owl:Class;
  rdfs:label "AMIODARONE <-> DIGOXINE"@fr;
  dct:identifier "IAM_10129";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633788;
  r:natureDuRisque "Dépression de l'automatisme (bradycardie excessive) et troubles de la conduction auriculo-ventriculaire. De plus, augmentation de la digoxinémie par diminution de la clairance de la digoxine."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et, s'il y a lieu, contrôle de la digoxinémie et adaptation de la posologie de la digoxine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633794, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633788 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633789 .

_:807f36cf91fe4e8caa53aadeff92477633789 rdf:first _:807f36cf91fe4e8caa53aadeff92477633790;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633791 .

_:807f36cf91fe4e8caa53aadeff92477633790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633791 rdf:first _:807f36cf91fe4e8caa53aadeff92477633792;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477633794 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10130-1 a owl:Class;
  rdfs:label "AMIODARONE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10130";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633796;
  r:natureDuRisque """Pour diltiazem voie injectable : risque de bradycardie et de bloc auriculo-ventriculaire

Pour diltiazem per os : risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez les personnes âgées."""@fr;
  r:conduiteATenir """Précaution d'emploi avec :
- le diltiazem per os
Surveillance clinique et ECG."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633802, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633796 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633797 .

_:807f36cf91fe4e8caa53aadeff92477633797 rdf:first _:807f36cf91fe4e8caa53aadeff92477633798;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633799 .

_:807f36cf91fe4e8caa53aadeff92477633798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633799 rdf:first _:807f36cf91fe4e8caa53aadeff92477633800;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477633802 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10131-1 a owl:Class;
  rdfs:label "AMIODARONE <-> ESMOLOL"@fr;
  dct:identifier "IAM_10131";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633804;
  r:natureDuRisque "Troubles de la contractilité, de l'automatisme et de la conduction (suppression des mécanismes sympathiques compensateurs)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633810, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633804 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633805 .

_:807f36cf91fe4e8caa53aadeff92477633805 rdf:first _:807f36cf91fe4e8caa53aadeff92477633806;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633807 .

_:807f36cf91fe4e8caa53aadeff92477633806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633807 rdf:first _:807f36cf91fe4e8caa53aadeff92477633808;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:807f36cf91fe4e8caa53aadeff92477633810 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10132-1 a owl:Class;
  rdfs:label "AMIODARONE <-> FIDAXOMICINE"@fr;
  dct:identifier "IAM_10132";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633812;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633818, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633812 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633813 .

_:807f36cf91fe4e8caa53aadeff92477633813 rdf:first _:807f36cf91fe4e8caa53aadeff92477633814;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633815 .

_:807f36cf91fe4e8caa53aadeff92477633814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633815 rdf:first _:807f36cf91fe4e8caa53aadeff92477633816;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:807f36cf91fe4e8caa53aadeff92477633818 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10133-1 a owl:Class;
  rdfs:label "AMIODARONE <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10133";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633820;
  r:natureDuRisque "Risque d’allongement de l’intervalle QT."@fr;
  r:conduiteATenir "Surveillance clinique, particulièrement aux fortes doses de fluconazole (800 mg/j)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633826, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633820 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633821 .

_:807f36cf91fe4e8caa53aadeff92477633821 rdf:first _:807f36cf91fe4e8caa53aadeff92477633822;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633823 .

_:807f36cf91fe4e8caa53aadeff92477633822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633823 rdf:first _:807f36cf91fe4e8caa53aadeff92477633824;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477633826 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10134-1 a owl:Class;
  rdfs:label "AMIODARONE <-> IBRUTINIB"@fr;
  dct:identifier "IAM_10134";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633828;
  r:natureDuRisque "Risque d'augmentation des concentrations plasmatiques d’ibrutinib par diminution de son métabolisme hépatique par l’amiodarone."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique étroite et réduction de la dose d’ibrutinib à 140 mg par jour pendant la durée de l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633834, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633828 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633829 .

_:807f36cf91fe4e8caa53aadeff92477633829 rdf:first _:807f36cf91fe4e8caa53aadeff92477633830;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633831 .

_:807f36cf91fe4e8caa53aadeff92477633830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633831 rdf:first _:807f36cf91fe4e8caa53aadeff92477633832;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10441 .

_:807f36cf91fe4e8caa53aadeff92477633834 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10135-1 a owl:Class;
  rdfs:label "AMIODARONE <-> LÉDIPASVIR"@fr;
  dct:identifier "IAM_10135";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633836;
  r:natureDuRisque "Uniquement lors de la bithérapie lédipasvir/sofosbuvir, survenue de bradycardie, éventuellement brutale, pouvant avoir des conséquences fatales."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, il est recommandé de surveiller étroitement les patients, en particulier pendant les premières semaines de traitement par la bithérapie (surveillance clinique et ECG)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633842, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633836 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633837 .

_:807f36cf91fe4e8caa53aadeff92477633837 rdf:first _:807f36cf91fe4e8caa53aadeff92477633838;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633839 .

_:807f36cf91fe4e8caa53aadeff92477633838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633839 rdf:first _:807f36cf91fe4e8caa53aadeff92477633840;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:807f36cf91fe4e8caa53aadeff92477633842 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10059-1 a owl:Class;
  rdfs:label "ALBENDAZOLE <-> ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10059";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633844;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques de l’albendazole et de son métabolite actif par l’inducteur, avec risque de baisse de son efficacité."@fr;
  r:conduiteATenir "Surveillance clinique de la réponse thérapeutique et adaptation éventuelle de la posologie de l’albendazole pendant le traitement avec l’inducteur enzymatique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633850, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633844 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633845 .

_:807f36cf91fe4e8caa53aadeff92477633845 rdf:first _:807f36cf91fe4e8caa53aadeff92477633846;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633847 .

_:807f36cf91fe4e8caa53aadeff92477633846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477633847 rdf:first _:807f36cf91fe4e8caa53aadeff92477633848;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477633850 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10137-1 a owl:Class;
  rdfs:label "AMIODARONE <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_10137";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633852;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par l'amiodarone."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633858, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633852 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633853 .

_:807f36cf91fe4e8caa53aadeff92477633853 rdf:first _:807f36cf91fe4e8caa53aadeff92477633854;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633855 .

_:807f36cf91fe4e8caa53aadeff92477633854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633855 rdf:first _:807f36cf91fe4e8caa53aadeff92477633856;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477633858 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10124-1 a owl:Class;
  rdfs:label "AMIODARONE <-> BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE"@fr;
  dct:identifier "IAM_10124";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633860;
  r:chapeau """A l’heure actuelle, 4 bêta-bloquants ont l'indication \"insuffisance cardiaque\" : le carvédilol, le bisoprolol, le métoprolol et le névibolol.
Les interactions médicamenteuses des bêta-bloquants, lorsqu’ils sont prescrits dans l’insuffisance cardiaque, pe"""@fr;
  r:natureDuRisque "Troubles de l'automatisme et de la conduction cardiaque avec risque de bradycardie excessive."@fr;
  r:conduiteATenir "Surveillance clinique et ECG régulière."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633866, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633860 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633861 .

_:807f36cf91fe4e8caa53aadeff92477633861 rdf:first _:807f36cf91fe4e8caa53aadeff92477633862;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633863 .

_:807f36cf91fe4e8caa53aadeff92477633862 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477633863 rdf:first _:807f36cf91fe4e8caa53aadeff92477633864;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633866 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10139-1 a owl:Class;
  rdfs:label "AMIODARONE <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10139";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633868;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'amiodarone par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633874, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633868 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633869 .

_:807f36cf91fe4e8caa53aadeff92477633869 rdf:first _:807f36cf91fe4e8caa53aadeff92477633870;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633871 .

_:807f36cf91fe4e8caa53aadeff92477633870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477633871 rdf:first _:807f36cf91fe4e8caa53aadeff92477633872;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633874 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10140-1 a owl:Class;
  rdfs:label "AMIODARONE <-> ORLISTAT"@fr;
  dct:identifier "IAM_10140";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633876;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de l'amiodarone et de son métabolite actif."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633882, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633876 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633877 .

_:807f36cf91fe4e8caa53aadeff92477633877 rdf:first _:807f36cf91fe4e8caa53aadeff92477633878;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633879 .

_:807f36cf91fe4e8caa53aadeff92477633878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633879 rdf:first _:807f36cf91fe4e8caa53aadeff92477633880;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477633882 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10141-1 a owl:Class;
  rdfs:label "AMIODARONE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10141";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633884;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la phénytoïne avec signes de surdosage, en particulier neurologiques (diminution du métabolisme hépatique de la phénytoïne)."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques de phénytoïne et adaptation éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633890, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633884 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633885 .

_:807f36cf91fe4e8caa53aadeff92477633885 rdf:first _:807f36cf91fe4e8caa53aadeff92477633886;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633887 .

_:807f36cf91fe4e8caa53aadeff92477633886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477633887 rdf:first _:807f36cf91fe4e8caa53aadeff92477633888;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633890 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10142-1 a owl:Class;
  rdfs:label "AMIODARONE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10142";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633892;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de la simvastatine)."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 20 mg/j de simvastatine ou utiliser une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633898, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633892 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633893 .

_:807f36cf91fe4e8caa53aadeff92477633893 rdf:first _:807f36cf91fe4e8caa53aadeff92477633894;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633895 .

_:807f36cf91fe4e8caa53aadeff92477633894 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633895 rdf:first _:807f36cf91fe4e8caa53aadeff92477633896;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477633898 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10143-1 a owl:Class;
  rdfs:label "AMIODARONE <-> SOFOSBUVIR"@fr;
  dct:identifier "IAM_10143";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633900;
  r:natureDuRisque """Uniquement lors de la bithérapie daclatasvir/sofosbuvir ou lédipasvir/sofosbuvir :
Survenue de bradycardie éventuellement brutale, pouvant avoir des conséquences fatales."""@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique et ECG étroite, en particulier pendant les premières semaines de traitement par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633906, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633900 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633901 .

_:807f36cf91fe4e8caa53aadeff92477633901 rdf:first _:807f36cf91fe4e8caa53aadeff92477633902;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633903 .

_:807f36cf91fe4e8caa53aadeff92477633902 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633903 rdf:first _:807f36cf91fe4e8caa53aadeff92477633904;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10850 .

_:807f36cf91fe4e8caa53aadeff92477633906 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10144-1 a owl:Class;
  rdfs:label "AMIODARONE <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10144";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633908;
  r:natureDuRisque "Augmentation des concentrations sanguines de tacrolimus par inhibition de son métabolisme par l’amiodarone."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de tacrolimus, contrôle de la fonction rénale et adaptation de la posologie de tacrolimus pendant l’association et à l’arrêt de l’amiodarone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633914, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633908 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633909 .

_:807f36cf91fe4e8caa53aadeff92477633909 rdf:first _:807f36cf91fe4e8caa53aadeff92477633910;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633911 .

_:807f36cf91fe4e8caa53aadeff92477633910 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633911 rdf:first _:807f36cf91fe4e8caa53aadeff92477633912;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477633914 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10145-1 a owl:Class;
  rdfs:label "AMIODARONE <-> TAMSULOSINE"@fr;
  dct:identifier "IAM_10145";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633916;
  r:natureDuRisque "Risque de majoration des effets indésirables de la tamsulosine, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la tamsulosine pendant le traitement par l’inhibiteur enzymatique et après son arrêt, le cas échéant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633922, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633916 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633917 .

_:807f36cf91fe4e8caa53aadeff92477633917 rdf:first _:807f36cf91fe4e8caa53aadeff92477633918;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633919 .

_:807f36cf91fe4e8caa53aadeff92477633918 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633919 rdf:first _:807f36cf91fe4e8caa53aadeff92477633920;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10883 .

_:807f36cf91fe4e8caa53aadeff92477633922 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10147-1 a owl:Class;
  rdfs:label "AMIODARONE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10147";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633924;
  r:natureDuRisque """Pour vérapamil voie injectable :
-risque de bradycardie ou de bloc auriculo-ventriculaire.

Pour vérapamil per os :
-risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez les personnes âgées."""@fr;
  r:conduiteATenir """Association déconseillée avec :
- le vérapamil IV
Si l'association ne peut être évitée, surveillance clinique et ECG continu.

Précaution d'emploi avec :
- le vérapamil per os
Surveillance clinique et ECG."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633930, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633924 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633925 .

_:807f36cf91fe4e8caa53aadeff92477633925 rdf:first _:807f36cf91fe4e8caa53aadeff92477633926;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633927 .

_:807f36cf91fe4e8caa53aadeff92477633926 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633927 rdf:first _:807f36cf91fe4e8caa53aadeff92477633928;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477633930 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10148-1 a owl:Class;
  rdfs:label "AMIODARONE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10148";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633932;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes, par possible diminution du métabolisme de l’amiodarone."@fr;
  r:conduiteATenir "Surveillance clinique et ECG, et adaptation éventuelle de la posologie de l’amiodarone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633938, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633932 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633933 .

_:807f36cf91fe4e8caa53aadeff92477633933 rdf:first _:807f36cf91fe4e8caa53aadeff92477633934;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633935 .

_:807f36cf91fe4e8caa53aadeff92477633934 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633935 rdf:first _:807f36cf91fe4e8caa53aadeff92477633936;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477633938 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10136-1 a owl:Class;
  rdfs:label "AMIODARONE <-> LIDOCAINE"@fr;
  dct:identifier "IAM_10136";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633940;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de lidocaïne, avec possibilité d’effets indésirables neurologiques et cardiaques, par diminution de son métabolisme hépatique par l’amiodarone."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement contrôle des concentrations plasmatiques de lidocaïne. Si besoin, adaptation de la posologie de la lidocaïne pendant le traitement par amiodarone et après son arrêt."@fr;
  rdfs:comment "La littérature rapporte des cas d’augmentation des effets indésirables de la lidocaïne lorsqu'elle est associée à l’amiodarone. Il s’agit d’une interaction métabolique avec augmentation des concentrations plasmatiques de lidocaïne, l’amiodarone étant un i"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633946, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633940 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633941 .

_:807f36cf91fe4e8caa53aadeff92477633941 rdf:first _:807f36cf91fe4e8caa53aadeff92477633942;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633943 .

_:807f36cf91fe4e8caa53aadeff92477633942 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477633943 rdf:first _:807f36cf91fe4e8caa53aadeff92477633944;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10523 .

_:807f36cf91fe4e8caa53aadeff92477633946 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10115-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> CEFALOTINE"@fr;
  dct:identifier "IAM_10115";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633948;
  r:natureDuRisque "L'augmentation de la néphrotoxicité des aminosides par la céfalotine est discutée."@fr;
  r:conduiteATenir "Surveillance de la fonction rénale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633954, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633948 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633949 .

_:807f36cf91fe4e8caa53aadeff92477633949 rdf:first _:807f36cf91fe4e8caa53aadeff92477633950;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633951 .

_:807f36cf91fe4e8caa53aadeff92477633950 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477633951 rdf:first _:807f36cf91fe4e8caa53aadeff92477633952;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10168 .

_:807f36cf91fe4e8caa53aadeff92477633954 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11079-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> RANOLAZINE"@fr;
  dct:identifier "IAM_11079";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633956;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme par la ranolazine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique, et adaptation éventuelle de la posologie de l’immunosuppresseur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633962, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633956 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633957 .

_:807f36cf91fe4e8caa53aadeff92477633957 rdf:first _:807f36cf91fe4e8caa53aadeff92477633958;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633959 .

_:807f36cf91fe4e8caa53aadeff92477633958 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477633959 rdf:first _:807f36cf91fe4e8caa53aadeff92477633960;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:807f36cf91fe4e8caa53aadeff92477633962 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10061-1 a owl:Class;
  rdfs:label "ALBENDAZOLE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10061";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633964;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques de l’albendazole et de son métabolite actif par l’inducteur, avec risque de baisse de son efficacité."@fr;
  r:conduiteATenir "Surveillance clinique de la réponse thérapeutique et adaptation éventuelle de la posologie de l’albendazole pendant le traitement avec l’inducteur enzymatique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633970, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633964 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633965 .

_:807f36cf91fe4e8caa53aadeff92477633965 rdf:first _:807f36cf91fe4e8caa53aadeff92477633966;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633967 .

_:807f36cf91fe4e8caa53aadeff92477633966 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477633967 rdf:first _:807f36cf91fe4e8caa53aadeff92477633968;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477633970 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10062-1 a owl:Class;
  rdfs:label "ALCALINISANTS URINAIRES <-> HYDROQUINIDINE"@fr;
  dct:identifier "IAM_10062";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633972;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'hydroquinidine et risque de surdosage (diminution de l'excrétion rénale de l'hydroquinidine par alcalinisation des urines)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement contrôle des concentrations de l'hydroquinidine ; si besoin, adaptation de la posologie pendant le traitement alcalinisant et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633978, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633972 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633973 .

_:807f36cf91fe4e8caa53aadeff92477633973 rdf:first _:807f36cf91fe4e8caa53aadeff92477633974;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633975 .

_:807f36cf91fe4e8caa53aadeff92477633974 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10006 .

_:807f36cf91fe4e8caa53aadeff92477633975 rdf:first _:807f36cf91fe4e8caa53aadeff92477633976;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10434 .

_:807f36cf91fe4e8caa53aadeff92477633978 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10063-1 a owl:Class;
  rdfs:label "ALCALINISANTS URINAIRES <-> QUINIDINE"@fr;
  dct:identifier "IAM_10063";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633980;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la quinidine et risque de surdosage (diminution de l'excrétion rénale de la quinidine par alcalinisation des urines)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement contrôle de la quinidinémie ; si besoin, adaptation de la posologie pendant le traitement alcalinisant et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633986, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633980 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633981 .

_:807f36cf91fe4e8caa53aadeff92477633981 rdf:first _:807f36cf91fe4e8caa53aadeff92477633982;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633983 .

_:807f36cf91fe4e8caa53aadeff92477633982 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10006 .

_:807f36cf91fe4e8caa53aadeff92477633983 rdf:first _:807f36cf91fe4e8caa53aadeff92477633984;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477633986 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10064-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE DOPAMINERGIQUES <-> ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS"@fr;
  dct:identifier "IAM_10064";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633988;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  rdfs:comment "Les propriétés pharmacologiques des dérivés de l'ergot exposent à un risque de vasoconstriction, qui peut être grave selon les antécédents du patient. Les risques vasculaires sont en effet communs à tous les dérivés de l'ergot et pourraient s'additionner"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477633994, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633988 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633989 .

_:807f36cf91fe4e8caa53aadeff92477633989 rdf:first _:807f36cf91fe4e8caa53aadeff92477633990;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633991 .

_:807f36cf91fe4e8caa53aadeff92477633990 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10007 .

_:807f36cf91fe4e8caa53aadeff92477633991 rdf:first _:807f36cf91fe4e8caa53aadeff92477633992;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477633992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477633994 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10065-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE DOPAMINERGIQUES <-> ANTIPARKINSONIENS ANTICHOLINERGIQUES"@fr;
  dct:identifier "IAM_10065";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477633996;
  r:natureDuRisque "Risque de majoration des troubles neuropsychiques."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634002, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477633996 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477633997 .

_:807f36cf91fe4e8caa53aadeff92477633997 rdf:first _:807f36cf91fe4e8caa53aadeff92477633998;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477633999 .

_:807f36cf91fe4e8caa53aadeff92477633998 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10007 .

_:807f36cf91fe4e8caa53aadeff92477633999 rdf:first _:807f36cf91fe4e8caa53aadeff92477634000;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10037 .

_:807f36cf91fe4e8caa53aadeff92477634002 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10066-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE DOPAMINERGIQUES <-> MACROLIDES (SAUF SPIRAMYCINE)"@fr;
  dct:identifier "IAM_10066";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634004;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du dopaminergique avec accroissement possible de son activité ou apparition de signes de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634010, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634004 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634005 .

_:807f36cf91fe4e8caa53aadeff92477634005 rdf:first _:807f36cf91fe4e8caa53aadeff92477634006;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634007 .

_:807f36cf91fe4e8caa53aadeff92477634006 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10007 .

_:807f36cf91fe4e8caa53aadeff92477634007 rdf:first _:807f36cf91fe4e8caa53aadeff92477634008;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10107 .

_:807f36cf91fe4e8caa53aadeff92477634010 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10067-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE DOPAMINERGIQUES <-> SYMPATHOMIMÉTIQUES ALPHA (VOIES ORALE ET/OU NASALE)"@fr;
  dct:identifier "IAM_10067";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634012;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634018, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634012 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634013 .

_:807f36cf91fe4e8caa53aadeff92477634013 rdf:first _:807f36cf91fe4e8caa53aadeff92477634014;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634015 .

_:807f36cf91fe4e8caa53aadeff92477634014 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10007 .

_:807f36cf91fe4e8caa53aadeff92477634015 rdf:first _:807f36cf91fe4e8caa53aadeff92477634016;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10148 .

_:807f36cf91fe4e8caa53aadeff92477634018 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10068-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE DOPAMINERGIQUES <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_10068";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634020;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  rdfs:comment """Les décisions suivantes, émanant de trois instances de l'Afssaps, ont été prises en compte : 
- la Commission Nationale de Pharmacovigilance a pris acte d'une toxicité de la phénylpropanolamine supérieure à celle des autres sympathomimétiques indirects ("""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634026, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634020 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634021 .

_:807f36cf91fe4e8caa53aadeff92477634021 rdf:first _:807f36cf91fe4e8caa53aadeff92477634022;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634023 .

_:807f36cf91fe4e8caa53aadeff92477634022 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10007 .

_:807f36cf91fe4e8caa53aadeff92477634023 rdf:first _:807f36cf91fe4e8caa53aadeff92477634024;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477634026 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10126-1 a owl:Class;
  rdfs:label "AMIODARONE <-> COBICISTAT"@fr;
  dct:identifier "IAM_10126";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634028;
  r:natureDuRisque "Risque de majoration des effets indésirables de l'amiodarone par diminution de son métabolisme par le cobicistat."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634034, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634028 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634029 .

_:807f36cf91fe4e8caa53aadeff92477634029 rdf:first _:807f36cf91fe4e8caa53aadeff92477634030;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634031 .

_:807f36cf91fe4e8caa53aadeff92477634030 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477634031 rdf:first _:807f36cf91fe4e8caa53aadeff92477634032;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477634034 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10070-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10070";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634036;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Risque de vasoconstriction coronaire ou des extrémités (ergotisme), ou de poussées hypertensives."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634042, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634036 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634037 .

_:807f36cf91fe4e8caa53aadeff92477634037 rdf:first _:807f36cf91fe4e8caa53aadeff92477634038;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634039 .

_:807f36cf91fe4e8caa53aadeff92477634038 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477634039 rdf:first _:807f36cf91fe4e8caa53aadeff92477634040;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477634042 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10125-1 a owl:Class;
  rdfs:label "AMIODARONE <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10125";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634044;
  r:natureDuRisque "Augmentation des concentrations sanguines de ciclosporine, par diminution de son métabolisme hépatique, avec risque d'effets néphrotoxiques."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de ciclosporine, contrôle de la fonction rénale et adaptation de la posologie de la ciclosporine pendant le traitement par l'amiodarone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634050, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634044 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634045 .

_:807f36cf91fe4e8caa53aadeff92477634045 rdf:first _:807f36cf91fe4e8caa53aadeff92477634046;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634047 .

_:807f36cf91fe4e8caa53aadeff92477634046 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477634047 rdf:first _:807f36cf91fe4e8caa53aadeff92477634048;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477634050 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10116-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10116";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634052;
  r:natureDuRisque "Augmentation de la créatininémie plus importante que sous ciclosporine seule, avec majoration du risque néphrotoxique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634058, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634052 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634053 .

_:807f36cf91fe4e8caa53aadeff92477634053 rdf:first _:807f36cf91fe4e8caa53aadeff92477634054;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634055 .

_:807f36cf91fe4e8caa53aadeff92477634054 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477634055 rdf:first _:807f36cf91fe4e8caa53aadeff92477634056;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477634058 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10117-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> CURARES"@fr;
  dct:identifier "IAM_10117";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634060;
  r:chapeau """Certaines substances peuvent modifier l'intensité et/ou la durée de l'effet des curares non dépolarisants. 
Les médicaments susceptibles de potentialiser l'action des curares non dépolarisants sont :
- les anesthésiques volatils tels que isoflurane, enflu"""@fr;
  r:natureDuRisque "Potentialisation des curares lorque l'antibiotique est administré par voie parentérale et/ou péritonéale avant, pendant ou après l'agent curarisant."@fr;
  r:conduiteATenir "Surveiller le degré de curarisation en fin d'anesthésie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634066, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634060 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634061 .

_:807f36cf91fe4e8caa53aadeff92477634061 rdf:first _:807f36cf91fe4e8caa53aadeff92477634062;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634063 .

_:807f36cf91fe4e8caa53aadeff92477634062 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477634063 rdf:first _:807f36cf91fe4e8caa53aadeff92477634064;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10057 .

_:807f36cf91fe4e8caa53aadeff92477634066 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10118-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> DIURÉTIQUES DE L'ANSE"@fr;
  dct:identifier "IAM_10118";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634068;
  r:natureDuRisque "Augmentation des risques néphrotoxiques et ototoxiques de l'aminoside (insuffisance rénale fonctionnelle liée à la déshydratation entraînée par le diurétique)."@fr;
  r:conduiteATenir "Association possible sous contrôle de l'état d'hydratation, des fonctions rénale et cochléovestibulaire, et éventuellement, des concentrations plasmatiques de l'aminoside."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634074, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634068 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634069 .

_:807f36cf91fe4e8caa53aadeff92477634069 rdf:first _:807f36cf91fe4e8caa53aadeff92477634070;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634071 .

_:807f36cf91fe4e8caa53aadeff92477634070 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477634071 rdf:first _:807f36cf91fe4e8caa53aadeff92477634072;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10064 .

_:807f36cf91fe4e8caa53aadeff92477634074 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10119-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> ORGANOPLATINES"@fr;
  dct:identifier "IAM_10119";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634076;
  r:natureDuRisque "Addition des effets néphrotoxiques et/ou ototoxiques, notamment en cas d'insuffisance rénale préalable."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634082, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634076 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634077 .

_:807f36cf91fe4e8caa53aadeff92477634077 rdf:first _:807f36cf91fe4e8caa53aadeff92477634078;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634079 .

_:807f36cf91fe4e8caa53aadeff92477634078 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477634079 rdf:first _:807f36cf91fe4e8caa53aadeff92477634080;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff92477634082 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10120-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> POLYMYXINE B"@fr;
  dct:identifier "IAM_10120";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634084;
  r:natureDuRisque "Addition des effets néphrotoxiques."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance stricte avec une justification bactériologique indiscutable."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634090, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634084 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634085 .

_:807f36cf91fe4e8caa53aadeff92477634085 rdf:first _:807f36cf91fe4e8caa53aadeff92477634086;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634087 .

_:807f36cf91fe4e8caa53aadeff92477634086 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477634087 rdf:first _:807f36cf91fe4e8caa53aadeff92477634088;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10739 .

_:807f36cf91fe4e8caa53aadeff92477634090 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10121-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10121";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634092;
  r:natureDuRisque "Augmentation de la créatininémie plus importante que sous tacrolimus seul (synergie des effets néphrotoxiques des deux substances)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634098, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634092 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634093 .

_:807f36cf91fe4e8caa53aadeff92477634093 rdf:first _:807f36cf91fe4e8caa53aadeff92477634094;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634095 .

_:807f36cf91fe4e8caa53aadeff92477634094 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477634095 rdf:first _:807f36cf91fe4e8caa53aadeff92477634096;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477634098 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10146-1 a owl:Class;
  rdfs:label "AMIODARONE <-> TELAPREVIR"@fr;
  dct:identifier "IAM_10146";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634100;
  r:natureDuRisque "Troubles de l'automatisme et de la conduction cardiaque avec risque de bradycardie excessive."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634106, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634100 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634101 .

_:807f36cf91fe4e8caa53aadeff92477634101 rdf:first _:807f36cf91fe4e8caa53aadeff92477634102;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634103 .

_:807f36cf91fe4e8caa53aadeff92477634102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477634103 rdf:first _:807f36cf91fe4e8caa53aadeff92477634104;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477634106 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10122-1 a owl:Class;
  rdfs:label "AMIODARONE <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10122";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634108;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par l'amiodarone et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634114, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634108 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634109 .

_:807f36cf91fe4e8caa53aadeff92477634109 rdf:first _:807f36cf91fe4e8caa53aadeff92477634110;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634111 .

_:807f36cf91fe4e8caa53aadeff92477634110 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477634111 rdf:first _:807f36cf91fe4e8caa53aadeff92477634112;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477634114 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10123-1 a owl:Class;
  rdfs:label "AMIODARONE <-> BÊTA-BLOQUANTS (SAUF ESMOLOL ET SOTALOL)"@fr;
  dct:identifier "IAM_10123";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634116;
  r:natureDuRisque "Troubles de l'automatisme et de la conduction (suppression des mécanismes sympathiques compensateurs)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG."@fr;
  rdfs:comment """L'amiodarone a longtemps été déconseillée avec les bêta-bloquants, en raison d’une majoration possible du risque de bradycardie et de torsades de pointes.
Cependant, considérant que :
- le risque de torsades de pointes est exceptionnel avec l’amiodarone,"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634122, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634116 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634117 .

_:807f36cf91fe4e8caa53aadeff92477634117 rdf:first _:807f36cf91fe4e8caa53aadeff92477634118;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634119 .

_:807f36cf91fe4e8caa53aadeff92477634118 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10053 .

_:807f36cf91fe4e8caa53aadeff92477634119 rdf:first _:807f36cf91fe4e8caa53aadeff92477634120;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477634122 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10151-1 a owl:Class;
  rdfs:label "AMPHOTERICINE B <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10151";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634124;
  r:natureDuRisque "Avec l'amphotéricine B administrée par voie IV : augmentation de la créatininémie plus importante que sous tacrolimus seul (synergie des effets néphrotoxiques des deux substances)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634130, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634124 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634125 .

_:807f36cf91fe4e8caa53aadeff92477634125 rdf:first _:807f36cf91fe4e8caa53aadeff92477634126;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634127 .

_:807f36cf91fe4e8caa53aadeff92477634126 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10072 .

_:807f36cf91fe4e8caa53aadeff92477634127 rdf:first _:807f36cf91fe4e8caa53aadeff92477634128;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477634130 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10069-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10069";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634132;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de vasoconstriction coronaire ou des extrémités (ergotisme), ou de poussées hypertensives."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634138, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634132 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634133 .

_:807f36cf91fe4e8caa53aadeff92477634133 rdf:first _:807f36cf91fe4e8caa53aadeff92477634134;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634135 .

_:807f36cf91fe4e8caa53aadeff92477634134 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477634135 rdf:first _:807f36cf91fe4e8caa53aadeff92477634136;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477634138 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10185-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10185";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634140;
  r:natureDuRisque "Dans les indications où cette association est possible, risque accru de dégradation de la fonction rénale, voire insuffisance rénale aiguë, et majoration de l'hyperkaliémie, ainsi que de l'hypotension et des syncopes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634146, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634140 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634141 .

_:807f36cf91fe4e8caa53aadeff92477634141 rdf:first _:807f36cf91fe4e8caa53aadeff92477634142;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634143 .

_:807f36cf91fe4e8caa53aadeff92477634142 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477634143 rdf:first _:807f36cf91fe4e8caa53aadeff92477634144;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477634146 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10149-1 a owl:Class;
  rdfs:label "AMLODIPINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10149";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634148;
  r:natureDuRisque "Risque majoré d’effets indésirables (dose-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’hypocholestérolémiant)."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 20 mg/j de simvastatine ou utiliser une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634154, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634148 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634149 .

_:807f36cf91fe4e8caa53aadeff92477634149 rdf:first _:807f36cf91fe4e8caa53aadeff92477634150;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634151 .

_:807f36cf91fe4e8caa53aadeff92477634150 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10069 .

_:807f36cf91fe4e8caa53aadeff92477634151 rdf:first _:807f36cf91fe4e8caa53aadeff92477634152;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477634154 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10176-1 a owl:Class;
  rdfs:label "ANESTHÉSIQUES VOLATILS HALOGÉNÉS <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_10176";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634156;
  r:natureDuRisque "Poussée hypertensive peropératoire."@fr;
  r:conduiteATenir "En cas d'intervention programmée, il est préférable d'interrompre le traitement quelques jours avant l'intervention."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634162, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634156 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634157 .

_:807f36cf91fe4e8caa53aadeff92477634157 rdf:first _:807f36cf91fe4e8caa53aadeff92477634158;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634159 .

_:807f36cf91fe4e8caa53aadeff92477634158 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:807f36cf91fe4e8caa53aadeff92477634159 rdf:first _:807f36cf91fe4e8caa53aadeff92477634160;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477634162 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10075-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> ANTABUSE (RÉACTION)"@fr;
  dct:identifier "IAM_10075";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634164;
  r:natureDuRisque "Effet antabuse (chaleur, rougeurs, vomissements, tachycardie)."@fr;
  r:conduiteATenir "Eviter la prise de boissons alcoolisées et de médicaments contenant de l'alcool. Tenir compte de l’élimination complète des médicaments en se référant à leur demi-vie avant la reprise de boissons alcoolisées ou du médicament contenant de l’alcool."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634170, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634164 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634165 .

_:807f36cf91fe4e8caa53aadeff92477634165 rdf:first _:807f36cf91fe4e8caa53aadeff92477634166;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634167 .

_:807f36cf91fe4e8caa53aadeff92477634166 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10018 .

_:807f36cf91fe4e8caa53aadeff92477634167 rdf:first _:807f36cf91fe4e8caa53aadeff92477634168;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:807f36cf91fe4e8caa53aadeff92477634170 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10177-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES CANAUX CALCIQUES <-> ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10177";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634172;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antagoniste du calcium par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir """Précaution d'emploi :
Surveillance clinique et adaptation éventuelle de la posologie de l'antagoniste du calcium pendant le traitement par l'anticonvulsivant et après son arrêt."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634178, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634172 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634173 .

_:807f36cf91fe4e8caa53aadeff92477634173 rdf:first _:807f36cf91fe4e8caa53aadeff92477634174;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634175 .

_:807f36cf91fe4e8caa53aadeff92477634174 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10019 .

_:807f36cf91fe4e8caa53aadeff92477634175 rdf:first _:807f36cf91fe4e8caa53aadeff92477634176;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477634178 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10178-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES CANAUX CALCIQUES <-> IDÉLALISIB"@fr;
  dct:identifier "IAM_10178";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634180;
  r:natureDuRisque "Majoration des effets indésirables de l’antagoniste des canaux calciques, à type d’hypotension orthostatique, notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de l’antagoniste calcique pendant le traitement par l’idélalisib et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634186, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634180 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634181 .

_:807f36cf91fe4e8caa53aadeff92477634181 rdf:first _:807f36cf91fe4e8caa53aadeff92477634182;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634183 .

_:807f36cf91fe4e8caa53aadeff92477634182 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10019 .

_:807f36cf91fe4e8caa53aadeff92477634183 rdf:first _:807f36cf91fe4e8caa53aadeff92477634184;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10444 .

_:807f36cf91fe4e8caa53aadeff92477634186 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10179-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES CANAUX CALCIQUES <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10179";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634188;
  r:natureDuRisque "Majoration des effets indésirables de l’antagoniste des canaux calciques, le plus souvent à type d'hypotension notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation posologique pendant le traitement par l’inhibiteur enzymatique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634194, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634188 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634189 .

_:807f36cf91fe4e8caa53aadeff92477634189 rdf:first _:807f36cf91fe4e8caa53aadeff92477634190;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634191 .

_:807f36cf91fe4e8caa53aadeff92477634190 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10019 .

_:807f36cf91fe4e8caa53aadeff92477634191 rdf:first _:807f36cf91fe4e8caa53aadeff92477634192;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477634194 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10180-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES CANAUX CALCIQUES <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10180";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634196;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antagoniste du calcium par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir """Précaution d'emploi :
Surveillance clinique et adaptation éventuelle de la posologie de l'antagoniste du calcium pendant le traitement par la rifampicine et après son arrêt."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634202, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634196 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634197 .

_:807f36cf91fe4e8caa53aadeff92477634197 rdf:first _:807f36cf91fe4e8caa53aadeff92477634198;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634199 .

_:807f36cf91fe4e8caa53aadeff92477634198 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10019 .

_:807f36cf91fe4e8caa53aadeff92477634199 rdf:first _:807f36cf91fe4e8caa53aadeff92477634200;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477634202 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10181-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> ANTI-INFLAMMATOIRES NON STÉROÏDIENS"@fr;
  dct:identifier "IAM_10181";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634204;
  r:natureDuRisque "Insuffisance rénale aiguë chez le patient à risque (sujet âgé, déshydratation, traitement associé avec diurétiques, altération de la fonction rénale), par diminution de la filtration glomérulaire (inhibition des prostaglandines vasodilatatrices due aux an"@fr;
  r:conduiteATenir "Hydrater le malade et surveiller la fonction rénale en début de traitement et régulièrement pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634210, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634204 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634205 .

_:807f36cf91fe4e8caa53aadeff92477634205 rdf:first _:807f36cf91fe4e8caa53aadeff92477634206;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634207 .

_:807f36cf91fe4e8caa53aadeff92477634206 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477634207 rdf:first _:807f36cf91fe4e8caa53aadeff92477634208;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477634210 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10182-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS)"@fr;
  dct:identifier "IAM_10182";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634212;
  r:natureDuRisque "Risque d'hyperkaliémie (potentiellement létale) surtout en cas d'insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir """Précaution d'emploi :
- pour la spironolactone à des doses comprises entre 12,5 mg et 50 mg/jour, et pour l’éplérénone utilisées dans le traitement de l'insuffisance cardiaque, ainsi qu'en cas d'hypokaliémie : contrôle strict de la kaliémie et de la fonct"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634218, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634212 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634213 .

_:807f36cf91fe4e8caa53aadeff92477634213 rdf:first _:807f36cf91fe4e8caa53aadeff92477634214;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634215 .

_:807f36cf91fe4e8caa53aadeff92477634214 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477634215 rdf:first _:807f36cf91fe4e8caa53aadeff92477634216;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477634218 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10174-1 a owl:Class;
  rdfs:label "ANESTHÉSIQUES VOLATILS HALOGÉNÉS <-> ISOPRENALINE"@fr;
  dct:identifier "IAM_10174";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634220;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634226, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634220 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634221 .

_:807f36cf91fe4e8caa53aadeff92477634221 rdf:first _:807f36cf91fe4e8caa53aadeff92477634222;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634223 .

_:807f36cf91fe4e8caa53aadeff92477634222 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:807f36cf91fe4e8caa53aadeff92477634223 rdf:first _:807f36cf91fe4e8caa53aadeff92477634224;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10491 .

_:807f36cf91fe4e8caa53aadeff92477634226 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10184-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> EPLERENONE"@fr;
  dct:identifier "IAM_10184";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634228;
  r:natureDuRisque "Majoration du risque d’hyperkaliémie, notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Contrôle strict de la kaliémie et de la fonction rénale pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634234, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634228 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634229 .

_:807f36cf91fe4e8caa53aadeff92477634229 rdf:first _:807f36cf91fe4e8caa53aadeff92477634230;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634231 .

_:807f36cf91fe4e8caa53aadeff92477634230 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477634231 rdf:first _:807f36cf91fe4e8caa53aadeff92477634232;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10329 .

_:807f36cf91fe4e8caa53aadeff92477634234 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10173-1 a owl:Class;
  rdfs:label "ANESTHÉSIQUES VOLATILS HALOGÉNÉS <-> ISONIAZIDE"@fr;
  dct:identifier "IAM_10173";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634236;
  r:natureDuRisque "Potentialisation de l'effet hépatotoxique de l'isonazide, avec formation accrue de métabolites toxiques de l'isoniazide."@fr;
  r:conduiteATenir "En cas d'intervention programmée, arrêter, par prudence, le traitement par l'isoniazide une semaine avant l'intervention et ne le reprendre que 15 jours après."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634242, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634236 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634237 .

_:807f36cf91fe4e8caa53aadeff92477634237 rdf:first _:807f36cf91fe4e8caa53aadeff92477634238;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634239 .

_:807f36cf91fe4e8caa53aadeff92477634238 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:807f36cf91fe4e8caa53aadeff92477634239 rdf:first _:807f36cf91fe4e8caa53aadeff92477634240;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634240 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:807f36cf91fe4e8caa53aadeff92477634242 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10186-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> LITHIUM"@fr;
  dct:identifier "IAM_10186";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634244;
  r:natureDuRisque "Augmentation de la lithémie pouvant atteindre des valeurs toxiques (diminution de l'excrétion rénale du lithium)."@fr;
  r:conduiteATenir "Si l'usage d'un antagoniste de l'angiotensine II est indispensable, surveillance stricte de la lithémie et adaptation de la posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634250, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634244 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634245 .

_:807f36cf91fe4e8caa53aadeff92477634245 rdf:first _:807f36cf91fe4e8caa53aadeff92477634246;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634247 .

_:807f36cf91fe4e8caa53aadeff92477634246 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477634247 rdf:first _:807f36cf91fe4e8caa53aadeff92477634248;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634248 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477634250 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10187-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> POTASSIUM"@fr;
  dct:identifier "IAM_10187";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634252;
  r:natureDuRisque "Hyperkaliémie (potentiellement létale) surtout lors d'une insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Eviter cette association sauf s'il existe une hypokaliémie préalable."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634258, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634252 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634253 .

_:807f36cf91fe4e8caa53aadeff92477634253 rdf:first _:807f36cf91fe4e8caa53aadeff92477634254;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634255 .

_:807f36cf91fe4e8caa53aadeff92477634254 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477634255 rdf:first _:807f36cf91fe4e8caa53aadeff92477634256;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634256 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10742 .

_:807f36cf91fe4e8caa53aadeff92477634258 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10188-1 a owl:Class;
  rdfs:label "ANTIAGRÉGANTS PLAQUETTAIRES <-> ANTICOAGULANTS ORAUX"@fr;
  dct:identifier "IAM_10188";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634260;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634266, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634260 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634261 .

_:807f36cf91fe4e8caa53aadeff92477634261 rdf:first _:807f36cf91fe4e8caa53aadeff92477634262;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634263 .

_:807f36cf91fe4e8caa53aadeff92477634262 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10023 .

_:807f36cf91fe4e8caa53aadeff92477634263 rdf:first _:807f36cf91fe4e8caa53aadeff92477634264;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634264 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477634266 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10189-1 a owl:Class;
  rdfs:label "ANTIAGRÉGANTS PLAQUETTAIRES <-> DÉFIBROTIDE"@fr;
  dct:identifier "IAM_10189";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634268;
  r:natureDuRisque "Risque hémorragique accru."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634274, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634268 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634269 .

_:807f36cf91fe4e8caa53aadeff92477634269 rdf:first _:807f36cf91fe4e8caa53aadeff92477634270;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634271 .

_:807f36cf91fe4e8caa53aadeff92477634270 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10023 .

_:807f36cf91fe4e8caa53aadeff92477634271 rdf:first _:807f36cf91fe4e8caa53aadeff92477634272;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634272 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10262 .

_:807f36cf91fe4e8caa53aadeff92477634274 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10190-1 a owl:Class;
  rdfs:label "ANTIAGRÉGANTS PLAQUETTAIRES <-> HÉPARINES"@fr;
  dct:identifier "IAM_10190";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634276;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634282, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634276 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634277 .

_:807f36cf91fe4e8caa53aadeff92477634277 rdf:first _:807f36cf91fe4e8caa53aadeff92477634278;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634279 .

_:807f36cf91fe4e8caa53aadeff92477634278 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10023 .

_:807f36cf91fe4e8caa53aadeff92477634279 rdf:first _:807f36cf91fe4e8caa53aadeff92477634280;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634280 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10088 .

_:807f36cf91fe4e8caa53aadeff92477634282 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10191-1 a owl:Class;
  rdfs:label "ANTIAGRÉGANTS PLAQUETTAIRES <-> THROMBOLYTIQUES"@fr;
  dct:identifier "IAM_10191";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634284;
  r:chapeau """Plusieurs substances sont impliquées dans des interactions, du fait de leurs propriétés antiagrégantes plaquettaires. 
L’utilisation de plusieurs antiagrégants plaquettaires majore le risque de saignement, de même que leur association à l’héparine et aux"""@fr;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634290, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634284 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634285 .

_:807f36cf91fe4e8caa53aadeff92477634285 rdf:first _:807f36cf91fe4e8caa53aadeff92477634286;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634287 .

_:807f36cf91fe4e8caa53aadeff92477634286 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10023 .

_:807f36cf91fe4e8caa53aadeff92477634287 rdf:first _:807f36cf91fe4e8caa53aadeff92477634288;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634288 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10151 .

_:807f36cf91fe4e8caa53aadeff92477634290 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10192-1 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES <-> AUTRES ANTIARYTHMIQUES"@fr;
  dct:identifier "IAM_10192";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634292;
  r:natureDuRisque "L'association de deux antiarythmiques est très délicate. Elle est dans la majorité des cas, contre-indiquée ou déconseillée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634294, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10024 .

_:807f36cf91fe4e8caa53aadeff92477634294 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10193-1 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES CLASSE I (SAUF LIDOCAÏNE) <-> BÊTA-BLOQUANTS (SAUF ESMOLOL ET SOTALOL)"@fr;
  dct:identifier "IAM_10193";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634296;
  r:natureDuRisque "Troubles de la contractilité, de l'automatisme et de la conduction (suppression des mécanismes sympathiques compensateurs)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634302, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634296 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634297 .

_:807f36cf91fe4e8caa53aadeff92477634297 rdf:first _:807f36cf91fe4e8caa53aadeff92477634298;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634299 .

_:807f36cf91fe4e8caa53aadeff92477634298 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10025 .

_:807f36cf91fe4e8caa53aadeff92477634299 rdf:first _:807f36cf91fe4e8caa53aadeff92477634300;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10053 .

_:807f36cf91fe4e8caa53aadeff92477634302 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10194-1 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES CLASSE I (SAUF LIDOCAÏNE) <-> BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE"@fr;
  dct:identifier "IAM_10194";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634304;
  r:chapeau """A l’heure actuelle, 4 bêta-bloquants ont l'indication \"insuffisance cardiaque\" : le carvédilol, le bisoprolol, le métoprolol et le névibolol.
Les interactions médicamenteuses des bêta-bloquants, lorsqu’ils sont prescrits dans l’insuffisance cardiaque, pe"""@fr;
  r:natureDuRisque "Effet inotrope négatif avec risque de décompensation cardiaque."@fr;
  rdfs:comment """Les études effectuées avec des antiarythmiques de classe I prescrits à des insuffisants cardiaques ont montré une surmortalité dans le groupe traité.
Ces études ont été faites avant l'utilisation des bêta-bloquants dans cette indication, mais qu'il s'agis"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634310, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634304 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634305 .

_:807f36cf91fe4e8caa53aadeff92477634305 rdf:first _:807f36cf91fe4e8caa53aadeff92477634306;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634307 .

_:807f36cf91fe4e8caa53aadeff92477634306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10025 .

_:807f36cf91fe4e8caa53aadeff92477634307 rdf:first _:807f36cf91fe4e8caa53aadeff92477634308;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477634310 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10195-1 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES CLASSE IA <-> ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10195";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634312;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de l'antiarythmique, par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et contrôle des concentrations plasmatiques ; si besoin, adaptation de la posologie de l'antiarythmique pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634318, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634312 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634313 .

_:807f36cf91fe4e8caa53aadeff92477634313 rdf:first _:807f36cf91fe4e8caa53aadeff92477634314;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634315 .

_:807f36cf91fe4e8caa53aadeff92477634314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10026 .

_:807f36cf91fe4e8caa53aadeff92477634315 rdf:first _:807f36cf91fe4e8caa53aadeff92477634316;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477634318 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10183-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> DIURÉTIQUES HYPOKALIÉMIANTS"@fr;
  dct:identifier "IAM_10183";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634320;
  r:natureDuRisque "Risque d'hypotension artérielle brutale et/ou d'insuffisance rénale aiguë lors de l'instauration ou de l'augmentation de la posologie d'un traitement par un antagoniste de l'angiotensine II en cas de déplétion hydrosodée préexistante."@fr;
  r:conduiteATenir """Dans l'hypertension artérielle, lorsqu'un traitement diurétique préalable a pu entraîner une déplétion hydrosodée, il faut : 
- soit arrêter le diurétique avant de débuter le traitement par l'antagoniste de l'angiotensine II, et réintroduire un diurétique"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634326, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634320 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634321 .

_:807f36cf91fe4e8caa53aadeff92477634321 rdf:first _:807f36cf91fe4e8caa53aadeff92477634322;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634323 .

_:807f36cf91fe4e8caa53aadeff92477634322 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477634323 rdf:first _:807f36cf91fe4e8caa53aadeff92477634324;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10065 .

_:807f36cf91fe4e8caa53aadeff92477634326 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10162-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES DE PALIER III <-> MORPHINIQUES AGONISTES-ANTAGONISTES"@fr;
  dct:identifier "IAM_10162";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634328;
  r:natureDuRisque "Diminution de l'effet antalgique par blocage compétitif des récepteurs, avec risque d'apparition d'un syndrome de sevrage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634334, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634328 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634329 .

_:807f36cf91fe4e8caa53aadeff92477634329 rdf:first _:807f36cf91fe4e8caa53aadeff92477634330;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634331 .

_:807f36cf91fe4e8caa53aadeff92477634330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10014 .

_:807f36cf91fe4e8caa53aadeff92477634331 rdf:first _:807f36cf91fe4e8caa53aadeff92477634332;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10110 .

_:807f36cf91fe4e8caa53aadeff92477634334 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10058-1 a owl:Class;
  rdfs:label "AGOMELATINE <-> FLUVOXAMINE"@fr;
  dct:identifier "IAM_10058";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634336;
  r:natureDuRisque "Augmentation des concentrations d'agomélatine, avec risque de majoration des effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634342, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634336 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634337 .

_:807f36cf91fe4e8caa53aadeff92477634337 rdf:first _:807f36cf91fe4e8caa53aadeff92477634338;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634339 .

_:807f36cf91fe4e8caa53aadeff92477634338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10041 .

_:807f36cf91fe4e8caa53aadeff92477634339 rdf:first _:807f36cf91fe4e8caa53aadeff92477634340;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477634342 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10152-1 a owl:Class;
  rdfs:label "AMPHOTERICINE B <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_10152";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634344;
  r:natureDuRisque "Avec l'amphotéricine B administrée par voie IV : augmentation de la toxicité hématologique (addition d'effets de toxicité médullaire)."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'hémogramme."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634350, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634344 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634345 .

_:807f36cf91fe4e8caa53aadeff92477634345 rdf:first _:807f36cf91fe4e8caa53aadeff92477634346;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634347 .

_:807f36cf91fe4e8caa53aadeff92477634346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10072 .

_:807f36cf91fe4e8caa53aadeff92477634347 rdf:first _:807f36cf91fe4e8caa53aadeff92477634348;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:807f36cf91fe4e8caa53aadeff92477634350 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10153-1 a owl:Class;
  rdfs:label "ANAGRELIDE <-> ANTIAGRÉGANTS PLAQUETTAIRES"@fr;
  dct:identifier "IAM_10153";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634352;
  r:natureDuRisque "Majoration des événements hémorragiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634358, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634352 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634353 .

_:807f36cf91fe4e8caa53aadeff92477634353 rdf:first _:807f36cf91fe4e8caa53aadeff92477634354;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634355 .

_:807f36cf91fe4e8caa53aadeff92477634354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10023 .

_:807f36cf91fe4e8caa53aadeff92477634355 rdf:first _:807f36cf91fe4e8caa53aadeff92477634356;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff92477634358 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10154-1 a owl:Class;
  rdfs:label "ANAGRELIDE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10154";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634360;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Surveillance clinique et électrocardiographique pendant
l'association."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634366, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634360 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634361 .

_:807f36cf91fe4e8caa53aadeff92477634361 rdf:first _:807f36cf91fe4e8caa53aadeff92477634362;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634363 .

_:807f36cf91fe4e8caa53aadeff92477634362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477634363 rdf:first _:807f36cf91fe4e8caa53aadeff92477634364;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff92477634366 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10155-1 a owl:Class;
  rdfs:label "ANAKINRA <-> ANTI-TNF ALPHA"@fr;
  dct:identifier "IAM_10155";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634368;
  r:natureDuRisque "Risque accru d'infections graves et de neutropénies."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634374, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634368 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634369 .

_:807f36cf91fe4e8caa53aadeff92477634369 rdf:first _:807f36cf91fe4e8caa53aadeff92477634370;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634371 .

_:807f36cf91fe4e8caa53aadeff92477634370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10021 .

_:807f36cf91fe4e8caa53aadeff92477634371 rdf:first _:807f36cf91fe4e8caa53aadeff92477634372;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10076 .

_:807f36cf91fe4e8caa53aadeff92477634374 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10156-1 a owl:Class;
  rdfs:label "ANAKINRA <-> ETANERCEPT"@fr;
  dct:identifier "IAM_10156";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634376;
  r:natureDuRisque "Risque accru d'infections graves et de neutropénies."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634382, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634376 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634377 .

_:807f36cf91fe4e8caa53aadeff92477634377 rdf:first _:807f36cf91fe4e8caa53aadeff92477634378;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634379 .

_:807f36cf91fe4e8caa53aadeff92477634378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10076 .

_:807f36cf91fe4e8caa53aadeff92477634379 rdf:first _:807f36cf91fe4e8caa53aadeff92477634380;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10349 .

_:807f36cf91fe4e8caa53aadeff92477634382 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10159-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES AGONISTES <-> AUTRES ANALGÉSIQUES MORPHINIQUES AGONISTES"@fr;
  dct:identifier "IAM_10159";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634384;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634386, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634384 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477634386 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10157-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES AGONISTES <-> ANTITUSSIFS MORPHINE-LIKE"@fr;
  dct:identifier "IAM_10157";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634388;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634394, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634388 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634389 .

_:807f36cf91fe4e8caa53aadeff92477634389 rdf:first _:807f36cf91fe4e8caa53aadeff92477634390;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634391 .

_:807f36cf91fe4e8caa53aadeff92477634390 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477634391 rdf:first _:807f36cf91fe4e8caa53aadeff92477634392;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634392 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10044 .

_:807f36cf91fe4e8caa53aadeff92477634394 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10158-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES AGONISTES <-> ANTITUSSIFS MORPHINIQUES VRAIS"@fr;
  dct:identifier "IAM_10158";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634396;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634402, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634396 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634397 .

_:807f36cf91fe4e8caa53aadeff92477634397 rdf:first _:807f36cf91fe4e8caa53aadeff92477634398;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634399 .

_:807f36cf91fe4e8caa53aadeff92477634398 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477634399 rdf:first _:807f36cf91fe4e8caa53aadeff92477634400;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634400 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10045 .

_:807f36cf91fe4e8caa53aadeff92477634402 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10175-1 a owl:Class;
  rdfs:label "ANESTHÉSIQUES VOLATILS HALOGÉNÉS <-> SYMPATHOMIMÉTIQUES ALPHA ET BÊTA (VOIE IM ET IV)"@fr;
  dct:identifier "IAM_10175";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634404;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634410, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634404 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634405 .

_:807f36cf91fe4e8caa53aadeff92477634405 rdf:first _:807f36cf91fe4e8caa53aadeff92477634406;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634407 .

_:807f36cf91fe4e8caa53aadeff92477634406 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:807f36cf91fe4e8caa53aadeff92477634407 rdf:first _:807f36cf91fe4e8caa53aadeff92477634408;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634408 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10149 .

_:807f36cf91fe4e8caa53aadeff92477634410 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10161-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES DE PALIER II <-> MORPHINIQUES ANTAGONISTES PARTIELS"@fr;
  dct:identifier "IAM_10161";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634412;
  r:natureDuRisque "Risque de diminution de l’effet antalgique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634418, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634412 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634413 .

_:807f36cf91fe4e8caa53aadeff92477634413 rdf:first _:807f36cf91fe4e8caa53aadeff92477634414;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634415 .

_:807f36cf91fe4e8caa53aadeff92477634414 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10013 .

_:807f36cf91fe4e8caa53aadeff92477634415 rdf:first _:807f36cf91fe4e8caa53aadeff92477634416;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634416 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10111 .

_:807f36cf91fe4e8caa53aadeff92477634418 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10150-1 a owl:Class;
  rdfs:label "AMPHOTERICINE B <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10150";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634420;
  r:natureDuRisque "Avec l'amphotéricine B administrée par voie IV : augmentation de la créatininémie plus importante que sous ciclosporine seule (synergie des effets néphrotoxiques des deux substances)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634426, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634420 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634421 .

_:807f36cf91fe4e8caa53aadeff92477634421 rdf:first _:807f36cf91fe4e8caa53aadeff92477634422;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634423 .

_:807f36cf91fe4e8caa53aadeff92477634422 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10072 .

_:807f36cf91fe4e8caa53aadeff92477634423 rdf:first _:807f36cf91fe4e8caa53aadeff92477634424;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634424 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477634426 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10163-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES DE PALIER III <-> MORPHINIQUES ANTAGONISTES PARTIELS"@fr;
  dct:identifier "IAM_10163";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634428;
  r:natureDuRisque "Risque de diminution de l’effet antalgique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634434, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634428 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634429 .

_:807f36cf91fe4e8caa53aadeff92477634429 rdf:first _:807f36cf91fe4e8caa53aadeff92477634430;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634431 .

_:807f36cf91fe4e8caa53aadeff92477634430 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10014 .

_:807f36cf91fe4e8caa53aadeff92477634431 rdf:first _:807f36cf91fe4e8caa53aadeff92477634432;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634432 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10111 .

_:807f36cf91fe4e8caa53aadeff92477634434 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10164-1 a owl:Class;
  rdfs:label "ANALOGUES DE LA SOMATOSTATINE <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10164";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634436;
  r:natureDuRisque "Avec la ciclosporine administrée par voie orale : baisse des concentrations sanguines de ciclosporine (diminution de son absorption intestinale)."@fr;
  r:conduiteATenir "Augmentation des doses de ciclosporine sous contrôle des concentrations plasmatiques et réduction de la posologie après l'arrêt du traitement par l'analogue de la somatostatine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634442, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634436 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634437 .

_:807f36cf91fe4e8caa53aadeff92477634437 rdf:first _:807f36cf91fe4e8caa53aadeff92477634438;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634439 .

_:807f36cf91fe4e8caa53aadeff92477634438 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10015 .

_:807f36cf91fe4e8caa53aadeff92477634439 rdf:first _:807f36cf91fe4e8caa53aadeff92477634440;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634440 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477634442 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10165-1 a owl:Class;
  rdfs:label "ANALOGUES DE LA SOMATOSTATINE <-> INSULINE"@fr;
  dct:identifier "IAM_10165";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634444;
  r:natureDuRisque "Risque d'hypoglycémie ou d'hyperglycémie : diminution ou augmentation des besoins en insuline, par diminution ou augmentation de la sécrétion de glucagon endogène."@fr;
  r:conduiteATenir "Prévenir le patient du risque d'hypoglycémie ou d'hyperglycémie, renforcer l'autosurveillance glycémique et adapter si besoin la posologie de l'insuline pendant le traitement par l'analogue de la somatostatine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634450, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634444 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634445 .

_:807f36cf91fe4e8caa53aadeff92477634445 rdf:first _:807f36cf91fe4e8caa53aadeff92477634446;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634447 .

_:807f36cf91fe4e8caa53aadeff92477634446 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10015 .

_:807f36cf91fe4e8caa53aadeff92477634447 rdf:first _:807f36cf91fe4e8caa53aadeff92477634448;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634448 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:807f36cf91fe4e8caa53aadeff92477634450 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10166-1 a owl:Class;
  rdfs:label "ANALOGUES DE LA SOMATOSTATINE <-> PIOGLITAZONE"@fr;
  dct:identifier "IAM_10166";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634452;
  r:natureDuRisque """Risque d’hypoglycémie ou d’hyperglycémie : diminution ou
augmentation des besoins en glitazone, par diminution ou
augmentation de la sécrétion de glucagon endogène."""@fr;
  r:conduiteATenir """Renforcer l’autosurveillance glycémique et adapter si besoin la
posologie de la glitazone pendant le traitement par l'analogue de la
somatostatine."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634458, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634452 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634453 .

_:807f36cf91fe4e8caa53aadeff92477634453 rdf:first _:807f36cf91fe4e8caa53aadeff92477634454;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634455 .

_:807f36cf91fe4e8caa53aadeff92477634454 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10015 .

_:807f36cf91fe4e8caa53aadeff92477634455 rdf:first _:807f36cf91fe4e8caa53aadeff92477634456;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634456 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10723 .

_:807f36cf91fe4e8caa53aadeff92477634458 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10167-1 a owl:Class;
  rdfs:label "ANALOGUES DE LA SOMATOSTATINE <-> REPAGLINIDE"@fr;
  dct:identifier "IAM_10167";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634460;
  r:natureDuRisque "Risque d'hypoglycémie ou d'hyperglycémie : diminution ou augmentation des besoins en repaglidine, par diminution ou augmentation de la sécrétion de glucagon endogène."@fr;
  r:conduiteATenir "Renforcer l'autosurveillance glycémique et adapter si besoin la posologie de la repaglidine pendant le traitement par l'analogue de la somatostatine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634466, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634460 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634461 .

_:807f36cf91fe4e8caa53aadeff92477634461 rdf:first _:807f36cf91fe4e8caa53aadeff92477634462;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634463 .

_:807f36cf91fe4e8caa53aadeff92477634462 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10015 .

_:807f36cf91fe4e8caa53aadeff92477634463 rdf:first _:807f36cf91fe4e8caa53aadeff92477634464;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634464 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:807f36cf91fe4e8caa53aadeff92477634466 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10168-1 a owl:Class;
  rdfs:label "ANALOGUES DE LA SOMATOSTATINE <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10168";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634468;
  r:natureDuRisque "Risque d'hypoglycémie ou d'hyperglycémie : diminution ou augmentation des besoins en sulfamide hypoglycemiant, par diminution ou augmentation de la sécrétion de glucagon endogène."@fr;
  r:conduiteATenir "Renforcer l'autosurveillance glycémique et adapter si besoin la posologie du sulfamide hypoglycemiant pendant le traitement par l'analogue de la somatostatine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634474, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634468 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634469 .

_:807f36cf91fe4e8caa53aadeff92477634469 rdf:first _:807f36cf91fe4e8caa53aadeff92477634470;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634471 .

_:807f36cf91fe4e8caa53aadeff92477634470 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10015 .

_:807f36cf91fe4e8caa53aadeff92477634471 rdf:first _:807f36cf91fe4e8caa53aadeff92477634472;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634472 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477634474 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10169-1 a owl:Class;
  rdfs:label "ANDROGÈNES <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10169";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634476;
  r:natureDuRisque "Augmentation du risque hémorragique par effet direct sur la coagulation et/ou les systèmes fibrinolytiques."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation de la posologie de l’antivitamine K pendant le traitement par l'androgène et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634482, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634476 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634477 .

_:807f36cf91fe4e8caa53aadeff92477634477 rdf:first _:807f36cf91fe4e8caa53aadeff92477634478;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634479 .

_:807f36cf91fe4e8caa53aadeff92477634478 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10016 .

_:807f36cf91fe4e8caa53aadeff92477634479 rdf:first _:807f36cf91fe4e8caa53aadeff92477634480;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634480 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477634482 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10170-1 a owl:Class;
  rdfs:label "ANDROGÈNES <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10170";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634484;
  r:chapeau "Certains médicaments ont la propriété d'activer considérablement certaines voies métaboliques hépatiques par induction enzymatique. Associés à des médicaments fortement métabolisés au niveau du foie, ils sont, de ce fait, en mesure d'en modifier les conce"@fr;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de l'androgène et par conséquent de son efficacité, par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et biologique pendant l’association et 1 à 2 semaines après l’arrêt de l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634490, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634484 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634485 .

_:807f36cf91fe4e8caa53aadeff92477634485 rdf:first _:807f36cf91fe4e8caa53aadeff92477634486;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634487 .

_:807f36cf91fe4e8caa53aadeff92477634486 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10016 .

_:807f36cf91fe4e8caa53aadeff92477634487 rdf:first _:807f36cf91fe4e8caa53aadeff92477634488;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634488 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477634490 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10171-1 a owl:Class;
  rdfs:label "ANESTHÉSIQUES VOLATILS HALOGÉNÉS <-> BÊTA-BLOQUANTS (SAUF ESMOLOL)"@fr;
  dct:identifier "IAM_10171";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634492;
  r:natureDuRisque "Réduction des réactions cardiovasculaires de compensation par les bêta-bloquants. L'inhibition bêta-adrénergique peut être levée durant l'intervention par les bêta-mimétiques."@fr;
  r:conduiteATenir "En règle générale, ne pas arrêter le traitement bêta-bloquant et, de toute façon, éviter l'arrêt brutal. Informer l'anesthésiste de ce traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634498, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634492 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634493 .

_:807f36cf91fe4e8caa53aadeff92477634493 rdf:first _:807f36cf91fe4e8caa53aadeff92477634494;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634495 .

_:807f36cf91fe4e8caa53aadeff92477634494 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:807f36cf91fe4e8caa53aadeff92477634495 rdf:first _:807f36cf91fe4e8caa53aadeff92477634496;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634496 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff92477634498 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10172-1 a owl:Class;
  rdfs:label "ANESTHÉSIQUES VOLATILS HALOGÉNÉS <-> BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE"@fr;
  dct:identifier "IAM_10172";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634500;
  r:natureDuRisque "Réduction des réactions cardiovasculaires de compensation par les bêta-bloquants. L'inhibition bêta-adrénergique peut être levée durant l'intervention par les bêta-stimulants."@fr;
  r:conduiteATenir "En règle générale, ne pas arrêter le traitement bêta-bloquant et, de toute façon, éviter l'arrêt brutal. Informer l'anesthésiste de ce traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634506, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634500 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634501 .

_:807f36cf91fe4e8caa53aadeff92477634501 rdf:first _:807f36cf91fe4e8caa53aadeff92477634502;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634503 .

_:807f36cf91fe4e8caa53aadeff92477634502 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:807f36cf91fe4e8caa53aadeff92477634503 rdf:first _:807f36cf91fe4e8caa53aadeff92477634504;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634504 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477634506 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10160-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES DE PALIER II <-> MORPHINIQUES AGONISTES-ANTAGONISTES"@fr;
  dct:identifier "IAM_10160";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634508;
  r:natureDuRisque "Diminution de l'effet antalgique par blocage compétitif des récepteurs, avec risque d'apparition d'un syndrome de sevrage."@fr;
  rdfs:comment "L’association d’agonistes-antagonistes morphiniques (buprénorphine, nalbuphine, pentazocine) avec des analgésiques morphiniques agonistes a été contre-indiquée jusqu'à présent, et ce, quel que soit leur niveau (palier II ou III de la classification de l'O"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634514, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634508 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634509 .

_:807f36cf91fe4e8caa53aadeff92477634509 rdf:first _:807f36cf91fe4e8caa53aadeff92477634510;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634511 .

_:807f36cf91fe4e8caa53aadeff92477634510 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10013 .

_:807f36cf91fe4e8caa53aadeff92477634511 rdf:first _:807f36cf91fe4e8caa53aadeff92477634512;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634512 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10110 .

_:807f36cf91fe4e8caa53aadeff92477634514 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10101-1 a owl:Class;
  rdfs:label "ALLOPURINOL <-> VIDARABINE"@fr;
  dct:identifier "IAM_10101";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634516;
  r:natureDuRisque "Risque accru de troubles neurologiques (tremblements, confusion) par inhibition partielle du métabolisme de l'antiviral."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634522, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634516 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634517 .

_:807f36cf91fe4e8caa53aadeff92477634517 rdf:first _:807f36cf91fe4e8caa53aadeff92477634518;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634519 .

_:807f36cf91fe4e8caa53aadeff92477634518 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10051 .

_:807f36cf91fe4e8caa53aadeff92477634519 rdf:first _:807f36cf91fe4e8caa53aadeff92477634520;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634520 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10981 .

_:807f36cf91fe4e8caa53aadeff92477634522 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10090-1 a owl:Class;
  rdfs:label "ALISKIREN <-> ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II"@fr;
  dct:identifier "IAM_10090";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634524;
  r:natureDuRisque "Risque d’hyperkaliémie, d’insuffisance rénale, d’augmentation de la morbi-mortalité cardio-vasculaire."@fr;
  r:conduiteATenir """Contre-indication :
- chez le patient diabétique ou insuffisant rénal

Association déconseillée :
- dans les autres cas"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634530, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634524 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634525 .

_:807f36cf91fe4e8caa53aadeff92477634525 rdf:first _:807f36cf91fe4e8caa53aadeff92477634526;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634527 .

_:807f36cf91fe4e8caa53aadeff92477634526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477634527 rdf:first _:807f36cf91fe4e8caa53aadeff92477634528;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634528 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477634530 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10091-1 a owl:Class;
  rdfs:label "ALISKIREN <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10091";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634532;
  r:natureDuRisque "Augmentation de près de 5 fois des concentrations plasmatiques d’aliskiren et majoration du risque de ses effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634538, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634532 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634533 .

_:807f36cf91fe4e8caa53aadeff92477634533 rdf:first _:807f36cf91fe4e8caa53aadeff92477634534;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634535 .

_:807f36cf91fe4e8caa53aadeff92477634534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477634535 rdf:first _:807f36cf91fe4e8caa53aadeff92477634536;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634536 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477634538 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10092-1 a owl:Class;
  rdfs:label "ALISKIREN <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10092";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634540;
  r:natureDuRisque "Risque d’hyperkaliémie, d’insuffisance rénale, d’augmentation de la morbi-mortalité cardio-vasculaire."@fr;
  r:conduiteATenir """Contre-indication :
- chez le patient diabétique ou insuffisant rénal

Association déconseillée :
- dans les autres cas"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634546, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634540 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634541 .

_:807f36cf91fe4e8caa53aadeff92477634541 rdf:first _:807f36cf91fe4e8caa53aadeff92477634542;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634543 .

_:807f36cf91fe4e8caa53aadeff92477634542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477634543 rdf:first _:807f36cf91fe4e8caa53aadeff92477634544;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634544 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477634546 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10093-1 a owl:Class;
  rdfs:label "ALISKIREN <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10093";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634548;
  r:natureDuRisque "Augmentation de près de 6 fois des concentrations plasmatiques d’aliskiren et majoration du risque de ses effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634554, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634548 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634549 .

_:807f36cf91fe4e8caa53aadeff92477634549 rdf:first _:807f36cf91fe4e8caa53aadeff92477634550;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634551 .

_:807f36cf91fe4e8caa53aadeff92477634550 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477634551 rdf:first _:807f36cf91fe4e8caa53aadeff92477634552;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634552 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477634554 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10094-1 a owl:Class;
  rdfs:label "ALISKIREN <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_10094";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634556;
  r:natureDuRisque "Risque de diminution de l’efficacité de l’aliskiren en cas de consommation de pamplemousse."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634562, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634556 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634557 .

_:807f36cf91fe4e8caa53aadeff92477634557 rdf:first _:807f36cf91fe4e8caa53aadeff92477634558;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634559 .

_:807f36cf91fe4e8caa53aadeff92477634558 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477634559 rdf:first _:807f36cf91fe4e8caa53aadeff92477634560;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634560 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477634562 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10095-1 a owl:Class;
  rdfs:label "ALISKIREN <-> QUINIDINE"@fr;
  dct:identifier "IAM_10095";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634564;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’aliskiren et majoration du risque de ses effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634570, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634564 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634565 .

_:807f36cf91fe4e8caa53aadeff92477634565 rdf:first _:807f36cf91fe4e8caa53aadeff92477634566;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634567 .

_:807f36cf91fe4e8caa53aadeff92477634566 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477634567 rdf:first _:807f36cf91fe4e8caa53aadeff92477634568;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634568 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477634570 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10096-1 a owl:Class;
  rdfs:label "ALISKIREN <-> SACUBITRIL"@fr;
  dct:identifier "IAM_10096";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634572;
  r:natureDuRisque "Chez les patients diabétiques ou insuffisants rénaux, augmentation des effets indésirables tels que hypotension, hyperkaliémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634578, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634572 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634573 .

_:807f36cf91fe4e8caa53aadeff92477634573 rdf:first _:807f36cf91fe4e8caa53aadeff92477634574;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634575 .

_:807f36cf91fe4e8caa53aadeff92477634574 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477634575 rdf:first _:807f36cf91fe4e8caa53aadeff92477634576;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634576 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10821 .

_:807f36cf91fe4e8caa53aadeff92477634578 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10097-1 a owl:Class;
  rdfs:label "ALISKIREN <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10097";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634580;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’aliskiren et majoration du risque de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634586, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634580 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634581 .

_:807f36cf91fe4e8caa53aadeff92477634581 rdf:first _:807f36cf91fe4e8caa53aadeff92477634582;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634583 .

_:807f36cf91fe4e8caa53aadeff92477634582 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477634583 rdf:first _:807f36cf91fe4e8caa53aadeff92477634584;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634584 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477634586 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10098-1 a owl:Class;
  rdfs:label "ALLOPURINOL <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10098";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634588;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique (diminution de son métabolisme hépatique)."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par l'allopurinol et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634594, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634588 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634589 .

_:807f36cf91fe4e8caa53aadeff92477634589 rdf:first _:807f36cf91fe4e8caa53aadeff92477634590;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634591 .

_:807f36cf91fe4e8caa53aadeff92477634590 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477634591 rdf:first _:807f36cf91fe4e8caa53aadeff92477634592;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634592 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10051 .

_:807f36cf91fe4e8caa53aadeff92477634594 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10060-1 a owl:Class;
  rdfs:label "ALBENDAZOLE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10060";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634596;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques de l’albendazole et de son métabolite actif par le ritonavir, avec risque de baisse de son efficacité."@fr;
  r:conduiteATenir "Surveillance clinique de la réponse thérapeutique et adaptation éventuelle de la posologie de l’albendazole pendant le traitement avec l’inducteur enzymatique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634602, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634596 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634597 .

_:807f36cf91fe4e8caa53aadeff92477634597 rdf:first _:807f36cf91fe4e8caa53aadeff92477634598;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634599 .

_:807f36cf91fe4e8caa53aadeff92477634598 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477634599 rdf:first _:807f36cf91fe4e8caa53aadeff92477634600;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634600 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477634602 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10100-1 a owl:Class;
  rdfs:label "ALLOPURINOL <-> PÉNICILLINES A"@fr;
  dct:identifier "IAM_10100";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634604;
  r:natureDuRisque "Risque accru de réactions cutanées."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634610, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634604 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634605 .

_:807f36cf91fe4e8caa53aadeff92477634605 rdf:first _:807f36cf91fe4e8caa53aadeff92477634606;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634607 .

_:807f36cf91fe4e8caa53aadeff92477634606 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10139 .

_:807f36cf91fe4e8caa53aadeff92477634607 rdf:first _:807f36cf91fe4e8caa53aadeff92477634608;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634608 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10051 .

_:807f36cf91fe4e8caa53aadeff92477634610 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10087-1 a owl:Class;
  rdfs:label "ALFENTANIL <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10087";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634612;
  r:natureDuRisque "Augmentation de l'effet dépresseur respiratoire de l'analgésique opiacé par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de l’analgésique opiacé en cas de traitement par un inhibiteur puissant du CYP3A4."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634618, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634612 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634613 .

_:807f36cf91fe4e8caa53aadeff92477634613 rdf:first _:807f36cf91fe4e8caa53aadeff92477634614;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634615 .

_:807f36cf91fe4e8caa53aadeff92477634614 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477634615 rdf:first _:807f36cf91fe4e8caa53aadeff92477634616;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634616 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10045 .

_:807f36cf91fe4e8caa53aadeff92477634618 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10103-1 a owl:Class;
  rdfs:label "ALPHABLOQUANTS À VISÉE UROLOGIQUE <-> ANTIHYPERTENSEURS SAUF ALPHA-BLOQUANTS"@fr;
  dct:identifier "IAM_10103";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634620;
  r:natureDuRisque "Majoration de l'effet hypotenseur. Risque d'hypotension orthostatique majoré."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634626, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634620 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634621 .

_:807f36cf91fe4e8caa53aadeff92477634621 rdf:first _:807f36cf91fe4e8caa53aadeff92477634622;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634623 .

_:807f36cf91fe4e8caa53aadeff92477634622 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10009 .

_:807f36cf91fe4e8caa53aadeff92477634623 rdf:first _:807f36cf91fe4e8caa53aadeff92477634624;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634624 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10035 .

_:807f36cf91fe4e8caa53aadeff92477634626 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10102-1 a owl:Class;
  rdfs:label "ALPHABLOQUANTS À VISÉE UROLOGIQUE <-> ANTIHYPERTENSEURS ALPHA-BLOQUANTS"@fr;
  dct:identifier "IAM_10102";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634628;
  r:natureDuRisque "Majoration de l'effet hypotenseur. Risque d'hypotension orthostatique sévère."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634634, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634628 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634629 .

_:807f36cf91fe4e8caa53aadeff92477634629 rdf:first _:807f36cf91fe4e8caa53aadeff92477634630;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634631 .

_:807f36cf91fe4e8caa53aadeff92477634630 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10009 .

_:807f36cf91fe4e8caa53aadeff92477634631 rdf:first _:807f36cf91fe4e8caa53aadeff92477634632;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634632 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10033 .

_:807f36cf91fe4e8caa53aadeff92477634634 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10104-1 a owl:Class;
  rdfs:label "ALPHABLOQUANTS À VISÉE UROLOGIQUE <-> INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5"@fr;
  dct:identifier "IAM_10104";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634636;
  r:natureDuRisque "Risque d’hypotension orthostatique, notamment chez le sujet âgé."@fr;
  r:conduiteATenir """Association déconseillée :
- avec la doxazosine

Précaution d'emploi :
- avec les autres alpha-bloquants
Débuter le traitement aux posologies minimales recommandées et adapter progressivement les doses si besoin."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634642, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634636 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634637 .

_:807f36cf91fe4e8caa53aadeff92477634637 rdf:first _:807f36cf91fe4e8caa53aadeff92477634638;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634639 .

_:807f36cf91fe4e8caa53aadeff92477634638 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10009 .

_:807f36cf91fe4e8caa53aadeff92477634639 rdf:first _:807f36cf91fe4e8caa53aadeff92477634640;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634640 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:807f36cf91fe4e8caa53aadeff92477634642 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10105-1 a owl:Class;
  rdfs:label "ALPHA-TOCOPHEROL <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10105";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634644;
  r:natureDuRisque "Avec la vitamine E utilisée à des doses supérieures ou égales à 500 mg/j : augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par vitamine E et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634650, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634644 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634645 .

_:807f36cf91fe4e8caa53aadeff92477634645 rdf:first _:807f36cf91fe4e8caa53aadeff92477634646;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634647 .

_:807f36cf91fe4e8caa53aadeff92477634646 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477634647 rdf:first _:807f36cf91fe4e8caa53aadeff92477634648;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634648 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff92477634650 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10106-1 a owl:Class;
  rdfs:label "ALPRAZOLAM <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10106";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634652;
  r:natureDuRisque "Possible augmentation de l'effet sédatif de l'alprazolam."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634658, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634652 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634653 .

_:807f36cf91fe4e8caa53aadeff92477634653 rdf:first _:807f36cf91fe4e8caa53aadeff92477634654;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634655 .

_:807f36cf91fe4e8caa53aadeff92477634654 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477634655 rdf:first _:807f36cf91fe4e8caa53aadeff92477634656;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634656 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477634658 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10107-1 a owl:Class;
  rdfs:label "ALUMINIUM (SELS) <-> CITRATES"@fr;
  dct:identifier "IAM_10107";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634660;
  r:natureDuRisque "Risque de facilitation du passage systémique de l’aluminium, notamment en cas de fonction rénale altérée."@fr;
  r:conduiteATenir "Prendre les topiques gastro-intestinaux à base d'aluminium à distance des citrates (plus de 2 heures si possible), y compris les citrates naturels (jus d'agrumes)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634666, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634660 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634661 .

_:807f36cf91fe4e8caa53aadeff92477634661 rdf:first _:807f36cf91fe4e8caa53aadeff92477634662;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634663 .

_:807f36cf91fe4e8caa53aadeff92477634662 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10010 .

_:807f36cf91fe4e8caa53aadeff92477634663 rdf:first _:807f36cf91fe4e8caa53aadeff92477634664;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634664 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10056 .

_:807f36cf91fe4e8caa53aadeff92477634666 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10108-1 a owl:Class;
  rdfs:label "AMBRISENTAN <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10108";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634668;
  r:natureDuRisque "Doublement des concentrations d’ambrisentan, avec majoration de l’effet vasodilatateur (céphalées)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634674, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634668 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634669 .

_:807f36cf91fe4e8caa53aadeff92477634669 rdf:first _:807f36cf91fe4e8caa53aadeff92477634670;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634671 .

_:807f36cf91fe4e8caa53aadeff92477634670 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10061 .

_:807f36cf91fe4e8caa53aadeff92477634671 rdf:first _:807f36cf91fe4e8caa53aadeff92477634672;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634672 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477634674 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10109-1 a owl:Class;
  rdfs:label "AMINOGLUTETHIMIDE <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10109";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634676;
  r:natureDuRisque "Décrit pour warfarine et acénocoumarol. Diminution de l'effet de l'antivitamine K, par augmentation de son métabolisme hépatique par l'aminogluthétimide."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par aminogluthétimide et deux semaines après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634682, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634676 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634677 .

_:807f36cf91fe4e8caa53aadeff92477634677 rdf:first _:807f36cf91fe4e8caa53aadeff92477634678;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634679 .

_:807f36cf91fe4e8caa53aadeff92477634678 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477634679 rdf:first _:807f36cf91fe4e8caa53aadeff92477634680;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634680 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10064 .

_:807f36cf91fe4e8caa53aadeff92477634682 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10110-1 a owl:Class;
  rdfs:label "AMINOGLUTETHIMIDE <-> DEXAMETHASONE"@fr;
  dct:identifier "IAM_10110";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634684;
  r:natureDuRisque "Diminution de l'efficacité de la dexaméthasone, par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Adaptation de la posologie de la dexaméthasone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634690, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634684 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634685 .

_:807f36cf91fe4e8caa53aadeff92477634685 rdf:first _:807f36cf91fe4e8caa53aadeff92477634686;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634687 .

_:807f36cf91fe4e8caa53aadeff92477634686 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10064 .

_:807f36cf91fe4e8caa53aadeff92477634687 rdf:first _:807f36cf91fe4e8caa53aadeff92477634688;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634688 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477634690 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10099-1 a owl:Class;
  rdfs:label "ALLOPURINOL <-> DIDANOSINE"@fr;
  dct:identifier "IAM_10099";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634692;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de didanosine et de ses effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634698, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634692 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634693 .

_:807f36cf91fe4e8caa53aadeff92477634693 rdf:first _:807f36cf91fe4e8caa53aadeff92477634694;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634695 .

_:807f36cf91fe4e8caa53aadeff92477634694 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10051 .

_:807f36cf91fe4e8caa53aadeff92477634695 rdf:first _:807f36cf91fe4e8caa53aadeff92477634696;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634696 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:807f36cf91fe4e8caa53aadeff92477634698 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10013-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANAGRELIDE"@fr;
  dct:identifier "IAM_10013";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634700;
  r:natureDuRisque "Majoration des événements hémorragiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634706, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634700 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634701 .

_:807f36cf91fe4e8caa53aadeff92477634701 rdf:first _:807f36cf91fe4e8caa53aadeff92477634702;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634703 .

_:807f36cf91fe4e8caa53aadeff92477634702 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477634703 rdf:first _:807f36cf91fe4e8caa53aadeff92477634704;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634704 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff92477634706 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10002-1 a owl:Class;
  rdfs:label "ABATACEPT <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10002";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634708;
  r:natureDuRisque "Risque de maladie vaccinale généralisée, éventuellement mortelle."@fr;
  r:conduiteATenir "ainsi que pendant les 3 mois suivant l'arrêt du traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634714, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634708 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634709 .

_:807f36cf91fe4e8caa53aadeff92477634709 rdf:first _:807f36cf91fe4e8caa53aadeff92477634710;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634711 .

_:807f36cf91fe4e8caa53aadeff92477634710 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477634711 rdf:first _:807f36cf91fe4e8caa53aadeff92477634712;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477634714 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10003-1 a owl:Class;
  rdfs:label "ABIRATERONE <-> ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10003";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634716;
  r:natureDuRisque "Diminution notable des concentrations plasmatiques de l’abiratérone, avec risque de moindre efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634722, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634716 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634717 .

_:807f36cf91fe4e8caa53aadeff92477634717 rdf:first _:807f36cf91fe4e8caa53aadeff92477634718;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634719 .

_:807f36cf91fe4e8caa53aadeff92477634718 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477634719 rdf:first _:807f36cf91fe4e8caa53aadeff92477634720;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477634722 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10004-1 a owl:Class;
  rdfs:label "ABIRATERONE <-> FLECAINIDE"@fr;
  dct:identifier "IAM_10004";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634724;
  r:natureDuRisque "Risque d'augmentation des effets indésirables du flecaïnide, par diminution de son métabolisme hépatique par l'abiratérone."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du flécaïnide pendant le traitement par l'abiratérone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634730, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634724 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634725 .

_:807f36cf91fe4e8caa53aadeff92477634725 rdf:first _:807f36cf91fe4e8caa53aadeff92477634726;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634727 .

_:807f36cf91fe4e8caa53aadeff92477634726 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477634727 rdf:first _:807f36cf91fe4e8caa53aadeff92477634728;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:807f36cf91fe4e8caa53aadeff92477634730 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10005-1 a owl:Class;
  rdfs:label "ABIRATERONE <-> METOPROLOL"@fr;
  dct:identifier "IAM_10005";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634732;
  r:natureDuRisque "Chez l'insuffisant cardiaque, risque d'augmentation des effets indésirables du métoprolol, par diminution de son métabolisme hépatique par l'abiratérone."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du métoprolol pendant le traitement par l'abiratérone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634738, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634732 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634733 .

_:807f36cf91fe4e8caa53aadeff92477634733 rdf:first _:807f36cf91fe4e8caa53aadeff92477634734;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634735 .

_:807f36cf91fe4e8caa53aadeff92477634734 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477634735 rdf:first _:807f36cf91fe4e8caa53aadeff92477634736;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477634738 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10006-1 a owl:Class;
  rdfs:label "ABIRATERONE <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10006";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634740;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la propafénone, par diminution de son métabolisme hépatique par l'abiratérone."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la propafénone pendant le traitement par l'abiratérone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634746, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634740 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634741 .

_:807f36cf91fe4e8caa53aadeff92477634741 rdf:first _:807f36cf91fe4e8caa53aadeff92477634742;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634743 .

_:807f36cf91fe4e8caa53aadeff92477634742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477634743 rdf:first _:807f36cf91fe4e8caa53aadeff92477634744;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477634746 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10007-1 a owl:Class;
  rdfs:label "ABIRATERONE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10007";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634748;
  r:natureDuRisque "Diminution notable des concentrations plasmatiques de l’abiratérone, avec risque de moindre efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634754, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634748 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634749 .

_:807f36cf91fe4e8caa53aadeff92477634749 rdf:first _:807f36cf91fe4e8caa53aadeff92477634750;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634751 .

_:807f36cf91fe4e8caa53aadeff92477634750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477634751 rdf:first _:807f36cf91fe4e8caa53aadeff92477634752;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477634754 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10008-1 a owl:Class;
  rdfs:label "ACETAZOLAMIDE <-> ACIDE ACETYLSALICYLIQUE"@fr;
  dct:identifier "IAM_10008";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634756;
  r:natureDuRisque "Majoration des effets indésirables, et notamment de l'acidose métabolique, de l'acide acétylsalicylique à doses élevées et de l'acétazolamide, par diminution de l'élimination de l'acide acétylsalicylique par l'acétazolamide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634762, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634756 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634757 .

_:807f36cf91fe4e8caa53aadeff92477634757 rdf:first _:807f36cf91fe4e8caa53aadeff92477634758;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634759 .

_:807f36cf91fe4e8caa53aadeff92477634758 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477634759 rdf:first _:807f36cf91fe4e8caa53aadeff92477634760;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477634762 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10009-1 a owl:Class;
  rdfs:label "ACETAZOLAMIDE <-> CARBAMAZEPINE"@fr;
  dct:identifier "IAM_10009";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634764;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, contrôle des concentrations plasmatiques de carbamazépine et réduction éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634770, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634764 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634765 .

_:807f36cf91fe4e8caa53aadeff92477634765 rdf:first _:807f36cf91fe4e8caa53aadeff92477634766;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634767 .

_:807f36cf91fe4e8caa53aadeff92477634766 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477634767 rdf:first _:807f36cf91fe4e8caa53aadeff92477634768;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477634770 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10010-1 a owl:Class;
  rdfs:label "ACETAZOLAMIDE <-> LITHIUM"@fr;
  dct:identifier "IAM_10010";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634772;
  r:natureDuRisque "Diminution de la lithémie avec risque de baisse de l’efficacité thérapeutique."@fr;
  r:conduiteATenir "Surveillance stricte de la lithémie et adaptation éventuelle de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634778, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634772 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634773 .

_:807f36cf91fe4e8caa53aadeff92477634773 rdf:first _:807f36cf91fe4e8caa53aadeff92477634774;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634775 .

_:807f36cf91fe4e8caa53aadeff92477634774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477634775 rdf:first _:807f36cf91fe4e8caa53aadeff92477634776;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477634778 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10089-1 a owl:Class;
  rdfs:label "ALFUZOSINE <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10089";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634780;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'afuzosine par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634786, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634780 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634781 .

_:807f36cf91fe4e8caa53aadeff92477634781 rdf:first _:807f36cf91fe4e8caa53aadeff92477634782;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634783 .

_:807f36cf91fe4e8caa53aadeff92477634782 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477634783 rdf:first _:807f36cf91fe4e8caa53aadeff92477634784;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477634786 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10012-1 a owl:Class;
  rdfs:label "ACIDE ACETOHYDROXAMIQUE <-> FER"@fr;
  dct:identifier "IAM_10012";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634788;
  r:natureDuRisque "Diminution de l'absorption digestive de ces deux médicaments par chélation du fer."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634794, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634788 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634789 .

_:807f36cf91fe4e8caa53aadeff92477634789 rdf:first _:807f36cf91fe4e8caa53aadeff92477634790;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634791 .

_:807f36cf91fe4e8caa53aadeff92477634790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477634791 rdf:first _:807f36cf91fe4e8caa53aadeff92477634792;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477634794 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10088-1 a owl:Class;
  rdfs:label "ALFUZOSINE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10088";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634796;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de l’alfuzosine et de ses effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634802, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634796 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634797 .

_:807f36cf91fe4e8caa53aadeff92477634797 rdf:first _:807f36cf91fe4e8caa53aadeff92477634798;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634799 .

_:807f36cf91fe4e8caa53aadeff92477634798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477634799 rdf:first _:807f36cf91fe4e8caa53aadeff92477634800;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477634802 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10071-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10071";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634804;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'alcaloïde de l'ergot de seigle vasoconstricteur par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634810, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634804 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634805 .

_:807f36cf91fe4e8caa53aadeff92477634805 rdf:first _:807f36cf91fe4e8caa53aadeff92477634806;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634807 .

_:807f36cf91fe4e8caa53aadeff92477634806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477634807 rdf:first _:807f36cf91fe4e8caa53aadeff92477634808;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477634810 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10072-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS <-> SYMPATHOMIMÉTIQUES ALPHA (VOIES ORALE ET/OU NASALE)"@fr;
  dct:identifier "IAM_10072";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634812;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634818, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634812 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634813 .

_:807f36cf91fe4e8caa53aadeff92477634813 rdf:first _:807f36cf91fe4e8caa53aadeff92477634814;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634815 .

_:807f36cf91fe4e8caa53aadeff92477634814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477634815 rdf:first _:807f36cf91fe4e8caa53aadeff92477634816;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10148 .

_:807f36cf91fe4e8caa53aadeff92477634818 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10073-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_10073";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634820;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  rdfs:comment """Les décisions suivantes, émanant de trois instances de l'Afssaps, ont été prises en compte : 
- la Commission Nationale de Pharmacovigilance a pris acte d'une toxicité de la phénylpropanolamine supérieure à celle des autres sympathomimétiques indirects ("""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634826, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634820 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634821 .

_:807f36cf91fe4e8caa53aadeff92477634821 rdf:first _:807f36cf91fe4e8caa53aadeff92477634822;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634823 .

_:807f36cf91fe4e8caa53aadeff92477634822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477634823 rdf:first _:807f36cf91fe4e8caa53aadeff92477634824;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477634826 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10074-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS <-> TRIPTANS"@fr;
  dct:identifier "IAM_10074";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634828;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  r:conduiteATenir "Respecter un délai de 6 à 24 heures, selon le triptan, entre la prise de celui-ci et celle de l'alcaloïde ergoté"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634834, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634828 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634829 .

_:807f36cf91fe4e8caa53aadeff92477634829 rdf:first _:807f36cf91fe4e8caa53aadeff92477634830;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634831 .

_:807f36cf91fe4e8caa53aadeff92477634830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477634831 rdf:first _:807f36cf91fe4e8caa53aadeff92477634832;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10156 .

_:807f36cf91fe4e8caa53aadeff92477634834 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10082-1 a owl:Class;
  rdfs:label "ALDESLEUKINE <-> PRODUITS DE CONTRASTE IODÉS"@fr;
  dct:identifier "IAM_10082";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634836;
  r:natureDuRisque "Majoration du risque de réaction aux produits de contraste en cas de traitement antérieur par interleukine 2 : éruption cutanée ou plus rarement hypotension, oligurie voire insuffisance rénale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634842, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634836 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634837 .

_:807f36cf91fe4e8caa53aadeff92477634837 rdf:first _:807f36cf91fe4e8caa53aadeff92477634838;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634839 .

_:807f36cf91fe4e8caa53aadeff92477634838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10133 .

_:807f36cf91fe4e8caa53aadeff92477634839 rdf:first _:807f36cf91fe4e8caa53aadeff92477634840;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477634842 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10083-1 a owl:Class;
  rdfs:label "ALFENTANIL <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10083";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634844;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation de l'effet dépresseur respiratoire de l'analgésique opiacé par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Adapter la posologie de l'alfentanil en cas de traitement par la cimétidine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634850, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634844 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634845 .

_:807f36cf91fe4e8caa53aadeff92477634845 rdf:first _:807f36cf91fe4e8caa53aadeff92477634846;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634847 .

_:807f36cf91fe4e8caa53aadeff92477634846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10045 .

_:807f36cf91fe4e8caa53aadeff92477634847 rdf:first _:807f36cf91fe4e8caa53aadeff92477634848;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477634850 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10084-1 a owl:Class;
  rdfs:label "ALFENTANIL <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10084";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634852;
  r:natureDuRisque "Augmentation de l'effet dépresseur respiratoire de l'analgésique opiacé par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Adapter la posologie de l'alfentanil en cas de traitement par le diltiazem."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634858, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634852 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634853 .

_:807f36cf91fe4e8caa53aadeff92477634853 rdf:first _:807f36cf91fe4e8caa53aadeff92477634854;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634855 .

_:807f36cf91fe4e8caa53aadeff92477634854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10045 .

_:807f36cf91fe4e8caa53aadeff92477634855 rdf:first _:807f36cf91fe4e8caa53aadeff92477634856;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477634858 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10085-1 a owl:Class;
  rdfs:label "ALFENTANIL <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10085";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634860;
  r:natureDuRisque "Augmentation de l'effet dépresseur respiratoire de l'analgésique opiacé par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Adapter la posologie de l'alfentanil en cas de traitement par l'érythromycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634866, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634860 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634861 .

_:807f36cf91fe4e8caa53aadeff92477634861 rdf:first _:807f36cf91fe4e8caa53aadeff92477634862;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634863 .

_:807f36cf91fe4e8caa53aadeff92477634862 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10045 .

_:807f36cf91fe4e8caa53aadeff92477634863 rdf:first _:807f36cf91fe4e8caa53aadeff92477634864;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477634866 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10086-1 a owl:Class;
  rdfs:label "ALFENTANIL <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10086";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634868;
  r:natureDuRisque "Augmentation de l'effet dépresseur respiratoire de l'analgésique opiacé par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Adapter la posologie de l'alfentanil en cas de traitement par le fluconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634874, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634868 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634869 .

_:807f36cf91fe4e8caa53aadeff92477634869 rdf:first _:807f36cf91fe4e8caa53aadeff92477634870;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634871 .

_:807f36cf91fe4e8caa53aadeff92477634870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10045 .

_:807f36cf91fe4e8caa53aadeff92477634871 rdf:first _:807f36cf91fe4e8caa53aadeff92477634872;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477634874 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10112-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> ATALUREN"@fr;
  dct:identifier "IAM_10112";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634876;
  r:natureDuRisque "Risque de potentialisation de la toxicité rénale de l’aminoside."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634882, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634876 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634877 .

_:807f36cf91fe4e8caa53aadeff92477634877 rdf:first _:807f36cf91fe4e8caa53aadeff92477634878;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634879 .

_:807f36cf91fe4e8caa53aadeff92477634878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477634879 rdf:first _:807f36cf91fe4e8caa53aadeff92477634880;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10086 .

_:807f36cf91fe4e8caa53aadeff92477634882 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10011-1 a owl:Class;
  rdfs:label "ACETAZOLAMIDE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_10011";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634884;
  r:natureDuRisque "Augmentation de l'hyperammoniémie, avec risque accru d'encéphalopathie."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634890, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634884 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634885 .

_:807f36cf91fe4e8caa53aadeff92477634885 rdf:first _:807f36cf91fe4e8caa53aadeff92477634886;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634887 .

_:807f36cf91fe4e8caa53aadeff92477634886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477634887 rdf:first _:807f36cf91fe4e8caa53aadeff92477634888;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477634890 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10047-1 a owl:Class;
  rdfs:label "AFATINIB <-> AMIODARONE"@fr;
  dct:identifier "IAM_10047";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634892;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’afatinib par augmentation de son absorption par l'amiodarone."@fr;
  r:conduiteATenir """Il est recommandé d’administrer l'amiodarone le plus à distance possible de l’afatinib, en respectant de préférence un intervalle
de 6 heures ou de 12 heures par rapport à la prise d’afatinib."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634898, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634892 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634893 .

_:807f36cf91fe4e8caa53aadeff92477634893 rdf:first _:807f36cf91fe4e8caa53aadeff92477634894;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634895 .

_:807f36cf91fe4e8caa53aadeff92477634894 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477634895 rdf:first _:807f36cf91fe4e8caa53aadeff92477634896;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477634898 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10113-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> AUTRES AMINOSIDES"@fr;
  dct:identifier "IAM_10113";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634900;
  r:natureDuRisque "Risque accru de néphrotoxicité et d'ototoxicité (l'ototoxicité est cumulative en cas d'administrations successives)."@fr;
  r:conduiteATenir """A prendre en compte :
- en cas d'administrations successives"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634902, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634900 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477634902 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10037-1 a owl:Class;
  rdfs:label "ACIDE FUSIDIQUE <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10037";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634904;
  r:natureDuRisque """Risque majoré d'effets indésirables (concentration-dépendants) à
type de rhabdomyolyse."""@fr;
  r:conduiteATenir """Arrêter le traitement par l'inhibiteur de l'HMG Co-A
réductase avant d'initier un traitement par acide fusidique ou utiliser un autre antibiotique."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634910, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634904 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634905 .

_:807f36cf91fe4e8caa53aadeff92477634905 rdf:first _:807f36cf91fe4e8caa53aadeff92477634906;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634907 .

_:807f36cf91fe4e8caa53aadeff92477634906 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff92477634907 rdf:first _:807f36cf91fe4e8caa53aadeff92477634908;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634908 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10021 .

_:807f36cf91fe4e8caa53aadeff92477634910 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10038-1 a owl:Class;
  rdfs:label "ACIDE FUSIDIQUE <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10038";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634912;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'acide fusidique par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634918, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634912 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634913 .

_:807f36cf91fe4e8caa53aadeff92477634913 rdf:first _:807f36cf91fe4e8caa53aadeff92477634914;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634915 .

_:807f36cf91fe4e8caa53aadeff92477634914 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477634915 rdf:first _:807f36cf91fe4e8caa53aadeff92477634916;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634916 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10021 .

_:807f36cf91fe4e8caa53aadeff92477634918 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10039-1 a owl:Class;
  rdfs:label "ACIDE NICOTINIQUE <-> ALCOOL (BOISSON OU EXCIPIENT)"@fr;
  dct:identifier "IAM_10039";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634920;
  r:natureDuRisque "Risque de prurit, de rougeur et de chaleur, lié à une potentialisation de l'effet vasodilatateur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634926, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634920 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634921 .

_:807f36cf91fe4e8caa53aadeff92477634921 rdf:first _:807f36cf91fe4e8caa53aadeff92477634922;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634923 .

_:807f36cf91fe4e8caa53aadeff92477634922 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10026 .

_:807f36cf91fe4e8caa53aadeff92477634923 rdf:first _:807f36cf91fe4e8caa53aadeff92477634924;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634924 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:807f36cf91fe4e8caa53aadeff92477634926 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10040-1 a owl:Class;
  rdfs:label "ACIDE URSODESOXYCHOLIQUE <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10040";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634928;
  r:natureDuRisque "Risque de variation des concentrations sanguines de ciclosporine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634934, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634928 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634929 .

_:807f36cf91fe4e8caa53aadeff92477634929 rdf:first _:807f36cf91fe4e8caa53aadeff92477634930;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634931 .

_:807f36cf91fe4e8caa53aadeff92477634930 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10033 .

_:807f36cf91fe4e8caa53aadeff92477634931 rdf:first _:807f36cf91fe4e8caa53aadeff92477634932;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634932 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477634934 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10041-1 a owl:Class;
  rdfs:label "ACITRETINE <-> ALCOOL (BOISSON OU EXCIPIENT)"@fr;
  dct:identifier "IAM_10041";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634936;
  r:natureDuRisque "Chez la femme en âge de procréer, risque de transformation de l’acitrétine en étrétinate, puissant tératogène dont la demi-vie très prolongée (120 jours) expose à un risque tératogène majeur en cas de grossesse, pendant le traitement et les 2 mois suivan"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634942, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634936 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634937 .

_:807f36cf91fe4e8caa53aadeff92477634937 rdf:first _:807f36cf91fe4e8caa53aadeff92477634938;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634939 .

_:807f36cf91fe4e8caa53aadeff92477634938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10036 .

_:807f36cf91fe4e8caa53aadeff92477634939 rdf:first _:807f36cf91fe4e8caa53aadeff92477634940;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634940 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:807f36cf91fe4e8caa53aadeff92477634942 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10042-1 a owl:Class;
  rdfs:label "ACITRETINE <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10042";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634944;
  r:natureDuRisque "Risque de majoration de l’hépatotoxicité du méthotrexate."@fr;
  r:conduiteATenir "Si l’association est jugée nécessaire, renforcer la surveillance du bilan hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634950, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634944 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634945 .

_:807f36cf91fe4e8caa53aadeff92477634945 rdf:first _:807f36cf91fe4e8caa53aadeff92477634946;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634947 .

_:807f36cf91fe4e8caa53aadeff92477634946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10036 .

_:807f36cf91fe4e8caa53aadeff92477634947 rdf:first _:807f36cf91fe4e8caa53aadeff92477634948;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634948 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477634950 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10045-1 a owl:Class;
  rdfs:label "ADRÉNALINE (VOIE BUCCO-DENTAIRE OU SOUS-CUTANÉE) <-> IMAO IRRÉVERSIBLES"@fr;
  dct:identifier "IAM_10045";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634952;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  r:conduiteATenir "Limiter l'apport, par exemple : moins de 0,1 mg d'adrénaline en 10 minutes ou 0,3 mg en 1 heure chez l'adulte."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634958, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634952 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634953 .

_:807f36cf91fe4e8caa53aadeff92477634953 rdf:first _:807f36cf91fe4e8caa53aadeff92477634954;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634955 .

_:807f36cf91fe4e8caa53aadeff92477634954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477634955 rdf:first _:807f36cf91fe4e8caa53aadeff92477634956;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634956 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10005 .

_:807f36cf91fe4e8caa53aadeff92477634958 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10043-1 a owl:Class;
  rdfs:label "ADRÉNALINE (VOIE BUCCO-DENTAIRE OU SOUS-CUTANÉE) <-> ANESTHÉSIQUES VOLATILS HALOGÉNÉS"@fr;
  dct:identifier "IAM_10043";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634960;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  r:conduiteATenir "Limiter l'apport, par exemple : moins de 0,1 mg d'adrénaline en 10 minutes ou 0,3 mg en 1 heure chez l'adulte."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634966, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634960 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634961 .

_:807f36cf91fe4e8caa53aadeff92477634961 rdf:first _:807f36cf91fe4e8caa53aadeff92477634962;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634963 .

_:807f36cf91fe4e8caa53aadeff92477634962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10005 .

_:807f36cf91fe4e8caa53aadeff92477634963 rdf:first _:807f36cf91fe4e8caa53aadeff92477634964;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634964 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:807f36cf91fe4e8caa53aadeff92477634966 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10035-1 a owl:Class;
  rdfs:label "ACIDE CLODRONIQUE <-> ESTRAMUSTINE"@fr;
  dct:identifier "IAM_10035";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634968;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques d’estramustine par le clodronate."@fr;
  r:conduiteATenir "Surveillance clinique au cours de l’association."@fr;
  rdfs:comment "Une étude effectuée chez 12 patients ne montre pas de modification significative des paramètres pharmacocinétiques (Cmax, AUC) ou de l’excrétion diurne du clodronate, lorsqu’il est associé à l’estramustine. En revanche, une augmentation de 77% de la Cmax"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634974, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634968 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634969 .

_:807f36cf91fe4e8caa53aadeff92477634969 rdf:first _:807f36cf91fe4e8caa53aadeff92477634970;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634971 .

_:807f36cf91fe4e8caa53aadeff92477634970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10017 .

_:807f36cf91fe4e8caa53aadeff92477634971 rdf:first _:807f36cf91fe4e8caa53aadeff92477634972;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634972 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10345 .

_:807f36cf91fe4e8caa53aadeff92477634974 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10046-1 a owl:Class;
  rdfs:label "ADRÉNALINE (VOIE BUCCO-DENTAIRE OU SOUS-CUTANÉE) <-> MÉDICAMENTS MIXTES ADRÉNERGIQUES-SÉROTONINERGIQUES"@fr;
  dct:identifier "IAM_10046";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634976;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  r:conduiteATenir "Limiter l'apport, par exemple : moins de 0,1 mg d'adrénaline en 10 minutes ou 0,3 mg en 1 heure chez l'adulte."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634982, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634976 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634977 .

_:807f36cf91fe4e8caa53aadeff92477634977 rdf:first _:807f36cf91fe4e8caa53aadeff92477634978;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634979 .

_:807f36cf91fe4e8caa53aadeff92477634978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10005 .

_:807f36cf91fe4e8caa53aadeff92477634979 rdf:first _:807f36cf91fe4e8caa53aadeff92477634980;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634980 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10116 .

_:807f36cf91fe4e8caa53aadeff92477634982 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10034-1 a owl:Class;
  rdfs:label "ACIDE CHOLIQUE <-> PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE)"@fr;
  dct:identifier "IAM_10034";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634984;
  r:natureDuRisque "Effet antagoniste du barbiturique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634990, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634984 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634985 .

_:807f36cf91fe4e8caa53aadeff92477634985 rdf:first _:807f36cf91fe4e8caa53aadeff92477634986;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634987 .

_:807f36cf91fe4e8caa53aadeff92477634986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477634987 rdf:first _:807f36cf91fe4e8caa53aadeff92477634988;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634988 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10016 .

_:807f36cf91fe4e8caa53aadeff92477634990 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10048-1 a owl:Class;
  rdfs:label "AFATINIB <-> ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10048";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477634992;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’afatinib par augmentation de son métabolisme par ces substances."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association et 1 à 2 semaines après leur arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477634998, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477634992 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477634993 .

_:807f36cf91fe4e8caa53aadeff92477634993 rdf:first _:807f36cf91fe4e8caa53aadeff92477634994;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477634995 .

_:807f36cf91fe4e8caa53aadeff92477634994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477634995 rdf:first _:807f36cf91fe4e8caa53aadeff92477634996;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477634996 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477634998 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10049-1 a owl:Class;
  rdfs:label "AFATINIB <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10049";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635000;
  r:natureDuRisque "Augmentation des concentrations plasmatique d’afatinib par augmentation de son absorption par la ciclosporine."@fr;
  r:conduiteATenir """Il est recommandé d’administrer la ciclosporine le plus à distance possible de l’afatinib, en respectant de préférence un intervalle
 de 6 heures ou de 12 heures par rapport à la prise d’afatinib."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635006, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635000 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635001 .

_:807f36cf91fe4e8caa53aadeff92477635001 rdf:first _:807f36cf91fe4e8caa53aadeff92477635002;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635003 .

_:807f36cf91fe4e8caa53aadeff92477635002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477635003 rdf:first _:807f36cf91fe4e8caa53aadeff92477635004;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635004 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477635006 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10050-1 a owl:Class;
  rdfs:label "AFATINIB <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10050";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635008;
  r:natureDuRisque "Augmentation des concentrations plasmatique d’afatinib par augmentation de son absorption par l'érythromycine."@fr;
  r:conduiteATenir """Il est recommandé d’administrer l'érythromycine le plus à distance possible de l’afatinib, en respectant de préférence un intervalle
 de 6 heures ou de 12 heures par rapport à la prise d’afatinib."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635014, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635008 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635009 .

_:807f36cf91fe4e8caa53aadeff92477635009 rdf:first _:807f36cf91fe4e8caa53aadeff92477635010;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635011 .

_:807f36cf91fe4e8caa53aadeff92477635010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477635011 rdf:first _:807f36cf91fe4e8caa53aadeff92477635012;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635012 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477635014 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10051-1 a owl:Class;
  rdfs:label "AFATINIB <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10051";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635016;
  r:natureDuRisque "Augmentation des concentrations plasmatique d’afatinib par augmentation de son absorption par l'inhibiteur de protéases."@fr;
  r:conduiteATenir "Il est recommandé d’administrer l'inhibiteur de protéases le plus à distance possible de l’afatinib, en respectant de préférence un intervalle de 6 heures ou de 12 heures par rapport à la prise d’afatinib."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635022, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635016 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635017 .

_:807f36cf91fe4e8caa53aadeff92477635017 rdf:first _:807f36cf91fe4e8caa53aadeff92477635018;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635019 .

_:807f36cf91fe4e8caa53aadeff92477635018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477635019 rdf:first _:807f36cf91fe4e8caa53aadeff92477635020;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635020 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477635022 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10052-1 a owl:Class;
  rdfs:label "AFATINIB <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10052";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635024;
  r:natureDuRisque "Augmentation des concentrations plasmatique d’afatinib par augmentation de son absorption par l'itraconazole."@fr;
  r:conduiteATenir """Il est recommandé d’administrer l'itraconazole le plus à distance possible de l’afatinib, en respectant de préférence un intervalle
de 6 heures ou de 12 heures par rapport à la prise d’afatinib."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635030, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635024 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635025 .

_:807f36cf91fe4e8caa53aadeff92477635025 rdf:first _:807f36cf91fe4e8caa53aadeff92477635026;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635027 .

_:807f36cf91fe4e8caa53aadeff92477635026 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477635027 rdf:first _:807f36cf91fe4e8caa53aadeff92477635028;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635028 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477635030 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10053-1 a owl:Class;
  rdfs:label "AFATINIB <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10053";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635032;
  r:natureDuRisque "Augmentation des concentrations plasmatique d’afatinib par augmentation de son absorption par le kétoconazole."@fr;
  r:conduiteATenir """Il est recommandé d’administrer le kétoconazole le plus à distance possible de l’afatinib, en respectant de préférence un intervalle 
de 6 heures ou de 12 heures par rapport à la prise d’afatinib."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635038, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635032 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635033 .

_:807f36cf91fe4e8caa53aadeff92477635033 rdf:first _:807f36cf91fe4e8caa53aadeff92477635034;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635035 .

_:807f36cf91fe4e8caa53aadeff92477635034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477635035 rdf:first _:807f36cf91fe4e8caa53aadeff92477635036;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635036 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477635038 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10054-1 a owl:Class;
  rdfs:label "AFATINIB <-> PRIMIDONE"@fr;
  dct:identifier "IAM_10054";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635040;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’afatinib par augmentation de son métabolisme par la primidone."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association et 1 à 2 semaines après leur arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635046, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635040 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635041 .

_:807f36cf91fe4e8caa53aadeff92477635041 rdf:first _:807f36cf91fe4e8caa53aadeff92477635042;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635043 .

_:807f36cf91fe4e8caa53aadeff92477635042 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477635043 rdf:first _:807f36cf91fe4e8caa53aadeff92477635044;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635044 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10756 .

_:807f36cf91fe4e8caa53aadeff92477635046 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10055-1 a owl:Class;
  rdfs:label "AFATINIB <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10055";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635048;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’afatinib par augmentation de son métabolisme par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association et 1 à 2 semaines après leur arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635054, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635048 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635049 .

_:807f36cf91fe4e8caa53aadeff92477635049 rdf:first _:807f36cf91fe4e8caa53aadeff92477635050;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635051 .

_:807f36cf91fe4e8caa53aadeff92477635050 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477635051 rdf:first _:807f36cf91fe4e8caa53aadeff92477635052;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635052 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477635054 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10056-1 a owl:Class;
  rdfs:label "AFATINIB <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10056";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635056;
  r:natureDuRisque "Augmentation des concentrations plasmatique d’afatinib par augmentation de son absorption par le vérapamil."@fr;
  r:conduiteATenir """Il est recommandé d’administrer le vérapamil le plus à distance possible de l’afatinib, en respectant de préférence un intervalle
de 6 heures ou de 12 heures par rapport à la prise d’afatinib."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635062, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635056 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635057 .

_:807f36cf91fe4e8caa53aadeff92477635057 rdf:first _:807f36cf91fe4e8caa53aadeff92477635058;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635059 .

_:807f36cf91fe4e8caa53aadeff92477635058 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477635059 rdf:first _:807f36cf91fe4e8caa53aadeff92477635060;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635060 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477635062 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10057-1 a owl:Class;
  rdfs:label "AGOMELATINE <-> CIPROFLOXACINE"@fr;
  dct:identifier "IAM_10057";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635064;
  r:natureDuRisque """Augmentation des concentrations d'agomélatine, avec risque de 
majoration des effets indésirables."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635070, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635064 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635065 .

_:807f36cf91fe4e8caa53aadeff92477635065 rdf:first _:807f36cf91fe4e8caa53aadeff92477635066;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635067 .

_:807f36cf91fe4e8caa53aadeff92477635066 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10041 .

_:807f36cf91fe4e8caa53aadeff92477635067 rdf:first _:807f36cf91fe4e8caa53aadeff92477635068;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635068 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:807f36cf91fe4e8caa53aadeff92477635070 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10044-1 a owl:Class;
  rdfs:label "ADRÉNALINE (VOIE BUCCO-DENTAIRE OU SOUS-CUTANÉE) <-> ANTIDÉPRESSEURS IMIPRAMINIQUES"@fr;
  dct:identifier "IAM_10044";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635072;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  r:conduiteATenir "Limiter l'apport, par exemple : moins de 0,1 mg d'adrénaline en 10 minutes ou 0,3 mg en 1 heure chez l'adulte."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635078, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635072 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635073 .

_:807f36cf91fe4e8caa53aadeff92477635073 rdf:first _:807f36cf91fe4e8caa53aadeff92477635074;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635075 .

_:807f36cf91fe4e8caa53aadeff92477635074 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10005 .

_:807f36cf91fe4e8caa53aadeff92477635075 rdf:first _:807f36cf91fe4e8caa53aadeff92477635076;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635076 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:807f36cf91fe4e8caa53aadeff92477635078 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10023-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> HÉPARINES NON FRACTIONNÉES (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10023";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635080;
  r:natureDuRisque "Augmentation du risque hémorragique (inhibition de la fonction plaquettaire et agression de la muqueuse gastroduodénale par l’acide acétylsalicylique)."@fr;
  r:conduiteATenir """A prendre en compte avec :
- des doses antiagrégantes (de 50 mg à 375 mg par jour)."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635086, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635080 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635081 .

_:807f36cf91fe4e8caa53aadeff92477635081 rdf:first _:807f36cf91fe4e8caa53aadeff92477635082;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635083 .

_:807f36cf91fe4e8caa53aadeff92477635082 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10091 .

_:807f36cf91fe4e8caa53aadeff92477635083 rdf:first _:807f36cf91fe4e8caa53aadeff92477635084;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635084 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477635086 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10205-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_10205";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635088;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Surveillance clinique et, le cas échéant, contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'anticoagulant oral pendant la durée de l'association et à son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635094, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635088 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635089 .

_:807f36cf91fe4e8caa53aadeff92477635089 rdf:first _:807f36cf91fe4e8caa53aadeff92477635090;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635091 .

_:807f36cf91fe4e8caa53aadeff92477635090 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477635091 rdf:first _:807f36cf91fe4e8caa53aadeff92477635092;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635092 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477635094 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10114-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> BOTULIQUE (TOXINE)"@fr;
  dct:identifier "IAM_10114";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635096;
  r:natureDuRisque "Risque d'augmentation des effets de la toxine botulique avec les aminosides (par extrapolation à partir des effets observés au cours du botulisme)."@fr;
  r:conduiteATenir "Utiliser un autre antibiotique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635102, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635096 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635097 .

_:807f36cf91fe4e8caa53aadeff92477635097 rdf:first _:807f36cf91fe4e8caa53aadeff92477635098;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635099 .

_:807f36cf91fe4e8caa53aadeff92477635098 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477635099 rdf:first _:807f36cf91fe4e8caa53aadeff92477635100;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635100 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477635102 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10014-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II"@fr;
  dct:identifier "IAM_10014";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635104;
  r:natureDuRisque """Pour des doses anti-inflammatoires d'acide acétylsalicylique (>= 1g par prise et/ou >= 3g par jour) ou pour des doses antalgiques ou antipyrétiques (>= 500 mg par prise et/ou < 3g par jour) : 

Insuffisance rénale aiguë chez le malade déshydraté, par dimi"""@fr;
  r:conduiteATenir "Hydrater le malade et surveiller la fonction rénale en début de traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635110, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635104 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635105 .

_:807f36cf91fe4e8caa53aadeff92477635105 rdf:first _:807f36cf91fe4e8caa53aadeff92477635106;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635107 .

_:807f36cf91fe4e8caa53aadeff92477635106 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477635107 rdf:first _:807f36cf91fe4e8caa53aadeff92477635108;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635108 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477635110 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10015-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANTICOAGULANTS ORAUX"@fr;
  dct:identifier "IAM_10015";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635112;
  r:natureDuRisque "Majoration du risque hémorragique, notamment en cas d’antécédent d’ulcère gastro-duodénal."@fr;
  r:conduiteATenir """A prendre en compte avec :
- des doses antiagrégantes (de 50 mg à 375 mg par jour)"""@fr;
  rdfs:comment "Jusqu'à présent, cette interaction se présentait selon deux niveaux distincts : une contre-indication avec l'acide acétylsalicylique administré à doses anti-inflammatoires et une association déconseillée avec l'aspirine donnée à doses antalgiques ou anti"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635118, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635112 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635113 .

_:807f36cf91fe4e8caa53aadeff92477635113 rdf:first _:807f36cf91fe4e8caa53aadeff92477635114;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635115 .

_:807f36cf91fe4e8caa53aadeff92477635114 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477635115 rdf:first _:807f36cf91fe4e8caa53aadeff92477635116;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635116 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477635118 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10016-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANTI-INFLAMMATOIRES NON STÉROÏDIENS"@fr;
  dct:identifier "IAM_10016";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635120;
  r:natureDuRisque "Majoration du risque ulcérogène et hémorragique digestif."@fr;
  r:conduiteATenir """A prendre en compte avec :
- des doses antiagrégantes (de 50 mg à 375 mg par jour en 1 ou plusieurs prises)"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635126, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635120 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635121 .

_:807f36cf91fe4e8caa53aadeff92477635121 rdf:first _:807f36cf91fe4e8caa53aadeff92477635122;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635123 .

_:807f36cf91fe4e8caa53aadeff92477635122 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477635123 rdf:first _:807f36cf91fe4e8caa53aadeff92477635124;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635124 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477635126 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10017-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> CLOPIDOGREL"@fr;
  dct:identifier "IAM_10017";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635128;
  r:natureDuRisque "Majoration du risque hémorragique par addition des activités antiagrégantes plaquettaires."@fr;
  r:conduiteATenir """Association déconseillée :
- en dehors des indications validées pour cette association dans les syndromes coronariens aigus.

Précaution d'emploi :
- dans les indications validées pour cette association dans les syndromes coronariens aigus. Surveillance c"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635134, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635128 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635129 .

_:807f36cf91fe4e8caa53aadeff92477635129 rdf:first _:807f36cf91fe4e8caa53aadeff92477635130;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635131 .

_:807f36cf91fe4e8caa53aadeff92477635130 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477635131 rdf:first _:807f36cf91fe4e8caa53aadeff92477635132;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635132 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10216 .

_:807f36cf91fe4e8caa53aadeff92477635134 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10018-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> DEFERASIROX"@fr;
  dct:identifier "IAM_10018";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635136;
  r:natureDuRisque "Majoration du risque ulcérogène et hémorragique digestif."@fr;
  r:conduiteATenir """A prendre en compte :
- Pour des doses anti-inflammatoires d'acide acétylsalicylique (1g par prise et/ou 3g par jour)
- Pour des doses antalgiques ou antipyrétiques d'acide acétylsalicylique (500 mg par prise et/ou <3g par jour) et (500 mg par prise e"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635142, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635136 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635137 .

_:807f36cf91fe4e8caa53aadeff92477635137 rdf:first _:807f36cf91fe4e8caa53aadeff92477635138;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635139 .

_:807f36cf91fe4e8caa53aadeff92477635138 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477635139 rdf:first _:807f36cf91fe4e8caa53aadeff92477635140;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635140 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:807f36cf91fe4e8caa53aadeff92477635142 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10019-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> DIURÉTIQUES"@fr;
  dct:identifier "IAM_10019";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635144;
  r:natureDuRisque """Pour des doses anti-inflammatoires d'acide acétylsalicylique (>= 1g par prise et/ou >= 3g par jour) ou pour des doses antalgiques ou antipyrétiques (>= 500 mg par prise et/ou < 3g par jour) : 

Insuffisance rénale aiguë chez le malade déshydraté, par dimi"""@fr;
  r:conduiteATenir "Hydrater le malade et surveiller la fonction rénale en début de traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635150, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635144 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635145 .

_:807f36cf91fe4e8caa53aadeff92477635145 rdf:first _:807f36cf91fe4e8caa53aadeff92477635146;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635147 .

_:807f36cf91fe4e8caa53aadeff92477635146 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10063 .

_:807f36cf91fe4e8caa53aadeff92477635147 rdf:first _:807f36cf91fe4e8caa53aadeff92477635148;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635148 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477635150 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10020-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10020";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635152;
  r:natureDuRisque "Majoration du risque hémorragique."@fr;
  r:conduiteATenir """Association déconseillée avec :
- des doses anti-inflammatoires d'acide acétylsalicylique (>=1g par prise et/ou >=3g par jour)

A prendre en compte avec :
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour)."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635158, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635152 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635153 .

_:807f36cf91fe4e8caa53aadeff92477635153 rdf:first _:807f36cf91fe4e8caa53aadeff92477635154;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635155 .

_:807f36cf91fe4e8caa53aadeff92477635154 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477635155 rdf:first _:807f36cf91fe4e8caa53aadeff92477635156;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635156 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477635158 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10036-1 a owl:Class;
  rdfs:label "ACIDE FOLINIQUE <-> FLUOROURACILE (ET, PAR EXTRAPOLATION, AUTRES FLUOROPYRIMIDINES)"@fr;
  dct:identifier "IAM_10036";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635160;
  r:natureDuRisque "Potentialisation des effets, à la fois cytostatiques et indésirables, du fluoro-uracile."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635166, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635160 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635161 .

_:807f36cf91fe4e8caa53aadeff92477635161 rdf:first _:807f36cf91fe4e8caa53aadeff92477635162;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635163 .

_:807f36cf91fe4e8caa53aadeff92477635162 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10076 .

_:807f36cf91fe4e8caa53aadeff92477635163 rdf:first _:807f36cf91fe4e8caa53aadeff92477635164;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635164 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10019 .

_:807f36cf91fe4e8caa53aadeff92477635166 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10022-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES PRÉVENTIVES)"@fr;
  dct:identifier "IAM_10022";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635168;
  r:natureDuRisque "L’utilisation conjointe de médicaments agissant à divers niveaux de l’hémostase majore le risque de saignement. Ainsi, chez le sujet de moins de 65 ans, l’association de l'héparine à doses préventives, ou de substances apparentées, à l’acide acétylsalicyl"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635174, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635168 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635169 .

_:807f36cf91fe4e8caa53aadeff92477635169 rdf:first _:807f36cf91fe4e8caa53aadeff92477635170;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635171 .

_:807f36cf91fe4e8caa53aadeff92477635170 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10090 .

_:807f36cf91fe4e8caa53aadeff92477635171 rdf:first _:807f36cf91fe4e8caa53aadeff92477635172;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635172 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477635174 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10111-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> AMPHOTERICINE B"@fr;
  dct:identifier "IAM_10111";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635176;
  r:natureDuRisque "Avec l'amphotéricine B administrée par voie IV : risque accru de néphrotoxicité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635182, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635176 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635177 .

_:807f36cf91fe4e8caa53aadeff92477635177 rdf:first _:807f36cf91fe4e8caa53aadeff92477635178;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635179 .

_:807f36cf91fe4e8caa53aadeff92477635178 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477635179 rdf:first _:807f36cf91fe4e8caa53aadeff92477635180;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635180 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10072 .

_:807f36cf91fe4e8caa53aadeff92477635182 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10024-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> HÉPARINES NON FRACTIONNÉES (DOSES PRÉVENTIVES)"@fr;
  dct:identifier "IAM_10024";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635184;
  r:natureDuRisque "L’utilisation conjointe de médicaments agissant à divers niveaux de l’hémostase majore le risque de saignement. Ainsi, chez le sujet de moins de 65 ans, l’association des héparines à doses préventives à l’acide acétylsalicylique, quelle que soit la dose,"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635190, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635184 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635185 .

_:807f36cf91fe4e8caa53aadeff92477635185 rdf:first _:807f36cf91fe4e8caa53aadeff92477635186;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635187 .

_:807f36cf91fe4e8caa53aadeff92477635186 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10092 .

_:807f36cf91fe4e8caa53aadeff92477635187 rdf:first _:807f36cf91fe4e8caa53aadeff92477635188;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635188 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477635190 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10025-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10025";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635192;
  r:natureDuRisque """Pour des doses anti-inflammatoires d'acide acétylsalicylique (>= 1g par prise et/ou >= 3g par jour) ou pour des doses antalgiques ou antipyrétiques (>= 500 mg par prise et/ou < 3g par jour) : 

Insuffisance rénale aiguë chez le malade déshydraté, par dim"""@fr;
  r:conduiteATenir "Hydrater le malade et surveiller la fonction rénale en début de traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635198, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635192 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635193 .

_:807f36cf91fe4e8caa53aadeff92477635193 rdf:first _:807f36cf91fe4e8caa53aadeff92477635194;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635195 .

_:807f36cf91fe4e8caa53aadeff92477635194 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477635195 rdf:first _:807f36cf91fe4e8caa53aadeff92477635196;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635196 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477635198 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10026-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_10026";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635200;
  r:natureDuRisque "Majoration du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635206, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635200 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635201 .

_:807f36cf91fe4e8caa53aadeff92477635201 rdf:first _:807f36cf91fe4e8caa53aadeff92477635202;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635203 .

_:807f36cf91fe4e8caa53aadeff92477635202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477635203 rdf:first _:807f36cf91fe4e8caa53aadeff92477635204;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635204 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477635206 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10027-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10027";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635208;
  r:natureDuRisque "Majoration de la toxicité, notamment hématologique, du méthotrexate (diminution de sa clairance rénale par l'acide acétylsalicylique)."@fr;
  r:conduiteATenir """Avec le méthotrexate utilisé à des doses > 20 mg/semaine : 
- contre-indication avec l'acide acétylsalicylique utilisé à doses antalgiques, antipyrétiques ou anti-inflammatoires
- précaution d'emploi avec des doses antiagrégantes plaquettaires d'acide acé"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635214, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635208 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635209 .

_:807f36cf91fe4e8caa53aadeff92477635209 rdf:first _:807f36cf91fe4e8caa53aadeff92477635210;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635211 .

_:807f36cf91fe4e8caa53aadeff92477635210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477635211 rdf:first _:807f36cf91fe4e8caa53aadeff92477635212;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635212 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477635214 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10028-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> PEMETREXED"@fr;
  dct:identifier "IAM_10028";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635216;
  r:natureDuRisque "Risque de majoration de la toxicité du pemetrexed (diminution de sa clairance rénale par l’acide acétylsalicylique à doses anti-inflammatoires)."@fr;
  r:conduiteATenir """Association déconseillée : 
- en cas de fonction rénale faible à modérée .

Précaution d'emploi :
- en cas de fonction rénale normale. Surveillance biologique de la fonction rénale."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635222, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635216 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635217 .

_:807f36cf91fe4e8caa53aadeff92477635217 rdf:first _:807f36cf91fe4e8caa53aadeff92477635218;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635219 .

_:807f36cf91fe4e8caa53aadeff92477635218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477635219 rdf:first _:807f36cf91fe4e8caa53aadeff92477635220;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635220 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10700 .

_:807f36cf91fe4e8caa53aadeff92477635222 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10029-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> PROBENECIDE"@fr;
  dct:identifier "IAM_10029";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635224;
  r:natureDuRisque "Diminution de l’effet uricosurique par compétition de l’élimination de l’acide urique au niveau des tubules rénaux."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635230, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635224 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635225 .

_:807f36cf91fe4e8caa53aadeff92477635225 rdf:first _:807f36cf91fe4e8caa53aadeff92477635226;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635227 .

_:807f36cf91fe4e8caa53aadeff92477635226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477635227 rdf:first _:807f36cf91fe4e8caa53aadeff92477635228;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635228 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10758 .

_:807f36cf91fe4e8caa53aadeff92477635230 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10030-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> THROMBOLYTIQUES"@fr;
  dct:identifier "IAM_10030";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635232;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635238, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635232 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635233 .

_:807f36cf91fe4e8caa53aadeff92477635233 rdf:first _:807f36cf91fe4e8caa53aadeff92477635234;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635235 .

_:807f36cf91fe4e8caa53aadeff92477635234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10151 .

_:807f36cf91fe4e8caa53aadeff92477635235 rdf:first _:807f36cf91fe4e8caa53aadeff92477635236;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635236 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477635238 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10031-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> TICAGRELOR"@fr;
  dct:identifier "IAM_10031";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635240;
  r:natureDuRisque """Majoration du risque hémorragique par addition des activités
antiagrégantes plaquettaires."""@fr;
  r:conduiteATenir """Association déconseillée :
- en dehors des indications validées pour cette association dans les syndromes coronariens aigus.

Précaution d'emploi :
- dans les indications validées pour cette association dans les syndromes coronariens aigus. Surveillance c"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635246, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635240 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635241 .

_:807f36cf91fe4e8caa53aadeff92477635241 rdf:first _:807f36cf91fe4e8caa53aadeff92477635242;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635243 .

_:807f36cf91fe4e8caa53aadeff92477635242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477635243 rdf:first _:807f36cf91fe4e8caa53aadeff92477635244;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635244 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477635246 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10032-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> TICLOPIDINE"@fr;
  dct:identifier "IAM_10032";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635248;
  r:natureDuRisque "Majoration du risque hémorragique par addition des activités antiagrégantes plaquettaires."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635254, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635248 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635249 .

_:807f36cf91fe4e8caa53aadeff92477635249 rdf:first _:807f36cf91fe4e8caa53aadeff92477635250;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635251 .

_:807f36cf91fe4e8caa53aadeff92477635250 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477635251 rdf:first _:807f36cf91fe4e8caa53aadeff92477635252;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635252 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10928 .

_:807f36cf91fe4e8caa53aadeff92477635254 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10033-1 a owl:Class;
  rdfs:label "ACIDE ASCORBIQUE <-> DÉFÉROXAMINE"@fr;
  dct:identifier "IAM_10033";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635256;
  r:natureDuRisque "Avec l'acide ascorbique à fortes doses et par voie IV : anomalies de la fonction cardiaque, voire insuffisance cardiaque aiguë (en général réversible à l'arrêt de la vitamine C)."@fr;
  r:conduiteATenir "En cas d'hémochromatose, ne donner de la vitamine C qu'après avoir commencé le traitement par la déféroxamine. Surveiller la fonction cardiaque en cas d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635262, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635256 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635257 .

_:807f36cf91fe4e8caa53aadeff92477635257 rdf:first _:807f36cf91fe4e8caa53aadeff92477635258;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635259 .

_:807f36cf91fe4e8caa53aadeff92477635258 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10015 .

_:807f36cf91fe4e8caa53aadeff92477635259 rdf:first _:807f36cf91fe4e8caa53aadeff92477635260;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635260 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10261 .

_:807f36cf91fe4e8caa53aadeff92477635262 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10021-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10021";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635264;
  r:natureDuRisque "Augmentation du risque hémorragique (inhibition de la fonction plaquettaire et agression de la muqueuse gastroduodénale par l’acide acétylsalicylique."@fr;
  r:conduiteATenir """A prendre en compte avec :
- des doses antiagrégantes (de 50 mg à 375 mg par jour)."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635270, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635264 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635265 .

_:807f36cf91fe4e8caa53aadeff92477635265 rdf:first _:807f36cf91fe4e8caa53aadeff92477635266;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635267 .

_:807f36cf91fe4e8caa53aadeff92477635266 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477635267 rdf:first _:807f36cf91fe4e8caa53aadeff92477635268;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635268 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477635270 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10245-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_10245";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635272;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la télithromycine, avec risque d'échec du traitement anti-infectieux, par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  rdfs:comment "Compte tenu de la baisse très importante (80%) des concentrations de télithromycine en présence de rifampicine, l'interaction a été extrapolée aux autres inducteurs enzymatiques puissants, le phénobarbital, la primidone, la phénytoïne et la carbamazépine,"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635278, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635272 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635273 .

_:807f36cf91fe4e8caa53aadeff92477635273 rdf:first _:807f36cf91fe4e8caa53aadeff92477635274;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635275 .

_:807f36cf91fe4e8caa53aadeff92477635274 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635275 rdf:first _:807f36cf91fe4e8caa53aadeff92477635276;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477635278 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10232-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> MONTELUKAST"@fr;
  dct:identifier "IAM_10232";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635280;
  r:natureDuRisque "Risque de baisse de l'efficacité du montélukast par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l'anti-asthmatique pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635286, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635280 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635281 .

_:807f36cf91fe4e8caa53aadeff92477635281 rdf:first _:807f36cf91fe4e8caa53aadeff92477635282;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635283 .

_:807f36cf91fe4e8caa53aadeff92477635282 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635283 rdf:first _:807f36cf91fe4e8caa53aadeff92477635284;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10604 .

_:807f36cf91fe4e8caa53aadeff92477635286 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10233-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> NIMODIPINE"@fr;
  dct:identifier "IAM_10233";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635288;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antagoniste du calcium par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l'antagoniste du calcium pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635294, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635288 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635289 .

_:807f36cf91fe4e8caa53aadeff92477635289 rdf:first _:807f36cf91fe4e8caa53aadeff92477635290;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635291 .

_:807f36cf91fe4e8caa53aadeff92477635290 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635291 rdf:first _:807f36cf91fe4e8caa53aadeff92477635292;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10636 .

_:807f36cf91fe4e8caa53aadeff92477635294 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10234-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> PÉRAMPANEL"@fr;
  dct:identifier "IAM_10234";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635296;
  r:natureDuRisque "Diminution importante (jusqu’aux deux-tiers) des concentrations de pérampanel."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635302, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635296 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635297 .

_:807f36cf91fe4e8caa53aadeff92477635297 rdf:first _:807f36cf91fe4e8caa53aadeff92477635298;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635299 .

_:807f36cf91fe4e8caa53aadeff92477635298 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635299 rdf:first _:807f36cf91fe4e8caa53aadeff92477635300;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10706 .

_:807f36cf91fe4e8caa53aadeff92477635302 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10235-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_10235";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635304;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité du posaconazole."@fr;
  r:conduiteATenir "Surveillance clinique. Si possible, dosages plasmatiques du posaconazole et adaptation éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635310, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635304 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635305 .

_:807f36cf91fe4e8caa53aadeff92477635305 rdf:first _:807f36cf91fe4e8caa53aadeff92477635306;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635307 .

_:807f36cf91fe4e8caa53aadeff92477635306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635307 rdf:first _:807f36cf91fe4e8caa53aadeff92477635308;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477635310 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10236-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> PRAZIQUANTEL"@fr;
  dct:identifier "IAM_10236";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635312;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques du praziquantel, avec risque d'échec du traitement, par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  rdfs:comment "La mesure des concentrations du praziquantel chez des patients traités par anticonvulsivants inducteurs enzymatiques, suggère que l'effet inducteur du phénobarbital, de la phénytoine ou de la carbamazépine retentit de façon importante sur le métabolisme d"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635318, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635312 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635313 .

_:807f36cf91fe4e8caa53aadeff92477635313 rdf:first _:807f36cf91fe4e8caa53aadeff92477635314;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635315 .

_:807f36cf91fe4e8caa53aadeff92477635314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635315 rdf:first _:807f36cf91fe4e8caa53aadeff92477635316;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10750 .

_:807f36cf91fe4e8caa53aadeff92477635318 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10238-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10238";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635320;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la propafénone par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. S'il y a lieu, adaptation de la posologie de la propafénone pendant l'association et après l'arrêt de l'inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635326, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635320 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635321 .

_:807f36cf91fe4e8caa53aadeff92477635321 rdf:first _:807f36cf91fe4e8caa53aadeff92477635322;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635323 .

_:807f36cf91fe4e8caa53aadeff92477635322 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635323 rdf:first _:807f36cf91fe4e8caa53aadeff92477635324;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477635326 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10239-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> QUETIAPINE"@fr;
  dct:identifier "IAM_10239";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635328;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques de quétiapine par augmentation de son métabolisme hépatique par l'inducteur, avec risque d’inefficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635334, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635328 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635329 .

_:807f36cf91fe4e8caa53aadeff92477635329 rdf:first _:807f36cf91fe4e8caa53aadeff92477635330;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635331 .

_:807f36cf91fe4e8caa53aadeff92477635330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635331 rdf:first _:807f36cf91fe4e8caa53aadeff92477635332;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10773 .

_:807f36cf91fe4e8caa53aadeff92477635334 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10240-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> QUININE"@fr;
  dct:identifier "IAM_10240";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635336;
  r:natureDuRisque "Risque de perte de l’efficacité de la quinine par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la quinine pendant le traitement par l’inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635342, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635336 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635337 .

_:807f36cf91fe4e8caa53aadeff92477635337 rdf:first _:807f36cf91fe4e8caa53aadeff92477635338;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635339 .

_:807f36cf91fe4e8caa53aadeff92477635338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635339 rdf:first _:807f36cf91fe4e8caa53aadeff92477635340;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10777 .

_:807f36cf91fe4e8caa53aadeff92477635342 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10241-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> RANOLAZINE"@fr;
  dct:identifier "IAM_10241";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635344;
  r:natureDuRisque "Risque de diminution importante des concentrations de ranolazine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635350, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635344 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635345 .

_:807f36cf91fe4e8caa53aadeff92477635345 rdf:first _:807f36cf91fe4e8caa53aadeff92477635346;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635347 .

_:807f36cf91fe4e8caa53aadeff92477635346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635347 rdf:first _:807f36cf91fe4e8caa53aadeff92477635348;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:807f36cf91fe4e8caa53aadeff92477635350 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10196-1 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES CLASSE IA <-> ESMOLOL"@fr;
  dct:identifier "IAM_10196";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635352;
  r:natureDuRisque "Troubles de la contractilité, de l'automatisme et de la conduction (suppression des mécanismes sympathiques compensateurs)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635358, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635352 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635353 .

_:807f36cf91fe4e8caa53aadeff92477635353 rdf:first _:807f36cf91fe4e8caa53aadeff92477635354;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635355 .

_:807f36cf91fe4e8caa53aadeff92477635354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10026 .

_:807f36cf91fe4e8caa53aadeff92477635355 rdf:first _:807f36cf91fe4e8caa53aadeff92477635356;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:807f36cf91fe4e8caa53aadeff92477635358 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10243-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10243";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635360;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'anticonvulsivant, avec risque de surdosage, par inhibition de son métabolisme hépatique par le stiripentol."@fr;
  r:conduiteATenir "Surveillance clinique et dosage plasmatique, lorsque cela est possible, de l'anticonvulsivant associé au stiripentol et adaptation éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635366, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635360 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635361 .

_:807f36cf91fe4e8caa53aadeff92477635361 rdf:first _:807f36cf91fe4e8caa53aadeff92477635362;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635363 .

_:807f36cf91fe4e8caa53aadeff92477635362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635363 rdf:first _:807f36cf91fe4e8caa53aadeff92477635364;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477635366 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11010-1 a owl:Class;
  rdfs:label "HALOPERIDOL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11010";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635368;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de l'halopéridol et de son efficacité thérapeutique, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, adaptation posologique pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635374, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635368 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635369 .

_:807f36cf91fe4e8caa53aadeff92477635369 rdf:first _:807f36cf91fe4e8caa53aadeff92477635370;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635371 .

_:807f36cf91fe4e8caa53aadeff92477635370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10426 .

_:807f36cf91fe4e8caa53aadeff92477635371 rdf:first _:807f36cf91fe4e8caa53aadeff92477635372;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477635374 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10246-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10246";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635376;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de la théophylline par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, de la théophyllinémie. Adaptation éventuelle de la posologie de la théophylline pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635382, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635376 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635377 .

_:807f36cf91fe4e8caa53aadeff92477635377 rdf:first _:807f36cf91fe4e8caa53aadeff92477635378;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635379 .

_:807f36cf91fe4e8caa53aadeff92477635378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635379 rdf:first _:807f36cf91fe4e8caa53aadeff92477635380;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477635382 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10247-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> TIAGABINE"@fr;
  dct:identifier "IAM_10247";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635384;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la tiagabine par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Une augmentation de la posologie de tiagabine peut s'avérer nécessaire en cas d'association à un anticonvulsivant inducteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635390, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635384 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635385 .

_:807f36cf91fe4e8caa53aadeff92477635385 rdf:first _:807f36cf91fe4e8caa53aadeff92477635386;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635387 .

_:807f36cf91fe4e8caa53aadeff92477635386 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635387 rdf:first _:807f36cf91fe4e8caa53aadeff92477635388;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10922 .

_:807f36cf91fe4e8caa53aadeff92477635390 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10248-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> TICAGRELOR"@fr;
  dct:identifier "IAM_10248";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635392;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques de ticagrelor par augmentation de son métabolisme hépatique par l'anticonvulsivant inducteur enzymatique, avec risque de diminution de l’effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635398, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635392 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635393 .

_:807f36cf91fe4e8caa53aadeff92477635393 rdf:first _:807f36cf91fe4e8caa53aadeff92477635394;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635395 .

_:807f36cf91fe4e8caa53aadeff92477635394 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635395 rdf:first _:807f36cf91fe4e8caa53aadeff92477635396;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477635398 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10249-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_10249";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635400;
  r:natureDuRisque "Risque de diminution de l’effet de l’ulipristal, par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  r:conduiteATenir "Préférer une alternative thérapeutique peu ou pas métabolisée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635406, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635400 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635401 .

_:807f36cf91fe4e8caa53aadeff92477635401 rdf:first _:807f36cf91fe4e8caa53aadeff92477635402;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635403 .

_:807f36cf91fe4e8caa53aadeff92477635402 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635403 rdf:first _:807f36cf91fe4e8caa53aadeff92477635404;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477635406 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10250-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> VITAMINE D"@fr;
  dct:identifier "IAM_10250";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635408;
  r:natureDuRisque "Diminution des concentrations de vitamine D plus marquée qu’en l’absence d'inducteur."@fr;
  r:conduiteATenir "Dosage des concentrations de vitamine D et supplémentation si nécessaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635414, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635408 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635409 .

_:807f36cf91fe4e8caa53aadeff92477635409 rdf:first _:807f36cf91fe4e8caa53aadeff92477635410;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635411 .

_:807f36cf91fe4e8caa53aadeff92477635410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635411 rdf:first _:807f36cf91fe4e8caa53aadeff92477635412;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10162 .

_:807f36cf91fe4e8caa53aadeff92477635414 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10251-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10251";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635416;
  r:natureDuRisque """- pour carbamazépine, phénobarbital, primidone : Risque de baisse de l'efficacité du voriconazole par augmentation de son métabolisme hépatique par l'inducteur.

- pour phénytoïne, fosphénytoïne : 
Diminution importante des concentrations plasmatiques du"""@fr;
  r:conduiteATenir """Contre-indication :
- pour carbamazépine, phénobarbital, primidone

Association déconseillée :
- pour phénytoïne, fosphénytoïne
Si l'association ne peut être évitée, surveillance clinique étroite, dosage des concentrations plasmatiques de phénytoïne et ad"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635422, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635416 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635417 .

_:807f36cf91fe4e8caa53aadeff92477635417 rdf:first _:807f36cf91fe4e8caa53aadeff92477635418;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635419 .

_:807f36cf91fe4e8caa53aadeff92477635418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635419 rdf:first _:807f36cf91fe4e8caa53aadeff92477635420;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477635422 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10237-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> PROCARBAZINE"@fr;
  dct:identifier "IAM_10237";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635424;
  r:natureDuRisque "Augmentation des réactions d'hypersensibilité (hyperéosinophilie, rash), par augmentation du métabolisme de la procarbazine par l'inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635430, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635424 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635425 .

_:807f36cf91fe4e8caa53aadeff92477635425 rdf:first _:807f36cf91fe4e8caa53aadeff92477635426;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635427 .

_:807f36cf91fe4e8caa53aadeff92477635426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635427 rdf:first _:807f36cf91fe4e8caa53aadeff92477635428;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10759 .

_:807f36cf91fe4e8caa53aadeff92477635430 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10252-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS MÉTABOLISÉS <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10252";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635432;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques et de l'efficacité de l'anticonvulsivant."@fr;
  rdfs:comment "Une contre-indication a été retenue entre la quasi totalité des médicaments anticonvulsivants et le millepertuis. Cette plante médicinale est un inducteur enzymatique puissant qui expose à une baisse des concentrations plasmatiques de nombreux médicaments"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635438, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635432 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635433 .

_:807f36cf91fe4e8caa53aadeff92477635433 rdf:first _:807f36cf91fe4e8caa53aadeff92477635434;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635435 .

_:807f36cf91fe4e8caa53aadeff92477635434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10030 .

_:807f36cf91fe4e8caa53aadeff92477635435 rdf:first _:807f36cf91fe4e8caa53aadeff92477635436;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477635438 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10253-1 a owl:Class;
  rdfs:label "ANTICORPS MONOCLONAUX (HORS ANTI-TNF ALPHA) <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10253";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635440;
  r:natureDuRisque "Risque de maladie vaccinale généralisée, éventuellement mortelle."@fr;
  r:conduiteATenir """Association déconseillée avec :
- bélimumab, blinatumomab, canakinumab, obinutuzumab, ofatumumab, rituximab, tocilizumab, ustékinumab 

A prendre en compte avec :
- alemtuzumab, bevacizumab, brentuximab, cetuximab, daratumumab, dénosumab, ibritumomab, ipi"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635446, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635440 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635441 .

_:807f36cf91fe4e8caa53aadeff92477635441 rdf:first _:807f36cf91fe4e8caa53aadeff92477635442;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635443 .

_:807f36cf91fe4e8caa53aadeff92477635442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10031 .

_:807f36cf91fe4e8caa53aadeff92477635443 rdf:first _:807f36cf91fe4e8caa53aadeff92477635444;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477635446 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10242-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> RIVAROXABAN"@fr;
  dct:identifier "IAM_10242";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635448;
  r:natureDuRisque "Diminution des concentrations plasmatiques de rivaroxaban, avec risque de diminution de l'effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635454, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635448 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635449 .

_:807f36cf91fe4e8caa53aadeff92477635449 rdf:first _:807f36cf91fe4e8caa53aadeff92477635450;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635451 .

_:807f36cf91fe4e8caa53aadeff92477635450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635451 rdf:first _:807f36cf91fe4e8caa53aadeff92477635452;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10808 .

_:807f36cf91fe4e8caa53aadeff92477635454 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11000-1 a owl:Class;
  rdfs:label "GLUCOCORTICOÏDES (SAUF HYDROCORTISONE) <-> ISONIAZIDE"@fr;
  dct:identifier "IAM_11000";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635456;
  r:natureDuRisque "Décrit pour la prednisolone. Diminution des concentrations plasmatiques de l'isoniazide. Mécanisme invoqué : augmentation du métabolisme hépatique de l'isoniazide et diminution de celui des glucocorticoïdes."@fr;
  r:conduiteATenir "Surveillance clinique et biologique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635462, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635456 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635457 .

_:807f36cf91fe4e8caa53aadeff92477635457 rdf:first _:807f36cf91fe4e8caa53aadeff92477635458;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635459 .

_:807f36cf91fe4e8caa53aadeff92477635458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477635459 rdf:first _:807f36cf91fe4e8caa53aadeff92477635460;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:807f36cf91fe4e8caa53aadeff92477635462 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10343-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10343";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635464;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par l'itraconazole et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635470, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635464 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635465 .

_:807f36cf91fe4e8caa53aadeff92477635465 rdf:first _:807f36cf91fe4e8caa53aadeff92477635466;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635467 .

_:807f36cf91fe4e8caa53aadeff92477635466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477635467 rdf:first _:807f36cf91fe4e8caa53aadeff92477635468;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477635470 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10344-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> LEVOCARNITINE"@fr;
  dct:identifier "IAM_10344";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635472;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique"@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la lévocarnitine et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635478, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635472 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635473 .

_:807f36cf91fe4e8caa53aadeff92477635473 rdf:first _:807f36cf91fe4e8caa53aadeff92477635474;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635475 .

_:807f36cf91fe4e8caa53aadeff92477635474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477635475 rdf:first _:807f36cf91fe4e8caa53aadeff92477635476;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10516 .

_:807f36cf91fe4e8caa53aadeff92477635478 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10345-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> MACROLIDES (SAUF SPIRAMYCINE)"@fr;
  dct:identifier "IAM_10345";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635480;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par le macrolide et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635486, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635480 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635481 .

_:807f36cf91fe4e8caa53aadeff92477635481 rdf:first _:807f36cf91fe4e8caa53aadeff92477635482;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635483 .

_:807f36cf91fe4e8caa53aadeff92477635482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477635483 rdf:first _:807f36cf91fe4e8caa53aadeff92477635484;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10107 .

_:807f36cf91fe4e8caa53aadeff92477635486 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10346-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> METHYLPREDNISOLONE"@fr;
  dct:identifier "IAM_10346";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635488;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Pour des doses de 0,5 à 1g de méthylprednisolone administrées en bolus : augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle de l'INR 2 à 4 jours après le bolus de méthylprednisolone ou en présence de tous signes hémorragiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635494, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635488 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635489 .

_:807f36cf91fe4e8caa53aadeff92477635489 rdf:first _:807f36cf91fe4e8caa53aadeff92477635490;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635491 .

_:807f36cf91fe4e8caa53aadeff92477635490 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477635491 rdf:first _:807f36cf91fe4e8caa53aadeff92477635492;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10576 .

_:807f36cf91fe4e8caa53aadeff92477635494 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10347-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> MICONAZOLE"@fr;
  dct:identifier "IAM_10347";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635496;
  r:natureDuRisque "Hémorragies imprévisibles, éventuellement graves."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635502, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635496 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635497 .

_:807f36cf91fe4e8caa53aadeff92477635497 rdf:first _:807f36cf91fe4e8caa53aadeff92477635498;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635499 .

_:807f36cf91fe4e8caa53aadeff92477635498 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477635499 rdf:first _:807f36cf91fe4e8caa53aadeff92477635500;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10584 .

_:807f36cf91fe4e8caa53aadeff92477635502 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10348-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10348";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635504;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antivitamine K, en raison de son effet inducteur enzymatique, avec risque de baisse d'efficacité voire d'annulation de l'effet dont les conséquences peuvent être éventuellement graves (évènement thrombotique"@fr;
  r:conduiteATenir "En cas d'association fortuite, ne pas interrompre brutalement la prise de millepertuis mais contrôler l'INR avant puis après l'arrêt du millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635510, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635504 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635505 .

_:807f36cf91fe4e8caa53aadeff92477635505 rdf:first _:807f36cf91fe4e8caa53aadeff92477635506;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635507 .

_:807f36cf91fe4e8caa53aadeff92477635506 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477635507 rdf:first _:807f36cf91fe4e8caa53aadeff92477635508;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477635510 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10349-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_10349";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635512;
  r:natureDuRisque "Diminution de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635518, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635512 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635513 .

_:807f36cf91fe4e8caa53aadeff92477635513 rdf:first _:807f36cf91fe4e8caa53aadeff92477635514;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635515 .

_:807f36cf91fe4e8caa53aadeff92477635514 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477635515 rdf:first _:807f36cf91fe4e8caa53aadeff92477635516;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:807f36cf91fe4e8caa53aadeff92477635518 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10350-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> NOSCAPINE"@fr;
  dct:identifier "IAM_10350";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635520;
  r:natureDuRisque "Augmentation de l’effet de l’antivitamine K et du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635526, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635520 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635521 .

_:807f36cf91fe4e8caa53aadeff92477635521 rdf:first _:807f36cf91fe4e8caa53aadeff92477635522;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635523 .

_:807f36cf91fe4e8caa53aadeff92477635522 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477635523 rdf:first _:807f36cf91fe4e8caa53aadeff92477635524;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10653 .

_:807f36cf91fe4e8caa53aadeff92477635526 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10351-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> ORLISTAT"@fr;
  dct:identifier "IAM_10351";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635528;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par l'orlistat et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635534, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635528 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635529 .

_:807f36cf91fe4e8caa53aadeff92477635529 rdf:first _:807f36cf91fe4e8caa53aadeff92477635530;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635531 .

_:807f36cf91fe4e8caa53aadeff92477635530 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477635531 rdf:first _:807f36cf91fe4e8caa53aadeff92477635532;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477635534 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10231-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> MINÉRALOCORTICOÏDES"@fr;
  dct:identifier "IAM_10231";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635536;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité des corticoïdes par augmentation de leur métabolisme hépatique par l'inducteur : les conséquences sont particulièrement importantes chez les addisoniens traités par l'hydrocortisone et en cas d"@fr;
  r:conduiteATenir "Surveillance clinique et biologique ; adaptation de la posologie des corticoïdes pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635542, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635536 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635537 .

_:807f36cf91fe4e8caa53aadeff92477635537 rdf:first _:807f36cf91fe4e8caa53aadeff92477635538;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635539 .

_:807f36cf91fe4e8caa53aadeff92477635538 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635539 rdf:first _:807f36cf91fe4e8caa53aadeff92477635540;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10108 .

_:807f36cf91fe4e8caa53aadeff92477635542 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10999-1 a owl:Class;
  rdfs:label "GLOBULINES ANTILYMPHOCYTAIRES <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10999";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635544;
  r:natureDuRisque "Risque de maladie généralisée éventuellement mortelle. Ce risque est majoré chez les sujets âgés déjà immunodéprimés par la maladie sous-jacente."@fr;
  r:conduiteATenir "En particulier, utiliser un vaccin inactivé lorsqu'il existe (poliomyélite)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635550, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635544 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635545 .

_:807f36cf91fe4e8caa53aadeff92477635545 rdf:first _:807f36cf91fe4e8caa53aadeff92477635546;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635547 .

_:807f36cf91fe4e8caa53aadeff92477635546 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff92477635547 rdf:first _:807f36cf91fe4e8caa53aadeff92477635548;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477635550 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10230-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> MIDAZOLAM"@fr;
  dct:identifier "IAM_10230";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635552;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques du midazolam par l'anticonvulsivant."@fr;
  rdfs:comment """L’administration de carbamazépine ou de phénytoïne diminue significativement les concentrations plasmatiques et la demi-vie d’une dose orale de 15 mg de midazolam.
Le midazolam administré par voie orale subit un effet de premier passage hépatique importan"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635558, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635552 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635553 .

_:807f36cf91fe4e8caa53aadeff92477635553 rdf:first _:807f36cf91fe4e8caa53aadeff92477635554;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635555 .

_:807f36cf91fe4e8caa53aadeff92477635554 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635555 rdf:first _:807f36cf91fe4e8caa53aadeff92477635556;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477635558 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11001-1 a owl:Class;
  rdfs:label "GLUCOCORTICOÏDES (SAUF HYDROCORTISONE) <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11001";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635560;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité des corticoïdes par augmentation de leur métabolisme hépatique par la rifampicine ; les conséquences sont particulièrement importantes chez les addisoniens traités par l'hydrocortisone et en ca"@fr;
  r:conduiteATenir "Surveillance clinique et biologique ; adaptation de la posologie des corticoïdes pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635566, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635560 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635561 .

_:807f36cf91fe4e8caa53aadeff92477635561 rdf:first _:807f36cf91fe4e8caa53aadeff92477635562;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635563 .

_:807f36cf91fe4e8caa53aadeff92477635562 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477635563 rdf:first _:807f36cf91fe4e8caa53aadeff92477635564;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477635566 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11002-1 a owl:Class;
  rdfs:label "GLUCOCORTICOÏDES (SAUF HYDROCORTISONE) <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_11002";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635568;
  r:natureDuRisque "A l'exception des voies inhalées et locales, et pour des posologies supérieures à 10 mg/j d’équivalent-prednisone (ou > 2 mg/kg/j chez l’enfant ou > 20 mg/j chez l’enfant de plus de 10 kg) pendant plus de deux semaines et pour les « bolus » de corticoïdes"@fr;
  r:conduiteATenir "Et pendant les 3 mois suivant l'arrêt de la corticothérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635574, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635568 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635569 .

_:807f36cf91fe4e8caa53aadeff92477635569 rdf:first _:807f36cf91fe4e8caa53aadeff92477635570;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635571 .

_:807f36cf91fe4e8caa53aadeff92477635570 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477635571 rdf:first _:807f36cf91fe4e8caa53aadeff92477635572;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477635574 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11003-1 a owl:Class;
  rdfs:label "GLYCEROL <-> LITHIUM"@fr;
  dct:identifier "IAM_11003";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635576;
  r:natureDuRisque "Diminution de la lithémie avec risque de baisse de l’efficacité thérapeutique."@fr;
  r:conduiteATenir "Surveillance stricte de la lithémie et adaptation éventuelle de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635582, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635576 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635577 .

_:807f36cf91fe4e8caa53aadeff92477635577 rdf:first _:807f36cf91fe4e8caa53aadeff92477635578;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635579 .

_:807f36cf91fe4e8caa53aadeff92477635578 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10419 .

_:807f36cf91fe4e8caa53aadeff92477635579 rdf:first _:807f36cf91fe4e8caa53aadeff92477635580;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477635582 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11004-1 a owl:Class;
  rdfs:label "GRISEOFULVINE <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_11004";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635584;
  r:natureDuRisque "Risque de diminution de l'efficacité du contraceptif hormonal par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive fiable, additionnelle ou alternative, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635590, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635584 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635585 .

_:807f36cf91fe4e8caa53aadeff92477635585 rdf:first _:807f36cf91fe4e8caa53aadeff92477635586;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635587 .

_:807f36cf91fe4e8caa53aadeff92477635586 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:807f36cf91fe4e8caa53aadeff92477635587 rdf:first _:807f36cf91fe4e8caa53aadeff92477635588;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10422 .

_:807f36cf91fe4e8caa53aadeff92477635590 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11005-1 a owl:Class;
  rdfs:label "GUANETHIDINE <-> IMAO IRRÉVERSIBLES"@fr;
  dct:identifier "IAM_11005";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635592;
  r:natureDuRisque "Avec la guanéthidine utilisée par voie IV : risque de réactions vasculaires imprévisibles, notamment d'hypotension."@fr;
  r:conduiteATenir "Interrompre le traitement par IMAO 15 jours avant le traitement par guanéthidine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635598, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635592 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635593 .

_:807f36cf91fe4e8caa53aadeff92477635593 rdf:first _:807f36cf91fe4e8caa53aadeff92477635594;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635595 .

_:807f36cf91fe4e8caa53aadeff92477635594 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477635595 rdf:first _:807f36cf91fe4e8caa53aadeff92477635596;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10423 .

_:807f36cf91fe4e8caa53aadeff92477635598 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11006-1 a owl:Class;
  rdfs:label "HALOFANTRINE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11006";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635600;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaires, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre l'inhibiteur. Si l'association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635606, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635600 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635601 .

_:807f36cf91fe4e8caa53aadeff92477635601 rdf:first _:807f36cf91fe4e8caa53aadeff92477635602;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635603 .

_:807f36cf91fe4e8caa53aadeff92477635602 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477635603 rdf:first _:807f36cf91fe4e8caa53aadeff92477635604;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10425 .

_:807f36cf91fe4e8caa53aadeff92477635606 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11007-1 a owl:Class;
  rdfs:label "HALOFANTRINE <-> JOSAMYCINE"@fr;
  dct:identifier "IAM_11007";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635608;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre le macrolide. Si l’association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635614, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635608 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635609 .

_:807f36cf91fe4e8caa53aadeff92477635609 rdf:first _:807f36cf91fe4e8caa53aadeff92477635610;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635611 .

_:807f36cf91fe4e8caa53aadeff92477635610 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10425 .

_:807f36cf91fe4e8caa53aadeff92477635611 rdf:first _:807f36cf91fe4e8caa53aadeff92477635612;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477635614 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11008-1 a owl:Class;
  rdfs:label "HALOFANTRINE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_11008";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635616;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635622, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635616 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635617 .

_:807f36cf91fe4e8caa53aadeff92477635617 rdf:first _:807f36cf91fe4e8caa53aadeff92477635618;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635619 .

_:807f36cf91fe4e8caa53aadeff92477635618 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477635619 rdf:first _:807f36cf91fe4e8caa53aadeff92477635620;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10425 .

_:807f36cf91fe4e8caa53aadeff92477635622 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11009-1 a owl:Class;
  rdfs:label "HALOFANTRINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_11009";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635624;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635630, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635624 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635625 .

_:807f36cf91fe4e8caa53aadeff92477635625 rdf:first _:807f36cf91fe4e8caa53aadeff92477635626;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635627 .

_:807f36cf91fe4e8caa53aadeff92477635626 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10425 .

_:807f36cf91fe4e8caa53aadeff92477635627 rdf:first _:807f36cf91fe4e8caa53aadeff92477635628;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477635630 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10256-1 a owl:Class;
  rdfs:label "ANTIDÉPRESSEURS IMIPRAMINIQUES <-> CLONIDINE"@fr;
  dct:identifier "IAM_10256";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635632;
  r:natureDuRisque "Décrit pour désipramine, imipramine : inhibition de l'effet antihypertenseur de la clonidine (antagonisme au niveau des récepteurs adrénergiques)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635638, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635632 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635633 .

_:807f36cf91fe4e8caa53aadeff92477635633 rdf:first _:807f36cf91fe4e8caa53aadeff92477635634;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635635 .

_:807f36cf91fe4e8caa53aadeff92477635634 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:807f36cf91fe4e8caa53aadeff92477635635 rdf:first _:807f36cf91fe4e8caa53aadeff92477635636;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10214 .

_:807f36cf91fe4e8caa53aadeff92477635638 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10352-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> PARACETAMOL"@fr;
  dct:identifier "IAM_10352";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635640;
  r:natureDuRisque "Risque d’augmentation de l’effet de l’antivitamine K et du risque hémorragique en cas de prise de paracétamol aux doses maximales (4 g/j) pendant au moins 4 jours."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation éventuelle de la posologie de l’antivitamine K pendant le traitement par le paracétamol et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635646, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635640 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635641 .

_:807f36cf91fe4e8caa53aadeff92477635641 rdf:first _:807f36cf91fe4e8caa53aadeff92477635642;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635643 .

_:807f36cf91fe4e8caa53aadeff92477635642 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477635643 rdf:first _:807f36cf91fe4e8caa53aadeff92477635644;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10690 .

_:807f36cf91fe4e8caa53aadeff92477635646 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10292-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10292";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635648;
  r:natureDuRisque "Diminution de l'absorption de l'azolé antifongique, par augmentation du pH intragastrique par l'antisécrétoire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635654, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635648 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635649 .

_:807f36cf91fe4e8caa53aadeff92477635649 rdf:first _:807f36cf91fe4e8caa53aadeff92477635650;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635651 .

_:807f36cf91fe4e8caa53aadeff92477635650 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477635651 rdf:first _:807f36cf91fe4e8caa53aadeff92477635652;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477635654 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10254-1 a owl:Class;
  rdfs:label "ANTIDÉPRESSEURS IMIPRAMINIQUES <-> BACLOFENE"@fr;
  dct:identifier "IAM_10254";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635656;
  r:natureDuRisque "Risque d'augmentation de l'hypotonie musculaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635662, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635656 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635657 .

_:807f36cf91fe4e8caa53aadeff92477635657 rdf:first _:807f36cf91fe4e8caa53aadeff92477635658;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635659 .

_:807f36cf91fe4e8caa53aadeff92477635658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:807f36cf91fe4e8caa53aadeff92477635659 rdf:first _:807f36cf91fe4e8caa53aadeff92477635660;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10102 .

_:807f36cf91fe4e8caa53aadeff92477635662 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10282-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> TENOFOVIR DISOPROXIL"@fr;
  dct:identifier "IAM_10282";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635664;
  r:natureDuRisque "Risque de majoration de la néphrotoxicité du ténofovir, notamment avec des doses élevées de l'anti-inflammatoire ou en présence de facteurs de risque d'insuffisance rénale."@fr;
  r:conduiteATenir "En cas d’association, surveiller la fonction rénale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635670, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635664 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635665 .

_:807f36cf91fe4e8caa53aadeff92477635665 rdf:first _:807f36cf91fe4e8caa53aadeff92477635666;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635667 .

_:807f36cf91fe4e8caa53aadeff92477635666 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477635667 rdf:first _:807f36cf91fe4e8caa53aadeff92477635668;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635668 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10896 .

_:807f36cf91fe4e8caa53aadeff92477635670 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10283-1 a owl:Class;
  rdfs:label "ANTIPARASITAIRES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10283";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635672;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication:
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine
et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes.
Si cela est possible, interrompre l'un des d"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635678, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635672 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635673 .

_:807f36cf91fe4e8caa53aadeff92477635673 rdf:first _:807f36cf91fe4e8caa53aadeff92477635674;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635675 .

_:807f36cf91fe4e8caa53aadeff92477635674 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10036 .

_:807f36cf91fe4e8caa53aadeff92477635675 rdf:first _:807f36cf91fe4e8caa53aadeff92477635676;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635676 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477635678 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10284-1 a owl:Class;
  rdfs:label "ANTIPARKINSONIENS DOPAMINERGIQUES <-> NEUROLEPTIQUES ANTIPSYCHOTIQUES (SAUF CLOZAPINE)"@fr;
  dct:identifier "IAM_10284";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635680;
  r:natureDuRisque "Antagonisme réciproque du dopaminergique et des neuroleptiques. Le dopaminergique peut provoquer ou aggraver les troubles psychotiques. En cas de nécessité d'un traitement par neuroleptiques chez le patient parkinsonien traité par dopaminergique, ces dern"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635686, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635680 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635681 .

_:807f36cf91fe4e8caa53aadeff92477635681 rdf:first _:807f36cf91fe4e8caa53aadeff92477635682;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635683 .

_:807f36cf91fe4e8caa53aadeff92477635682 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10038 .

_:807f36cf91fe4e8caa53aadeff92477635683 rdf:first _:807f36cf91fe4e8caa53aadeff92477635684;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635684 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10125 .

_:807f36cf91fe4e8caa53aadeff92477635686 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10285-1 a owl:Class;
  rdfs:label "ANTIPURINES <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10285";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635688;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Diminution de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K à la mise en route du traitement par l'immunomodulateur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635694, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635688 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635689 .

_:807f36cf91fe4e8caa53aadeff92477635689 rdf:first _:807f36cf91fe4e8caa53aadeff92477635690;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635691 .

_:807f36cf91fe4e8caa53aadeff92477635690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10039 .

_:807f36cf91fe4e8caa53aadeff92477635691 rdf:first _:807f36cf91fe4e8caa53aadeff92477635692;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635692 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477635694 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10286-1 a owl:Class;
  rdfs:label "ANTIPURINES <-> DÉRIVÉS DE L'ACIDE AMINOSALICYLIQUE (ASA)"@fr;
  dct:identifier "IAM_10286";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635696;
  r:natureDuRisque "Risque de majoration de l'effet myélosuppresseur de l'immunomodulateur par inhibition de son métabolisme hépatique par le dérivé de l'ASA, notamment chez les sujets présentant un déficit partiel en thiopurine méthyltransférase (TPMT)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635702, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635696 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635697 .

_:807f36cf91fe4e8caa53aadeff92477635697 rdf:first _:807f36cf91fe4e8caa53aadeff92477635698;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635699 .

_:807f36cf91fe4e8caa53aadeff92477635698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10039 .

_:807f36cf91fe4e8caa53aadeff92477635699 rdf:first _:807f36cf91fe4e8caa53aadeff92477635700;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635700 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10070 .

_:807f36cf91fe4e8caa53aadeff92477635702 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10287-1 a owl:Class;
  rdfs:label "ANTIPURINES <-> INHIBITEURS DE LA XANTHINE OXYDASE"@fr;
  dct:identifier "IAM_10287";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635704;
  r:natureDuRisque "Insuffisance médullaire éventuellement grave."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635710, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635704 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635705 .

_:807f36cf91fe4e8caa53aadeff92477635705 rdf:first _:807f36cf91fe4e8caa53aadeff92477635706;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635707 .

_:807f36cf91fe4e8caa53aadeff92477635706 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10039 .

_:807f36cf91fe4e8caa53aadeff92477635707 rdf:first _:807f36cf91fe4e8caa53aadeff92477635708;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635708 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10099 .

_:807f36cf91fe4e8caa53aadeff92477635710 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10288-1 a owl:Class;
  rdfs:label "ANTIPURINES <-> RIBAVIRINE"@fr;
  dct:identifier "IAM_10288";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635712;
  r:natureDuRisque "Risque majoré d'effets indésirables graves, par inhibition du métabolisme de l'immunomodulateur par la ribavirine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635718, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635712 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635713 .

_:807f36cf91fe4e8caa53aadeff92477635713 rdf:first _:807f36cf91fe4e8caa53aadeff92477635714;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635715 .

_:807f36cf91fe4e8caa53aadeff92477635714 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10039 .

_:807f36cf91fe4e8caa53aadeff92477635715 rdf:first _:807f36cf91fe4e8caa53aadeff92477635716;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635716 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10797 .

_:807f36cf91fe4e8caa53aadeff92477635718 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10289-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> ATAZANAVIR"@fr;
  dct:identifier "IAM_10289";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635720;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de l'atazanavir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635726, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635720 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635721 .

_:807f36cf91fe4e8caa53aadeff92477635721 rdf:first _:807f36cf91fe4e8caa53aadeff92477635722;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635723 .

_:807f36cf91fe4e8caa53aadeff92477635722 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477635723 rdf:first _:807f36cf91fe4e8caa53aadeff92477635724;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635724 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:807f36cf91fe4e8caa53aadeff92477635726 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10280-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> PENTOXIFYLLINE"@fr;
  dct:identifier "IAM_10280";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635728;
  r:natureDuRisque "Majoration du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635734, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635728 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635729 .

_:807f36cf91fe4e8caa53aadeff92477635729 rdf:first _:807f36cf91fe4e8caa53aadeff92477635730;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635731 .

_:807f36cf91fe4e8caa53aadeff92477635730 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477635731 rdf:first _:807f36cf91fe4e8caa53aadeff92477635732;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635732 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10705 .

_:807f36cf91fe4e8caa53aadeff92477635734 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10291-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS"@fr;
  dct:identifier "IAM_10291";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635736;
  r:natureDuRisque "Risque de diminution de la biodisponibilité de l’inhibiteur de tyrosine kinases, en raison de son absorption pH-dépendante."@fr;
  r:conduiteATenir "- sauf avec le vandétanib."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635742, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635736 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635737 .

_:807f36cf91fe4e8caa53aadeff92477635737 rdf:first _:807f36cf91fe4e8caa53aadeff92477635738;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635739 .

_:807f36cf91fe4e8caa53aadeff92477635738 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477635739 rdf:first _:807f36cf91fe4e8caa53aadeff92477635740;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635740 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:807f36cf91fe4e8caa53aadeff92477635742 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10279-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> PEMETREXED"@fr;
  dct:identifier "IAM_10279";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635744;
  r:natureDuRisque "Risque de majoration de la toxicité du pemetrexed (diminution de sa clairance rénale par les AINS)."@fr;
  r:conduiteATenir """Association déconseillée : 
- en cas de fonction rénale faible à modérée.

Précaution d'emploi :
- en cas de fonction rénale normale. Surveillance biologique de la fonction rénale."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635750, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635744 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635745 .

_:807f36cf91fe4e8caa53aadeff92477635745 rdf:first _:807f36cf91fe4e8caa53aadeff92477635746;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635747 .

_:807f36cf91fe4e8caa53aadeff92477635746 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477635747 rdf:first _:807f36cf91fe4e8caa53aadeff92477635748;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635748 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10700 .

_:807f36cf91fe4e8caa53aadeff92477635750 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10293-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10293";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635752;
  r:natureDuRisque "Diminution de l'absorption de l'azolé antifongique, par augmentation du pH intragastrique par l'antisécrétoire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635758, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635752 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635753 .

_:807f36cf91fe4e8caa53aadeff92477635753 rdf:first _:807f36cf91fe4e8caa53aadeff92477635754;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635755 .

_:807f36cf91fe4e8caa53aadeff92477635754 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477635755 rdf:first _:807f36cf91fe4e8caa53aadeff92477635756;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635756 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477635758 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10294-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_10294";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635760;
  r:natureDuRisque "Diminution de l'absorption de l'azolé antifongique, par augmentation du pH intragastrique par l'antisécrétoire."@fr;
  r:conduiteATenir """Association déconseillée:
- uniquement avec la forme suspension buvable de posaconazole."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635766, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635760 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635761 .

_:807f36cf91fe4e8caa53aadeff92477635761 rdf:first _:807f36cf91fe4e8caa53aadeff92477635762;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635763 .

_:807f36cf91fe4e8caa53aadeff92477635762 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477635763 rdf:first _:807f36cf91fe4e8caa53aadeff92477635764;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635764 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477635766 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10295-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> RILPIVIRINE"@fr;
  dct:identifier "IAM_10295";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635768;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de la rilpivirine."@fr;
  r:conduiteATenir "Si nécessaire, utiliser un antihistaminique H2 actif en une prise par jour, à prendre au moins 12 heures avant, ou au moins 4 heures après."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635774, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635768 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635769 .

_:807f36cf91fe4e8caa53aadeff92477635769 rdf:first _:807f36cf91fe4e8caa53aadeff92477635770;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635771 .

_:807f36cf91fe4e8caa53aadeff92477635770 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477635771 rdf:first _:807f36cf91fe4e8caa53aadeff92477635772;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635772 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10803 .

_:807f36cf91fe4e8caa53aadeff92477635774 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10296-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_10296";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635776;
  r:natureDuRisque "Risque de diminution de l’effet de l’ulipristal, par diminution de son absorption."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635782, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635776 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635777 .

_:807f36cf91fe4e8caa53aadeff92477635777 rdf:first _:807f36cf91fe4e8caa53aadeff92477635778;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635779 .

_:807f36cf91fe4e8caa53aadeff92477635778 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477635779 rdf:first _:807f36cf91fe4e8caa53aadeff92477635780;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635780 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477635782 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10297-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> ATAZANAVIR"@fr;
  dct:identifier "IAM_10297";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635784;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques de l'atazanavir, avec risque d'échec thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635790, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635784 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635785 .

_:807f36cf91fe4e8caa53aadeff92477635785 rdf:first _:807f36cf91fe4e8caa53aadeff92477635786;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635787 .

_:807f36cf91fe4e8caa53aadeff92477635786 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477635787 rdf:first _:807f36cf91fe4e8caa53aadeff92477635788;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635788 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:807f36cf91fe4e8caa53aadeff92477635790 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10298-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> CYANOCOBALAMINE"@fr;
  dct:identifier "IAM_10298";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635792;
  r:natureDuRisque "Risque de carence en cyanocobalamine après traitement prolongé (quelques années), la réduction de l’acidité gastrique par ces médicaments pouvant diminuer l’absorption digestive de la vitamine B12."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635798, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635792 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635793 .

_:807f36cf91fe4e8caa53aadeff92477635793 rdf:first _:807f36cf91fe4e8caa53aadeff92477635794;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635795 .

_:807f36cf91fe4e8caa53aadeff92477635794 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477635795 rdf:first _:807f36cf91fe4e8caa53aadeff92477635796;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635796 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10233 .

_:807f36cf91fe4e8caa53aadeff92477635798 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10299-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS"@fr;
  dct:identifier "IAM_10299";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635800;
  r:natureDuRisque "Risque de diminution de la biodisponibilité de l’inhibiteur de tyrosine kinases, en raison de son absorption pH-dépendante."@fr;
  r:conduiteATenir "- sauf avec l'imatinib et le vandétanib"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635806, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635800 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635801 .

_:807f36cf91fe4e8caa53aadeff92477635801 rdf:first _:807f36cf91fe4e8caa53aadeff92477635802;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635803 .

_:807f36cf91fe4e8caa53aadeff92477635802 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477635803 rdf:first _:807f36cf91fe4e8caa53aadeff92477635804;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635804 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:807f36cf91fe4e8caa53aadeff92477635806 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10300-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10300";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635808;
  r:natureDuRisque "Diminution de l'absorption de l'azolé antifongique, par augmentation du pH intragastrique par l'antisécrétoire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635814, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635808 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635809 .

_:807f36cf91fe4e8caa53aadeff92477635809 rdf:first _:807f36cf91fe4e8caa53aadeff92477635810;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635811 .

_:807f36cf91fe4e8caa53aadeff92477635810 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477635811 rdf:first _:807f36cf91fe4e8caa53aadeff92477635812;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635812 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477635814 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10301-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10301";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635816;
  r:natureDuRisque "Diminution de l'absorption de l'azolé antifongique, par augmentation du pH intragastrique par l'antisécrétoire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635822, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635816 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635817 .

_:807f36cf91fe4e8caa53aadeff92477635817 rdf:first _:807f36cf91fe4e8caa53aadeff92477635818;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635819 .

_:807f36cf91fe4e8caa53aadeff92477635818 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477635819 rdf:first _:807f36cf91fe4e8caa53aadeff92477635820;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635820 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477635822 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10715-1 a owl:Class;
  rdfs:label "DACLATASVIR <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10715";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635824;
  r:natureDuRisque "Diminution des concentrations plasmatiques de daclatasvir par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir """Contre-indication:
- avec la rifampicine
- avec les anticonvulsivants inducteurs enzymatiques
- avec l'oxcarbazépine

Précaution d'emploi:
- avec les autres inducteurs, la dose recommandée est de 90 mg/jour de daclatasvir"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635830, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635824 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635825 .

_:807f36cf91fe4e8caa53aadeff92477635825 rdf:first _:807f36cf91fe4e8caa53aadeff92477635826;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635827 .

_:807f36cf91fe4e8caa53aadeff92477635826 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477635827 rdf:first _:807f36cf91fe4e8caa53aadeff92477635828;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635828 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10243 .

_:807f36cf91fe4e8caa53aadeff92477635830 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10290-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> CYANOCOBALAMINE"@fr;
  dct:identifier "IAM_10290";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635832;
  r:natureDuRisque "Risque de carence en cyanocobalamine après traitement prolongé (quelques années), la réduction de l’acidité gastrique par ces médicaments pouvant diminuer l’absorption digestive de la vitamine B12."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635838, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635832 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635833 .

_:807f36cf91fe4e8caa53aadeff92477635833 rdf:first _:807f36cf91fe4e8caa53aadeff92477635834;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635835 .

_:807f36cf91fe4e8caa53aadeff92477635834 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477635835 rdf:first _:807f36cf91fe4e8caa53aadeff92477635836;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635836 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10233 .

_:807f36cf91fe4e8caa53aadeff92477635838 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10268-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> DEFERASIROX"@fr;
  dct:identifier "IAM_10268";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635840;
  r:natureDuRisque "Majoration du risque ulcérogène et hémorragique digestif."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635846, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635840 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635841 .

_:807f36cf91fe4e8caa53aadeff92477635841 rdf:first _:807f36cf91fe4e8caa53aadeff92477635842;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635843 .

_:807f36cf91fe4e8caa53aadeff92477635842 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477635843 rdf:first _:807f36cf91fe4e8caa53aadeff92477635844;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635844 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:807f36cf91fe4e8caa53aadeff92477635846 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10227-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> IVABRADINE"@fr;
  dct:identifier "IAM_10227";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635848;
  r:natureDuRisque "Risque de diminution de l'efficacité de l’ivabradine, par augmentation de son métabolisme par l’inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de l’ivabradine pendant l’association et après l’arrêt de l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635854, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635848 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635849 .

_:807f36cf91fe4e8caa53aadeff92477635849 rdf:first _:807f36cf91fe4e8caa53aadeff92477635850;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635851 .

_:807f36cf91fe4e8caa53aadeff92477635850 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477635851 rdf:first _:807f36cf91fe4e8caa53aadeff92477635852;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635852 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:807f36cf91fe4e8caa53aadeff92477635854 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10257-1 a owl:Class;
  rdfs:label "ANTIDÉPRESSEURS IMIPRAMINIQUES <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_10257";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635856;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'antidépresseur imipraminique avec risque de convulsions et augmentation des effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique accrue et, si nécessaire, adaptation posologique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635862, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635856 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635857 .

_:807f36cf91fe4e8caa53aadeff92477635857 rdf:first _:807f36cf91fe4e8caa53aadeff92477635858;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635859 .

_:807f36cf91fe4e8caa53aadeff92477635858 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:807f36cf91fe4e8caa53aadeff92477635859 rdf:first _:807f36cf91fe4e8caa53aadeff92477635860;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635860 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477635862 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10258-1 a owl:Class;
  rdfs:label "ANTIDÉPRESSEURS IMIPRAMINIQUES <-> ORLISTAT"@fr;
  dct:identifier "IAM_10258";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635864;
  r:natureDuRisque "Risque d'échec thérapeutique en cas de traitement concomitant par orlistat."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635870, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635864 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635865 .

_:807f36cf91fe4e8caa53aadeff92477635865 rdf:first _:807f36cf91fe4e8caa53aadeff92477635866;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635867 .

_:807f36cf91fe4e8caa53aadeff92477635866 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:807f36cf91fe4e8caa53aadeff92477635867 rdf:first _:807f36cf91fe4e8caa53aadeff92477635868;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635868 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477635870 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10259-1 a owl:Class;
  rdfs:label "ANTIDÉPRESSEURS IMIPRAMINIQUES <-> SYMPATHOMIMÉTIQUES ALPHA ET BÊTA (VOIE IM ET IV)"@fr;
  dct:identifier "IAM_10259";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635872;
  r:natureDuRisque "Hypertension paroxystique avec possibilité de troubles du rythme (inhibition de l'entrée du sympathomimétique dans la fibre sympathique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635878, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635872 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635873 .

_:807f36cf91fe4e8caa53aadeff92477635873 rdf:first _:807f36cf91fe4e8caa53aadeff92477635874;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635875 .

_:807f36cf91fe4e8caa53aadeff92477635874 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:807f36cf91fe4e8caa53aadeff92477635875 rdf:first _:807f36cf91fe4e8caa53aadeff92477635876;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635876 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10149 .

_:807f36cf91fe4e8caa53aadeff92477635878 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10260-1 a owl:Class;
  rdfs:label "ANTIHYPERTENSEURS ALPHA-BLOQUANTS <-> ANTIHYPERTENSEURS SAUF ALPHA-BLOQUANTS"@fr;
  dct:identifier "IAM_10260";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635880;
  r:natureDuRisque "Majoration de l'effet hypotenseur. Risque majoré d'hypotension orthostatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635886, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635880 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635881 .

_:807f36cf91fe4e8caa53aadeff92477635881 rdf:first _:807f36cf91fe4e8caa53aadeff92477635882;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635883 .

_:807f36cf91fe4e8caa53aadeff92477635882 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10033 .

_:807f36cf91fe4e8caa53aadeff92477635883 rdf:first _:807f36cf91fe4e8caa53aadeff92477635884;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635884 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10035 .

_:807f36cf91fe4e8caa53aadeff92477635886 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10261-1 a owl:Class;
  rdfs:label "ANTIHYPERTENSEURS ALPHA-BLOQUANTS <-> INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5"@fr;
  dct:identifier "IAM_10261";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635888;
  r:natureDuRisque "Risque d’hypotension orthostatique, notamment chez le sujet âgé."@fr;
  r:conduiteATenir """Association déconseillée :
- avec la doxazosine 

Précaution d'emploi :
- avec les autres alpha-bloquants
Débuter le traitement aux posologies minimales recommandées et adapter progressivement les doses si besoin."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635894, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635888 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635889 .

_:807f36cf91fe4e8caa53aadeff92477635889 rdf:first _:807f36cf91fe4e8caa53aadeff92477635890;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635891 .

_:807f36cf91fe4e8caa53aadeff92477635890 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10033 .

_:807f36cf91fe4e8caa53aadeff92477635891 rdf:first _:807f36cf91fe4e8caa53aadeff92477635892;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635892 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:807f36cf91fe4e8caa53aadeff92477635894 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10262-1 a owl:Class;
  rdfs:label "ANTIHYPERTENSEURS CENTRAUX <-> BÊTA-BLOQUANTS (SAUF ESMOLOL)"@fr;
  dct:identifier "IAM_10262";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635896;
  r:natureDuRisque "Augmentation importante de la pression artérielle en cas d'arrêt brutal du traitement par l'antihypertenseur central."@fr;
  r:conduiteATenir "Eviter l'arrêt brutal du traitement par l'antihypertenseur central. Surveillance clinique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635902, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635896 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635897 .

_:807f36cf91fe4e8caa53aadeff92477635897 rdf:first _:807f36cf91fe4e8caa53aadeff92477635898;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635899 .

_:807f36cf91fe4e8caa53aadeff92477635898 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10034 .

_:807f36cf91fe4e8caa53aadeff92477635899 rdf:first _:807f36cf91fe4e8caa53aadeff92477635900;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635900 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff92477635902 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10263-1 a owl:Class;
  rdfs:label "ANTIHYPERTENSEURS CENTRAUX <-> BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE"@fr;
  dct:identifier "IAM_10263";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635904;
  r:natureDuRisque "Diminution centrale du tonus sympathique et effet vasodilatateur des antihypertenseurs centraux, préjudiciables en cas d'insuffisance cardiaque traitée par bêta-bloquant et vasodilatateur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635910, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635904 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635905 .

_:807f36cf91fe4e8caa53aadeff92477635905 rdf:first _:807f36cf91fe4e8caa53aadeff92477635906;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635907 .

_:807f36cf91fe4e8caa53aadeff92477635906 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10034 .

_:807f36cf91fe4e8caa53aadeff92477635907 rdf:first _:807f36cf91fe4e8caa53aadeff92477635908;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635908 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477635910 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10265-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> AUTRES ANTI-INFLAMMATOIRES NON STÉROÏDIENS"@fr;
  dct:identifier "IAM_10265";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635912;
  r:natureDuRisque "Avec les autres anti-inflammatoires non stéroïdiens : majoration du risque ulcérogène et hémorragique digestif."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635914, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477635914 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10281-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10281";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635916;
  r:natureDuRisque "Risque d’addition des effets néphrotoxiques, notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Surveiller la fonction rénale en début de traitement par l’AINS."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635922, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635916 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635917 .

_:807f36cf91fe4e8caa53aadeff92477635917 rdf:first _:807f36cf91fe4e8caa53aadeff92477635918;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635919 .

_:807f36cf91fe4e8caa53aadeff92477635918 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477635919 rdf:first _:807f36cf91fe4e8caa53aadeff92477635920;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477635922 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10267-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10267";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635924;
  r:natureDuRisque "Risque d’addition des effets néphrotoxiques, notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Surveiller la fonction rénale en début de traitement par l’AINS."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635930, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635924 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635925 .

_:807f36cf91fe4e8caa53aadeff92477635925 rdf:first _:807f36cf91fe4e8caa53aadeff92477635926;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635927 .

_:807f36cf91fe4e8caa53aadeff92477635926 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477635927 rdf:first _:807f36cf91fe4e8caa53aadeff92477635928;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477635930 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10255-1 a owl:Class;
  rdfs:label "ANTIDÉPRESSEURS IMIPRAMINIQUES <-> BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE"@fr;
  dct:identifier "IAM_10255";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635932;
  r:natureDuRisque "Effet vasodilatateur et risque d'hypotension, notamment orthostatique (effet additif)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635938, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635932 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635933 .

_:807f36cf91fe4e8caa53aadeff92477635933 rdf:first _:807f36cf91fe4e8caa53aadeff92477635934;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635935 .

_:807f36cf91fe4e8caa53aadeff92477635934 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:807f36cf91fe4e8caa53aadeff92477635935 rdf:first _:807f36cf91fe4e8caa53aadeff92477635936;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477635938 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10269-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> DIURÉTIQUES"@fr;
  dct:identifier "IAM_10269";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635940;
  r:natureDuRisque "Insuffisance rénale aiguë chez le malade à risque (sujet âgé et/ou déshydraté) par diminution de la filtration glomérulaire (inhibition des prostaglandines vasodilatatrices due aux anti-inflammatoires non stéroïdiens). Par ailleurs, réduction de l'effet a"@fr;
  r:conduiteATenir "Hydrater le malade et surveiller la fonction rénale en début de traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635946, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635940 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635941 .

_:807f36cf91fe4e8caa53aadeff92477635941 rdf:first _:807f36cf91fe4e8caa53aadeff92477635942;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635943 .

_:807f36cf91fe4e8caa53aadeff92477635942 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477635943 rdf:first _:807f36cf91fe4e8caa53aadeff92477635944;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10063 .

_:807f36cf91fe4e8caa53aadeff92477635946 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10270-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10270";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635948;
  r:natureDuRisque "Augmentation du risque d’ulcération et d’hémorragie gastro-intestinale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635954, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635948 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635949 .

_:807f36cf91fe4e8caa53aadeff92477635949 rdf:first _:807f36cf91fe4e8caa53aadeff92477635950;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635951 .

_:807f36cf91fe4e8caa53aadeff92477635950 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477635951 rdf:first _:807f36cf91fe4e8caa53aadeff92477635952;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477635954 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10271-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10271";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635956;
  r:natureDuRisque "Augmentation du risque hémorragique (agression de la muqueuse gastroduodénale par les anti-inflammatoires non stéroïdiens)."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635962, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635956 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635957 .

_:807f36cf91fe4e8caa53aadeff92477635957 rdf:first _:807f36cf91fe4e8caa53aadeff92477635958;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635959 .

_:807f36cf91fe4e8caa53aadeff92477635958 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477635959 rdf:first _:807f36cf91fe4e8caa53aadeff92477635960;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477635962 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10272-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES PRÉVENTIVES)"@fr;
  dct:identifier "IAM_10272";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635964;
  r:chapeau """Dans le cas de leur utilisation à doses prophylactiques (en dehors du sujet âgé), l'utilisation de médicaments agissant à divers niveaux de l'hémostase majore le risque de saignement. 
Ainsi, chez le sujet non âgé, l'association de l'héparine ou de molécu"""@fr;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635970, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635964 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635965 .

_:807f36cf91fe4e8caa53aadeff92477635965 rdf:first _:807f36cf91fe4e8caa53aadeff92477635966;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635967 .

_:807f36cf91fe4e8caa53aadeff92477635966 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477635967 rdf:first _:807f36cf91fe4e8caa53aadeff92477635968;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10090 .

_:807f36cf91fe4e8caa53aadeff92477635970 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10274-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> HÉPARINES NON FRACTIONNÉES (DOSES PRÉVENTIVES)"@fr;
  dct:identifier "IAM_10274";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635972;
  r:chapeau """Dans le cas de leur utilisation à doses prophylactiques (en dehors du sujet âgé), l'utilisation de médicaments agissant à divers niveaux de l'hémostase majore le risque de saignement. 
Ainsi, chez le sujet non âgé, l'association de l'héparine ou de molécu"""@fr;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635978, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635972 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635973 .

_:807f36cf91fe4e8caa53aadeff92477635973 rdf:first _:807f36cf91fe4e8caa53aadeff92477635974;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635975 .

_:807f36cf91fe4e8caa53aadeff92477635974 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477635975 rdf:first _:807f36cf91fe4e8caa53aadeff92477635976;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10092 .

_:807f36cf91fe4e8caa53aadeff92477635978 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10273-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> HÉPARINES NON FRACTIONNÉES (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10273";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635980;
  r:natureDuRisque "Augmentation du risque hémorragique (agression de la muqueuse gastroduodénale par les anti-inflammatoires non stéroïdiens)."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635986, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635980 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635981 .

_:807f36cf91fe4e8caa53aadeff92477635981 rdf:first _:807f36cf91fe4e8caa53aadeff92477635982;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635983 .

_:807f36cf91fe4e8caa53aadeff92477635982 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477635983 rdf:first _:807f36cf91fe4e8caa53aadeff92477635984;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10091 .

_:807f36cf91fe4e8caa53aadeff92477635986 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10275-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10275";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635988;
  r:natureDuRisque "Insuffisance rénale aiguë chez le patient à risque (âgé, déshydraté, sous diurétiques, avec une fonction rénale altérée), par diminution de la filtration glomérulaire (inhibition des prostaglandines vasodilatatrices due aux anti-inflammatoires non stéroïd"@fr;
  r:conduiteATenir "Hydrater le malade et surveiller la fonction rénale en début de traitement et régulièrement pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477635994, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635988 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635989 .

_:807f36cf91fe4e8caa53aadeff92477635989 rdf:first _:807f36cf91fe4e8caa53aadeff92477635990;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635991 .

_:807f36cf91fe4e8caa53aadeff92477635990 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477635991 rdf:first _:807f36cf91fe4e8caa53aadeff92477635992;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477635992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477635994 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10276-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_10276";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477635996;
  r:natureDuRisque "Majoration du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636002, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477635996 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477635997 .

_:807f36cf91fe4e8caa53aadeff92477635997 rdf:first _:807f36cf91fe4e8caa53aadeff92477635998;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477635999 .

_:807f36cf91fe4e8caa53aadeff92477635998 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477635999 rdf:first _:807f36cf91fe4e8caa53aadeff92477636000;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477636002 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10277-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> LITHIUM"@fr;
  dct:identifier "IAM_10277";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636004;
  r:natureDuRisque "Augmentation de la lithémie pouvant atteindre des valeurs toxiques (diminution de l'excrétion rénale du lithium)."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveiller étroitement la lithémie et adapter la posologie du lithium pendant l'association et après l'arrêt de l'anti-inflammatoire non stéroïdien."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636010, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636004 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636005 .

_:807f36cf91fe4e8caa53aadeff92477636005 rdf:first _:807f36cf91fe4e8caa53aadeff92477636006;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636007 .

_:807f36cf91fe4e8caa53aadeff92477636006 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477636007 rdf:first _:807f36cf91fe4e8caa53aadeff92477636008;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477636010 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10278-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10278";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636012;
  r:natureDuRisque "Augmentation de la toxicité hématologique du méthotrexate (diminution de la clairance rénale du méthotrexate par les anti-inflammatoires)."@fr;
  r:conduiteATenir """Association déconseillée:
- pour des doses de méthotrexate supérieures à 20 mg par semaine.
- avec le kétoprofène et le méthotrexate à des doses supérieures à 20 mg par semaines, respecter un intervalle d'au moins 12 heures entre l'arrêt ou le début d'un"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636018, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636012 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636013 .

_:807f36cf91fe4e8caa53aadeff92477636013 rdf:first _:807f36cf91fe4e8caa53aadeff92477636014;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636015 .

_:807f36cf91fe4e8caa53aadeff92477636014 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477636015 rdf:first _:807f36cf91fe4e8caa53aadeff92477636016;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477636018 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10266-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> BÊTA-BLOQUANTS (SAUF ESMOLOL)"@fr;
  dct:identifier "IAM_10266";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636020;
  r:natureDuRisque "Réduction de l'effet antihypertenseur (inhibition des prostaglandines vasodilatatrices par les anti-inflammatoires non stéroïdiens)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636026, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636020 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636021 .

_:807f36cf91fe4e8caa53aadeff92477636021 rdf:first _:807f36cf91fe4e8caa53aadeff92477636022;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636023 .

_:807f36cf91fe4e8caa53aadeff92477636022 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477636023 rdf:first _:807f36cf91fe4e8caa53aadeff92477636024;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff92477636026 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10677-1 a owl:Class;
  rdfs:label "COLCHICINE <-> FIBRATES"@fr;
  dct:identifier "IAM_10677";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636028;
  r:natureDuRisque "Risque de majoration des effets indésirables musculaires de ces substances, et notamment de rhabdomyolyse."@fr;
  r:conduiteATenir "Surveillance clinique et biologique, particulièrement au début de l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636034, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636028 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636029 .

_:807f36cf91fe4e8caa53aadeff92477636029 rdf:first _:807f36cf91fe4e8caa53aadeff92477636030;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636031 .

_:807f36cf91fe4e8caa53aadeff92477636030 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10074 .

_:807f36cf91fe4e8caa53aadeff92477636031 rdf:first _:807f36cf91fe4e8caa53aadeff92477636032;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477636034 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11229-1 a owl:Class;
  rdfs:label "LÉDIPASVIR <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11229";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636036;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques du lédipasvir par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636042, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636036 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636037 .

_:807f36cf91fe4e8caa53aadeff92477636037 rdf:first _:807f36cf91fe4e8caa53aadeff92477636038;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636039 .

_:807f36cf91fe4e8caa53aadeff92477636038 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:807f36cf91fe4e8caa53aadeff92477636039 rdf:first _:807f36cf91fe4e8caa53aadeff92477636040;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477636042 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10264-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> ANTICOAGULANTS ORAUX"@fr;
  dct:identifier "IAM_10264";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636044;
  r:natureDuRisque "Augmentation du risque hémorragique de l'anticoagulant oral (agression de la muqueuse gastroduodénale par les anti-inflammatoires non stéroïdiens)."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite, voire biologique ."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636050, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636044 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636045 .

_:807f36cf91fe4e8caa53aadeff92477636045 rdf:first _:807f36cf91fe4e8caa53aadeff92477636046;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636047 .

_:807f36cf91fe4e8caa53aadeff92477636046 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477636047 rdf:first _:807f36cf91fe4e8caa53aadeff92477636048;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477636050 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10202-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> DÉFIBROTIDE"@fr;
  dct:identifier "IAM_10202";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636052;
  r:natureDuRisque "Risque hémorragique accru."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636058, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636052 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636053 .

_:807f36cf91fe4e8caa53aadeff92477636053 rdf:first _:807f36cf91fe4e8caa53aadeff92477636054;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636055 .

_:807f36cf91fe4e8caa53aadeff92477636054 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477636055 rdf:first _:807f36cf91fe4e8caa53aadeff92477636056;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10262 .

_:807f36cf91fe4e8caa53aadeff92477636058 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10203-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10203";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636060;
  r:natureDuRisque "Glucocorticoïdes (voies générale et rectale) : impact éventuel de la corticothérapie sur le métabolisme de l'antivitamine K et sur celui des facteurs de la coagulation. Risque hémorragique propre à la corticothérapie (muqueuse digestive, fragilité vascula"@fr;
  r:conduiteATenir "Lorsque l'association est justifiée, renforcer la surveillance : le cas échéant, avec les antivitamines K, contrôle biologique au 8e jour, puis tous les 15 jours pendant la corticothérapie et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636066, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636060 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636061 .

_:807f36cf91fe4e8caa53aadeff92477636061 rdf:first _:807f36cf91fe4e8caa53aadeff92477636062;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636063 .

_:807f36cf91fe4e8caa53aadeff92477636062 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477636063 rdf:first _:807f36cf91fe4e8caa53aadeff92477636064;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477636066 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10353-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> PENTOXIFYLLINE"@fr;
  dct:identifier "IAM_10353";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636068;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la pentoxifylline et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636074, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636068 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636069 .

_:807f36cf91fe4e8caa53aadeff92477636069 rdf:first _:807f36cf91fe4e8caa53aadeff92477636070;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636071 .

_:807f36cf91fe4e8caa53aadeff92477636070 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477636071 rdf:first _:807f36cf91fe4e8caa53aadeff92477636072;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10705 .

_:807f36cf91fe4e8caa53aadeff92477636074 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10354-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> PRISTINAMYCINE"@fr;
  dct:identifier "IAM_10354";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636076;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la pristinamycine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636082, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636076 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636077 .

_:807f36cf91fe4e8caa53aadeff92477636077 rdf:first _:807f36cf91fe4e8caa53aadeff92477636078;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636079 .

_:807f36cf91fe4e8caa53aadeff92477636078 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477636079 rdf:first _:807f36cf91fe4e8caa53aadeff92477636080;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10757 .

_:807f36cf91fe4e8caa53aadeff92477636082 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10355-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> PROGUANIL"@fr;
  dct:identifier "IAM_10355";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636084;
  r:natureDuRisque "Risque d’augmentation de l’effet de l’antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation éventuelle de la posologie de l’antivitamine K pendant le traitement par le proguanil et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636090, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636084 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636085 .

_:807f36cf91fe4e8caa53aadeff92477636085 rdf:first _:807f36cf91fe4e8caa53aadeff92477636086;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636087 .

_:807f36cf91fe4e8caa53aadeff92477636086 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477636087 rdf:first _:807f36cf91fe4e8caa53aadeff92477636088;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10761 .

_:807f36cf91fe4e8caa53aadeff92477636090 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10356-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10356";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636092;
  r:natureDuRisque "Augmentation de l'effet anticoagulant et du risque hémorragique. Mécanisme invoqué : inhibition du métabolisme de l'antivitamine K."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la propafénone et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636098, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636092 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636093 .

_:807f36cf91fe4e8caa53aadeff92477636093 rdf:first _:807f36cf91fe4e8caa53aadeff92477636094;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636095 .

_:807f36cf91fe4e8caa53aadeff92477636094 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477636095 rdf:first _:807f36cf91fe4e8caa53aadeff92477636096;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477636098 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10673-1 a owl:Class;
  rdfs:label "COBICISTAT <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10673";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636100;
  r:natureDuRisque "Risque de diminution de l’efficacité du cobicistat par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636106, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636100 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636101 .

_:807f36cf91fe4e8caa53aadeff92477636101 rdf:first _:807f36cf91fe4e8caa53aadeff92477636102;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636103 .

_:807f36cf91fe4e8caa53aadeff92477636102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477636103 rdf:first _:807f36cf91fe4e8caa53aadeff92477636104;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477636106 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10200-1 a owl:Class;
  rdfs:label "ANTICHOLINESTÉRASIQUES <-> SUXAMETHONIUM"@fr;
  dct:identifier "IAM_10200";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636108;
  r:chapeau """(voir aussi \"bradycardisants\")

+ MEDICAMENTS ATROPINIQUES
Il convient de prendre en compte le risque lié à l'association d'un médicament à action atropinique (imipraminiques, neuroleptiques phénothiaziniques, antispasmodiques, certains antihistaminiques"""@fr;
  r:natureDuRisque "Risque d'allongement du bloc moteur, majoré en cas de déficit partiel en pseudocholinestérase."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636114, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636108 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636109 .

_:807f36cf91fe4e8caa53aadeff92477636109 rdf:first _:807f36cf91fe4e8caa53aadeff92477636110;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636111 .

_:807f36cf91fe4e8caa53aadeff92477636110 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10027 .

_:807f36cf91fe4e8caa53aadeff92477636111 rdf:first _:807f36cf91fe4e8caa53aadeff92477636112;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10878 .

_:807f36cf91fe4e8caa53aadeff92477636114 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10676-1 a owl:Class;
  rdfs:label "COCAINE <-> DISULFIRAME"@fr;
  dct:identifier "IAM_10676";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636116;
  r:natureDuRisque "Augmentation des concentrations de cocaïne par diminution de son métabolisme par le disulfirame, avec risque majoré de survenue de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636122, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636116 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636117 .

_:807f36cf91fe4e8caa53aadeff92477636117 rdf:first _:807f36cf91fe4e8caa53aadeff92477636118;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636119 .

_:807f36cf91fe4e8caa53aadeff92477636118 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10223 .

_:807f36cf91fe4e8caa53aadeff92477636119 rdf:first _:807f36cf91fe4e8caa53aadeff92477636120;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10299 .

_:807f36cf91fe4e8caa53aadeff92477636122 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10199-1 a owl:Class;
  rdfs:label "ANTICHOLINESTÉRASIQUES <-> PILOCARPINE"@fr;
  dct:identifier "IAM_10199";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636124;
  r:natureDuRisque "Risque d'addition des effets indésirables cholinergiques, notamment digestifs."@fr;
  rdfs:comment "La pilocarpine est un parasympathomimétique direct utilisé dans le traitement du glaucome sous forme de collyre. Il existe aussi une AMM par voie orale dont l’indication est l’hyposialie et la xérostomie après radiothérapie chez l’adulte, ainsi que les sé"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636130, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636124 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636125 .

_:807f36cf91fe4e8caa53aadeff92477636125 rdf:first _:807f36cf91fe4e8caa53aadeff92477636126;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636127 .

_:807f36cf91fe4e8caa53aadeff92477636126 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10027 .

_:807f36cf91fe4e8caa53aadeff92477636127 rdf:first _:807f36cf91fe4e8caa53aadeff92477636128;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10719 .

_:807f36cf91fe4e8caa53aadeff92477636130 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10678-1 a owl:Class;
  rdfs:label "COLCHICINE <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10678";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636132;
  r:natureDuRisque "Augmentation des effets indésirables de la colchicine, aux conséquences potentiellement fatales."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636138, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636132 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636133 .

_:807f36cf91fe4e8caa53aadeff92477636133 rdf:first _:807f36cf91fe4e8caa53aadeff92477636134;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636135 .

_:807f36cf91fe4e8caa53aadeff92477636134 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477636135 rdf:first _:807f36cf91fe4e8caa53aadeff92477636136;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477636138 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10679-1 a owl:Class;
  rdfs:label "COLCHICINE <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10679";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636140;
  r:natureDuRisque "Risque de majoration des effets indésirables musculaires de ces substances, et notamment de rhabdomyolyse."@fr;
  r:conduiteATenir "Surveillance clinique et biologique, notamment au début de l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636146, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636140 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636141 .

_:807f36cf91fe4e8caa53aadeff92477636141 rdf:first _:807f36cf91fe4e8caa53aadeff92477636142;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636143 .

_:807f36cf91fe4e8caa53aadeff92477636142 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff92477636143 rdf:first _:807f36cf91fe4e8caa53aadeff92477636144;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477636146 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10680-1 a owl:Class;
  rdfs:label "COLCHICINE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10680";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636148;
  r:natureDuRisque "Augmentation des effets indésirables de la colchicine, aux conséquences potentiellement fatales."@fr;
  r:conduiteATenir """Contre-indication :
- avec les macrolides

Association déconseillée :
- avec les antifongiques azolés, les inhibiteurs de protéases boostés par ritonavir et le cobicistat"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636154, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636148 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636149 .

_:807f36cf91fe4e8caa53aadeff92477636149 rdf:first _:807f36cf91fe4e8caa53aadeff92477636150;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636151 .

_:807f36cf91fe4e8caa53aadeff92477636150 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477636151 rdf:first _:807f36cf91fe4e8caa53aadeff92477636152;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477636154 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10681-1 a owl:Class;
  rdfs:label "COLCHICINE <-> MACROLIDES (SAUF SPIRAMYCINE)"@fr;
  dct:identifier "IAM_10681";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636156;
  r:natureDuRisque "Augmentation des effets indésirables de la colchicine, aux conséquences potentiellement fatales."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636162, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636156 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636157 .

_:807f36cf91fe4e8caa53aadeff92477636157 rdf:first _:807f36cf91fe4e8caa53aadeff92477636158;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636159 .

_:807f36cf91fe4e8caa53aadeff92477636158 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10107 .

_:807f36cf91fe4e8caa53aadeff92477636159 rdf:first _:807f36cf91fe4e8caa53aadeff92477636160;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477636162 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10682-1 a owl:Class;
  rdfs:label "COLCHICINE <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10682";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636164;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la colchicine par diminution de son métabolisme hépatique par la bithérapie."@fr;
  r:conduiteATenir """Contre-indication:
- chez les patients insuffisants rénaux et/ou hépatiques."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636170, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636164 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636165 .

_:807f36cf91fe4e8caa53aadeff92477636165 rdf:first _:807f36cf91fe4e8caa53aadeff92477636166;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636167 .

_:807f36cf91fe4e8caa53aadeff92477636166 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477636167 rdf:first _:807f36cf91fe4e8caa53aadeff92477636168;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477636170 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10683-1 a owl:Class;
  rdfs:label "COLCHICINE <-> PRISTINAMYCINE"@fr;
  dct:identifier "IAM_10683";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636172;
  r:natureDuRisque "Augmentation des effets indésirables de la colchicine aux conséquences potentiellement fatales."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636178, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636172 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636173 .

_:807f36cf91fe4e8caa53aadeff92477636173 rdf:first _:807f36cf91fe4e8caa53aadeff92477636174;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636175 .

_:807f36cf91fe4e8caa53aadeff92477636174 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477636175 rdf:first _:807f36cf91fe4e8caa53aadeff92477636176;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10757 .

_:807f36cf91fe4e8caa53aadeff92477636178 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10684-1 a owl:Class;
  rdfs:label "COLCHICINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10684";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636180;
  r:natureDuRisque "Risque de majoration des effets indésirables de la colchicine, par augmentation de ses concentrations plasmatiques par le vérapamil."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636186, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636180 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636181 .

_:807f36cf91fe4e8caa53aadeff92477636181 rdf:first _:807f36cf91fe4e8caa53aadeff92477636182;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636183 .

_:807f36cf91fe4e8caa53aadeff92477636182 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477636183 rdf:first _:807f36cf91fe4e8caa53aadeff92477636184;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477636186 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10685-1 a owl:Class;
  rdfs:label "COLISTINE <-> CURARES"@fr;
  dct:identifier "IAM_10685";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636188;
  r:natureDuRisque "Potentialisation des curares lorque l'antibiotique est administré par voie parentérale et/ou péritonéale avant, pendant ou après l'agent curarisant."@fr;
  r:conduiteATenir "Surveiller le degré de curarisation en fin d'anesthésie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636194, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636188 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636189 .

_:807f36cf91fe4e8caa53aadeff92477636189 rdf:first _:807f36cf91fe4e8caa53aadeff92477636190;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636191 .

_:807f36cf91fe4e8caa53aadeff92477636190 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10057 .

_:807f36cf91fe4e8caa53aadeff92477636191 rdf:first _:807f36cf91fe4e8caa53aadeff92477636192;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10228 .

_:807f36cf91fe4e8caa53aadeff92477636194 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10686-1 a owl:Class;
  rdfs:label "CRIZOTINIB <-> SUBSTRATS À RISQUE DU CYP3A4"@fr;
  dct:identifier "IAM_10686";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636196;
  r:natureDuRisque "Risque de majoration de la toxicité de ces molécules par diminution de leur métabolisme et/ou augmentation de leur biodisponibilité par le crizotinib."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636202, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636196 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636197 .

_:807f36cf91fe4e8caa53aadeff92477636197 rdf:first _:807f36cf91fe4e8caa53aadeff92477636198;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636199 .

_:807f36cf91fe4e8caa53aadeff92477636198 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10145 .

_:807f36cf91fe4e8caa53aadeff92477636199 rdf:first _:807f36cf91fe4e8caa53aadeff92477636200;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10231 .

_:807f36cf91fe4e8caa53aadeff92477636202 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10229-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> METRONIDAZOLE"@fr;
  dct:identifier "IAM_10229";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636204;
  r:natureDuRisque "Diminution des concentrations plasmatiques du métronidazole par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de métronidazole pendant le traitement par l’inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636210, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636204 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636205 .

_:807f36cf91fe4e8caa53aadeff92477636205 rdf:first _:807f36cf91fe4e8caa53aadeff92477636206;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636207 .

_:807f36cf91fe4e8caa53aadeff92477636206 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636207 rdf:first _:807f36cf91fe4e8caa53aadeff92477636208;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10580 .

_:807f36cf91fe4e8caa53aadeff92477636210 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10674-1 a owl:Class;
  rdfs:label "COBICISTAT <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_10674";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636212;
  r:natureDuRisque "Avec l'atazanavir, le darunavir ou le lopinavir boostés par cobicistat, augmentation des concentrations plasmatiques du ténofovir alafénamide par augmentation de son absorption."@fr;
  r:conduiteATenir "En cas de co-administration, la dose de ténofovir alafénamide doit être limitée à 10 mg par jour. L’association avec les autres inhibiteurs de protéases du VIH n’a pas été étudiée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636218, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636212 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636213 .

_:807f36cf91fe4e8caa53aadeff92477636213 rdf:first _:807f36cf91fe4e8caa53aadeff92477636214;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636215 .

_:807f36cf91fe4e8caa53aadeff92477636214 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477636215 rdf:first _:807f36cf91fe4e8caa53aadeff92477636216;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff92477636218 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10215-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> DEFERASIROX"@fr;
  dct:identifier "IAM_10215";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636220;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de déférasirox."@fr;
  r:conduiteATenir "Surveiller la ferritinémie pendant et après le traitement par l’inducteur enzymatique. Si besoin, adaptation de la posologie de déférasirox."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636226, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636220 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636221 .

_:807f36cf91fe4e8caa53aadeff92477636221 rdf:first _:807f36cf91fe4e8caa53aadeff92477636222;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636223 .

_:807f36cf91fe4e8caa53aadeff92477636222 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636223 rdf:first _:807f36cf91fe4e8caa53aadeff92477636224;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:807f36cf91fe4e8caa53aadeff92477636226 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11078-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> QUINUPRISTINE"@fr;
  dct:identifier "IAM_11078";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636228;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636234, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636228 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636229 .

_:807f36cf91fe4e8caa53aadeff92477636229 rdf:first _:807f36cf91fe4e8caa53aadeff92477636230;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636231 .

_:807f36cf91fe4e8caa53aadeff92477636230 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477636231 rdf:first _:807f36cf91fe4e8caa53aadeff92477636232;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10778 .

_:807f36cf91fe4e8caa53aadeff92477636234 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10206-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> IPILIMUMAB"@fr;
  dct:identifier "IAM_10206";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636236;
  r:natureDuRisque "Augmentation du risque d'hémorragies digestives."@fr;
  r:conduiteATenir "Surveillance clinique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636242, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636236 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636237 .

_:807f36cf91fe4e8caa53aadeff92477636237 rdf:first _:807f36cf91fe4e8caa53aadeff92477636238;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636239 .

_:807f36cf91fe4e8caa53aadeff92477636238 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477636239 rdf:first _:807f36cf91fe4e8caa53aadeff92477636240;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636240 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10482 .

_:807f36cf91fe4e8caa53aadeff92477636242 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10207-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> MÉDICAMENTS MIXTES ADRÉNERGIQUES-SÉROTONINERGIQUES"@fr;
  dct:identifier "IAM_10207";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636244;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Surveillance clinique et, le cas échéant, contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'anticoagulant oral pendant la durée de l'association et à son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636250, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636244 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636245 .

_:807f36cf91fe4e8caa53aadeff92477636245 rdf:first _:807f36cf91fe4e8caa53aadeff92477636246;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636247 .

_:807f36cf91fe4e8caa53aadeff92477636246 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477636247 rdf:first _:807f36cf91fe4e8caa53aadeff92477636248;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636248 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10116 .

_:807f36cf91fe4e8caa53aadeff92477636250 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10244-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> TELAPREVIR"@fr;
  dct:identifier "IAM_10244";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636252;
  r:natureDuRisque "Risque de diminution très importante des concentrations de télaprévir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636258, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636252 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636253 .

_:807f36cf91fe4e8caa53aadeff92477636253 rdf:first _:807f36cf91fe4e8caa53aadeff92477636254;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636255 .

_:807f36cf91fe4e8caa53aadeff92477636254 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636255 rdf:first _:807f36cf91fe4e8caa53aadeff92477636256;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636256 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477636258 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10208-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10208";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636260;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Diminution (ou, rarement, augmentation avec la phénytoïne) de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique par l'anticonvulsivant inducteur."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par l'anticonvulsivant inducteur et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636266, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636260 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636261 .

_:807f36cf91fe4e8caa53aadeff92477636261 rdf:first _:807f36cf91fe4e8caa53aadeff92477636262;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636263 .

_:807f36cf91fe4e8caa53aadeff92477636262 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636263 rdf:first _:807f36cf91fe4e8caa53aadeff92477636264;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636264 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477636266 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10209-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> APIXABAN"@fr;
  dct:identifier "IAM_10209";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636268;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’apixaban par l' anticonvulsivant inducteur enzymatique, avec risque de diminution de l’effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636274, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636268 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636269 .

_:807f36cf91fe4e8caa53aadeff92477636269 rdf:first _:807f36cf91fe4e8caa53aadeff92477636270;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636271 .

_:807f36cf91fe4e8caa53aadeff92477636270 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636271 rdf:first _:807f36cf91fe4e8caa53aadeff92477636272;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636272 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10078 .

_:807f36cf91fe4e8caa53aadeff92477636274 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10210-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> APREPITANT"@fr;
  dct:identifier "IAM_10210";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636276;
  r:natureDuRisque "Risque de diminution très importante des concentrations d'aprépitant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636282, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636276 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636277 .

_:807f36cf91fe4e8caa53aadeff92477636277 rdf:first _:807f36cf91fe4e8caa53aadeff92477636278;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636279 .

_:807f36cf91fe4e8caa53aadeff92477636278 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636279 rdf:first _:807f36cf91fe4e8caa53aadeff92477636280;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636280 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff92477636282 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10211-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> BOCEPREVIR"@fr;
  dct:identifier "IAM_10211";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636284;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de bocéprévir."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636290, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636284 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636285 .

_:807f36cf91fe4e8caa53aadeff92477636285 rdf:first _:807f36cf91fe4e8caa53aadeff92477636286;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636287 .

_:807f36cf91fe4e8caa53aadeff92477636286 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636287 rdf:first _:807f36cf91fe4e8caa53aadeff92477636288;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636288 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff92477636290 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10212-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> BOSENTAN"@fr;
  dct:identifier "IAM_10212";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636292;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de bosentan."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636298, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636292 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636293 .

_:807f36cf91fe4e8caa53aadeff92477636293 rdf:first _:807f36cf91fe4e8caa53aadeff92477636294;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636295 .

_:807f36cf91fe4e8caa53aadeff92477636294 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636295 rdf:first _:807f36cf91fe4e8caa53aadeff92477636296;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636296 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff92477636298 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10201-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> AUTRES ANTICOAGULANTS ORAUX"@fr;
  dct:identifier "IAM_10201";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636300;
  r:natureDuRisque "Risque de majoration des événements hémorragiques lors du relais d'un anticoagulant oral par un autre."@fr;
  r:conduiteATenir "Tenir compte de la demi-vie de l'anticoagulant oral et observer, le cas échéant, un délai de carence avant le début du traitement par l'autre. Penser à informer le patient."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636302, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477636302 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10214-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> DABIGATRAN"@fr;
  dct:identifier "IAM_10214";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636304;
  r:natureDuRisque "Diminution des concentrations plasmatiques de dabigatran, avec risque de diminution de l'effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636310, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636304 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636305 .

_:807f36cf91fe4e8caa53aadeff92477636305 rdf:first _:807f36cf91fe4e8caa53aadeff92477636306;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636307 .

_:807f36cf91fe4e8caa53aadeff92477636306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636307 rdf:first _:807f36cf91fe4e8caa53aadeff92477636308;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff92477636310 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11230-1 a owl:Class;
  rdfs:label "LÉDIPASVIR <-> TENOFOVIR DISOPROXIL"@fr;
  dct:identifier "IAM_11230";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636312;
  r:natureDuRisque "Lors de sa co-administration avec un inhibiteur de protéase, augmentation des concentrations plasmatiques du ténofovir par le lédipasvir."@fr;
  r:conduiteATenir "Surveillance clinique et biologique, notamment de la fonction rénale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636318, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636312 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636313 .

_:807f36cf91fe4e8caa53aadeff92477636313 rdf:first _:807f36cf91fe4e8caa53aadeff92477636314;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636315 .

_:807f36cf91fe4e8caa53aadeff92477636314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:807f36cf91fe4e8caa53aadeff92477636315 rdf:first _:807f36cf91fe4e8caa53aadeff92477636316;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10896 .

_:807f36cf91fe4e8caa53aadeff92477636318 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10216-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> DÉLAMANID"@fr;
  dct:identifier "IAM_10216";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636320;
  r:natureDuRisque "Diminution des concentrations plasmatiques de delamanid par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636326, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636320 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636321 .

_:807f36cf91fe4e8caa53aadeff92477636321 rdf:first _:807f36cf91fe4e8caa53aadeff92477636322;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636323 .

_:807f36cf91fe4e8caa53aadeff92477636322 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636323 rdf:first _:807f36cf91fe4e8caa53aadeff92477636324;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10263 .

_:807f36cf91fe4e8caa53aadeff92477636326 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10217-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> DOXYCYCLINE"@fr;
  dct:identifier "IAM_10217";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636328;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la doxycycline par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la doxycycline."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636334, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636328 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636329 .

_:807f36cf91fe4e8caa53aadeff92477636329 rdf:first _:807f36cf91fe4e8caa53aadeff92477636330;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636331 .

_:807f36cf91fe4e8caa53aadeff92477636330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636331 rdf:first _:807f36cf91fe4e8caa53aadeff92477636332;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10309 .

_:807f36cf91fe4e8caa53aadeff92477636334 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10218-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> DRONEDARONE"@fr;
  dct:identifier "IAM_10218";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636336;
  r:natureDuRisque "Diminution importante des concentrations de dronédarone par augmentation de son métabolisme, sans modification notable du métabolite actif."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636342, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636336 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636337 .

_:807f36cf91fe4e8caa53aadeff92477636337 rdf:first _:807f36cf91fe4e8caa53aadeff92477636338;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636339 .

_:807f36cf91fe4e8caa53aadeff92477636338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636339 rdf:first _:807f36cf91fe4e8caa53aadeff92477636340;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477636342 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10219-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> ESTROGÈNES NON CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10219";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636344;
  r:natureDuRisque "Diminution de l'efficacité de l'estrogène."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du traitement hormonal pendant l'administration de l'anticonvulsivant inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636350, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636344 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636345 .

_:807f36cf91fe4e8caa53aadeff92477636345 rdf:first _:807f36cf91fe4e8caa53aadeff92477636346;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636347 .

_:807f36cf91fe4e8caa53aadeff92477636346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636347 rdf:first _:807f36cf91fe4e8caa53aadeff92477636348;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10072 .

_:807f36cf91fe4e8caa53aadeff92477636350 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10220-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> FENTANYL"@fr;
  dct:identifier "IAM_10220";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636352;
  r:natureDuRisque "Diminution des concentrations plasmatiques de fentanyl par augmentation de son métabolisme hépatique par l'anticonvulsivant."@fr;
  r:conduiteATenir "Préférer un autre morphinique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636358, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636352 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636353 .

_:807f36cf91fe4e8caa53aadeff92477636353 rdf:first _:807f36cf91fe4e8caa53aadeff92477636354;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636355 .

_:807f36cf91fe4e8caa53aadeff92477636354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636355 rdf:first _:807f36cf91fe4e8caa53aadeff92477636356;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10374 .

_:807f36cf91fe4e8caa53aadeff92477636358 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10221-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10221";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636360;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité des corticoïdes par augmentation de leur métabolisme hépatique par l'inducteur : les conséquences sont particulièrement importantes chez les addisoniens traités par l'hydrocortisone et en cas d"@fr;
  r:conduiteATenir "Surveillance clinique et biologique ; adaptation de la posologie des corticoïdes pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636366, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636360 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636361 .

_:807f36cf91fe4e8caa53aadeff92477636361 rdf:first _:807f36cf91fe4e8caa53aadeff92477636362;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636363 .

_:807f36cf91fe4e8caa53aadeff92477636362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636363 rdf:first _:807f36cf91fe4e8caa53aadeff92477636364;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477636366 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10222-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> HALOPERIDOL"@fr;
  dct:identifier "IAM_10222";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636368;
  r:natureDuRisque "Surveillance clinique et, si besoin, adaptation posologique pendant le traitement par la carbamazépine et après son arrêt."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, adaptation posologique pendant le traitement par la carbamazépine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636374, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636368 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636369 .

_:807f36cf91fe4e8caa53aadeff92477636369 rdf:first _:807f36cf91fe4e8caa53aadeff92477636370;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636371 .

_:807f36cf91fe4e8caa53aadeff92477636370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636371 rdf:first _:807f36cf91fe4e8caa53aadeff92477636372;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10426 .

_:807f36cf91fe4e8caa53aadeff92477636374 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10223-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> HORMONES THYROÏDIENNES"@fr;
  dct:identifier "IAM_10223";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636376;
  r:natureDuRisque "Risque d'hypothyroïdie clinique chez les patients hypothyroïdiens, par augmentation du métabolisme de la T3 et de la T4."@fr;
  r:conduiteATenir "Surveillance des concentrations sériques de T3 et de T4 et adaptation, si besoin, de la posologie des hormones thyroïdiennes pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636382, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636376 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636377 .

_:807f36cf91fe4e8caa53aadeff92477636377 rdf:first _:807f36cf91fe4e8caa53aadeff92477636378;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636379 .

_:807f36cf91fe4e8caa53aadeff92477636378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636379 rdf:first _:807f36cf91fe4e8caa53aadeff92477636380;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477636382 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10197-1 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES CLASSE IA <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10197";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636384;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de l'antiarythmique (augmentation de son métabolisme hépatique)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement de la concentration plasmatique de l'antiarythmique. Si besoin, adaptation de la posologie de l'antiarythmique pendant le traitement par la rifampicine et après son arrêt (risque de surdosage en antiarythmique)"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636390, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636384 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636385 .

_:807f36cf91fe4e8caa53aadeff92477636385 rdf:first _:807f36cf91fe4e8caa53aadeff92477636386;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636387 .

_:807f36cf91fe4e8caa53aadeff92477636386 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10026 .

_:807f36cf91fe4e8caa53aadeff92477636387 rdf:first _:807f36cf91fe4e8caa53aadeff92477636388;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477636390 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10198-1 a owl:Class;
  rdfs:label "ANTICHOLINESTÉRASIQUES <-> BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE"@fr;
  dct:identifier "IAM_10198";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636392;
  r:chapeau """(voir aussi \"bradycardisants\")

+ MEDICAMENTS ATROPINIQUES
Il convient de prendre en compte le risque lié à l'association d'un médicament à action atropinique (imipraminiques, neuroleptiques phénothiaziniques, antispasmodiques, certains antihistaminiques"""@fr;
  r:natureDuRisque "Risque de bradycardie excessive (addition des effets bradycardisants)."@fr;
  r:conduiteATenir "Surveillance clinique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636398, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636392 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636393 .

_:807f36cf91fe4e8caa53aadeff92477636393 rdf:first _:807f36cf91fe4e8caa53aadeff92477636394;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636395 .

_:807f36cf91fe4e8caa53aadeff92477636394 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10027 .

_:807f36cf91fe4e8caa53aadeff92477636395 rdf:first _:807f36cf91fe4e8caa53aadeff92477636396;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477636398 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10213-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> COBICISTAT"@fr;
  dct:identifier "IAM_10213";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636400;
  r:natureDuRisque "Risque de diminution de l’efficacité du cobicistat par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636406, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636400 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636401 .

_:807f36cf91fe4e8caa53aadeff92477636401 rdf:first _:807f36cf91fe4e8caa53aadeff92477636402;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636403 .

_:807f36cf91fe4e8caa53aadeff92477636402 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636403 rdf:first _:807f36cf91fe4e8caa53aadeff92477636404;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477636406 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10588-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> FIDAXOMICINE"@fr;
  dct:identifier "IAM_10588";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636408;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636414, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636408 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636409 .

_:807f36cf91fe4e8caa53aadeff92477636409 rdf:first _:807f36cf91fe4e8caa53aadeff92477636410;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636411 .

_:807f36cf91fe4e8caa53aadeff92477636410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477636411 rdf:first _:807f36cf91fe4e8caa53aadeff92477636412;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:807f36cf91fe4e8caa53aadeff92477636414 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10998-1 a owl:Class;
  rdfs:label "GLOBULINES ANTILYMPHOCYTAIRES <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10998";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636416;
  r:natureDuRisque "Immunodépression excessive avec risque de lymphoprolifération."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636422, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636416 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636417 .

_:807f36cf91fe4e8caa53aadeff92477636417 rdf:first _:807f36cf91fe4e8caa53aadeff92477636418;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636419 .

_:807f36cf91fe4e8caa53aadeff92477636418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff92477636419 rdf:first _:807f36cf91fe4e8caa53aadeff92477636420;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477636422 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10578-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> CLINDAMYCINE"@fr;
  dct:identifier "IAM_10578";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636424;
  r:natureDuRisque "Diminution des concentrations sanguines de l'immunosuppresseur avec risque de perte de l'activité immunosuppressive."@fr;
  r:conduiteATenir "Contrôle renforcé des dosages sanguins de ciclosporine et augmentation éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636430, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636424 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636425 .

_:807f36cf91fe4e8caa53aadeff92477636425 rdf:first _:807f36cf91fe4e8caa53aadeff92477636426;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636427 .

_:807f36cf91fe4e8caa53aadeff92477636426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477636427 rdf:first _:807f36cf91fe4e8caa53aadeff92477636428;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10209 .

_:807f36cf91fe4e8caa53aadeff92477636430 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10579-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> COLCHICINE"@fr;
  dct:identifier "IAM_10579";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636432;
  r:natureDuRisque "Risque d’addition des effets indésirables neuromusculaires et augmentation de la toxicité de la colchicine avec risque de surdosage par inhibition de son élimination par la ciclosporine, notamment en cas d’insuffisance rénale préexistante."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636438, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636432 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636433 .

_:807f36cf91fe4e8caa53aadeff92477636433 rdf:first _:807f36cf91fe4e8caa53aadeff92477636434;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636435 .

_:807f36cf91fe4e8caa53aadeff92477636434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477636435 rdf:first _:807f36cf91fe4e8caa53aadeff92477636436;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477636438 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10580-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> DABIGATRAN"@fr;
  dct:identifier "IAM_10580";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636440;
  r:natureDuRisque "Augmentation de plus du double des concentrations plasmatiques de dabigatran, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636446, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636440 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636441 .

_:807f36cf91fe4e8caa53aadeff92477636441 rdf:first _:807f36cf91fe4e8caa53aadeff92477636442;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636443 .

_:807f36cf91fe4e8caa53aadeff92477636442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477636443 rdf:first _:807f36cf91fe4e8caa53aadeff92477636444;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff92477636446 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10581-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> DANAZOL"@fr;
  dct:identifier "IAM_10581";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636448;
  r:natureDuRisque "Augmentation des concentrations sanguines de ciclosporine par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636454, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636448 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636449 .

_:807f36cf91fe4e8caa53aadeff92477636449 rdf:first _:807f36cf91fe4e8caa53aadeff92477636450;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636451 .

_:807f36cf91fe4e8caa53aadeff92477636450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477636451 rdf:first _:807f36cf91fe4e8caa53aadeff92477636452;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:807f36cf91fe4e8caa53aadeff92477636454 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10582-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS)"@fr;
  dct:identifier "IAM_10582";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636456;
  r:natureDuRisque "Hyperkaliémie potentiellement létale, surtout lors d'une insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636462, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636456 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636457 .

_:807f36cf91fe4e8caa53aadeff92477636457 rdf:first _:807f36cf91fe4e8caa53aadeff92477636458;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636459 .

_:807f36cf91fe4e8caa53aadeff92477636458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477636459 rdf:first _:807f36cf91fe4e8caa53aadeff92477636460;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477636462 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10583-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> DIURÉTIQUES HYPOKALIÉMIANTS"@fr;
  dct:identifier "IAM_10583";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636464;
  r:natureDuRisque "Risque d'augmentation de la créatininémie sans modification des concentrations sanguines de ciclosporine, même en l'absence de déplétion hydrosodée. Egalement, risque d'hyperuricémie et de complications comme la goutte."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636470, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636464 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636465 .

_:807f36cf91fe4e8caa53aadeff92477636465 rdf:first _:807f36cf91fe4e8caa53aadeff92477636466;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636467 .

_:807f36cf91fe4e8caa53aadeff92477636466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10065 .

_:807f36cf91fe4e8caa53aadeff92477636467 rdf:first _:807f36cf91fe4e8caa53aadeff92477636468;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477636470 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10584-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> ÉRIBULINE"@fr;
  dct:identifier "IAM_10584";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636472;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’éribuline par la ciclosporine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636478, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636472 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636473 .

_:807f36cf91fe4e8caa53aadeff92477636473 rdf:first _:807f36cf91fe4e8caa53aadeff92477636474;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636475 .

_:807f36cf91fe4e8caa53aadeff92477636474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477636475 rdf:first _:807f36cf91fe4e8caa53aadeff92477636476;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10335 .

_:807f36cf91fe4e8caa53aadeff92477636478 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10585-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> EVEROLIMUS"@fr;
  dct:identifier "IAM_10585";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636480;
  r:natureDuRisque "Augmentation des concentrations sanguines de l’évérolimus par la ciclosporine. La néphrotoxicité de la ciclosporine est également augmentée lors de l’association."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines d’évérolimus, éventuellement adaptation de la posologie et contrôle de la fonction rénale, pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636486, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636480 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636481 .

_:807f36cf91fe4e8caa53aadeff92477636481 rdf:first _:807f36cf91fe4e8caa53aadeff92477636482;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636483 .

_:807f36cf91fe4e8caa53aadeff92477636482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477636483 rdf:first _:807f36cf91fe4e8caa53aadeff92477636484;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10363 .

_:807f36cf91fe4e8caa53aadeff92477636486 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10510-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10510";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636488;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la buspirone par diminution de son métabolisme hépatique par le diltiazem, avec augmentation de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la buspirone si nécessaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636494, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636488 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636489 .

_:807f36cf91fe4e8caa53aadeff92477636489 rdf:first _:807f36cf91fe4e8caa53aadeff92477636490;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636491 .

_:807f36cf91fe4e8caa53aadeff92477636490 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff92477636491 rdf:first _:807f36cf91fe4e8caa53aadeff92477636492;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477636494 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10587-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> FENOFIBRATE"@fr;
  dct:identifier "IAM_10587";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636496;
  r:natureDuRisque "Risque d'augmentation de la néphrotoxicité de la ciclosporine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique de la fonction rénale, pendant et après l'association."@fr;
  rdfs:comment "Des augmentations réversibles de la créatininémie ont été rapportées parmi les évènements indésirables rares du fénofibrate. De plus, diverses données bibliographiques indiquent une potentialisation du risque de néphrotoxicité chez des patients transplant"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636502, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636496 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636497 .

_:807f36cf91fe4e8caa53aadeff92477636497 rdf:first _:807f36cf91fe4e8caa53aadeff92477636498;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636499 .

_:807f36cf91fe4e8caa53aadeff92477636498 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477636499 rdf:first _:807f36cf91fe4e8caa53aadeff92477636500;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10371 .

_:807f36cf91fe4e8caa53aadeff92477636502 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10509-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> DIAZEPAM"@fr;
  dct:identifier "IAM_10509";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636504;
  r:natureDuRisque "Risque de majoration des effets indésirables de la buspirone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636510, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636504 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636505 .

_:807f36cf91fe4e8caa53aadeff92477636505 rdf:first _:807f36cf91fe4e8caa53aadeff92477636506;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636507 .

_:807f36cf91fe4e8caa53aadeff92477636506 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff92477636507 rdf:first _:807f36cf91fe4e8caa53aadeff92477636508;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10280 .

_:807f36cf91fe4e8caa53aadeff92477636510 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10882-1 a owl:Class;
  rdfs:label "EPLERENONE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10882";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636512;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de l’éplérénone par l'inhibiteur et de ses effets indésirables, notamment l’hyperkaliémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636518, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636512 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636513 .

_:807f36cf91fe4e8caa53aadeff92477636513 rdf:first _:807f36cf91fe4e8caa53aadeff92477636514;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636515 .

_:807f36cf91fe4e8caa53aadeff92477636514 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477636515 rdf:first _:807f36cf91fe4e8caa53aadeff92477636516;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10329 .

_:807f36cf91fe4e8caa53aadeff92477636518 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10883-1 a owl:Class;
  rdfs:label "ERGOTAMINE <-> MACROLIDES (SAUF SPIRAMYCINE)"@fr;
  dct:identifier "IAM_10883";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636520;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (diminution de l'élimination hépatique de l'ergotamine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636526, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636520 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636521 .

_:807f36cf91fe4e8caa53aadeff92477636521 rdf:first _:807f36cf91fe4e8caa53aadeff92477636522;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636523 .

_:807f36cf91fe4e8caa53aadeff92477636522 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10107 .

_:807f36cf91fe4e8caa53aadeff92477636523 rdf:first _:807f36cf91fe4e8caa53aadeff92477636524;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:807f36cf91fe4e8caa53aadeff92477636526 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10884-1 a owl:Class;
  rdfs:label "ERGOTAMINE <-> OXPRENOLOL"@fr;
  dct:identifier "IAM_10884";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636528;
  r:natureDuRisque "Ergotisme : quelques cas de spasme artériel avec ischémie des extrémités ont été observés (addition d'effets vasculaires)."@fr;
  r:conduiteATenir "Surveillance clinique renforcée, en particulier pendant les premières semaines de l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636534, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636528 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636529 .

_:807f36cf91fe4e8caa53aadeff92477636529 rdf:first _:807f36cf91fe4e8caa53aadeff92477636530;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636531 .

_:807f36cf91fe4e8caa53aadeff92477636530 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:807f36cf91fe4e8caa53aadeff92477636531 rdf:first _:807f36cf91fe4e8caa53aadeff92477636532;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10678 .

_:807f36cf91fe4e8caa53aadeff92477636534 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10885-1 a owl:Class;
  rdfs:label "ERGOTAMINE <-> PROPRANOLOL"@fr;
  dct:identifier "IAM_10885";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636536;
  r:natureDuRisque "Ergotisme : quelques cas de spasme artériel avec ischémie des extrémités ont été observés (addition d'effets vasculaires)."@fr;
  r:conduiteATenir "Surveillance clinique renforcée, en particulier pendant les premières semaines de l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636542, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636536 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636537 .

_:807f36cf91fe4e8caa53aadeff92477636537 rdf:first _:807f36cf91fe4e8caa53aadeff92477636538;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636539 .

_:807f36cf91fe4e8caa53aadeff92477636538 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:807f36cf91fe4e8caa53aadeff92477636539 rdf:first _:807f36cf91fe4e8caa53aadeff92477636540;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10767 .

_:807f36cf91fe4e8caa53aadeff92477636542 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10886-1 a owl:Class;
  rdfs:label "ERGOTAMINE <-> QUINUPRISTINE"@fr;
  dct:identifier "IAM_10886";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636544;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636550, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636544 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636545 .

_:807f36cf91fe4e8caa53aadeff92477636545 rdf:first _:807f36cf91fe4e8caa53aadeff92477636546;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636547 .

_:807f36cf91fe4e8caa53aadeff92477636546 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:807f36cf91fe4e8caa53aadeff92477636547 rdf:first _:807f36cf91fe4e8caa53aadeff92477636548;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10778 .

_:807f36cf91fe4e8caa53aadeff92477636550 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10887-1 a owl:Class;
  rdfs:label "ERGOTAMINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10887";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636552;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition de l’élimination hépatique de l'alcaloïde de l’ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636558, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636552 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636553 .

_:807f36cf91fe4e8caa53aadeff92477636553 rdf:first _:807f36cf91fe4e8caa53aadeff92477636554;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636555 .

_:807f36cf91fe4e8caa53aadeff92477636554 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:807f36cf91fe4e8caa53aadeff92477636555 rdf:first _:807f36cf91fe4e8caa53aadeff92477636556;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477636558 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10224-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> IDÉLALISIB"@fr;
  dct:identifier "IAM_10224";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636560;
  r:natureDuRisque "Diminution des concentrations plasmatiques d’idélalisib par augmentation de son métabolisme hépatique par l'anticonvulsivant inducteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636566, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636560 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636561 .

_:807f36cf91fe4e8caa53aadeff92477636561 rdf:first _:807f36cf91fe4e8caa53aadeff92477636562;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636563 .

_:807f36cf91fe4e8caa53aadeff92477636562 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636563 rdf:first _:807f36cf91fe4e8caa53aadeff92477636564;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10444 .

_:807f36cf91fe4e8caa53aadeff92477636566 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10225-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10225";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636568;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de baisse de l'efficacité de l'inhibiteur de protéases par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636574, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636568 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636569 .

_:807f36cf91fe4e8caa53aadeff92477636569 rdf:first _:807f36cf91fe4e8caa53aadeff92477636570;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636571 .

_:807f36cf91fe4e8caa53aadeff92477636570 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636571 rdf:first _:807f36cf91fe4e8caa53aadeff92477636572;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477636574 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10226-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS"@fr;
  dct:identifier "IAM_10226";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636576;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l’efficacité de l’inhibiteur de tyrosine kinase, par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636582, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636576 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636577 .

_:807f36cf91fe4e8caa53aadeff92477636577 rdf:first _:807f36cf91fe4e8caa53aadeff92477636578;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636579 .

_:807f36cf91fe4e8caa53aadeff92477636578 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636579 rdf:first _:807f36cf91fe4e8caa53aadeff92477636580;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:807f36cf91fe4e8caa53aadeff92477636582 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10204-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10204";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636584;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, renforcer la surveillance clinique et, le cas échéant, biologique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636590, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636584 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636585 .

_:807f36cf91fe4e8caa53aadeff92477636585 rdf:first _:807f36cf91fe4e8caa53aadeff92477636586;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636587 .

_:807f36cf91fe4e8caa53aadeff92477636586 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477636587 rdf:first _:807f36cf91fe4e8caa53aadeff92477636588;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477636590 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10586-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> EZETIMIBE"@fr;
  dct:identifier "IAM_10586";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636592;
  r:natureDuRisque "D’une part, risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par augmentation des concentrations d’ézétimibe ; d’autre part, possible augmentation des concentrations de ciclosporine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636598, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636592 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636593 .

_:807f36cf91fe4e8caa53aadeff92477636593 rdf:first _:807f36cf91fe4e8caa53aadeff92477636594;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636595 .

_:807f36cf91fe4e8caa53aadeff92477636594 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477636595 rdf:first _:807f36cf91fe4e8caa53aadeff92477636596;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10365 .

_:807f36cf91fe4e8caa53aadeff92477636598 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10409-1 a owl:Class;
  rdfs:label "AUTRES CORTICOÏDES, NOTAMMENT INHALÉS <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10409";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636600;
  r:natureDuRisque "En cas d’utilisation prolongée par voie orale ou inhalée : augmentation des concentrations plasmatiques du corticoïde par diminution de son métabolisme hépatique par l’inhibiteur de protéases, avec risque d’apparition d’un syndrome cushingoïde voire d’une"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636606, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636600 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636601 .

_:807f36cf91fe4e8caa53aadeff92477636601 rdf:first _:807f36cf91fe4e8caa53aadeff92477636602;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636603 .

_:807f36cf91fe4e8caa53aadeff92477636602 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10047 .

_:807f36cf91fe4e8caa53aadeff92477636603 rdf:first _:807f36cf91fe4e8caa53aadeff92477636604;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477636606 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11231-1 a owl:Class;
  rdfs:label "LERCANIDIPINE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_11231";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636608;
  r:natureDuRisque "Risque majoré d'effets indésirables, notamment d'oedèmes, par diminution du métabolisme intestinal de la dihydropyridine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636614, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636608 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636609 .

_:807f36cf91fe4e8caa53aadeff92477636609 rdf:first _:807f36cf91fe4e8caa53aadeff92477636610;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636611 .

_:807f36cf91fe4e8caa53aadeff92477636610 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477636611 rdf:first _:807f36cf91fe4e8caa53aadeff92477636612;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10514 .

_:807f36cf91fe4e8caa53aadeff92477636614 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11232-1 a owl:Class;
  rdfs:label "LEVODOPA <-> METHYLDOPA"@fr;
  dct:identifier "IAM_11232";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636616;
  r:natureDuRisque "Augmentation des effets de la lévodopa mais également de ses effets indésirables. Majoration de l'effet antihypertenseur de la méthyldopa."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement diminution des doses de lévodopa."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636622, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636616 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636617 .

_:807f36cf91fe4e8caa53aadeff92477636617 rdf:first _:807f36cf91fe4e8caa53aadeff92477636618;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636619 .

_:807f36cf91fe4e8caa53aadeff92477636618 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:807f36cf91fe4e8caa53aadeff92477636619 rdf:first _:807f36cf91fe4e8caa53aadeff92477636620;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10572 .

_:807f36cf91fe4e8caa53aadeff92477636622 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11233-1 a owl:Class;
  rdfs:label "LEVODOPA <-> NEUROLEPTIQUES ANTIÉMÉTIQUES"@fr;
  dct:identifier "IAM_11233";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636624;
  r:natureDuRisque "Antagonisme réciproque entre la lévodopa et le neuroleptique."@fr;
  r:conduiteATenir "Utiliser un antiémétique dénué d'effets extrapyramidaux."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636630, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636624 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636625 .

_:807f36cf91fe4e8caa53aadeff92477636625 rdf:first _:807f36cf91fe4e8caa53aadeff92477636626;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636627 .

_:807f36cf91fe4e8caa53aadeff92477636626 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff92477636627 rdf:first _:807f36cf91fe4e8caa53aadeff92477636628;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:807f36cf91fe4e8caa53aadeff92477636630 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11234-1 a owl:Class;
  rdfs:label "LEVODOPA <-> NEUROLEPTIQUES ANTIPSYCHOTIQUES (SAUF CLOZAPINE)"@fr;
  dct:identifier "IAM_11234";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636632;
  r:natureDuRisque "Antagonisme réciproque de la lévodopa et des neuroleptiques."@fr;
  r:conduiteATenir "Chez le patient parkinsonien, utiliser les doses minimales efficaces de chacun des deux médicaments."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636638, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636632 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636633 .

_:807f36cf91fe4e8caa53aadeff92477636633 rdf:first _:807f36cf91fe4e8caa53aadeff92477636634;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636635 .

_:807f36cf91fe4e8caa53aadeff92477636634 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10125 .

_:807f36cf91fe4e8caa53aadeff92477636635 rdf:first _:807f36cf91fe4e8caa53aadeff92477636636;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:807f36cf91fe4e8caa53aadeff92477636638 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11235-1 a owl:Class;
  rdfs:label "LEVODOPA <-> RESERPINE"@fr;
  dct:identifier "IAM_11235";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636640;
  r:natureDuRisque "Inhibition des effets de la lévodopa."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636646, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636640 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636641 .

_:807f36cf91fe4e8caa53aadeff92477636641 rdf:first _:807f36cf91fe4e8caa53aadeff92477636642;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636643 .

_:807f36cf91fe4e8caa53aadeff92477636642 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:807f36cf91fe4e8caa53aadeff92477636643 rdf:first _:807f36cf91fe4e8caa53aadeff92477636644;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10792 .

_:807f36cf91fe4e8caa53aadeff92477636646 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10303-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10303";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636648;
  r:natureDuRisque "Risque d’augmentation de la toxicité du méthotrexate par diminution de son élimination."@fr;
  r:conduiteATenir """Association déconseillée :
- avec le méthotrexate aux doses > 20 mg / semaine

A prendre en compte :
- pour des doses inférieures"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636654, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636648 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636649 .

_:807f36cf91fe4e8caa53aadeff92477636649 rdf:first _:807f36cf91fe4e8caa53aadeff92477636650;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636651 .

_:807f36cf91fe4e8caa53aadeff92477636650 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477636651 rdf:first _:807f36cf91fe4e8caa53aadeff92477636652;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477636654 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10403-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10403";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636656;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d'hypocholestérolémiant. Si l'objectif thérapeutique n'est pas atteint, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636662, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636656 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636657 .

_:807f36cf91fe4e8caa53aadeff92477636657 rdf:first _:807f36cf91fe4e8caa53aadeff92477636658;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636659 .

_:807f36cf91fe4e8caa53aadeff92477636658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477636659 rdf:first _:807f36cf91fe4e8caa53aadeff92477636660;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477636662 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10404-1 a owl:Class;
  rdfs:label "ATOVAQUONE <-> EFAVIRENZ"@fr;
  dct:identifier "IAM_10404";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636664;
  r:natureDuRisque "Diminution des concentrations plasmatiques d'atovaquone par l'inducteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636670, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636664 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636665 .

_:807f36cf91fe4e8caa53aadeff92477636665 rdf:first _:807f36cf91fe4e8caa53aadeff92477636666;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636667 .

_:807f36cf91fe4e8caa53aadeff92477636666 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10090 .

_:807f36cf91fe4e8caa53aadeff92477636667 rdf:first _:807f36cf91fe4e8caa53aadeff92477636668;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636668 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477636670 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10405-1 a owl:Class;
  rdfs:label "ATOVAQUONE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10405";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636672;
  r:natureDuRisque "Diminution, éventuellement très importante, des concentrations plasmatiques de l’atovaquone par augmentation de son métabolisme."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636678, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636672 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636673 .

_:807f36cf91fe4e8caa53aadeff92477636673 rdf:first _:807f36cf91fe4e8caa53aadeff92477636674;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636675 .

_:807f36cf91fe4e8caa53aadeff92477636674 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477636675 rdf:first _:807f36cf91fe4e8caa53aadeff92477636676;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636676 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10090 .

_:807f36cf91fe4e8caa53aadeff92477636678 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10577-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10577";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636680;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation des concentrations sanguines de ciclosporine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636686, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636680 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636681 .

_:807f36cf91fe4e8caa53aadeff92477636681 rdf:first _:807f36cf91fe4e8caa53aadeff92477636682;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636683 .

_:807f36cf91fe4e8caa53aadeff92477636682 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477636683 rdf:first _:807f36cf91fe4e8caa53aadeff92477636684;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636684 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477636686 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10407-1 a owl:Class;
  rdfs:label "ATOVAQUONE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10407";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636688;
  r:natureDuRisque "Diminution des concentrations plasmatiques d'atovaquone par l'inducteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636694, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636688 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636689 .

_:807f36cf91fe4e8caa53aadeff92477636689 rdf:first _:807f36cf91fe4e8caa53aadeff92477636690;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636691 .

_:807f36cf91fe4e8caa53aadeff92477636690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10090 .

_:807f36cf91fe4e8caa53aadeff92477636691 rdf:first _:807f36cf91fe4e8caa53aadeff92477636692;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636692 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477636694 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10228-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> LÉDIPASVIR"@fr;
  dct:identifier "IAM_10228";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636696;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques du lédipasvir par augmentation de son métabolisme hépatique par l'anticonvulsivant inducteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636702, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636696 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636697 .

_:807f36cf91fe4e8caa53aadeff92477636697 rdf:first _:807f36cf91fe4e8caa53aadeff92477636698;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636699 .

_:807f36cf91fe4e8caa53aadeff92477636698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477636699 rdf:first _:807f36cf91fe4e8caa53aadeff92477636700;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636700 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:807f36cf91fe4e8caa53aadeff92477636702 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10410-1 a owl:Class;
  rdfs:label "AUTRES CORTICOÏDES, NOTAMMENT INHALÉS <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10410";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636704;
  r:natureDuRisque "En cas d’utilisation prolongée par voie orale ou inhalée : augmentation des concentrations plasmatiques du corticoïde par diminution de son métabolisme hépatique par l’itraconazole, avec risque d’apparition d’un syndrome cushingoïde voire d’une insuffisan"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636710, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636704 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636705 .

_:807f36cf91fe4e8caa53aadeff92477636705 rdf:first _:807f36cf91fe4e8caa53aadeff92477636706;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636707 .

_:807f36cf91fe4e8caa53aadeff92477636706 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10047 .

_:807f36cf91fe4e8caa53aadeff92477636707 rdf:first _:807f36cf91fe4e8caa53aadeff92477636708;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636708 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477636710 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10411-1 a owl:Class;
  rdfs:label "AUTRES CORTICOÏDES, NOTAMMENT INHALÉS <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10411";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636712;
  r:natureDuRisque "En cas d’utilisation prolongée par voie orale ou inhalée : augmentation des concentrations plasmatiques du corticoïde par diminution de son métabolisme hépatique par le kétoconazole, avec risque d’apparition d’un syndrome cushingoïde voire d’une insuffisa"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636718, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636712 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636713 .

_:807f36cf91fe4e8caa53aadeff92477636713 rdf:first _:807f36cf91fe4e8caa53aadeff92477636714;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636715 .

_:807f36cf91fe4e8caa53aadeff92477636714 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10047 .

_:807f36cf91fe4e8caa53aadeff92477636715 rdf:first _:807f36cf91fe4e8caa53aadeff92477636716;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636716 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477636718 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10500-1 a owl:Class;
  rdfs:label "BUPROPION <-> FLECAINIDE"@fr;
  dct:identifier "IAM_10500";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636720;
  r:natureDuRisque "Risque d'augmentation des effets indésirables du flécaïnide par diminution de son métabolisme hépatique par le bupropion."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du flécaïnide pendant le traitement par le bupropion."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636726, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636720 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636721 .

_:807f36cf91fe4e8caa53aadeff92477636721 rdf:first _:807f36cf91fe4e8caa53aadeff92477636722;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636723 .

_:807f36cf91fe4e8caa53aadeff92477636722 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477636723 rdf:first _:807f36cf91fe4e8caa53aadeff92477636724;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636724 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:807f36cf91fe4e8caa53aadeff92477636726 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10503-1 a owl:Class;
  rdfs:label "BUPROPION <-> METOPROLOL"@fr;
  dct:identifier "IAM_10503";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636728;
  r:natureDuRisque "Avec le métoprolol utilisé dans l'insuffisance cardiaque : risque d'augmentation des effets indésirables du métoprolol par diminution de son métabolisme hépatique par le bupropion."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du métoprolol pendant le traitement par le bupropion."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636734, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636728 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636729 .

_:807f36cf91fe4e8caa53aadeff92477636729 rdf:first _:807f36cf91fe4e8caa53aadeff92477636730;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636731 .

_:807f36cf91fe4e8caa53aadeff92477636730 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477636731 rdf:first _:807f36cf91fe4e8caa53aadeff92477636732;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636732 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477636734 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10504-1 a owl:Class;
  rdfs:label "BUPROPION <-> NORTRIPTYLINE"@fr;
  dct:identifier "IAM_10504";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636736;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la nortriptyline par diminution de son métabolisme hépatique par le bupropion."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la nortriptyline pendant le traitement par le bupropion."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636742, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636736 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636737 .

_:807f36cf91fe4e8caa53aadeff92477636737 rdf:first _:807f36cf91fe4e8caa53aadeff92477636738;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636739 .

_:807f36cf91fe4e8caa53aadeff92477636738 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477636739 rdf:first _:807f36cf91fe4e8caa53aadeff92477636740;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636740 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10652 .

_:807f36cf91fe4e8caa53aadeff92477636742 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10502-1 a owl:Class;
  rdfs:label "BUPROPION <-> MEQUITAZINE"@fr;
  dct:identifier "IAM_10502";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636744;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méquitazine, par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636750, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636744 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636745 .

_:807f36cf91fe4e8caa53aadeff92477636745 rdf:first _:807f36cf91fe4e8caa53aadeff92477636746;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636747 .

_:807f36cf91fe4e8caa53aadeff92477636746 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477636747 rdf:first _:807f36cf91fe4e8caa53aadeff92477636748;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636748 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10561 .

_:807f36cf91fe4e8caa53aadeff92477636750 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10505-1 a owl:Class;
  rdfs:label "BUPROPION <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10505";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636752;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la propafénone par diminution de son métabolisme hépatique par le bupropion."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la propafénone pendant le traitement par le bupropion."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636758, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636752 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636753 .

_:807f36cf91fe4e8caa53aadeff92477636753 rdf:first _:807f36cf91fe4e8caa53aadeff92477636754;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636755 .

_:807f36cf91fe4e8caa53aadeff92477636754 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477636755 rdf:first _:807f36cf91fe4e8caa53aadeff92477636756;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636756 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477636758 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10506-1 a owl:Class;
  rdfs:label "BUPROPION <-> TAMOXIFENE"@fr;
  dct:identifier "IAM_10506";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636760;
  r:natureDuRisque "Risque de baisse de l'efficacité du tamoxifène, par inhibition de la formation de son métabolite actif par la terbinafine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636766, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636760 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636761 .

_:807f36cf91fe4e8caa53aadeff92477636761 rdf:first _:807f36cf91fe4e8caa53aadeff92477636762;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636763 .

_:807f36cf91fe4e8caa53aadeff92477636762 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477636763 rdf:first _:807f36cf91fe4e8caa53aadeff92477636764;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636764 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:807f36cf91fe4e8caa53aadeff92477636766 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10507-1 a owl:Class;
  rdfs:label "BUPROPION <-> TRAMADOL"@fr;
  dct:identifier "IAM_10507";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636768;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du tramadol par diminution de son métabolisme hépatique par le bupropion. De plus, risque de convulsions par addition des effets des deux médicaments."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636774, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636768 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636769 .

_:807f36cf91fe4e8caa53aadeff92477636769 rdf:first _:807f36cf91fe4e8caa53aadeff92477636770;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636771 .

_:807f36cf91fe4e8caa53aadeff92477636770 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477636771 rdf:first _:807f36cf91fe4e8caa53aadeff92477636772;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636772 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:807f36cf91fe4e8caa53aadeff92477636774 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10508-1 a owl:Class;
  rdfs:label "BUPROPION <-> VÉMURAFÉNIB"@fr;
  dct:identifier "IAM_10508";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636776;
  r:natureDuRisque "Risque de diminution des concentrations du bupropion, avec augmentation de son métabolite actif et toxicité majorée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636782, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636776 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636777 .

_:807f36cf91fe4e8caa53aadeff92477636777 rdf:first _:807f36cf91fe4e8caa53aadeff92477636778;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636779 .

_:807f36cf91fe4e8caa53aadeff92477636778 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477636779 rdf:first _:807f36cf91fe4e8caa53aadeff92477636780;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636780 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10978 .

_:807f36cf91fe4e8caa53aadeff92477636782 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10406-1 a owl:Class;
  rdfs:label "ATOVAQUONE <-> RIFABUTINE"@fr;
  dct:identifier "IAM_10406";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636784;
  r:natureDuRisque "Diminution modérée des concentrations plasmatiques d'atovaquone par l'inducteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636790, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636784 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636785 .

_:807f36cf91fe4e8caa53aadeff92477636785 rdf:first _:807f36cf91fe4e8caa53aadeff92477636786;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636787 .

_:807f36cf91fe4e8caa53aadeff92477636786 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10090 .

_:807f36cf91fe4e8caa53aadeff92477636787 rdf:first _:807f36cf91fe4e8caa53aadeff92477636788;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636788 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff92477636790 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11263-1 a owl:Class;
  rdfs:label "MEQUITAZINE <-> TERBINAFINE"@fr;
  dct:identifier "IAM_11263";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636792;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méquitazine, par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636798, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636792 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636793 .

_:807f36cf91fe4e8caa53aadeff92477636793 rdf:first _:807f36cf91fe4e8caa53aadeff92477636794;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636795 .

_:807f36cf91fe4e8caa53aadeff92477636794 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10561 .

_:807f36cf91fe4e8caa53aadeff92477636795 rdf:first _:807f36cf91fe4e8caa53aadeff92477636796;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636796 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:807f36cf91fe4e8caa53aadeff92477636798 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10418-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS ABAISSANT LE SEUIL ÉPILEPTOGÈNE <-> MÉDICAMENTS ABAISSANT LE SEUIL ÉPILEPTOGÈNE"@fr;
  dct:identifier "IAM_10418";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636800;
  r:chapeau "L'utilisation conjointe de médicaments proconvulsivants, ou abaissant le seuil épileptogène, devra être soigneusement pesée, en raison de la sévérité du risque encouru. Ces médicaments sont représentés notamment par la plupart des antidépresseurs (imipram"@fr;
  r:natureDuRisque "Risque accru de convulsions."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636802, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10114 .

_:807f36cf91fe4e8caa53aadeff92477636802 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10420-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS ATROPINIQUES <-> MÉDICAMENTS ATROPINIQUES"@fr;
  dct:identifier "IAM_10420";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636804;
  r:natureDuRisque "Addition des effets indésirables atropiniques à type de rétention urinaire, constipation, sécheresse de la bouche…."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636806, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636804 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10115 .

_:807f36cf91fe4e8caa53aadeff92477636806 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10422-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS MÉTHÉMOGLOBINISANTS <-> MÉDICAMENTS MÉTHÉMOGLOBINISANTS"@fr;
  dct:identifier "IAM_10422";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636808;
  r:natureDuRisque "Risque d'addition des effets méthémoglobinisants."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636810, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10117 .

_:807f36cf91fe4e8caa53aadeff92477636810 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11258-1 a owl:Class;
  rdfs:label "MÉDICAMENTS MIXTES ADRÉNERGIQUES-SÉROTONINERGIQUES <-> ORLISTAT"@fr;
  dct:identifier "IAM_11258";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636812;
  r:natureDuRisque "Risque d'échec thérapeutique en cas de traitement concomitant par orlistat."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636818, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636812 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636813 .

_:807f36cf91fe4e8caa53aadeff92477636813 rdf:first _:807f36cf91fe4e8caa53aadeff92477636814;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636815 .

_:807f36cf91fe4e8caa53aadeff92477636814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10116 .

_:807f36cf91fe4e8caa53aadeff92477636815 rdf:first _:807f36cf91fe4e8caa53aadeff92477636816;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477636818 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11259-1 a owl:Class;
  rdfs:label "MÉDICAMENTS MIXTES ADRÉNERGIQUES-SÉROTONINERGIQUES <-> SYMPATHOMIMÉTIQUES ALPHA ET BÊTA (VOIE IM ET IV)"@fr;
  dct:identifier "IAM_11259";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636820;
  r:natureDuRisque "Hypertension paroxystique avec possibilité de troubles du rythme (inhibition de l'entrée du sympathomimétique dans la fibre sympathique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636826, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636820 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636821 .

_:807f36cf91fe4e8caa53aadeff92477636821 rdf:first _:807f36cf91fe4e8caa53aadeff92477636822;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636823 .

_:807f36cf91fe4e8caa53aadeff92477636822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10116 .

_:807f36cf91fe4e8caa53aadeff92477636823 rdf:first _:807f36cf91fe4e8caa53aadeff92477636824;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10149 .

_:807f36cf91fe4e8caa53aadeff92477636826 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10423-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS NÉPHROTOXIQUES <-> MÉDICAMENTS NÉPHROTOXIQUES"@fr;
  dct:identifier "IAM_10423";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636828;
  r:chapeau """L'utilisation conjointe de médicaments ayant une toxicité rénale propre augmente le risque de néphrotoxicité. Si une telle association est nécessaire, il faut renforcer la surveillance biologique rénale.
Les médicaments concernés sont représentés notammen"""@fr;
  r:natureDuRisque "Risque de majoration de la néphrotoxicité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636830, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636828 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10118 .

_:807f36cf91fe4e8caa53aadeff92477636830 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10424-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS OTOTOXIQUES <-> MÉDICAMENTS OTOTOXIQUES"@fr;
  dct:identifier "IAM_10424";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636832;
  r:natureDuRisque "Majoration de l'ototoxicité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636834, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10119 .

_:807f36cf91fe4e8caa53aadeff92477636834 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10079-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> MÉDICAMENTS SÉDATIFS"@fr;
  dct:identifier "IAM_10079";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636836;
  r:natureDuRisque "Majoration par l'alcool de l'effet sédatif de ces substances. L'altération de la vigilance peut rendre dangereuses la conduite de véhicules et l'utilisation de machines."@fr;
  r:conduiteATenir "Eviter la prise de boissons alcoolisées et de médicaments contenant de l'alcool."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636842, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636836 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636837 .

_:807f36cf91fe4e8caa53aadeff92477636837 rdf:first _:807f36cf91fe4e8caa53aadeff92477636838;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636839 .

_:807f36cf91fe4e8caa53aadeff92477636838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10120 .

_:807f36cf91fe4e8caa53aadeff92477636839 rdf:first _:807f36cf91fe4e8caa53aadeff92477636840;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:807f36cf91fe4e8caa53aadeff92477636842 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10425-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS SÉDATIFS <-> MÉDICAMENTS SÉDATIFS"@fr;
  dct:identifier "IAM_10425";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636844;
  r:natureDuRisque """Majoration de la dépression centrale.
L'altération de la vigilance peut rendre dangereuses la conduite de véhicules et l'utilisation de machines."""@fr;
  r:conduiteATenir """Association déconseillée:
- avec l'oxybate de sodium.

A prendre en compte:
- avec les autres médicaments sédatifs."""@fr;
  rdfs:comment "A"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636846, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636844 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10120 .

_:807f36cf91fe4e8caa53aadeff92477636846 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11218-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11218";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636848;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité des deux anti-infectieux (induction enzymatique par la rifampicine et diminution de l'absorption intestinale par l’azolé antifongique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636854, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636848 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636849 .

_:807f36cf91fe4e8caa53aadeff92477636849 rdf:first _:807f36cf91fe4e8caa53aadeff92477636850;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636851 .

_:807f36cf91fe4e8caa53aadeff92477636850 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477636851 rdf:first _:807f36cf91fe4e8caa53aadeff92477636852;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636852 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477636854 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11262-1 a owl:Class;
  rdfs:label "MEQUITAZINE <-> PAROXETINE"@fr;
  dct:identifier "IAM_11262";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636856;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méquitazine, par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636862, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636856 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636857 .

_:807f36cf91fe4e8caa53aadeff92477636857 rdf:first _:807f36cf91fe4e8caa53aadeff92477636858;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636859 .

_:807f36cf91fe4e8caa53aadeff92477636858 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10561 .

_:807f36cf91fe4e8caa53aadeff92477636859 rdf:first _:807f36cf91fe4e8caa53aadeff92477636860;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636860 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:807f36cf91fe4e8caa53aadeff92477636862 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10417-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS À L'ORIGINE D'UN SYNDROME SÉROTONINERGIQUE <-> MÉDICAMENTS À L'ORIGINE D'UN SYNDROME SÉROTONINERGIQUE"@fr;
  dct:identifier "IAM_10417";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636864;
  r:natureDuRisque "Risque d'apparition ou de majoration d'un syndrome sérotoninergique en cas d'association de ces médicaments."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636866, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10121 .

_:807f36cf91fe4e8caa53aadeff92477636866 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10080-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> METFORMINE"@fr;
  dct:identifier "IAM_10080";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636868;
  r:natureDuRisque "Risque majoré d'acidose lactique lors d'intoxication alcoolique aiguë, particulièrement en cas de jeûne ou dénutrition, ou bien d'insuffisance hépatocellulaire."@fr;
  r:conduiteATenir "Eviter la prise de boissons alcoolisées et de médicaments contenant de l'alcool."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636874, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636868 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636869 .

_:807f36cf91fe4e8caa53aadeff92477636869 rdf:first _:807f36cf91fe4e8caa53aadeff92477636870;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636871 .

_:807f36cf91fe4e8caa53aadeff92477636870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10566 .

_:807f36cf91fe4e8caa53aadeff92477636871 rdf:first _:807f36cf91fe4e8caa53aadeff92477636872;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:807f36cf91fe4e8caa53aadeff92477636874 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11264-1 a owl:Class;
  rdfs:label "METFORMINE <-> PRODUITS DE CONTRASTE IODÉS"@fr;
  dct:identifier "IAM_11264";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636876;
  r:natureDuRisque "Acidose lactique liée aux concentrations élevées de metformine en rapport avec l'insuffisance rénale fonctionnelle induite par l'examen radiologique."@fr;
  r:conduiteATenir "Le traitement par la metformine doit être suspendu au moment de l'examen radiologique pour n'être repris que 2 jours après."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636882, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636876 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636877 .

_:807f36cf91fe4e8caa53aadeff92477636877 rdf:first _:807f36cf91fe4e8caa53aadeff92477636878;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636879 .

_:807f36cf91fe4e8caa53aadeff92477636878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10133 .

_:807f36cf91fe4e8caa53aadeff92477636879 rdf:first _:807f36cf91fe4e8caa53aadeff92477636880;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10566 .

_:807f36cf91fe4e8caa53aadeff92477636882 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11265-1 a owl:Class;
  rdfs:label "METHADONE <-> MORPHINIQUES AGONISTES-ANTAGONISTES"@fr;
  dct:identifier "IAM_11265";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636884;
  r:natureDuRisque "Diminution de l'effet de la méthadone par blocage compétitif des récepteurs."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636890, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636884 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636885 .

_:807f36cf91fe4e8caa53aadeff92477636885 rdf:first _:807f36cf91fe4e8caa53aadeff92477636886;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636887 .

_:807f36cf91fe4e8caa53aadeff92477636886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10110 .

_:807f36cf91fe4e8caa53aadeff92477636887 rdf:first _:807f36cf91fe4e8caa53aadeff92477636888;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff92477636890 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11266-1 a owl:Class;
  rdfs:label "METHADONE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11266";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636892;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication :
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine
et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636898, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636892 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636893 .

_:807f36cf91fe4e8caa53aadeff92477636893 rdf:first _:807f36cf91fe4e8caa53aadeff92477636894;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636895 .

_:807f36cf91fe4e8caa53aadeff92477636894 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477636895 rdf:first _:807f36cf91fe4e8caa53aadeff92477636896;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff92477636898 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11267-1 a owl:Class;
  rdfs:label "METHENAMINE <-> SULFAMETHIZOL"@fr;
  dct:identifier "IAM_11267";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636900;
  r:natureDuRisque "Précipitation cristalline dans les voies urinaires (favorisée par l'acidification des urines)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636906, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636900 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636901 .

_:807f36cf91fe4e8caa53aadeff92477636901 rdf:first _:807f36cf91fe4e8caa53aadeff92477636902;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636903 .

_:807f36cf91fe4e8caa53aadeff92477636902 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10568 .

_:807f36cf91fe4e8caa53aadeff92477636903 rdf:first _:807f36cf91fe4e8caa53aadeff92477636904;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10870 .

_:807f36cf91fe4e8caa53aadeff92477636906 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11268-1 a owl:Class;
  rdfs:label "METHOTREXATE <-> PÉNICILLINES"@fr;
  dct:identifier "IAM_11268";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636908;
  r:natureDuRisque "Augmentation des effets et de la toxicité hématologique du méthotrexate : inhibition de la sécrétion tubulaire rénale du méthotrexate par les pénicillines."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636914, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636908 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636909 .

_:807f36cf91fe4e8caa53aadeff92477636909 rdf:first _:807f36cf91fe4e8caa53aadeff92477636910;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636911 .

_:807f36cf91fe4e8caa53aadeff92477636910 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10138 .

_:807f36cf91fe4e8caa53aadeff92477636911 rdf:first _:807f36cf91fe4e8caa53aadeff92477636912;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477636914 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11269-1 a owl:Class;
  rdfs:label "METHOTREXATE <-> PROBENECIDE"@fr;
  dct:identifier "IAM_11269";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636916;
  r:natureDuRisque "Augmentation de la toxicité du méthotrexate : inhibition de la sécrétion tubulaire rénale du méthotrexate par le probénécide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636922, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636916 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636917 .

_:807f36cf91fe4e8caa53aadeff92477636917 rdf:first _:807f36cf91fe4e8caa53aadeff92477636918;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636919 .

_:807f36cf91fe4e8caa53aadeff92477636918 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477636919 rdf:first _:807f36cf91fe4e8caa53aadeff92477636920;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10758 .

_:807f36cf91fe4e8caa53aadeff92477636922 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11270-1 a owl:Class;
  rdfs:label "METHOTREXATE <-> SULFAMIDES ANTIBACTÉRIENS"@fr;
  dct:identifier "IAM_11270";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636924;
  r:natureDuRisque "Augmentation de la toxicité hématologique du méthotrexate."@fr;
  r:conduiteATenir "Dosage des concentrations de méthotrexate. Adapatation posologique si nécessaire pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636930, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636924 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636925 .

_:807f36cf91fe4e8caa53aadeff92477636925 rdf:first _:807f36cf91fe4e8caa53aadeff92477636926;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636927 .

_:807f36cf91fe4e8caa53aadeff92477636926 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10146 .

_:807f36cf91fe4e8caa53aadeff92477636927 rdf:first _:807f36cf91fe4e8caa53aadeff92477636928;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477636930 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11271-1 a owl:Class;
  rdfs:label "METHOTREXATE <-> TRIMETHOPRIME"@fr;
  dct:identifier "IAM_11271";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636932;
  r:natureDuRisque "Augmentation de la toxicité hématologique du méthotrexate (diminution de son excrétion rénale ainsi qu'inhibition de la dihydrofolate réductase)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636938, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636932 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636933 .

_:807f36cf91fe4e8caa53aadeff92477636933 rdf:first _:807f36cf91fe4e8caa53aadeff92477636934;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636935 .

_:807f36cf91fe4e8caa53aadeff92477636934 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477636935 rdf:first _:807f36cf91fe4e8caa53aadeff92477636936;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10955 .

_:807f36cf91fe4e8caa53aadeff92477636938 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11261-1 a owl:Class;
  rdfs:label "MEFLOQUINE <-> QUININE"@fr;
  dct:identifier "IAM_11261";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636940;
  r:natureDuRisque "Pour la quinine administrée par voie IV : risque majoré de survenue de crises épileptiques par addition des effets proconvulsivants."@fr;
  r:conduiteATenir "Respecter un délai minimum de 12 heures entre la fin de l'administration IV de quinine et le début de l'administration de méfloquine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636946, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636940 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636941 .

_:807f36cf91fe4e8caa53aadeff92477636941 rdf:first _:807f36cf91fe4e8caa53aadeff92477636942;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636943 .

_:807f36cf91fe4e8caa53aadeff92477636942 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10555 .

_:807f36cf91fe4e8caa53aadeff92477636943 rdf:first _:807f36cf91fe4e8caa53aadeff92477636944;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10777 .

_:807f36cf91fe4e8caa53aadeff92477636946 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11244-1 a owl:Class;
  rdfs:label "LITHIUM <-> ORLISTAT"@fr;
  dct:identifier "IAM_11244";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636948;
  r:natureDuRisque "Risque d'échec thérapeutique en cas de traitement concomitant par orlistat."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636954, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636948 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636949 .

_:807f36cf91fe4e8caa53aadeff92477636949 rdf:first _:807f36cf91fe4e8caa53aadeff92477636950;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636951 .

_:807f36cf91fe4e8caa53aadeff92477636950 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477636951 rdf:first _:807f36cf91fe4e8caa53aadeff92477636952;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477636954 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11321-1 a owl:Class;
  rdfs:label "MYCOPHENOLATE SODIQUE <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_11321";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636956;
  r:natureDuRisque "Risque de maladie vaccinale généralisée éventuellement mortelle."@fr;
  r:conduiteATenir "Et pendant les 3 mois suivant l'arrêt du traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636962, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636956 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636957 .

_:807f36cf91fe4e8caa53aadeff92477636957 rdf:first _:807f36cf91fe4e8caa53aadeff92477636958;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636959 .

_:807f36cf91fe4e8caa53aadeff92477636958 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477636959 rdf:first _:807f36cf91fe4e8caa53aadeff92477636960;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10610 .

_:807f36cf91fe4e8caa53aadeff92477636962 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11220-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11220";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636964;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l'hypocholestérolémiant)."@fr;
  r:conduiteATenir "Utiliser une statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636970, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636964 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636965 .

_:807f36cf91fe4e8caa53aadeff92477636965 rdf:first _:807f36cf91fe4e8caa53aadeff92477636966;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636967 .

_:807f36cf91fe4e8caa53aadeff92477636966 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477636967 rdf:first _:807f36cf91fe4e8caa53aadeff92477636968;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477636970 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11221-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_11221";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636972;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du ténofovir alafénamide par augmentation de son absorption."@fr;
  r:conduiteATenir "En cas de co-administration avec le kétoconazole, la dose de ténofovir alafénamide doit être limitée à 10 mg par jour."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636978, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636972 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636973 .

_:807f36cf91fe4e8caa53aadeff92477636973 rdf:first _:807f36cf91fe4e8caa53aadeff92477636974;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636975 .

_:807f36cf91fe4e8caa53aadeff92477636974 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477636975 rdf:first _:807f36cf91fe4e8caa53aadeff92477636976;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff92477636978 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11236-1 a owl:Class;
  rdfs:label "LEVODOPA <-> SPIRAMYCINE"@fr;
  dct:identifier "IAM_11236";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636980;
  r:natureDuRisque "En cas d'association avec la carbidopa : inhibition de l'absorption de la carbidopa avec diminution des concentrations plasmatiques de la lévodopa."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la lévodopa."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636986, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636980 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636981 .

_:807f36cf91fe4e8caa53aadeff92477636981 rdf:first _:807f36cf91fe4e8caa53aadeff92477636982;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636983 .

_:807f36cf91fe4e8caa53aadeff92477636982 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:807f36cf91fe4e8caa53aadeff92477636983 rdf:first _:807f36cf91fe4e8caa53aadeff92477636984;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10856 .

_:807f36cf91fe4e8caa53aadeff92477636986 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11237-1 a owl:Class;
  rdfs:label "LEVODOPA <-> TETRABENAZINE"@fr;
  dct:identifier "IAM_11237";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636988;
  r:natureDuRisque "Antagonisme réciproque entre la lévodopa et la tétrabénazine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477636994, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636988 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636989 .

_:807f36cf91fe4e8caa53aadeff92477636989 rdf:first _:807f36cf91fe4e8caa53aadeff92477636990;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636991 .

_:807f36cf91fe4e8caa53aadeff92477636990 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:807f36cf91fe4e8caa53aadeff92477636991 rdf:first _:807f36cf91fe4e8caa53aadeff92477636992;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477636992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10908 .

_:807f36cf91fe4e8caa53aadeff92477636994 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11238-1 a owl:Class;
  rdfs:label "LEVOFLOXACINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11238";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477636996;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Surveillance clinique et électrocardiographique pendant
l'association."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637002, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477636996 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477636997 .

_:807f36cf91fe4e8caa53aadeff92477636997 rdf:first _:807f36cf91fe4e8caa53aadeff92477636998;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477636999 .

_:807f36cf91fe4e8caa53aadeff92477636998 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477636999 rdf:first _:807f36cf91fe4e8caa53aadeff92477637000;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10518 .

_:807f36cf91fe4e8caa53aadeff92477637002 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11239-1 a owl:Class;
  rdfs:label "LINEZOLIDE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11239";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637004;
  r:natureDuRisque "Risque de diminution de l'efficacité du linézolide par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et augmentation éventuelle de la posologie du linézolide pendant le traitement par la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637010, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637004 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637005 .

_:807f36cf91fe4e8caa53aadeff92477637005 rdf:first _:807f36cf91fe4e8caa53aadeff92477637006;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637007 .

_:807f36cf91fe4e8caa53aadeff92477637006 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10526 .

_:807f36cf91fe4e8caa53aadeff92477637007 rdf:first _:807f36cf91fe4e8caa53aadeff92477637008;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477637010 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11240-1 a owl:Class;
  rdfs:label "LITHIUM <-> MANNITOL"@fr;
  dct:identifier "IAM_11240";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637012;
  r:natureDuRisque "Diminution de la lithémie avec risque de baisse de l’efficacité thérapeutique."@fr;
  r:conduiteATenir "Surveillance stricte de la lithémie et adaptation éventuelle de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637018, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637012 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637013 .

_:807f36cf91fe4e8caa53aadeff92477637013 rdf:first _:807f36cf91fe4e8caa53aadeff92477637014;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637015 .

_:807f36cf91fe4e8caa53aadeff92477637014 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477637015 rdf:first _:807f36cf91fe4e8caa53aadeff92477637016;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10549 .

_:807f36cf91fe4e8caa53aadeff92477637018 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11241-1 a owl:Class;
  rdfs:label "LITHIUM <-> METHYLDOPA"@fr;
  dct:identifier "IAM_11241";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637020;
  r:natureDuRisque "Augmentation de la lithémie pouvant atteindre des valeurs toxiques, avec signes de surdosage en lithium."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637026, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637020 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637021 .

_:807f36cf91fe4e8caa53aadeff92477637021 rdf:first _:807f36cf91fe4e8caa53aadeff92477637022;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637023 .

_:807f36cf91fe4e8caa53aadeff92477637022 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477637023 rdf:first _:807f36cf91fe4e8caa53aadeff92477637024;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10572 .

_:807f36cf91fe4e8caa53aadeff92477637026 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11254-1 a owl:Class;
  rdfs:label "MÉDICAMENTS À RISQUE LORS DU SEVRAGE TABAGIQUE <-> TRAITEMENTS DE SUBSTITUTION NICOTINIQUE"@fr;
  dct:identifier "IAM_11254";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637028;
  r:natureDuRisque "Risque de surdosage lors du remplacement du tabac par le traitement substitutif."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637034, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637028 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637029 .

_:807f36cf91fe4e8caa53aadeff92477637029 rdf:first _:807f36cf91fe4e8caa53aadeff92477637030;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637031 .

_:807f36cf91fe4e8caa53aadeff92477637030 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10123 .

_:807f36cf91fe4e8caa53aadeff92477637031 rdf:first _:807f36cf91fe4e8caa53aadeff92477637032;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10155 .

_:807f36cf91fe4e8caa53aadeff92477637034 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11243-1 a owl:Class;
  rdfs:label "LITHIUM <-> NEUROLEPTIQUES"@fr;
  dct:identifier "IAM_11243";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637036;
  r:natureDuRisque "Risque d’apparition de signes neuropsychiques évocateurs d’un syndrome malin des neuroleptiques ou d’une intoxication au lithium."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637042, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637036 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637037 .

_:807f36cf91fe4e8caa53aadeff92477637037 rdf:first _:807f36cf91fe4e8caa53aadeff92477637038;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637039 .

_:807f36cf91fe4e8caa53aadeff92477637038 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10124 .

_:807f36cf91fe4e8caa53aadeff92477637039 rdf:first _:807f36cf91fe4e8caa53aadeff92477637040;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477637042 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11255-1 a owl:Class;
  rdfs:label "MÉDICAMENTS ABAISSANT LA PRESSION ARTÉRIELLE <-> MÉDICAMENTS À L'ORIGINE D'UNE HYPOTENSION ORTHOSTATIQUE"@fr;
  dct:identifier "IAM_11255";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637044;
  r:natureDuRisque "Risque de majoration d’une hypotension, notamment orthostatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637050, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637044 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637045 .

_:807f36cf91fe4e8caa53aadeff92477637045 rdf:first _:807f36cf91fe4e8caa53aadeff92477637046;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637047 .

_:807f36cf91fe4e8caa53aadeff92477637046 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10113 .

_:807f36cf91fe4e8caa53aadeff92477637047 rdf:first _:807f36cf91fe4e8caa53aadeff92477637048;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10122 .

_:807f36cf91fe4e8caa53aadeff92477637050 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11245-1 a owl:Class;
  rdfs:label "LITHIUM <-> SODIUM (BICARBONATE DE)"@fr;
  dct:identifier "IAM_11245";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637052;
  r:natureDuRisque "Risque de baisse de l’efficacité du lithium par augmentation de son élimination rénale par les sels de sodium."@fr;
  r:conduiteATenir "Eviter les surcharges sodées et tenir compte de la présence de sodium dans certains médicaments comme les antiacides."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637058, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637052 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637053 .

_:807f36cf91fe4e8caa53aadeff92477637053 rdf:first _:807f36cf91fe4e8caa53aadeff92477637054;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637055 .

_:807f36cf91fe4e8caa53aadeff92477637054 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477637055 rdf:first _:807f36cf91fe4e8caa53aadeff92477637056;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10841 .

_:807f36cf91fe4e8caa53aadeff92477637058 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11246-1 a owl:Class;
  rdfs:label "LITHIUM <-> SODIUM (CHLORURE DE)"@fr;
  dct:identifier "IAM_11246";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637060;
  r:natureDuRisque "Risque de baisse de l’efficacité du lithium par augmentation de son élimination rénale par les sels de sodium."@fr;
  r:conduiteATenir "Eviter les surcharges sodées et tenir compte de la présence de sodium dans certains médicaments comme les antiacides."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637066, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637060 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637061 .

_:807f36cf91fe4e8caa53aadeff92477637061 rdf:first _:807f36cf91fe4e8caa53aadeff92477637062;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637063 .

_:807f36cf91fe4e8caa53aadeff92477637062 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477637063 rdf:first _:807f36cf91fe4e8caa53aadeff92477637064;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10842 .

_:807f36cf91fe4e8caa53aadeff92477637066 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11247-1 a owl:Class;
  rdfs:label "LITHIUM <-> THEOPHYLLINE"@fr;
  dct:identifier "IAM_11247";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637068;
  r:natureDuRisque "Diminution de la lithémie avec risque de baisse de l’efficacité thérapeutique."@fr;
  r:conduiteATenir "Surveillance stricte de la lithémie et adaptation éventuelle de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637074, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637068 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637069 .

_:807f36cf91fe4e8caa53aadeff92477637069 rdf:first _:807f36cf91fe4e8caa53aadeff92477637070;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637071 .

_:807f36cf91fe4e8caa53aadeff92477637070 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477637071 rdf:first _:807f36cf91fe4e8caa53aadeff92477637072;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10915 .

_:807f36cf91fe4e8caa53aadeff92477637074 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11248-1 a owl:Class;
  rdfs:label "LITHIUM <-> TOPIRAMATE"@fr;
  dct:identifier "IAM_11248";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637076;
  r:natureDuRisque "Pour des doses de topiramate >= 200 mg par jour : augmentation de la lithémie pouvant atteindre des valeurs toxiques, avec signes de surdosage en lithium."@fr;
  r:conduiteATenir "Surveillance clinique et biologique. Adaptation de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637082, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637076 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637077 .

_:807f36cf91fe4e8caa53aadeff92477637077 rdf:first _:807f36cf91fe4e8caa53aadeff92477637078;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637079 .

_:807f36cf91fe4e8caa53aadeff92477637078 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477637079 rdf:first _:807f36cf91fe4e8caa53aadeff92477637080;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10941 .

_:807f36cf91fe4e8caa53aadeff92477637082 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11249-1 a owl:Class;
  rdfs:label "LOMITAPIDE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11249";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637084;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques du lomitapide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637090, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637084 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637085 .

_:807f36cf91fe4e8caa53aadeff92477637085 rdf:first _:807f36cf91fe4e8caa53aadeff92477637086;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637087 .

_:807f36cf91fe4e8caa53aadeff92477637086 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10533 .

_:807f36cf91fe4e8caa53aadeff92477637087 rdf:first _:807f36cf91fe4e8caa53aadeff92477637088;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637090 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11250-1 a owl:Class;
  rdfs:label "LURASIDONE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11250";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637092;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la lurasidone par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637098, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637092 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637093 .

_:807f36cf91fe4e8caa53aadeff92477637093 rdf:first _:807f36cf91fe4e8caa53aadeff92477637094;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637095 .

_:807f36cf91fe4e8caa53aadeff92477637094 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10542 .

_:807f36cf91fe4e8caa53aadeff92477637095 rdf:first _:807f36cf91fe4e8caa53aadeff92477637096;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637098 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11251-1 a owl:Class;
  rdfs:label "LURASIDONE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_11251";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637100;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la lurasidone par diminution de son métabolisme par le pamplemousse."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637106, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637100 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637101 .

_:807f36cf91fe4e8caa53aadeff92477637101 rdf:first _:807f36cf91fe4e8caa53aadeff92477637102;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637103 .

_:807f36cf91fe4e8caa53aadeff92477637102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477637103 rdf:first _:807f36cf91fe4e8caa53aadeff92477637104;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10542 .

_:807f36cf91fe4e8caa53aadeff92477637106 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11252-1 a owl:Class;
  rdfs:label "MACITENTAN <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11252";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637108;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de macitentan par augmentation de son métabolisme par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637114, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637108 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637109 .

_:807f36cf91fe4e8caa53aadeff92477637109 rdf:first _:807f36cf91fe4e8caa53aadeff92477637110;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637111 .

_:807f36cf91fe4e8caa53aadeff92477637110 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10544 .

_:807f36cf91fe4e8caa53aadeff92477637111 rdf:first _:807f36cf91fe4e8caa53aadeff92477637112;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637114 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11253-1 a owl:Class;
  rdfs:label "MARAVIROC <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11253";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637116;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de maraviroc pouvant conduire à une perte de la réponse virologique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637122, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637116 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637117 .

_:807f36cf91fe4e8caa53aadeff92477637117 rdf:first _:807f36cf91fe4e8caa53aadeff92477637118;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637119 .

_:807f36cf91fe4e8caa53aadeff92477637118 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10551 .

_:807f36cf91fe4e8caa53aadeff92477637119 rdf:first _:807f36cf91fe4e8caa53aadeff92477637120;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637122 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11274-1 a owl:Class;
  rdfs:label "METOPROLOL <-> PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE)"@fr;
  dct:identifier "IAM_11274";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637124;
  r:natureDuRisque "Diminution des concentrations plasmatiques du métoprolol avec réduction de ses effets cliniques (augmentation de son métabolisme hépatique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637130, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637124 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637125 .

_:807f36cf91fe4e8caa53aadeff92477637125 rdf:first _:807f36cf91fe4e8caa53aadeff92477637126;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637127 .

_:807f36cf91fe4e8caa53aadeff92477637126 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477637127 rdf:first _:807f36cf91fe4e8caa53aadeff92477637128;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477637130 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11242-1 a owl:Class;
  rdfs:label "LITHIUM <-> METRONIDAZOLE"@fr;
  dct:identifier "IAM_11242";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637132;
  r:natureDuRisque "Augmentation de la lithémie pouvant atteindre des valeurs toxiques, avec signes de surdosage en lithium."@fr;
  r:conduiteATenir "Surveillance stricte de la lithémie et adaptation éventuelle de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637138, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637132 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637133 .

_:807f36cf91fe4e8caa53aadeff92477637133 rdf:first _:807f36cf91fe4e8caa53aadeff92477637134;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637135 .

_:807f36cf91fe4e8caa53aadeff92477637134 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477637135 rdf:first _:807f36cf91fe4e8caa53aadeff92477637136;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10580 .

_:807f36cf91fe4e8caa53aadeff92477637138 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11310-1 a owl:Class;
  rdfs:label "MIRABÉGRON <-> PROPAFENONE"@fr;
  dct:identifier "IAM_11310";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637140;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la propafénone par diminution de son métabolisme par le mirabégron."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de la propafénone pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637146, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637140 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637141 .

_:807f36cf91fe4e8caa53aadeff92477637141 rdf:first _:807f36cf91fe4e8caa53aadeff92477637142;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637143 .

_:807f36cf91fe4e8caa53aadeff92477637142 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10591 .

_:807f36cf91fe4e8caa53aadeff92477637143 rdf:first _:807f36cf91fe4e8caa53aadeff92477637144;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477637146 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11272-1 a owl:Class;
  rdfs:label "METOPROLOL <-> MIRABÉGRON"@fr;
  dct:identifier "IAM_11272";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637148;
  r:natureDuRisque "Avec le métoprolol utilisé dans l'insuffisance cardiaque, augmentation des concentrations plasmatiques du métoprolol par diminution de son métabolisme par le mirabégron."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie du métoprolol pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637154, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637148 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637149 .

_:807f36cf91fe4e8caa53aadeff92477637149 rdf:first _:807f36cf91fe4e8caa53aadeff92477637150;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637151 .

_:807f36cf91fe4e8caa53aadeff92477637150 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477637151 rdf:first _:807f36cf91fe4e8caa53aadeff92477637152;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10591 .

_:807f36cf91fe4e8caa53aadeff92477637154 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11300-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> SOFOSBUVIR"@fr;
  dct:identifier "IAM_11300";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637156;
  r:natureDuRisque """Risque de diminution des concentrations plasmatiques de 
sofosbuvir par diminution de son absorption intestinale par
le millepertuis."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637162, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637156 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637157 .

_:807f36cf91fe4e8caa53aadeff92477637157 rdf:first _:807f36cf91fe4e8caa53aadeff92477637158;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637159 .

_:807f36cf91fe4e8caa53aadeff92477637158 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637159 rdf:first _:807f36cf91fe4e8caa53aadeff92477637160;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10850 .

_:807f36cf91fe4e8caa53aadeff92477637162 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11301-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> TELAPREVIR"@fr;
  dct:identifier "IAM_11301";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637164;
  r:natureDuRisque "Risque de diminution très importante des concentrations de télaprévir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637170, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637164 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637165 .

_:807f36cf91fe4e8caa53aadeff92477637165 rdf:first _:807f36cf91fe4e8caa53aadeff92477637166;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637167 .

_:807f36cf91fe4e8caa53aadeff92477637166 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637167 rdf:first _:807f36cf91fe4e8caa53aadeff92477637168;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477637170 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11302-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_11302";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637172;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la télithromycine, avec risque d'échec du traitement anti-infectieux, par augmentation du métabolisme hépatique de la télithromycine par le millepertuis."@fr;
  rdfs:comment "Le millepertuis a des propriétés d'induction enzymatique importantes. En raison du risque d'échec de l'antibiothérapie, une contre-indication a été retenue entre la télithromycine et le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637178, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637172 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637173 .

_:807f36cf91fe4e8caa53aadeff92477637173 rdf:first _:807f36cf91fe4e8caa53aadeff92477637174;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637175 .

_:807f36cf91fe4e8caa53aadeff92477637174 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637175 rdf:first _:807f36cf91fe4e8caa53aadeff92477637176;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477637178 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11303-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11303";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637180;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la théophylline, en raison de l'effet inducteur enzymatique du millepertuis, avec risque de baisse d'efficacité voire d'annulation de l'effet dont les conséquences peuvent être éventuellement graves (survenue"@fr;
  r:conduiteATenir "En cas d'association fortuite, ne pas interrompre brutalement la prise de millepertuis mais contrôler les concentrations plasmatiques (ou l'efficacité) du médicament associé avant puis après l'arrêt du millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637186, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637180 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637181 .

_:807f36cf91fe4e8caa53aadeff92477637181 rdf:first _:807f36cf91fe4e8caa53aadeff92477637182;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637183 .

_:807f36cf91fe4e8caa53aadeff92477637182 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477637183 rdf:first _:807f36cf91fe4e8caa53aadeff92477637184;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637186 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11304-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> TICAGRELOR"@fr;
  dct:identifier "IAM_11304";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637188;
  r:natureDuRisque "Risque de diminution importante des concentrations plasmatiques de ticagrelor par augmentation de son métabolisme hépatique par le millepertuis, avec diminution de son effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637194, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637188 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637189 .

_:807f36cf91fe4e8caa53aadeff92477637189 rdf:first _:807f36cf91fe4e8caa53aadeff92477637190;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637191 .

_:807f36cf91fe4e8caa53aadeff92477637190 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637191 rdf:first _:807f36cf91fe4e8caa53aadeff92477637192;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477637194 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11305-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_11305";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637196;
  r:natureDuRisque "Risque de diminution de l’effet de l’ulipristal, par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  r:conduiteATenir "Préférer une alternative thérapeutique peu ou pas métabolisée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637202, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637196 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637197 .

_:807f36cf91fe4e8caa53aadeff92477637197 rdf:first _:807f36cf91fe4e8caa53aadeff92477637198;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637199 .

_:807f36cf91fe4e8caa53aadeff92477637198 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637199 rdf:first _:807f36cf91fe4e8caa53aadeff92477637200;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477637202 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11306-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11306";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637204;
  r:natureDuRisque "Réduction importante des concentrations de vérapamil, avec risque de perte de son effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637210, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637204 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637205 .

_:807f36cf91fe4e8caa53aadeff92477637205 rdf:first _:807f36cf91fe4e8caa53aadeff92477637206;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637207 .

_:807f36cf91fe4e8caa53aadeff92477637206 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637207 rdf:first _:807f36cf91fe4e8caa53aadeff92477637208;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477637210 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11307-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> VISMODÉGIB"@fr;
  dct:identifier "IAM_11307";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637212;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de vismodégib."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637218, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637212 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637213 .

_:807f36cf91fe4e8caa53aadeff92477637213 rdf:first _:807f36cf91fe4e8caa53aadeff92477637214;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637215 .

_:807f36cf91fe4e8caa53aadeff92477637214 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637215 rdf:first _:807f36cf91fe4e8caa53aadeff92477637216;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10996 .

_:807f36cf91fe4e8caa53aadeff92477637218 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11298-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> SIMÉPRÉVIR"@fr;
  dct:identifier "IAM_11298";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637220;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de simeprévir par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637226, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637220 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637221 .

_:807f36cf91fe4e8caa53aadeff92477637221 rdf:first _:807f36cf91fe4e8caa53aadeff92477637222;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637223 .

_:807f36cf91fe4e8caa53aadeff92477637222 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637223 rdf:first _:807f36cf91fe4e8caa53aadeff92477637224;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10837 .

_:807f36cf91fe4e8caa53aadeff92477637226 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11309-1 a owl:Class;
  rdfs:label "MINÉRALOCORTICOÏDES <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11309";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637228;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité des corticoïdes par augmentation de leur métabolisme hépatique par la rifampicine ; les conséquences sont particulièrement importantes chez les addisoniens traités par l'hydrocortisone et en ca"@fr;
  r:conduiteATenir "Surveillance clinique et biologique ; adaptation de la posologie des corticoïdes pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637234, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637228 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637229 .

_:807f36cf91fe4e8caa53aadeff92477637229 rdf:first _:807f36cf91fe4e8caa53aadeff92477637230;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637231 .

_:807f36cf91fe4e8caa53aadeff92477637230 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10108 .

_:807f36cf91fe4e8caa53aadeff92477637231 rdf:first _:807f36cf91fe4e8caa53aadeff92477637232;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477637234 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11297-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> RILPIVIRINE"@fr;
  dct:identifier "IAM_11297";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637236;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de rilpivirine par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637242, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637236 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637237 .

_:807f36cf91fe4e8caa53aadeff92477637237 rdf:first _:807f36cf91fe4e8caa53aadeff92477637238;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637239 .

_:807f36cf91fe4e8caa53aadeff92477637238 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637239 rdf:first _:807f36cf91fe4e8caa53aadeff92477637240;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637240 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10803 .

_:807f36cf91fe4e8caa53aadeff92477637242 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11311-1 a owl:Class;
  rdfs:label "MITOMYCINE C <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_11311";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637244;
  r:natureDuRisque "Risque de majoration de la toxicité pulmonaire de la mitomycine et des vinca-alcaloïdes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637250, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637244 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637245 .

_:807f36cf91fe4e8caa53aadeff92477637245 rdf:first _:807f36cf91fe4e8caa53aadeff92477637246;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637247 .

_:807f36cf91fe4e8caa53aadeff92477637246 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:807f36cf91fe4e8caa53aadeff92477637247 rdf:first _:807f36cf91fe4e8caa53aadeff92477637248;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637248 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10593 .

_:807f36cf91fe4e8caa53aadeff92477637250 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11312-1 a owl:Class;
  rdfs:label "MITOTANE <-> SPIRONOLACTONE"@fr;
  dct:identifier "IAM_11312";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637252;
  r:natureDuRisque "Risque de blocage de l’action du mitotane par la spironolactone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637258, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637252 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637253 .

_:807f36cf91fe4e8caa53aadeff92477637253 rdf:first _:807f36cf91fe4e8caa53aadeff92477637254;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637255 .

_:807f36cf91fe4e8caa53aadeff92477637254 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10594 .

_:807f36cf91fe4e8caa53aadeff92477637255 rdf:first _:807f36cf91fe4e8caa53aadeff92477637256;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637256 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10857 .

_:807f36cf91fe4e8caa53aadeff92477637258 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11313-1 a owl:Class;
  rdfs:label "MIZOLASTINE <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_11313";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637260;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637266, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637260 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637261 .

_:807f36cf91fe4e8caa53aadeff92477637261 rdf:first _:807f36cf91fe4e8caa53aadeff92477637262;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637263 .

_:807f36cf91fe4e8caa53aadeff92477637262 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10597 .

_:807f36cf91fe4e8caa53aadeff92477637263 rdf:first _:807f36cf91fe4e8caa53aadeff92477637264;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637264 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477637266 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11314-1 a owl:Class;
  rdfs:label "MODAFINIL <-> SOFOSBUVIR"@fr;
  dct:identifier "IAM_11314";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637268;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de sofosbuvir par diminution de son absorption intestinale par le modafinil."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637274, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637268 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637269 .

_:807f36cf91fe4e8caa53aadeff92477637269 rdf:first _:807f36cf91fe4e8caa53aadeff92477637270;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637271 .

_:807f36cf91fe4e8caa53aadeff92477637270 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10599 .

_:807f36cf91fe4e8caa53aadeff92477637271 rdf:first _:807f36cf91fe4e8caa53aadeff92477637272;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637272 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10850 .

_:807f36cf91fe4e8caa53aadeff92477637274 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11315-1 a owl:Class;
  rdfs:label "MONTELUKAST <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11315";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637276;
  r:natureDuRisque "Risque de baisse de l'efficacité du montélukast par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l'antiasthmatique pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637282, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637276 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637277 .

_:807f36cf91fe4e8caa53aadeff92477637277 rdf:first _:807f36cf91fe4e8caa53aadeff92477637278;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637279 .

_:807f36cf91fe4e8caa53aadeff92477637278 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10604 .

_:807f36cf91fe4e8caa53aadeff92477637279 rdf:first _:807f36cf91fe4e8caa53aadeff92477637280;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637280 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477637282 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11316-1 a owl:Class;
  rdfs:label "MORPHINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11316";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637284;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de la morphine et de son métabolite actif."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la morphine pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637290, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637284 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637285 .

_:807f36cf91fe4e8caa53aadeff92477637285 rdf:first _:807f36cf91fe4e8caa53aadeff92477637286;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637287 .

_:807f36cf91fe4e8caa53aadeff92477637286 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10606 .

_:807f36cf91fe4e8caa53aadeff92477637287 rdf:first _:807f36cf91fe4e8caa53aadeff92477637288;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637288 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477637290 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11317-1 a owl:Class;
  rdfs:label "MORPHINIQUES AGONISTES-ANTAGONISTES <-> MORPHINIQUES ANTAGONISTES PARTIELS"@fr;
  dct:identifier "IAM_11317";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637292;
  r:natureDuRisque "Risque de diminution de l’effet antalgique et/ou d’apparition d’un syndrome de sevrage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637298, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637292 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637293 .

_:807f36cf91fe4e8caa53aadeff92477637293 rdf:first _:807f36cf91fe4e8caa53aadeff92477637294;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637295 .

_:807f36cf91fe4e8caa53aadeff92477637294 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10110 .

_:807f36cf91fe4e8caa53aadeff92477637295 rdf:first _:807f36cf91fe4e8caa53aadeff92477637296;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637296 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10111 .

_:807f36cf91fe4e8caa53aadeff92477637298 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11318-1 a owl:Class;
  rdfs:label "MORPHINIQUES ANTAGONISTES PARTIELS <-> MORPHINIQUES EN TRAITEMENT DE SUBSTITUTION"@fr;
  dct:identifier "IAM_11318";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637300;
  r:natureDuRisque "Risque d’apparition d’un syndrome de sevrage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637306, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637300 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637301 .

_:807f36cf91fe4e8caa53aadeff92477637301 rdf:first _:807f36cf91fe4e8caa53aadeff92477637302;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637303 .

_:807f36cf91fe4e8caa53aadeff92477637302 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10111 .

_:807f36cf91fe4e8caa53aadeff92477637303 rdf:first _:807f36cf91fe4e8caa53aadeff92477637304;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637304 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10112 .

_:807f36cf91fe4e8caa53aadeff92477637306 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11319-1 a owl:Class;
  rdfs:label "MYCOPHENOLATE MOFETIL <-> PÉNICILLINES A"@fr;
  dct:identifier "IAM_11319";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637308;
  r:natureDuRisque "Diminution des concentrations de l’acide mycophénolique d’environ un tiers, avec risque potentiel de baisse d’efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637314, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637308 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637309 .

_:807f36cf91fe4e8caa53aadeff92477637309 rdf:first _:807f36cf91fe4e8caa53aadeff92477637310;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637311 .

_:807f36cf91fe4e8caa53aadeff92477637310 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10139 .

_:807f36cf91fe4e8caa53aadeff92477637311 rdf:first _:807f36cf91fe4e8caa53aadeff92477637312;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637312 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10609 .

_:807f36cf91fe4e8caa53aadeff92477637314 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10713-1 a owl:Class;
  rdfs:label "DACARBAZINE <-> FOTEMUSTINE"@fr;
  dct:identifier "IAM_10713";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637316;
  r:natureDuRisque "Avec la dacarbazine à doses élevées : risque de toxicité pulmonaire (syndrome de détresse respiratoire aiguë de l'adulte)."@fr;
  r:conduiteATenir "Ne pas utiliser simultanément mais respecter un délai d'une semaine entre la dernière administration de fotémustine et le premier jour de la cure de dacarbazine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637322, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637316 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637317 .

_:807f36cf91fe4e8caa53aadeff92477637317 rdf:first _:807f36cf91fe4e8caa53aadeff92477637318;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637319 .

_:807f36cf91fe4e8caa53aadeff92477637318 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10242 .

_:807f36cf91fe4e8caa53aadeff92477637319 rdf:first _:807f36cf91fe4e8caa53aadeff92477637320;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637320 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10404 .

_:807f36cf91fe4e8caa53aadeff92477637322 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11308-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11308";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637324;
  r:natureDuRisque "Réduction importante des concentrations de voriconazole, avec risque de perte de son effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637330, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637324 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637325 .

_:807f36cf91fe4e8caa53aadeff92477637325 rdf:first _:807f36cf91fe4e8caa53aadeff92477637326;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637327 .

_:807f36cf91fe4e8caa53aadeff92477637326 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637327 rdf:first _:807f36cf91fe4e8caa53aadeff92477637328;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637328 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477637330 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11285-1 a owl:Class;
  rdfs:label "MIDAZOLAM <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11285";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637332;
  r:natureDuRisque "Risque d'absence d'effet du midazolam, avec diminution très importante de ses concentrations plasmatiques, par augmentation de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637338, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637332 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637333 .

_:807f36cf91fe4e8caa53aadeff92477637333 rdf:first _:807f36cf91fe4e8caa53aadeff92477637334;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637335 .

_:807f36cf91fe4e8caa53aadeff92477637334 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477637335 rdf:first _:807f36cf91fe4e8caa53aadeff92477637336;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637336 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477637338 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11217-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_11217";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637340;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par le kétoconazole."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637346, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637340 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637341 .

_:807f36cf91fe4e8caa53aadeff92477637341 rdf:first _:807f36cf91fe4e8caa53aadeff92477637342;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637343 .

_:807f36cf91fe4e8caa53aadeff92477637342 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477637343 rdf:first _:807f36cf91fe4e8caa53aadeff92477637344;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637344 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477637346 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11275-1 a owl:Class;
  rdfs:label "METOPROLOL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11275";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637348;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité du bêta-bloquant (augmentation de son métabolisme hépatique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637354, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637348 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637349 .

_:807f36cf91fe4e8caa53aadeff92477637349 rdf:first _:807f36cf91fe4e8caa53aadeff92477637350;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637351 .

_:807f36cf91fe4e8caa53aadeff92477637350 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477637351 rdf:first _:807f36cf91fe4e8caa53aadeff92477637352;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637352 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477637354 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11276-1 a owl:Class;
  rdfs:label "METOPROLOL <-> TERBINAFINE"@fr;
  dct:identifier "IAM_11276";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637356;
  r:natureDuRisque "Chez l'insuffisant cardiaque, risque d'augmentation des effets indésirables du métoprolol, par diminution de son métabolisme hépatique par la terbinafine."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du métoprolol pendant le traitement par la terbinafine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637362, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637356 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637357 .

_:807f36cf91fe4e8caa53aadeff92477637357 rdf:first _:807f36cf91fe4e8caa53aadeff92477637358;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637359 .

_:807f36cf91fe4e8caa53aadeff92477637358 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477637359 rdf:first _:807f36cf91fe4e8caa53aadeff92477637360;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637360 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:807f36cf91fe4e8caa53aadeff92477637362 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11277-1 a owl:Class;
  rdfs:label "METRONIDAZOLE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11277";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637364;
  r:natureDuRisque "Diminution des concentrations plasmatiques du métronidazole par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de métronidazole pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637370, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637364 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637365 .

_:807f36cf91fe4e8caa53aadeff92477637365 rdf:first _:807f36cf91fe4e8caa53aadeff92477637366;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637367 .

_:807f36cf91fe4e8caa53aadeff92477637366 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10580 .

_:807f36cf91fe4e8caa53aadeff92477637367 rdf:first _:807f36cf91fe4e8caa53aadeff92477637368;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637368 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477637370 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11278-1 a owl:Class;
  rdfs:label "METYRAPONE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_11278";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637372;
  r:natureDuRisque "Risque de faux négatif du test à la métyrapone, dû à une diminution de ses concentrations plasmatiques, par augmentation de son métabolisme hépatique par la phénytoïne."@fr;
  r:conduiteATenir "Doubler la posologie de métyrapone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637378, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637372 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637373 .

_:807f36cf91fe4e8caa53aadeff92477637373 rdf:first _:807f36cf91fe4e8caa53aadeff92477637374;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637375 .

_:807f36cf91fe4e8caa53aadeff92477637374 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477637375 rdf:first _:807f36cf91fe4e8caa53aadeff92477637376;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637376 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10581 .

_:807f36cf91fe4e8caa53aadeff92477637378 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11279-1 a owl:Class;
  rdfs:label "MEXILETINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_11279";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637380;
  r:natureDuRisque "Diminution de l'activité antiarythmique, des concentrations plasmatiques et de la demi-vie de la méxilétine (augmentation de son métabolisme hépatique)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement des concentrations plasmatiques de la mexilétine ; s'il y a lieu, adaptation de la posologie de la mexilétine pendant le traitement par la phénytoïne et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637386, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637380 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637381 .

_:807f36cf91fe4e8caa53aadeff92477637381 rdf:first _:807f36cf91fe4e8caa53aadeff92477637382;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637383 .

_:807f36cf91fe4e8caa53aadeff92477637382 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477637383 rdf:first _:807f36cf91fe4e8caa53aadeff92477637384;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637384 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10582 .

_:807f36cf91fe4e8caa53aadeff92477637386 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11280-1 a owl:Class;
  rdfs:label "MEXILETINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11280";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637388;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage (diminution du métabolisme hépatique de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; s'il y a lieu, adaptation de la posologie de la théophylline pendant le traitement par la mexilétine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637394, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637388 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637389 .

_:807f36cf91fe4e8caa53aadeff92477637389 rdf:first _:807f36cf91fe4e8caa53aadeff92477637390;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637391 .

_:807f36cf91fe4e8caa53aadeff92477637390 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477637391 rdf:first _:807f36cf91fe4e8caa53aadeff92477637392;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637392 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10582 .

_:807f36cf91fe4e8caa53aadeff92477637394 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11281-1 a owl:Class;
  rdfs:label "MICONAZOLE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_11281";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637396;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne pouvant atteindre des valeurs toxiques. Mécanisme invoqué : inhibition du métabolisme hépatique de la phénytoïne."@fr;
  r:conduiteATenir "Surveillance clinique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637402, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637396 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637397 .

_:807f36cf91fe4e8caa53aadeff92477637397 rdf:first _:807f36cf91fe4e8caa53aadeff92477637398;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637399 .

_:807f36cf91fe4e8caa53aadeff92477637398 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477637399 rdf:first _:807f36cf91fe4e8caa53aadeff92477637400;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637400 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10584 .

_:807f36cf91fe4e8caa53aadeff92477637402 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11282-1 a owl:Class;
  rdfs:label "MICONAZOLE <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_11282";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637404;
  r:natureDuRisque "Avec le miconazole par voie générale et gel buccal : augmentation de l'effet hypoglycémiant avec survenue possible de manifestations hypoglycémiques, voire de coma."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637410, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637404 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637405 .

_:807f36cf91fe4e8caa53aadeff92477637405 rdf:first _:807f36cf91fe4e8caa53aadeff92477637406;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637407 .

_:807f36cf91fe4e8caa53aadeff92477637406 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477637407 rdf:first _:807f36cf91fe4e8caa53aadeff92477637408;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637408 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10584 .

_:807f36cf91fe4e8caa53aadeff92477637410 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11299-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11299";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637412;
  r:natureDuRisque "Diminution de l’efficacité de l’hypocholestérolémiant par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637418, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637412 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637413 .

_:807f36cf91fe4e8caa53aadeff92477637413 rdf:first _:807f36cf91fe4e8caa53aadeff92477637414;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637415 .

_:807f36cf91fe4e8caa53aadeff92477637414 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637415 rdf:first _:807f36cf91fe4e8caa53aadeff92477637416;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637416 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477637418 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11284-1 a owl:Class;
  rdfs:label "MIDAZOLAM <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_11284";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637420;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du midazolam par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637426, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637420 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637421 .

_:807f36cf91fe4e8caa53aadeff92477637421 rdf:first _:807f36cf91fe4e8caa53aadeff92477637422;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637423 .

_:807f36cf91fe4e8caa53aadeff92477637422 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477637423 rdf:first _:807f36cf91fe4e8caa53aadeff92477637424;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637424 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477637426 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11273-1 a owl:Class;
  rdfs:label "METOPROLOL <-> PAROXETINE"@fr;
  dct:identifier "IAM_11273";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637428;
  r:natureDuRisque "Risque de majoration des effets indésirables du métoprolol, avec notamment bradycardie excessive, par inhibition de son métabolisme par la paroxétine."@fr;
  r:conduiteATenir "Surveillance clinique accrue ; si besoin, adaptation de la posologie du métoprolol pendant la durée du traitement par la paroxétine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637434, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637428 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637429 .

_:807f36cf91fe4e8caa53aadeff92477637429 rdf:first _:807f36cf91fe4e8caa53aadeff92477637430;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637431 .

_:807f36cf91fe4e8caa53aadeff92477637430 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477637431 rdf:first _:807f36cf91fe4e8caa53aadeff92477637432;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637432 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:807f36cf91fe4e8caa53aadeff92477637434 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11286-1 a owl:Class;
  rdfs:label "MIDAZOLAM <-> ROXITHROMYCINE"@fr;
  dct:identifier "IAM_11286";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637436;
  r:natureDuRisque "Majoration légère de la sédation."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637442, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637436 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637437 .

_:807f36cf91fe4e8caa53aadeff92477637437 rdf:first _:807f36cf91fe4e8caa53aadeff92477637438;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637439 .

_:807f36cf91fe4e8caa53aadeff92477637438 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477637439 rdf:first _:807f36cf91fe4e8caa53aadeff92477637440;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637440 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10817 .

_:807f36cf91fe4e8caa53aadeff92477637442 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11287-1 a owl:Class;
  rdfs:label "MIDAZOLAM <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_11287";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637444;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du midazolam par diminution de son métabolisme hépatique avec majoration de la sédation."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie pendant le traitement par le stiripentol."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637450, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637444 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637445 .

_:807f36cf91fe4e8caa53aadeff92477637445 rdf:first _:807f36cf91fe4e8caa53aadeff92477637446;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637447 .

_:807f36cf91fe4e8caa53aadeff92477637446 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477637447 rdf:first _:807f36cf91fe4e8caa53aadeff92477637448;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637448 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477637450 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11288-1 a owl:Class;
  rdfs:label "MIDAZOLAM <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11288";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637452;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de midazolam (diminution de son métabolisme hépatique avec majoration de la sédation)."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie de midazolam pendant le traitement par le vérapamil."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637458, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637452 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637453 .

_:807f36cf91fe4e8caa53aadeff92477637453 rdf:first _:807f36cf91fe4e8caa53aadeff92477637454;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637455 .

_:807f36cf91fe4e8caa53aadeff92477637454 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477637455 rdf:first _:807f36cf91fe4e8caa53aadeff92477637456;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637456 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477637458 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11290-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_11290";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637460;
  r:natureDuRisque "Risque de diminution significative des concentrations plasmatiques de la névirapine par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637466, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637460 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637461 .

_:807f36cf91fe4e8caa53aadeff92477637461 rdf:first _:807f36cf91fe4e8caa53aadeff92477637462;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637463 .

_:807f36cf91fe4e8caa53aadeff92477637462 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637463 rdf:first _:807f36cf91fe4e8caa53aadeff92477637464;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637464 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:807f36cf91fe4e8caa53aadeff92477637466 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11291-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_11291";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637468;
  r:natureDuRisque "Diminution des concentrations plasmatiques du nintédanib par diminution de son absorption par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637474, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637468 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637469 .

_:807f36cf91fe4e8caa53aadeff92477637469 rdf:first _:807f36cf91fe4e8caa53aadeff92477637470;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637471 .

_:807f36cf91fe4e8caa53aadeff92477637470 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637471 rdf:first _:807f36cf91fe4e8caa53aadeff92477637472;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637472 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477637474 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11292-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> OXYCODONE"@fr;
  dct:identifier "IAM_11292";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637476;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’oxycodone par augmentation de son métabolisme par le millepertuis."@fr;
  r:conduiteATenir "Adaptation éventuelle de la posologie de l’oxycodone ."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637482, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637476 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637477 .

_:807f36cf91fe4e8caa53aadeff92477637477 rdf:first _:807f36cf91fe4e8caa53aadeff92477637478;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637479 .

_:807f36cf91fe4e8caa53aadeff92477637478 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637479 rdf:first _:807f36cf91fe4e8caa53aadeff92477637480;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637480 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10681 .

_:807f36cf91fe4e8caa53aadeff92477637482 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11293-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_11293";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637484;
  r:natureDuRisque "Diminution des concentrations plasmatiques du contraceptif hormonal, en raison de l'effet inducteur enzymatique du millepertuis, avec risque de baisse d'efficacité voire d'annulation de l'effet dont les conséquences peuvent être éventuellement graves (sur"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637490, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637484 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637485 .

_:807f36cf91fe4e8caa53aadeff92477637485 rdf:first _:807f36cf91fe4e8caa53aadeff92477637486;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637487 .

_:807f36cf91fe4e8caa53aadeff92477637486 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:807f36cf91fe4e8caa53aadeff92477637487 rdf:first _:807f36cf91fe4e8caa53aadeff92477637488;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637488 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637490 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11294-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> PROPAFENONE"@fr;
  dct:identifier "IAM_11294";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637492;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la propafénone par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. S'il y a lieu, adaptation de la posologie de la propafénone pendant l'association et après l'arrêt du millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637498, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637492 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637493 .

_:807f36cf91fe4e8caa53aadeff92477637493 rdf:first _:807f36cf91fe4e8caa53aadeff92477637494;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637495 .

_:807f36cf91fe4e8caa53aadeff92477637494 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637495 rdf:first _:807f36cf91fe4e8caa53aadeff92477637496;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637496 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477637498 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11295-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> QUETIAPINE"@fr;
  dct:identifier "IAM_11295";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637500;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques de quétiapine par augmentation de son métabolisme hépatique par l'inducteur, avec risque d’inefficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637506, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637500 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637501 .

_:807f36cf91fe4e8caa53aadeff92477637501 rdf:first _:807f36cf91fe4e8caa53aadeff92477637502;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637503 .

_:807f36cf91fe4e8caa53aadeff92477637502 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637503 rdf:first _:807f36cf91fe4e8caa53aadeff92477637504;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637504 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10773 .

_:807f36cf91fe4e8caa53aadeff92477637506 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11296-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> RÉGORAFÉNIB"@fr;
  dct:identifier "IAM_11296";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637508;
  r:natureDuRisque "Diminution des concentrations plasmatiques de régorafenib par augmentation de son métabolisme par le millepertuis"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637514, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637508 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637509 .

_:807f36cf91fe4e8caa53aadeff92477637509 rdf:first _:807f36cf91fe4e8caa53aadeff92477637510;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637511 .

_:807f36cf91fe4e8caa53aadeff92477637510 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637511 rdf:first _:807f36cf91fe4e8caa53aadeff92477637512;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637512 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10789 .

_:807f36cf91fe4e8caa53aadeff92477637514 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11283-1 a owl:Class;
  rdfs:label "MIDAZOLAM <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11283";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637516;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de midazolam par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637522, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637516 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637517 .

_:807f36cf91fe4e8caa53aadeff92477637517 rdf:first _:807f36cf91fe4e8caa53aadeff92477637518;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637519 .

_:807f36cf91fe4e8caa53aadeff92477637518 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477637519 rdf:first _:807f36cf91fe4e8caa53aadeff92477637520;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637520 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637522 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11147-1 a owl:Class;
  rdfs:label "INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11147";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637524;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l’efficacité de l’inhibiteur de tyrosine kinase, par augmentation de son métabolisme par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637530, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637524 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637525 .

_:807f36cf91fe4e8caa53aadeff92477637525 rdf:first _:807f36cf91fe4e8caa53aadeff92477637526;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637527 .

_:807f36cf91fe4e8caa53aadeff92477637526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:807f36cf91fe4e8caa53aadeff92477637527 rdf:first _:807f36cf91fe4e8caa53aadeff92477637528;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637528 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637530 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11135-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> RIFABUTINE"@fr;
  dct:identifier "IAM_11135";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637532;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de baisse de l'efficacité de l'inhibiteur de protéases (ce d'autant que la posologie de la rifabutine est importante) d'une part, et risque d'augmentation des effets indésirables (uvéites) de la rifabutine, d'autre part."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637538, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637532 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637533 .

_:807f36cf91fe4e8caa53aadeff92477637533 rdf:first _:807f36cf91fe4e8caa53aadeff92477637534;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637535 .

_:807f36cf91fe4e8caa53aadeff92477637534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477637535 rdf:first _:807f36cf91fe4e8caa53aadeff92477637536;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637536 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff92477637538 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11136-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11136";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637540;
  r:natureDuRisque """Diminution très importante des concentrations plasmatiques de l'inhibiteur de protéases, par augmentation de son métabolisme hépatique par la rifampicine.

Pour l'association (saquinavir + ritonavir) :
risque de toxicité hépatocellulaire sévère."""@fr;
  r:conduiteATenir "Dans l'attente de données complémentaires avec les inhibiteurs de protéases \"boostés\"."@fr;
  rdfs:comment "La rifampicine est un inducteur enzymatique puissant des CYP450 et diminue fortement la concentration des inhibiteurs de protéases avec un risque de perte d’efficacité du traitement antirétroviral. Une contre-indication entre la majorité des inhibiteurs d"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637546, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637540 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637541 .

_:807f36cf91fe4e8caa53aadeff92477637541 rdf:first _:807f36cf91fe4e8caa53aadeff92477637542;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637543 .

_:807f36cf91fe4e8caa53aadeff92477637542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477637543 rdf:first _:807f36cf91fe4e8caa53aadeff92477637544;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637544 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477637546 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11137-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> ROSUVASTATINE"@fr;
  dct:identifier "IAM_11137";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637548;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la rosuvastatine par augmentation de son absorption."@fr;
  r:conduiteATenir "Surveillance clinique et biologique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637554, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637548 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637549 .

_:807f36cf91fe4e8caa53aadeff92477637549 rdf:first _:807f36cf91fe4e8caa53aadeff92477637550;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637551 .

_:807f36cf91fe4e8caa53aadeff92477637550 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477637551 rdf:first _:807f36cf91fe4e8caa53aadeff92477637552;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637552 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10814 .

_:807f36cf91fe4e8caa53aadeff92477637554 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11138-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11138";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637556;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de la simvastatine)."@fr;
  rdfs:comment "Le groupe de travail européen de pharmacovigilance a émis des recommandations s'appliquant à tous les inhibiteurs de protéases (IPs), inhibiteurs puissants du CYP3A4. Celles-ci modulent les niveaux de contrainte existants entre les IPs et les statines mét"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637562, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637556 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637557 .

_:807f36cf91fe4e8caa53aadeff92477637557 rdf:first _:807f36cf91fe4e8caa53aadeff92477637558;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637559 .

_:807f36cf91fe4e8caa53aadeff92477637558 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477637559 rdf:first _:807f36cf91fe4e8caa53aadeff92477637560;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637560 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477637562 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11140-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_11140";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637564;
  r:natureDuRisque "Avec l'atazanavir, le darunavir ou le lopinavir, augmentation des concentrations plasmatiques du ténofovir alafénamide par augmentation de son absorption."@fr;
  r:conduiteATenir "En cas de co-administration, la dose de ténofovir alafénamide doit être limitée à 10 mg par jour. L’association avec les autres inhibiteurs de protéases du VIH n’a pas été étudiée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637570, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637564 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637565 .

_:807f36cf91fe4e8caa53aadeff92477637565 rdf:first _:807f36cf91fe4e8caa53aadeff92477637566;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637567 .

_:807f36cf91fe4e8caa53aadeff92477637566 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477637567 rdf:first _:807f36cf91fe4e8caa53aadeff92477637568;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637568 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff92477637570 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11141-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11141";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637572;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la théophylline, par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; s'il y a lieu, adaptation de la posologie de la théophylline pendant le traitement par l'inhibiteur de protéases et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637578, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637572 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637573 .

_:807f36cf91fe4e8caa53aadeff92477637573 rdf:first _:807f36cf91fe4e8caa53aadeff92477637574;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637575 .

_:807f36cf91fe4e8caa53aadeff92477637574 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477637575 rdf:first _:807f36cf91fe4e8caa53aadeff92477637576;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637576 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477637578 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11142-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_11142";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637580;
  r:natureDuRisque "Risque de diminution de l’effet de l’ulipristal, par augmentation de son métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir "Préférer une alternative thérapeutique peu ou pas métabolisée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637586, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637580 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637581 .

_:807f36cf91fe4e8caa53aadeff92477637581 rdf:first _:807f36cf91fe4e8caa53aadeff92477637582;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637583 .

_:807f36cf91fe4e8caa53aadeff92477637582 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477637583 rdf:first _:807f36cf91fe4e8caa53aadeff92477637584;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637584 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477637586 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11143-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_11143";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637588;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637594, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637588 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637589 .

_:807f36cf91fe4e8caa53aadeff92477637589 rdf:first _:807f36cf91fe4e8caa53aadeff92477637590;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637591 .

_:807f36cf91fe4e8caa53aadeff92477637590 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477637591 rdf:first _:807f36cf91fe4e8caa53aadeff92477637592;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637592 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:807f36cf91fe4e8caa53aadeff92477637594 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11145-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11145";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637596;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Baisse très importante des concentrations de l’antifongique par augmentation de son métabolisme par le ritonavir, avec risque d’échec du traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637602, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637596 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637597 .

_:807f36cf91fe4e8caa53aadeff92477637597 rdf:first _:807f36cf91fe4e8caa53aadeff92477637598;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637599 .

_:807f36cf91fe4e8caa53aadeff92477637598 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477637599 rdf:first _:807f36cf91fe4e8caa53aadeff92477637600;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637600 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477637602 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11219-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> SALMETEROL"@fr;
  dct:identifier "IAM_11219";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637604;
  r:natureDuRisque "Augmentation importante des concentrations de salmétérol par diminution de son métabolisme hépatique par le kétoconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637610, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637604 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637605 .

_:807f36cf91fe4e8caa53aadeff92477637605 rdf:first _:807f36cf91fe4e8caa53aadeff92477637606;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637607 .

_:807f36cf91fe4e8caa53aadeff92477637606 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477637607 rdf:first _:807f36cf91fe4e8caa53aadeff92477637608;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637608 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10823 .

_:807f36cf91fe4e8caa53aadeff92477637610 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11149-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> IRINOTECAN"@fr;
  dct:identifier "IAM_11149";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637612;
  r:natureDuRisque "Risque de majoration des effets indésirables de l’irinotécan par augmentation des concentrations plasmatiques de son métabolite actif."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637618, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637612 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637613 .

_:807f36cf91fe4e8caa53aadeff92477637613 rdf:first _:807f36cf91fe4e8caa53aadeff92477637614;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637615 .

_:807f36cf91fe4e8caa53aadeff92477637614 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477637615 rdf:first _:807f36cf91fe4e8caa53aadeff92477637616;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637616 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10486 .

_:807f36cf91fe4e8caa53aadeff92477637618 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11119-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> SACUBITRIL"@fr;
  dct:identifier "IAM_11119";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637620;
  r:natureDuRisque "Augmentation du risque d'angioedème."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637626, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637620 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637621 .

_:807f36cf91fe4e8caa53aadeff92477637621 rdf:first _:807f36cf91fe4e8caa53aadeff92477637622;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637623 .

_:807f36cf91fe4e8caa53aadeff92477637622 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477637623 rdf:first _:807f36cf91fe4e8caa53aadeff92477637624;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637624 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10821 .

_:807f36cf91fe4e8caa53aadeff92477637626 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11148-1 a owl:Class;
  rdfs:label "INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11148";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637628;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l’efficacité de l’inhibiteur de tyrosine kinase, par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637634, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637628 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637629 .

_:807f36cf91fe4e8caa53aadeff92477637629 rdf:first _:807f36cf91fe4e8caa53aadeff92477637630;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637631 .

_:807f36cf91fe4e8caa53aadeff92477637630 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:807f36cf91fe4e8caa53aadeff92477637631 rdf:first _:807f36cf91fe4e8caa53aadeff92477637632;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637632 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477637634 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10419-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS AGISSANT SUR L'HÉMOSTASE <-> INHIBITEURS DIRECTS DE LA THROMBINE À INDICATION SPÉCIFIQUE"@fr;
  dct:identifier "IAM_10419";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637636;
  r:natureDuRisque "Majoration du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637642, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637636 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637637 .

_:807f36cf91fe4e8caa53aadeff92477637637 rdf:first _:807f36cf91fe4e8caa53aadeff92477637638;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637639 .

_:807f36cf91fe4e8caa53aadeff92477637638 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10102 .

_:807f36cf91fe4e8caa53aadeff92477637639 rdf:first _:807f36cf91fe4e8caa53aadeff92477637640;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637640 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10163 .

_:807f36cf91fe4e8caa53aadeff92477637642 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11150-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> ISAVUCONAZOLE"@fr;
  dct:identifier "IAM_11150";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637644;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’isavuconazole par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  r:conduiteATenir """Contre-indication:
- avec le kétoconazole


Précaution d'emploi:
- avec les autres inhibiteurs puissants du CYP3A4"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637650, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637644 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637645 .

_:807f36cf91fe4e8caa53aadeff92477637645 rdf:first _:807f36cf91fe4e8caa53aadeff92477637646;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637647 .

_:807f36cf91fe4e8caa53aadeff92477637646 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477637647 rdf:first _:807f36cf91fe4e8caa53aadeff92477637648;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637648 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10487 .

_:807f36cf91fe4e8caa53aadeff92477637650 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11151-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> IVABRADINE"@fr;
  dct:identifier "IAM_11151";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637652;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l’ivabradine et par conséquent de ses effets indésirables (inhibition de son métabolisme hépatique par l’inhibiteur)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637658, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637652 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637653 .

_:807f36cf91fe4e8caa53aadeff92477637653 rdf:first _:807f36cf91fe4e8caa53aadeff92477637654;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637655 .

_:807f36cf91fe4e8caa53aadeff92477637654 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477637655 rdf:first _:807f36cf91fe4e8caa53aadeff92477637656;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637656 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:807f36cf91fe4e8caa53aadeff92477637658 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11152-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> IVACAFTOR"@fr;
  dct:identifier "IAM_11152";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637660;
  r:natureDuRisque "Augmentation importante des concentrations d’ivacaftor, avec risques de majoration des effets indésirables."@fr;
  r:conduiteATenir "Réduire la dose du quart, soit 150 mg 1 jour sur 2."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637666, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637660 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637661 .

_:807f36cf91fe4e8caa53aadeff92477637661 rdf:first _:807f36cf91fe4e8caa53aadeff92477637662;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637663 .

_:807f36cf91fe4e8caa53aadeff92477637662 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477637663 rdf:first _:807f36cf91fe4e8caa53aadeff92477637664;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637664 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10498 .

_:807f36cf91fe4e8caa53aadeff92477637666 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11153-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> LOMITAPIDE"@fr;
  dct:identifier "IAM_11153";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637668;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du lomitapide par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637674, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637668 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637669 .

_:807f36cf91fe4e8caa53aadeff92477637669 rdf:first _:807f36cf91fe4e8caa53aadeff92477637670;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637671 .

_:807f36cf91fe4e8caa53aadeff92477637670 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477637671 rdf:first _:807f36cf91fe4e8caa53aadeff92477637672;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637672 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10533 .

_:807f36cf91fe4e8caa53aadeff92477637674 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11154-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> LURASIDONE"@fr;
  dct:identifier "IAM_11154";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637676;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la lurasidone par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637682, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637676 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637677 .

_:807f36cf91fe4e8caa53aadeff92477637677 rdf:first _:807f36cf91fe4e8caa53aadeff92477637678;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637679 .

_:807f36cf91fe4e8caa53aadeff92477637678 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477637679 rdf:first _:807f36cf91fe4e8caa53aadeff92477637680;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637680 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10542 .

_:807f36cf91fe4e8caa53aadeff92477637682 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11155-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> MARAVIROC"@fr;
  dct:identifier "IAM_11155";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637684;
  r:natureDuRisque "Augmentation des concentrations de maraviroc par l’inhibiteur."@fr;
  r:conduiteATenir """La dose de maraviroc doit être diminuée à 150 mg deux fois par jour en cas de co-administration avec cet inhibiteur.
A l'exception du tipranavir boosté par ritonavir où la dose de maraviroc doit être de 300 mg deux fois par jour."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637690, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637684 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637685 .

_:807f36cf91fe4e8caa53aadeff92477637685 rdf:first _:807f36cf91fe4e8caa53aadeff92477637686;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637687 .

_:807f36cf91fe4e8caa53aadeff92477637686 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477637687 rdf:first _:807f36cf91fe4e8caa53aadeff92477637688;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637688 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10551 .

_:807f36cf91fe4e8caa53aadeff92477637690 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11156-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> METHYLPREDNISOLONE"@fr;
  dct:identifier "IAM_11156";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637692;
  r:natureDuRisque "En cas d’utilisation prolongée, augmentation des concentrations plasmatiques du corticoïde par diminution de son métabolisme hépatique par l’inhibiteur, avec risque d'apparition d'un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637698, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637692 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637693 .

_:807f36cf91fe4e8caa53aadeff92477637693 rdf:first _:807f36cf91fe4e8caa53aadeff92477637694;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637695 .

_:807f36cf91fe4e8caa53aadeff92477637694 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477637695 rdf:first _:807f36cf91fe4e8caa53aadeff92477637696;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637696 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10576 .

_:807f36cf91fe4e8caa53aadeff92477637698 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11146-1 a owl:Class;
  rdfs:label "INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11146";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637700;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque """Risque de majoration des effets indésirables de l’inhibiteur de
tyrosine kinase par diminution de son métabolisme."""@fr;
  r:conduiteATenir """Association déconseillée :
- avec l'axitinib, le bosutinib, le céritinib, le cobimétinib, le dabrafenib, le dasatinib, le nilotinib, le sunitinib
- avec l'ibrutinib, si l’association ne peut être évitée ,surveillance clinique étroite et réduction de la do"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637706, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637700 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637701 .

_:807f36cf91fe4e8caa53aadeff92477637701 rdf:first _:807f36cf91fe4e8caa53aadeff92477637702;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637703 .

_:807f36cf91fe4e8caa53aadeff92477637702 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:807f36cf91fe4e8caa53aadeff92477637703 rdf:first _:807f36cf91fe4e8caa53aadeff92477637704;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637704 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477637706 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11109-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> VISMODÉGIB"@fr;
  dct:identifier "IAM_11109";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637708;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de vismodegib par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637714, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637708 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637709 .

_:807f36cf91fe4e8caa53aadeff92477637709 rdf:first _:807f36cf91fe4e8caa53aadeff92477637710;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637711 .

_:807f36cf91fe4e8caa53aadeff92477637710 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477637711 rdf:first _:807f36cf91fe4e8caa53aadeff92477637712;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10996 .

_:807f36cf91fe4e8caa53aadeff92477637714 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11098-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_11098";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637716;
  r:chapeau "Certains médicaments ont la propriété d'activer considérablement certaines voies métaboliques hépatiques par induction enzymatique. Associés à des médicaments fortement métabolisés au niveau du foie, ils sont, de ce fait, en mesure d'en modifier les conce"@fr;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la bithérapie par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637722, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637716 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637717 .

_:807f36cf91fe4e8caa53aadeff92477637717 rdf:first _:807f36cf91fe4e8caa53aadeff92477637718;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637719 .

_:807f36cf91fe4e8caa53aadeff92477637718 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477637719 rdf:first _:807f36cf91fe4e8caa53aadeff92477637720;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477637722 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11099-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> OXYCODONE"@fr;
  dct:identifier "IAM_11099";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637724;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’oxycodone par augmentation de son métabolisme par l’inducteur."@fr;
  r:conduiteATenir "Adaptation éventuelle de la posologie d’oxycodone ."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637730, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637724 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637725 .

_:807f36cf91fe4e8caa53aadeff92477637725 rdf:first _:807f36cf91fe4e8caa53aadeff92477637726;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637727 .

_:807f36cf91fe4e8caa53aadeff92477637726 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477637727 rdf:first _:807f36cf91fe4e8caa53aadeff92477637728;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10681 .

_:807f36cf91fe4e8caa53aadeff92477637730 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11100-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_11100";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637732;
  r:natureDuRisque "Diminution de l'efficacité contraceptive du contraceptif hormonal, par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637738, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637732 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637733 .

_:807f36cf91fe4e8caa53aadeff92477637733 rdf:first _:807f36cf91fe4e8caa53aadeff92477637734;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637735 .

_:807f36cf91fe4e8caa53aadeff92477637734 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477637735 rdf:first _:807f36cf91fe4e8caa53aadeff92477637736;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:807f36cf91fe4e8caa53aadeff92477637738 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11101-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> PROGESTATIFS NON CONTRACEPTIFS, ASSOCIÉS OU NON À UN ESTROGÈNE"@fr;
  dct:identifier "IAM_11101";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637740;
  r:chapeau "Certains médicaments ont la propriété d'activer considérablement certaines voies métaboliques hépatiques par induction enzymatique. Associés à des médicaments fortement métabolisés au niveau du foie, ils sont, de ce fait, en mesure d'en modifier les conce"@fr;
  r:natureDuRisque "Diminution de l'efficacité du progestatif."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du traitement hormonal pendant l'administration de l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637746, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637740 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637741 .

_:807f36cf91fe4e8caa53aadeff92477637741 rdf:first _:807f36cf91fe4e8caa53aadeff92477637742;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637743 .

_:807f36cf91fe4e8caa53aadeff92477637742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477637743 rdf:first _:807f36cf91fe4e8caa53aadeff92477637744;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10135 .

_:807f36cf91fe4e8caa53aadeff92477637746 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11102-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> RÉGORAFÉNIB"@fr;
  dct:identifier "IAM_11102";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637748;
  r:natureDuRisque "Diminution des concentrations plasmatiques de régorafenib par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637754, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637748 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637749 .

_:807f36cf91fe4e8caa53aadeff92477637749 rdf:first _:807f36cf91fe4e8caa53aadeff92477637750;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637751 .

_:807f36cf91fe4e8caa53aadeff92477637750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477637751 rdf:first _:807f36cf91fe4e8caa53aadeff92477637752;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10789 .

_:807f36cf91fe4e8caa53aadeff92477637754 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11103-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> RILPIVIRINE"@fr;
  dct:identifier "IAM_11103";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637756;
  r:natureDuRisque "Diminution significative des concentrations plasmatiques de rilpivirine par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637762, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637756 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637757 .

_:807f36cf91fe4e8caa53aadeff92477637757 rdf:first _:807f36cf91fe4e8caa53aadeff92477637758;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637759 .

_:807f36cf91fe4e8caa53aadeff92477637758 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477637759 rdf:first _:807f36cf91fe4e8caa53aadeff92477637760;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10803 .

_:807f36cf91fe4e8caa53aadeff92477637762 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11104-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> SERTRALINE"@fr;
  dct:identifier "IAM_11104";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637764;
  r:natureDuRisque "Risque d’inefficacité du traitement antidépresseur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637770, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637764 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637765 .

_:807f36cf91fe4e8caa53aadeff92477637765 rdf:first _:807f36cf91fe4e8caa53aadeff92477637766;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637767 .

_:807f36cf91fe4e8caa53aadeff92477637766 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477637767 rdf:first _:807f36cf91fe4e8caa53aadeff92477637768;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10831 .

_:807f36cf91fe4e8caa53aadeff92477637770 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11105-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> SIMÉPRÉVIR"@fr;
  dct:identifier "IAM_11105";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637772;
  r:natureDuRisque "Diminution des concentrations plasmatiques de simeprévir par augmentation de son métabolisme hépatique par l’inducteur"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637778, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637772 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637773 .

_:807f36cf91fe4e8caa53aadeff92477637773 rdf:first _:807f36cf91fe4e8caa53aadeff92477637774;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637775 .

_:807f36cf91fe4e8caa53aadeff92477637774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477637775 rdf:first _:807f36cf91fe4e8caa53aadeff92477637776;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10837 .

_:807f36cf91fe4e8caa53aadeff92477637778 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11106-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> SOFOSBUVIR"@fr;
  dct:identifier "IAM_11106";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637780;
  r:natureDuRisque """Risque de diminution des concentrations plasmatiques de 
sofosbuvir par diminution de son absorption intestinale par
l’inducteur."""@fr;
  r:conduiteATenir """Contre-indication :
- avec la rifampicine
- avec les anticonvulsivants inducteurs enzymatiques

Association déconseillée:
- avec les autres inducteurs."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637786, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637780 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637781 .

_:807f36cf91fe4e8caa53aadeff92477637781 rdf:first _:807f36cf91fe4e8caa53aadeff92477637782;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637783 .

_:807f36cf91fe4e8caa53aadeff92477637782 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477637783 rdf:first _:807f36cf91fe4e8caa53aadeff92477637784;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10850 .

_:807f36cf91fe4e8caa53aadeff92477637786 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11134-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> QUINIDINE"@fr;
  dct:identifier "IAM_11134";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637788;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637794, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637788 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637789 .

_:807f36cf91fe4e8caa53aadeff92477637789 rdf:first _:807f36cf91fe4e8caa53aadeff92477637790;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637791 .

_:807f36cf91fe4e8caa53aadeff92477637790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477637791 rdf:first _:807f36cf91fe4e8caa53aadeff92477637792;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477637794 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11108-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> VÉMURAFÉNIB"@fr;
  dct:identifier "IAM_11108";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637796;
  r:natureDuRisque "Risque de diminution des concentrations du vémurafénib, avec moindre efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637802, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637796 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637797 .

_:807f36cf91fe4e8caa53aadeff92477637797 rdf:first _:807f36cf91fe4e8caa53aadeff92477637798;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637799 .

_:807f36cf91fe4e8caa53aadeff92477637798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477637799 rdf:first _:807f36cf91fe4e8caa53aadeff92477637800;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10978 .

_:807f36cf91fe4e8caa53aadeff92477637802 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11133-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_11133";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637804;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de diminution de l'efficacité contraceptive par diminution des concentrations en contraceptif hormonal, dûe à l'augmentation de son métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique (préservatif ou stérilet), pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637810, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637804 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637805 .

_:807f36cf91fe4e8caa53aadeff92477637805 rdf:first _:807f36cf91fe4e8caa53aadeff92477637806;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637807 .

_:807f36cf91fe4e8caa53aadeff92477637806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477637807 rdf:first _:807f36cf91fe4e8caa53aadeff92477637808;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:807f36cf91fe4e8caa53aadeff92477637810 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11110-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> VORTIOXÉTINE"@fr;
  dct:identifier "IAM_11110";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637812;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la vortioxétine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la vortioxétine pendant l'association et 1 à 2 semaines après l’arrêt de l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637818, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637812 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637813 .

_:807f36cf91fe4e8caa53aadeff92477637813 rdf:first _:807f36cf91fe4e8caa53aadeff92477637814;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637815 .

_:807f36cf91fe4e8caa53aadeff92477637814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477637815 rdf:first _:807f36cf91fe4e8caa53aadeff92477637816;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10999 .

_:807f36cf91fe4e8caa53aadeff92477637818 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11111-1 a owl:Class;
  rdfs:label "INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5 <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11111";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637820;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Augmentation (très importante pour l'avanafil et le vardénafil) des concentrations plasmatiques de l'IPDE5, avec risque d'hypotension (sévère avec le vardénafil)."@fr;
  r:conduiteATenir "Pour connaître les risques et les niveaux de contrainte de chaque IPDE5 avec les inhibiteurs puissants du CYP3A4, il convient de se reporter aux AMM specifiques à chacun d'eux."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637826, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637820 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637821 .

_:807f36cf91fe4e8caa53aadeff92477637821 rdf:first _:807f36cf91fe4e8caa53aadeff92477637822;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637823 .

_:807f36cf91fe4e8caa53aadeff92477637822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:807f36cf91fe4e8caa53aadeff92477637823 rdf:first _:807f36cf91fe4e8caa53aadeff92477637824;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477637826 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11112-1 a owl:Class;
  rdfs:label "INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5 <-> RIOCIGUAT"@fr;
  dct:identifier "IAM_11112";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637828;
  r:natureDuRisque "Risque d'hypotension importante (effet synergique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637834, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637828 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637829 .

_:807f36cf91fe4e8caa53aadeff92477637829 rdf:first _:807f36cf91fe4e8caa53aadeff92477637830;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637831 .

_:807f36cf91fe4e8caa53aadeff92477637830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:807f36cf91fe4e8caa53aadeff92477637831 rdf:first _:807f36cf91fe4e8caa53aadeff92477637832;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10804 .

_:807f36cf91fe4e8caa53aadeff92477637834 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11113-1 a owl:Class;
  rdfs:label "INHIBITEURS DE LA XANTHINE OXYDASE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11113";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637836;
  r:natureDuRisque "En cas de posologies élevées de l'inhibiteur, augmentation des concentrations plasmatiques de théophylline par inhibition de son métabolisme."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle de la théophyllinémie jusqu'à deux à trois semaines après la mise en route du traitement par l'inhibiteur ; s'il y a lieu, adaptation de la posologie pendant le traitement par l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637842, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637836 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637837 .

_:807f36cf91fe4e8caa53aadeff92477637837 rdf:first _:807f36cf91fe4e8caa53aadeff92477637838;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637839 .

_:807f36cf91fe4e8caa53aadeff92477637838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10099 .

_:807f36cf91fe4e8caa53aadeff92477637839 rdf:first _:807f36cf91fe4e8caa53aadeff92477637840;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477637842 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11114-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> INSULINE"@fr;
  dct:identifier "IAM_11114";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637844;
  r:natureDuRisque "L'utilisation des IEC peut entraîner une majoration de l'effet hypoglycémiant chez le diabétique traité par insuline. La survenue de malaises hypoglycémiques semble exceptionnelle (amélioration de la tolérance au glucose qui aurait pour conséquence une ré"@fr;
  r:conduiteATenir "Renforcer l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637850, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637844 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637845 .

_:807f36cf91fe4e8caa53aadeff92477637845 rdf:first _:807f36cf91fe4e8caa53aadeff92477637846;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637847 .

_:807f36cf91fe4e8caa53aadeff92477637846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477637847 rdf:first _:807f36cf91fe4e8caa53aadeff92477637848;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:807f36cf91fe4e8caa53aadeff92477637850 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11115-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> LITHIUM"@fr;
  dct:identifier "IAM_11115";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637852;
  r:natureDuRisque "Augmentation de la lithémie pouvant atteindre des valeurs toxiques (diminution de l'excrétion rénale du lithium)."@fr;
  r:conduiteATenir "Si l'usage d'un IEC est indispensable, surveillance stricte de la lithémie et adaptation de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637858, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637852 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637853 .

_:807f36cf91fe4e8caa53aadeff92477637853 rdf:first _:807f36cf91fe4e8caa53aadeff92477637854;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637855 .

_:807f36cf91fe4e8caa53aadeff92477637854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477637855 rdf:first _:807f36cf91fe4e8caa53aadeff92477637856;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477637858 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11116-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> OR"@fr;
  dct:identifier "IAM_11116";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637860;
  r:natureDuRisque "Avec les sels d'or administrés par voie IV : risque de réaction «nitritoïde» à l’introduction de l’IEC (nausées, vomissements, effets vasomoteurs à type de flush, hypotension, éventuellement collapsus)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637866, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637860 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637861 .

_:807f36cf91fe4e8caa53aadeff92477637861 rdf:first _:807f36cf91fe4e8caa53aadeff92477637862;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637863 .

_:807f36cf91fe4e8caa53aadeff92477637862 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477637863 rdf:first _:807f36cf91fe4e8caa53aadeff92477637864;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10666 .

_:807f36cf91fe4e8caa53aadeff92477637866 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11117-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> POTASSIUM"@fr;
  dct:identifier "IAM_11117";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637868;
  r:natureDuRisque "Hyperkaliémie (potentiellement létale) surtout lors d'une insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Sauf s'il existe une hypokaliémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637874, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637868 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637869 .

_:807f36cf91fe4e8caa53aadeff92477637869 rdf:first _:807f36cf91fe4e8caa53aadeff92477637870;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637871 .

_:807f36cf91fe4e8caa53aadeff92477637870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477637871 rdf:first _:807f36cf91fe4e8caa53aadeff92477637872;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10742 .

_:807f36cf91fe4e8caa53aadeff92477637874 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11118-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> RACECADOTRIL"@fr;
  dct:identifier "IAM_11118";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637876;
  r:natureDuRisque "Risque de majoration des effets indésirables à type d'œdème angio-neurotique (angio-œdème)."@fr;
  r:conduiteATenir """Contre-indication:
- en cas d'antécédents d'angio-oedème sous IEC.

Association déconseillée:
- en l'absence d’antécédents d'angio-oedème sous IEC."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637882, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637876 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637877 .

_:807f36cf91fe4e8caa53aadeff92477637877 rdf:first _:807f36cf91fe4e8caa53aadeff92477637878;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637879 .

_:807f36cf91fe4e8caa53aadeff92477637878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477637879 rdf:first _:807f36cf91fe4e8caa53aadeff92477637880;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10780 .

_:807f36cf91fe4e8caa53aadeff92477637882 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11159-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_11159";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637884;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la bithérapie par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  r:conduiteATenir """Contre-indication: 
- sauf avec le ritonavir."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637890, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637884 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637885 .

_:807f36cf91fe4e8caa53aadeff92477637885 rdf:first _:807f36cf91fe4e8caa53aadeff92477637886;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637887 .

_:807f36cf91fe4e8caa53aadeff92477637886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477637887 rdf:first _:807f36cf91fe4e8caa53aadeff92477637888;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477637890 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11107-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_11107";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637892;
  r:natureDuRisque "Diminution des concentrations plasmatiques du ténofovir alafénamide par diminution de son absorption par l’inducteur."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique pendant l’association et 1 à 2 semaines après l’arrêt de l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637898, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637892 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637893 .

_:807f36cf91fe4e8caa53aadeff92477637893 rdf:first _:807f36cf91fe4e8caa53aadeff92477637894;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637895 .

_:807f36cf91fe4e8caa53aadeff92477637894 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477637895 rdf:first _:807f36cf91fe4e8caa53aadeff92477637896;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff92477637898 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11203-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_11203";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637900;
  r:natureDuRisque "Majoration de la neurotoxicité de l'antimitotique, par diminution de son métabolisme hépatique par l'itraconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637906, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637900 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637901 .

_:807f36cf91fe4e8caa53aadeff92477637901 rdf:first _:807f36cf91fe4e8caa53aadeff92477637902;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637903 .

_:807f36cf91fe4e8caa53aadeff92477637902 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:807f36cf91fe4e8caa53aadeff92477637903 rdf:first _:807f36cf91fe4e8caa53aadeff92477637904;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477637906 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11157-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> MIDAZOLAM"@fr;
  dct:identifier "IAM_11157";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637908;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de midazolam par diminution de son métabolisme hépatique, avec majoration de la sédation."@fr;
  r:conduiteATenir """Association déconseillée:
- avec le midazolam per os

Précaution d'emploi avec :
- avec le midazolam IV et sublingual
Surveillance clinique et réduction de la posologie de midazolam en cas de traitement par l'inhibiteur."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637914, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637908 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637909 .

_:807f36cf91fe4e8caa53aadeff92477637909 rdf:first _:807f36cf91fe4e8caa53aadeff92477637910;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637911 .

_:807f36cf91fe4e8caa53aadeff92477637910 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477637911 rdf:first _:807f36cf91fe4e8caa53aadeff92477637912;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477637914 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10078-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> INSULINE"@fr;
  dct:identifier "IAM_10078";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637916;
  r:natureDuRisque "Augmentation de la réaction hypoglycémique (inhibition des réactions de compensation pouvant faciliter la survenue de coma hypoglycémique)."@fr;
  r:conduiteATenir "Eviter la prise de boissons alcoolisées et de médicaments contenant de l'alcool."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637922, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637916 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637917 .

_:807f36cf91fe4e8caa53aadeff92477637917 rdf:first _:807f36cf91fe4e8caa53aadeff92477637918;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637919 .

_:807f36cf91fe4e8caa53aadeff92477637918 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:807f36cf91fe4e8caa53aadeff92477637919 rdf:first _:807f36cf91fe4e8caa53aadeff92477637920;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:807f36cf91fe4e8caa53aadeff92477637922 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11184-1 a owl:Class;
  rdfs:label "IRINOTECAN <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11184";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637924;
  r:natureDuRisque "Diminution des concentrations plasmatiques du métabolite actif de l'irinotécan, avec risque d'échec du traitement cytotoxique."@fr;
  rdfs:comment "Une étude randomisée, chez 5 patients traités par irinotécan, a mis en évidence une diminution de 42 % des concentrations de son métabolite actif, le SN-38, qui est un substrat de l'isoenzyme CYP3A4. En cas d'association de l'irinotécan avec le millepertu"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637930, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637924 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637925 .

_:807f36cf91fe4e8caa53aadeff92477637925 rdf:first _:807f36cf91fe4e8caa53aadeff92477637926;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637927 .

_:807f36cf91fe4e8caa53aadeff92477637926 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10486 .

_:807f36cf91fe4e8caa53aadeff92477637927 rdf:first _:807f36cf91fe4e8caa53aadeff92477637928;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637930 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11185-1 a owl:Class;
  rdfs:label "ISAVUCONAZOLE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11185";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637932;
  r:natureDuRisque "Diminution des concentrations plasmatiques d’isavuconazole par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637938, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637932 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637933 .

_:807f36cf91fe4e8caa53aadeff92477637933 rdf:first _:807f36cf91fe4e8caa53aadeff92477637934;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637935 .

_:807f36cf91fe4e8caa53aadeff92477637934 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10487 .

_:807f36cf91fe4e8caa53aadeff92477637935 rdf:first _:807f36cf91fe4e8caa53aadeff92477637936;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477637938 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11186-1 a owl:Class;
  rdfs:label "ISONIAZIDE <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_11186";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637940;
  r:natureDuRisque "Diminution des concentrations plasmatiques de kétoconazole."@fr;
  r:conduiteATenir "Espacer les prises des deux anti-infectieux d'au moins 12 heures. Surveiller les concentrations plasmatiques du kétoconazole et adapter éventuellement sa posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637946, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637940 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637941 .

_:807f36cf91fe4e8caa53aadeff92477637941 rdf:first _:807f36cf91fe4e8caa53aadeff92477637942;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637943 .

_:807f36cf91fe4e8caa53aadeff92477637942 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:807f36cf91fe4e8caa53aadeff92477637943 rdf:first _:807f36cf91fe4e8caa53aadeff92477637944;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477637946 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11187-1 a owl:Class;
  rdfs:label "ISONIAZIDE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_11187";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637948;
  r:natureDuRisque "Surdosage en phénytoïne (diminution de son métabolisme)."@fr;
  r:conduiteATenir "Surveillance clinique étroite, dosage des concentrations plasmatiques de phénytoïne et adaptation éventuelle de sa posologie pendant le traitement par l'isoniazide et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637954, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637948 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637949 .

_:807f36cf91fe4e8caa53aadeff92477637949 rdf:first _:807f36cf91fe4e8caa53aadeff92477637950;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637951 .

_:807f36cf91fe4e8caa53aadeff92477637950 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477637951 rdf:first _:807f36cf91fe4e8caa53aadeff92477637952;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:807f36cf91fe4e8caa53aadeff92477637954 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11188-1 a owl:Class;
  rdfs:label "ISONIAZIDE <-> PYRAZINAMIDE"@fr;
  dct:identifier "IAM_11188";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637956;
  r:natureDuRisque "Addition des effets hépatotoxiques."@fr;
  r:conduiteATenir "Surveillance clinique et biologique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637962, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637956 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637957 .

_:807f36cf91fe4e8caa53aadeff92477637957 rdf:first _:807f36cf91fe4e8caa53aadeff92477637958;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637959 .

_:807f36cf91fe4e8caa53aadeff92477637958 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:807f36cf91fe4e8caa53aadeff92477637959 rdf:first _:807f36cf91fe4e8caa53aadeff92477637960;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10770 .

_:807f36cf91fe4e8caa53aadeff92477637962 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11189-1 a owl:Class;
  rdfs:label "ISONIAZIDE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11189";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637964;
  r:natureDuRisque "Augmentation de l'hépatotoxicité de l'isoniazide (augmentation de la formation de métabolites toxiques de l'isoniazide)."@fr;
  r:conduiteATenir "Surveillance clinique et biologique de cette association classique. En cas d'hépatite, arrêter l'isoniazide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637970, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637964 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637965 .

_:807f36cf91fe4e8caa53aadeff92477637965 rdf:first _:807f36cf91fe4e8caa53aadeff92477637966;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637967 .

_:807f36cf91fe4e8caa53aadeff92477637966 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:807f36cf91fe4e8caa53aadeff92477637967 rdf:first _:807f36cf91fe4e8caa53aadeff92477637968;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477637970 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11190-1 a owl:Class;
  rdfs:label "ISONIAZIDE <-> STAVUDINE"@fr;
  dct:identifier "IAM_11190";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637972;
  r:natureDuRisque "Risque majoré de survenue de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637978, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637972 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637973 .

_:807f36cf91fe4e8caa53aadeff92477637973 rdf:first _:807f36cf91fe4e8caa53aadeff92477637974;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637975 .

_:807f36cf91fe4e8caa53aadeff92477637974 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:807f36cf91fe4e8caa53aadeff92477637975 rdf:first _:807f36cf91fe4e8caa53aadeff92477637976;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10858 .

_:807f36cf91fe4e8caa53aadeff92477637978 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11182-1 a owl:Class;
  rdfs:label "INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE <-> TRAMADOL"@fr;
  dct:identifier "IAM_11182";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637980;
  r:natureDuRisque "Risque d'apparition de convulsions et/ou d'un syndrome sérotoninergique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637986, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637980 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637981 .

_:807f36cf91fe4e8caa53aadeff92477637981 rdf:first _:807f36cf91fe4e8caa53aadeff92477637982;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637983 .

_:807f36cf91fe4e8caa53aadeff92477637982 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477637983 rdf:first _:807f36cf91fe4e8caa53aadeff92477637984;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:807f36cf91fe4e8caa53aadeff92477637986 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11192-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> LUMEFANTRINE"@fr;
  dct:identifier "IAM_11192";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637988;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre le torsadogène associé. Si l'association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477637994, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637988 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637989 .

_:807f36cf91fe4e8caa53aadeff92477637989 rdf:first _:807f36cf91fe4e8caa53aadeff92477637990;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637991 .

_:807f36cf91fe4e8caa53aadeff92477637990 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477637991 rdf:first _:807f36cf91fe4e8caa53aadeff92477637992;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477637992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10541 .

_:807f36cf91fe4e8caa53aadeff92477637994 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11181-1 a owl:Class;
  rdfs:label "INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE <-> ORLISTAT"@fr;
  dct:identifier "IAM_11181";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477637996;
  r:natureDuRisque "Risque d'échec thérapeutique en cas de traitement concomitant par orlistat."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638002, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477637996 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477637997 .

_:807f36cf91fe4e8caa53aadeff92477637997 rdf:first _:807f36cf91fe4e8caa53aadeff92477637998;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477637999 .

_:807f36cf91fe4e8caa53aadeff92477637998 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477637999 rdf:first _:807f36cf91fe4e8caa53aadeff92477638000;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477638002 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11191-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> LERCANIDIPINE"@fr;
  dct:identifier "IAM_11191";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638004;
  r:natureDuRisque "Risque majoré d'effets indesirables, notamment d'oedèmes, par diminution du métabolisme hépatique de la dihydropyridine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638010, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638004 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638005 .

_:807f36cf91fe4e8caa53aadeff92477638005 rdf:first _:807f36cf91fe4e8caa53aadeff92477638006;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638007 .

_:807f36cf91fe4e8caa53aadeff92477638006 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477638007 rdf:first _:807f36cf91fe4e8caa53aadeff92477638008;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10514 .

_:807f36cf91fe4e8caa53aadeff92477638010 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11193-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11193";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638012;
  r:natureDuRisque "Risque de diminution importante des concentrations plasmatiques d’itraconazole, avec risque de perte d’efficacité, par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638018, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638012 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638013 .

_:807f36cf91fe4e8caa53aadeff92477638013 rdf:first _:807f36cf91fe4e8caa53aadeff92477638014;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638015 .

_:807f36cf91fe4e8caa53aadeff92477638014 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477638015 rdf:first _:807f36cf91fe4e8caa53aadeff92477638016;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477638018 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11210-1 a owl:Class;
  rdfs:label "JOSAMYCINE <-> SILDENAFIL"@fr;
  dct:identifier "IAM_11210";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638020;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de sildénafil, avec risque d'hypotension."@fr;
  r:conduiteATenir "Débuter le traitement par sildénafil à la dose minimale en cas d'association avec la josamycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638026, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638020 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638021 .

_:807f36cf91fe4e8caa53aadeff92477638021 rdf:first _:807f36cf91fe4e8caa53aadeff92477638022;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638023 .

_:807f36cf91fe4e8caa53aadeff92477638022 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477638023 rdf:first _:807f36cf91fe4e8caa53aadeff92477638024;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10834 .

_:807f36cf91fe4e8caa53aadeff92477638026 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11211-1 a owl:Class;
  rdfs:label "JOSAMYCINE <-> TACROLIMUS"@fr;
  dct:identifier "IAM_11211";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638028;
  r:natureDuRisque "Augmentation des concentrations sanguines de tacrolimus et de la créatininémie, par inhibition du métabolisme hépatique du tacrolimus par la josamycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638034, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638028 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638029 .

_:807f36cf91fe4e8caa53aadeff92477638029 rdf:first _:807f36cf91fe4e8caa53aadeff92477638030;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638031 .

_:807f36cf91fe4e8caa53aadeff92477638030 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477638031 rdf:first _:807f36cf91fe4e8caa53aadeff92477638032;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477638034 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11212-1 a owl:Class;
  rdfs:label "JOSAMYCINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11212";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638036;
  r:natureDuRisque "Risque d'augmentation de la théophyllinémie, particulièrement chez l'enfant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638042, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638036 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638037 .

_:807f36cf91fe4e8caa53aadeff92477638037 rdf:first _:807f36cf91fe4e8caa53aadeff92477638038;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638039 .

_:807f36cf91fe4e8caa53aadeff92477638038 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477638039 rdf:first _:807f36cf91fe4e8caa53aadeff92477638040;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477638042 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11223-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_11223";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638044;
  r:natureDuRisque "Majoration de la neurotoxicité de l'antimitotique, par diminution de son métabolisme hépatique par le kétoconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638050, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638044 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638045 .

_:807f36cf91fe4e8caa53aadeff92477638045 rdf:first _:807f36cf91fe4e8caa53aadeff92477638046;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638047 .

_:807f36cf91fe4e8caa53aadeff92477638046 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:807f36cf91fe4e8caa53aadeff92477638047 rdf:first _:807f36cf91fe4e8caa53aadeff92477638048;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477638050 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11214-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> LUMEFANTRINE"@fr;
  dct:identifier "IAM_11214";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638052;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre le torsadogène associé. Si l'association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638058, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638052 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638053 .

_:807f36cf91fe4e8caa53aadeff92477638053 rdf:first _:807f36cf91fe4e8caa53aadeff92477638054;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638055 .

_:807f36cf91fe4e8caa53aadeff92477638054 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477638055 rdf:first _:807f36cf91fe4e8caa53aadeff92477638056;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10541 .

_:807f36cf91fe4e8caa53aadeff92477638058 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11213-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> LERCANIDIPINE"@fr;
  dct:identifier "IAM_11213";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638060;
  r:natureDuRisque "Risque majoré d'effets indesirables, notamment d'oedèmes, par diminution du métabolisme hépatique de la dihydropyridine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638066, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638060 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638061 .

_:807f36cf91fe4e8caa53aadeff92477638061 rdf:first _:807f36cf91fe4e8caa53aadeff92477638062;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638063 .

_:807f36cf91fe4e8caa53aadeff92477638062 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477638063 rdf:first _:807f36cf91fe4e8caa53aadeff92477638064;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10514 .

_:807f36cf91fe4e8caa53aadeff92477638066 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11215-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> MIZOLASTINE"@fr;
  dct:identifier "IAM_11215";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638068;
  r:natureDuRisque "Risque de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638074, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638068 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638069 .

_:807f36cf91fe4e8caa53aadeff92477638069 rdf:first _:807f36cf91fe4e8caa53aadeff92477638070;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638071 .

_:807f36cf91fe4e8caa53aadeff92477638070 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477638071 rdf:first _:807f36cf91fe4e8caa53aadeff92477638072;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10597 .

_:807f36cf91fe4e8caa53aadeff92477638074 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11216-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_11216";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638076;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de névirapine par diminution de son métabolisme hépatique par le kétoconazole, d'une part, et diminution des concentrations plasmatiques du kétoconazole par augmentation de son métabolisme hépatique par la névi"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638082, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638076 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638077 .

_:807f36cf91fe4e8caa53aadeff92477638077 rdf:first _:807f36cf91fe4e8caa53aadeff92477638078;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638079 .

_:807f36cf91fe4e8caa53aadeff92477638078 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477638079 rdf:first _:807f36cf91fe4e8caa53aadeff92477638080;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:807f36cf91fe4e8caa53aadeff92477638082 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11199-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> TELAPREVIR"@fr;
  dct:identifier "IAM_11199";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638084;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de télaprévir et de l’itraconazole."@fr;
  r:conduiteATenir "Surveillance clinique. Eviter des doses élevées d’itraconazole (> 200 mg par jour)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638090, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638084 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638085 .

_:807f36cf91fe4e8caa53aadeff92477638085 rdf:first _:807f36cf91fe4e8caa53aadeff92477638086;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638087 .

_:807f36cf91fe4e8caa53aadeff92477638086 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477638087 rdf:first _:807f36cf91fe4e8caa53aadeff92477638088;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477638090 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11170-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> SUBSTRATS À RISQUE DU CYP3A4"@fr;
  dct:identifier "IAM_11170";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638092;
  r:chapeau "Pour connaître les risques et les niveaux de contrainte de chacun de ces substrats avec les inhibiteurs puissants du CYP3A4, il convient de se reporter aux interactions spécifiques de chaque substrat."@fr;
  r:natureDuRisque "Majoration des effets indésirables propres à chaque substrat, avec conséquences souvent sévères."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638098, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638092 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638093 .

_:807f36cf91fe4e8caa53aadeff92477638093 rdf:first _:807f36cf91fe4e8caa53aadeff92477638094;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638095 .

_:807f36cf91fe4e8caa53aadeff92477638094 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638095 rdf:first _:807f36cf91fe4e8caa53aadeff92477638096;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10145 .

_:807f36cf91fe4e8caa53aadeff92477638098 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11322-1 a owl:Class;
  rdfs:label "NEBIVOLOL <-> PAROXETINE"@fr;
  dct:identifier "IAM_11322";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638100;
  r:natureDuRisque "Risque de majoration des effets indésirables du nébivolol avec notamment bradycardie excessive, par inhibition de son métabolisme par l’antidépresseur."@fr;
  r:conduiteATenir "Surveillance clinique accrue ; si besoin, adaptation de la posologie du nébivolol pendant la durée du traitement par l’antidépresseur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638106, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638100 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638101 .

_:807f36cf91fe4e8caa53aadeff92477638101 rdf:first _:807f36cf91fe4e8caa53aadeff92477638102;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638103 .

_:807f36cf91fe4e8caa53aadeff92477638102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10623 .

_:807f36cf91fe4e8caa53aadeff92477638103 rdf:first _:807f36cf91fe4e8caa53aadeff92477638104;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:807f36cf91fe4e8caa53aadeff92477638106 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11160-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> OXYCODONE"@fr;
  dct:identifier "IAM_11160";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638108;
  r:natureDuRisque "Majoration des effets indésirables, notamment respiratoires, de l’oxycodone par diminution de son métabolisme par l'inhibiteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l’oxycodone pendant le traitement par l'inhibiteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638114, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638108 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638109 .

_:807f36cf91fe4e8caa53aadeff92477638109 rdf:first _:807f36cf91fe4e8caa53aadeff92477638110;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638111 .

_:807f36cf91fe4e8caa53aadeff92477638110 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638111 rdf:first _:807f36cf91fe4e8caa53aadeff92477638112;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10681 .

_:807f36cf91fe4e8caa53aadeff92477638114 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11161-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> PANOBINOSTAT"@fr;
  dct:identifier "IAM_11161";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638116;
  r:natureDuRisque "Risque de majoration des effets indésirables, notamment cardiaques, du panobinostat par diminution de son métabolisme par l’inhibiteur."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. Débuter le traitement à dose réduite de moitié (10 mg)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638122, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638116 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638117 .

_:807f36cf91fe4e8caa53aadeff92477638117 rdf:first _:807f36cf91fe4e8caa53aadeff92477638118;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638119 .

_:807f36cf91fe4e8caa53aadeff92477638118 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638119 rdf:first _:807f36cf91fe4e8caa53aadeff92477638120;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10688 .

_:807f36cf91fe4e8caa53aadeff92477638122 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11162-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> PIMOZIDE"@fr;
  dct:identifier "IAM_11162";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638124;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638130, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638124 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638125 .

_:807f36cf91fe4e8caa53aadeff92477638125 rdf:first _:807f36cf91fe4e8caa53aadeff92477638126;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638127 .

_:807f36cf91fe4e8caa53aadeff92477638126 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638127 rdf:first _:807f36cf91fe4e8caa53aadeff92477638128;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477638130 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11163-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> QUETIAPINE"@fr;
  dct:identifier "IAM_11163";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638132;
  r:natureDuRisque "Augmentation importante des concentrations de quétiapine, avec risque de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638138, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638132 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638133 .

_:807f36cf91fe4e8caa53aadeff92477638133 rdf:first _:807f36cf91fe4e8caa53aadeff92477638134;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638135 .

_:807f36cf91fe4e8caa53aadeff92477638134 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638135 rdf:first _:807f36cf91fe4e8caa53aadeff92477638136;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10773 .

_:807f36cf91fe4e8caa53aadeff92477638138 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11164-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> QUININE"@fr;
  dct:identifier "IAM_11164";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638140;
  r:natureDuRisque "Risque de majoration des effets indésirables de la quinine, notamment troubles du rythme ventriculaire et troubles neurosensoriels (cinchonisme)."@fr;
  r:conduiteATenir """Association déconseillée : 
- avec les inhibiteurs de protéases

Précaution d’emploi : 
- avec les azolés antifongiques et certains macrolides.
Surveillance clinique et ECG. Adaptation éventuelle de la posologie de la quinine pendant le traitement par l’i"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638146, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638140 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638141 .

_:807f36cf91fe4e8caa53aadeff92477638141 rdf:first _:807f36cf91fe4e8caa53aadeff92477638142;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638143 .

_:807f36cf91fe4e8caa53aadeff92477638142 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638143 rdf:first _:807f36cf91fe4e8caa53aadeff92477638144;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10777 .

_:807f36cf91fe4e8caa53aadeff92477638146 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11165-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> RANOLAZINE"@fr;
  dct:identifier "IAM_11165";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638148;
  r:natureDuRisque "Augmentation des concentrations de ranolazine par diminution de son métabolisme par l'inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638154, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638148 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638149 .

_:807f36cf91fe4e8caa53aadeff92477638149 rdf:first _:807f36cf91fe4e8caa53aadeff92477638150;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638151 .

_:807f36cf91fe4e8caa53aadeff92477638150 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638151 rdf:first _:807f36cf91fe4e8caa53aadeff92477638152;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:807f36cf91fe4e8caa53aadeff92477638154 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11166-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> RÉGORAFÉNIB"@fr;
  dct:identifier "IAM_11166";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638156;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de régorafenib par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638162, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638156 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638157 .

_:807f36cf91fe4e8caa53aadeff92477638157 rdf:first _:807f36cf91fe4e8caa53aadeff92477638158;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638159 .

_:807f36cf91fe4e8caa53aadeff92477638158 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638159 rdf:first _:807f36cf91fe4e8caa53aadeff92477638160;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10789 .

_:807f36cf91fe4e8caa53aadeff92477638162 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11167-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> RIOCIGUAT"@fr;
  dct:identifier "IAM_11167";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638164;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de riociguat par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638170, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638164 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638165 .

_:807f36cf91fe4e8caa53aadeff92477638165 rdf:first _:807f36cf91fe4e8caa53aadeff92477638166;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638167 .

_:807f36cf91fe4e8caa53aadeff92477638166 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638167 rdf:first _:807f36cf91fe4e8caa53aadeff92477638168;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10804 .

_:807f36cf91fe4e8caa53aadeff92477638170 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11183-1 a owl:Class;
  rdfs:label "INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE <-> TRIPTANS"@fr;
  dct:identifier "IAM_11183";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638172;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638178, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638172 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638173 .

_:807f36cf91fe4e8caa53aadeff92477638173 rdf:first _:807f36cf91fe4e8caa53aadeff92477638174;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638175 .

_:807f36cf91fe4e8caa53aadeff92477638174 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477638175 rdf:first _:807f36cf91fe4e8caa53aadeff92477638176;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10156 .

_:807f36cf91fe4e8caa53aadeff92477638178 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11169-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> SIMÉPRÉVIR"@fr;
  dct:identifier "IAM_11169";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638180;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de siméprévir par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638186, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638180 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638181 .

_:807f36cf91fe4e8caa53aadeff92477638181 rdf:first _:807f36cf91fe4e8caa53aadeff92477638182;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638183 .

_:807f36cf91fe4e8caa53aadeff92477638182 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638183 rdf:first _:807f36cf91fe4e8caa53aadeff92477638184;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10837 .

_:807f36cf91fe4e8caa53aadeff92477638186 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11158-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> OLAPARIB"@fr;
  dct:identifier "IAM_11158";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638188;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’olaparib par l’inhibiteur."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, limiter la dose d’olaparib à 150 mg deux fois par jour."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638194, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638188 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638189 .

_:807f36cf91fe4e8caa53aadeff92477638189 rdf:first _:807f36cf91fe4e8caa53aadeff92477638190;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638191 .

_:807f36cf91fe4e8caa53aadeff92477638190 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638191 rdf:first _:807f36cf91fe4e8caa53aadeff92477638192;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10659 .

_:807f36cf91fe4e8caa53aadeff92477638194 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11171-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> SUFENTANIL"@fr;
  dct:identifier "IAM_11171";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638196;
  r:natureDuRisque "Augmentation de l’effet dépresseur respiratoire de l’analgésique opiacé par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de l’analgésique opiacé en cas de traitement par un inhibiteur puissant du CYP3A4."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638202, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638196 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638197 .

_:807f36cf91fe4e8caa53aadeff92477638197 rdf:first _:807f36cf91fe4e8caa53aadeff92477638198;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638199 .

_:807f36cf91fe4e8caa53aadeff92477638198 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638199 rdf:first _:807f36cf91fe4e8caa53aadeff92477638200;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10865 .

_:807f36cf91fe4e8caa53aadeff92477638202 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11172-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> TAMSULOSINE"@fr;
  dct:identifier "IAM_11172";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638204;
  r:natureDuRisque "Risque de majoration des effets indésirables de la tamsulosine, par inhibition de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638210, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638204 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638205 .

_:807f36cf91fe4e8caa53aadeff92477638205 rdf:first _:807f36cf91fe4e8caa53aadeff92477638206;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638207 .

_:807f36cf91fe4e8caa53aadeff92477638206 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638207 rdf:first _:807f36cf91fe4e8caa53aadeff92477638208;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10883 .

_:807f36cf91fe4e8caa53aadeff92477638210 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11173-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_11173";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638212;
  r:natureDuRisque "Risque de majoration des effets indésirables, notamment à type de troubles du rythme cardiaque."@fr;
  r:conduiteATenir "chez le patient insuffisant rénal ou hépatique sévère."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638218, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638212 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638213 .

_:807f36cf91fe4e8caa53aadeff92477638213 rdf:first _:807f36cf91fe4e8caa53aadeff92477638214;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638215 .

_:807f36cf91fe4e8caa53aadeff92477638214 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638215 rdf:first _:807f36cf91fe4e8caa53aadeff92477638216;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477638218 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11174-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> TICAGRELOR"@fr;
  dct:identifier "IAM_11174";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638220;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de ticagrelor par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638226, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638220 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638221 .

_:807f36cf91fe4e8caa53aadeff92477638221 rdf:first _:807f36cf91fe4e8caa53aadeff92477638222;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638223 .

_:807f36cf91fe4e8caa53aadeff92477638222 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638223 rdf:first _:807f36cf91fe4e8caa53aadeff92477638224;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477638226 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11175-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> TRASTUZUMAB EMTANSINE"@fr;
  dct:identifier "IAM_11175";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638228;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du DM1, un composant du trastuzumab emtansine, par inhibition de son métabolisme par l’inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638234, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638228 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638229 .

_:807f36cf91fe4e8caa53aadeff92477638229 rdf:first _:807f36cf91fe4e8caa53aadeff92477638230;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638231 .

_:807f36cf91fe4e8caa53aadeff92477638230 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638231 rdf:first _:807f36cf91fe4e8caa53aadeff92477638232;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10948 .

_:807f36cf91fe4e8caa53aadeff92477638234 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11176-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11176";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638236;
  r:natureDuRisque "Bradycardie et/ou troubles de la conduction auriculo-ventriculaire, par diminution du métabolisme hépatique du vérapamil par l’inhibiteur."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. S’il y a lieu, adaptation de la posologie du vérapamil pendant le traitement par l’inhibiteur, et après son arrêt, le cas échéant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638242, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638236 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638237 .

_:807f36cf91fe4e8caa53aadeff92477638237 rdf:first _:807f36cf91fe4e8caa53aadeff92477638238;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638239 .

_:807f36cf91fe4e8caa53aadeff92477638238 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638239 rdf:first _:807f36cf91fe4e8caa53aadeff92477638240;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638240 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477638242 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11177-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> ZOLPIDEM"@fr;
  dct:identifier "IAM_11177";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638244;
  r:natureDuRisque "Légère augmentation de l'effet sédatif du zolpidem."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638250, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638244 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638245 .

_:807f36cf91fe4e8caa53aadeff92477638245 rdf:first _:807f36cf91fe4e8caa53aadeff92477638246;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638247 .

_:807f36cf91fe4e8caa53aadeff92477638246 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638247 rdf:first _:807f36cf91fe4e8caa53aadeff92477638248;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638248 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11008 .

_:807f36cf91fe4e8caa53aadeff92477638250 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11178-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> ZOPICLONE"@fr;
  dct:identifier "IAM_11178";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638252;
  r:natureDuRisque "Légère augmentation de l'effet sédatif de la zopiclone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638258, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638252 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638253 .

_:807f36cf91fe4e8caa53aadeff92477638253 rdf:first _:807f36cf91fe4e8caa53aadeff92477638254;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638255 .

_:807f36cf91fe4e8caa53aadeff92477638254 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638255 rdf:first _:807f36cf91fe4e8caa53aadeff92477638256;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638256 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11010 .

_:807f36cf91fe4e8caa53aadeff92477638258 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11179-1 a owl:Class;
  rdfs:label "INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE <-> LITHIUM"@fr;
  dct:identifier "IAM_11179";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638260;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638266, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638260 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638261 .

_:807f36cf91fe4e8caa53aadeff92477638261 rdf:first _:807f36cf91fe4e8caa53aadeff92477638262;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638263 .

_:807f36cf91fe4e8caa53aadeff92477638262 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477638263 rdf:first _:807f36cf91fe4e8caa53aadeff92477638264;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638264 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477638266 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11180-1 a owl:Class;
  rdfs:label "INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11180";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638268;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638274, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638268 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638269 .

_:807f36cf91fe4e8caa53aadeff92477638269 rdf:first _:807f36cf91fe4e8caa53aadeff92477638270;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638271 .

_:807f36cf91fe4e8caa53aadeff92477638270 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477638271 rdf:first _:807f36cf91fe4e8caa53aadeff92477638272;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638272 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477638274 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11168-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> RIVAROXABAN"@fr;
  dct:identifier "IAM_11168";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638276;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de rivaroxaban, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638282, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638276 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638277 .

_:807f36cf91fe4e8caa53aadeff92477638277 rdf:first _:807f36cf91fe4e8caa53aadeff92477638278;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638279 .

_:807f36cf91fe4e8caa53aadeff92477638278 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638279 rdf:first _:807f36cf91fe4e8caa53aadeff92477638280;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638280 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10808 .

_:807f36cf91fe4e8caa53aadeff92477638282 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11448-1 a owl:Class;
  rdfs:label "TÉNOFOVIR ALAFÉNAMIDE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11448";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638284;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du ténofovir alafénamide par augmentation de son absorption."@fr;
  r:conduiteATenir "En cas de co-administration avec le vérapamil, la dose de ténofovir alafénamide doit être limitée à 10 mg par jour."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638290, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638284 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638285 .

_:807f36cf91fe4e8caa53aadeff92477638285 rdf:first _:807f36cf91fe4e8caa53aadeff92477638286;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638287 .

_:807f36cf91fe4e8caa53aadeff92477638286 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff92477638287 rdf:first _:807f36cf91fe4e8caa53aadeff92477638288;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638288 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477638290 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11439-1 a owl:Class;
  rdfs:label "SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES <-> TORSADOGÈNES (SAUF ANTIPARASITAIRES, NEUROLEPTIQUES, MÉTHADONE)"@fr;
  dct:identifier "IAM_11439";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638292;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication:
- Pour l'érythromycine et la vincamine, seules les formes administrées par voie intraveineuse sont concernées par cette interaction.
- Pour la spiramycine, la voie IV et la voie orale sont concernées.

Association déconseillée:
- avec l"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638298, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638292 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638293 .

_:807f36cf91fe4e8caa53aadeff92477638293 rdf:first _:807f36cf91fe4e8caa53aadeff92477638294;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638295 .

_:807f36cf91fe4e8caa53aadeff92477638294 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477638295 rdf:first _:807f36cf91fe4e8caa53aadeff92477638296;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638296 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10154 .

_:807f36cf91fe4e8caa53aadeff92477638298 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11440-1 a owl:Class;
  rdfs:label "SUCRALFATE <-> SULPIRIDE"@fr;
  dct:identifier "IAM_11440";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638300;
  r:natureDuRisque "Diminution de l'absorption digestive du sulpiride."@fr;
  r:conduiteATenir "Prendre le sucralfate à distance du sulpiride (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638306, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638300 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638301 .

_:807f36cf91fe4e8caa53aadeff92477638301 rdf:first _:807f36cf91fe4e8caa53aadeff92477638302;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638303 .

_:807f36cf91fe4e8caa53aadeff92477638302 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10864 .

_:807f36cf91fe4e8caa53aadeff92477638303 rdf:first _:807f36cf91fe4e8caa53aadeff92477638304;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638304 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10875 .

_:807f36cf91fe4e8caa53aadeff92477638306 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10081-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10081";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638308;
  r:natureDuRisque "Effet antabuse, notamment pour glibenclamide, glipizide, tolbutamide. Augmentation de la réaction hypoglycémique (inhibition des réactions de compensation) pouvant faciliter la survenue de coma hypoglycémique."@fr;
  r:conduiteATenir "Eviter la prise de boissons alcoolisées et de médicaments contenant de l'alcool."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638314, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638308 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638309 .

_:807f36cf91fe4e8caa53aadeff92477638309 rdf:first _:807f36cf91fe4e8caa53aadeff92477638310;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638311 .

_:807f36cf91fe4e8caa53aadeff92477638310 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477638311 rdf:first _:807f36cf91fe4e8caa53aadeff92477638312;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638312 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:807f36cf91fe4e8caa53aadeff92477638314 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11441-1 a owl:Class;
  rdfs:label "SYMPATHOMIMÉTIQUES ALPHA (VOIES ORALE ET/OU NASALE) <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_11441";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638316;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638322, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638316 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638317 .

_:807f36cf91fe4e8caa53aadeff92477638317 rdf:first _:807f36cf91fe4e8caa53aadeff92477638318;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638319 .

_:807f36cf91fe4e8caa53aadeff92477638318 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10148 .

_:807f36cf91fe4e8caa53aadeff92477638319 rdf:first _:807f36cf91fe4e8caa53aadeff92477638320;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638320 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477638322 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10427-1 a owl:Class;
  rdfs:label "AUTRES SYMPATHOMIMETIQUES INDIRECTS <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_10427";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638324;
  r:natureDuRisque "Risque de vasoconstriction et/ou de crises hypertensives."@fr;
  rdfs:comment """Les décisions suivantes, émanant de trois instances de l'Afssaps, ont été prises en compte : 
- la Commission Nationale de Pharmacovigilance a pris acte d'une toxicité de la phénylpropanolamine supérieure à celle des autres sympathomimétiques indirects ("""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638326, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477638326 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11442-1 a owl:Class;
  rdfs:label "TACROLIMUS <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11442";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638328;
  r:natureDuRisque "Augmentation des concentrations sanguines du tacrolimus (diminution de son métabolisme hépatique par le verapamil)."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l’immunosuppresseur, contrôle de la fonction rénale et adaptation de la posologie pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638334, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638328 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638329 .

_:807f36cf91fe4e8caa53aadeff92477638329 rdf:first _:807f36cf91fe4e8caa53aadeff92477638330;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638331 .

_:807f36cf91fe4e8caa53aadeff92477638330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477638331 rdf:first _:807f36cf91fe4e8caa53aadeff92477638332;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477638334 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11443-1 a owl:Class;
  rdfs:label "TAMOXIFENE <-> TERBINAFINE"@fr;
  dct:identifier "IAM_11443";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638336;
  r:natureDuRisque "Risque de baisse de l'efficacité du tamoxifène, par inhibition de la formation de son métabolite actif par la terbinafine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638342, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638336 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638337 .

_:807f36cf91fe4e8caa53aadeff92477638337 rdf:first _:807f36cf91fe4e8caa53aadeff92477638338;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638339 .

_:807f36cf91fe4e8caa53aadeff92477638338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:807f36cf91fe4e8caa53aadeff92477638339 rdf:first _:807f36cf91fe4e8caa53aadeff92477638340;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:807f36cf91fe4e8caa53aadeff92477638342 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11444-1 a owl:Class;
  rdfs:label "TAMSULOSINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11444";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638344;
  r:natureDuRisque "Risque de majoration des effets indésirables de la tamsulosine, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la tamsulosine pensant le traitement par l’inhibiteur enzymatique et après son arrêt, le cas échéant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638350, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638344 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638345 .

_:807f36cf91fe4e8caa53aadeff92477638345 rdf:first _:807f36cf91fe4e8caa53aadeff92477638346;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638347 .

_:807f36cf91fe4e8caa53aadeff92477638346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10883 .

_:807f36cf91fe4e8caa53aadeff92477638347 rdf:first _:807f36cf91fe4e8caa53aadeff92477638348;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477638350 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11445-1 a owl:Class;
  rdfs:label "TELAPREVIR <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_11445";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638352;
  r:natureDuRisque "Risque de diminution de l'efficacité du ténofovir alafénamide par diminution de son activité intracellulaire par le télaprévir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638358, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638352 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638353 .

_:807f36cf91fe4e8caa53aadeff92477638353 rdf:first _:807f36cf91fe4e8caa53aadeff92477638354;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638355 .

_:807f36cf91fe4e8caa53aadeff92477638354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477638355 rdf:first _:807f36cf91fe4e8caa53aadeff92477638356;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff92477638358 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11415-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> TIAGABINE"@fr;
  dct:identifier "IAM_11415";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638360;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la tiagabine par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Une augmentation de la posologie de la tiagabine peut s’avérer nécessaire en cas d’association à la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638366, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638360 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638361 .

_:807f36cf91fe4e8caa53aadeff92477638361 rdf:first _:807f36cf91fe4e8caa53aadeff92477638362;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638363 .

_:807f36cf91fe4e8caa53aadeff92477638362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477638363 rdf:first _:807f36cf91fe4e8caa53aadeff92477638364;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10922 .

_:807f36cf91fe4e8caa53aadeff92477638366 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11446-1 a owl:Class;
  rdfs:label "TELITHROMYCINE <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_11446";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638368;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638374, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638368 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638369 .

_:807f36cf91fe4e8caa53aadeff92477638369 rdf:first _:807f36cf91fe4e8caa53aadeff92477638370;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638371 .

_:807f36cf91fe4e8caa53aadeff92477638370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477638371 rdf:first _:807f36cf91fe4e8caa53aadeff92477638372;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:807f36cf91fe4e8caa53aadeff92477638374 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11436-1 a owl:Class;
  rdfs:label "STIRIPENTOL <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11436";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638376;
  r:natureDuRisque "Augmentation possible de la théophyllinémie, avec risque de surdosage, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique, dosage plasmatique et adaptation éventuelle de la posologie de théophylline."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638382, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638376 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638377 .

_:807f36cf91fe4e8caa53aadeff92477638377 rdf:first _:807f36cf91fe4e8caa53aadeff92477638378;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638379 .

_:807f36cf91fe4e8caa53aadeff92477638378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477638379 rdf:first _:807f36cf91fe4e8caa53aadeff92477638380;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477638382 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11449-1 a owl:Class;
  rdfs:label "TERBINAFINE <-> VORTIOXÉTINE"@fr;
  dct:identifier "IAM_11449";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638384;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la vortioxétine par diminution importante de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la vortioxétine pendant le traitement par la terbinafine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638390, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638384 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638385 .

_:807f36cf91fe4e8caa53aadeff92477638385 rdf:first _:807f36cf91fe4e8caa53aadeff92477638386;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638387 .

_:807f36cf91fe4e8caa53aadeff92477638386 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:807f36cf91fe4e8caa53aadeff92477638387 rdf:first _:807f36cf91fe4e8caa53aadeff92477638388;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10999 .

_:807f36cf91fe4e8caa53aadeff92477638390 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11450-1 a owl:Class;
  rdfs:label "TÉRIFLUNOMIDE <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_11450";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638392;
  r:natureDuRisque "Risque de maladie vaccinale généralisée, éventuellement mortelle."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638398, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638392 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638393 .

_:807f36cf91fe4e8caa53aadeff92477638393 rdf:first _:807f36cf91fe4e8caa53aadeff92477638394;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638395 .

_:807f36cf91fe4e8caa53aadeff92477638394 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477638395 rdf:first _:807f36cf91fe4e8caa53aadeff92477638396;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10902 .

_:807f36cf91fe4e8caa53aadeff92477638398 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11451-1 a owl:Class;
  rdfs:label "THALIDOMIDE <-> ZALCITABINE"@fr;
  dct:identifier "IAM_11451";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638400;
  r:natureDuRisque "Risque majoré de survenue de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638406, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638400 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638401 .

_:807f36cf91fe4e8caa53aadeff92477638401 rdf:first _:807f36cf91fe4e8caa53aadeff92477638402;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638403 .

_:807f36cf91fe4e8caa53aadeff92477638402 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10913 .

_:807f36cf91fe4e8caa53aadeff92477638403 rdf:first _:807f36cf91fe4e8caa53aadeff92477638404;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11002 .

_:807f36cf91fe4e8caa53aadeff92477638406 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11454-1 a owl:Class;
  rdfs:label "THEOPHYLLINE <-> VÉMURAFÉNIB"@fr;
  dct:identifier "IAM_11454";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638408;
  r:natureDuRisque "Augmentation importante des concentrations de théophylline, avec risques de majoration de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la théophylline pendant le traitement par vémurafénib et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638414, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638408 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638409 .

_:807f36cf91fe4e8caa53aadeff92477638409 rdf:first _:807f36cf91fe4e8caa53aadeff92477638410;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638411 .

_:807f36cf91fe4e8caa53aadeff92477638410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10915 .

_:807f36cf91fe4e8caa53aadeff92477638411 rdf:first _:807f36cf91fe4e8caa53aadeff92477638412;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10978 .

_:807f36cf91fe4e8caa53aadeff92477638414 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11452-1 a owl:Class;
  rdfs:label "THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE) <-> TIABENDAZOLE"@fr;
  dct:identifier "IAM_11452";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638416;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage, par diminution du métabolisme hépatique de la théophylline."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; s'il y a lieu, adaptation de la posologie de la théophylline pendant le traitement (et après son arrêt, dans le cas où l'anthelminthique est prescrit pour une durée excédant 48 heures)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638422, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638416 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638417 .

_:807f36cf91fe4e8caa53aadeff92477638417 rdf:first _:807f36cf91fe4e8caa53aadeff92477638418;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638419 .

_:807f36cf91fe4e8caa53aadeff92477638418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477638419 rdf:first _:807f36cf91fe4e8caa53aadeff92477638420;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10921 .

_:807f36cf91fe4e8caa53aadeff92477638422 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11453-1 a owl:Class;
  rdfs:label "THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE) <-> TICLOPIDINE"@fr;
  dct:identifier "IAM_11453";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638424;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage (diminution de la clairance plasmatique de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; s'il y a lieu, adaptation de la posologie de la théophylline pendant le traitement par la ticlopidine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638430, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638424 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638425 .

_:807f36cf91fe4e8caa53aadeff92477638425 rdf:first _:807f36cf91fe4e8caa53aadeff92477638426;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638427 .

_:807f36cf91fe4e8caa53aadeff92477638426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477638427 rdf:first _:807f36cf91fe4e8caa53aadeff92477638428;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10928 .

_:807f36cf91fe4e8caa53aadeff92477638430 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11455-1 a owl:Class;
  rdfs:label "TICAGRELOR <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11455";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638432;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de ticagrelor par diminution de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638438, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638432 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638433 .

_:807f36cf91fe4e8caa53aadeff92477638433 rdf:first _:807f36cf91fe4e8caa53aadeff92477638434;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638435 .

_:807f36cf91fe4e8caa53aadeff92477638434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477638435 rdf:first _:807f36cf91fe4e8caa53aadeff92477638436;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477638438 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11257-1 a owl:Class;
  rdfs:label "MÉDICAMENTS ADMINISTRÉS PAR VOIE ORALE <-> TOPIQUES GASTRO-INTESTINAUX, ANTIACIDES ET ADSORBANTS"@fr;
  dct:identifier "IAM_11257";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638440;
  r:natureDuRisque "Diminution de l'absorption de certains autres médicaments ingérés simultanément."@fr;
  r:conduiteATenir "Par mesure de précaution, il convient de prendre ces topiques ou antiacides à distance de tout autre médicament (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638446, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638440 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638441 .

_:807f36cf91fe4e8caa53aadeff92477638441 rdf:first _:807f36cf91fe4e8caa53aadeff92477638442;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638443 .

_:807f36cf91fe4e8caa53aadeff92477638442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10153 .

_:807f36cf91fe4e8caa53aadeff92477638443 rdf:first _:807f36cf91fe4e8caa53aadeff92477638444;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10166 .

_:807f36cf91fe4e8caa53aadeff92477638446 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11456-1 a owl:Class;
  rdfs:label "TOPIRAMATE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11456";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638448;
  r:natureDuRisque "Augmentation de l'hyperammoniémie, avec risque accru d'encéphalopathie."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638454, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638448 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638449 .

_:807f36cf91fe4e8caa53aadeff92477638449 rdf:first _:807f36cf91fe4e8caa53aadeff92477638450;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638451 .

_:807f36cf91fe4e8caa53aadeff92477638450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477638451 rdf:first _:807f36cf91fe4e8caa53aadeff92477638452;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10941 .

_:807f36cf91fe4e8caa53aadeff92477638454 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11447-1 a owl:Class;
  rdfs:label "TELITHROMYCINE <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_11447";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638456;
  r:natureDuRisque "Risque de majoration de la toxicité de l'antimitotique par diminution de son métabolisme hépatique par la télithromycine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique étroite. Eventuellement, utiliser un autre antibiotique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638462, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638456 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638457 .

_:807f36cf91fe4e8caa53aadeff92477638457 rdf:first _:807f36cf91fe4e8caa53aadeff92477638458;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638459 .

_:807f36cf91fe4e8caa53aadeff92477638458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:807f36cf91fe4e8caa53aadeff92477638459 rdf:first _:807f36cf91fe4e8caa53aadeff92477638460;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477638462 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11427-1 a owl:Class;
  rdfs:label "SIMVASTATINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_11427";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638464;
  r:natureDuRisque "Risque majoré d’effets indésirables (dose-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’hypocholestérolémiant)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638470, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638464 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638465 .

_:807f36cf91fe4e8caa53aadeff92477638465 rdf:first _:807f36cf91fe4e8caa53aadeff92477638466;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638467 .

_:807f36cf91fe4e8caa53aadeff92477638466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477638467 rdf:first _:807f36cf91fe4e8caa53aadeff92477638468;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477638470 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11320-1 a owl:Class;
  rdfs:label "MYCOPHENOLATE MOFETIL <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_11320";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638472;
  r:natureDuRisque "Risque de maladie vaccinale généralisée éventuellement mortelle."@fr;
  r:conduiteATenir "Et pendant les 3 mois suivant l'arrêt du traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638478, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638472 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638473 .

_:807f36cf91fe4e8caa53aadeff92477638473 rdf:first _:807f36cf91fe4e8caa53aadeff92477638474;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638475 .

_:807f36cf91fe4e8caa53aadeff92477638474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477638475 rdf:first _:807f36cf91fe4e8caa53aadeff92477638476;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10609 .

_:807f36cf91fe4e8caa53aadeff92477638478 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11417-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_11417";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638480;
  r:natureDuRisque "Risque de diminution de l’effet de l’ulipristal, par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  r:conduiteATenir "Préférer une alternative thérapeutique peu ou pas métabolisée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638486, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638480 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638481 .

_:807f36cf91fe4e8caa53aadeff92477638481 rdf:first _:807f36cf91fe4e8caa53aadeff92477638482;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638483 .

_:807f36cf91fe4e8caa53aadeff92477638482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477638483 rdf:first _:807f36cf91fe4e8caa53aadeff92477638484;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477638486 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11418-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11418";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638488;
  r:natureDuRisque "Risque de survenue de crises convulsives, par augmentation du métabolisme hépatique du valproate par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique, et adaptation éventuelle de la posologie de l'anticonvulsivant pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638494, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638488 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638489 .

_:807f36cf91fe4e8caa53aadeff92477638489 rdf:first _:807f36cf91fe4e8caa53aadeff92477638490;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638491 .

_:807f36cf91fe4e8caa53aadeff92477638490 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477638491 rdf:first _:807f36cf91fe4e8caa53aadeff92477638492;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477638494 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11419-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> VITAMINE D"@fr;
  dct:identifier "IAM_11419";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638496;
  r:natureDuRisque "Diminution des concentrations de vitamine D plus marquée qu’en l’absence de traitement par la rifampicine"@fr;
  r:conduiteATenir "Dosage des concentrations de vitamine D et supplémentation si nécessaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638502, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638496 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638497 .

_:807f36cf91fe4e8caa53aadeff92477638497 rdf:first _:807f36cf91fe4e8caa53aadeff92477638498;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638499 .

_:807f36cf91fe4e8caa53aadeff92477638498 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10162 .

_:807f36cf91fe4e8caa53aadeff92477638499 rdf:first _:807f36cf91fe4e8caa53aadeff92477638500;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477638502 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11420-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11420";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638504;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques du voriconazole avec risque de perte d'efficacité, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638510, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638504 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638505 .

_:807f36cf91fe4e8caa53aadeff92477638505 rdf:first _:807f36cf91fe4e8caa53aadeff92477638506;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638507 .

_:807f36cf91fe4e8caa53aadeff92477638506 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477638507 rdf:first _:807f36cf91fe4e8caa53aadeff92477638508;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477638510 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11421-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> ZOLPIDEM"@fr;
  dct:identifier "IAM_11421";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638512;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité du zolpidem par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique. Utiliser éventuellement un autre hypnotique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638518, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638512 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638513 .

_:807f36cf91fe4e8caa53aadeff92477638513 rdf:first _:807f36cf91fe4e8caa53aadeff92477638514;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638515 .

_:807f36cf91fe4e8caa53aadeff92477638514 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477638515 rdf:first _:807f36cf91fe4e8caa53aadeff92477638516;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11008 .

_:807f36cf91fe4e8caa53aadeff92477638518 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11422-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> ZOPICLONE"@fr;
  dct:identifier "IAM_11422";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638520;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de la zopiclone par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique. Utiliser éventuellement un autre hypnotique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638526, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638520 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638521 .

_:807f36cf91fe4e8caa53aadeff92477638521 rdf:first _:807f36cf91fe4e8caa53aadeff92477638522;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638523 .

_:807f36cf91fe4e8caa53aadeff92477638522 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477638523 rdf:first _:807f36cf91fe4e8caa53aadeff92477638524;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11010 .

_:807f36cf91fe4e8caa53aadeff92477638526 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11423-1 a owl:Class;
  rdfs:label "ROXITHROMYCINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11423";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638528;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d’hypocholestérolémiant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638534, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638528 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638529 .

_:807f36cf91fe4e8caa53aadeff92477638529 rdf:first _:807f36cf91fe4e8caa53aadeff92477638530;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638531 .

_:807f36cf91fe4e8caa53aadeff92477638530 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10817 .

_:807f36cf91fe4e8caa53aadeff92477638531 rdf:first _:807f36cf91fe4e8caa53aadeff92477638532;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477638534 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11424-1 a owl:Class;
  rdfs:label "ROXITHROMYCINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11424";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638536;
  r:natureDuRisque """Risque majoré de troubles du rythme ventriculaire, notamment de
torsades de pointes."""@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638542, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638536 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638537 .

_:807f36cf91fe4e8caa53aadeff92477638537 rdf:first _:807f36cf91fe4e8caa53aadeff92477638538;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638539 .

_:807f36cf91fe4e8caa53aadeff92477638538 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477638539 rdf:first _:807f36cf91fe4e8caa53aadeff92477638540;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10817 .

_:807f36cf91fe4e8caa53aadeff92477638542 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11438-1 a owl:Class;
  rdfs:label "SUBSTANCES À ABSORPTION RÉDUITE PAR LES TOPIQUES GASTRO-INTESTINAUX, ANTIACIDES ET ADSORBANTS <-> TOPIQUES GASTRO-INTESTINAUX, ANTIACIDES ET ADSORBANTS"@fr;
  dct:identifier "IAM_11438";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638544;
  r:natureDuRisque "Diminution de l'absorption de ces substances."@fr;
  r:conduiteATenir "Prendre les topiques ou antiacides, adsorbants à distance de ces substances (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638550, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638544 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638545 .

_:807f36cf91fe4e8caa53aadeff92477638545 rdf:first _:807f36cf91fe4e8caa53aadeff92477638546;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638547 .

_:807f36cf91fe4e8caa53aadeff92477638546 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10144 .

_:807f36cf91fe4e8caa53aadeff92477638547 rdf:first _:807f36cf91fe4e8caa53aadeff92477638548;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10153 .

_:807f36cf91fe4e8caa53aadeff92477638550 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11426-1 a owl:Class;
  rdfs:label "RUFINAMIDE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11426";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638552;
  r:natureDuRisque "Possible augmentation des concentrations de rufinamide, notamment chez l’enfant de moins de 30 kg."@fr;
  r:conduiteATenir """Chez l’enfant de moins de 30 kg :
ne pas dépasser la dose totale de 600 mg/j après la période de titration."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638558, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638552 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638553 .

_:807f36cf91fe4e8caa53aadeff92477638553 rdf:first _:807f36cf91fe4e8caa53aadeff92477638554;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638555 .

_:807f36cf91fe4e8caa53aadeff92477638554 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477638555 rdf:first _:807f36cf91fe4e8caa53aadeff92477638556;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10818 .

_:807f36cf91fe4e8caa53aadeff92477638558 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11437-1 a owl:Class;
  rdfs:label "STRONTIUM <-> ZINC"@fr;
  dct:identifier "IAM_11437";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638560;
  r:natureDuRisque "Diminution de l'absorption digestive du strontium."@fr;
  r:conduiteATenir "Prendre le strontium à distance des sels de zinc (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638566, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638560 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638561 .

_:807f36cf91fe4e8caa53aadeff92477638561 rdf:first _:807f36cf91fe4e8caa53aadeff92477638562;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638563 .

_:807f36cf91fe4e8caa53aadeff92477638562 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10863 .

_:807f36cf91fe4e8caa53aadeff92477638563 rdf:first _:807f36cf91fe4e8caa53aadeff92477638564;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11005 .

_:807f36cf91fe4e8caa53aadeff92477638566 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11428-1 a owl:Class;
  rdfs:label "SIMVASTATINE <-> TELAPREVIR"@fr;
  dct:identifier "IAM_11428";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638568;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de la simvastatine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638574, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638568 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638569 .

_:807f36cf91fe4e8caa53aadeff92477638569 rdf:first _:807f36cf91fe4e8caa53aadeff92477638570;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638571 .

_:807f36cf91fe4e8caa53aadeff92477638570 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477638571 rdf:first _:807f36cf91fe4e8caa53aadeff92477638572;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477638574 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11429-1 a owl:Class;
  rdfs:label "SIMVASTATINE <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_11429";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638576;
  r:natureDuRisque "Risque majoré d’effets indésirables (dose-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’hypocholestérolémiant)."@fr;
  rdfs:comment """La télithromycine est un inhibiteur du CYP3A4. Par conséquent, son administration peut inhiber le métabolisme des médicaments qui sont métabolisés par ce cytochrome, dont la simvastatine. 
L’association de la télithromycine avec la simvastatine augmente d"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638582, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638576 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638577 .

_:807f36cf91fe4e8caa53aadeff92477638577 rdf:first _:807f36cf91fe4e8caa53aadeff92477638578;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638579 .

_:807f36cf91fe4e8caa53aadeff92477638578 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477638579 rdf:first _:807f36cf91fe4e8caa53aadeff92477638580;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477638582 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11430-1 a owl:Class;
  rdfs:label "SIMVASTATINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11430";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638584;
  r:natureDuRisque "Risque majoré d’effets indésirables (dose-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’hypocholestérolémiant)."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 20 mg/j de simvastatine ou utiliser une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638590, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638584 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638585 .

_:807f36cf91fe4e8caa53aadeff92477638585 rdf:first _:807f36cf91fe4e8caa53aadeff92477638586;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638587 .

_:807f36cf91fe4e8caa53aadeff92477638586 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477638587 rdf:first _:807f36cf91fe4e8caa53aadeff92477638588;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477638590 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11431-1 a owl:Class;
  rdfs:label "SIMVASTATINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11431";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638592;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse par diminution du métabolisme hépatique de la simvastatine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638598, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638592 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638593 .

_:807f36cf91fe4e8caa53aadeff92477638593 rdf:first _:807f36cf91fe4e8caa53aadeff92477638594;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638595 .

_:807f36cf91fe4e8caa53aadeff92477638594 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477638595 rdf:first _:807f36cf91fe4e8caa53aadeff92477638596;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477638598 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11432-1 a owl:Class;
  rdfs:label "SIROLIMUS <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11432";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638600;
  r:natureDuRisque "Augmentation des concentrations sanguines du sirolimus (diminution de son métabolisme hépatique par le vérapamil)."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l’immunosuppresseur, contrôle de la fonction rénale et adaptation de la posologie pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638606, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638600 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638601 .

_:807f36cf91fe4e8caa53aadeff92477638601 rdf:first _:807f36cf91fe4e8caa53aadeff92477638602;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638603 .

_:807f36cf91fe4e8caa53aadeff92477638602 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10839 .

_:807f36cf91fe4e8caa53aadeff92477638603 rdf:first _:807f36cf91fe4e8caa53aadeff92477638604;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477638606 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11260-1 a owl:Class;
  rdfs:label "MÉDICAMENTS UTILISÉS PAR VOIE VAGINALE <-> SPERMICIDES"@fr;
  dct:identifier "IAM_11260";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638608;
  r:natureDuRisque "Tout traitement local vaginal est susceptible d'inactiver une contraception locale spermicide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638614, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638608 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638609 .

_:807f36cf91fe4e8caa53aadeff92477638609 rdf:first _:807f36cf91fe4e8caa53aadeff92477638610;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638611 .

_:807f36cf91fe4e8caa53aadeff92477638610 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10142 .

_:807f36cf91fe4e8caa53aadeff92477638611 rdf:first _:807f36cf91fe4e8caa53aadeff92477638612;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10165 .

_:807f36cf91fe4e8caa53aadeff92477638614 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11434-1 a owl:Class;
  rdfs:label "STAVUDINE <-> ZALCITABINE"@fr;
  dct:identifier "IAM_11434";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638616;
  r:natureDuRisque "Risque de diminution de l'efficacité de chaque antiviral, par antagonisme compétitif de la réaction de phosphorylation à l'origine des métabolites actifs."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638622, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638616 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638617 .

_:807f36cf91fe4e8caa53aadeff92477638617 rdf:first _:807f36cf91fe4e8caa53aadeff92477638618;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638619 .

_:807f36cf91fe4e8caa53aadeff92477638618 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10858 .

_:807f36cf91fe4e8caa53aadeff92477638619 rdf:first _:807f36cf91fe4e8caa53aadeff92477638620;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11002 .

_:807f36cf91fe4e8caa53aadeff92477638622 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11433-1 a owl:Class;
  rdfs:label "STAVUDINE <-> THALIDOMIDE"@fr;
  dct:identifier "IAM_11433";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638624;
  r:natureDuRisque "Risque majoré de survenue de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638630, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638624 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638625 .

_:807f36cf91fe4e8caa53aadeff92477638625 rdf:first _:807f36cf91fe4e8caa53aadeff92477638626;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638627 .

_:807f36cf91fe4e8caa53aadeff92477638626 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10858 .

_:807f36cf91fe4e8caa53aadeff92477638627 rdf:first _:807f36cf91fe4e8caa53aadeff92477638628;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10913 .

_:807f36cf91fe4e8caa53aadeff92477638630 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11435-1 a owl:Class;
  rdfs:label "STAVUDINE <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_11435";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638632;
  r:natureDuRisque "Risque de diminution de l'efficacité de chaque antiviral par antagoniste compétitif de la réaction de phosphorylation à l'origine des métabolites actifs."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638638, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638632 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638633 .

_:807f36cf91fe4e8caa53aadeff92477638633 rdf:first _:807f36cf91fe4e8caa53aadeff92477638634;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638635 .

_:807f36cf91fe4e8caa53aadeff92477638634 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10858 .

_:807f36cf91fe4e8caa53aadeff92477638635 rdf:first _:807f36cf91fe4e8caa53aadeff92477638636;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:807f36cf91fe4e8caa53aadeff92477638638 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11459-1 a owl:Class;
  rdfs:label "VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE <-> ZONISAMIDE"@fr;
  dct:identifier "IAM_11459";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638640;
  r:natureDuRisque "Augmentation de l'hyperammoniémie, avec risque accru d'encéphalopathie."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638646, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638640 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638641 .

_:807f36cf91fe4e8caa53aadeff92477638641 rdf:first _:807f36cf91fe4e8caa53aadeff92477638642;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638643 .

_:807f36cf91fe4e8caa53aadeff92477638642 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477638643 rdf:first _:807f36cf91fe4e8caa53aadeff92477638644;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11009 .

_:807f36cf91fe4e8caa53aadeff92477638646 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11425-1 a owl:Class;
  rdfs:label "ROXITHROMYCINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11425";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638648;
  r:natureDuRisque "Risque d'augmentation de la théophyllinémie, particulièrement chez l'enfant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638654, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638648 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638649 .

_:807f36cf91fe4e8caa53aadeff92477638649 rdf:first _:807f36cf91fe4e8caa53aadeff92477638650;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638651 .

_:807f36cf91fe4e8caa53aadeff92477638650 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477638651 rdf:first _:807f36cf91fe4e8caa53aadeff92477638652;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10817 .

_:807f36cf91fe4e8caa53aadeff92477638654 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10104-2 a owl:Class;
  rdfs:label "ALPHABLOQUANTS À VISÉE UROLOGIQUE <-> INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5"@fr;
  dct:identifier "IAM_10104";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638656;
  r:natureDuRisque "Risque d’hypotension orthostatique, notamment chez le sujet âgé."@fr;
  r:conduiteATenir """Association déconseillée :
- avec la doxazosine

Précaution d'emploi :
- avec les autres alpha-bloquants
Débuter le traitement aux posologies minimales recommandées et adapter progressivement les doses si besoin."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638662, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638656 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638657 .

_:807f36cf91fe4e8caa53aadeff92477638657 rdf:first _:807f36cf91fe4e8caa53aadeff92477638658;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638659 .

_:807f36cf91fe4e8caa53aadeff92477638658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10009 .

_:807f36cf91fe4e8caa53aadeff92477638659 rdf:first _:807f36cf91fe4e8caa53aadeff92477638660;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:807f36cf91fe4e8caa53aadeff92477638662 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11457-1 a owl:Class;
  rdfs:label "TRAMADOL <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_11457";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638664;
  r:natureDuRisque "Risque d'apparition de convulsions et/ou d'un syndrome sérotoninergique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638670, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638664 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638665 .

_:807f36cf91fe4e8caa53aadeff92477638665 rdf:first _:807f36cf91fe4e8caa53aadeff92477638666;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638667 .

_:807f36cf91fe4e8caa53aadeff92477638666 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:807f36cf91fe4e8caa53aadeff92477638667 rdf:first _:807f36cf91fe4e8caa53aadeff92477638668;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638668 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:807f36cf91fe4e8caa53aadeff92477638670 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10092-2 a owl:Class;
  rdfs:label "ALISKIREN <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10092";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638672;
  r:natureDuRisque "Risque d’hyperkaliémie, d’insuffisance rénale, d’augmentation de la morbi-mortalité cardio-vasculaire."@fr;
  r:conduiteATenir """Contre-indication :
- chez le patient diabétique ou insuffisant rénal

Association déconseillée :
- dans les autres cas"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638678, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638672 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638673 .

_:807f36cf91fe4e8caa53aadeff92477638673 rdf:first _:807f36cf91fe4e8caa53aadeff92477638674;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638675 .

_:807f36cf91fe4e8caa53aadeff92477638674 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477638675 rdf:first _:807f36cf91fe4e8caa53aadeff92477638676;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638676 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477638678 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10680-2 a owl:Class;
  rdfs:label "COLCHICINE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10680";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638680;
  r:natureDuRisque "Augmentation des effets indésirables de la colchicine, aux conséquences potentiellement fatales."@fr;
  r:conduiteATenir """Contre-indication :
- avec les macrolides

Association déconseillée :
- avec les antifongiques azolés, les inhibiteurs de protéases boostés par ritonavir et le cobicistat"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638686, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638680 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638681 .

_:807f36cf91fe4e8caa53aadeff92477638681 rdf:first _:807f36cf91fe4e8caa53aadeff92477638682;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638683 .

_:807f36cf91fe4e8caa53aadeff92477638682 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638683 rdf:first _:807f36cf91fe4e8caa53aadeff92477638684;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638684 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477638686 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11324-2 a owl:Class;
  rdfs:label "NEUROLEPTIQUES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11324";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638688;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication :
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638694, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638688 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638689 .

_:807f36cf91fe4e8caa53aadeff92477638689 rdf:first _:807f36cf91fe4e8caa53aadeff92477638690;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638691 .

_:807f36cf91fe4e8caa53aadeff92477638690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10127 .

_:807f36cf91fe4e8caa53aadeff92477638691 rdf:first _:807f36cf91fe4e8caa53aadeff92477638692;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638692 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477638694 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10283-2 a owl:Class;
  rdfs:label "ANTIPARASITAIRES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10283";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638696;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication:
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine
et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes.
Si cela est possible, interrompre l'un des d"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638702, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638696 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638697 .

_:807f36cf91fe4e8caa53aadeff92477638697 rdf:first _:807f36cf91fe4e8caa53aadeff92477638698;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638699 .

_:807f36cf91fe4e8caa53aadeff92477638698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10036 .

_:807f36cf91fe4e8caa53aadeff92477638699 rdf:first _:807f36cf91fe4e8caa53aadeff92477638700;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638700 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477638702 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10113-2 a owl:Class;
  rdfs:label "AMINOSIDES <-> AUTRES AMINOSIDES"@fr;
  dct:identifier "IAM_10113";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638704;
  r:natureDuRisque "Risque accru de néphrotoxicité et d'ototoxicité (l'ototoxicité est cumulative en cas d'administrations successives)."@fr;
  r:conduiteATenir """Contre-indication :
- en cas d'administration simultanée"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638706, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638704 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477638706 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10182-2 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS)"@fr;
  dct:identifier "IAM_10182";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638708;
  r:natureDuRisque "Risque d'hyperkaliémie (potentiellement létale) surtout en cas d'insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir """Association déconseillée :
- si l'association est justifiée, contrôle strict de la kaliémie et de la fonctioénale"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638714, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638708 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638709 .

_:807f36cf91fe4e8caa53aadeff92477638709 rdf:first _:807f36cf91fe4e8caa53aadeff92477638710;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638711 .

_:807f36cf91fe4e8caa53aadeff92477638710 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477638711 rdf:first _:807f36cf91fe4e8caa53aadeff92477638712;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477638714 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11085-2 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11085";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638716;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique par le voriconazole."@fr;
  r:conduiteATenir """Association déconseillée
- avec l'évérolimus, le sirolimus, et le temsirolimus.

Précaution d'emploi
- avec la ciclosporine et le tacrolimus :
dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de la p"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638722, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638716 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638717 .

_:807f36cf91fe4e8caa53aadeff92477638717 rdf:first _:807f36cf91fe4e8caa53aadeff92477638718;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638719 .

_:807f36cf91fe4e8caa53aadeff92477638718 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477638719 rdf:first _:807f36cf91fe4e8caa53aadeff92477638720;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477638722 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10826-2 a owl:Class;
  rdfs:label "DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10826";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638724;
  r:natureDuRisque "Risque d'hyperkaliémie (potentiellement létale) surtout en cas d'insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir """Association déconseillée :
- si l'association est justifiée, contrôle strict de la kaliémie et de la fonction rénale"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638730, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638724 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638725 .

_:807f36cf91fe4e8caa53aadeff92477638725 rdf:first _:807f36cf91fe4e8caa53aadeff92477638726;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638727 .

_:807f36cf91fe4e8caa53aadeff92477638726 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477638727 rdf:first _:807f36cf91fe4e8caa53aadeff92477638728;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477638730 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11106-2 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> SOFOSBUVIR"@fr;
  dct:identifier "IAM_11106";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638732;
  r:natureDuRisque """Risque de diminution des concentrations plasmatiques de 
sofosbuvir par diminution de son absorption intestinale par
l’inducteur."""@fr;
  r:conduiteATenir """Contre-indication :
- avec la rifampicine
- avec les anticonvulsivants inducteurs enzymatiques

Association déconseillée:
- avec les autres inducteurs."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638738, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638732 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638733 .

_:807f36cf91fe4e8caa53aadeff92477638733 rdf:first _:807f36cf91fe4e8caa53aadeff92477638734;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638735 .

_:807f36cf91fe4e8caa53aadeff92477638734 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477638735 rdf:first _:807f36cf91fe4e8caa53aadeff92477638736;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10850 .

_:807f36cf91fe4e8caa53aadeff92477638738 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10278-2 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10278";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638740;
  r:natureDuRisque "Augmentation de la toxicité hématologique du méthotrexate (diminution de la clairance rénale du méthotrexate par les anti-inflammatoires)."@fr;
  r:conduiteATenir """Association déconseillée:
- pour des doses de méthotrexate supérieures à 20 mg par semaine.
- avec le kétoprofène et le méthotrexate à des doses supérieures à 20 mg par semaines, respecter un intervalle d'au moins 12 heures entre l'arrêt ou le début d'un"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638746, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638740 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638741 .

_:807f36cf91fe4e8caa53aadeff92477638741 rdf:first _:807f36cf91fe4e8caa53aadeff92477638742;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638743 .

_:807f36cf91fe4e8caa53aadeff92477638742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477638743 rdf:first _:807f36cf91fe4e8caa53aadeff92477638744;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477638746 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10251-2 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10251";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638748;
  r:natureDuRisque """- pour carbamazépine, phénobarbital, primidone : Risque de baisse de l'efficacité du voriconazole par augmentation de son métabolisme hépatique par l'inducteur.

- pour phénytoïne, fosphénytoïne : 
Diminution importante des concentrations plasmatiques du"""@fr;
  r:conduiteATenir """Contre-indication :
- pour carbamazépine, phénobarbital, primidone

Association déconseillée :
- pour phénytoïne, fosphénytoïne
Si l'association ne peut être évitée, surveillance clinique étroite, dosage des concentrations plasmatiques de phénytoïne et ad"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638754, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638748 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638749 .

_:807f36cf91fe4e8caa53aadeff92477638749 rdf:first _:807f36cf91fe4e8caa53aadeff92477638750;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638751 .

_:807f36cf91fe4e8caa53aadeff92477638750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477638751 rdf:first _:807f36cf91fe4e8caa53aadeff92477638752;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477638754 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11127-2 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> LAMOTRIGINE"@fr;
  dct:identifier "IAM_11127";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638756;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de diminution des concentrations et de l’efficacité de la lamotrigine par augmentation de son métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir """Association déconseillée 
- Eviter de mettre en route le traitement par ritonavir pendant la période d’ajustement posologique de la lamotrigine.

Précaution d'emploi
- Surveillance clinique et adaptation de la posologie de la lamotrigine lors de la mise e"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638762, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638756 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638757 .

_:807f36cf91fe4e8caa53aadeff92477638757 rdf:first _:807f36cf91fe4e8caa53aadeff92477638758;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638759 .

_:807f36cf91fe4e8caa53aadeff92477638758 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477638759 rdf:first _:807f36cf91fe4e8caa53aadeff92477638760;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:807f36cf91fe4e8caa53aadeff92477638762 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11146-2 a owl:Class;
  rdfs:label "INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11146";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638764;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque """Risque de majoration des effets indésirables de l’inhibiteur de
tyrosine kinase par diminution de son métabolisme."""@fr;
  r:conduiteATenir """Association déconseillée :
- avec l'axitinib, le bosutinib, le céritinib, le cobimétinib, le dabrafenib, le dasatinib, le nilotinib, le sunitinib
- avec l'ibrutinib, si l’association ne peut être évitée ,surveillance clinique étroite et réduction de la do"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638770, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638764 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638765 .

_:807f36cf91fe4e8caa53aadeff92477638765 rdf:first _:807f36cf91fe4e8caa53aadeff92477638766;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638767 .

_:807f36cf91fe4e8caa53aadeff92477638766 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:807f36cf91fe4e8caa53aadeff92477638767 rdf:first _:807f36cf91fe4e8caa53aadeff92477638768;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638770 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10903-2 a owl:Class;
  rdfs:label "ESMOLOL <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10903";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638772;
  r:natureDuRisque "Troubles de l'automatisme (bradycardie excessive, arrêt sinusal), troubles de la conduction sino-auriculaire et auriculo-ventriculaire et défaillance cardiaque."@fr;
  r:conduiteATenir """Association déconseillée :
- en cas d'altération de la fonction ventriculaire gauche."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638778, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638772 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638773 .

_:807f36cf91fe4e8caa53aadeff92477638773 rdf:first _:807f36cf91fe4e8caa53aadeff92477638774;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638775 .

_:807f36cf91fe4e8caa53aadeff92477638774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:807f36cf91fe4e8caa53aadeff92477638775 rdf:first _:807f36cf91fe4e8caa53aadeff92477638776;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477638778 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10180-2 a owl:Class;
  rdfs:label "ANTAGONISTES DES CANAUX CALCIQUES <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10180";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638780;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antagoniste du calcium par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Association déconseillée avec la nimodipine"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638786, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638780 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638781 .

_:807f36cf91fe4e8caa53aadeff92477638781 rdf:first _:807f36cf91fe4e8caa53aadeff92477638782;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638783 .

_:807f36cf91fe4e8caa53aadeff92477638782 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10019 .

_:807f36cf91fe4e8caa53aadeff92477638783 rdf:first _:807f36cf91fe4e8caa53aadeff92477638784;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477638786 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10697-2 a owl:Class;
  rdfs:label "CYPROTERONE <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10697";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638788;
  r:natureDuRisque "Risque de diminution de l'efficacité de la cyprotérone."@fr;
  r:conduiteATenir """Association déconseillée:
- dans son utilisation comme contraceptif hormonal: utiliser de préférence une autre méthode de contraception en particulier de type mécanique, pendant la durée de l'association et un cycle suivant.

Précaution d'emploi
- dans se"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638794, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638788 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638789 .

_:807f36cf91fe4e8caa53aadeff92477638789 rdf:first _:807f36cf91fe4e8caa53aadeff92477638790;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638791 .

_:807f36cf91fe4e8caa53aadeff92477638790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477638791 rdf:first _:807f36cf91fe4e8caa53aadeff92477638792;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff92477638794 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10261-2 a owl:Class;
  rdfs:label "ANTIHYPERTENSEURS ALPHA-BLOQUANTS <-> INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5"@fr;
  dct:identifier "IAM_10261";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638796;
  r:natureDuRisque "Risque d’hypotension orthostatique, notamment chez le sujet âgé."@fr;
  r:conduiteATenir """Association déconseillée :
- avec la doxazosine 

Précaution d'emploi :
- avec les autres alpha-bloquants
Débuter le traitement aux posologies minimales recommandées et adapter progressivement les doses si besoin."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638802, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638796 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638797 .

_:807f36cf91fe4e8caa53aadeff92477638797 rdf:first _:807f36cf91fe4e8caa53aadeff92477638798;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638799 .

_:807f36cf91fe4e8caa53aadeff92477638798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10033 .

_:807f36cf91fe4e8caa53aadeff92477638799 rdf:first _:807f36cf91fe4e8caa53aadeff92477638800;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:807f36cf91fe4e8caa53aadeff92477638802 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10023-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> HÉPARINES NON FRACTIONNÉES (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10023";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638804;
  r:natureDuRisque "Augmentation du risque hémorragique (inhibition de la fonction plaquettaire et agression de la muqueuse gastroduodénale par l’acide acétylsalicylique)."@fr;
  r:conduiteATenir """Association déconseillée avec :
- des doses anti-inflammatoires d'acide acétylsalicylique (>=1g par prise et/ou >=3g par jour) 
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour)
Utiliser un autre anti-inflammatoire ou un au"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638810, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638804 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638805 .

_:807f36cf91fe4e8caa53aadeff92477638805 rdf:first _:807f36cf91fe4e8caa53aadeff92477638806;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638807 .

_:807f36cf91fe4e8caa53aadeff92477638806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10091 .

_:807f36cf91fe4e8caa53aadeff92477638807 rdf:first _:807f36cf91fe4e8caa53aadeff92477638808;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477638810 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10020-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10020";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638812;
  r:natureDuRisque "Majoration du risque hémorragique."@fr;
  r:conduiteATenir """Association déconseillée avec :
- des doses anti-inflammatoires d'acide acétylsalicylique (>=1g par prise et/ou >=3g par jour)

A prendre en compte avec :
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour)."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638818, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638812 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638813 .

_:807f36cf91fe4e8caa53aadeff92477638813 rdf:first _:807f36cf91fe4e8caa53aadeff92477638814;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638815 .

_:807f36cf91fe4e8caa53aadeff92477638814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477638815 rdf:first _:807f36cf91fe4e8caa53aadeff92477638816;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477638818 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10021-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10021";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638820;
  r:natureDuRisque "Augmentation du risque hémorragique (inhibition de la fonction plaquettaire et agression de la muqueuse gastroduodénale par l’acide acétylsalicylique."@fr;
  r:conduiteATenir """Association déconseillée avec :
- des doses anti-inflammatoires d'acide acétylsalicylique (>=1g par prise et/ou >=3g par jour) 
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour)
Utiliser un autre anti-inflammatoire ou un au"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638826, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638820 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638821 .

_:807f36cf91fe4e8caa53aadeff92477638821 rdf:first _:807f36cf91fe4e8caa53aadeff92477638822;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638823 .

_:807f36cf91fe4e8caa53aadeff92477638822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477638823 rdf:first _:807f36cf91fe4e8caa53aadeff92477638824;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477638826 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10303-2 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10303";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638828;
  r:natureDuRisque "Risque d’augmentation de la toxicité du méthotrexate par diminution de son élimination."@fr;
  r:conduiteATenir """Association déconseillée :
- avec le méthotrexate aux doses > 20 mg / semaine

A prendre en compte :
- pour des doses inférieures"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638834, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638828 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638829 .

_:807f36cf91fe4e8caa53aadeff92477638829 rdf:first _:807f36cf91fe4e8caa53aadeff92477638830;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638831 .

_:807f36cf91fe4e8caa53aadeff92477638830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477638831 rdf:first _:807f36cf91fe4e8caa53aadeff92477638832;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477638834 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11157-2 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> MIDAZOLAM"@fr;
  dct:identifier "IAM_11157";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638836;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de midazolam par diminution de son métabolisme hépatique, avec majoration de la sédation."@fr;
  r:conduiteATenir """Association déconseillée:
- avec le midazolam per os

Précaution d'emploi avec :
- avec le midazolam IV et sublingual
Surveillance clinique et réduction de la posologie de midazolam en cas de traitement par l'inhibiteur."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638842, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638836 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638837 .

_:807f36cf91fe4e8caa53aadeff92477638837 rdf:first _:807f36cf91fe4e8caa53aadeff92477638838;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638839 .

_:807f36cf91fe4e8caa53aadeff92477638838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638839 rdf:first _:807f36cf91fe4e8caa53aadeff92477638840;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477638842 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11150-2 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> ISAVUCONAZOLE"@fr;
  dct:identifier "IAM_11150";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638844;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’isavuconazole par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  r:conduiteATenir """Contre-indication:
- avec le kétoconazole


Précaution d'emploi:
- avec les autres inhibiteurs puissants du CYP3A4"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638850, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638844 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638845 .

_:807f36cf91fe4e8caa53aadeff92477638845 rdf:first _:807f36cf91fe4e8caa53aadeff92477638846;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638847 .

_:807f36cf91fe4e8caa53aadeff92477638846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638847 rdf:first _:807f36cf91fe4e8caa53aadeff92477638848;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10487 .

_:807f36cf91fe4e8caa53aadeff92477638850 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11414-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11414";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638852;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de la théophylline (augmentation de son métabolisme par induction enzymatique)."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, de la théophyllinémie. Adapter, s'il y a lieu, la posologie de la théophylline pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638858, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638852 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638853 .

_:807f36cf91fe4e8caa53aadeff92477638853 rdf:first _:807f36cf91fe4e8caa53aadeff92477638854;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638855 .

_:807f36cf91fe4e8caa53aadeff92477638854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477638855 rdf:first _:807f36cf91fe4e8caa53aadeff92477638856;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477638858 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11460-1 a owl:Class;
  rdfs:label "VENLAFAXINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11460";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638860;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638866, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638860 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638861 .

_:807f36cf91fe4e8caa53aadeff92477638861 rdf:first _:807f36cf91fe4e8caa53aadeff92477638862;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638863 .

_:807f36cf91fe4e8caa53aadeff92477638862 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:807f36cf91fe4e8caa53aadeff92477638863 rdf:first _:807f36cf91fe4e8caa53aadeff92477638864;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477638866 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10310-2 a owl:Class;
  rdfs:label "ANTISPASMODIQUES URINAIRES <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10310";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638868;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Risque de majoration des effets indésirables."@fr;
  r:conduiteATenir """Contre-indication :
- avec la darifénacine
- avec la fésotérodine et la solifénacine, en cas d'insuffisance rénale ou hépatique, modérée à sévère.

Association déconseillée : 
- avec la toltérodine

Précaution d'emploi:
- avec la fésotérodine ou la solifé"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638874, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638868 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638869 .

_:807f36cf91fe4e8caa53aadeff92477638869 rdf:first _:807f36cf91fe4e8caa53aadeff92477638870;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638871 .

_:807f36cf91fe4e8caa53aadeff92477638870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10041 .

_:807f36cf91fe4e8caa53aadeff92477638871 rdf:first _:807f36cf91fe4e8caa53aadeff92477638872;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638874 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11111-2 a owl:Class;
  rdfs:label "INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5 <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11111";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638876;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Augmentation (très importante pour l'avanafil et le vardénafil) des concentrations plasmatiques de l'IPDE5, avec risque d'hypotension (sévère avec le vardénafil)."@fr;
  r:conduiteATenir "Pour connaître les risques et les niveaux de contrainte de chaque IPDE5 avec les inhibiteurs puissants du CYP3A4, il convient de se reporter aux AMM specifiques à chacun d'eux."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638882, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638876 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638877 .

_:807f36cf91fe4e8caa53aadeff92477638877 rdf:first _:807f36cf91fe4e8caa53aadeff92477638878;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638879 .

_:807f36cf91fe4e8caa53aadeff92477638878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:807f36cf91fe4e8caa53aadeff92477638879 rdf:first _:807f36cf91fe4e8caa53aadeff92477638880;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638882 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10015-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANTICOAGULANTS ORAUX"@fr;
  dct:identifier "IAM_10015";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638884;
  r:natureDuRisque "Majoration du risque hémorragique, notamment en cas d’antécédent d’ulcère gastro-duodénal."@fr;
  r:conduiteATenir """Association déconseillée avec :
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour) en l'absence d’antécédent d’ulcère gastro-duodénal
- des doses antiagrégantes (de 50 mg à 375 mg par jour) et en cas d’antécédent d’ulcère ga"""@fr;
  rdfs:comment "Jusqu'à présent, cette interaction se présentait selon deux niveaux distincts : une contre-indication avec l'acide acétylsalicylique administré à doses anti-inflammatoires et une association déconseillée avec l'aspirine donnée à doses antalgiques ou anti"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638890, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638884 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638885 .

_:807f36cf91fe4e8caa53aadeff92477638885 rdf:first _:807f36cf91fe4e8caa53aadeff92477638886;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638887 .

_:807f36cf91fe4e8caa53aadeff92477638886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477638887 rdf:first _:807f36cf91fe4e8caa53aadeff92477638888;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477638890 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10192-2 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES <-> AUTRES ANTIARYTHMIQUES"@fr;
  dct:identifier "IAM_10192";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638892;
  r:natureDuRisque "L'association de deux antiarythmiques est très délicate. Elle est dans la majorité des cas, contre-indiquée ou déconseillée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638894, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638892 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10024 .

_:807f36cf91fe4e8caa53aadeff92477638894 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10310-3 a owl:Class;
  rdfs:label "ANTISPASMODIQUES URINAIRES <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10310";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638896;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Risque de majoration des effets indésirables."@fr;
  r:conduiteATenir """Contre-indication :
- avec la darifénacine
- avec la fésotérodine et la solifénacine, en cas d'insuffisance rénale ou hépatique, modérée à sévère.

Association déconseillée : 
- avec la toltérodine

Précaution d'emploi:
- avec la fésotérodine ou la solifé"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638902, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638896 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638897 .

_:807f36cf91fe4e8caa53aadeff92477638897 rdf:first _:807f36cf91fe4e8caa53aadeff92477638898;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638899 .

_:807f36cf91fe4e8caa53aadeff92477638898 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10041 .

_:807f36cf91fe4e8caa53aadeff92477638899 rdf:first _:807f36cf91fe4e8caa53aadeff92477638900;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638900 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638902 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11111-3 a owl:Class;
  rdfs:label "INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5 <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11111";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638904;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Augmentation (très importante pour l'avanafil et le vardénafil) des concentrations plasmatiques de l'IPDE5, avec risque d'hypotension (sévère avec le vardénafil)."@fr;
  r:conduiteATenir "Pour connaître les risques et les niveaux de contrainte de chaque IPDE5 avec les inhibiteurs puissants du CYP3A4, il convient de se reporter aux AMM specifiques à chacun d'eux."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638910, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638904 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638905 .

_:807f36cf91fe4e8caa53aadeff92477638905 rdf:first _:807f36cf91fe4e8caa53aadeff92477638906;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638907 .

_:807f36cf91fe4e8caa53aadeff92477638906 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:807f36cf91fe4e8caa53aadeff92477638907 rdf:first _:807f36cf91fe4e8caa53aadeff92477638908;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638908 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477638910 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10015-3 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANTICOAGULANTS ORAUX"@fr;
  dct:identifier "IAM_10015";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638912;
  r:natureDuRisque "Majoration du risque hémorragique, notamment en cas d’antécédent d’ulcère gastro-duodénal."@fr;
  r:conduiteATenir """Contre-indication avec :
- des doses anti-inflammatoires d'acide acétylsalicylique (>=1g par prise et/ou >=3g par jour)
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour) et en cas d’antécédent d’ulcère gastro-duodénal"""@fr;
  rdfs:comment "Jusqu'à présent, cette interaction se présentait selon deux niveaux distincts : une contre-indication avec l'acide acétylsalicylique administré à doses anti-inflammatoires et une association déconseillée avec l'aspirine donnée à doses antalgiques ou anti"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638918, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638912 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638913 .

_:807f36cf91fe4e8caa53aadeff92477638913 rdf:first _:807f36cf91fe4e8caa53aadeff92477638914;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638915 .

_:807f36cf91fe4e8caa53aadeff92477638914 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477638915 rdf:first _:807f36cf91fe4e8caa53aadeff92477638916;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638916 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477638918 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11118-2 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> RACECADOTRIL"@fr;
  dct:identifier "IAM_11118";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638920;
  r:natureDuRisque "Risque de majoration des effets indésirables à type d'œdème angio-neurotique (angio-œdème)."@fr;
  r:conduiteATenir """Contre-indication:
- en cas d'antécédents d'angio-oedème sous IEC.

Association déconseillée:
- en l'absence d’antécédents d'angio-oedème sous IEC."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638926, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638920 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638921 .

_:807f36cf91fe4e8caa53aadeff92477638921 rdf:first _:807f36cf91fe4e8caa53aadeff92477638922;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638923 .

_:807f36cf91fe4e8caa53aadeff92477638922 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477638923 rdf:first _:807f36cf91fe4e8caa53aadeff92477638924;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638924 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10780 .

_:807f36cf91fe4e8caa53aadeff92477638926 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10530-2 a owl:Class;
  rdfs:label "CALCIUM <-> DIGOXINE"@fr;
  dct:identifier "IAM_10530";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638928;
  r:natureDuRisque "Risque de troubles du rythme graves, voire mortels avec les sels de calcium administrés par voie IV."@fr;
  r:conduiteATenir """Contre-indication :
- avec les sels de calcium IV, hormis supplémentation parentérale.

Précaution d'emploi :
- avec les sels de calcium par voie orale.
Surveillance clinique et, s'il y a lieu, contrôle de l'ECG et de la calcémie."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638934, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638928 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638929 .

_:807f36cf91fe4e8caa53aadeff92477638929 rdf:first _:807f36cf91fe4e8caa53aadeff92477638930;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638931 .

_:807f36cf91fe4e8caa53aadeff92477638930 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477638931 rdf:first _:807f36cf91fe4e8caa53aadeff92477638932;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638932 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477638934 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11458-1 a owl:Class;
  rdfs:label "VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_11458";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638936;
  r:natureDuRisque "Risque d’augmentation des effets indésirables, notamment hématologiques, de la zidovudine par diminution de son métabolisme par l’acide valproïque."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière. Un hémogramme à la recherche d’une anémie devrait être réalisé au cours des deux premiers mois de l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638942, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638936 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638937 .

_:807f36cf91fe4e8caa53aadeff92477638937 rdf:first _:807f36cf91fe4e8caa53aadeff92477638938;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638939 .

_:807f36cf91fe4e8caa53aadeff92477638938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477638939 rdf:first _:807f36cf91fe4e8caa53aadeff92477638940;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638940 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:807f36cf91fe4e8caa53aadeff92477638942 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10715-2 a owl:Class;
  rdfs:label "DACLATASVIR <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10715";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638944;
  r:natureDuRisque "Diminution des concentrations plasmatiques de daclatasvir par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir """Contre-indication:
- avec la rifampicine
- avec les anticonvulsivants inducteurs enzymatiques
- avec l'oxcarbazépine

Précaution d'emploi:
- avec les autres inducteurs, la dose recommandée est de 90 mg/jour de daclatasvir"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638950, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638944 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638945 .

_:807f36cf91fe4e8caa53aadeff92477638945 rdf:first _:807f36cf91fe4e8caa53aadeff92477638946;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638947 .

_:807f36cf91fe4e8caa53aadeff92477638946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477638947 rdf:first _:807f36cf91fe4e8caa53aadeff92477638948;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638948 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10243 .

_:807f36cf91fe4e8caa53aadeff92477638950 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10027-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10027";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638952;
  r:natureDuRisque "Majoration de la toxicité, notamment hématologique, du méthotrexate (diminution de sa clairance rénale par l'acide acétylsalicylique)."@fr;
  r:conduiteATenir """Avec le méthotrexate utilisé à des doses > 20 mg/semaine : 
- contre-indication avec l'acide acétylsalicylique utilisé à doses antalgiques, antipyrétiques ou anti-inflammatoires
- précaution d'emploi avec des doses antiagrégantes plaquettaires d'acide acé"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638958, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638952 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638953 .

_:807f36cf91fe4e8caa53aadeff92477638953 rdf:first _:807f36cf91fe4e8caa53aadeff92477638954;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638955 .

_:807f36cf91fe4e8caa53aadeff92477638954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477638955 rdf:first _:807f36cf91fe4e8caa53aadeff92477638956;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638956 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477638958 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11122-2 a owl:Class;
  rdfs:label "INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES) <-> LÉDIPASVIR"@fr;
  dct:identifier "IAM_11122";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638960;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de la statine et de ses effets indésirables à type de rhabdomyolyse."@fr;
  r:conduiteATenir """Contre-indication :
- avec la rosuvastatine.

Précaution d'emploi :
- avec les autres inhibiteurs de l'HMG Co-A réductase.
Surveillance clinique et biologique. Adaptation éventuelle de la posologie de la statine."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638966, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638960 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638961 .

_:807f36cf91fe4e8caa53aadeff92477638961 rdf:first _:807f36cf91fe4e8caa53aadeff92477638962;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638963 .

_:807f36cf91fe4e8caa53aadeff92477638962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff92477638963 rdf:first _:807f36cf91fe4e8caa53aadeff92477638964;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638964 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:807f36cf91fe4e8caa53aadeff92477638966 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11266-2 a owl:Class;
  rdfs:label "METHADONE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11266";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638968;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication :
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine
et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638974, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638968 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638969 .

_:807f36cf91fe4e8caa53aadeff92477638969 rdf:first _:807f36cf91fe4e8caa53aadeff92477638970;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638971 .

_:807f36cf91fe4e8caa53aadeff92477638970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477638971 rdf:first _:807f36cf91fe4e8caa53aadeff92477638972;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638972 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff92477638974 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11059-2 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_11059";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638976;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  r:conduiteATenir """Contre-indication :
avec le bupropion

Association déconseillée :
avec les autres sympathomimétiques indirects"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638982, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638976 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638977 .

_:807f36cf91fe4e8caa53aadeff92477638977 rdf:first _:807f36cf91fe4e8caa53aadeff92477638978;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638979 .

_:807f36cf91fe4e8caa53aadeff92477638978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477638979 rdf:first _:807f36cf91fe4e8caa53aadeff92477638980;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638980 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477638982 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11439-2 a owl:Class;
  rdfs:label "SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES <-> TORSADOGÈNES (SAUF ANTIPARASITAIRES, NEUROLEPTIQUES, MÉTHADONE)"@fr;
  dct:identifier "IAM_11439";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638984;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication:
- Pour l'érythromycine et la vincamine, seules les formes administrées par voie intraveineuse sont concernées par cette interaction.
- Pour la spiramycine, la voie IV et la voie orale sont concernées.

Association déconseillée:
- avec l"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638990, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638984 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638985 .

_:807f36cf91fe4e8caa53aadeff92477638985 rdf:first _:807f36cf91fe4e8caa53aadeff92477638986;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638987 .

_:807f36cf91fe4e8caa53aadeff92477638986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477638987 rdf:first _:807f36cf91fe4e8caa53aadeff92477638988;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638988 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10154 .

_:807f36cf91fe4e8caa53aadeff92477638990 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10939-2 a owl:Class;
  rdfs:label "FIBRATES <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10939";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477638992;
  r:natureDuRisque "Risque d'addition d'effets indésirables (dose-dépendants) à type de rhabdomyolyse. En outre, avec le gemfibrozil, diminution du métabolisme de la simvastatine et de la rosuvastatine, ce qui majore le risque musculaire, ainsi que la néphrotoxicité de la ro"@fr;
  r:conduiteATenir """Contre-indication 
- entre le gemfibrozil et la simvastatine
- pour des doses de rosuvastatine de 40 mg

Association déconseillée 
- entre les autres fibrates et les autres statines 
- ne pas dépasser 10 mg de simvastatine (cette restriction de doses ne"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477638998, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477638992 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477638993 .

_:807f36cf91fe4e8caa53aadeff92477638993 rdf:first _:807f36cf91fe4e8caa53aadeff92477638994;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477638995 .

_:807f36cf91fe4e8caa53aadeff92477638994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10074 .

_:807f36cf91fe4e8caa53aadeff92477638995 rdf:first _:807f36cf91fe4e8caa53aadeff92477638996;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477638996 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff92477638998 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10828-2 a owl:Class;
  rdfs:label "DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> POTASSIUM"@fr;
  dct:identifier "IAM_10828";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639000;
  r:natureDuRisque "Hyperkaliémie potentiellement létale, notamment chez l'insuffisant rénal (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Contre-indication:-en dehors d'une hypokaliémie ou en cas d'utilisation parentérale des sels de potassium"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639006, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639000 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639001 .

_:807f36cf91fe4e8caa53aadeff92477639001 rdf:first _:807f36cf91fe4e8caa53aadeff92477639002;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639003 .

_:807f36cf91fe4e8caa53aadeff92477639002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477639003 rdf:first _:807f36cf91fe4e8caa53aadeff92477639004;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639004 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10742 .

_:807f36cf91fe4e8caa53aadeff92477639006 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10090-2 a owl:Class;
  rdfs:label "ALISKIREN <-> ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II"@fr;
  dct:identifier "IAM_10090";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639008;
  r:natureDuRisque "Risque d’hyperkaliémie, d’insuffisance rénale, d’augmentation de la morbi-mortalité cardio-vasculaire."@fr;
  r:conduiteATenir """Contre-indication :
- chez le patient diabétique ou insuffisant rénal

Association déconseillée :
- dans les autres cas"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639014, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639008 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639009 .

_:807f36cf91fe4e8caa53aadeff92477639009 rdf:first _:807f36cf91fe4e8caa53aadeff92477639010;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639011 .

_:807f36cf91fe4e8caa53aadeff92477639010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477639011 rdf:first _:807f36cf91fe4e8caa53aadeff92477639012;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639012 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477639014 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11029-2 a owl:Class;
  rdfs:label "HYDROXYCHLOROQUINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11029";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639016;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication :
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639022, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639016 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639017 .

_:807f36cf91fe4e8caa53aadeff92477639017 rdf:first _:807f36cf91fe4e8caa53aadeff92477639018;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639019 .

_:807f36cf91fe4e8caa53aadeff92477639018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477639019 rdf:first _:807f36cf91fe4e8caa53aadeff92477639020;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639020 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10437 .

_:807f36cf91fe4e8caa53aadeff92477639022 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10192-3 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES <-> AUTRES ANTIARYTHMIQUES"@fr;
  dct:identifier "IAM_10192";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639024;
  r:natureDuRisque "L'association de deux antiarythmiques est très délicate. Elle est dans la majorité des cas, contre-indiquée ou déconseillée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639026, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10024 .

_:807f36cf91fe4e8caa53aadeff92477639026 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11358-1 a owl:Class;
  rdfs:label "PEG-INTERFERON ALFA-2A <-> TELBIVUDINE"@fr;
  dct:identifier "IAM_11358";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639028;
  r:natureDuRisque "Risque majoré de neuropathies périphériques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639034, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639028 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639029 .

_:807f36cf91fe4e8caa53aadeff92477639029 rdf:first _:807f36cf91fe4e8caa53aadeff92477639030;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639031 .

_:807f36cf91fe4e8caa53aadeff92477639030 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10698 .

_:807f36cf91fe4e8caa53aadeff92477639031 rdf:first _:807f36cf91fe4e8caa53aadeff92477639032;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10888 .

_:807f36cf91fe4e8caa53aadeff92477639034 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11347-1 a owl:Class;
  rdfs:label "PAMPLEMOUSSE (JUS ET FRUIT) <-> RÉGORAFÉNIB"@fr;
  dct:identifier "IAM_11347";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639036;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de régorafenib par diminution de son métabolisme hépatique par le pamplemousse."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639042, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639036 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639037 .

_:807f36cf91fe4e8caa53aadeff92477639037 rdf:first _:807f36cf91fe4e8caa53aadeff92477639038;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639039 .

_:807f36cf91fe4e8caa53aadeff92477639038 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477639039 rdf:first _:807f36cf91fe4e8caa53aadeff92477639040;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10789 .

_:807f36cf91fe4e8caa53aadeff92477639042 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11348-1 a owl:Class;
  rdfs:label "PAMPLEMOUSSE (JUS ET FRUIT) <-> SERTRALINE"@fr;
  dct:identifier "IAM_11348";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639044;
  r:natureDuRisque "Augmentation parfois importante des concentrations de l’antidépresseur chez certains patients par diminution de son métabolisme intestinal."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639050, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639044 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639045 .

_:807f36cf91fe4e8caa53aadeff92477639045 rdf:first _:807f36cf91fe4e8caa53aadeff92477639046;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639047 .

_:807f36cf91fe4e8caa53aadeff92477639046 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477639047 rdf:first _:807f36cf91fe4e8caa53aadeff92477639048;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10831 .

_:807f36cf91fe4e8caa53aadeff92477639050 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11349-1 a owl:Class;
  rdfs:label "PAMPLEMOUSSE (JUS ET FRUIT) <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11349";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639052;
  r:natureDuRisque "Augmentation considérable des concentrations plasmatiques de l'hypolipémiant, avec risque de survenue d'effets indésirables, notamment musculaires."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639058, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639052 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639053 .

_:807f36cf91fe4e8caa53aadeff92477639053 rdf:first _:807f36cf91fe4e8caa53aadeff92477639054;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639055 .

_:807f36cf91fe4e8caa53aadeff92477639054 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477639055 rdf:first _:807f36cf91fe4e8caa53aadeff92477639056;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477639058 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11350-1 a owl:Class;
  rdfs:label "PAMPLEMOUSSE (JUS ET FRUIT) <-> TICAGRELOR"@fr;
  dct:identifier "IAM_11350";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639060;
  r:natureDuRisque "Doublement des concentrations plasmatiques de l'antiagrégant, avec risque de majoration des effets indésirables, notamment hémorragiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639066, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639060 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639061 .

_:807f36cf91fe4e8caa53aadeff92477639061 rdf:first _:807f36cf91fe4e8caa53aadeff92477639062;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639063 .

_:807f36cf91fe4e8caa53aadeff92477639062 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477639063 rdf:first _:807f36cf91fe4e8caa53aadeff92477639064;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477639066 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11351-1 a owl:Class;
  rdfs:label "PAMPLEMOUSSE (JUS ET FRUIT) <-> VARDENAFIL"@fr;
  dct:identifier "IAM_11351";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639068;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du vardénafil, avec risque d’hypotension."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639074, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639068 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639069 .

_:807f36cf91fe4e8caa53aadeff92477639069 rdf:first _:807f36cf91fe4e8caa53aadeff92477639070;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639071 .

_:807f36cf91fe4e8caa53aadeff92477639070 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477639071 rdf:first _:807f36cf91fe4e8caa53aadeff92477639072;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10975 .

_:807f36cf91fe4e8caa53aadeff92477639074 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11352-1 a owl:Class;
  rdfs:label "PAMPLEMOUSSE (JUS ET FRUIT) <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11352";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639076;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de vérapamil, avec risque de survenue d’effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639082, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639076 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639077 .

_:807f36cf91fe4e8caa53aadeff92477639077 rdf:first _:807f36cf91fe4e8caa53aadeff92477639078;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639079 .

_:807f36cf91fe4e8caa53aadeff92477639078 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477639079 rdf:first _:807f36cf91fe4e8caa53aadeff92477639080;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477639082 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11353-1 a owl:Class;
  rdfs:label "PAROXETINE <-> PIMOZIDE"@fr;
  dct:identifier "IAM_11353";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639084;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639090, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639084 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639085 .

_:807f36cf91fe4e8caa53aadeff92477639085 rdf:first _:807f36cf91fe4e8caa53aadeff92477639086;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639087 .

_:807f36cf91fe4e8caa53aadeff92477639086 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:807f36cf91fe4e8caa53aadeff92477639087 rdf:first _:807f36cf91fe4e8caa53aadeff92477639088;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477639090 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11354-1 a owl:Class;
  rdfs:label "PAROXETINE <-> RISPERIDONE"@fr;
  dct:identifier "IAM_11354";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639092;
  r:natureDuRisque "Augmentation de la fraction active de la rispéridone par diminution de son métabolisme hépatique par la paroxétine, avec risque de majoration des effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, adaptation posologique de la rispéridone."@fr;
  rdfs:comment "La rispéridone est majoritairement métabolisée par le CYP2D6 en 9-OH-rispéridone, métabolite actif. La fraction pharmacologiquement active de la rispéridone est ainsi constituée par la molécule mère et son métabolite hydroxylé. La paroxétine est un inhibi"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639098, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639092 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639093 .

_:807f36cf91fe4e8caa53aadeff92477639093 rdf:first _:807f36cf91fe4e8caa53aadeff92477639094;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639095 .

_:807f36cf91fe4e8caa53aadeff92477639094 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:807f36cf91fe4e8caa53aadeff92477639095 rdf:first _:807f36cf91fe4e8caa53aadeff92477639096;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10805 .

_:807f36cf91fe4e8caa53aadeff92477639098 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11355-1 a owl:Class;
  rdfs:label "PAROXETINE <-> TAMOXIFENE"@fr;
  dct:identifier "IAM_11355";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639100;
  r:natureDuRisque "Baisse de l’efficacité du tamoxifène, par inhibition de la formation de son métabolite actif par la paroxétine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639106, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639100 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639101 .

_:807f36cf91fe4e8caa53aadeff92477639101 rdf:first _:807f36cf91fe4e8caa53aadeff92477639102;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639103 .

_:807f36cf91fe4e8caa53aadeff92477639102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:807f36cf91fe4e8caa53aadeff92477639103 rdf:first _:807f36cf91fe4e8caa53aadeff92477639104;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:807f36cf91fe4e8caa53aadeff92477639106 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11416-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> TICAGRELOR"@fr;
  dct:identifier "IAM_11416";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639108;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques de ticagrelor par augmentation de son métabolisme hépatique par la rifampicine, avec risque de diminution de l’effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639114, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639108 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639109 .

_:807f36cf91fe4e8caa53aadeff92477639109 rdf:first _:807f36cf91fe4e8caa53aadeff92477639110;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639111 .

_:807f36cf91fe4e8caa53aadeff92477639110 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639111 rdf:first _:807f36cf91fe4e8caa53aadeff92477639112;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477639114 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11357-1 a owl:Class;
  rdfs:label "PEFLOXACINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11357";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639116;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage (diminution du métabolisme de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639122, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639116 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639117 .

_:807f36cf91fe4e8caa53aadeff92477639117 rdf:first _:807f36cf91fe4e8caa53aadeff92477639118;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639119 .

_:807f36cf91fe4e8caa53aadeff92477639118 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477639119 rdf:first _:807f36cf91fe4e8caa53aadeff92477639120;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10697 .

_:807f36cf91fe4e8caa53aadeff92477639122 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11344-1 a owl:Class;
  rdfs:label "ORLISTAT <-> VITAMINE D"@fr;
  dct:identifier "IAM_11344";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639124;
  r:natureDuRisque "Diminution de l'absorption de la vitamine D."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639130, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639124 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639125 .

_:807f36cf91fe4e8caa53aadeff92477639125 rdf:first _:807f36cf91fe4e8caa53aadeff92477639126;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639127 .

_:807f36cf91fe4e8caa53aadeff92477639126 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10162 .

_:807f36cf91fe4e8caa53aadeff92477639127 rdf:first _:807f36cf91fe4e8caa53aadeff92477639128;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477639130 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11359-1 a owl:Class;
  rdfs:label "PÉNEMS <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11359";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639132;
  r:natureDuRisque "Risque de survenue de crises convulsives, par diminution rapide des concentrations plasmatiques de l’acide valproïque, pouvant devenir indétectables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639138, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639132 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639133 .

_:807f36cf91fe4e8caa53aadeff92477639133 rdf:first _:807f36cf91fe4e8caa53aadeff92477639134;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639135 .

_:807f36cf91fe4e8caa53aadeff92477639134 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10137 .

_:807f36cf91fe4e8caa53aadeff92477639135 rdf:first _:807f36cf91fe4e8caa53aadeff92477639136;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477639138 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11361-1 a owl:Class;
  rdfs:label "PENTAMIDINE <-> ZALCITABINE"@fr;
  dct:identifier "IAM_11361";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639140;
  r:natureDuRisque "Risque accru de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639146, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639140 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639141 .

_:807f36cf91fe4e8caa53aadeff92477639141 rdf:first _:807f36cf91fe4e8caa53aadeff92477639142;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639143 .

_:807f36cf91fe4e8caa53aadeff92477639142 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10703 .

_:807f36cf91fe4e8caa53aadeff92477639143 rdf:first _:807f36cf91fe4e8caa53aadeff92477639144;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11002 .

_:807f36cf91fe4e8caa53aadeff92477639146 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11360-1 a owl:Class;
  rdfs:label "PENTAMIDINE <-> STAVUDINE"@fr;
  dct:identifier "IAM_11360";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639148;
  r:natureDuRisque "Risque majoré de survenue de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639154, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639148 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639149 .

_:807f36cf91fe4e8caa53aadeff92477639149 rdf:first _:807f36cf91fe4e8caa53aadeff92477639150;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639151 .

_:807f36cf91fe4e8caa53aadeff92477639150 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10703 .

_:807f36cf91fe4e8caa53aadeff92477639151 rdf:first _:807f36cf91fe4e8caa53aadeff92477639152;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10858 .

_:807f36cf91fe4e8caa53aadeff92477639154 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11362-1 a owl:Class;
  rdfs:label "PENTOXIFYLLINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11362";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639156;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage (compétition au niveau du métabolisme hépatique de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; s'il y a lieu, adaptation de la posologie de la théophylline pendant le traitement par la pentoxifylline et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639162, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639156 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639157 .

_:807f36cf91fe4e8caa53aadeff92477639157 rdf:first _:807f36cf91fe4e8caa53aadeff92477639158;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639159 .

_:807f36cf91fe4e8caa53aadeff92477639158 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477639159 rdf:first _:807f36cf91fe4e8caa53aadeff92477639160;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10705 .

_:807f36cf91fe4e8caa53aadeff92477639162 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11384-1 a owl:Class;
  rdfs:label "PROGESTATIFS CONTRACEPTIFS <-> PÉRAMPANEL"@fr;
  dct:identifier "IAM_11384";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639164;
  r:natureDuRisque "Pour des doses de pérampanel >= 12 mg/jour : Risque de diminution de l’efficacité contraceptive."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639170, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639164 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639165 .

_:807f36cf91fe4e8caa53aadeff92477639165 rdf:first _:807f36cf91fe4e8caa53aadeff92477639166;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639167 .

_:807f36cf91fe4e8caa53aadeff92477639166 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:807f36cf91fe4e8caa53aadeff92477639167 rdf:first _:807f36cf91fe4e8caa53aadeff92477639168;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10706 .

_:807f36cf91fe4e8caa53aadeff92477639170 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11363-1 a owl:Class;
  rdfs:label "PÉRAMPANEL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11363";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639172;
  r:natureDuRisque "Diminution importante (jusqu’aux deux-tiers) des concentrations de pérampanel."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639178, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639172 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639173 .

_:807f36cf91fe4e8caa53aadeff92477639173 rdf:first _:807f36cf91fe4e8caa53aadeff92477639174;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639175 .

_:807f36cf91fe4e8caa53aadeff92477639174 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10706 .

_:807f36cf91fe4e8caa53aadeff92477639175 rdf:first _:807f36cf91fe4e8caa53aadeff92477639176;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639178 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11364-1 a owl:Class;
  rdfs:label "PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE) <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_11364";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639180;
  r:natureDuRisque """En cas de traitement antérieur par le phénobarbital ou la primidone, et adjonction de phénytoïne, augmentation des concentrations plasmatiques de phénobarbital pouvant entraîner des signes toxiques (inhibition du métabolisme par compétition).

En cas de t"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639186, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639180 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639181 .

_:807f36cf91fe4e8caa53aadeff92477639181 rdf:first _:807f36cf91fe4e8caa53aadeff92477639182;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639183 .

_:807f36cf91fe4e8caa53aadeff92477639182 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477639183 rdf:first _:807f36cf91fe4e8caa53aadeff92477639184;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477639186 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11365-1 a owl:Class;
  rdfs:label "PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE) <-> PROPRANOLOL"@fr;
  dct:identifier "IAM_11365";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639188;
  r:natureDuRisque "Diminution des concentrations plasmatiques du propranolol avec réduction de ses effets cliniques (augmentation de son métabolisme hépatique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639194, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639188 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639189 .

_:807f36cf91fe4e8caa53aadeff92477639189 rdf:first _:807f36cf91fe4e8caa53aadeff92477639190;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639191 .

_:807f36cf91fe4e8caa53aadeff92477639190 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477639191 rdf:first _:807f36cf91fe4e8caa53aadeff92477639192;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10767 .

_:807f36cf91fe4e8caa53aadeff92477639194 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11366-1 a owl:Class;
  rdfs:label "PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE) <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11366";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639196;
  r:natureDuRisque "Augmentation de l'hyperammoniémie, avec risque accru d'encéphalopathie."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639202, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639196 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639197 .

_:807f36cf91fe4e8caa53aadeff92477639197 rdf:first _:807f36cf91fe4e8caa53aadeff92477639198;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639199 .

_:807f36cf91fe4e8caa53aadeff92477639198 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477639199 rdf:first _:807f36cf91fe4e8caa53aadeff92477639200;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477639202 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11356-1 a owl:Class;
  rdfs:label "PAROXETINE <-> VORTIOXÉTINE"@fr;
  dct:identifier "IAM_11356";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639204;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la vortioxétine par diminution importante de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la vortioxétine pendant le traitement par la paroxétine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639210, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639204 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639205 .

_:807f36cf91fe4e8caa53aadeff92477639205 rdf:first _:807f36cf91fe4e8caa53aadeff92477639206;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639207 .

_:807f36cf91fe4e8caa53aadeff92477639206 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:807f36cf91fe4e8caa53aadeff92477639207 rdf:first _:807f36cf91fe4e8caa53aadeff92477639208;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10999 .

_:807f36cf91fe4e8caa53aadeff92477639210 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11334-1 a owl:Class;
  rdfs:label "OLAPARIB <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11334";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639212;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’olaparib par le vérapamil."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, limiter la dose d’olaparib à 200 mg deux fois par jour."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639218, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639212 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639213 .

_:807f36cf91fe4e8caa53aadeff92477639213 rdf:first _:807f36cf91fe4e8caa53aadeff92477639214;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639215 .

_:807f36cf91fe4e8caa53aadeff92477639214 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10659 .

_:807f36cf91fe4e8caa53aadeff92477639215 rdf:first _:807f36cf91fe4e8caa53aadeff92477639216;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477639218 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11323-1 a owl:Class;
  rdfs:label "NEUROLEPTIQUES <-> ORLISTAT"@fr;
  dct:identifier "IAM_11323";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639220;
  r:natureDuRisque "Risque d'échec thérapeutique en cas de traitement concomitant par orlistat."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639226, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639220 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639221 .

_:807f36cf91fe4e8caa53aadeff92477639221 rdf:first _:807f36cf91fe4e8caa53aadeff92477639222;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639223 .

_:807f36cf91fe4e8caa53aadeff92477639222 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10124 .

_:807f36cf91fe4e8caa53aadeff92477639223 rdf:first _:807f36cf91fe4e8caa53aadeff92477639224;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477639226 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11324-1 a owl:Class;
  rdfs:label "NEUROLEPTIQUES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11324";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639228;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication :
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639234, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639228 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639229 .

_:807f36cf91fe4e8caa53aadeff92477639229 rdf:first _:807f36cf91fe4e8caa53aadeff92477639230;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639231 .

_:807f36cf91fe4e8caa53aadeff92477639230 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10127 .

_:807f36cf91fe4e8caa53aadeff92477639231 rdf:first _:807f36cf91fe4e8caa53aadeff92477639232;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477639234 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11325-1 a owl:Class;
  rdfs:label "NEVIRAPINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11325";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639236;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la névirapine par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639242, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639236 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639237 .

_:807f36cf91fe4e8caa53aadeff92477639237 rdf:first _:807f36cf91fe4e8caa53aadeff92477639238;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639239 .

_:807f36cf91fe4e8caa53aadeff92477639238 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:807f36cf91fe4e8caa53aadeff92477639239 rdf:first _:807f36cf91fe4e8caa53aadeff92477639240;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639240 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639242 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11326-1 a owl:Class;
  rdfs:label "NEVIRAPINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11326";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639244;
  r:natureDuRisque "Risque de baisse de l'efficacité du voriconazole par augmentation de son métabolisme hépatique par la névirapine."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite et adaptation éventuelle de la posologie du voriconazole pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639250, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639244 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639245 .

_:807f36cf91fe4e8caa53aadeff92477639245 rdf:first _:807f36cf91fe4e8caa53aadeff92477639246;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639247 .

_:807f36cf91fe4e8caa53aadeff92477639246 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:807f36cf91fe4e8caa53aadeff92477639247 rdf:first _:807f36cf91fe4e8caa53aadeff92477639248;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639248 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477639250 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11327-1 a owl:Class;
  rdfs:label "NIMODIPINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11327";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639252;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antagoniste du calcium par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l'antagoniste du calcium pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639258, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639252 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639253 .

_:807f36cf91fe4e8caa53aadeff92477639253 rdf:first _:807f36cf91fe4e8caa53aadeff92477639254;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639255 .

_:807f36cf91fe4e8caa53aadeff92477639254 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10636 .

_:807f36cf91fe4e8caa53aadeff92477639255 rdf:first _:807f36cf91fe4e8caa53aadeff92477639256;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639256 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639258 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11328-1 a owl:Class;
  rdfs:label "NIMODIPINE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11328";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639260;
  r:natureDuRisque "Avec la nimodipine par voie orale, et par extrapolation, par voie injectable : risque de majoration de l'effet hypotenseur de la nimodipine par augmentation de ses concentrations plasmatiques (diminution de son métabolisme par l'acide valproïque)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639266, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639260 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639261 .

_:807f36cf91fe4e8caa53aadeff92477639261 rdf:first _:807f36cf91fe4e8caa53aadeff92477639262;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639263 .

_:807f36cf91fe4e8caa53aadeff92477639262 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477639263 rdf:first _:807f36cf91fe4e8caa53aadeff92477639264;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639264 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10636 .

_:807f36cf91fe4e8caa53aadeff92477639266 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11329-1 a owl:Class;
  rdfs:label "NINTÉDANIB <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_11329";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639268;
  r:natureDuRisque "Diminution des concentrations plasmatiques du nintédanib par diminution de son absorption par la phénytoïne ou la fosphénytoïne."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639274, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639268 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639269 .

_:807f36cf91fe4e8caa53aadeff92477639269 rdf:first _:807f36cf91fe4e8caa53aadeff92477639270;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639271 .

_:807f36cf91fe4e8caa53aadeff92477639270 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477639271 rdf:first _:807f36cf91fe4e8caa53aadeff92477639272;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639272 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477639274 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11330-1 a owl:Class;
  rdfs:label "NINTÉDANIB <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11330";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639276;
  r:natureDuRisque "Diminution des concentrations plasmatiques du nintédanib par diminution de son absorption par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639282, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639276 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639277 .

_:807f36cf91fe4e8caa53aadeff92477639277 rdf:first _:807f36cf91fe4e8caa53aadeff92477639278;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639279 .

_:807f36cf91fe4e8caa53aadeff92477639278 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477639279 rdf:first _:807f36cf91fe4e8caa53aadeff92477639280;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639280 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639282 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11331-1 a owl:Class;
  rdfs:label "NINTÉDANIB <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11331";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639284;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par le vérapamil."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639290, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639284 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639285 .

_:807f36cf91fe4e8caa53aadeff92477639285 rdf:first _:807f36cf91fe4e8caa53aadeff92477639286;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639287 .

_:807f36cf91fe4e8caa53aadeff92477639286 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477639287 rdf:first _:807f36cf91fe4e8caa53aadeff92477639288;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639288 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477639290 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11346-1 a owl:Class;
  rdfs:label "OXCARBAZEPINE <-> TOPIRAMATE"@fr;
  dct:identifier "IAM_11346";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639292;
  r:natureDuRisque "Risque de diminution des concentrations du topiramate avec risque de moindre efficacité, par augmentation de son métabolisme hépatique par l'oxcarbazépine."@fr;
  r:conduiteATenir "Surveillance clinique, et si besoin, adaptation posologique du topiramate pendant le traitement par l'oxcarbazépine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639298, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639292 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639293 .

_:807f36cf91fe4e8caa53aadeff92477639293 rdf:first _:807f36cf91fe4e8caa53aadeff92477639294;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639295 .

_:807f36cf91fe4e8caa53aadeff92477639294 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10674 .

_:807f36cf91fe4e8caa53aadeff92477639295 rdf:first _:807f36cf91fe4e8caa53aadeff92477639296;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639296 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10941 .

_:807f36cf91fe4e8caa53aadeff92477639298 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11333-1 a owl:Class;
  rdfs:label "NORFLOXACINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11333";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639300;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage (diminution du métabolisme de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639306, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639300 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639301 .

_:807f36cf91fe4e8caa53aadeff92477639301 rdf:first _:807f36cf91fe4e8caa53aadeff92477639302;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639303 .

_:807f36cf91fe4e8caa53aadeff92477639302 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477639303 rdf:first _:807f36cf91fe4e8caa53aadeff92477639304;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639304 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10650 .

_:807f36cf91fe4e8caa53aadeff92477639306 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11345-1 a owl:Class;
  rdfs:label "OXCARBAZEPINE <-> PÉRAMPANEL"@fr;
  dct:identifier "IAM_11345";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639308;
  r:natureDuRisque "Diminution de moitié des concentrations de pérampanel et légère augmentation de celles de l’oxcarbazépine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639314, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639308 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639309 .

_:807f36cf91fe4e8caa53aadeff92477639309 rdf:first _:807f36cf91fe4e8caa53aadeff92477639310;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639311 .

_:807f36cf91fe4e8caa53aadeff92477639310 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10674 .

_:807f36cf91fe4e8caa53aadeff92477639311 rdf:first _:807f36cf91fe4e8caa53aadeff92477639312;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639312 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10706 .

_:807f36cf91fe4e8caa53aadeff92477639314 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11335-1 a owl:Class;
  rdfs:label "OMBITASVIR + PARITAPRÉVIR <-> PIMOZIDE"@fr;
  dct:identifier "IAM_11335";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639316;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du pimozide par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639322, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639316 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639317 .

_:807f36cf91fe4e8caa53aadeff92477639317 rdf:first _:807f36cf91fe4e8caa53aadeff92477639318;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639319 .

_:807f36cf91fe4e8caa53aadeff92477639318 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477639319 rdf:first _:807f36cf91fe4e8caa53aadeff92477639320;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639320 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477639322 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11336-1 a owl:Class;
  rdfs:label "OMBITASVIR + PARITAPRÉVIR <-> QUETIAPINE"@fr;
  dct:identifier "IAM_11336";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639324;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la quétiapine par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639330, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639324 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639325 .

_:807f36cf91fe4e8caa53aadeff92477639325 rdf:first _:807f36cf91fe4e8caa53aadeff92477639326;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639327 .

_:807f36cf91fe4e8caa53aadeff92477639326 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477639327 rdf:first _:807f36cf91fe4e8caa53aadeff92477639328;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639328 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10773 .

_:807f36cf91fe4e8caa53aadeff92477639330 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11337-1 a owl:Class;
  rdfs:label "OMBITASVIR + PARITAPRÉVIR <-> QUINIDINE"@fr;
  dct:identifier "IAM_11337";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639332;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la quinidine par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639338, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639332 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639333 .

_:807f36cf91fe4e8caa53aadeff92477639333 rdf:first _:807f36cf91fe4e8caa53aadeff92477639334;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639335 .

_:807f36cf91fe4e8caa53aadeff92477639334 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477639335 rdf:first _:807f36cf91fe4e8caa53aadeff92477639336;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639336 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477639338 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11338-1 a owl:Class;
  rdfs:label "OMBITASVIR + PARITAPRÉVIR <-> SILDENAFIL"@fr;
  dct:identifier "IAM_11338";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639340;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du sildénafil par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639346, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639340 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639341 .

_:807f36cf91fe4e8caa53aadeff92477639341 rdf:first _:807f36cf91fe4e8caa53aadeff92477639342;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639343 .

_:807f36cf91fe4e8caa53aadeff92477639342 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477639343 rdf:first _:807f36cf91fe4e8caa53aadeff92477639344;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639344 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10834 .

_:807f36cf91fe4e8caa53aadeff92477639346 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11339-1 a owl:Class;
  rdfs:label "OMBITASVIR + PARITAPRÉVIR <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11339";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639348;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la simvastatine par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639354, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639348 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639349 .

_:807f36cf91fe4e8caa53aadeff92477639349 rdf:first _:807f36cf91fe4e8caa53aadeff92477639350;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639351 .

_:807f36cf91fe4e8caa53aadeff92477639350 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477639351 rdf:first _:807f36cf91fe4e8caa53aadeff92477639352;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639352 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477639354 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11340-1 a owl:Class;
  rdfs:label "OMBITASVIR + PARITAPRÉVIR <-> TICAGRELOR"@fr;
  dct:identifier "IAM_11340";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639356;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du ticagrélor par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639362, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639356 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639357 .

_:807f36cf91fe4e8caa53aadeff92477639357 rdf:first _:807f36cf91fe4e8caa53aadeff92477639358;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639359 .

_:807f36cf91fe4e8caa53aadeff92477639358 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477639359 rdf:first _:807f36cf91fe4e8caa53aadeff92477639360;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639360 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477639362 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11341-1 a owl:Class;
  rdfs:label "OMEPRAZOLE <-> TACROLIMUS"@fr;
  dct:identifier "IAM_11341";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639364;
  r:natureDuRisque "Augmentation des concentrations sanguines du tacrolimus."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines du tacrolimus, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639370, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639364 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639365 .

_:807f36cf91fe4e8caa53aadeff92477639365 rdf:first _:807f36cf91fe4e8caa53aadeff92477639366;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639367 .

_:807f36cf91fe4e8caa53aadeff92477639366 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10664 .

_:807f36cf91fe4e8caa53aadeff92477639367 rdf:first _:807f36cf91fe4e8caa53aadeff92477639368;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639368 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477639370 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11342-1 a owl:Class;
  rdfs:label "ONDANSETRON <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11342";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639372;
  r:natureDuRisque """Risque majoré de troubles du rythme ventriculaire, notamment de
torsades de pointes."""@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639378, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639372 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639373 .

_:807f36cf91fe4e8caa53aadeff92477639373 rdf:first _:807f36cf91fe4e8caa53aadeff92477639374;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639375 .

_:807f36cf91fe4e8caa53aadeff92477639374 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477639375 rdf:first _:807f36cf91fe4e8caa53aadeff92477639376;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639376 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10665 .

_:807f36cf91fe4e8caa53aadeff92477639378 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11343-1 a owl:Class;
  rdfs:label "ONDANSETRON <-> TRAMADOL"@fr;
  dct:identifier "IAM_11343";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639380;
  r:natureDuRisque "Diminution de l’intensité et de la durée de l’effet analgésique du tramadol et risque de diminution de l’effet antiémétique de l’ondansétron."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639386, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639380 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639381 .

_:807f36cf91fe4e8caa53aadeff92477639381 rdf:first _:807f36cf91fe4e8caa53aadeff92477639382;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639383 .

_:807f36cf91fe4e8caa53aadeff92477639382 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10665 .

_:807f36cf91fe4e8caa53aadeff92477639383 rdf:first _:807f36cf91fe4e8caa53aadeff92477639384;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639384 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:807f36cf91fe4e8caa53aadeff92477639386 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11369-1 a owl:Class;
  rdfs:label "PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE) <-> SULFAMETHIZOL"@fr;
  dct:identifier "IAM_11369";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639388;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne jusqu'à des valeurs toxiques (inhibition de son métabolisme)."@fr;
  r:conduiteATenir "Utiliser de préférence une autre classe d'anti-infectieux, sinon surveillance clinique étroite, dosage des concentrations de phénytoïne et adaptation éventuelle de sa posologie pendant le traitement par le sulfamide anti-infectieux et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639394, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639388 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639389 .

_:807f36cf91fe4e8caa53aadeff92477639389 rdf:first _:807f36cf91fe4e8caa53aadeff92477639390;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639391 .

_:807f36cf91fe4e8caa53aadeff92477639390 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477639391 rdf:first _:807f36cf91fe4e8caa53aadeff92477639392;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639392 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10870 .

_:807f36cf91fe4e8caa53aadeff92477639394 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11332-1 a owl:Class;
  rdfs:label "NORFLOXACINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11332";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639396;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Surveillance clinique et électrocardiographique pendant
l'association."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639402, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639396 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639397 .

_:807f36cf91fe4e8caa53aadeff92477639397 rdf:first _:807f36cf91fe4e8caa53aadeff92477639398;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639399 .

_:807f36cf91fe4e8caa53aadeff92477639398 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477639399 rdf:first _:807f36cf91fe4e8caa53aadeff92477639400;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639400 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10650 .

_:807f36cf91fe4e8caa53aadeff92477639402 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10426-1 a owl:Class;
  rdfs:label "AUTRES RÉTINOÏDES <-> RÉTINOÏDES"@fr;
  dct:identifier "IAM_10426";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639404;
  r:natureDuRisque "Risque de symptômes évocateurs d’une hypervitaminose A."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639406, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff92477639406 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11367-1 a owl:Class;
  rdfs:label "PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE) <-> SUCRALFATE"@fr;
  dct:identifier "IAM_11367";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639408;
  r:natureDuRisque "Diminution de l'absorption digestive de la phénytoïne."@fr;
  r:conduiteATenir "Prendre le sucralfate à distance de la phénytoïne (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639414, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639408 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639409 .

_:807f36cf91fe4e8caa53aadeff92477639409 rdf:first _:807f36cf91fe4e8caa53aadeff92477639410;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639411 .

_:807f36cf91fe4e8caa53aadeff92477639410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477639411 rdf:first _:807f36cf91fe4e8caa53aadeff92477639412;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10864 .

_:807f36cf91fe4e8caa53aadeff92477639414 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11395-1 a owl:Class;
  rdfs:label "QUINIDINE <-> TRICLABENDAZOLE"@fr;
  dct:identifier "IAM_11395";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639416;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes (inhibition du métabolisme hépatique du médicament torsadogène)."@fr;
  r:conduiteATenir "Respecter un délai de 24 heures entre l’arrêt du triclabendazole et la prise du médicament torsadogène, et inversement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639422, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639416 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639417 .

_:807f36cf91fe4e8caa53aadeff92477639417 rdf:first _:807f36cf91fe4e8caa53aadeff92477639418;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639419 .

_:807f36cf91fe4e8caa53aadeff92477639418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477639419 rdf:first _:807f36cf91fe4e8caa53aadeff92477639420;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10953 .

_:807f36cf91fe4e8caa53aadeff92477639422 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11396-1 a owl:Class;
  rdfs:label "QUINIDINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11396";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639424;
  r:natureDuRisque "Risque de majoration importante des effets hémodynamiques du vérapamil, avec hypotension et bradycardie sévères."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639430, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639424 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639425 .

_:807f36cf91fe4e8caa53aadeff92477639425 rdf:first _:807f36cf91fe4e8caa53aadeff92477639426;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639427 .

_:807f36cf91fe4e8caa53aadeff92477639426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477639427 rdf:first _:807f36cf91fe4e8caa53aadeff92477639428;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477639430 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11397-1 a owl:Class;
  rdfs:label "QUINIDINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11397";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639432;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639438, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639432 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639433 .

_:807f36cf91fe4e8caa53aadeff92477639433 rdf:first _:807f36cf91fe4e8caa53aadeff92477639434;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639435 .

_:807f36cf91fe4e8caa53aadeff92477639434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477639435 rdf:first _:807f36cf91fe4e8caa53aadeff92477639436;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477639438 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11398-1 a owl:Class;
  rdfs:label "QUINIDINE <-> VORTIOXÉTINE"@fr;
  dct:identifier "IAM_11398";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639440;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la vortioxétine par diminution importante de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la vortioxétine pendant le traitement par la quinidine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639446, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639440 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639441 .

_:807f36cf91fe4e8caa53aadeff92477639441 rdf:first _:807f36cf91fe4e8caa53aadeff92477639442;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639443 .

_:807f36cf91fe4e8caa53aadeff92477639442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477639443 rdf:first _:807f36cf91fe4e8caa53aadeff92477639444;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10999 .

_:807f36cf91fe4e8caa53aadeff92477639446 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11399-1 a owl:Class;
  rdfs:label "QUININE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11399";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639448;
  r:natureDuRisque "Risque de perte de l’efficacité de la quinine par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639454, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639448 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639449 .

_:807f36cf91fe4e8caa53aadeff92477639449 rdf:first _:807f36cf91fe4e8caa53aadeff92477639450;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639451 .

_:807f36cf91fe4e8caa53aadeff92477639450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10777 .

_:807f36cf91fe4e8caa53aadeff92477639451 rdf:first _:807f36cf91fe4e8caa53aadeff92477639452;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639454 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11400-1 a owl:Class;
  rdfs:label "RALTÉGRAVIR <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11400";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639456;
  r:natureDuRisque "Diminution des concentrations du raltégravir par la rifampicine."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, un doublement de la dose de raltégravir peut être envisagé."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639462, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639456 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639457 .

_:807f36cf91fe4e8caa53aadeff92477639457 rdf:first _:807f36cf91fe4e8caa53aadeff92477639458;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639459 .

_:807f36cf91fe4e8caa53aadeff92477639458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10781 .

_:807f36cf91fe4e8caa53aadeff92477639459 rdf:first _:807f36cf91fe4e8caa53aadeff92477639460;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639462 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11401-1 a owl:Class;
  rdfs:label "RANOLAZINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11401";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639464;
  r:natureDuRisque "Diminution très importante des concentrations de ranolazine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639470, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639464 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639465 .

_:807f36cf91fe4e8caa53aadeff92477639465 rdf:first _:807f36cf91fe4e8caa53aadeff92477639466;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639467 .

_:807f36cf91fe4e8caa53aadeff92477639466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:807f36cf91fe4e8caa53aadeff92477639467 rdf:first _:807f36cf91fe4e8caa53aadeff92477639468;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639470 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11402-1 a owl:Class;
  rdfs:label "RANOLAZINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11402";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639472;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse par inhibition du métabolisme de la simvastatine par la ranolazine."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 20 mg/j de simvastatine ou utiliser une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639478, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639472 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639473 .

_:807f36cf91fe4e8caa53aadeff92477639473 rdf:first _:807f36cf91fe4e8caa53aadeff92477639474;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639475 .

_:807f36cf91fe4e8caa53aadeff92477639474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:807f36cf91fe4e8caa53aadeff92477639475 rdf:first _:807f36cf91fe4e8caa53aadeff92477639476;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477639478 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11393-1 a owl:Class;
  rdfs:label "QUINIDINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_11393";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639480;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639486, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639480 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639481 .

_:807f36cf91fe4e8caa53aadeff92477639481 rdf:first _:807f36cf91fe4e8caa53aadeff92477639482;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639483 .

_:807f36cf91fe4e8caa53aadeff92477639482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477639483 rdf:first _:807f36cf91fe4e8caa53aadeff92477639484;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477639486 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11256-1 a owl:Class;
  rdfs:label "MÉDICAMENTS ADMINISTRÉS PAR VOIE ORALE <-> RÉSINES CHÉLATRICES"@fr;
  dct:identifier "IAM_11256";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639488;
  r:natureDuRisque "La prise de résine chélatrice peut diminuer l’absorption intestinale et, potentiellement, l’efficacité d’autres médicaments pris simultanément."@fr;
  r:conduiteATenir "D’une façon générale, la prise de la résine doit se faire à distance de celle des autres médicaments, en respectant un intervalle de plus de 2 heures, si possible."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639494, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639488 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639489 .

_:807f36cf91fe4e8caa53aadeff92477639489 rdf:first _:807f36cf91fe4e8caa53aadeff92477639490;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639491 .

_:807f36cf91fe4e8caa53aadeff92477639490 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477639491 rdf:first _:807f36cf91fe4e8caa53aadeff92477639492;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10166 .

_:807f36cf91fe4e8caa53aadeff92477639494 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11392-1 a owl:Class;
  rdfs:label "QUETIAPINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11392";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639496;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques de quétiapine par augmentation de son métabolisme hépatique par l'inducteur, avec risque d’inefficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639502, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639496 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639497 .

_:807f36cf91fe4e8caa53aadeff92477639497 rdf:first _:807f36cf91fe4e8caa53aadeff92477639498;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639499 .

_:807f36cf91fe4e8caa53aadeff92477639498 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10773 .

_:807f36cf91fe4e8caa53aadeff92477639499 rdf:first _:807f36cf91fe4e8caa53aadeff92477639500;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639502 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11404-1 a owl:Class;
  rdfs:label "RÉTINOÏDES <-> VITAMINE A"@fr;
  dct:identifier "IAM_11404";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639504;
  r:natureDuRisque "Risque de symptômes évocateurs d’une hypervitaminose A."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639510, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639504 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639505 .

_:807f36cf91fe4e8caa53aadeff92477639505 rdf:first _:807f36cf91fe4e8caa53aadeff92477639506;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639507 .

_:807f36cf91fe4e8caa53aadeff92477639506 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff92477639507 rdf:first _:807f36cf91fe4e8caa53aadeff92477639508;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10997 .

_:807f36cf91fe4e8caa53aadeff92477639510 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11405-1 a owl:Class;
  rdfs:label "RIBAVIRINE <-> STAVUDINE"@fr;
  dct:identifier "IAM_11405";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639512;
  r:natureDuRisque "Risque de diminution de l'efficacité de chaque antiviral, par antagonisme compétitif de la réaction de phosphorylation à l'origine des métabolites actifs."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639518, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639512 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639513 .

_:807f36cf91fe4e8caa53aadeff92477639513 rdf:first _:807f36cf91fe4e8caa53aadeff92477639514;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639515 .

_:807f36cf91fe4e8caa53aadeff92477639514 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10797 .

_:807f36cf91fe4e8caa53aadeff92477639515 rdf:first _:807f36cf91fe4e8caa53aadeff92477639516;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10858 .

_:807f36cf91fe4e8caa53aadeff92477639518 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11406-1 a owl:Class;
  rdfs:label "RIBAVIRINE <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_11406";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639520;
  r:natureDuRisque "Risque de diminution de l'efficacité de chaque antiviral, par antagonisme compétitif de la réaction de phosphorylation à l'origine des métabolites actifs."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639526, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639520 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639521 .

_:807f36cf91fe4e8caa53aadeff92477639521 rdf:first _:807f36cf91fe4e8caa53aadeff92477639522;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639523 .

_:807f36cf91fe4e8caa53aadeff92477639522 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10797 .

_:807f36cf91fe4e8caa53aadeff92477639523 rdf:first _:807f36cf91fe4e8caa53aadeff92477639524;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:807f36cf91fe4e8caa53aadeff92477639526 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11407-1 a owl:Class;
  rdfs:label "RIFABUTINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11407";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639528;
  r:natureDuRisque "Diminution des concentrations plasmatiques du voriconazole avec risque de perte d'efficacité, par augmentation de son métabolisme hépatique par la rifabutine d'une part, et risque d'augmentation des effets indésirables (uvéites) de la rifabutine d'autre p"@fr;
  r:conduiteATenir "Si l'association est jugée néccessaire, surveillance clinique et adaptation de la posologie du voriconazole (en général doublée) pendant le traitement par la rifabutine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639534, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639528 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639529 .

_:807f36cf91fe4e8caa53aadeff92477639529 rdf:first _:807f36cf91fe4e8caa53aadeff92477639530;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639531 .

_:807f36cf91fe4e8caa53aadeff92477639530 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff92477639531 rdf:first _:807f36cf91fe4e8caa53aadeff92477639532;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477639534 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11408-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> RIVAROXABAN"@fr;
  dct:identifier "IAM_11408";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639536;
  r:natureDuRisque "Diminution des concentrations plasmatiques de rivaroxaban, avec risque de diminution de l'effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639542, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639536 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639537 .

_:807f36cf91fe4e8caa53aadeff92477639537 rdf:first _:807f36cf91fe4e8caa53aadeff92477639538;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639539 .

_:807f36cf91fe4e8caa53aadeff92477639538 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639539 rdf:first _:807f36cf91fe4e8caa53aadeff92477639540;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10808 .

_:807f36cf91fe4e8caa53aadeff92477639542 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11409-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11409";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639544;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques de simvastatine, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639550, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639544 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639545 .

_:807f36cf91fe4e8caa53aadeff92477639545 rdf:first _:807f36cf91fe4e8caa53aadeff92477639546;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639547 .

_:807f36cf91fe4e8caa53aadeff92477639546 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639547 rdf:first _:807f36cf91fe4e8caa53aadeff92477639548;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477639550 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11410-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> TELAPREVIR"@fr;
  dct:identifier "IAM_11410";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639552;
  r:natureDuRisque "Diminution très importante des concentrations de télaprévir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639558, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639552 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639553 .

_:807f36cf91fe4e8caa53aadeff92477639553 rdf:first _:807f36cf91fe4e8caa53aadeff92477639554;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639555 .

_:807f36cf91fe4e8caa53aadeff92477639554 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639555 rdf:first _:807f36cf91fe4e8caa53aadeff92477639556;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477639558 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11411-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_11411";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639560;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques de la télithromycine, avec risque d'échec du traitement anti-infectieux, par augmentation du métabolisme hépatique de la télithromycine par la rifampicine."@fr;
  rdfs:comment """La rifampicine est l'un des inducteurs enzymatiques les plus puissants. Administrée avec la télithromycine, elle diminue ses concentrations de 80%.
Le risque important d'échec de l'antibiothérapie justifie une association déconseillée."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639566, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639560 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639561 .

_:807f36cf91fe4e8caa53aadeff92477639561 rdf:first _:807f36cf91fe4e8caa53aadeff92477639562;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639563 .

_:807f36cf91fe4e8caa53aadeff92477639562 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639563 rdf:first _:807f36cf91fe4e8caa53aadeff92477639564;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477639566 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11412-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_11412";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639568;
  r:natureDuRisque "Diminution des concentrations plasmatiques du ténofovir alafénamide par diminution de son absorption par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association et 1 à 2 semaines après l’arrêt de la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639574, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639568 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639569 .

_:807f36cf91fe4e8caa53aadeff92477639569 rdf:first _:807f36cf91fe4e8caa53aadeff92477639570;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639571 .

_:807f36cf91fe4e8caa53aadeff92477639570 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639571 rdf:first _:807f36cf91fe4e8caa53aadeff92477639572;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff92477639574 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11413-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> TERBINAFINE"@fr;
  dct:identifier "IAM_11413";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639576;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de la terbinafine, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la terbinafine pendant le traitement par la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639582, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639576 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639577 .

_:807f36cf91fe4e8caa53aadeff92477639577 rdf:first _:807f36cf91fe4e8caa53aadeff92477639578;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639579 .

_:807f36cf91fe4e8caa53aadeff92477639578 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639579 rdf:first _:807f36cf91fe4e8caa53aadeff92477639580;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:807f36cf91fe4e8caa53aadeff92477639582 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11403-1 a owl:Class;
  rdfs:label "REPAGLINIDE <-> TRIMETHOPRIME"@fr;
  dct:identifier "IAM_11403";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639584;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de répaglinide par inhibition de son métabolisme hépatique par le triméthoprime."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique et biologique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639590, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639584 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639585 .

_:807f36cf91fe4e8caa53aadeff92477639585 rdf:first _:807f36cf91fe4e8caa53aadeff92477639586;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639587 .

_:807f36cf91fe4e8caa53aadeff92477639586 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:807f36cf91fe4e8caa53aadeff92477639587 rdf:first _:807f36cf91fe4e8caa53aadeff92477639588;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10955 .

_:807f36cf91fe4e8caa53aadeff92477639590 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11379-1 a owl:Class;
  rdfs:label "POSACONAZOLE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11379";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639592;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité des deux anti-infectieux (induction enzymatique par la rifampicine et diminution de l'absorption intestinale par l’azolé antifongique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639598, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639592 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639593 .

_:807f36cf91fe4e8caa53aadeff92477639593 rdf:first _:807f36cf91fe4e8caa53aadeff92477639594;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639595 .

_:807f36cf91fe4e8caa53aadeff92477639594 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477639595 rdf:first _:807f36cf91fe4e8caa53aadeff92477639596;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639598 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11095-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> METHADONE"@fr;
  dct:identifier "IAM_11095";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639600;
  r:natureDuRisque "Diminution des concentrations plasmatiques de méthadone avec risque d'apparition d'un syndrome de sevrage, par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Augmenter la fréquence des prises de méthadone (2 à 3 fois par jour au lieu d'une fois par jour)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639606, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639600 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639601 .

_:807f36cf91fe4e8caa53aadeff92477639601 rdf:first _:807f36cf91fe4e8caa53aadeff92477639602;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639603 .

_:807f36cf91fe4e8caa53aadeff92477639602 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477639603 rdf:first _:807f36cf91fe4e8caa53aadeff92477639604;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff92477639606 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11370-1 a owl:Class;
  rdfs:label "PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE) <-> SULFAMETHOXAZOLE"@fr;
  dct:identifier "IAM_11370";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639608;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne jusqu'à des valeurs toxiques (inhibition de son métabolisme)."@fr;
  r:conduiteATenir "Utiliser de préférence une autre classe d'anti-infectieux, sinon surveillance clinique étroite, dosage des concentrations de phénytoïne et adaptation éventuelle de sa posologie pendant le traitement par le sulfamide anti-infectieux et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639614, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639608 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639609 .

_:807f36cf91fe4e8caa53aadeff92477639609 rdf:first _:807f36cf91fe4e8caa53aadeff92477639610;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639611 .

_:807f36cf91fe4e8caa53aadeff92477639610 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477639611 rdf:first _:807f36cf91fe4e8caa53aadeff92477639612;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10871 .

_:807f36cf91fe4e8caa53aadeff92477639614 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11371-1 a owl:Class;
  rdfs:label "PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE) <-> TICLOPIDINE"@fr;
  dct:identifier "IAM_11371";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639616;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne avec signes de surdosage (inhibition du métabolisme de la phénytoïne)."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques de phénytoïne."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639622, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639616 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639617 .

_:807f36cf91fe4e8caa53aadeff92477639617 rdf:first _:807f36cf91fe4e8caa53aadeff92477639618;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639619 .

_:807f36cf91fe4e8caa53aadeff92477639618 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477639619 rdf:first _:807f36cf91fe4e8caa53aadeff92477639620;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10928 .

_:807f36cf91fe4e8caa53aadeff92477639622 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11372-1 a owl:Class;
  rdfs:label "PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE) <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11372";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639624;
  r:natureDuRisque "Augmentation de l'hyperammoniémie, avec risque accru d'encéphalopathie."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639630, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639624 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639625 .

_:807f36cf91fe4e8caa53aadeff92477639625 rdf:first _:807f36cf91fe4e8caa53aadeff92477639626;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639627 .

_:807f36cf91fe4e8caa53aadeff92477639626 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477639627 rdf:first _:807f36cf91fe4e8caa53aadeff92477639628;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477639630 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11373-1 a owl:Class;
  rdfs:label "PIMOZIDE <-> QUINUPRISTINE"@fr;
  dct:identifier "IAM_11373";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639632;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639638, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639632 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639633 .

_:807f36cf91fe4e8caa53aadeff92477639633 rdf:first _:807f36cf91fe4e8caa53aadeff92477639634;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639635 .

_:807f36cf91fe4e8caa53aadeff92477639634 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477639635 rdf:first _:807f36cf91fe4e8caa53aadeff92477639636;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10778 .

_:807f36cf91fe4e8caa53aadeff92477639638 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11374-1 a owl:Class;
  rdfs:label "PIMOZIDE <-> SERTRALINE"@fr;
  dct:identifier "IAM_11374";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639640;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:comment """Le pimozide est un neuroleptique métabolisé par le CYP3A4 et à marge thérapeutique étroite. Il peut entraîner des torsades de pointes en cas de surdosage.
Une étude d’interaction pharmacocinétique entre la sertraline et le pimozide a été réalisée chez 15"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639646, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639640 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639641 .

_:807f36cf91fe4e8caa53aadeff92477639641 rdf:first _:807f36cf91fe4e8caa53aadeff92477639642;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639643 .

_:807f36cf91fe4e8caa53aadeff92477639642 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477639643 rdf:first _:807f36cf91fe4e8caa53aadeff92477639644;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10831 .

_:807f36cf91fe4e8caa53aadeff92477639646 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11375-1 a owl:Class;
  rdfs:label "PIMOZIDE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_11375";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639648;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639654, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639648 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639649 .

_:807f36cf91fe4e8caa53aadeff92477639649 rdf:first _:807f36cf91fe4e8caa53aadeff92477639650;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639651 .

_:807f36cf91fe4e8caa53aadeff92477639650 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477639651 rdf:first _:807f36cf91fe4e8caa53aadeff92477639652;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477639654 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11376-1 a owl:Class;
  rdfs:label "PIMOZIDE <-> TRICLABENDAZOLE"@fr;
  dct:identifier "IAM_11376";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639656;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes (inhibition du métabolisme hépatique du médicament torsadogène)."@fr;
  r:conduiteATenir "Respecter un délai de 24 heures entre l’arrêt du triclabendazole et la prise du médicament torsadogène, et inversement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639662, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639656 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639657 .

_:807f36cf91fe4e8caa53aadeff92477639657 rdf:first _:807f36cf91fe4e8caa53aadeff92477639658;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639659 .

_:807f36cf91fe4e8caa53aadeff92477639658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477639659 rdf:first _:807f36cf91fe4e8caa53aadeff92477639660;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10953 .

_:807f36cf91fe4e8caa53aadeff92477639662 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11377-1 a owl:Class;
  rdfs:label "PIOGLITAZONE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11377";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639664;
  r:natureDuRisque """Diminution des concentrations plasmatiques de la glitazone par
augmentation de son métabolisme par la rifampicine."""@fr;
  r:conduiteATenir """Surveillance clinique et biologique ; adaptation de la posologie de la
glitazone pendant le traitement par la rifampicine et après son arrêt."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639670, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639664 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639665 .

_:807f36cf91fe4e8caa53aadeff92477639665 rdf:first _:807f36cf91fe4e8caa53aadeff92477639666;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639667 .

_:807f36cf91fe4e8caa53aadeff92477639666 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10723 .

_:807f36cf91fe4e8caa53aadeff92477639667 rdf:first _:807f36cf91fe4e8caa53aadeff92477639668;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639668 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639670 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11394-1 a owl:Class;
  rdfs:label "QUINIDINE <-> TAMOXIFENE"@fr;
  dct:identifier "IAM_11394";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639672;
  r:natureDuRisque "Risque de baisse de l'efficacité du tamoxifène, par inhibition de la formation de son métabolite actif par la quinidine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639678, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639672 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639673 .

_:807f36cf91fe4e8caa53aadeff92477639673 rdf:first _:807f36cf91fe4e8caa53aadeff92477639674;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639675 .

_:807f36cf91fe4e8caa53aadeff92477639674 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477639675 rdf:first _:807f36cf91fe4e8caa53aadeff92477639676;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639676 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:807f36cf91fe4e8caa53aadeff92477639678 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11378-1 a owl:Class;
  rdfs:label "POSACONAZOLE <-> RIFABUTINE"@fr;
  dct:identifier "IAM_11378";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639680;
  r:natureDuRisque "Risque d'accroissement des effets indésirables de la rifabutine (uvéites), par augmentation de ses concentrations et de celles de son métabolite actif."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639686, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639680 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639681 .

_:807f36cf91fe4e8caa53aadeff92477639681 rdf:first _:807f36cf91fe4e8caa53aadeff92477639682;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639683 .

_:807f36cf91fe4e8caa53aadeff92477639682 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477639683 rdf:first _:807f36cf91fe4e8caa53aadeff92477639684;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639684 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff92477639686 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11368-1 a owl:Class;
  rdfs:label "PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE) <-> SULFAFURAZOL"@fr;
  dct:identifier "IAM_11368";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639688;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne jusqu'à des valeurs toxiques (inhibition de son métabolisme)."@fr;
  r:conduiteATenir "Utiliser de préférence une autre classe d'anti-infectieux, sinon surveillance clinique étroite, dosage des concentrations de phénytoïne et adaptation éventuelle de sa posologie pendant le traitement par le sulfamide anti-infectieux et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639694, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639688 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639689 .

_:807f36cf91fe4e8caa53aadeff92477639689 rdf:first _:807f36cf91fe4e8caa53aadeff92477639690;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639691 .

_:807f36cf91fe4e8caa53aadeff92477639690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477639691 rdf:first _:807f36cf91fe4e8caa53aadeff92477639692;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639692 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10868 .

_:807f36cf91fe4e8caa53aadeff92477639694 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11380-1 a owl:Class;
  rdfs:label "POSACONAZOLE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11380";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639696;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’inhibiteur de l’HMG-CoA reductase)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639702, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639696 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639697 .

_:807f36cf91fe4e8caa53aadeff92477639697 rdf:first _:807f36cf91fe4e8caa53aadeff92477639698;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639699 .

_:807f36cf91fe4e8caa53aadeff92477639698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477639699 rdf:first _:807f36cf91fe4e8caa53aadeff92477639700;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639700 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477639702 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11382-1 a owl:Class;
  rdfs:label "POTASSIUM <-> TACROLIMUS"@fr;
  dct:identifier "IAM_11382";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639704;
  r:natureDuRisque "Hyperkaliémie essentiellement létale, surtout lors d'une insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Eviter cette association sauf s'il existe une hypokaliémie préalable."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639710, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639704 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639705 .

_:807f36cf91fe4e8caa53aadeff92477639705 rdf:first _:807f36cf91fe4e8caa53aadeff92477639706;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639707 .

_:807f36cf91fe4e8caa53aadeff92477639706 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10742 .

_:807f36cf91fe4e8caa53aadeff92477639707 rdf:first _:807f36cf91fe4e8caa53aadeff92477639708;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639708 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477639710 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11383-1 a owl:Class;
  rdfs:label "PRAZIQUANTEL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11383";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639712;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques du praziquantel, avec risque d'échec du traitement, par augmentation du métabolisme hépatique du praziquantel par la rifampicine."@fr;
  rdfs:comment """Une étude montre que l'effet inducteur puissant de la rifampicine retentit de façon majeure sur le métabolisme du praziquantel, avec une diminution de l'AUC de 90%.
Bien que la durée du traitement antiparasitaire soit brève, une association déconseillée s"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639718, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639712 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639713 .

_:807f36cf91fe4e8caa53aadeff92477639713 rdf:first _:807f36cf91fe4e8caa53aadeff92477639714;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639715 .

_:807f36cf91fe4e8caa53aadeff92477639714 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10750 .

_:807f36cf91fe4e8caa53aadeff92477639715 rdf:first _:807f36cf91fe4e8caa53aadeff92477639716;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639716 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639718 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11385-1 a owl:Class;
  rdfs:label "PROGESTATIFS CONTRACEPTIFS <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_11385";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639720;
  r:natureDuRisque "Risque d'antagonisme des effets du progestatif."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive additionnelle de type mécanique pendant quelques jours après l’arrêt de l’ulipristal."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639726, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639720 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639721 .

_:807f36cf91fe4e8caa53aadeff92477639721 rdf:first _:807f36cf91fe4e8caa53aadeff92477639722;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639723 .

_:807f36cf91fe4e8caa53aadeff92477639722 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:807f36cf91fe4e8caa53aadeff92477639723 rdf:first _:807f36cf91fe4e8caa53aadeff92477639724;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639724 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477639726 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11386-1 a owl:Class;
  rdfs:label "PROGESTATIFS NON CONTRACEPTIFS, ASSOCIÉS OU NON À UN ESTROGÈNE <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_11386";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639728;
  r:natureDuRisque "Risque d'antagonisme des effets du progestatif."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive additionnelle de type mécanique pendant quelques jours après l’arrêt de l’ulipristal."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639734, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639728 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639729 .

_:807f36cf91fe4e8caa53aadeff92477639729 rdf:first _:807f36cf91fe4e8caa53aadeff92477639730;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639731 .

_:807f36cf91fe4e8caa53aadeff92477639730 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10135 .

_:807f36cf91fe4e8caa53aadeff92477639731 rdf:first _:807f36cf91fe4e8caa53aadeff92477639732;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639732 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477639734 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11387-1 a owl:Class;
  rdfs:label "PROPAFENONE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11387";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639736;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la propafénone, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. S'il y a lieu, adaptation de la posologie de la propafénone pendant l'association et après l'arrêt de la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639742, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639736 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639737 .

_:807f36cf91fe4e8caa53aadeff92477639737 rdf:first _:807f36cf91fe4e8caa53aadeff92477639738;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639739 .

_:807f36cf91fe4e8caa53aadeff92477639738 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477639739 rdf:first _:807f36cf91fe4e8caa53aadeff92477639740;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639740 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639742 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11388-1 a owl:Class;
  rdfs:label "PROPAFENONE <-> TERBINAFINE"@fr;
  dct:identifier "IAM_11388";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639744;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la propafénone, par diminution de son métabolisme hépatique par la terbinafine."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la propafénone pendant le traitement par la terbinafine."@fr;
  rdfs:comment """L’effet inhibiteur enzymatique de la terbinafine sur le CYP2D6 a été suggéré sur l’observation chez 12 volontaires sains d’une diminution du métabolisme hépatique de la désipramine, marqueur de l’activité de ce cytochrome.
Afin de prendre acte de cet effe"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639750, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639744 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639745 .

_:807f36cf91fe4e8caa53aadeff92477639745 rdf:first _:807f36cf91fe4e8caa53aadeff92477639746;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639747 .

_:807f36cf91fe4e8caa53aadeff92477639746 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477639747 rdf:first _:807f36cf91fe4e8caa53aadeff92477639748;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639748 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:807f36cf91fe4e8caa53aadeff92477639750 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11389-1 a owl:Class;
  rdfs:label "PROPAFENONE <-> THEOPHYLLINE"@fr;
  dct:identifier "IAM_11389";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639752;
  r:natureDuRisque "Risque d’augmentation de la théophyllinémie par diminution de son métabolisme hépatique par la propafénone."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639758, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639752 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639753 .

_:807f36cf91fe4e8caa53aadeff92477639753 rdf:first _:807f36cf91fe4e8caa53aadeff92477639754;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639755 .

_:807f36cf91fe4e8caa53aadeff92477639754 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477639755 rdf:first _:807f36cf91fe4e8caa53aadeff92477639756;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639756 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10915 .

_:807f36cf91fe4e8caa53aadeff92477639758 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11390-1 a owl:Class;
  rdfs:label "PROPRANOLOL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11390";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639760;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité du bêta-bloquant (augmentation de son métabolisme hépatique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639766, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639760 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639761 .

_:807f36cf91fe4e8caa53aadeff92477639761 rdf:first _:807f36cf91fe4e8caa53aadeff92477639762;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639763 .

_:807f36cf91fe4e8caa53aadeff92477639762 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10767 .

_:807f36cf91fe4e8caa53aadeff92477639763 rdf:first _:807f36cf91fe4e8caa53aadeff92477639764;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639764 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477639766 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11391-1 a owl:Class;
  rdfs:label "PYRIMETHAMINE <-> TRIMETHOPRIME"@fr;
  dct:identifier "IAM_11391";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639768;
  r:natureDuRisque "Anémie mégaloblastique, plus particulièrement à fortes doses des deux produits (déficit en acide folique par l'association de deux 2-4 diaminopyrimidines)."@fr;
  r:conduiteATenir "Contrôle régulier de l'hémogramme et association d'un traitement par l'acide folique (injections IM régulières)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639774, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639768 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639769 .

_:807f36cf91fe4e8caa53aadeff92477639769 rdf:first _:807f36cf91fe4e8caa53aadeff92477639770;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639771 .

_:807f36cf91fe4e8caa53aadeff92477639770 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10772 .

_:807f36cf91fe4e8caa53aadeff92477639771 rdf:first _:807f36cf91fe4e8caa53aadeff92477639772;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639772 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10955 .

_:807f36cf91fe4e8caa53aadeff92477639774 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11381-1 a owl:Class;
  rdfs:label "POSACONAZOLE <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_11381";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639776;
  r:natureDuRisque "Majoration de la neurotoxicité de l'antimitotique, par diminution de son métabolisme hépatique par le posaconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639782, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639776 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639777 .

_:807f36cf91fe4e8caa53aadeff92477639777 rdf:first _:807f36cf91fe4e8caa53aadeff92477639778;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639779 .

_:807f36cf91fe4e8caa53aadeff92477639778 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:807f36cf91fe4e8caa53aadeff92477639779 rdf:first _:807f36cf91fe4e8caa53aadeff92477639780;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639780 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477639782 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10823-1 a owl:Class;
  rdfs:label "DIURÉTIQUES DE L'ANSE <-> LITHIUM"@fr;
  dct:identifier "IAM_10823";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639784;
  r:natureDuRisque "Augmentation de la lithémie avec signes de surdosage en lithium, comme lors d’un régime désodé (diminution de l’excrétion urinaire du lithium)."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance stricte de la lithémie et adaptation de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639790, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639784 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639785 .

_:807f36cf91fe4e8caa53aadeff92477639785 rdf:first _:807f36cf91fe4e8caa53aadeff92477639786;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639787 .

_:807f36cf91fe4e8caa53aadeff92477639786 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10064 .

_:807f36cf91fe4e8caa53aadeff92477639787 rdf:first _:807f36cf91fe4e8caa53aadeff92477639788;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639788 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477639790 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10812-1 a owl:Class;
  rdfs:label "DIMÉTHYLE ( FUMARATE DE) <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10812";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639792;
  r:natureDuRisque "Possible augmentation du risque infectieux."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639798, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639792 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639793 .

_:807f36cf91fe4e8caa53aadeff92477639793 rdf:first _:807f36cf91fe4e8caa53aadeff92477639794;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639795 .

_:807f36cf91fe4e8caa53aadeff92477639794 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477639795 rdf:first _:807f36cf91fe4e8caa53aadeff92477639796;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639796 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10292 .

_:807f36cf91fe4e8caa53aadeff92477639798 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10813-1 a owl:Class;
  rdfs:label "DIPROPHYLLINE <-> PROBENECIDE"@fr;
  dct:identifier "IAM_10813";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639800;
  r:natureDuRisque "Risque de surdosage par augmentation des concentrations plasmatiques de diprophylline (inhibition de sa sécrétion tubulaire rénale)."@fr;
  r:conduiteATenir "Réduire la posologie de diprophylline pendant le traitement par le probénécide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639806, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639800 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639801 .

_:807f36cf91fe4e8caa53aadeff92477639801 rdf:first _:807f36cf91fe4e8caa53aadeff92477639802;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639803 .

_:807f36cf91fe4e8caa53aadeff92477639802 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10296 .

_:807f36cf91fe4e8caa53aadeff92477639803 rdf:first _:807f36cf91fe4e8caa53aadeff92477639804;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639804 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10758 .

_:807f36cf91fe4e8caa53aadeff92477639806 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10814-1 a owl:Class;
  rdfs:label "DIPYRIDAMOLE <-> THÉINE"@fr;
  dct:identifier "IAM_10814";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639808;
  r:natureDuRisque "Avec le dipyridamole par voie injectable : réduction de l’effet vasodilatateur du dipyridamole par la théine."@fr;
  r:conduiteATenir "Eviter la consommation de produits à base de théine dans les 24 heures qui précèdent une imagerie myocardique avec le dipyridamole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639814, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639808 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639809 .

_:807f36cf91fe4e8caa53aadeff92477639809 rdf:first _:807f36cf91fe4e8caa53aadeff92477639810;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639811 .

_:807f36cf91fe4e8caa53aadeff92477639810 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10297 .

_:807f36cf91fe4e8caa53aadeff92477639811 rdf:first _:807f36cf91fe4e8caa53aadeff92477639812;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639812 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11014 .

_:807f36cf91fe4e8caa53aadeff92477639814 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10815-1 a owl:Class;
  rdfs:label "DIPYRIDAMOLE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10815";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639816;
  r:natureDuRisque "Avec le dipyridamole par voie injectable : réduction de l’effet vasodilatateur du dipyridamole par la théophylline."@fr;
  r:conduiteATenir "Interrompre un traitement par théophylline au moins 5 jours avant une imagerie myocardique avec le dipyridamole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639822, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639816 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639817 .

_:807f36cf91fe4e8caa53aadeff92477639817 rdf:first _:807f36cf91fe4e8caa53aadeff92477639818;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639819 .

_:807f36cf91fe4e8caa53aadeff92477639818 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477639819 rdf:first _:807f36cf91fe4e8caa53aadeff92477639820;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639820 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10297 .

_:807f36cf91fe4e8caa53aadeff92477639822 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10816-1 a owl:Class;
  rdfs:label "DISOPYRAMIDE <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10816";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639824;
  r:natureDuRisque "Risque de diminution des concentrations du disopyramide par l’inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement adaptation de la posologie du disopyramide pendant l’associaiton et 1 à 2 semaines après l’arrêt de l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639830, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639824 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639825 .

_:807f36cf91fe4e8caa53aadeff92477639825 rdf:first _:807f36cf91fe4e8caa53aadeff92477639826;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639827 .

_:807f36cf91fe4e8caa53aadeff92477639826 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477639827 rdf:first _:807f36cf91fe4e8caa53aadeff92477639828;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639828 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10298 .

_:807f36cf91fe4e8caa53aadeff92477639830 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10817-1 a owl:Class;
  rdfs:label "DISOPYRAMIDE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10817";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639832;
  r:natureDuRisque "Risque d’augmentation des effets indésirables du disopyramide par diminution de son métabolisme."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du disopyramide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639838, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639832 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639833 .

_:807f36cf91fe4e8caa53aadeff92477639833 rdf:first _:807f36cf91fe4e8caa53aadeff92477639834;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639835 .

_:807f36cf91fe4e8caa53aadeff92477639834 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477639835 rdf:first _:807f36cf91fe4e8caa53aadeff92477639836;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639836 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10298 .

_:807f36cf91fe4e8caa53aadeff92477639838 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10818-1 a owl:Class;
  rdfs:label "DISOPYRAMIDE <-> JOSAMYCINE"@fr;
  dct:identifier "IAM_10818";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639840;
  r:natureDuRisque "Risque de majoration des effets indésirables du disopyramide : hypoglycémies sévères, allongement de l’intervalle QT et troubles du rythme ventriculaire graves, notamment à type de torsades de pointes."@fr;
  r:conduiteATenir "Surveillance clinique, biologique et électrocardiographique régulière."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639846, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639840 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639841 .

_:807f36cf91fe4e8caa53aadeff92477639841 rdf:first _:807f36cf91fe4e8caa53aadeff92477639842;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639843 .

_:807f36cf91fe4e8caa53aadeff92477639842 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10298 .

_:807f36cf91fe4e8caa53aadeff92477639843 rdf:first _:807f36cf91fe4e8caa53aadeff92477639844;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639844 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477639846 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10819-1 a owl:Class;
  rdfs:label "DISULFIRAME <-> ISONIAZIDE"@fr;
  dct:identifier "IAM_10819";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639848;
  r:natureDuRisque "Troubles du comportement et de la coordination."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639854, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639848 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639849 .

_:807f36cf91fe4e8caa53aadeff92477639849 rdf:first _:807f36cf91fe4e8caa53aadeff92477639850;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639851 .

_:807f36cf91fe4e8caa53aadeff92477639850 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10299 .

_:807f36cf91fe4e8caa53aadeff92477639851 rdf:first _:807f36cf91fe4e8caa53aadeff92477639852;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639852 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:807f36cf91fe4e8caa53aadeff92477639854 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10820-1 a owl:Class;
  rdfs:label "DISULFIRAME <-> METRONIDAZOLE"@fr;
  dct:identifier "IAM_10820";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639856;
  r:natureDuRisque "Risque d’épisodes de psychose aiguë ou d’état confusionnel, réversibles à l’arrêt de l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639862, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639856 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639857 .

_:807f36cf91fe4e8caa53aadeff92477639857 rdf:first _:807f36cf91fe4e8caa53aadeff92477639858;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639859 .

_:807f36cf91fe4e8caa53aadeff92477639858 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10299 .

_:807f36cf91fe4e8caa53aadeff92477639859 rdf:first _:807f36cf91fe4e8caa53aadeff92477639860;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639860 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10580 .

_:807f36cf91fe4e8caa53aadeff92477639862 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10786-1 a owl:Class;
  rdfs:label "DIGOXINE <-> RANOLAZINE"@fr;
  dct:identifier "IAM_10786";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639864;
  r:natureDuRisque "Augmentation de la digoxinémie."@fr;
  r:conduiteATenir "Surveillance clinique, biologique et éventuellement ECG. Adaptation de la posologie de la digoxine, si besoin."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639870, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639864 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639865 .

_:807f36cf91fe4e8caa53aadeff92477639865 rdf:first _:807f36cf91fe4e8caa53aadeff92477639866;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639867 .

_:807f36cf91fe4e8caa53aadeff92477639866 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477639867 rdf:first _:807f36cf91fe4e8caa53aadeff92477639868;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639868 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:807f36cf91fe4e8caa53aadeff92477639870 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10822-1 a owl:Class;
  rdfs:label "DIURÉTIQUES <-> PRODUITS DE CONTRASTE IODÉS"@fr;
  dct:identifier "IAM_10822";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639872;
  r:natureDuRisque "En cas de déshydratation provoquée par les diurétiques, risque majoré d'insuffisance rénale fonctionnelle aiguë, en particulier lors d'utilisation de doses importantes de produits de contraste iodés."@fr;
  r:conduiteATenir "Réhydratation avant administration du produit iodé."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639878, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639872 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639873 .

_:807f36cf91fe4e8caa53aadeff92477639873 rdf:first _:807f36cf91fe4e8caa53aadeff92477639874;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639875 .

_:807f36cf91fe4e8caa53aadeff92477639874 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10063 .

_:807f36cf91fe4e8caa53aadeff92477639875 rdf:first _:807f36cf91fe4e8caa53aadeff92477639876;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639876 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10133 .

_:807f36cf91fe4e8caa53aadeff92477639878 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10809-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10809";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639880;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 20 mg/jour de simvastatine. Si l'objectif thérapeutique n'est pas atteint à cette posologie, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639886, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639880 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639881 .

_:807f36cf91fe4e8caa53aadeff92477639881 rdf:first _:807f36cf91fe4e8caa53aadeff92477639882;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639883 .

_:807f36cf91fe4e8caa53aadeff92477639882 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477639883 rdf:first _:807f36cf91fe4e8caa53aadeff92477639884;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639884 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477639886 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10824-1 a owl:Class;
  rdfs:label "DIURÉTIQUES DE L'ANSE <-> METFORMINE"@fr;
  dct:identifier "IAM_10824";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639888;
  r:natureDuRisque "Acidose lactique due à la metformine, déclenchée par une éventuelle insuffisance rénale fonctionnelle, liée aux diurétiques de l'anse."@fr;
  r:conduiteATenir "Ne pas utiliser la metformine lorsque la créatininémie dépasse 15 mg/l (135 µmol/l) chez l'homme, et 12 mg/l (110 µmol/l) chez la femme."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639894, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639888 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639889 .

_:807f36cf91fe4e8caa53aadeff92477639889 rdf:first _:807f36cf91fe4e8caa53aadeff92477639890;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639891 .

_:807f36cf91fe4e8caa53aadeff92477639890 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10064 .

_:807f36cf91fe4e8caa53aadeff92477639891 rdf:first _:807f36cf91fe4e8caa53aadeff92477639892;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639892 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10566 .

_:807f36cf91fe4e8caa53aadeff92477639894 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10825-1 a owl:Class;
  rdfs:label "DIURÉTIQUES DE L'ANSE <-> ORGANOPLATINES"@fr;
  dct:identifier "IAM_10825";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639896;
  r:natureDuRisque "Risque d’addition des effets ototoxiques et/ou néphrotoxiques."@fr;
  rdfs:comment """La néphrotoxicité et l’ototoxicité des organoplatines, cytotoxiques majoritairement éliminés par voie rénale, sont bien documentées. L’administration concomitante avec un médicament diminuant leur élimination rénale peut majorer ce risque.
En favorisant l"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639902, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639896 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639897 .

_:807f36cf91fe4e8caa53aadeff92477639897 rdf:first _:807f36cf91fe4e8caa53aadeff92477639898;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639899 .

_:807f36cf91fe4e8caa53aadeff92477639898 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10064 .

_:807f36cf91fe4e8caa53aadeff92477639899 rdf:first _:807f36cf91fe4e8caa53aadeff92477639900;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639900 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff92477639902 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10413-1 a owl:Class;
  rdfs:label "AUTRES DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS)"@fr;
  dct:identifier "IAM_10413";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639904;
  r:natureDuRisque "Hyperkaliémie potentiellement létale, notamment chez l'insuffisant rénal (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Contre-indiqué sauf s'il existe une hypokaliémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639906, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477639906 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10830-1 a owl:Class;
  rdfs:label "DIURÉTIQUES HYPOKALIÉMIANTS <-> DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS)"@fr;
  dct:identifier "IAM_10830";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639908;
  r:natureDuRisque "L'association rationnelle, utile pour certains patients, n'exclut pas la survenue d'hypokaliémie ou, en particulier chez l'insuffisant rénal et le diabétique, d'hyperkaliémie."@fr;
  r:conduiteATenir "Surveiller la kaliémie, éventuellement l'ECG et, s'il y a lieu, reconsidérer le traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639914, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639908 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639909 .

_:807f36cf91fe4e8caa53aadeff92477639909 rdf:first _:807f36cf91fe4e8caa53aadeff92477639910;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639911 .

_:807f36cf91fe4e8caa53aadeff92477639910 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10065 .

_:807f36cf91fe4e8caa53aadeff92477639911 rdf:first _:807f36cf91fe4e8caa53aadeff92477639912;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477639914 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10826-1 a owl:Class;
  rdfs:label "DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10826";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639916;
  r:natureDuRisque "Risque d'hyperkaliémie (potentiellement létale) surtout en cas d'insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir """Précaution d'emploi :
- pour la spironolactone à des doses comprises entre 12,5 mg et 50 mg/jour, et pour l’éplérénone utilisées dans le traitement de l'insuffisance cardiaque, ainsi qu'en cas d'hypokaliémie : contrôle strict de la kaliémie et de la fonct"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639922, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639916 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639917 .

_:807f36cf91fe4e8caa53aadeff92477639917 rdf:first _:807f36cf91fe4e8caa53aadeff92477639918;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639919 .

_:807f36cf91fe4e8caa53aadeff92477639918 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477639919 rdf:first _:807f36cf91fe4e8caa53aadeff92477639920;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477639922 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10827-1 a owl:Class;
  rdfs:label "DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> LITHIUM"@fr;
  dct:identifier "IAM_10827";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639924;
  r:natureDuRisque "Augmentation de la lithémie avec signes de surdosage en lithium, comme lors d’un régime désodé (diminution de l’excrétion urinaire du lithium)."@fr;
  r:conduiteATenir "Surveillance stricte de la lithémie et adaptation éventuelle de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639930, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639924 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639925 .

_:807f36cf91fe4e8caa53aadeff92477639925 rdf:first _:807f36cf91fe4e8caa53aadeff92477639926;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639927 .

_:807f36cf91fe4e8caa53aadeff92477639926 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477639927 rdf:first _:807f36cf91fe4e8caa53aadeff92477639928;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477639930 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10828-1 a owl:Class;
  rdfs:label "DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> POTASSIUM"@fr;
  dct:identifier "IAM_10828";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639932;
  r:natureDuRisque "Hyperkaliémie potentiellement létale, notamment chez l'insuffisant rénal (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Association déconseillée:-en cas d'hypokaliémie ou d'utilisation parentérale des sels de potassium"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639938, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639932 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639933 .

_:807f36cf91fe4e8caa53aadeff92477639933 rdf:first _:807f36cf91fe4e8caa53aadeff92477639934;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639935 .

_:807f36cf91fe4e8caa53aadeff92477639934 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477639935 rdf:first _:807f36cf91fe4e8caa53aadeff92477639936;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10742 .

_:807f36cf91fe4e8caa53aadeff92477639938 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10829-1 a owl:Class;
  rdfs:label "DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10829";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639940;
  r:natureDuRisque "Hyperkaliémie potentiellement létale, surtout lors d'une insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639946, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639940 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639941 .

_:807f36cf91fe4e8caa53aadeff92477639941 rdf:first _:807f36cf91fe4e8caa53aadeff92477639942;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639943 .

_:807f36cf91fe4e8caa53aadeff92477639942 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477639943 rdf:first _:807f36cf91fe4e8caa53aadeff92477639944;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477639946 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10831-1 a owl:Class;
  rdfs:label "DIURÉTIQUES HYPOKALIÉMIANTS <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10831";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639948;
  r:natureDuRisque "Risque d'hypotension artérielle brutale et/ou d'insuffisance rénale aiguë lors de l'instauration ou de l'augmentation de la posologie d'un traitement par un inhibiteur de l'enzyme de conversion en cas de déplétion hydrosodée préexistante."@fr;
  r:conduiteATenir """Dans l'hypertension artérielle, lorsqu'un traitement diurétique préalable a pu entraîner une déplétion hydrosodée, il faut : 
- soit arrêter le diurétique avant de débuter le traitement par l'IEC, et réintroduire un diurétique hypokaliémiant si nécessaire"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639954, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639948 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639949 .

_:807f36cf91fe4e8caa53aadeff92477639949 rdf:first _:807f36cf91fe4e8caa53aadeff92477639950;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639951 .

_:807f36cf91fe4e8caa53aadeff92477639950 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10065 .

_:807f36cf91fe4e8caa53aadeff92477639951 rdf:first _:807f36cf91fe4e8caa53aadeff92477639952;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477639954 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10821-1 a owl:Class;
  rdfs:label "DISULFIRAME <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10821";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639956;
  r:natureDuRisque "Augmentation importante et rapide des concentrations plasmatiques de phénytoïne avec signes toxiques (inhibition de son métabolisme)."@fr;
  r:conduiteATenir "Si elle ne peut être évitée, contrôle clinique et des concentrations plasmatiques de phénytoïne pendant le traitement par le disulfirame et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639962, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639956 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639957 .

_:807f36cf91fe4e8caa53aadeff92477639957 rdf:first _:807f36cf91fe4e8caa53aadeff92477639958;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639959 .

_:807f36cf91fe4e8caa53aadeff92477639958 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477639959 rdf:first _:807f36cf91fe4e8caa53aadeff92477639960;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10299 .

_:807f36cf91fe4e8caa53aadeff92477639962 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10799-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> DRONEDARONE"@fr;
  dct:identifier "IAM_10799";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639964;
  r:natureDuRisque "Risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez le sujet âgé. Par ailleurs, légère augmentation des concentrations de dronédarone par diminution de son métabolisme par l’antagoniste des canaux calciques."@fr;
  r:conduiteATenir "Débuter le traitement par l’antagoniste calcique aux posologies minimales recommandées, et ajuster les doses en fonction de l’ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639970, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639964 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639965 .

_:807f36cf91fe4e8caa53aadeff92477639965 rdf:first _:807f36cf91fe4e8caa53aadeff92477639966;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639967 .

_:807f36cf91fe4e8caa53aadeff92477639966 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477639967 rdf:first _:807f36cf91fe4e8caa53aadeff92477639968;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477639970 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11097-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> OLAPARIB"@fr;
  dct:identifier "IAM_11097";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639972;
  r:natureDuRisque "Diminution, éventuellement très importante selon l’inducteur, des concentrations plasmatiques de l’olaparib par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639978, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639972 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639973 .

_:807f36cf91fe4e8caa53aadeff92477639973 rdf:first _:807f36cf91fe4e8caa53aadeff92477639974;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639975 .

_:807f36cf91fe4e8caa53aadeff92477639974 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477639975 rdf:first _:807f36cf91fe4e8caa53aadeff92477639976;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10659 .

_:807f36cf91fe4e8caa53aadeff92477639978 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10788-1 a owl:Class;
  rdfs:label "DIGOXINE <-> SULFASALAZINE"@fr;
  dct:identifier "IAM_10788";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639980;
  r:natureDuRisque "Diminution de la digoxinémie pouvant atteindre 50 %."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et, éventuellement, de la digoxinémie. S'il y a lieu, adaptation de la posologie de la digoxine pendant le traitement par la sulfasalazine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639986, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639980 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639981 .

_:807f36cf91fe4e8caa53aadeff92477639981 rdf:first _:807f36cf91fe4e8caa53aadeff92477639982;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639983 .

_:807f36cf91fe4e8caa53aadeff92477639982 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477639983 rdf:first _:807f36cf91fe4e8caa53aadeff92477639984;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10872 .

_:807f36cf91fe4e8caa53aadeff92477639986 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10790-1 a owl:Class;
  rdfs:label "DIGOXINE <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_10790";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639988;
  r:natureDuRisque "Augmentation de la digoxinémie par augmentation de son absorption."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la digoxinémie pendant le traitement par la télithromycine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477639994, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639988 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639989 .

_:807f36cf91fe4e8caa53aadeff92477639989 rdf:first _:807f36cf91fe4e8caa53aadeff92477639990;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639991 .

_:807f36cf91fe4e8caa53aadeff92477639990 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477639991 rdf:first _:807f36cf91fe4e8caa53aadeff92477639992;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477639992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477639994 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10791-1 a owl:Class;
  rdfs:label "DIGOXINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10791";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477639996;
  r:natureDuRisque "Bradycardie excessive et bloc auriculo-ventriculaire par majoration des effets de la digoxine sur l'automatisme et la conduction et par diminution de l'élimination rénale et extrarénale de la digoxine."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et, éventuellement, contrôle de la digoxinémie. S'il y a lieu, adaptation de la posologie de la digoxine pendant le traitement par le vérapamil et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640002, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477639996 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477639997 .

_:807f36cf91fe4e8caa53aadeff92477639997 rdf:first _:807f36cf91fe4e8caa53aadeff92477639998;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477639999 .

_:807f36cf91fe4e8caa53aadeff92477639998 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477639999 rdf:first _:807f36cf91fe4e8caa53aadeff92477640000;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477640002 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10792-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10792";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640004;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:comment "Le diltiazem est un un inhibiteur du CYP3A4. Même si elle est modeste, son activité inhibitrice doit être prise en compte, notamment lorsqu'il est associé à des médicaments à marge thérapeutique étroite comme la dihydroergotamine. Une faible augmentation"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640010, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640004 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640005 .

_:807f36cf91fe4e8caa53aadeff92477640005 rdf:first _:807f36cf91fe4e8caa53aadeff92477640006;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640007 .

_:807f36cf91fe4e8caa53aadeff92477640006 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:807f36cf91fe4e8caa53aadeff92477640007 rdf:first _:807f36cf91fe4e8caa53aadeff92477640008;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477640010 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10793-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> EFAVIRENZ"@fr;
  dct:identifier "IAM_10793";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640012;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640018, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640012 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640013 .

_:807f36cf91fe4e8caa53aadeff92477640013 rdf:first _:807f36cf91fe4e8caa53aadeff92477640014;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640015 .

_:807f36cf91fe4e8caa53aadeff92477640014 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:807f36cf91fe4e8caa53aadeff92477640015 rdf:first _:807f36cf91fe4e8caa53aadeff92477640016;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477640018 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10794-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> MACROLIDES (SAUF SPIRAMYCINE)"@fr;
  dct:identifier "IAM_10794";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640020;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition de l’élimination hépatique de l'alcaloïde de l’ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640026, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640020 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640021 .

_:807f36cf91fe4e8caa53aadeff92477640021 rdf:first _:807f36cf91fe4e8caa53aadeff92477640022;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640023 .

_:807f36cf91fe4e8caa53aadeff92477640022 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10107 .

_:807f36cf91fe4e8caa53aadeff92477640023 rdf:first _:807f36cf91fe4e8caa53aadeff92477640024;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:807f36cf91fe4e8caa53aadeff92477640026 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10795-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> QUINUPRISTINE"@fr;
  dct:identifier "IAM_10795";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640028;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640034, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640028 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640029 .

_:807f36cf91fe4e8caa53aadeff92477640029 rdf:first _:807f36cf91fe4e8caa53aadeff92477640030;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640031 .

_:807f36cf91fe4e8caa53aadeff92477640030 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:807f36cf91fe4e8caa53aadeff92477640031 rdf:first _:807f36cf91fe4e8caa53aadeff92477640032;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10778 .

_:807f36cf91fe4e8caa53aadeff92477640034 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10796-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10796";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640036;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition de l’élimination hépatique de l'alcaloïde de l’ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640042, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640036 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640037 .

_:807f36cf91fe4e8caa53aadeff92477640037 rdf:first _:807f36cf91fe4e8caa53aadeff92477640038;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640039 .

_:807f36cf91fe4e8caa53aadeff92477640038 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:807f36cf91fe4e8caa53aadeff92477640039 rdf:first _:807f36cf91fe4e8caa53aadeff92477640040;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477640042 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10811-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> TICAGRELOR"@fr;
  dct:identifier "IAM_10811";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640044;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de ticagrelor par diminution de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640050, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640044 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640045 .

_:807f36cf91fe4e8caa53aadeff92477640045 rdf:first _:807f36cf91fe4e8caa53aadeff92477640046;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640047 .

_:807f36cf91fe4e8caa53aadeff92477640046 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477640047 rdf:first _:807f36cf91fe4e8caa53aadeff92477640048;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477640050 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10798-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10798";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640052;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l’ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640058, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640052 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640053 .

_:807f36cf91fe4e8caa53aadeff92477640053 rdf:first _:807f36cf91fe4e8caa53aadeff92477640054;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640055 .

_:807f36cf91fe4e8caa53aadeff92477640054 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:807f36cf91fe4e8caa53aadeff92477640055 rdf:first _:807f36cf91fe4e8caa53aadeff92477640056;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477640058 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10810-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> TAMSULOSINE"@fr;
  dct:identifier "IAM_10810";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640060;
  r:natureDuRisque "Risque de majoration des effets indésirables de la tamsulosine, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la tamsulosine pensant le traitement par l’inhibiteur enzymatique et après son arrêt, le cas échéant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640066, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640060 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640061 .

_:807f36cf91fe4e8caa53aadeff92477640061 rdf:first _:807f36cf91fe4e8caa53aadeff92477640062;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640063 .

_:807f36cf91fe4e8caa53aadeff92477640062 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477640063 rdf:first _:807f36cf91fe4e8caa53aadeff92477640064;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10883 .

_:807f36cf91fe4e8caa53aadeff92477640066 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10800-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> ERGOTAMINE"@fr;
  dct:identifier "IAM_10800";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640068;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:comment "Le diltiazem est un inhibiteur du CYP3A4. Même si elle est modeste, son activité inhibitrice doit être prise en compte, notamment lorsqu'il est associé à des médicaments à marge thérapeutique étroite comme l'ergotamine. Une faible augmentation des concent"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640074, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640068 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640069 .

_:807f36cf91fe4e8caa53aadeff92477640069 rdf:first _:807f36cf91fe4e8caa53aadeff92477640070;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640071 .

_:807f36cf91fe4e8caa53aadeff92477640070 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477640071 rdf:first _:807f36cf91fe4e8caa53aadeff92477640072;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:807f36cf91fe4e8caa53aadeff92477640074 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10801-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> ESMOLOL"@fr;
  dct:identifier "IAM_10801";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640076;
  r:natureDuRisque "Troubles de l'automatisme (bradycardie excessive, arrêt sinusal), troubles de la conduction sino-auriculaire et auriculo-ventriculaire et défaillance cardiaque."@fr;
  r:conduiteATenir """Précaution d'emploi :
- si la fonction ventriculaire gauche est normale.
Surveillance clinique et ECG."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640082, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640076 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640077 .

_:807f36cf91fe4e8caa53aadeff92477640077 rdf:first _:807f36cf91fe4e8caa53aadeff92477640078;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640079 .

_:807f36cf91fe4e8caa53aadeff92477640078 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477640079 rdf:first _:807f36cf91fe4e8caa53aadeff92477640080;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:807f36cf91fe4e8caa53aadeff92477640082 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10802-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> IBRUTINIB"@fr;
  dct:identifier "IAM_10802";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640084;
  r:natureDuRisque "Risque d'augmentation des concentrations plasmatiques d’ibrutinib par diminution de son métabolisme hépatique par le diltiazem."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique étroite et réduction de la dose d’ibrutinib à 140 mg par jour pendant la durée de l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640090, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640084 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640085 .

_:807f36cf91fe4e8caa53aadeff92477640085 rdf:first _:807f36cf91fe4e8caa53aadeff92477640086;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640087 .

_:807f36cf91fe4e8caa53aadeff92477640086 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477640087 rdf:first _:807f36cf91fe4e8caa53aadeff92477640088;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10441 .

_:807f36cf91fe4e8caa53aadeff92477640090 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10803-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10803";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640092;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par diminution de son métabolisme."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640098, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640092 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640093 .

_:807f36cf91fe4e8caa53aadeff92477640093 rdf:first _:807f36cf91fe4e8caa53aadeff92477640094;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640095 .

_:807f36cf91fe4e8caa53aadeff92477640094 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477640095 rdf:first _:807f36cf91fe4e8caa53aadeff92477640096;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477640098 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10804-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> IVABRADINE"@fr;
  dct:identifier "IAM_10804";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640100;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l’ivabradine et de ses effets indésirables, notamment cardiaques (inhibition de son métabolisme hépatique par le diltiazem), qui s’ajoutent aux effets bradycardisants de ces molécules."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640106, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640100 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640101 .

_:807f36cf91fe4e8caa53aadeff92477640101 rdf:first _:807f36cf91fe4e8caa53aadeff92477640102;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640103 .

_:807f36cf91fe4e8caa53aadeff92477640102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477640103 rdf:first _:807f36cf91fe4e8caa53aadeff92477640104;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:807f36cf91fe4e8caa53aadeff92477640106 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10805-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> MIDAZOLAM"@fr;
  dct:identifier "IAM_10805";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640108;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de midazolam par diminution de son métabolisme hépatique, avec majoration de la sédation."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie pendant le traitement par le diltiazem."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640114, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640108 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640109 .

_:807f36cf91fe4e8caa53aadeff92477640109 rdf:first _:807f36cf91fe4e8caa53aadeff92477640110;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640111 .

_:807f36cf91fe4e8caa53aadeff92477640110 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477640111 rdf:first _:807f36cf91fe4e8caa53aadeff92477640112;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477640114 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10806-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> NIFEDIPINE"@fr;
  dct:identifier "IAM_10806";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640116;
  r:natureDuRisque "Augmentation importantes des concentrations de nifédipine par diminution de son métabolisme hépatique par le diltiazem, avec risque d'hypotension sévère."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640122, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640116 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640117 .

_:807f36cf91fe4e8caa53aadeff92477640117 rdf:first _:807f36cf91fe4e8caa53aadeff92477640118;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640119 .

_:807f36cf91fe4e8caa53aadeff92477640118 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477640119 rdf:first _:807f36cf91fe4e8caa53aadeff92477640120;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10633 .

_:807f36cf91fe4e8caa53aadeff92477640122 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10807-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> OLAPARIB"@fr;
  dct:identifier "IAM_10807";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640124;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’olaparib par le diltiazem."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, limiter la dose d’olaparib à 200 mg deux fois par jour."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640130, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640124 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640125 .

_:807f36cf91fe4e8caa53aadeff92477640125 rdf:first _:807f36cf91fe4e8caa53aadeff92477640126;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640127 .

_:807f36cf91fe4e8caa53aadeff92477640126 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477640127 rdf:first _:807f36cf91fe4e8caa53aadeff92477640128;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10659 .

_:807f36cf91fe4e8caa53aadeff92477640130 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10808-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> PIMOZIDE"@fr;
  dct:identifier "IAM_10808";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640132;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:comment "Le diltiazem est un inhibiteur du CYP3A4. Même si elle est modeste, son activité inhibitrice doit être prise en compte, notamment lorsqu'il est associé à des médicaments à marge thérapeutique étroite comme le pimozide. Une faible augmentation des concentr"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640138, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640132 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640133 .

_:807f36cf91fe4e8caa53aadeff92477640133 rdf:first _:807f36cf91fe4e8caa53aadeff92477640134;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640135 .

_:807f36cf91fe4e8caa53aadeff92477640134 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477640135 rdf:first _:807f36cf91fe4e8caa53aadeff92477640136;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477640138 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10834-1 a owl:Class;
  rdfs:label "DOCETAXEL <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10834";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640140;
  r:natureDuRisque "Diminution des concentrations du cytotoxique par augmentation de son métabolisme par l’inducteur, avec risque de moindre efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640146, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640140 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640141 .

_:807f36cf91fe4e8caa53aadeff92477640141 rdf:first _:807f36cf91fe4e8caa53aadeff92477640142;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640143 .

_:807f36cf91fe4e8caa53aadeff92477640142 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477640143 rdf:first _:807f36cf91fe4e8caa53aadeff92477640144;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10300 .

_:807f36cf91fe4e8caa53aadeff92477640146 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10797-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> TRICLABENDAZOLE"@fr;
  dct:identifier "IAM_10797";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640148;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l’alcaloïde de l’ergot de seigle)."@fr;
  r:conduiteATenir "Respecter un délai de 24 heures entre l’arrêt du triclabendazole et la prise du médicament dérivé de l’ergot, et inversement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640154, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640148 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640149 .

_:807f36cf91fe4e8caa53aadeff92477640149 rdf:first _:807f36cf91fe4e8caa53aadeff92477640150;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640151 .

_:807f36cf91fe4e8caa53aadeff92477640150 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:807f36cf91fe4e8caa53aadeff92477640151 rdf:first _:807f36cf91fe4e8caa53aadeff92477640152;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10953 .

_:807f36cf91fe4e8caa53aadeff92477640154 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11054-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_11054";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640156;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique très étroite. Débuter l'association aux posologies minimales recommandées."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640162, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640156 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640157 .

_:807f36cf91fe4e8caa53aadeff92477640157 rdf:first _:807f36cf91fe4e8caa53aadeff92477640158;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640159 .

_:807f36cf91fe4e8caa53aadeff92477640158 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477640159 rdf:first _:807f36cf91fe4e8caa53aadeff92477640160;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477640162 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10832-1 a owl:Class;
  rdfs:label "DIURÉTIQUES THIAZIDIQUES ET APPARENTÉS <-> LITHIUM"@fr;
  dct:identifier "IAM_10832";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640164;
  r:natureDuRisque "Augmentation de la lithémie avec signes de surdosage en lithium, comme lors d’un régime désodé (diminution de l’excrétion urinaire du lithium)."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance stricte de la lithémie et adaptation de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640170, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640164 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640165 .

_:807f36cf91fe4e8caa53aadeff92477640165 rdf:first _:807f36cf91fe4e8caa53aadeff92477640166;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640167 .

_:807f36cf91fe4e8caa53aadeff92477640166 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477640167 rdf:first _:807f36cf91fe4e8caa53aadeff92477640168;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477640170 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10859-1 a owl:Class;
  rdfs:label "DULOXETINE <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10859";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640172;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de propafénone avec risque de surdosage, par diminution de son métabolisme hépatique par la duloxétine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie de la propafénone pendant le traitement par la duloxétine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640178, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640172 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640173 .

_:807f36cf91fe4e8caa53aadeff92477640173 rdf:first _:807f36cf91fe4e8caa53aadeff92477640174;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640175 .

_:807f36cf91fe4e8caa53aadeff92477640174 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:807f36cf91fe4e8caa53aadeff92477640175 rdf:first _:807f36cf91fe4e8caa53aadeff92477640176;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477640178 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11046-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> SYMPATHOMIMÉTIQUES ALPHA ET BÊTA (VOIE IM ET IV)"@fr;
  dct:identifier "IAM_11046";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640180;
  r:natureDuRisque "Augmentation de l'action pressive du sympathomimétique, le plus souvent modérée."@fr;
  r:conduiteATenir "A n'utiliser que sous contrôle médical strict."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640186, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640180 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640181 .

_:807f36cf91fe4e8caa53aadeff92477640181 rdf:first _:807f36cf91fe4e8caa53aadeff92477640182;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640183 .

_:807f36cf91fe4e8caa53aadeff92477640182 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477640183 rdf:first _:807f36cf91fe4e8caa53aadeff92477640184;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10149 .

_:807f36cf91fe4e8caa53aadeff92477640186 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11045-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> SYMPATHOMIMÉTIQUES ALPHA (VOIES ORALE ET/OU NASALE)"@fr;
  dct:identifier "IAM_11045";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640188;
  r:natureDuRisque "Crises hypertensives (inhibition du métabolisme des amines pressives). Du fait de la durée d'action de l'IMAO, cette interaction est encore possible 15 jours après l'arrêt de l'IMAO."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640194, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640188 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640189 .

_:807f36cf91fe4e8caa53aadeff92477640189 rdf:first _:807f36cf91fe4e8caa53aadeff92477640190;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640191 .

_:807f36cf91fe4e8caa53aadeff92477640190 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477640191 rdf:first _:807f36cf91fe4e8caa53aadeff92477640192;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10148 .

_:807f36cf91fe4e8caa53aadeff92477640194 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11047-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_11047";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640196;
  r:natureDuRisque "Hypertension paroxystique, hyperthermie pouvant être fatale. Du fait de la durée d'action de l'IMAO, cette interaction est encore possible 15 jours après l'arrêt de l'IMAO."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640202, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640196 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640197 .

_:807f36cf91fe4e8caa53aadeff92477640197 rdf:first _:807f36cf91fe4e8caa53aadeff92477640198;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640199 .

_:807f36cf91fe4e8caa53aadeff92477640198 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477640199 rdf:first _:807f36cf91fe4e8caa53aadeff92477640200;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477640202 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11048-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> TETRABENAZINE"@fr;
  dct:identifier "IAM_11048";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640204;
  r:natureDuRisque "Risque de crises hypertensives. Du fait de la durée d'action de l'IMAO, cette interaction est encore théoriquement possible 15 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640210, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640204 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640205 .

_:807f36cf91fe4e8caa53aadeff92477640205 rdf:first _:807f36cf91fe4e8caa53aadeff92477640206;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640207 .

_:807f36cf91fe4e8caa53aadeff92477640206 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477640207 rdf:first _:807f36cf91fe4e8caa53aadeff92477640208;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10908 .

_:807f36cf91fe4e8caa53aadeff92477640210 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11049-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> TIANEPTINE"@fr;
  dct:identifier "IAM_11049";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640212;
  r:natureDuRisque "Risque de collapsus, hypertension paroxystique, hyperthermie, convulsions, décès."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640218, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640212 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640213 .

_:807f36cf91fe4e8caa53aadeff92477640213 rdf:first _:807f36cf91fe4e8caa53aadeff92477640214;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640215 .

_:807f36cf91fe4e8caa53aadeff92477640214 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477640215 rdf:first _:807f36cf91fe4e8caa53aadeff92477640216;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10923 .

_:807f36cf91fe4e8caa53aadeff92477640218 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11050-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> TRAMADOL"@fr;
  dct:identifier "IAM_11050";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640220;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, sueurs, tremblements, confusion, voire coma."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640226, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640220 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640221 .

_:807f36cf91fe4e8caa53aadeff92477640221 rdf:first _:807f36cf91fe4e8caa53aadeff92477640222;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640223 .

_:807f36cf91fe4e8caa53aadeff92477640222 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477640223 rdf:first _:807f36cf91fe4e8caa53aadeff92477640224;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:807f36cf91fe4e8caa53aadeff92477640226 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11052-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> TRIPTANS NON MÉTABOLISÉS PAR LA MAO"@fr;
  dct:identifier "IAM_11052";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640228;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640234, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640228 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640229 .

_:807f36cf91fe4e8caa53aadeff92477640229 rdf:first _:807f36cf91fe4e8caa53aadeff92477640230;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640231 .

_:807f36cf91fe4e8caa53aadeff92477640230 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477640231 rdf:first _:807f36cf91fe4e8caa53aadeff92477640232;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477640234 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10858-1 a owl:Class;
  rdfs:label "DULOXETINE <-> METOPROLOL"@fr;
  dct:identifier "IAM_10858";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640236;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de métoprolol avec risque de surdosage, par diminution de son métabolisme hépatique par la duloxétine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du métoprolol pendant le traitement par la duloxétine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640242, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640236 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640237 .

_:807f36cf91fe4e8caa53aadeff92477640237 rdf:first _:807f36cf91fe4e8caa53aadeff92477640238;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640239 .

_:807f36cf91fe4e8caa53aadeff92477640238 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:807f36cf91fe4e8caa53aadeff92477640239 rdf:first _:807f36cf91fe4e8caa53aadeff92477640240;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640240 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477640242 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11053-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> IMAO-B"@fr;
  dct:identifier "IAM_11053";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640244;
  r:natureDuRisque "Risque de poussée hypertensive, par perte de sélectivité sur la monoamine oxydase, notamment en cas d’alimentation riche en tyramine (fromage, bière,…)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640250, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640244 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640245 .

_:807f36cf91fe4e8caa53aadeff92477640245 rdf:first _:807f36cf91fe4e8caa53aadeff92477640246;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640247 .

_:807f36cf91fe4e8caa53aadeff92477640246 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477640247 rdf:first _:807f36cf91fe4e8caa53aadeff92477640248;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640248 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477640250 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10856-1 a owl:Class;
  rdfs:label "DULOXETINE <-> FLUVOXAMINE"@fr;
  dct:identifier "IAM_10856";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640252;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la duloxétine par diminution de son métabolisme hépatique par la fluvoxamine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640258, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640252 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640253 .

_:807f36cf91fe4e8caa53aadeff92477640253 rdf:first _:807f36cf91fe4e8caa53aadeff92477640254;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640255 .

_:807f36cf91fe4e8caa53aadeff92477640254 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:807f36cf91fe4e8caa53aadeff92477640255 rdf:first _:807f36cf91fe4e8caa53aadeff92477640256;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640256 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477640258 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11055-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> MÉDICAMENTS MIXTES ADRÉNERGIQUES-SÉROTONINERGIQUES"@fr;
  dct:identifier "IAM_11055";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640260;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueur, confusion voire coma."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique très étroite. Débuter l'association aux posologies minimales recommandées."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640266, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640260 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640261 .

_:807f36cf91fe4e8caa53aadeff92477640261 rdf:first _:807f36cf91fe4e8caa53aadeff92477640262;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640263 .

_:807f36cf91fe4e8caa53aadeff92477640262 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477640263 rdf:first _:807f36cf91fe4e8caa53aadeff92477640264;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640264 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10116 .

_:807f36cf91fe4e8caa53aadeff92477640266 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11194-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> MIZOLASTINE"@fr;
  dct:identifier "IAM_11194";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640268;
  r:natureDuRisque "Risque de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640274, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640268 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640269 .

_:807f36cf91fe4e8caa53aadeff92477640269 rdf:first _:807f36cf91fe4e8caa53aadeff92477640270;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640271 .

_:807f36cf91fe4e8caa53aadeff92477640270 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477640271 rdf:first _:807f36cf91fe4e8caa53aadeff92477640272;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640272 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10597 .

_:807f36cf91fe4e8caa53aadeff92477640274 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11195-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_11195";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640276;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par l'itraconazole."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640282, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640276 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640277 .

_:807f36cf91fe4e8caa53aadeff92477640277 rdf:first _:807f36cf91fe4e8caa53aadeff92477640278;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640279 .

_:807f36cf91fe4e8caa53aadeff92477640278 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477640279 rdf:first _:807f36cf91fe4e8caa53aadeff92477640280;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640280 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477640282 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11196-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> QUINIDINE"@fr;
  dct:identifier "IAM_11196";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640284;
  r:natureDuRisque """Risque majoré de troubles du rythme ventriculaire, notamment de
torsades de pointes, ainsi que d'acouphènes et/ou de diminution de l'acuité auditive (cinchonisme), par diminution du métabolisme
hépatique de la quinidine."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640290, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640284 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640285 .

_:807f36cf91fe4e8caa53aadeff92477640285 rdf:first _:807f36cf91fe4e8caa53aadeff92477640286;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640287 .

_:807f36cf91fe4e8caa53aadeff92477640286 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477640287 rdf:first _:807f36cf91fe4e8caa53aadeff92477640288;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640288 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477640290 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11197-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> SALMETEROL"@fr;
  dct:identifier "IAM_11197";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640292;
  r:natureDuRisque "Augmentation importante des concentrations de salmétérol par diminution de son métabolisme hépatique par l'itraconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640298, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640292 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640293 .

_:807f36cf91fe4e8caa53aadeff92477640293 rdf:first _:807f36cf91fe4e8caa53aadeff92477640294;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640295 .

_:807f36cf91fe4e8caa53aadeff92477640294 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477640295 rdf:first _:807f36cf91fe4e8caa53aadeff92477640296;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640296 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10823 .

_:807f36cf91fe4e8caa53aadeff92477640298 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11198-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11198";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640300;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de la simvastatine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640306, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640300 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640301 .

_:807f36cf91fe4e8caa53aadeff92477640301 rdf:first _:807f36cf91fe4e8caa53aadeff92477640302;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640303 .

_:807f36cf91fe4e8caa53aadeff92477640302 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477640303 rdf:first _:807f36cf91fe4e8caa53aadeff92477640304;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640304 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477640306 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11200-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_11200";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640308;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du ténofovir alafénamide par augmentation de son absorption."@fr;
  r:conduiteATenir "En cas de co-administration avec l’itraconazole, la dose de ténofovir alafénamide doit être limitée à 10 mg par jour."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640314, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640308 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640309 .

_:807f36cf91fe4e8caa53aadeff92477640309 rdf:first _:807f36cf91fe4e8caa53aadeff92477640310;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640311 .

_:807f36cf91fe4e8caa53aadeff92477640310 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477640311 rdf:first _:807f36cf91fe4e8caa53aadeff92477640312;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640312 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff92477640314 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11201-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> TRABECTÉDINE"@fr;
  dct:identifier "IAM_11201";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640316;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de la trabectedine par l’itraconazole."@fr;
  r:conduiteATenir "Si l’association est nécessaire, surveillance clinique et adaptation éventuelle de la posologie de la trabectedine pendant la durée du traitement par l’itraconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640322, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640316 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640317 .

_:807f36cf91fe4e8caa53aadeff92477640317 rdf:first _:807f36cf91fe4e8caa53aadeff92477640318;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640319 .

_:807f36cf91fe4e8caa53aadeff92477640318 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477640319 rdf:first _:807f36cf91fe4e8caa53aadeff92477640320;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640320 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10944 .

_:807f36cf91fe4e8caa53aadeff92477640322 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11202-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_11202";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640324;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640330, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640324 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640325 .

_:807f36cf91fe4e8caa53aadeff92477640325 rdf:first _:807f36cf91fe4e8caa53aadeff92477640326;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640327 .

_:807f36cf91fe4e8caa53aadeff92477640326 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477640327 rdf:first _:807f36cf91fe4e8caa53aadeff92477640328;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640328 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:807f36cf91fe4e8caa53aadeff92477640330 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11204-1 a owl:Class;
  rdfs:label "IVABRADINE <-> JOSAMYCINE"@fr;
  dct:identifier "IAM_11204";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640332;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'ivabradine et par conséquent de ses effets indésirables (inhibition de son métabolisme hépatique par la josamycine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640338, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640332 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640333 .

_:807f36cf91fe4e8caa53aadeff92477640333 rdf:first _:807f36cf91fe4e8caa53aadeff92477640334;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640335 .

_:807f36cf91fe4e8caa53aadeff92477640334 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:807f36cf91fe4e8caa53aadeff92477640335 rdf:first _:807f36cf91fe4e8caa53aadeff92477640336;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640336 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477640338 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11051-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> TRIPTANS MÉTABOLISÉS PAR LA MAO"@fr;
  dct:identifier "IAM_11051";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640340;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640346, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640340 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640341 .

_:807f36cf91fe4e8caa53aadeff92477640341 rdf:first _:807f36cf91fe4e8caa53aadeff92477640342;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640343 .

_:807f36cf91fe4e8caa53aadeff92477640342 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477640343 rdf:first _:807f36cf91fe4e8caa53aadeff92477640344;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640344 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10157 .

_:807f36cf91fe4e8caa53aadeff92477640346 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10845-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> FIDAXOMICINE"@fr;
  dct:identifier "IAM_10845";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640348;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640354, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640348 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640349 .

_:807f36cf91fe4e8caa53aadeff92477640349 rdf:first _:807f36cf91fe4e8caa53aadeff92477640350;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640351 .

_:807f36cf91fe4e8caa53aadeff92477640350 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477640351 rdf:first _:807f36cf91fe4e8caa53aadeff92477640352;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640352 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:807f36cf91fe4e8caa53aadeff92477640354 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10785-1 a owl:Class;
  rdfs:label "DIGOXINE <-> QUININE"@fr;
  dct:identifier "IAM_10785";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640356;
  r:natureDuRisque "Augmentation modérée de la digoxinémie."@fr;
  r:conduiteATenir "Surveillance clinique et ECG, si besoin, avec adaptation éventuelle des doses de digoxine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640362, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640356 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640357 .

_:807f36cf91fe4e8caa53aadeff92477640357 rdf:first _:807f36cf91fe4e8caa53aadeff92477640358;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640359 .

_:807f36cf91fe4e8caa53aadeff92477640358 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477640359 rdf:first _:807f36cf91fe4e8caa53aadeff92477640360;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640360 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10777 .

_:807f36cf91fe4e8caa53aadeff92477640362 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10835-1 a owl:Class;
  rdfs:label "DOCETAXEL <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10835";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640364;
  r:natureDuRisque "Risque de majoration des effets indésirables dose-dépendants du docétaxel par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du docétaxel pendant le traitement par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640370, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640364 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640365 .

_:807f36cf91fe4e8caa53aadeff92477640365 rdf:first _:807f36cf91fe4e8caa53aadeff92477640366;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640367 .

_:807f36cf91fe4e8caa53aadeff92477640366 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477640367 rdf:first _:807f36cf91fe4e8caa53aadeff92477640368;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640368 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10300 .

_:807f36cf91fe4e8caa53aadeff92477640370 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10836-1 a owl:Class;
  rdfs:label "DOLUTÉGRAVIR <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10836";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640372;
  r:natureDuRisque "Diminution des concentrations plasmatiques de dolutégravir par augmentation de son métabolisme par l’inducteur."@fr;
  r:conduiteATenir """Association déconseillée :
- en cas de résistance à la classe des inhibiteurs d'intégrase

Précaution d'emploi :
- en l'absence de résistance à la classe des inhibiteurs d'intégrase
Adaptation de la posologie de dolutégravir à 50 mg 2 fois par jour penda"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640378, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640372 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640373 .

_:807f36cf91fe4e8caa53aadeff92477640373 rdf:first _:807f36cf91fe4e8caa53aadeff92477640374;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640375 .

_:807f36cf91fe4e8caa53aadeff92477640374 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477640375 rdf:first _:807f36cf91fe4e8caa53aadeff92477640376;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640376 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10301 .

_:807f36cf91fe4e8caa53aadeff92477640378 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10837-1 a owl:Class;
  rdfs:label "DOLUTÉGRAVIR <-> METFORMINE"@fr;
  dct:identifier "IAM_10837";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640380;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de metformine par le dolutegravir et de ses effets indésirables à type d’acidose lactique."@fr;
  r:conduiteATenir "Chez le patient avec une insuffisance rénale modérée (stade 3a, clairance de la créatinine comprise entre 45 et 59 ml/min), surveillance clinique et biologique, et adaptation éventuelle de la posologie de metformine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640386, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640380 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640381 .

_:807f36cf91fe4e8caa53aadeff92477640381 rdf:first _:807f36cf91fe4e8caa53aadeff92477640382;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640383 .

_:807f36cf91fe4e8caa53aadeff92477640382 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10301 .

_:807f36cf91fe4e8caa53aadeff92477640383 rdf:first _:807f36cf91fe4e8caa53aadeff92477640384;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640384 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10566 .

_:807f36cf91fe4e8caa53aadeff92477640386 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10838-1 a owl:Class;
  rdfs:label "DOLUTÉGRAVIR <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10838";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640388;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de dolutégravir par augmentation de son métabolisme par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640394, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640388 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640389 .

_:807f36cf91fe4e8caa53aadeff92477640389 rdf:first _:807f36cf91fe4e8caa53aadeff92477640390;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640391 .

_:807f36cf91fe4e8caa53aadeff92477640390 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10301 .

_:807f36cf91fe4e8caa53aadeff92477640391 rdf:first _:807f36cf91fe4e8caa53aadeff92477640392;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640392 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477640394 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10839-1 a owl:Class;
  rdfs:label "DOMPERIDONE <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10839";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640396;
  r:natureDuRisque "Risque de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640402, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640396 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640397 .

_:807f36cf91fe4e8caa53aadeff92477640397 rdf:first _:807f36cf91fe4e8caa53aadeff92477640398;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640399 .

_:807f36cf91fe4e8caa53aadeff92477640398 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10302 .

_:807f36cf91fe4e8caa53aadeff92477640399 rdf:first _:807f36cf91fe4e8caa53aadeff92477640400;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640400 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477640402 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10840-1 a owl:Class;
  rdfs:label "DOMPERIDONE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10840";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640404;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de dompéridone par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640410, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640404 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640405 .

_:807f36cf91fe4e8caa53aadeff92477640405 rdf:first _:807f36cf91fe4e8caa53aadeff92477640406;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640407 .

_:807f36cf91fe4e8caa53aadeff92477640406 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477640407 rdf:first _:807f36cf91fe4e8caa53aadeff92477640408;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640408 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10302 .

_:807f36cf91fe4e8caa53aadeff92477640410 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10841-1 a owl:Class;
  rdfs:label "DOPAMINERGIQUES <-> NEUROLEPTIQUES ANTIÉMÉTIQUES"@fr;
  dct:identifier "IAM_10841";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640412;
  r:natureDuRisque "Antagonisme réciproque entre le dopaminergique et le neuroleptique."@fr;
  r:conduiteATenir "Utiliser un antiémétique dénué d'effets extrapyramidaux."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640418, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640412 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640413 .

_:807f36cf91fe4e8caa53aadeff92477640413 rdf:first _:807f36cf91fe4e8caa53aadeff92477640414;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640415 .

_:807f36cf91fe4e8caa53aadeff92477640414 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10068 .

_:807f36cf91fe4e8caa53aadeff92477640415 rdf:first _:807f36cf91fe4e8caa53aadeff92477640416;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640416 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff92477640418 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10842-1 a owl:Class;
  rdfs:label "DOPAMINERGIQUES <-> TETRABENAZINE"@fr;
  dct:identifier "IAM_10842";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640420;
  r:natureDuRisque "Antagonisme réciproque entre le dopaminergique et la tétrabénazine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640426, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640420 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640421 .

_:807f36cf91fe4e8caa53aadeff92477640421 rdf:first _:807f36cf91fe4e8caa53aadeff92477640422;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640423 .

_:807f36cf91fe4e8caa53aadeff92477640422 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10068 .

_:807f36cf91fe4e8caa53aadeff92477640423 rdf:first _:807f36cf91fe4e8caa53aadeff92477640424;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640424 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10908 .

_:807f36cf91fe4e8caa53aadeff92477640426 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10857-1 a owl:Class;
  rdfs:label "DULOXETINE <-> MEQUITAZINE"@fr;
  dct:identifier "IAM_10857";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640428;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méquitazine, par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640434, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640428 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640429 .

_:807f36cf91fe4e8caa53aadeff92477640429 rdf:first _:807f36cf91fe4e8caa53aadeff92477640430;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640431 .

_:807f36cf91fe4e8caa53aadeff92477640430 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:807f36cf91fe4e8caa53aadeff92477640431 rdf:first _:807f36cf91fe4e8caa53aadeff92477640432;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640432 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10561 .

_:807f36cf91fe4e8caa53aadeff92477640434 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10844-1 a owl:Class;
  rdfs:label "DOXORUBICINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10844";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640436;
  r:natureDuRisque "Risque de majoration de la toxicité de la doxorubicine par augmentation de ses concentrations plasmatiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640442, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640436 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640437 .

_:807f36cf91fe4e8caa53aadeff92477640437 rdf:first _:807f36cf91fe4e8caa53aadeff92477640438;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640439 .

_:807f36cf91fe4e8caa53aadeff92477640438 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10308 .

_:807f36cf91fe4e8caa53aadeff92477640439 rdf:first _:807f36cf91fe4e8caa53aadeff92477640440;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640440 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477640442 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10833-1 a owl:Class;
  rdfs:label "DOCETAXEL <-> DRONEDARONE"@fr;
  dct:identifier "IAM_10833";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640444;
  r:natureDuRisque "Risque de majoration de la toxicité du docétaxel par diminution de son métabolisme."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du docétaxel pendant le traitement par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640450, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640444 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640445 .

_:807f36cf91fe4e8caa53aadeff92477640445 rdf:first _:807f36cf91fe4e8caa53aadeff92477640446;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640447 .

_:807f36cf91fe4e8caa53aadeff92477640446 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10300 .

_:807f36cf91fe4e8caa53aadeff92477640447 rdf:first _:807f36cf91fe4e8caa53aadeff92477640448;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640448 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477640450 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10846-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10846";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640452;
  r:natureDuRisque "Augmentation importante des concentrations sanguines de l’immunosuppresseur par diminution de son métabolisme."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640458, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640452 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640453 .

_:807f36cf91fe4e8caa53aadeff92477640453 rdf:first _:807f36cf91fe4e8caa53aadeff92477640454;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640455 .

_:807f36cf91fe4e8caa53aadeff92477640454 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477640455 rdf:first _:807f36cf91fe4e8caa53aadeff92477640456;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640456 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477640458 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10847-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10847";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640460;
  r:natureDuRisque "Augmentation importante des concentrations de dronédarone par diminution de son métabolisme."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640466, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640460 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640461 .

_:807f36cf91fe4e8caa53aadeff92477640461 rdf:first _:807f36cf91fe4e8caa53aadeff92477640462;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640463 .

_:807f36cf91fe4e8caa53aadeff92477640462 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477640463 rdf:first _:807f36cf91fe4e8caa53aadeff92477640464;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640464 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477640466 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10848-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10848";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640468;
  r:natureDuRisque "Diminution importante des concentrations de dronédarone par augmentation de son métabolisme, sans modification notable du métabolite actif."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640474, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640468 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640469 .

_:807f36cf91fe4e8caa53aadeff92477640469 rdf:first _:807f36cf91fe4e8caa53aadeff92477640470;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640471 .

_:807f36cf91fe4e8caa53aadeff92477640470 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477640471 rdf:first _:807f36cf91fe4e8caa53aadeff92477640472;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640472 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477640474 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10849-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_10849";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640476;
  r:natureDuRisque "Augmentation des concentrations de dronédarone par inhibition de son métabolisme par le pamplemousse."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640482, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640476 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640477 .

_:807f36cf91fe4e8caa53aadeff92477640477 rdf:first _:807f36cf91fe4e8caa53aadeff92477640478;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640479 .

_:807f36cf91fe4e8caa53aadeff92477640478 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477640479 rdf:first _:807f36cf91fe4e8caa53aadeff92477640480;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640480 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477640482 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10850-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> QUINIDINE"@fr;
  dct:identifier "IAM_10850";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640484;
  r:natureDuRisque "Risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez le sujet âgé. Par ailleurs, légère augmentation des concentrations de dronédarone par diminution de son métabolisme par la quinidine."@fr;
  r:conduiteATenir "Débuter le traitement par la quinidine aux posologies minimales recommandées, et ajuster les doses en fonction de l’ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640490, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640484 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640485 .

_:807f36cf91fe4e8caa53aadeff92477640485 rdf:first _:807f36cf91fe4e8caa53aadeff92477640486;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640487 .

_:807f36cf91fe4e8caa53aadeff92477640486 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477640487 rdf:first _:807f36cf91fe4e8caa53aadeff92477640488;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640488 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477640490 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10851-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10851";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640492;
  r:natureDuRisque "Diminution importante des concentrations de dronédarone par augmentation de son métabolisme, sans modification notable du métabolite actif."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640498, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640492 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640493 .

_:807f36cf91fe4e8caa53aadeff92477640493 rdf:first _:807f36cf91fe4e8caa53aadeff92477640494;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640495 .

_:807f36cf91fe4e8caa53aadeff92477640494 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477640495 rdf:first _:807f36cf91fe4e8caa53aadeff92477640496;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640496 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477640498 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10852-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10852";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640500;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de la simvastatine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640506, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640500 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640501 .

_:807f36cf91fe4e8caa53aadeff92477640501 rdf:first _:807f36cf91fe4e8caa53aadeff92477640502;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640503 .

_:807f36cf91fe4e8caa53aadeff92477640502 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477640503 rdf:first _:807f36cf91fe4e8caa53aadeff92477640504;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640504 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477640506 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10853-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10853";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640508;
  r:natureDuRisque "Risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez le sujet âgé. Par ailleurs, légère augmentation des concentrations de dronédarone par diminution de son métabolisme par l’antagoniste des canaux calciques."@fr;
  r:conduiteATenir "Débuter le traitement par l’antagoniste calcique aux posologies minimales recommandées, et ajuster les doses en fonction de l’ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640514, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640508 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640509 .

_:807f36cf91fe4e8caa53aadeff92477640509 rdf:first _:807f36cf91fe4e8caa53aadeff92477640510;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640511 .

_:807f36cf91fe4e8caa53aadeff92477640510 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477640511 rdf:first _:807f36cf91fe4e8caa53aadeff92477640512;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640512 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477640514 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10854-1 a owl:Class;
  rdfs:label "DULOXETINE <-> ENOXACINE"@fr;
  dct:identifier "IAM_10854";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640516;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la duloxétine par diminution de son métabolisme hépatique par l'énoxacine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640522, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640516 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640517 .

_:807f36cf91fe4e8caa53aadeff92477640517 rdf:first _:807f36cf91fe4e8caa53aadeff92477640518;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640519 .

_:807f36cf91fe4e8caa53aadeff92477640518 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:807f36cf91fe4e8caa53aadeff92477640519 rdf:first _:807f36cf91fe4e8caa53aadeff92477640520;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640520 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10323 .

_:807f36cf91fe4e8caa53aadeff92477640522 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10855-1 a owl:Class;
  rdfs:label "DULOXETINE <-> FLECAINIDE"@fr;
  dct:identifier "IAM_10855";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640524;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de flecainide avec risque de surdosage, par diminution de son métabolisme hépatique par la duloxétine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du flecainide pendant le traitement par la duloxétine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640530, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640524 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640525 .

_:807f36cf91fe4e8caa53aadeff92477640525 rdf:first _:807f36cf91fe4e8caa53aadeff92477640526;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640527 .

_:807f36cf91fe4e8caa53aadeff92477640526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:807f36cf91fe4e8caa53aadeff92477640527 rdf:first _:807f36cf91fe4e8caa53aadeff92477640528;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640528 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:807f36cf91fe4e8caa53aadeff92477640530 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10843-1 a owl:Class;
  rdfs:label "DOPAMINERGIQUES, HORS PARKINSON <-> NEUROLEPTIQUES ANTIPSYCHOTIQUES (SAUF CLOZAPINE)"@fr;
  dct:identifier "IAM_10843";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640532;
  r:natureDuRisque "Antagonisme réciproque de l'agoniste dopaminergique et des neuroleptiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640538, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640532 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640533 .

_:807f36cf91fe4e8caa53aadeff92477640533 rdf:first _:807f36cf91fe4e8caa53aadeff92477640534;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640535 .

_:807f36cf91fe4e8caa53aadeff92477640534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10069 .

_:807f36cf91fe4e8caa53aadeff92477640535 rdf:first _:807f36cf91fe4e8caa53aadeff92477640536;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640536 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10125 .

_:807f36cf91fe4e8caa53aadeff92477640538 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10751-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10751";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640540;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640546, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640540 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640541 .

_:807f36cf91fe4e8caa53aadeff92477640541 rdf:first _:807f36cf91fe4e8caa53aadeff92477640542;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640543 .

_:807f36cf91fe4e8caa53aadeff92477640542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477640543 rdf:first _:807f36cf91fe4e8caa53aadeff92477640544;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640544 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477640546 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10740-1 a owl:Class;
  rdfs:label "DASABUVIR <-> MITOTANE"@fr;
  dct:identifier "IAM_10740";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640548;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques du dasabuvir par le mitotane."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640554, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640548 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640549 .

_:807f36cf91fe4e8caa53aadeff92477640549 rdf:first _:807f36cf91fe4e8caa53aadeff92477640550;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640551 .

_:807f36cf91fe4e8caa53aadeff92477640550 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10255 .

_:807f36cf91fe4e8caa53aadeff92477640551 rdf:first _:807f36cf91fe4e8caa53aadeff92477640552;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640552 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10594 .

_:807f36cf91fe4e8caa53aadeff92477640554 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10741-1 a owl:Class;
  rdfs:label "DEFERASIROX <-> DÉFÉRIPRONE"@fr;
  dct:identifier "IAM_10741";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640556;
  r:natureDuRisque "Risque d'hyperchélation."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640562, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640556 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640557 .

_:807f36cf91fe4e8caa53aadeff92477640557 rdf:first _:807f36cf91fe4e8caa53aadeff92477640558;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640559 .

_:807f36cf91fe4e8caa53aadeff92477640558 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:807f36cf91fe4e8caa53aadeff92477640559 rdf:first _:807f36cf91fe4e8caa53aadeff92477640560;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640560 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10260 .

_:807f36cf91fe4e8caa53aadeff92477640562 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10742-1 a owl:Class;
  rdfs:label "DEFERASIROX <-> DÉFÉROXAMINE"@fr;
  dct:identifier "IAM_10742";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640564;
  r:natureDuRisque "Risque d'hyperchélation."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640570, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640564 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640565 .

_:807f36cf91fe4e8caa53aadeff92477640565 rdf:first _:807f36cf91fe4e8caa53aadeff92477640566;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640567 .

_:807f36cf91fe4e8caa53aadeff92477640566 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:807f36cf91fe4e8caa53aadeff92477640567 rdf:first _:807f36cf91fe4e8caa53aadeff92477640568;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640568 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10261 .

_:807f36cf91fe4e8caa53aadeff92477640570 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10743-1 a owl:Class;
  rdfs:label "DEFERASIROX <-> REPAGLINIDE"@fr;
  dct:identifier "IAM_10743";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640572;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatique de répaglinide, par inhibition de son métabolisme hépatique par le deferasirox."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique et biologique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640578, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640572 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640573 .

_:807f36cf91fe4e8caa53aadeff92477640573 rdf:first _:807f36cf91fe4e8caa53aadeff92477640574;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640575 .

_:807f36cf91fe4e8caa53aadeff92477640574 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:807f36cf91fe4e8caa53aadeff92477640575 rdf:first _:807f36cf91fe4e8caa53aadeff92477640576;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640576 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:807f36cf91fe4e8caa53aadeff92477640578 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10744-1 a owl:Class;
  rdfs:label "DEFERASIROX <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10744";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640580;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de déférasirox."@fr;
  r:conduiteATenir "Surveiller la ferritinémie pendant et après le traitement par l’inducteur enzymatique. Si besoin, adaptation de la posologie de déférasirox."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640586, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640580 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640581 .

_:807f36cf91fe4e8caa53aadeff92477640581 rdf:first _:807f36cf91fe4e8caa53aadeff92477640582;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640583 .

_:807f36cf91fe4e8caa53aadeff92477640582 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:807f36cf91fe4e8caa53aadeff92477640583 rdf:first _:807f36cf91fe4e8caa53aadeff92477640584;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640584 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477640586 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10745-1 a owl:Class;
  rdfs:label "DÉFIBROTIDE <-> HÉPARINES"@fr;
  dct:identifier "IAM_10745";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640588;
  r:natureDuRisque "Risque hémorragique accru."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640594, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640588 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640589 .

_:807f36cf91fe4e8caa53aadeff92477640589 rdf:first _:807f36cf91fe4e8caa53aadeff92477640590;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640591 .

_:807f36cf91fe4e8caa53aadeff92477640590 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10088 .

_:807f36cf91fe4e8caa53aadeff92477640591 rdf:first _:807f36cf91fe4e8caa53aadeff92477640592;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640592 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10262 .

_:807f36cf91fe4e8caa53aadeff92477640594 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10746-1 a owl:Class;
  rdfs:label "DÉFIBROTIDE <-> THROMBOLYTIQUES"@fr;
  dct:identifier "IAM_10746";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640596;
  r:natureDuRisque "Risque hémorragique accru."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640602, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640596 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640597 .

_:807f36cf91fe4e8caa53aadeff92477640597 rdf:first _:807f36cf91fe4e8caa53aadeff92477640598;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640599 .

_:807f36cf91fe4e8caa53aadeff92477640598 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10151 .

_:807f36cf91fe4e8caa53aadeff92477640599 rdf:first _:807f36cf91fe4e8caa53aadeff92477640600;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640600 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10262 .

_:807f36cf91fe4e8caa53aadeff92477640602 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10747-1 a owl:Class;
  rdfs:label "DÉLAMANID <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10747";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640604;
  r:natureDuRisque "Diminution des concentrations plasmatiques de delamanid par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640610, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640604 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640605 .

_:807f36cf91fe4e8caa53aadeff92477640605 rdf:first _:807f36cf91fe4e8caa53aadeff92477640606;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640607 .

_:807f36cf91fe4e8caa53aadeff92477640606 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10263 .

_:807f36cf91fe4e8caa53aadeff92477640607 rdf:first _:807f36cf91fe4e8caa53aadeff92477640608;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640608 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477640610 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10748-1 a owl:Class;
  rdfs:label "DÉRIVÉS NITRÉS ET APPARENTÉS <-> INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5"@fr;
  dct:identifier "IAM_10748";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640612;
  r:natureDuRisque "Risque d'hypotension importante (effet synergique) pouvant aggraver l'état d'ischémie myocardique et provoquer notamment un accident coronarien aigu."@fr;
  rdfs:comment "Les dérivés nitrés sont des donneurs de monoxyde d'azote (NO). A ce titre, ils sont contre-indiqués avec le sildénafil, le vardénafil et le tadalafil, en raison du risque de vasodilatation majeure, pouvant être à l'origine d'un collapsus."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640618, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640612 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640613 .

_:807f36cf91fe4e8caa53aadeff92477640613 rdf:first _:807f36cf91fe4e8caa53aadeff92477640614;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640615 .

_:807f36cf91fe4e8caa53aadeff92477640614 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10071 .

_:807f36cf91fe4e8caa53aadeff92477640615 rdf:first _:807f36cf91fe4e8caa53aadeff92477640616;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640616 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:807f36cf91fe4e8caa53aadeff92477640618 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10787-1 a owl:Class;
  rdfs:label "DIGOXINE <-> SUCRALFATE"@fr;
  dct:identifier "IAM_10787";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640620;
  r:natureDuRisque "Diminution de l'absorption digestive de la digoxine."@fr;
  r:conduiteATenir "Prendre le sucralfate à distance de la digoxine (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640626, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640620 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640621 .

_:807f36cf91fe4e8caa53aadeff92477640621 rdf:first _:807f36cf91fe4e8caa53aadeff92477640622;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640623 .

_:807f36cf91fe4e8caa53aadeff92477640622 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477640623 rdf:first _:807f36cf91fe4e8caa53aadeff92477640624;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640624 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10864 .

_:807f36cf91fe4e8caa53aadeff92477640626 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10750-1 a owl:Class;
  rdfs:label "DÉRIVÉS NITRÉS ET APPARENTÉS <-> RIOCIGUAT"@fr;
  dct:identifier "IAM_10750";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640628;
  r:natureDuRisque "Risque d'hypotension importante (effet synergique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640634, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640628 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640629 .

_:807f36cf91fe4e8caa53aadeff92477640629 rdf:first _:807f36cf91fe4e8caa53aadeff92477640630;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640631 .

_:807f36cf91fe4e8caa53aadeff92477640630 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10071 .

_:807f36cf91fe4e8caa53aadeff92477640631 rdf:first _:807f36cf91fe4e8caa53aadeff92477640632;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640632 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10804 .

_:807f36cf91fe4e8caa53aadeff92477640634 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10737-1 a owl:Class;
  rdfs:label "DASABUVIR <-> GEMFIBROZIL"@fr;
  dct:identifier "IAM_10737";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640636;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques du dasabuvir par le gemfibrozil."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640642, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640636 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640637 .

_:807f36cf91fe4e8caa53aadeff92477640637 rdf:first _:807f36cf91fe4e8caa53aadeff92477640638;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640639 .

_:807f36cf91fe4e8caa53aadeff92477640638 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10255 .

_:807f36cf91fe4e8caa53aadeff92477640639 rdf:first _:807f36cf91fe4e8caa53aadeff92477640640;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640640 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10411 .

_:807f36cf91fe4e8caa53aadeff92477640642 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10752-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10752";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640644;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur de protéases, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640650, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640644 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640645 .

_:807f36cf91fe4e8caa53aadeff92477640645 rdf:first _:807f36cf91fe4e8caa53aadeff92477640646;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640647 .

_:807f36cf91fe4e8caa53aadeff92477640646 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477640647 rdf:first _:807f36cf91fe4e8caa53aadeff92477640648;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640648 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477640650 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10753-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10753";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640652;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640658, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640652 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640653 .

_:807f36cf91fe4e8caa53aadeff92477640653 rdf:first _:807f36cf91fe4e8caa53aadeff92477640654;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640655 .

_:807f36cf91fe4e8caa53aadeff92477640654 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477640655 rdf:first _:807f36cf91fe4e8caa53aadeff92477640656;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640656 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477640658 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10754-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10754";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640660;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640666, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640660 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640661 .

_:807f36cf91fe4e8caa53aadeff92477640661 rdf:first _:807f36cf91fe4e8caa53aadeff92477640662;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640663 .

_:807f36cf91fe4e8caa53aadeff92477640662 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477640663 rdf:first _:807f36cf91fe4e8caa53aadeff92477640664;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640664 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477640666 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10755-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_10755";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640668;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640674, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640668 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640669 .

_:807f36cf91fe4e8caa53aadeff92477640669 rdf:first _:807f36cf91fe4e8caa53aadeff92477640670;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640671 .

_:807f36cf91fe4e8caa53aadeff92477640670 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477640671 rdf:first _:807f36cf91fe4e8caa53aadeff92477640672;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640672 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477640674 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10756-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> PRAZIQUANTEL"@fr;
  dct:identifier "IAM_10756";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640676;
  r:natureDuRisque "Diminution des concentrations plasmatiques du praziquantel, avec risque d'échec du traitement, par augmentation du métabolisme hépatique du praziquantel par la dexaméthasone."@fr;
  r:conduiteATenir "Décaler l'administration des deux médicaments d'au moins une semaine."@fr;
  rdfs:comment "La dexamethasone diminue les concentrations de praziquantel en cas d'administration simultanée. Compte tenu du mode d'utilisation du praziquantel, sur une période courte, il est préférable de différer l'administration de la dexaméthasone, utilisée dans ce"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640682, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640676 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640677 .

_:807f36cf91fe4e8caa53aadeff92477640677 rdf:first _:807f36cf91fe4e8caa53aadeff92477640678;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640679 .

_:807f36cf91fe4e8caa53aadeff92477640678 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477640679 rdf:first _:807f36cf91fe4e8caa53aadeff92477640680;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640680 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10750 .

_:807f36cf91fe4e8caa53aadeff92477640682 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10757-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> RILPIVIRINE"@fr;
  dct:identifier "IAM_10757";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640684;
  r:natureDuRisque "Avec la dexaméthasone par voie systémique (sauf en cas de prise unique), risque de diminution des concentrations plasmatiques de rilpivirine par augmentation de son métabolisme hépatique par la dexamethasone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640690, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640684 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640685 .

_:807f36cf91fe4e8caa53aadeff92477640685 rdf:first _:807f36cf91fe4e8caa53aadeff92477640686;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640687 .

_:807f36cf91fe4e8caa53aadeff92477640686 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477640687 rdf:first _:807f36cf91fe4e8caa53aadeff92477640688;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640688 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10803 .

_:807f36cf91fe4e8caa53aadeff92477640690 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10945-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10945";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640692;
  r:natureDuRisque "Risque d'augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme et de la créatininémie."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de sa posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640698, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640692 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640693 .

_:807f36cf91fe4e8caa53aadeff92477640693 rdf:first _:807f36cf91fe4e8caa53aadeff92477640694;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640695 .

_:807f36cf91fe4e8caa53aadeff92477640694 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477640695 rdf:first _:807f36cf91fe4e8caa53aadeff92477640696;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640696 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477640698 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10946-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> IVACAFTOR"@fr;
  dct:identifier "IAM_10946";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640700;
  r:natureDuRisque "Augmentation des concentrations d’ivacaftor, avec risques de majoration des effets indésirables."@fr;
  r:conduiteATenir "Réduire la dose de moitié, soit 150 mg/j."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640706, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640700 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640701 .

_:807f36cf91fe4e8caa53aadeff92477640701 rdf:first _:807f36cf91fe4e8caa53aadeff92477640702;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640703 .

_:807f36cf91fe4e8caa53aadeff92477640702 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477640703 rdf:first _:807f36cf91fe4e8caa53aadeff92477640704;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640704 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10498 .

_:807f36cf91fe4e8caa53aadeff92477640706 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10947-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> LOSARTAN"@fr;
  dct:identifier "IAM_10947";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640708;
  r:natureDuRisque "Risque de diminution de l’efficacité du losartan, par inhibition de la formation de son métabolite actif par le fluconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640714, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640708 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640709 .

_:807f36cf91fe4e8caa53aadeff92477640709 rdf:first _:807f36cf91fe4e8caa53aadeff92477640710;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640711 .

_:807f36cf91fe4e8caa53aadeff92477640710 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477640711 rdf:first _:807f36cf91fe4e8caa53aadeff92477640712;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10539 .

_:807f36cf91fe4e8caa53aadeff92477640714 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10749-1 a owl:Class;
  rdfs:label "DÉRIVÉS NITRÉS ET APPARENTÉS <-> MÉDICAMENTS ABAISSANT LA PRESSION ARTÉRIELLE"@fr;
  dct:identifier "IAM_10749";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640716;
  r:natureDuRisque "Majoration du risque d’hypotension, notamment orthostatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640722, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640716 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640717 .

_:807f36cf91fe4e8caa53aadeff92477640717 rdf:first _:807f36cf91fe4e8caa53aadeff92477640718;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640719 .

_:807f36cf91fe4e8caa53aadeff92477640718 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10071 .

_:807f36cf91fe4e8caa53aadeff92477640719 rdf:first _:807f36cf91fe4e8caa53aadeff92477640720;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10113 .

_:807f36cf91fe4e8caa53aadeff92477640722 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10727-1 a owl:Class;
  rdfs:label "DANTROLENE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10727";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640724;
  r:natureDuRisque "Avec le dantrolène administré par perfusion : chez l'animal, des cas de fibrillations ventriculaires mortelles sont constamment observés lors de l'administration de vérapamil et de dantrolène par voie IV. L'association d'un antagoniste du calcium et de da"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640730, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640724 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640725 .

_:807f36cf91fe4e8caa53aadeff92477640725 rdf:first _:807f36cf91fe4e8caa53aadeff92477640726;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640727 .

_:807f36cf91fe4e8caa53aadeff92477640726 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10249 .

_:807f36cf91fe4e8caa53aadeff92477640727 rdf:first _:807f36cf91fe4e8caa53aadeff92477640728;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477640730 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10716-1 a owl:Class;
  rdfs:label "DACLATASVIR <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10716";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640732;
  r:natureDuRisque "Augmentation des concentrations de daclatasvir par l’inhibiteur."@fr;
  r:conduiteATenir "La dose de daclatasvir doit être diminuée à 30 mg 1 fois par jour en cas de co-administration avec l'inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640738, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640732 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640733 .

_:807f36cf91fe4e8caa53aadeff92477640733 rdf:first _:807f36cf91fe4e8caa53aadeff92477640734;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640735 .

_:807f36cf91fe4e8caa53aadeff92477640734 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477640735 rdf:first _:807f36cf91fe4e8caa53aadeff92477640736;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10243 .

_:807f36cf91fe4e8caa53aadeff92477640738 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10717-1 a owl:Class;
  rdfs:label "DACLATASVIR <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10717";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640740;
  r:natureDuRisque "Risque de diminution significative des concentrations plasmatiques de daclatasvir par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640746, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640740 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640741 .

_:807f36cf91fe4e8caa53aadeff92477640741 rdf:first _:807f36cf91fe4e8caa53aadeff92477640742;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640743 .

_:807f36cf91fe4e8caa53aadeff92477640742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10243 .

_:807f36cf91fe4e8caa53aadeff92477640743 rdf:first _:807f36cf91fe4e8caa53aadeff92477640744;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477640746 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10718-1 a owl:Class;
  rdfs:label "DALFOPRISTINE <-> DIHYDROERGOTAMINE"@fr;
  dct:identifier "IAM_10718";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640748;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640754, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640748 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640749 .

_:807f36cf91fe4e8caa53aadeff92477640749 rdf:first _:807f36cf91fe4e8caa53aadeff92477640750;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640751 .

_:807f36cf91fe4e8caa53aadeff92477640750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10245 .

_:807f36cf91fe4e8caa53aadeff92477640751 rdf:first _:807f36cf91fe4e8caa53aadeff92477640752;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:807f36cf91fe4e8caa53aadeff92477640754 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10719-1 a owl:Class;
  rdfs:label "DALFOPRISTINE <-> ERGOTAMINE"@fr;
  dct:identifier "IAM_10719";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640756;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640762, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640756 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640757 .

_:807f36cf91fe4e8caa53aadeff92477640757 rdf:first _:807f36cf91fe4e8caa53aadeff92477640758;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640759 .

_:807f36cf91fe4e8caa53aadeff92477640758 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10245 .

_:807f36cf91fe4e8caa53aadeff92477640759 rdf:first _:807f36cf91fe4e8caa53aadeff92477640760;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:807f36cf91fe4e8caa53aadeff92477640762 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10720-1 a owl:Class;
  rdfs:label "DALFOPRISTINE <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10720";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640764;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640770, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640764 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640765 .

_:807f36cf91fe4e8caa53aadeff92477640765 rdf:first _:807f36cf91fe4e8caa53aadeff92477640766;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640767 .

_:807f36cf91fe4e8caa53aadeff92477640766 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477640767 rdf:first _:807f36cf91fe4e8caa53aadeff92477640768;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10245 .

_:807f36cf91fe4e8caa53aadeff92477640770 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10721-1 a owl:Class;
  rdfs:label "DALFOPRISTINE <-> PIMOZIDE"@fr;
  dct:identifier "IAM_10721";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640772;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640778, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640772 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640773 .

_:807f36cf91fe4e8caa53aadeff92477640773 rdf:first _:807f36cf91fe4e8caa53aadeff92477640774;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640775 .

_:807f36cf91fe4e8caa53aadeff92477640774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10245 .

_:807f36cf91fe4e8caa53aadeff92477640775 rdf:first _:807f36cf91fe4e8caa53aadeff92477640776;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477640778 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10722-1 a owl:Class;
  rdfs:label "DANAZOL <-> INSULINE"@fr;
  dct:identifier "IAM_10722";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640780;
  r:natureDuRisque "Effet diabétogène du danazol."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, prévenir le patient et renforcer l'autosurveillance glycémique. Adapter éventuellement la posologie de l'insuline pendant le traitement par le danazol et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640786, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640780 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640781 .

_:807f36cf91fe4e8caa53aadeff92477640781 rdf:first _:807f36cf91fe4e8caa53aadeff92477640782;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640783 .

_:807f36cf91fe4e8caa53aadeff92477640782 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:807f36cf91fe4e8caa53aadeff92477640783 rdf:first _:807f36cf91fe4e8caa53aadeff92477640784;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:807f36cf91fe4e8caa53aadeff92477640786 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10723-1 a owl:Class;
  rdfs:label "DANAZOL <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10723";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640788;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse par diminution du métabolisme de la simvastatine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640794, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640788 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640789 .

_:807f36cf91fe4e8caa53aadeff92477640789 rdf:first _:807f36cf91fe4e8caa53aadeff92477640790;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640791 .

_:807f36cf91fe4e8caa53aadeff92477640790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:807f36cf91fe4e8caa53aadeff92477640791 rdf:first _:807f36cf91fe4e8caa53aadeff92477640792;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477640794 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10724-1 a owl:Class;
  rdfs:label "DANAZOL <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10724";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640796;
  r:natureDuRisque "Effet diabétogène du danazol."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, prévenir le patient et renforcer l'autosurveillance glycémique. Adapter éventuellement la posologie de l'antidiabétique pendant le traitement par le danazol et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640802, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640796 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640797 .

_:807f36cf91fe4e8caa53aadeff92477640797 rdf:first _:807f36cf91fe4e8caa53aadeff92477640798;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640799 .

_:807f36cf91fe4e8caa53aadeff92477640798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477640799 rdf:first _:807f36cf91fe4e8caa53aadeff92477640800;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:807f36cf91fe4e8caa53aadeff92477640802 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10739-1 a owl:Class;
  rdfs:label "DASABUVIR <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10739";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640804;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques du dasabuvir par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640810, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640804 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640805 .

_:807f36cf91fe4e8caa53aadeff92477640805 rdf:first _:807f36cf91fe4e8caa53aadeff92477640806;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640807 .

_:807f36cf91fe4e8caa53aadeff92477640806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10255 .

_:807f36cf91fe4e8caa53aadeff92477640807 rdf:first _:807f36cf91fe4e8caa53aadeff92477640808;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477640810 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10726-1 a owl:Class;
  rdfs:label "DANTROLENE <-> DIHYDROPYRIDINES"@fr;
  dct:identifier "IAM_10726";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640812;
  r:natureDuRisque "Avec le dantrolène administré par perfusion : chez l'animal des cas de fibrillations ventriculaires mortelles sont constamment observés lors de l'administration de vérapamil et de dantrolène IV. L'association d'un antagoniste du calcium et de dantrolène e"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640818, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640812 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640813 .

_:807f36cf91fe4e8caa53aadeff92477640813 rdf:first _:807f36cf91fe4e8caa53aadeff92477640814;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640815 .

_:807f36cf91fe4e8caa53aadeff92477640814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10062 .

_:807f36cf91fe4e8caa53aadeff92477640815 rdf:first _:807f36cf91fe4e8caa53aadeff92477640816;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10249 .

_:807f36cf91fe4e8caa53aadeff92477640818 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10738-1 a owl:Class;
  rdfs:label "DASABUVIR <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10738";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640820;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques du dasabuvir par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640826, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640820 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640821 .

_:807f36cf91fe4e8caa53aadeff92477640821 rdf:first _:807f36cf91fe4e8caa53aadeff92477640822;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640823 .

_:807f36cf91fe4e8caa53aadeff92477640822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477640823 rdf:first _:807f36cf91fe4e8caa53aadeff92477640824;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10255 .

_:807f36cf91fe4e8caa53aadeff92477640826 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10728-1 a owl:Class;
  rdfs:label "DANTROLENE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10728";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640828;
  r:natureDuRisque "Avec le dantrolène administré par perfusion : chez l'animal, des cas de fibrillations ventriculaires mortelles sont constamment observés lors de l'administration de vérapamil et de dantrolène par voie IV. L'association d'un antagoniste du calcium et de da"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640834, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640828 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640829 .

_:807f36cf91fe4e8caa53aadeff92477640829 rdf:first _:807f36cf91fe4e8caa53aadeff92477640830;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640831 .

_:807f36cf91fe4e8caa53aadeff92477640830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10249 .

_:807f36cf91fe4e8caa53aadeff92477640831 rdf:first _:807f36cf91fe4e8caa53aadeff92477640832;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477640834 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10729-1 a owl:Class;
  rdfs:label "DAPOXÉTINE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10729";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640836;
  r:natureDuRisque "Risque de majoration des effets indésirables, notamment à type de vertiges ou de syncopes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640842, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640836 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640837 .

_:807f36cf91fe4e8caa53aadeff92477640837 rdf:first _:807f36cf91fe4e8caa53aadeff92477640838;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640839 .

_:807f36cf91fe4e8caa53aadeff92477640838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477640839 rdf:first _:807f36cf91fe4e8caa53aadeff92477640840;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10250 .

_:807f36cf91fe4e8caa53aadeff92477640842 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10730-1 a owl:Class;
  rdfs:label "DAPOXÉTINE <-> MÉDICAMENTS À L'ORIGINE D'UNE HYPOTENSION ORTHOSTATIQUE"@fr;
  dct:identifier "IAM_10730";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640844;
  r:natureDuRisque "Risque de majoration des effets indésirables, notamment à type de vertiges ou de syncopes."@fr;
  r:conduiteATenir """Association déconseillée
- avec les inhibiteurs de la phosphodiestérase de type 5

A prendre en compte 
- avec les autres classes thérapeutiques"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640850, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640844 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640845 .

_:807f36cf91fe4e8caa53aadeff92477640845 rdf:first _:807f36cf91fe4e8caa53aadeff92477640846;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640847 .

_:807f36cf91fe4e8caa53aadeff92477640846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10122 .

_:807f36cf91fe4e8caa53aadeff92477640847 rdf:first _:807f36cf91fe4e8caa53aadeff92477640848;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10250 .

_:807f36cf91fe4e8caa53aadeff92477640850 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10731-1 a owl:Class;
  rdfs:label "DAPSONE <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_10731";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640852;
  r:natureDuRisque "Augmentation de la toxicité hématologique (addition d'effets de toxicité médullaire)."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'hémogramme."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640858, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640852 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640853 .

_:807f36cf91fe4e8caa53aadeff92477640853 rdf:first _:807f36cf91fe4e8caa53aadeff92477640854;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640855 .

_:807f36cf91fe4e8caa53aadeff92477640854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10251 .

_:807f36cf91fe4e8caa53aadeff92477640855 rdf:first _:807f36cf91fe4e8caa53aadeff92477640856;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:807f36cf91fe4e8caa53aadeff92477640858 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10732-1 a owl:Class;
  rdfs:label "DAPTOMYCINE <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10732";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640860;
  r:natureDuRisque "Risque d’addition des effets indésirables (dose-dépendant) à type de rhabdomyolyse."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, renforcer la surveillance biologique (dosage des CPK plus d’une fois par semaine) et surveillance clinique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640866, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640860 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640861 .

_:807f36cf91fe4e8caa53aadeff92477640861 rdf:first _:807f36cf91fe4e8caa53aadeff92477640862;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640863 .

_:807f36cf91fe4e8caa53aadeff92477640862 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff92477640863 rdf:first _:807f36cf91fe4e8caa53aadeff92477640864;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10252 .

_:807f36cf91fe4e8caa53aadeff92477640866 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10733-1 a owl:Class;
  rdfs:label "DARIFENACINE <-> FLECAINIDE"@fr;
  dct:identifier "IAM_10733";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640868;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de flécaïnide, avec risque de surdosage, par diminution de son métabolisme hépatique par la darifénacine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du flécaïnide pendant le traitement par darifénacine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640874, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640868 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640869 .

_:807f36cf91fe4e8caa53aadeff92477640869 rdf:first _:807f36cf91fe4e8caa53aadeff92477640870;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640871 .

_:807f36cf91fe4e8caa53aadeff92477640870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10253 .

_:807f36cf91fe4e8caa53aadeff92477640871 rdf:first _:807f36cf91fe4e8caa53aadeff92477640872;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:807f36cf91fe4e8caa53aadeff92477640874 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10734-1 a owl:Class;
  rdfs:label "DARIFENACINE <-> METOPROLOL"@fr;
  dct:identifier "IAM_10734";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640876;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du métoprolol, avec risque de surdosage, par diminution de son métabolisme hépatique par la darifénacine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du métoprolol pendant le traitement par darifénacine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640882, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640876 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640877 .

_:807f36cf91fe4e8caa53aadeff92477640877 rdf:first _:807f36cf91fe4e8caa53aadeff92477640878;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640879 .

_:807f36cf91fe4e8caa53aadeff92477640878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10253 .

_:807f36cf91fe4e8caa53aadeff92477640879 rdf:first _:807f36cf91fe4e8caa53aadeff92477640880;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477640882 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10735-1 a owl:Class;
  rdfs:label "DARIFENACINE <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10735";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640884;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de propafénone, avec risque de surdosage, par diminution de son métabolisme hépatique par la darifénacine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie de la propafénone pendant le traitement par darifénacine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640890, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640884 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640885 .

_:807f36cf91fe4e8caa53aadeff92477640885 rdf:first _:807f36cf91fe4e8caa53aadeff92477640886;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640887 .

_:807f36cf91fe4e8caa53aadeff92477640886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10253 .

_:807f36cf91fe4e8caa53aadeff92477640887 rdf:first _:807f36cf91fe4e8caa53aadeff92477640888;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477640890 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10736-1 a owl:Class;
  rdfs:label "DASABUVIR <-> ETHINYLESTRADIOL"@fr;
  dct:identifier "IAM_10736";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640892;
  r:natureDuRisque "Augmentation de l’hépatotoxicité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640898, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640892 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640893 .

_:807f36cf91fe4e8caa53aadeff92477640893 rdf:first _:807f36cf91fe4e8caa53aadeff92477640894;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640895 .

_:807f36cf91fe4e8caa53aadeff92477640894 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10255 .

_:807f36cf91fe4e8caa53aadeff92477640895 rdf:first _:807f36cf91fe4e8caa53aadeff92477640896;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10351 .

_:807f36cf91fe4e8caa53aadeff92477640898 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10950-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> OLAPARIB"@fr;
  dct:identifier "IAM_10950";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640900;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’olaparib par le fluconazole."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, limiter la dose d’olaparib à 200 mg deux fois par jour."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640906, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640900 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640901 .

_:807f36cf91fe4e8caa53aadeff92477640901 rdf:first _:807f36cf91fe4e8caa53aadeff92477640902;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640903 .

_:807f36cf91fe4e8caa53aadeff92477640902 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477640903 rdf:first _:807f36cf91fe4e8caa53aadeff92477640904;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10659 .

_:807f36cf91fe4e8caa53aadeff92477640906 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10725-1 a owl:Class;
  rdfs:label "DANAZOL <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10725";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640908;
  r:natureDuRisque "Augmentation des concentrations sanguines du tacrolimus par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines du tacrolimus et adaptation de sa posologie pendant l'association et après son arrêt, avec contrôle de la fonction rénale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640914, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640908 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640909 .

_:807f36cf91fe4e8caa53aadeff92477640909 rdf:first _:807f36cf91fe4e8caa53aadeff92477640910;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640911 .

_:807f36cf91fe4e8caa53aadeff92477640910 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:807f36cf91fe4e8caa53aadeff92477640911 rdf:first _:807f36cf91fe4e8caa53aadeff92477640912;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477640914 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10774-1 a owl:Class;
  rdfs:label "DIGOXINE <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10774";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640916;
  r:natureDuRisque "Augmentation de la digoxinémie par augmentation de son absorption."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la digoxinémie pendant le traitement par l'érythromycine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640922, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640916 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640917 .

_:807f36cf91fe4e8caa53aadeff92477640917 rdf:first _:807f36cf91fe4e8caa53aadeff92477640918;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640919 .

_:807f36cf91fe4e8caa53aadeff92477640918 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477640919 rdf:first _:807f36cf91fe4e8caa53aadeff92477640920;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477640922 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10948-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> MIDAZOLAM"@fr;
  dct:identifier "IAM_10948";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640924;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de midazolam par diminution de son métabolisme hépatique, avec majoration de la sédation."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie de midazolam en cas de traitement par le fluconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640930, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640924 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640925 .

_:807f36cf91fe4e8caa53aadeff92477640925 rdf:first _:807f36cf91fe4e8caa53aadeff92477640926;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640927 .

_:807f36cf91fe4e8caa53aadeff92477640926 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477640927 rdf:first _:807f36cf91fe4e8caa53aadeff92477640928;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477640930 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10765-1 a owl:Class;
  rdfs:label "DIAZEPAM <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10765";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640932;
  r:natureDuRisque "Variations imprévisibles : les concentrations plasmatiques de phénytoïne peuvent augmenter, avec signes de surdosage, mais aussi diminuer ou rester stables."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques de phénytoïne."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640938, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640932 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640933 .

_:807f36cf91fe4e8caa53aadeff92477640933 rdf:first _:807f36cf91fe4e8caa53aadeff92477640934;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640935 .

_:807f36cf91fe4e8caa53aadeff92477640934 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477640935 rdf:first _:807f36cf91fe4e8caa53aadeff92477640936;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10280 .

_:807f36cf91fe4e8caa53aadeff92477640938 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10766-1 a owl:Class;
  rdfs:label "DIAZEPAM <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10766";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640940;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du diazépam, avec risque de surdosage, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et dosage plasmatique, lorsque cela est possible, de l'anticonvulsivant associé au stiripentol et éventuelle adaptation posologique de l'anticonvulsivant associé."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640946, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640940 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640941 .

_:807f36cf91fe4e8caa53aadeff92477640941 rdf:first _:807f36cf91fe4e8caa53aadeff92477640942;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640943 .

_:807f36cf91fe4e8caa53aadeff92477640942 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10280 .

_:807f36cf91fe4e8caa53aadeff92477640943 rdf:first _:807f36cf91fe4e8caa53aadeff92477640944;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477640946 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10772-1 a owl:Class;
  rdfs:label "DIDANOSINE <-> ZALCITABINE"@fr;
  dct:identifier "IAM_10772";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640948;
  r:natureDuRisque "Risque majoré de survenue de pancréatite et de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique régulière et surveillance de l'amylasémie. Ne pas associer si l'amylasémie est à la limite supérieure de la normale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640954, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640948 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640949 .

_:807f36cf91fe4e8caa53aadeff92477640949 rdf:first _:807f36cf91fe4e8caa53aadeff92477640950;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640951 .

_:807f36cf91fe4e8caa53aadeff92477640950 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:807f36cf91fe4e8caa53aadeff92477640951 rdf:first _:807f36cf91fe4e8caa53aadeff92477640952;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11002 .

_:807f36cf91fe4e8caa53aadeff92477640954 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10767-1 a owl:Class;
  rdfs:label "DIDANOSINE <-> GANCICLOVIR"@fr;
  dct:identifier "IAM_10767";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640956;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la didanosine, et notamment la toxicité mitochondriale, par augmentation importante de ses concentrations. De plus risque de diminution de l'efficacité du ganciclovir par diminution de ses concentrations, s"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640962, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640956 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640957 .

_:807f36cf91fe4e8caa53aadeff92477640957 rdf:first _:807f36cf91fe4e8caa53aadeff92477640958;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640959 .

_:807f36cf91fe4e8caa53aadeff92477640958 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:807f36cf91fe4e8caa53aadeff92477640959 rdf:first _:807f36cf91fe4e8caa53aadeff92477640960;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10408 .

_:807f36cf91fe4e8caa53aadeff92477640962 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10768-1 a owl:Class;
  rdfs:label "DIDANOSINE <-> PENTAMIDINE"@fr;
  dct:identifier "IAM_10768";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640964;
  r:natureDuRisque "Risque majoré de survenue de pancréatite par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance de l'amylasémie. Ne pas associer si l'amylasémie est à la limite supérieure de la normale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640970, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640964 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640965 .

_:807f36cf91fe4e8caa53aadeff92477640965 rdf:first _:807f36cf91fe4e8caa53aadeff92477640966;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640967 .

_:807f36cf91fe4e8caa53aadeff92477640966 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:807f36cf91fe4e8caa53aadeff92477640967 rdf:first _:807f36cf91fe4e8caa53aadeff92477640968;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10703 .

_:807f36cf91fe4e8caa53aadeff92477640970 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10769-1 a owl:Class;
  rdfs:label "DIDANOSINE <-> RIBAVIRINE"@fr;
  dct:identifier "IAM_10769";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640972;
  r:natureDuRisque "Risque de majoration de la toxicité mitochondriale de la didanosine par augmentation de son métabolite actif."@fr;
  rdfs:comment "La ribavirine, antiviral inhibant la synthèse des acides nucléiques du virus de l’hépatite C, augmente la concentration intra-cellulaire en inosine 5’ monophosphate (IMP) en inhibant l’IMP déhydrogénase. Cette augmentation entraîne une élévation de la con"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640978, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640972 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640973 .

_:807f36cf91fe4e8caa53aadeff92477640973 rdf:first _:807f36cf91fe4e8caa53aadeff92477640974;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640975 .

_:807f36cf91fe4e8caa53aadeff92477640974 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:807f36cf91fe4e8caa53aadeff92477640975 rdf:first _:807f36cf91fe4e8caa53aadeff92477640976;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10797 .

_:807f36cf91fe4e8caa53aadeff92477640978 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10770-1 a owl:Class;
  rdfs:label "DIDANOSINE <-> TENOFOVIR DISOPROXIL"@fr;
  dct:identifier "IAM_10770";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640980;
  r:natureDuRisque "Risque d'échec du traitement antirétroviral, voire émergence de résistances. De plus, majoration du risque de la toxicité mitochondriale de la didanosine."@fr;
  rdfs:comment "Il existe une augmentation de 60% de l'AUC de la didanosine (DDI), administrée sous forme de comprimé tamponné, lorsqu’elle est associée avec le ténofovir. Si un ajustement posologique n'est pas toujours justifié, compte tenu d'une sensibilité individuell"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640986, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640980 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640981 .

_:807f36cf91fe4e8caa53aadeff92477640981 rdf:first _:807f36cf91fe4e8caa53aadeff92477640982;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640983 .

_:807f36cf91fe4e8caa53aadeff92477640982 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:807f36cf91fe4e8caa53aadeff92477640983 rdf:first _:807f36cf91fe4e8caa53aadeff92477640984;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10896 .

_:807f36cf91fe4e8caa53aadeff92477640986 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10771-1 a owl:Class;
  rdfs:label "DIDANOSINE <-> THALIDOMIDE"@fr;
  dct:identifier "IAM_10771";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640988;
  r:natureDuRisque "Risque majoré de survenue de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477640994, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640988 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640989 .

_:807f36cf91fe4e8caa53aadeff92477640989 rdf:first _:807f36cf91fe4e8caa53aadeff92477640990;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640991 .

_:807f36cf91fe4e8caa53aadeff92477640990 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:807f36cf91fe4e8caa53aadeff92477640991 rdf:first _:807f36cf91fe4e8caa53aadeff92477640992;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477640992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10913 .

_:807f36cf91fe4e8caa53aadeff92477640994 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10763-1 a owl:Class;
  rdfs:label "DEXTROMETHORPHANE <-> IMAO IRRÉVERSIBLES"@fr;
  dct:identifier "IAM_10763";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477640996;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641002, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477640996 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477640997 .

_:807f36cf91fe4e8caa53aadeff92477640997 rdf:first _:807f36cf91fe4e8caa53aadeff92477640998;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477640999 .

_:807f36cf91fe4e8caa53aadeff92477640998 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477640999 rdf:first _:807f36cf91fe4e8caa53aadeff92477641000;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10278 .

_:807f36cf91fe4e8caa53aadeff92477641002 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10773-1 a owl:Class;
  rdfs:label "DIGOXINE <-> DRONEDARONE"@fr;
  dct:identifier "IAM_10773";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641004;
  r:natureDuRisque "Dépression de l'automatisme (bradycardie excessive) et troubles de la conduction auriculo-ventriculaire. En outre, augmentation de la digoxinémie par diminution du métabolisme de la digoxine. Surveillance clinique et ECG."@fr;
  r:conduiteATenir "Réduire de moitié les doses de digoxine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641010, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641004 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641005 .

_:807f36cf91fe4e8caa53aadeff92477641005 rdf:first _:807f36cf91fe4e8caa53aadeff92477641006;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641007 .

_:807f36cf91fe4e8caa53aadeff92477641006 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477641007 rdf:first _:807f36cf91fe4e8caa53aadeff92477641008;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477641010 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10762-1 a owl:Class;
  rdfs:label "DEXTRAN 40 <-> HÉPARINES NON FRACTIONNÉES (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10762";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641012;
  r:natureDuRisque "Augmentation du risque hémorragique (inhibition de la fonction plaquettaire par le dextran 40)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641018, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641012 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641013 .

_:807f36cf91fe4e8caa53aadeff92477641013 rdf:first _:807f36cf91fe4e8caa53aadeff92477641014;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641015 .

_:807f36cf91fe4e8caa53aadeff92477641014 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10061 .

_:807f36cf91fe4e8caa53aadeff92477641015 rdf:first _:807f36cf91fe4e8caa53aadeff92477641016;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10091 .

_:807f36cf91fe4e8caa53aadeff92477641018 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10775-1 a owl:Class;
  rdfs:label "DIGOXINE <-> HYDROQUINIDINE"@fr;
  dct:identifier "IAM_10775";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641020;
  r:natureDuRisque "Augmentation de la digoxinémie par diminution de la clairance rénale de la digoxine. De plus, troubles de l'automatisme (bradycardie excessive et troubles de la conduction auriculo-ventriculaire)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. En cas de réponse inattendue, contrôler la digoxinémie et adapter la posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641026, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641020 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641021 .

_:807f36cf91fe4e8caa53aadeff92477641021 rdf:first _:807f36cf91fe4e8caa53aadeff92477641022;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641023 .

_:807f36cf91fe4e8caa53aadeff92477641022 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477641023 rdf:first _:807f36cf91fe4e8caa53aadeff92477641024;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10434 .

_:807f36cf91fe4e8caa53aadeff92477641026 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10776-1 a owl:Class;
  rdfs:label "DIGOXINE <-> HYPOKALIÉMIANTS"@fr;
  dct:identifier "IAM_10776";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641028;
  r:natureDuRisque "Hypokaliémie favorisant les effets toxiques des digitaliques."@fr;
  r:conduiteATenir "Corriger auparavant toute hypokaliémie et réaliser une surveillance clinique, électrolytique et électrocardiographique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641034, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641028 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641029 .

_:807f36cf91fe4e8caa53aadeff92477641029 rdf:first _:807f36cf91fe4e8caa53aadeff92477641030;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641031 .

_:807f36cf91fe4e8caa53aadeff92477641030 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10086 .

_:807f36cf91fe4e8caa53aadeff92477641031 rdf:first _:807f36cf91fe4e8caa53aadeff92477641032;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477641034 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10777-1 a owl:Class;
  rdfs:label "DIGOXINE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10777";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641036;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Augmentation de la digoxinémie, plus marquée pour la voie intraveineuse, par augmentation de l’absorption de la digoxine ou diminution de sa clairance rénale."@fr;
  r:conduiteATenir "Surveillance clinique et, s’il y a lieu, de l’ECG et de la digoxinémie, avec adaptation éventuelle de la posologie de digoxine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641042, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641036 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641037 .

_:807f36cf91fe4e8caa53aadeff92477641037 rdf:first _:807f36cf91fe4e8caa53aadeff92477641038;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641039 .

_:807f36cf91fe4e8caa53aadeff92477641038 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477641039 rdf:first _:807f36cf91fe4e8caa53aadeff92477641040;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477641042 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10778-1 a owl:Class;
  rdfs:label "DIGOXINE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10778";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641044;
  r:natureDuRisque "Augmentation de la digoxinémie avec nausées, vomissements, troubles du rythme."@fr;
  r:conduiteATenir "Surveillance clinique et, s'il y a lieu, de l'ECG et de la digoxinémie avec adaptation de la posologie de la digoxine pendant le traitement par l'itraconazole et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641050, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641044 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641045 .

_:807f36cf91fe4e8caa53aadeff92477641045 rdf:first _:807f36cf91fe4e8caa53aadeff92477641046;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641047 .

_:807f36cf91fe4e8caa53aadeff92477641046 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477641047 rdf:first _:807f36cf91fe4e8caa53aadeff92477641048;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477641050 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10779-1 a owl:Class;
  rdfs:label "DIGOXINE <-> MIDODRINE"@fr;
  dct:identifier "IAM_10779";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641052;
  r:natureDuRisque "Troubles de l'automatisme (majoration de l'effet bradycardisant de la midodrine) et troubles de la conduction auriculo-ventriculaire."@fr;
  r:conduiteATenir "Si cette association ne peut être évitée, renforcer la surveillance clinique et ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641058, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641052 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641053 .

_:807f36cf91fe4e8caa53aadeff92477641053 rdf:first _:807f36cf91fe4e8caa53aadeff92477641054;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641055 .

_:807f36cf91fe4e8caa53aadeff92477641054 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477641055 rdf:first _:807f36cf91fe4e8caa53aadeff92477641056;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10587 .

_:807f36cf91fe4e8caa53aadeff92477641058 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10780-1 a owl:Class;
  rdfs:label "DIGOXINE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10780";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641060;
  r:natureDuRisque "Diminution de la digoxinémie, en raison de l'effet inducteur enzymatique du millepertuis, avec risque de baisse d'efficacité voire d'annulation de l'effet, dont les conséquences peuvent être éventuellement graves (décompensation d'une insuffisance cardiaq"@fr;
  r:conduiteATenir "En cas d'association fortuite, ne pas interrompre brutalement la prise de millepertuis mais contrôler les concentrations plasmatiques (ou l'efficacité) de la digoxine avant puis après l'arrêt du millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641066, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641060 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641061 .

_:807f36cf91fe4e8caa53aadeff92477641061 rdf:first _:807f36cf91fe4e8caa53aadeff92477641062;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641063 .

_:807f36cf91fe4e8caa53aadeff92477641062 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477641063 rdf:first _:807f36cf91fe4e8caa53aadeff92477641064;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477641066 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10781-1 a owl:Class;
  rdfs:label "DIGOXINE <-> OMEPRAZOLE"@fr;
  dct:identifier "IAM_10781";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641068;
  r:natureDuRisque "Augmentation modérée de la digoxinémie par majoration de son absorption par l'oméprazole."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et de la digoxinémie, particulièrement chez le sujet âgé."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641074, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641068 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641069 .

_:807f36cf91fe4e8caa53aadeff92477641069 rdf:first _:807f36cf91fe4e8caa53aadeff92477641070;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641071 .

_:807f36cf91fe4e8caa53aadeff92477641070 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477641071 rdf:first _:807f36cf91fe4e8caa53aadeff92477641072;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10664 .

_:807f36cf91fe4e8caa53aadeff92477641074 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10782-1 a owl:Class;
  rdfs:label "DIGOXINE <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_10782";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641076;
  r:natureDuRisque "Augmentation de la digoxinémie avec nausées, vomissements, troubles du rythme."@fr;
  r:conduiteATenir "Surveillance clinique et, s'il y a lieu, de l'ECG et de la digoxinémie, avec adaptation de la posologie de la digoxine pendant le traitement par le posaconazole et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641082, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641076 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641077 .

_:807f36cf91fe4e8caa53aadeff92477641077 rdf:first _:807f36cf91fe4e8caa53aadeff92477641078;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641079 .

_:807f36cf91fe4e8caa53aadeff92477641078 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477641079 rdf:first _:807f36cf91fe4e8caa53aadeff92477641080;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477641082 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10783-1 a owl:Class;
  rdfs:label "DIGOXINE <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10783";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641084;
  r:natureDuRisque "Risque d’augmentation de la digoxinémie, notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la digoxinémie pendant le traitement par propafénone et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641090, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641084 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641085 .

_:807f36cf91fe4e8caa53aadeff92477641085 rdf:first _:807f36cf91fe4e8caa53aadeff92477641086;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641087 .

_:807f36cf91fe4e8caa53aadeff92477641086 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477641087 rdf:first _:807f36cf91fe4e8caa53aadeff92477641088;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477641090 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10784-1 a owl:Class;
  rdfs:label "DIGOXINE <-> QUINIDINE"@fr;
  dct:identifier "IAM_10784";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641092;
  r:natureDuRisque "Augmentation de la digoxinémie par diminution de la clairance rénale de la digoxine. De plus, troubles de l'automatisme (bradycardie excessive et troubles de la conduction auriculo-ventriculaire)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. En cas de réponse inattendue, contrôler la digoxinémie et adapter la posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641098, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641092 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641093 .

_:807f36cf91fe4e8caa53aadeff92477641093 rdf:first _:807f36cf91fe4e8caa53aadeff92477641094;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641095 .

_:807f36cf91fe4e8caa53aadeff92477641094 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477641095 rdf:first _:807f36cf91fe4e8caa53aadeff92477641096;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477641098 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10789-1 a owl:Class;
  rdfs:label "DIGOXINE <-> TELAPREVIR"@fr;
  dct:identifier "IAM_10789";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641100;
  r:natureDuRisque "Augmentation de la digoxinémie."@fr;
  r:conduiteATenir "Surveillance clinique et biologique et adaptation, si besoin, de la posologie de la digoxine pendant le traitement par le télaprévir et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641106, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641100 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641101 .

_:807f36cf91fe4e8caa53aadeff92477641101 rdf:first _:807f36cf91fe4e8caa53aadeff92477641102;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641103 .

_:807f36cf91fe4e8caa53aadeff92477641102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477641103 rdf:first _:807f36cf91fe4e8caa53aadeff92477641104;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477641106 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11125-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11125";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641108;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de l’inhibiteur de protéase boosté par le ritonavir ou de l’inhibiteur du CYP3A4."@fr;
  r:conduiteATenir "Pour connaître les risques et les niveaux de contrainte de chaque inhibiteur de protéase boosté par le ritonavir avec les inhibiteurs puissants du CYP3A4, il convient de se reporter aux AMM spécifiques à chacun d'eux."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641114, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641108 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641109 .

_:807f36cf91fe4e8caa53aadeff92477641109 rdf:first _:807f36cf91fe4e8caa53aadeff92477641110;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641111 .

_:807f36cf91fe4e8caa53aadeff92477641110 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477641111 rdf:first _:807f36cf91fe4e8caa53aadeff92477641112;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477641114 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11207-1 a owl:Class;
  rdfs:label "IVABRADINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11207";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641116;
  r:natureDuRisque "Risque de diminution de l'efficacité de l’ivabradine, par augmentation de son métabolisme par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de l’ivabradine pendant l’association et après l’arrêt de la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641122, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641116 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641117 .

_:807f36cf91fe4e8caa53aadeff92477641117 rdf:first _:807f36cf91fe4e8caa53aadeff92477641118;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641119 .

_:807f36cf91fe4e8caa53aadeff92477641118 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:807f36cf91fe4e8caa53aadeff92477641119 rdf:first _:807f36cf91fe4e8caa53aadeff92477641120;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477641122 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10951-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> OXYCODONE"@fr;
  dct:identifier "IAM_10951";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641124;
  r:natureDuRisque "Majoration des effets indésirables, notamment respiratoires, de l’oxycodone par diminution de son métabolisme hépatique par le fluconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641130, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641124 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641125 .

_:807f36cf91fe4e8caa53aadeff92477641125 rdf:first _:807f36cf91fe4e8caa53aadeff92477641126;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641127 .

_:807f36cf91fe4e8caa53aadeff92477641126 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477641127 rdf:first _:807f36cf91fe4e8caa53aadeff92477641128;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10681 .

_:807f36cf91fe4e8caa53aadeff92477641130 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10952-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10952";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641132;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne pouvant atteindre des valeurs toxiques. Mécanisme invoqué : inhibition du métabolisme hépatique de la phénytoïne."@fr;
  r:conduiteATenir "Surveillance clinique et biologique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641138, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641132 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641133 .

_:807f36cf91fe4e8caa53aadeff92477641133 rdf:first _:807f36cf91fe4e8caa53aadeff92477641134;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641135 .

_:807f36cf91fe4e8caa53aadeff92477641134 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477641135 rdf:first _:807f36cf91fe4e8caa53aadeff92477641136;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477641138 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10953-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> PIMOZIDE"@fr;
  dct:identifier "IAM_10953";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641140;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641146, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641140 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641141 .

_:807f36cf91fe4e8caa53aadeff92477641141 rdf:first _:807f36cf91fe4e8caa53aadeff92477641142;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641143 .

_:807f36cf91fe4e8caa53aadeff92477641142 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477641143 rdf:first _:807f36cf91fe4e8caa53aadeff92477641144;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477641146 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11120-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> SPIRONOLACTONE"@fr;
  dct:identifier "IAM_11120";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641148;
  r:natureDuRisque """Avec la spironolactone à la posologie de 12,5 à 50 mg par jour, et avec des doses faibles d’IEC.

Dans le traitement de l’insuffisance cardiaque de classe III ou IV (NYHA) avec fraction d’éjection <35 % et préalablement traitée par l’association inhibiteu"""@fr;
  r:conduiteATenir "Vérifier au préalable l’absence d’hyperkaliémie et d’insuffisance rénale. Surveillance biologique étroite de la kaliémie et de la créatininémie (1 fois par semaine pendant le premier mois, puis une fois par mois ensuite)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641154, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641148 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641149 .

_:807f36cf91fe4e8caa53aadeff92477641149 rdf:first _:807f36cf91fe4e8caa53aadeff92477641150;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641151 .

_:807f36cf91fe4e8caa53aadeff92477641150 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477641151 rdf:first _:807f36cf91fe4e8caa53aadeff92477641152;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10857 .

_:807f36cf91fe4e8caa53aadeff92477641154 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11121-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_11121";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641156;
  r:natureDuRisque "L'utilisation des IEC peut entraîner une majoration de l'effet hypoglycémiant chez le diabétique traité par sulfamides hypoglycémiants. La survenue de malaises hypoglycémiques semble exceptionnelle (amélioration de la tolérance au glucose qui aurait pour"@fr;
  r:conduiteATenir "Renforcer l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641162, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641156 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641157 .

_:807f36cf91fe4e8caa53aadeff92477641157 rdf:first _:807f36cf91fe4e8caa53aadeff92477641158;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641159 .

_:807f36cf91fe4e8caa53aadeff92477641158 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477641159 rdf:first _:807f36cf91fe4e8caa53aadeff92477641160;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477641162 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11122-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES) <-> LÉDIPASVIR"@fr;
  dct:identifier "IAM_11122";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641164;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de la statine et de ses effets indésirables à type de rhabdomyolyse."@fr;
  r:conduiteATenir """Contre-indication :
- avec la rosuvastatine.

Précaution d'emploi :
- avec les autres inhibiteurs de l'HMG Co-A réductase.
Surveillance clinique et biologique. Adaptation éventuelle de la posologie de la statine."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641170, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641164 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641165 .

_:807f36cf91fe4e8caa53aadeff92477641165 rdf:first _:807f36cf91fe4e8caa53aadeff92477641166;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641167 .

_:807f36cf91fe4e8caa53aadeff92477641166 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff92477641167 rdf:first _:807f36cf91fe4e8caa53aadeff92477641168;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:807f36cf91fe4e8caa53aadeff92477641170 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11123-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES) <-> LENALIDOMIDE"@fr;
  dct:identifier "IAM_11123";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641172;
  r:natureDuRisque "Risque majoré de survenue de rhabdomyolyses."@fr;
  r:conduiteATenir "Renforcer le contrôle clinique et biologique, notamment durant les premières semaines de traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641178, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641172 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641173 .

_:807f36cf91fe4e8caa53aadeff92477641173 rdf:first _:807f36cf91fe4e8caa53aadeff92477641174;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641175 .

_:807f36cf91fe4e8caa53aadeff92477641174 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff92477641175 rdf:first _:807f36cf91fe4e8caa53aadeff92477641176;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10513 .

_:807f36cf91fe4e8caa53aadeff92477641178 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11128-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> LUMEFANTRINE"@fr;
  dct:identifier "IAM_11128";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641180;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641186, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641180 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641181 .

_:807f36cf91fe4e8caa53aadeff92477641181 rdf:first _:807f36cf91fe4e8caa53aadeff92477641182;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641183 .

_:807f36cf91fe4e8caa53aadeff92477641182 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477641183 rdf:first _:807f36cf91fe4e8caa53aadeff92477641184;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10541 .

_:807f36cf91fe4e8caa53aadeff92477641186 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10764-1 a owl:Class;
  rdfs:label "DEXTROMETHORPHANE <-> IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE"@fr;
  dct:identifier "IAM_10764";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641188;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641194, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641188 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641189 .

_:807f36cf91fe4e8caa53aadeff92477641189 rdf:first _:807f36cf91fe4e8caa53aadeff92477641190;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641191 .

_:807f36cf91fe4e8caa53aadeff92477641190 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477641191 rdf:first _:807f36cf91fe4e8caa53aadeff92477641192;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10278 .

_:807f36cf91fe4e8caa53aadeff92477641194 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11144-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_11144";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641196;
  r:natureDuRisque "Majoration de la toxicité de l’antimitotique, par diminution de son métabolisme hépatique par l’inhibiteur de protéases."@fr;
  r:conduiteATenir "Surveillance clinique étroite et adaptation éventuelle de la posologie de l’antimitotique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641202, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641196 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641197 .

_:807f36cf91fe4e8caa53aadeff92477641197 rdf:first _:807f36cf91fe4e8caa53aadeff92477641198;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641199 .

_:807f36cf91fe4e8caa53aadeff92477641198 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477641199 rdf:first _:807f36cf91fe4e8caa53aadeff92477641200;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:807f36cf91fe4e8caa53aadeff92477641202 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10949-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_10949";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641204;
  r:natureDuRisque "Doublement des concentrations de névirapine avec risque d'augmentation de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la névirapine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641210, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641204 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641205 .

_:807f36cf91fe4e8caa53aadeff92477641205 rdf:first _:807f36cf91fe4e8caa53aadeff92477641206;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641207 .

_:807f36cf91fe4e8caa53aadeff92477641206 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477641207 rdf:first _:807f36cf91fe4e8caa53aadeff92477641208;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:807f36cf91fe4e8caa53aadeff92477641210 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11126-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_11126";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641212;
  r:natureDuRisque "Risque d’augmentation des concentrations d’itraconazole par l’inhibiteur de protéases."@fr;
  r:conduiteATenir "Surveillance clinique lors de l’association. L’administration de doses élevées d’itraconazole (>200 mg par jour) n’est pas recommandée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641218, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641212 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641213 .

_:807f36cf91fe4e8caa53aadeff92477641213 rdf:first _:807f36cf91fe4e8caa53aadeff92477641214;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641215 .

_:807f36cf91fe4e8caa53aadeff92477641214 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477641215 rdf:first _:807f36cf91fe4e8caa53aadeff92477641216;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477641218 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11127-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> LAMOTRIGINE"@fr;
  dct:identifier "IAM_11127";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641220;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de diminution des concentrations et de l’efficacité de la lamotrigine par augmentation de son métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir """Association déconseillée 
- Eviter de mettre en route le traitement par ritonavir pendant la période d’ajustement posologique de la lamotrigine.

Précaution d'emploi
- Surveillance clinique et adaptation de la posologie de la lamotrigine lors de la mise e"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641226, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641220 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641221 .

_:807f36cf91fe4e8caa53aadeff92477641221 rdf:first _:807f36cf91fe4e8caa53aadeff92477641222;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641223 .

_:807f36cf91fe4e8caa53aadeff92477641222 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477641223 rdf:first _:807f36cf91fe4e8caa53aadeff92477641224;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:807f36cf91fe4e8caa53aadeff92477641226 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11129-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> METHADONE"@fr;
  dct:identifier "IAM_11129";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641228;
  r:natureDuRisque "Diminution des concentrations plasmatiques de méthadone avec risque d'apparition d'un syndrome de sevrage par augmentation de son métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir "Surveillance clinique régulière et adaptation éventuelle de la posologie de méthadone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641234, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641228 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641229 .

_:807f36cf91fe4e8caa53aadeff92477641229 rdf:first _:807f36cf91fe4e8caa53aadeff92477641230;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641231 .

_:807f36cf91fe4e8caa53aadeff92477641230 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477641231 rdf:first _:807f36cf91fe4e8caa53aadeff92477641232;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff92477641234 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11130-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11130";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641236;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'inhibiteur de protéases, en raison de l'effet inducteur enzymatique du millepertuis, avec risque de baisse d'efficacité voire d'annulation de l'effet dont les conséquences peuvent être éventuellement graves"@fr;
  r:conduiteATenir "En cas d'association fortuite, ne pas interrompre brutalement la prise de millepertuis mais contrôler les concentrations plasmatiques (ou l'efficacité) de l'inhibiteur de protéases avant puis après l'arrêt du millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641242, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641236 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641237 .

_:807f36cf91fe4e8caa53aadeff92477641237 rdf:first _:807f36cf91fe4e8caa53aadeff92477641238;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641239 .

_:807f36cf91fe4e8caa53aadeff92477641238 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477641239 rdf:first _:807f36cf91fe4e8caa53aadeff92477641240;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641240 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477641242 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11131-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> MIZOLASTINE"@fr;
  dct:identifier "IAM_11131";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641244;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641250, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641244 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641245 .

_:807f36cf91fe4e8caa53aadeff92477641245 rdf:first _:807f36cf91fe4e8caa53aadeff92477641246;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641247 .

_:807f36cf91fe4e8caa53aadeff92477641246 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477641247 rdf:first _:807f36cf91fe4e8caa53aadeff92477641248;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641248 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10597 .

_:807f36cf91fe4e8caa53aadeff92477641250 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11132-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_11132";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641252;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par l'inhibiteur de protéases boosté par ritonavir."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641258, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641252 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641253 .

_:807f36cf91fe4e8caa53aadeff92477641253 rdf:first _:807f36cf91fe4e8caa53aadeff92477641254;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641255 .

_:807f36cf91fe4e8caa53aadeff92477641254 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477641255 rdf:first _:807f36cf91fe4e8caa53aadeff92477641256;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641256 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477641258 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10758-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> SIMÉPRÉVIR"@fr;
  dct:identifier "IAM_10758";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641260;
  r:natureDuRisque "Avec la dexaméthasone à usage systémique, risque de diminution des concentrations plasmatiques de simeprevir par augmentation de son métabolisme hépatique par la dexamethasone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641266, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641260 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641261 .

_:807f36cf91fe4e8caa53aadeff92477641261 rdf:first _:807f36cf91fe4e8caa53aadeff92477641262;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641263 .

_:807f36cf91fe4e8caa53aadeff92477641262 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477641263 rdf:first _:807f36cf91fe4e8caa53aadeff92477641264;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641264 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10837 .

_:807f36cf91fe4e8caa53aadeff92477641266 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10759-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_10759";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641268;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641274, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641268 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641269 .

_:807f36cf91fe4e8caa53aadeff92477641269 rdf:first _:807f36cf91fe4e8caa53aadeff92477641270;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641271 .

_:807f36cf91fe4e8caa53aadeff92477641270 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477641271 rdf:first _:807f36cf91fe4e8caa53aadeff92477641272;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641272 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477641274 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10760-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10760";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641276;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641282, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641276 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641277 .

_:807f36cf91fe4e8caa53aadeff92477641277 rdf:first _:807f36cf91fe4e8caa53aadeff92477641278;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641279 .

_:807f36cf91fe4e8caa53aadeff92477641278 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477641279 rdf:first _:807f36cf91fe4e8caa53aadeff92477641280;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641280 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477641282 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10761-1 a owl:Class;
  rdfs:label "DEXTRAN 40 <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10761";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641284;
  r:natureDuRisque "Augmentation du risque hémorragique (inhibition de la fonction plaquettaire par le dextran 40)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641290, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641284 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641285 .

_:807f36cf91fe4e8caa53aadeff92477641285 rdf:first _:807f36cf91fe4e8caa53aadeff92477641286;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641287 .

_:807f36cf91fe4e8caa53aadeff92477641286 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10061 .

_:807f36cf91fe4e8caa53aadeff92477641287 rdf:first _:807f36cf91fe4e8caa53aadeff92477641288;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641288 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477641290 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11139-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> TELAPREVIR"@fr;
  dct:identifier "IAM_11139";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641292;
  r:natureDuRisque "Diminution des concentrations du télaprévir et du darunavir ou du fosamprénavir, avec risque d’échec thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641298, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641292 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641293 .

_:807f36cf91fe4e8caa53aadeff92477641293 rdf:first _:807f36cf91fe4e8caa53aadeff92477641294;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641295 .

_:807f36cf91fe4e8caa53aadeff92477641294 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477641295 rdf:first _:807f36cf91fe4e8caa53aadeff92477641296;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641296 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477641298 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10992-1 a owl:Class;
  rdfs:label "GANCICLOVIR <-> ZALCITABINE"@fr;
  dct:identifier "IAM_10992";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641300;
  r:natureDuRisque "Risque accru de survenue de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641306, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641300 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641301 .

_:807f36cf91fe4e8caa53aadeff92477641301 rdf:first _:807f36cf91fe4e8caa53aadeff92477641302;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641303 .

_:807f36cf91fe4e8caa53aadeff92477641302 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10408 .

_:807f36cf91fe4e8caa53aadeff92477641303 rdf:first _:807f36cf91fe4e8caa53aadeff92477641304;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641304 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11002 .

_:807f36cf91fe4e8caa53aadeff92477641306 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10981-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> PIRFENIDONE"@fr;
  dct:identifier "IAM_10981";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641308;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de pirfenidone avec signes de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641314, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641308 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641309 .

_:807f36cf91fe4e8caa53aadeff92477641309 rdf:first _:807f36cf91fe4e8caa53aadeff92477641310;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641311 .

_:807f36cf91fe4e8caa53aadeff92477641310 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477641311 rdf:first _:807f36cf91fe4e8caa53aadeff92477641312;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641312 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10731 .

_:807f36cf91fe4e8caa53aadeff92477641314 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10982-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> PROPRANOLOL"@fr;
  dct:identifier "IAM_10982";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641316;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de propranolol par inhibition de son métabolisme hépatique, avec majoration de l'activité et des effets indésirables, par exemple : bradycardie importante."@fr;
  r:conduiteATenir "Surveillance clinique accrue et, si besoin, adaptation de la posologie du propranolol pendant le traitement par la fluvoxamine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641322, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641316 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641317 .

_:807f36cf91fe4e8caa53aadeff92477641317 rdf:first _:807f36cf91fe4e8caa53aadeff92477641318;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641319 .

_:807f36cf91fe4e8caa53aadeff92477641318 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477641319 rdf:first _:807f36cf91fe4e8caa53aadeff92477641320;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641320 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10767 .

_:807f36cf91fe4e8caa53aadeff92477641322 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10983-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> ROPINIROLE"@fr;
  dct:identifier "IAM_10983";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641324;
  r:natureDuRisque "Augmentation des concentrations de ropinirole, avec risque de surdosage, par diminution de son métabolisme hépatique par la fluvoxamine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du ropinirole pendant le traitement par fluvoxamine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641330, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641324 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641325 .

_:807f36cf91fe4e8caa53aadeff92477641325 rdf:first _:807f36cf91fe4e8caa53aadeff92477641326;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641327 .

_:807f36cf91fe4e8caa53aadeff92477641326 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477641327 rdf:first _:807f36cf91fe4e8caa53aadeff92477641328;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641328 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10813 .

_:807f36cf91fe4e8caa53aadeff92477641330 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10984-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10984";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641332;
  r:natureDuRisque "Augmentation de la théophyllinémie avec signes de surdosage (diminution du métabolisme hépatique de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; si besoin, adaptation de la posologie de la théophylline pendant le traitement par la fluvoxamine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641338, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641332 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641333 .

_:807f36cf91fe4e8caa53aadeff92477641333 rdf:first _:807f36cf91fe4e8caa53aadeff92477641334;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641335 .

_:807f36cf91fe4e8caa53aadeff92477641334 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477641335 rdf:first _:807f36cf91fe4e8caa53aadeff92477641336;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641336 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477641338 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10985-1 a owl:Class;
  rdfs:label "FOLATES <-> PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE)"@fr;
  dct:identifier "IAM_10985";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641340;
  r:natureDuRisque "Diminution des concentrations plasmatiques du phénobarbital, par augmentation de son métabolisme dont les folates représentent un des cofacteurs."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques, et adaptation, s'il y a lieu, de la posologie du phénobarbital pendant la supplémentation folique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641346, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641340 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641341 .

_:807f36cf91fe4e8caa53aadeff92477641341 rdf:first _:807f36cf91fe4e8caa53aadeff92477641342;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641343 .

_:807f36cf91fe4e8caa53aadeff92477641342 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10077 .

_:807f36cf91fe4e8caa53aadeff92477641343 rdf:first _:807f36cf91fe4e8caa53aadeff92477641344;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641344 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477641346 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10986-1 a owl:Class;
  rdfs:label "FOLATES <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10986";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641348;
  r:natureDuRisque "Diminution des concentrations plasmatiques de phénytoïne par augmentation de son métabolisme dont les folates représentent un des cofacteurs."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques de phénytoïne. Adaptation éventuelle de la posologie de la phénytoïne pendant la supplémentation folique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641354, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641348 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641349 .

_:807f36cf91fe4e8caa53aadeff92477641349 rdf:first _:807f36cf91fe4e8caa53aadeff92477641350;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641351 .

_:807f36cf91fe4e8caa53aadeff92477641350 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10077 .

_:807f36cf91fe4e8caa53aadeff92477641351 rdf:first _:807f36cf91fe4e8caa53aadeff92477641352;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641352 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477641354 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10987-1 a owl:Class;
  rdfs:label "FOSAMPRENAVIR <-> MARAVIROC"@fr;
  dct:identifier "IAM_10987";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641356;
  r:natureDuRisque "Diminution significative des concentrations d’amprénavir pouvant conduire à une perte de la réponse virologique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641362, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641356 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641357 .

_:807f36cf91fe4e8caa53aadeff92477641357 rdf:first _:807f36cf91fe4e8caa53aadeff92477641358;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641359 .

_:807f36cf91fe4e8caa53aadeff92477641358 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10400 .

_:807f36cf91fe4e8caa53aadeff92477641359 rdf:first _:807f36cf91fe4e8caa53aadeff92477641360;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641360 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10551 .

_:807f36cf91fe4e8caa53aadeff92477641362 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10988-1 a owl:Class;
  rdfs:label "FOSAMPRENAVIR <-> METHADONE"@fr;
  dct:identifier "IAM_10988";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641364;
  r:natureDuRisque """Diminution des concentrations plasmatiques de méthadone avec
risque d'apparition d'un syndrome de sevrage par augmentation de son métabolisme hépatique par l'amprénavir."""@fr;
  r:conduiteATenir "Surveillance clinique régulière et adaptation éventuelle de la posologie de méthadone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641370, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641364 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641365 .

_:807f36cf91fe4e8caa53aadeff92477641365 rdf:first _:807f36cf91fe4e8caa53aadeff92477641366;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641367 .

_:807f36cf91fe4e8caa53aadeff92477641366 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10400 .

_:807f36cf91fe4e8caa53aadeff92477641367 rdf:first _:807f36cf91fe4e8caa53aadeff92477641368;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641368 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff92477641370 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10989-1 a owl:Class;
  rdfs:label "FOSAMPRENAVIR <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_10989";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641372;
  r:natureDuRisque "Risque de baisse de l'efficacité de l'amprénavir."@fr;
  r:conduiteATenir """Surveillance clinique et biologique régulière, notamment en début
d'association."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641378, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641372 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641373 .

_:807f36cf91fe4e8caa53aadeff92477641373 rdf:first _:807f36cf91fe4e8caa53aadeff92477641374;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641375 .

_:807f36cf91fe4e8caa53aadeff92477641374 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10400 .

_:807f36cf91fe4e8caa53aadeff92477641375 rdf:first _:807f36cf91fe4e8caa53aadeff92477641376;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641376 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:807f36cf91fe4e8caa53aadeff92477641378 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11205-1 a owl:Class;
  rdfs:label "IVABRADINE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11205";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641380;
  r:natureDuRisque "Risque de diminution de l'efficacité de l’ivabradine, par augmentation de son métabolisme par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641386, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641380 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641381 .

_:807f36cf91fe4e8caa53aadeff92477641381 rdf:first _:807f36cf91fe4e8caa53aadeff92477641382;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641383 .

_:807f36cf91fe4e8caa53aadeff92477641382 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:807f36cf91fe4e8caa53aadeff92477641383 rdf:first _:807f36cf91fe4e8caa53aadeff92477641384;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641384 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477641386 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10991-1 a owl:Class;
  rdfs:label "FUROSEMIDE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10991";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641388;
  r:natureDuRisque "Diminution de l'effet diurétique pouvant atteindre 50 %."@fr;
  r:conduiteATenir "Utiliser éventuellement des doses plus élevées de furosémide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641394, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641388 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641389 .

_:807f36cf91fe4e8caa53aadeff92477641389 rdf:first _:807f36cf91fe4e8caa53aadeff92477641390;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641391 .

_:807f36cf91fe4e8caa53aadeff92477641390 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477641391 rdf:first _:807f36cf91fe4e8caa53aadeff92477641392;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641392 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10406 .

_:807f36cf91fe4e8caa53aadeff92477641394 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10978-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> MEXILETINE"@fr;
  dct:identifier "IAM_10978";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641396;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méxilétine, par inhibition de son métabolisme par la fluvoxamine."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. Adaptation de la posologie de la méxilétine pendant le traitement par la fluvoxamine et après son arrêt."@fr;
  rdfs:comment "La méxilétine est un anti-arythmique de la classe Ib de la classification de Vaughan-Williams, indiquée dans le traitement et la prévention des arythmies ventriculaires mettant en jeu le pronostic vital. Son métabolisme dépend principalement du CYP2D6, et"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641402, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641396 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641397 .

_:807f36cf91fe4e8caa53aadeff92477641397 rdf:first _:807f36cf91fe4e8caa53aadeff92477641398;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641399 .

_:807f36cf91fe4e8caa53aadeff92477641398 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477641399 rdf:first _:807f36cf91fe4e8caa53aadeff92477641400;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641400 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10582 .

_:807f36cf91fe4e8caa53aadeff92477641402 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10993-1 a owl:Class;
  rdfs:label "GANCICLOVIR <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_10993";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641404;
  r:natureDuRisque "Augmentation de la toxicité hématologique (addition d'effets de toxicité médullaire)."@fr;
  r:conduiteATenir "Arrêter de façon transitoire la zidovudine ; contrôler la NFS et réintroduire, si possible, la zidovudine à doses faibles."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641410, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641404 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641405 .

_:807f36cf91fe4e8caa53aadeff92477641405 rdf:first _:807f36cf91fe4e8caa53aadeff92477641406;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641407 .

_:807f36cf91fe4e8caa53aadeff92477641406 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10408 .

_:807f36cf91fe4e8caa53aadeff92477641407 rdf:first _:807f36cf91fe4e8caa53aadeff92477641408;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641408 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:807f36cf91fe4e8caa53aadeff92477641410 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10994-1 a owl:Class;
  rdfs:label "GEMFIBROZIL <-> PIOGLITAZONE"@fr;
  dct:identifier "IAM_10994";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641412;
  r:natureDuRisque """Risque d’augmentation des effets indésirables de la glitazone par
diminution de son métabolisme hépatique par le gemfibrozil."""@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641418, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641412 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641413 .

_:807f36cf91fe4e8caa53aadeff92477641413 rdf:first _:807f36cf91fe4e8caa53aadeff92477641414;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641415 .

_:807f36cf91fe4e8caa53aadeff92477641414 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10411 .

_:807f36cf91fe4e8caa53aadeff92477641415 rdf:first _:807f36cf91fe4e8caa53aadeff92477641416;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641416 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10723 .

_:807f36cf91fe4e8caa53aadeff92477641418 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10995-1 a owl:Class;
  rdfs:label "GEMFIBROZIL <-> REPAGLINIDE"@fr;
  dct:identifier "IAM_10995";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641420;
  r:natureDuRisque "Risque d'hypoglycémie sévère voire de coma, par augmentation importante des concentrations plasmatiques de repaglinide par le gemfibrozil."@fr;
  rdfs:comment "Une publication montre que le gemfibrozil augmente d'environ huit fois les concentrations plasmatiques du répaglinide. Les auteurs attribuent cet effet à une inhibition du CYP2C8 par le gemfibrozil. Cette isoenzyme est en effet largement impliquée dans le"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641426, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641420 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641421 .

_:807f36cf91fe4e8caa53aadeff92477641421 rdf:first _:807f36cf91fe4e8caa53aadeff92477641422;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641423 .

_:807f36cf91fe4e8caa53aadeff92477641422 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10411 .

_:807f36cf91fe4e8caa53aadeff92477641423 rdf:first _:807f36cf91fe4e8caa53aadeff92477641424;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641424 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:807f36cf91fe4e8caa53aadeff92477641426 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10996-1 a owl:Class;
  rdfs:label "GLIPIZIDE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10996";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641428;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques du glipizide à l’origine d’hypoglycémies potentiellement sévères."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide pendant et après le traitement par voriconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641434, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641428 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641429 .

_:807f36cf91fe4e8caa53aadeff92477641429 rdf:first _:807f36cf91fe4e8caa53aadeff92477641430;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641431 .

_:807f36cf91fe4e8caa53aadeff92477641430 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10417 .

_:807f36cf91fe4e8caa53aadeff92477641431 rdf:first _:807f36cf91fe4e8caa53aadeff92477641432;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641432 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477641434 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10997-1 a owl:Class;
  rdfs:label "GLIPTINES <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10997";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641436;
  r:natureDuRisque "Majoration du risque de la survenue d’angio-oedèmes, par réduction de l’activité de l’enzyme dipeptidyl peptidase IV (DPP-IV) par la gliptine, chez les patients traités par inhibiteur de l’enzyme de conversion."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641442, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641436 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641437 .

_:807f36cf91fe4e8caa53aadeff92477641437 rdf:first _:807f36cf91fe4e8caa53aadeff92477641438;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641439 .

_:807f36cf91fe4e8caa53aadeff92477641438 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10079 .

_:807f36cf91fe4e8caa53aadeff92477641439 rdf:first _:807f36cf91fe4e8caa53aadeff92477641440;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641440 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477641442 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11011-1 a owl:Class;
  rdfs:label "HALOTHANE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11011";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641444;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641450, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641444 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641445 .

_:807f36cf91fe4e8caa53aadeff92477641445 rdf:first _:807f36cf91fe4e8caa53aadeff92477641446;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641447 .

_:807f36cf91fe4e8caa53aadeff92477641446 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477641447 rdf:first _:807f36cf91fe4e8caa53aadeff92477641448;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641448 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10427 .

_:807f36cf91fe4e8caa53aadeff92477641450 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11012-1 a owl:Class;
  rdfs:label "HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES CURATIVES ET/OU SUJET ÂGÉ) <-> THROMBOLYTIQUES"@fr;
  dct:identifier "IAM_11012";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641452;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641458, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641452 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641453 .

_:807f36cf91fe4e8caa53aadeff92477641453 rdf:first _:807f36cf91fe4e8caa53aadeff92477641454;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641455 .

_:807f36cf91fe4e8caa53aadeff92477641454 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477641455 rdf:first _:807f36cf91fe4e8caa53aadeff92477641456;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641456 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10151 .

_:807f36cf91fe4e8caa53aadeff92477641458 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11013-1 a owl:Class;
  rdfs:label "HÉPARINES NON FRACTIONNÉES (DOSES CURATIVES ET/OU SUJET ÂGÉ) <-> THROMBOLYTIQUES"@fr;
  dct:identifier "IAM_11013";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641460;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641466, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641460 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641461 .

_:807f36cf91fe4e8caa53aadeff92477641461 rdf:first _:807f36cf91fe4e8caa53aadeff92477641462;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641463 .

_:807f36cf91fe4e8caa53aadeff92477641462 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10091 .

_:807f36cf91fe4e8caa53aadeff92477641463 rdf:first _:807f36cf91fe4e8caa53aadeff92477641464;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641464 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10151 .

_:807f36cf91fe4e8caa53aadeff92477641466 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11014-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> IMATINIB"@fr;
  dct:identifier "IAM_11014";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641468;
  r:natureDuRisque "Risque de baisse de l’efficacité des hormones thyroïdiennes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641474, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641468 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641469 .

_:807f36cf91fe4e8caa53aadeff92477641469 rdf:first _:807f36cf91fe4e8caa53aadeff92477641470;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641471 .

_:807f36cf91fe4e8caa53aadeff92477641470 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477641471 rdf:first _:807f36cf91fe4e8caa53aadeff92477641472;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641472 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10448 .

_:807f36cf91fe4e8caa53aadeff92477641474 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10990-1 a owl:Class;
  rdfs:label "FOSCARNET <-> PENTAMIDINE"@fr;
  dct:identifier "IAM_10990";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641476;
  r:natureDuRisque "Risque d'hypocalcémie sévère."@fr;
  r:conduiteATenir "Surveillance de la calcémie et supplémentation si nécessaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641482, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641476 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641477 .

_:807f36cf91fe4e8caa53aadeff92477641477 rdf:first _:807f36cf91fe4e8caa53aadeff92477641478;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641479 .

_:807f36cf91fe4e8caa53aadeff92477641478 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10401 .

_:807f36cf91fe4e8caa53aadeff92477641479 rdf:first _:807f36cf91fe4e8caa53aadeff92477641480;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641480 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10703 .

_:807f36cf91fe4e8caa53aadeff92477641482 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10968-1 a owl:Class;
  rdfs:label "FLUOROURACILE (ET, PAR EXTRAPOLATION, AUTRES FLUOROPYRIMIDINES) <-> ORNIDAZOLE"@fr;
  dct:identifier "IAM_10968";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641484;
  r:natureDuRisque "Augmentation de la toxicité du fluoro-uracile par diminution de sa clairance."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641490, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641484 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641485 .

_:807f36cf91fe4e8caa53aadeff92477641485 rdf:first _:807f36cf91fe4e8caa53aadeff92477641486;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641487 .

_:807f36cf91fe4e8caa53aadeff92477641486 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10076 .

_:807f36cf91fe4e8caa53aadeff92477641487 rdf:first _:807f36cf91fe4e8caa53aadeff92477641488;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641488 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10668 .

_:807f36cf91fe4e8caa53aadeff92477641490 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10957-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10957";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641492;
  r:natureDuRisque "Augmentation du temps de demi-vie du sulfamide avec survenue possible de manifestations d'hypoglycémie."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide pendant le traitement par le fluconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641498, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641492 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641493 .

_:807f36cf91fe4e8caa53aadeff92477641493 rdf:first _:807f36cf91fe4e8caa53aadeff92477641494;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641495 .

_:807f36cf91fe4e8caa53aadeff92477641494 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477641495 rdf:first _:807f36cf91fe4e8caa53aadeff92477641496;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641496 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477641498 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10958-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10958";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641500;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage (diminution de la clairance de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; s'il y a lieu, adaptation de la posologie de la théophylline pendant le traitement par le fluconazole et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641506, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641500 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641501 .

_:807f36cf91fe4e8caa53aadeff92477641501 rdf:first _:807f36cf91fe4e8caa53aadeff92477641502;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641503 .

_:807f36cf91fe4e8caa53aadeff92477641502 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477641503 rdf:first _:807f36cf91fe4e8caa53aadeff92477641504;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641504 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477641506 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10959-1 a owl:Class;
  rdfs:label "FLUCYTOSINE <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_10959";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641508;
  r:natureDuRisque "Augmentation de la toxicité hématologique (addition d'effets de toxicité médullaire)."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'hémogramme."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641514, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641508 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641509 .

_:807f36cf91fe4e8caa53aadeff92477641509 rdf:first _:807f36cf91fe4e8caa53aadeff92477641510;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641511 .

_:807f36cf91fe4e8caa53aadeff92477641510 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10382 .

_:807f36cf91fe4e8caa53aadeff92477641511 rdf:first _:807f36cf91fe4e8caa53aadeff92477641512;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641512 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:807f36cf91fe4e8caa53aadeff92477641514 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10960-1 a owl:Class;
  rdfs:label "FLUDARABINE <-> PENTOSTATINE"@fr;
  dct:identifier "IAM_10960";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641516;
  r:natureDuRisque "Majoration du risque de toxicité pulmonaire pouvant être fatale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641522, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641516 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641517 .

_:807f36cf91fe4e8caa53aadeff92477641517 rdf:first _:807f36cf91fe4e8caa53aadeff92477641518;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641519 .

_:807f36cf91fe4e8caa53aadeff92477641518 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10383 .

_:807f36cf91fe4e8caa53aadeff92477641519 rdf:first _:807f36cf91fe4e8caa53aadeff92477641520;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641520 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10704 .

_:807f36cf91fe4e8caa53aadeff92477641522 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10961-1 a owl:Class;
  rdfs:label "FLUOROQUINOLONES <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10961";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641524;
  r:natureDuRisque "Possible majoration du risque de tendinopathie, voire de rupture tendineuse (exceptionnelle), particulièrement chez les patients recevant une corticothérapie prolongée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641530, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641524 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641525 .

_:807f36cf91fe4e8caa53aadeff92477641525 rdf:first _:807f36cf91fe4e8caa53aadeff92477641526;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641527 .

_:807f36cf91fe4e8caa53aadeff92477641526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff92477641527 rdf:first _:807f36cf91fe4e8caa53aadeff92477641528;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641528 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477641530 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10962-1 a owl:Class;
  rdfs:label "FLUOROQUINOLONES <-> MYCOPHENOLATE MOFETIL"@fr;
  dct:identifier "IAM_10962";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641532;
  r:natureDuRisque "Diminution des concentrations de l’acide mycophénolique d’environ un tiers, avec risque potentiel de baisse d’efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641538, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641532 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641533 .

_:807f36cf91fe4e8caa53aadeff92477641533 rdf:first _:807f36cf91fe4e8caa53aadeff92477641534;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641535 .

_:807f36cf91fe4e8caa53aadeff92477641534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff92477641535 rdf:first _:807f36cf91fe4e8caa53aadeff92477641536;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641536 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10609 .

_:807f36cf91fe4e8caa53aadeff92477641538 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10963-1 a owl:Class;
  rdfs:label "FLUOROQUINOLONES <-> STRONTIUM"@fr;
  dct:identifier "IAM_10963";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641540;
  r:natureDuRisque "Diminution de l'absorption digestive du strontium."@fr;
  r:conduiteATenir "Prendre le strontium à distance des fluoroquinolones (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641546, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641540 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641541 .

_:807f36cf91fe4e8caa53aadeff92477641541 rdf:first _:807f36cf91fe4e8caa53aadeff92477641542;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641543 .

_:807f36cf91fe4e8caa53aadeff92477641542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff92477641543 rdf:first _:807f36cf91fe4e8caa53aadeff92477641544;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641544 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10863 .

_:807f36cf91fe4e8caa53aadeff92477641546 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10964-1 a owl:Class;
  rdfs:label "FLUOROQUINOLONES <-> SUCRALFATE"@fr;
  dct:identifier "IAM_10964";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641548;
  r:natureDuRisque "Diminution de l'absorption digestive des fluoroquinolones."@fr;
  r:conduiteATenir "Prendre le sucralfate à distance des fluoroquinolones (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641554, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641548 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641549 .

_:807f36cf91fe4e8caa53aadeff92477641549 rdf:first _:807f36cf91fe4e8caa53aadeff92477641550;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641551 .

_:807f36cf91fe4e8caa53aadeff92477641550 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff92477641551 rdf:first _:807f36cf91fe4e8caa53aadeff92477641552;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641552 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10864 .

_:807f36cf91fe4e8caa53aadeff92477641554 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10965-1 a owl:Class;
  rdfs:label "FLUOROQUINOLONES <-> ZINC"@fr;
  dct:identifier "IAM_10965";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641556;
  r:natureDuRisque "Diminution de l'absorption digestives des fluoroquinolones."@fr;
  r:conduiteATenir "Prendre les sels de zinc à distance des fluoroquinolones (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641562, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641556 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641557 .

_:807f36cf91fe4e8caa53aadeff92477641557 rdf:first _:807f36cf91fe4e8caa53aadeff92477641558;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641559 .

_:807f36cf91fe4e8caa53aadeff92477641558 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff92477641559 rdf:first _:807f36cf91fe4e8caa53aadeff92477641560;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641560 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11005 .

_:807f36cf91fe4e8caa53aadeff92477641562 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10980-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10980";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641564;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne avec signes de surdosage, par inhibition du métabolisme hépatique de la phénytoïne."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement contröle des concentrations plamatiques de phénytoïne. Si besoin, adaptation posologique de la phénytoïne pendant le traitement par la fluvoxamine et après son arrët."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641570, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641564 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641565 .

_:807f36cf91fe4e8caa53aadeff92477641565 rdf:first _:807f36cf91fe4e8caa53aadeff92477641566;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641567 .

_:807f36cf91fe4e8caa53aadeff92477641566 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477641567 rdf:first _:807f36cf91fe4e8caa53aadeff92477641568;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641568 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477641570 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10967-1 a owl:Class;
  rdfs:label "FLUOROURACILE (ET, PAR EXTRAPOLATION, AUTRES FLUOROPYRIMIDINES) <-> METRONIDAZOLE"@fr;
  dct:identifier "IAM_10967";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641572;
  r:natureDuRisque "Augmentation de la toxicité du fluoro-uracile par diminution de sa clairance."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641578, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641572 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641573 .

_:807f36cf91fe4e8caa53aadeff92477641573 rdf:first _:807f36cf91fe4e8caa53aadeff92477641574;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641575 .

_:807f36cf91fe4e8caa53aadeff92477641574 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10076 .

_:807f36cf91fe4e8caa53aadeff92477641575 rdf:first _:807f36cf91fe4e8caa53aadeff92477641576;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641576 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10580 .

_:807f36cf91fe4e8caa53aadeff92477641578 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10979-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> OLANZAPINE"@fr;
  dct:identifier "IAM_10979";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641580;
  r:natureDuRisque "Augmentation des concentrations de l’olanzapine, avec risque de majoration des effets indésirables, par diminution de son métabolisme hépatique par la fluvoxamine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de l’olanzapine pendant le traitement par fluvoxamine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641586, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641580 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641581 .

_:807f36cf91fe4e8caa53aadeff92477641581 rdf:first _:807f36cf91fe4e8caa53aadeff92477641582;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641583 .

_:807f36cf91fe4e8caa53aadeff92477641582 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477641583 rdf:first _:807f36cf91fe4e8caa53aadeff92477641584;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641584 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10658 .

_:807f36cf91fe4e8caa53aadeff92477641586 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10970-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> METOPROLOL"@fr;
  dct:identifier "IAM_10970";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641588;
  r:natureDuRisque "Risque de majoration des effets indésirables du métoprolol, avec notamment bradycardie excessive, par inhibition de son métabolisme par la fluoxétine."@fr;
  r:conduiteATenir "Surveillance clinique accrue ; si besoin, adaptation de la posologie du métoprolol pendant la durée du traitement par la fluoxétine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641594, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641588 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641589 .

_:807f36cf91fe4e8caa53aadeff92477641589 rdf:first _:807f36cf91fe4e8caa53aadeff92477641590;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641591 .

_:807f36cf91fe4e8caa53aadeff92477641590 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:807f36cf91fe4e8caa53aadeff92477641591 rdf:first _:807f36cf91fe4e8caa53aadeff92477641592;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641592 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477641594 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10971-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> NEBIVOLOL"@fr;
  dct:identifier "IAM_10971";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641596;
  r:natureDuRisque "Risque de majoration des effets indésirables du nébivolol avec notamment bradycardie excessive, par inhibition de son métabolisme par l’antidépresseur."@fr;
  r:conduiteATenir "Surveillance clinique accrue ; si besoin, adaptation de la posologie du nébivolol pendant la durée du traitement par l’antidépresseur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641602, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641596 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641597 .

_:807f36cf91fe4e8caa53aadeff92477641597 rdf:first _:807f36cf91fe4e8caa53aadeff92477641598;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641599 .

_:807f36cf91fe4e8caa53aadeff92477641598 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:807f36cf91fe4e8caa53aadeff92477641599 rdf:first _:807f36cf91fe4e8caa53aadeff92477641600;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641600 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10623 .

_:807f36cf91fe4e8caa53aadeff92477641602 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10969-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> MEQUITAZINE"@fr;
  dct:identifier "IAM_10969";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641604;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méquitazine, par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641610, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641604 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641605 .

_:807f36cf91fe4e8caa53aadeff92477641605 rdf:first _:807f36cf91fe4e8caa53aadeff92477641606;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641607 .

_:807f36cf91fe4e8caa53aadeff92477641606 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:807f36cf91fe4e8caa53aadeff92477641607 rdf:first _:807f36cf91fe4e8caa53aadeff92477641608;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641608 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10561 .

_:807f36cf91fe4e8caa53aadeff92477641610 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10972-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10972";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641612;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne avec signes de surdosage, par inhibition du métabolisme de la phénytoïne."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement contrôle des concentrations plasmatiques de phénytoïne. Si besoin, adaptation posologique pendant le traitement par la fluoxétine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641618, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641612 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641613 .

_:807f36cf91fe4e8caa53aadeff92477641613 rdf:first _:807f36cf91fe4e8caa53aadeff92477641614;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641615 .

_:807f36cf91fe4e8caa53aadeff92477641614 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477641615 rdf:first _:807f36cf91fe4e8caa53aadeff92477641616;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641616 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:807f36cf91fe4e8caa53aadeff92477641618 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10973-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> RISPERIDONE"@fr;
  dct:identifier "IAM_10973";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641620;
  r:natureDuRisque "Augmentation de la fraction active de la rispéridone par diminution de son métabolisme hépatique par la fluoxétine, avec risque de majoration des effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, adaptation posologique de la rispéridone."@fr;
  rdfs:comment "La rispéridone est majoritairement métabolisée par le CYP2D6 en 9-OH-rispéridone, métabolite actif. La fraction pharmacologiquement active de la rispéridone est ainsi constituée par la molécule mère et son métabolite hydroxylé. La fluoxétine est un inhibi"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641626, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641620 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641621 .

_:807f36cf91fe4e8caa53aadeff92477641621 rdf:first _:807f36cf91fe4e8caa53aadeff92477641622;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641623 .

_:807f36cf91fe4e8caa53aadeff92477641622 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:807f36cf91fe4e8caa53aadeff92477641623 rdf:first _:807f36cf91fe4e8caa53aadeff92477641624;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641624 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10805 .

_:807f36cf91fe4e8caa53aadeff92477641626 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10974-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> TAMOXIFENE"@fr;
  dct:identifier "IAM_10974";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641628;
  r:natureDuRisque "Baisse de l’efficacité du tamoxifène, par inhibition de la formation de son métabolite actif par la fluoxétine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641634, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641628 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641629 .

_:807f36cf91fe4e8caa53aadeff92477641629 rdf:first _:807f36cf91fe4e8caa53aadeff92477641630;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641631 .

_:807f36cf91fe4e8caa53aadeff92477641630 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:807f36cf91fe4e8caa53aadeff92477641631 rdf:first _:807f36cf91fe4e8caa53aadeff92477641632;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641632 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:807f36cf91fe4e8caa53aadeff92477641634 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10975-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> VORTIOXÉTINE"@fr;
  dct:identifier "IAM_10975";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641636;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la vortioxétine par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la vortioxétine pendant le traitement par la fluoxétine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641642, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641636 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641637 .

_:807f36cf91fe4e8caa53aadeff92477641637 rdf:first _:807f36cf91fe4e8caa53aadeff92477641638;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641639 .

_:807f36cf91fe4e8caa53aadeff92477641638 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:807f36cf91fe4e8caa53aadeff92477641639 rdf:first _:807f36cf91fe4e8caa53aadeff92477641640;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641640 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10999 .

_:807f36cf91fe4e8caa53aadeff92477641642 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10976-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> LIDOCAINE"@fr;
  dct:identifier "IAM_10976";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641644;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la lidocaïne avec possibilités d’effets indésirables neurologiques et cardiaques (diminution de la clairance hépatique de la lidocaïne)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement contrôle des concentrations plasmatiques de la lidocaïne pendant et après l’arrêt de l’association. Adaptation, si besoin, de la posologie de la lidocaïne."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641650, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641644 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641645 .

_:807f36cf91fe4e8caa53aadeff92477641645 rdf:first _:807f36cf91fe4e8caa53aadeff92477641646;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641647 .

_:807f36cf91fe4e8caa53aadeff92477641646 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477641647 rdf:first _:807f36cf91fe4e8caa53aadeff92477641648;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641648 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10523 .

_:807f36cf91fe4e8caa53aadeff92477641650 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10977-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> METHADONE"@fr;
  dct:identifier "IAM_10977";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641652;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de méthadone avec surdosage et risque majoré d’allongement de l’intervalle QT et de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique renforcée ; si besoin, adaptation de la posologie de la méthadone pendant le traitement par la fluvoxamine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641658, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641652 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641653 .

_:807f36cf91fe4e8caa53aadeff92477641653 rdf:first _:807f36cf91fe4e8caa53aadeff92477641654;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641655 .

_:807f36cf91fe4e8caa53aadeff92477641654 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477641655 rdf:first _:807f36cf91fe4e8caa53aadeff92477641656;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641656 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff92477641658 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11017-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> PROGUANIL"@fr;
  dct:identifier "IAM_11017";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641660;
  r:natureDuRisque "Risque d’hypothyroïdie clinique chez les patients substitués par hormones thyroïdiennes."@fr;
  r:conduiteATenir "Surveillance des concentrations sériques de T3 et de T4 et adaptation, si besoin, de la posologie de l'hormone thyroïdienne pendant le traitement par l’antipaludique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641666, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641660 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641661 .

_:807f36cf91fe4e8caa53aadeff92477641661 rdf:first _:807f36cf91fe4e8caa53aadeff92477641662;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641663 .

_:807f36cf91fe4e8caa53aadeff92477641662 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477641663 rdf:first _:807f36cf91fe4e8caa53aadeff92477641664;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641664 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10761 .

_:807f36cf91fe4e8caa53aadeff92477641666 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10966-1 a owl:Class;
  rdfs:label "FLUOROURACILE (ET, PAR EXTRAPOLATION, AUTRES FLUOROPYRIMIDINES) <-> INTERFERON ALFA"@fr;
  dct:identifier "IAM_10966";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641668;
  r:natureDuRisque "Augmentation de la toxicité gastro-intestinale du fluorouracile."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641674, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641668 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641669 .

_:807f36cf91fe4e8caa53aadeff92477641669 rdf:first _:807f36cf91fe4e8caa53aadeff92477641670;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641671 .

_:807f36cf91fe4e8caa53aadeff92477641670 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10076 .

_:807f36cf91fe4e8caa53aadeff92477641671 rdf:first _:807f36cf91fe4e8caa53aadeff92477641672;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641672 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10474 .

_:807f36cf91fe4e8caa53aadeff92477641674 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11070-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_11070";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641676;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation de sa posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641682, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641676 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641677 .

_:807f36cf91fe4e8caa53aadeff92477641677 rdf:first _:807f36cf91fe4e8caa53aadeff92477641678;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641679 .

_:807f36cf91fe4e8caa53aadeff92477641678 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477641679 rdf:first _:807f36cf91fe4e8caa53aadeff92477641680;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641680 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477641682 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11015-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_11015";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641684;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de baisse de l’efficacité des hormones thyroïdiennes par augmentation de leur métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir "Surveillance clinique et biologique et adaptation éventuelle de la posologie des hormones thyroïdiennes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641690, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641684 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641685 .

_:807f36cf91fe4e8caa53aadeff92477641685 rdf:first _:807f36cf91fe4e8caa53aadeff92477641686;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641687 .

_:807f36cf91fe4e8caa53aadeff92477641686 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477641687 rdf:first _:807f36cf91fe4e8caa53aadeff92477641688;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641688 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477641690 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11062-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> TRIPTANS NON MÉTABOLISÉS PAR LA MAO"@fr;
  dct:identifier "IAM_11062";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641692;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641698, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641692 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641693 .

_:807f36cf91fe4e8caa53aadeff92477641693 rdf:first _:807f36cf91fe4e8caa53aadeff92477641694;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641695 .

_:807f36cf91fe4e8caa53aadeff92477641694 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477641695 rdf:first _:807f36cf91fe4e8caa53aadeff92477641696;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641696 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477641698 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11061-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> TRIPTANS MÉTABOLISÉS PAR LA MAO"@fr;
  dct:identifier "IAM_11061";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641700;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641706, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641700 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641701 .

_:807f36cf91fe4e8caa53aadeff92477641701 rdf:first _:807f36cf91fe4e8caa53aadeff92477641702;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641703 .

_:807f36cf91fe4e8caa53aadeff92477641702 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477641703 rdf:first _:807f36cf91fe4e8caa53aadeff92477641704;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641704 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10157 .

_:807f36cf91fe4e8caa53aadeff92477641706 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11063-1 a owl:Class;
  rdfs:label "IMAO-B <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_11063";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641708;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641714, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641708 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641709 .

_:807f36cf91fe4e8caa53aadeff92477641709 rdf:first _:807f36cf91fe4e8caa53aadeff92477641710;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641711 .

_:807f36cf91fe4e8caa53aadeff92477641710 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477641711 rdf:first _:807f36cf91fe4e8caa53aadeff92477641712;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477641714 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11064-1 a owl:Class;
  rdfs:label "IMAO-B <-> LEVODOPA"@fr;
  dct:identifier "IAM_11064";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641716;
  r:natureDuRisque "Augmentation du risque d'hypotension orthostatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641722, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641716 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641717 .

_:807f36cf91fe4e8caa53aadeff92477641717 rdf:first _:807f36cf91fe4e8caa53aadeff92477641718;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641719 .

_:807f36cf91fe4e8caa53aadeff92477641718 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477641719 rdf:first _:807f36cf91fe4e8caa53aadeff92477641720;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:807f36cf91fe4e8caa53aadeff92477641722 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11065-1 a owl:Class;
  rdfs:label "IMAO-B <-> PETHIDINE"@fr;
  dct:identifier "IAM_11065";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641724;
  r:natureDuRisque "Manifestations d'excitation centrale évoquant un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641730, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641724 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641725 .

_:807f36cf91fe4e8caa53aadeff92477641725 rdf:first _:807f36cf91fe4e8caa53aadeff92477641726;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641727 .

_:807f36cf91fe4e8caa53aadeff92477641726 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477641727 rdf:first _:807f36cf91fe4e8caa53aadeff92477641728;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10709 .

_:807f36cf91fe4e8caa53aadeff92477641730 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11066-1 a owl:Class;
  rdfs:label "IMAO-B <-> TRAMADOL"@fr;
  dct:identifier "IAM_11066";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641732;
  r:natureDuRisque "Risque d’apparition d’un syndrome sérotoninergique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641738, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641732 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641733 .

_:807f36cf91fe4e8caa53aadeff92477641733 rdf:first _:807f36cf91fe4e8caa53aadeff92477641734;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641735 .

_:807f36cf91fe4e8caa53aadeff92477641734 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477641735 rdf:first _:807f36cf91fe4e8caa53aadeff92477641736;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:807f36cf91fe4e8caa53aadeff92477641738 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11068-1 a owl:Class;
  rdfs:label "IMAO-B <-> TRIPTANS NON MÉTABOLISÉS PAR LA MAO"@fr;
  dct:identifier "IAM_11068";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641740;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641746, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641740 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641741 .

_:807f36cf91fe4e8caa53aadeff92477641741 rdf:first _:807f36cf91fe4e8caa53aadeff92477641742;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641743 .

_:807f36cf91fe4e8caa53aadeff92477641742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477641743 rdf:first _:807f36cf91fe4e8caa53aadeff92477641744;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477641746 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11067-1 a owl:Class;
  rdfs:label "IMAO-B <-> TRIPTANS MÉTABOLISÉS PAR LA MAO"@fr;
  dct:identifier "IAM_11067";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641748;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641754, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641748 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641749 .

_:807f36cf91fe4e8caa53aadeff92477641749 rdf:first _:807f36cf91fe4e8caa53aadeff92477641750;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641751 .

_:807f36cf91fe4e8caa53aadeff92477641750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477641751 rdf:first _:807f36cf91fe4e8caa53aadeff92477641752;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10157 .

_:807f36cf91fe4e8caa53aadeff92477641754 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11059-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_11059";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641756;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  r:conduiteATenir """Contre-indication :
avec le bupropion

Association déconseillée :
avec les autres sympathomimétiques indirects"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641762, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641756 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641757 .

_:807f36cf91fe4e8caa53aadeff92477641757 rdf:first _:807f36cf91fe4e8caa53aadeff92477641758;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641759 .

_:807f36cf91fe4e8caa53aadeff92477641758 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477641759 rdf:first _:807f36cf91fe4e8caa53aadeff92477641760;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477641762 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11069-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_11069";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641764;
  r:chapeau "Certains médicaments ont la propriété d'activer considérablement certaines voies métaboliques hépatiques par induction enzymatique. Associés à des médicaments fortement métabolisés au niveau du foie, ils sont, de ce fait, en mesure d'en modifier les conce"@fr;
  r:natureDuRisque "Diminution des concentrations sanguines et de l'efficacité de l'immunosuppresseur, par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Augmentation de la posologie de l'immunosuppresseur sous contrôle des concentrations sanguines. Réduction de la posologie après l'arrêt de l'inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641770, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641764 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641765 .

_:807f36cf91fe4e8caa53aadeff92477641765 rdf:first _:807f36cf91fe4e8caa53aadeff92477641766;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641767 .

_:807f36cf91fe4e8caa53aadeff92477641766 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477641767 rdf:first _:807f36cf91fe4e8caa53aadeff92477641768;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477641770 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11058-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> SYMPATHOMIMÉTIQUES ALPHA ET BÊTA (VOIE IM ET IV)"@fr;
  dct:identifier "IAM_11058";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641772;
  r:natureDuRisque "Par extrapolation à partir des IMAO non sélectifs : risque d'augmentation de l'action pressive."@fr;
  r:conduiteATenir "A n'utiliser que sous contrôle médical strict."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641778, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641772 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641773 .

_:807f36cf91fe4e8caa53aadeff92477641773 rdf:first _:807f36cf91fe4e8caa53aadeff92477641774;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641775 .

_:807f36cf91fe4e8caa53aadeff92477641774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477641775 rdf:first _:807f36cf91fe4e8caa53aadeff92477641776;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10149 .

_:807f36cf91fe4e8caa53aadeff92477641778 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11071-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_11071";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641780;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation éventuelle de la posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641786, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641780 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641781 .

_:807f36cf91fe4e8caa53aadeff92477641781 rdf:first _:807f36cf91fe4e8caa53aadeff92477641782;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641783 .

_:807f36cf91fe4e8caa53aadeff92477641782 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477641783 rdf:first _:807f36cf91fe4e8caa53aadeff92477641784;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477641786 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11072-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_11072";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641788;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation éventuelle de la posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641794, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641788 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641789 .

_:807f36cf91fe4e8caa53aadeff92477641789 rdf:first _:807f36cf91fe4e8caa53aadeff92477641790;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641791 .

_:807f36cf91fe4e8caa53aadeff92477641790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477641791 rdf:first _:807f36cf91fe4e8caa53aadeff92477641792;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477641794 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11073-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11073";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641796;
  r:natureDuRisque "Diminution des concentrations sanguines de l'immunosuppresseur, en raison de l'effet inducteur enzymatique du millepertuis, avec risque de baisse d'efficacité voire d'annulation de l'effet dont les conséquences peuvent être éventuellement graves (rejet de"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641802, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641796 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641797 .

_:807f36cf91fe4e8caa53aadeff92477641797 rdf:first _:807f36cf91fe4e8caa53aadeff92477641798;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641799 .

_:807f36cf91fe4e8caa53aadeff92477641798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477641799 rdf:first _:807f36cf91fe4e8caa53aadeff92477641800;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477641802 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11074-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> NICARDIPINE"@fr;
  dct:identifier "IAM_11074";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641804;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunodépresseur, par inhibition de son métabolisme."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de sa posologie pendant le traitement et après l'arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641810, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641804 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641805 .

_:807f36cf91fe4e8caa53aadeff92477641805 rdf:first _:807f36cf91fe4e8caa53aadeff92477641806;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641807 .

_:807f36cf91fe4e8caa53aadeff92477641806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477641807 rdf:first _:807f36cf91fe4e8caa53aadeff92477641808;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10630 .

_:807f36cf91fe4e8caa53aadeff92477641810 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11075-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_11075";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641812;
  r:chapeau "Le jus de pamplemousse peut augmenter la biodisponibilité de quelques médicaments, notamment certains immunosuppresseurs (ciclosporine, tacrolimus, sirolimus), les dihydropyridines, certaines statines et le cisapride. Les conséquences cliniques de ces int"@fr;
  r:natureDuRisque "Augmentation de la biodisponibilité de l’immunosuppresseur et par conséquent de ses effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641818, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641812 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641813 .

_:807f36cf91fe4e8caa53aadeff92477641813 rdf:first _:807f36cf91fe4e8caa53aadeff92477641814;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641815 .

_:807f36cf91fe4e8caa53aadeff92477641814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477641815 rdf:first _:807f36cf91fe4e8caa53aadeff92477641816;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477641818 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11076-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_11076";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641820;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation éventuelle de la posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641826, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641820 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641821 .

_:807f36cf91fe4e8caa53aadeff92477641821 rdf:first _:807f36cf91fe4e8caa53aadeff92477641822;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641823 .

_:807f36cf91fe4e8caa53aadeff92477641822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477641823 rdf:first _:807f36cf91fe4e8caa53aadeff92477641824;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477641826 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11077-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> PRISTINAMYCINE"@fr;
  dct:identifier "IAM_11077";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641828;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de sa posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641834, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641828 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641829 .

_:807f36cf91fe4e8caa53aadeff92477641829 rdf:first _:807f36cf91fe4e8caa53aadeff92477641830;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641831 .

_:807f36cf91fe4e8caa53aadeff92477641830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477641831 rdf:first _:807f36cf91fe4e8caa53aadeff92477641832;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10757 .

_:807f36cf91fe4e8caa53aadeff92477641834 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11093-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> MACITENTAN"@fr;
  dct:identifier "IAM_11093";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641836;
  r:natureDuRisque "Diminution des concentrations plasmatiques de macitentan par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641842, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641836 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641837 .

_:807f36cf91fe4e8caa53aadeff92477641837 rdf:first _:807f36cf91fe4e8caa53aadeff92477641838;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641839 .

_:807f36cf91fe4e8caa53aadeff92477641838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477641839 rdf:first _:807f36cf91fe4e8caa53aadeff92477641840;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10544 .

_:807f36cf91fe4e8caa53aadeff92477641842 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11094-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> MARAVIROC"@fr;
  dct:identifier "IAM_11094";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641844;
  r:natureDuRisque "En l’absence de co-administration avec un inhibiteur puissant du CYP3A4, diminution des concentrations de maraviroc par l’inducteur."@fr;
  r:conduiteATenir "La dose de maraviroc doit être augmentée à 600 mg deux fois par jour dans cette situation."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641850, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641844 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641845 .

_:807f36cf91fe4e8caa53aadeff92477641845 rdf:first _:807f36cf91fe4e8caa53aadeff92477641846;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641847 .

_:807f36cf91fe4e8caa53aadeff92477641846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477641847 rdf:first _:807f36cf91fe4e8caa53aadeff92477641848;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10551 .

_:807f36cf91fe4e8caa53aadeff92477641850 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10425-2 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS SÉDATIFS <-> MÉDICAMENTS SÉDATIFS"@fr;
  dct:identifier "IAM_10425";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641852;
  r:natureDuRisque """Majoration de la dépression centrale.
L'altération de la vigilance peut rendre dangereuses la conduite de véhicules et l'utilisation de machines."""@fr;
  r:conduiteATenir """Association déconseillée:
- avec l'oxybate de sodium.

A prendre en compte:
- avec les autres médicaments sédatifs."""@fr;
  rdfs:comment "A"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641854, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641852 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10120 .

_:807f36cf91fe4e8caa53aadeff92477641854 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11081-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> TELAPREVIR"@fr;
  dct:identifier "IAM_11081";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641856;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'immunosuppresseur par inhibition de son métabolisme hépatique par le télaprévir."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de sa posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641862, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641856 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641857 .

_:807f36cf91fe4e8caa53aadeff92477641857 rdf:first _:807f36cf91fe4e8caa53aadeff92477641858;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641859 .

_:807f36cf91fe4e8caa53aadeff92477641858 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477641859 rdf:first _:807f36cf91fe4e8caa53aadeff92477641860;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641860 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477641862 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11028-1 a owl:Class;
  rdfs:label "HYDROXYCHLOROQUINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11028";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641864;
  r:natureDuRisque "Risque de diminution de l'effet thérapeutique. de l’hydroxychloroquine, par augmentation de son métabolisme par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l’hydroxychloroquine pendant le traitement par rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641870, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641864 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641865 .

_:807f36cf91fe4e8caa53aadeff92477641865 rdf:first _:807f36cf91fe4e8caa53aadeff92477641866;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641867 .

_:807f36cf91fe4e8caa53aadeff92477641866 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10437 .

_:807f36cf91fe4e8caa53aadeff92477641867 rdf:first _:807f36cf91fe4e8caa53aadeff92477641868;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641868 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477641870 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10954-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> RIFABUTINE"@fr;
  dct:identifier "IAM_10954";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641872;
  r:natureDuRisque "Risque d'accroissement des effets indésirables de la rifabutine (uvéites), par augmentation de ses concentrations et de celles de son métabolite actif."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641878, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641872 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641873 .

_:807f36cf91fe4e8caa53aadeff92477641873 rdf:first _:807f36cf91fe4e8caa53aadeff92477641874;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641875 .

_:807f36cf91fe4e8caa53aadeff92477641874 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477641875 rdf:first _:807f36cf91fe4e8caa53aadeff92477641876;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641876 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff92477641878 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11018-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> RÉSINES CHÉLATRICES"@fr;
  dct:identifier "IAM_11018";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641880;
  r:natureDuRisque "Diminution de l'absorption digestive des hormones thyroïdiennes."@fr;
  r:conduiteATenir "Prendre les hormones thyroïdiennes à distance de la résine (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641886, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641880 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641881 .

_:807f36cf91fe4e8caa53aadeff92477641881 rdf:first _:807f36cf91fe4e8caa53aadeff92477641882;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641883 .

_:807f36cf91fe4e8caa53aadeff92477641882 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477641883 rdf:first _:807f36cf91fe4e8caa53aadeff92477641884;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641884 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477641886 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11019-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> RIFABUTINE"@fr;
  dct:identifier "IAM_11019";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641888;
  r:natureDuRisque "Décrit pour la phénytoïne, la rifampicine, la carbamazépine. Risque d'hypothyroïdie clinique chez les patients hypothyroïdiens, par augmentation du métabolisme de la T3 et de la T4."@fr;
  r:conduiteATenir "Surveillance des concentrations sériques de T3 et de T4 et adaptation, si besoin, de la posologie des hormones thyroïdiennes pendant le traitement par la rifabutine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641894, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641888 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641889 .

_:807f36cf91fe4e8caa53aadeff92477641889 rdf:first _:807f36cf91fe4e8caa53aadeff92477641890;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641891 .

_:807f36cf91fe4e8caa53aadeff92477641890 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477641891 rdf:first _:807f36cf91fe4e8caa53aadeff92477641892;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641892 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff92477641894 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11020-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11020";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641896;
  r:natureDuRisque "Risque d'hypothyroïdie clinique chez les patients hypothyroïdiens, par augmentation du métabolisme de la T3 et de la T4."@fr;
  r:conduiteATenir "Surveillance des concentrations sériques de T3 et de T4 et adaptation, si besoin, de la posologie des hormones thyroïdiennes pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641902, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641896 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641897 .

_:807f36cf91fe4e8caa53aadeff92477641897 rdf:first _:807f36cf91fe4e8caa53aadeff92477641898;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641899 .

_:807f36cf91fe4e8caa53aadeff92477641898 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477641899 rdf:first _:807f36cf91fe4e8caa53aadeff92477641900;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641900 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477641902 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11021-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> SUCRALFATE"@fr;
  dct:identifier "IAM_11021";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641904;
  r:natureDuRisque "Diminution de l'absorption digestive des hormones thyroïdiennes."@fr;
  r:conduiteATenir "Prendre les hormones thyroïdiennes à distance du sucralfate (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641910, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641904 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641905 .

_:807f36cf91fe4e8caa53aadeff92477641905 rdf:first _:807f36cf91fe4e8caa53aadeff92477641906;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641907 .

_:807f36cf91fe4e8caa53aadeff92477641906 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477641907 rdf:first _:807f36cf91fe4e8caa53aadeff92477641908;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641908 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10864 .

_:807f36cf91fe4e8caa53aadeff92477641910 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11022-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> SUNITINIB"@fr;
  dct:identifier "IAM_11022";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641912;
  r:natureDuRisque "Risque de baisse de l’efficacité des hormones thyroïdiennes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641918, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641912 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641913 .

_:807f36cf91fe4e8caa53aadeff92477641913 rdf:first _:807f36cf91fe4e8caa53aadeff92477641914;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641915 .

_:807f36cf91fe4e8caa53aadeff92477641914 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477641915 rdf:first _:807f36cf91fe4e8caa53aadeff92477641916;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641916 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10877 .

_:807f36cf91fe4e8caa53aadeff92477641918 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11023-1 a owl:Class;
  rdfs:label "HUILES MINÉRALES <-> PRÉSERVATIFS EN LATEX"@fr;
  dct:identifier "IAM_11023";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641920;
  r:natureDuRisque "Risque de rupture du préservatif lors de l'utilisation avec des corps gras ou des lubrifiants contenant des huiles minérales (huile de paraffine, huile de silicone, etc...)."@fr;
  r:conduiteATenir "Utiliser un lubrifiant hydrosoluble (glycérine, polyacrylamide...)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641926, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641920 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641921 .

_:807f36cf91fe4e8caa53aadeff92477641921 rdf:first _:807f36cf91fe4e8caa53aadeff92477641922;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641923 .

_:807f36cf91fe4e8caa53aadeff92477641922 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10083 .

_:807f36cf91fe4e8caa53aadeff92477641923 rdf:first _:807f36cf91fe4e8caa53aadeff92477641924;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641924 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10136 .

_:807f36cf91fe4e8caa53aadeff92477641926 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11024-1 a owl:Class;
  rdfs:label "HYDROCORTISONE <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_11024";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641928;
  r:natureDuRisque "Risque de diminution de l'efficacité de l'hydrocortisone (augmentation de son métabolisme) ; les conséquences sont graves lorsque l'hydrocortisone est administrée en traitement substitutif ou en cas de transplantation."@fr;
  r:conduiteATenir "Surveillance clinique et biologique ; adaptation de la posologie de l'hydrocortisone pendant l'association et après l'arrêt de l'inducteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641934, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641928 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641929 .

_:807f36cf91fe4e8caa53aadeff92477641929 rdf:first _:807f36cf91fe4e8caa53aadeff92477641930;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641931 .

_:807f36cf91fe4e8caa53aadeff92477641930 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477641931 rdf:first _:807f36cf91fe4e8caa53aadeff92477641932;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641932 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10432 .

_:807f36cf91fe4e8caa53aadeff92477641934 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11025-1 a owl:Class;
  rdfs:label "HYDROQUINIDINE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_11025";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641936;
  r:natureDuRisque "Risque d'acouphènes et/ou de diminution de l'acuité auditive : cinchonisme lié à une diminution du métabolisme hépatique de l'antiarythmique par l'itraconazole."@fr;
  r:conduiteATenir "Surveillance des concentrations plasmatiques de l'antiarythmique et diminution éventuelle de sa posologie si nécessaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641942, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641936 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641937 .

_:807f36cf91fe4e8caa53aadeff92477641937 rdf:first _:807f36cf91fe4e8caa53aadeff92477641938;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641939 .

_:807f36cf91fe4e8caa53aadeff92477641938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10434 .

_:807f36cf91fe4e8caa53aadeff92477641939 rdf:first _:807f36cf91fe4e8caa53aadeff92477641940;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641940 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477641942 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11060-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> TRAMADOL"@fr;
  dct:identifier "IAM_11060";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641944;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641950, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641944 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641945 .

_:807f36cf91fe4e8caa53aadeff92477641945 rdf:first _:807f36cf91fe4e8caa53aadeff92477641946;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641947 .

_:807f36cf91fe4e8caa53aadeff92477641946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477641947 rdf:first _:807f36cf91fe4e8caa53aadeff92477641948;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641948 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:807f36cf91fe4e8caa53aadeff92477641950 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11027-1 a owl:Class;
  rdfs:label "HYDROXYCHLOROQUINE <-> METOPROLOL"@fr;
  dct:identifier "IAM_11027";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641952;
  r:natureDuRisque "Avec le métoprolol utilisé dans l'insuffisance cardiaque : risque d'augmentation des effets indésirables du métoprolol par diminution de son métabolisme hépatique par l’hydroxychloroquine."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du métoprolol pendant le traitement par l’hydroxychloroquine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641958, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641952 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641953 .

_:807f36cf91fe4e8caa53aadeff92477641953 rdf:first _:807f36cf91fe4e8caa53aadeff92477641954;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641955 .

_:807f36cf91fe4e8caa53aadeff92477641954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10437 .

_:807f36cf91fe4e8caa53aadeff92477641955 rdf:first _:807f36cf91fe4e8caa53aadeff92477641956;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641956 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477641958 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11016-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> ORLISTAT"@fr;
  dct:identifier "IAM_11016";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641960;
  r:natureDuRisque "Risque de déséquilibre du traitement thyroïdien substitutif en cas de traitement par orlistat."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641966, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641960 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641961 .

_:807f36cf91fe4e8caa53aadeff92477641961 rdf:first _:807f36cf91fe4e8caa53aadeff92477641962;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641963 .

_:807f36cf91fe4e8caa53aadeff92477641962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477641963 rdf:first _:807f36cf91fe4e8caa53aadeff92477641964;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641964 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477641966 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11029-1 a owl:Class;
  rdfs:label "HYDROXYCHLOROQUINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11029";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641968;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication :
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641974, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641968 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641969 .

_:807f36cf91fe4e8caa53aadeff92477641969 rdf:first _:807f36cf91fe4e8caa53aadeff92477641970;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641971 .

_:807f36cf91fe4e8caa53aadeff92477641970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477641971 rdf:first _:807f36cf91fe4e8caa53aadeff92477641972;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641972 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10437 .

_:807f36cf91fe4e8caa53aadeff92477641974 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10414-1 a owl:Class;
  rdfs:label "AUTRES HYPERKALIÉMIANTS <-> HYPERKALIÉMIANTS"@fr;
  dct:identifier "IAM_10414";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641976;
  r:natureDuRisque "Risque de majoration de l’hyperkaliémie, potentiellement létale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641978, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10084 .

_:807f36cf91fe4e8caa53aadeff92477641978 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10415-1 a owl:Class;
  rdfs:label "AUTRES HYPNOTIQUES <-> HYPNOTIQUES"@fr;
  dct:identifier "IAM_10415";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641980;
  r:natureDuRisque "Majoration de la dépression centrale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641982, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641980 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10085 .

_:807f36cf91fe4e8caa53aadeff92477641982 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10416-1 a owl:Class;
  rdfs:label "AUTRES HYPOKALIÉMIANTS <-> HYPOKALIÉMIANTS"@fr;
  dct:identifier "IAM_10416";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641984;
  r:natureDuRisque "Risque majoré d'hypokaliémie."@fr;
  r:conduiteATenir "Surveillance de la kaliémie avec si besoin correction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641986, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10086 .

_:807f36cf91fe4e8caa53aadeff92477641986 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11030-1 a owl:Class;
  rdfs:label "HYPOKALIÉMIANTS <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11030";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641988;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Corriger toute hypokaliémie avant d’administrer le produit et réaliser une surveillance clinique, électrolytique et électrocardiographique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477641994, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641988 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641989 .

_:807f36cf91fe4e8caa53aadeff92477641989 rdf:first _:807f36cf91fe4e8caa53aadeff92477641990;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641991 .

_:807f36cf91fe4e8caa53aadeff92477641990 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10086 .

_:807f36cf91fe4e8caa53aadeff92477641991 rdf:first _:807f36cf91fe4e8caa53aadeff92477641992;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477641992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477641994 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11042-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11042";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477641996;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642002, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477641996 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477641997 .

_:807f36cf91fe4e8caa53aadeff92477641997 rdf:first _:807f36cf91fe4e8caa53aadeff92477641998;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477641999 .

_:807f36cf91fe4e8caa53aadeff92477641998 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477641999 rdf:first _:807f36cf91fe4e8caa53aadeff92477642000;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477642002 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11043-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> PETHIDINE"@fr;
  dct:identifier "IAM_11043";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642004;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642010, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642004 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642005 .

_:807f36cf91fe4e8caa53aadeff92477642005 rdf:first _:807f36cf91fe4e8caa53aadeff92477642006;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642007 .

_:807f36cf91fe4e8caa53aadeff92477642006 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477642007 rdf:first _:807f36cf91fe4e8caa53aadeff92477642008;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10709 .

_:807f36cf91fe4e8caa53aadeff92477642010 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11044-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> RESERPINE"@fr;
  dct:identifier "IAM_11044";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642012;
  r:natureDuRisque "Agitation psychomotrice, convulsions, hypertension."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642018, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642012 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642013 .

_:807f36cf91fe4e8caa53aadeff92477642013 rdf:first _:807f36cf91fe4e8caa53aadeff92477642014;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642015 .

_:807f36cf91fe4e8caa53aadeff92477642014 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477642015 rdf:first _:807f36cf91fe4e8caa53aadeff92477642016;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10792 .

_:807f36cf91fe4e8caa53aadeff92477642018 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11056-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11056";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642020;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642026, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642020 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642021 .

_:807f36cf91fe4e8caa53aadeff92477642021 rdf:first _:807f36cf91fe4e8caa53aadeff92477642022;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642023 .

_:807f36cf91fe4e8caa53aadeff92477642022 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477642023 rdf:first _:807f36cf91fe4e8caa53aadeff92477642024;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477642026 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_11057-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> PETHIDINE"@fr;
  dct:identifier "IAM_11057";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642028;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642034, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642028 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642029 .

_:807f36cf91fe4e8caa53aadeff92477642029 rdf:first _:807f36cf91fe4e8caa53aadeff92477642030;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642031 .

_:807f36cf91fe4e8caa53aadeff92477642030 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477642031 rdf:first _:807f36cf91fe4e8caa53aadeff92477642032;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10709 .

_:807f36cf91fe4e8caa53aadeff92477642034 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11026-1 a owl:Class;
  rdfs:label "HYDROXYCARBAMIDE <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_11026";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642036;
  r:natureDuRisque "Dans son indication chez le patient drépanocytaire, risque théorique de maladie vaccinale généralisée."@fr;
  r:conduiteATenir """L'association ne devra être envisagée que si les bénéfices sont estimés comme étant supérieurs à ce risque. 
S'il est décidé d’interrompre le traitement par hydroxycarbamide pour effectuer la vaccination, un délai de 3 mois après l’arrêt est recommandé."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642042, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642036 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642037 .

_:807f36cf91fe4e8caa53aadeff92477642037 rdf:first _:807f36cf91fe4e8caa53aadeff92477642038;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642039 .

_:807f36cf91fe4e8caa53aadeff92477642038 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477642039 rdf:first _:807f36cf91fe4e8caa53aadeff92477642040;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10436 .

_:807f36cf91fe4e8caa53aadeff92477642042 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10876-1 a owl:Class;
  rdfs:label "ELVITÉGRAVIR <-> RIFABUTINE"@fr;
  dct:identifier "IAM_10876";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642044;
  r:natureDuRisque "Diminution des concentrations minimales d’elvitégravir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642050, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642044 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642045 .

_:807f36cf91fe4e8caa53aadeff92477642045 rdf:first _:807f36cf91fe4e8caa53aadeff92477642046;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642047 .

_:807f36cf91fe4e8caa53aadeff92477642046 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10321 .

_:807f36cf91fe4e8caa53aadeff92477642047 rdf:first _:807f36cf91fe4e8caa53aadeff92477642048;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff92477642050 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10897-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10897";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642052;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642058, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642052 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642053 .

_:807f36cf91fe4e8caa53aadeff92477642053 rdf:first _:807f36cf91fe4e8caa53aadeff92477642054;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642055 .

_:807f36cf91fe4e8caa53aadeff92477642054 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477642055 rdf:first _:807f36cf91fe4e8caa53aadeff92477642056;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477642058 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10866-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> FOSAMPRENAVIR"@fr;
  dct:identifier "IAM_10866";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642060;
  r:natureDuRisque "Risque de baisse de l'efficacité de l'amprénavir."@fr;
  r:conduiteATenir """Surveillance clinique et biologique régulière, notamment en début
d'association."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642066, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642060 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642061 .

_:807f36cf91fe4e8caa53aadeff92477642061 rdf:first _:807f36cf91fe4e8caa53aadeff92477642062;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642063 .

_:807f36cf91fe4e8caa53aadeff92477642062 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477642063 rdf:first _:807f36cf91fe4e8caa53aadeff92477642064;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10400 .

_:807f36cf91fe4e8caa53aadeff92477642066 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10867-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> INDINAVIR"@fr;
  dct:identifier "IAM_10867";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642068;
  r:natureDuRisque "Risque de baisse de l'efficacité de l'indinavir."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642074, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642068 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642069 .

_:807f36cf91fe4e8caa53aadeff92477642069 rdf:first _:807f36cf91fe4e8caa53aadeff92477642070;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642071 .

_:807f36cf91fe4e8caa53aadeff92477642070 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477642071 rdf:first _:807f36cf91fe4e8caa53aadeff92477642072;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10455 .

_:807f36cf91fe4e8caa53aadeff92477642074 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10868-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> PIMOZIDE"@fr;
  dct:identifier "IAM_10868";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642076;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642082, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642076 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642077 .

_:807f36cf91fe4e8caa53aadeff92477642077 rdf:first _:807f36cf91fe4e8caa53aadeff92477642078;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642079 .

_:807f36cf91fe4e8caa53aadeff92477642078 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477642079 rdf:first _:807f36cf91fe4e8caa53aadeff92477642080;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477642082 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10869-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> RIFABUTINE"@fr;
  dct:identifier "IAM_10869";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642084;
  r:natureDuRisque "Diminution d’environ la moitié des concentrations de rifabutine, par augmentation de son métabolisme hépatique par l’éfavirenz."@fr;
  r:conduiteATenir "Adaptation de la posologie de la rifabutine pendant le traitement par efavirenz."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642090, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642084 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642085 .

_:807f36cf91fe4e8caa53aadeff92477642085 rdf:first _:807f36cf91fe4e8caa53aadeff92477642086;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642087 .

_:807f36cf91fe4e8caa53aadeff92477642086 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477642087 rdf:first _:807f36cf91fe4e8caa53aadeff92477642088;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff92477642090 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10870-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10870";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642092;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de l'éfavirenz par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642098, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642092 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642093 .

_:807f36cf91fe4e8caa53aadeff92477642093 rdf:first _:807f36cf91fe4e8caa53aadeff92477642094;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642095 .

_:807f36cf91fe4e8caa53aadeff92477642094 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477642095 rdf:first _:807f36cf91fe4e8caa53aadeff92477642096;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477642098 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10871-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10871";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642100;
  r:natureDuRisque "Risque de baisse de l'efficacité du voriconazole par augmentation de son métabolisme hépatique par l'efavirenz."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite et adaptation de la posologie du voriconazole et de l'éfavirenz pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642106, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642100 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642101 .

_:807f36cf91fe4e8caa53aadeff92477642101 rdf:first _:807f36cf91fe4e8caa53aadeff92477642102;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642103 .

_:807f36cf91fe4e8caa53aadeff92477642102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477642103 rdf:first _:807f36cf91fe4e8caa53aadeff92477642104;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477642106 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10872-1 a owl:Class;
  rdfs:label "ELTROMBOPAG <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10872";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642108;
  r:natureDuRisque "Risque de majoration de la toxicité des statines, par inhibition de leur recapture hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la statine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642114, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642108 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642109 .

_:807f36cf91fe4e8caa53aadeff92477642109 rdf:first _:807f36cf91fe4e8caa53aadeff92477642110;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642111 .

_:807f36cf91fe4e8caa53aadeff92477642110 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff92477642111 rdf:first _:807f36cf91fe4e8caa53aadeff92477642112;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10320 .

_:807f36cf91fe4e8caa53aadeff92477642114 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10873-1 a owl:Class;
  rdfs:label "ELVITÉGRAVIR <-> ESTROPROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10873";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642116;
  r:natureDuRisque "Diminution des concentrations d’éthinylestradiol, avec risque de moindre efficacité contraceptive. De plus, augmentation des concentrations du progestatif."@fr;
  r:conduiteATenir "Utiliser un estroprogestatif contraceptif avec au moins 30 µg d’éthinylestradiol."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642122, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642116 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642117 .

_:807f36cf91fe4e8caa53aadeff92477642117 rdf:first _:807f36cf91fe4e8caa53aadeff92477642118;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642119 .

_:807f36cf91fe4e8caa53aadeff92477642118 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477642119 rdf:first _:807f36cf91fe4e8caa53aadeff92477642120;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10321 .

_:807f36cf91fe4e8caa53aadeff92477642122 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10864-1 a owl:Class;
  rdfs:label "EBASTINE <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10864";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642124;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire chez les sujets prédisposés (syndrome du QT long congénital)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642130, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642124 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642125 .

_:807f36cf91fe4e8caa53aadeff92477642125 rdf:first _:807f36cf91fe4e8caa53aadeff92477642126;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642127 .

_:807f36cf91fe4e8caa53aadeff92477642126 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10316 .

_:807f36cf91fe4e8caa53aadeff92477642127 rdf:first _:807f36cf91fe4e8caa53aadeff92477642128;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477642130 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10875-1 a owl:Class;
  rdfs:label "ELVITÉGRAVIR <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10875";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642132;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’elvitegravir par diminution de son métabolisme par le kétoconazole."@fr;
  r:conduiteATenir "Avec l’elvitegravir co-administré avec le cobicistat, surveillance clinique. Limiter la dose maximale de kétoconazole à 200 mg/j."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642138, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642132 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642133 .

_:807f36cf91fe4e8caa53aadeff92477642133 rdf:first _:807f36cf91fe4e8caa53aadeff92477642134;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642135 .

_:807f36cf91fe4e8caa53aadeff92477642134 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10321 .

_:807f36cf91fe4e8caa53aadeff92477642135 rdf:first _:807f36cf91fe4e8caa53aadeff92477642136;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477642138 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10863-1 a owl:Class;
  rdfs:label "EBASTINE <-> JOSAMYCINE"@fr;
  dct:identifier "IAM_10863";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642140;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire chez les sujets prédisposés (syndrome du QT long, congénital)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642146, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642140 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642141 .

_:807f36cf91fe4e8caa53aadeff92477642141 rdf:first _:807f36cf91fe4e8caa53aadeff92477642142;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642143 .

_:807f36cf91fe4e8caa53aadeff92477642142 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10316 .

_:807f36cf91fe4e8caa53aadeff92477642143 rdf:first _:807f36cf91fe4e8caa53aadeff92477642144;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477642146 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10877-1 a owl:Class;
  rdfs:label "ENOXACINE <-> ROPINIROLE"@fr;
  dct:identifier "IAM_10877";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642148;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de ropinirole avec signes de surdosage par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du ropinirole pendant le traitement par l'énoxacine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642154, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642148 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642149 .

_:807f36cf91fe4e8caa53aadeff92477642149 rdf:first _:807f36cf91fe4e8caa53aadeff92477642150;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642151 .

_:807f36cf91fe4e8caa53aadeff92477642150 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10323 .

_:807f36cf91fe4e8caa53aadeff92477642151 rdf:first _:807f36cf91fe4e8caa53aadeff92477642152;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10813 .

_:807f36cf91fe4e8caa53aadeff92477642154 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10878-1 a owl:Class;
  rdfs:label "ENOXACINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10878";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642156;
  r:natureDuRisque "Surdosage en théophylline par diminution importante de son métabolisme."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642162, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642156 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642157 .

_:807f36cf91fe4e8caa53aadeff92477642157 rdf:first _:807f36cf91fe4e8caa53aadeff92477642158;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642159 .

_:807f36cf91fe4e8caa53aadeff92477642158 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477642159 rdf:first _:807f36cf91fe4e8caa53aadeff92477642160;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10323 .

_:807f36cf91fe4e8caa53aadeff92477642162 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10879-1 a owl:Class;
  rdfs:label "ENTACAPONE <-> FER"@fr;
  dct:identifier "IAM_10879";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642164;
  r:natureDuRisque "Diminution de l'absorption digestive de l'entacapone et du fer par chélation de celui-ci par l'entacapone."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance de l'entacapone (plus de 2 heures si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642170, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642164 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642165 .

_:807f36cf91fe4e8caa53aadeff92477642165 rdf:first _:807f36cf91fe4e8caa53aadeff92477642166;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642167 .

_:807f36cf91fe4e8caa53aadeff92477642166 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10325 .

_:807f36cf91fe4e8caa53aadeff92477642167 rdf:first _:807f36cf91fe4e8caa53aadeff92477642168;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477642170 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10880-1 a owl:Class;
  rdfs:label "ENZALUTAMIDE <-> GEMFIBROZIL"@fr;
  dct:identifier "IAM_10880";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642172;
  r:natureDuRisque "Majoration de la fraction active de l’enzalutamide."@fr;
  r:conduiteATenir "Réduire la dose d’enzalutamide par deux en cas d’association au gemfibrozil."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642178, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642172 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642173 .

_:807f36cf91fe4e8caa53aadeff92477642173 rdf:first _:807f36cf91fe4e8caa53aadeff92477642174;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642175 .

_:807f36cf91fe4e8caa53aadeff92477642174 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10326 .

_:807f36cf91fe4e8caa53aadeff92477642175 rdf:first _:807f36cf91fe4e8caa53aadeff92477642176;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10411 .

_:807f36cf91fe4e8caa53aadeff92477642178 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10881-1 a owl:Class;
  rdfs:label "EPLERENONE <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10881";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642180;
  r:natureDuRisque "Majoration du risque d’hyperkaliémie, notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Contrôle strict de la kaliémie et de la fonction rénale pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642186, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642180 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642181 .

_:807f36cf91fe4e8caa53aadeff92477642181 rdf:first _:807f36cf91fe4e8caa53aadeff92477642182;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642183 .

_:807f36cf91fe4e8caa53aadeff92477642182 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477642183 rdf:first _:807f36cf91fe4e8caa53aadeff92477642184;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10329 .

_:807f36cf91fe4e8caa53aadeff92477642186 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10891-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> GLIMEPIRIDE"@fr;
  dct:identifier "IAM_10891";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642188;
  r:natureDuRisque "Risque d'hypoglycémie par augmentation de l’absorption et des concentrations plasmatiques de l’antidiabétique."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide hypoglycémiant pendant le traitement par l’érythromycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642194, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642188 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642189 .

_:807f36cf91fe4e8caa53aadeff92477642189 rdf:first _:807f36cf91fe4e8caa53aadeff92477642190;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642191 .

_:807f36cf91fe4e8caa53aadeff92477642190 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477642191 rdf:first _:807f36cf91fe4e8caa53aadeff92477642192;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10416 .

_:807f36cf91fe4e8caa53aadeff92477642194 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10892-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10892";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642196;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation éventuelle de la posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642202, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642196 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642197 .

_:807f36cf91fe4e8caa53aadeff92477642197 rdf:first _:807f36cf91fe4e8caa53aadeff92477642198;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642199 .

_:807f36cf91fe4e8caa53aadeff92477642198 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477642199 rdf:first _:807f36cf91fe4e8caa53aadeff92477642200;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477642202 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10894-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> MIZOLASTINE"@fr;
  dct:identifier "IAM_10894";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642204;
  r:natureDuRisque "Risque de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642210, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642204 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642205 .

_:807f36cf91fe4e8caa53aadeff92477642205 rdf:first _:807f36cf91fe4e8caa53aadeff92477642206;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642207 .

_:807f36cf91fe4e8caa53aadeff92477642206 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477642207 rdf:first _:807f36cf91fe4e8caa53aadeff92477642208;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10597 .

_:807f36cf91fe4e8caa53aadeff92477642210 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10895-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_10895";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642212;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par l'érythromycine."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642218, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642212 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642213 .

_:807f36cf91fe4e8caa53aadeff92477642213 rdf:first _:807f36cf91fe4e8caa53aadeff92477642214;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642215 .

_:807f36cf91fe4e8caa53aadeff92477642214 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477642215 rdf:first _:807f36cf91fe4e8caa53aadeff92477642216;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477642218 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10956-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> RIVAROXABAN"@fr;
  dct:identifier "IAM_10956";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642220;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du rivaroxaban par le fluconazole, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642226, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642220 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642221 .

_:807f36cf91fe4e8caa53aadeff92477642221 rdf:first _:807f36cf91fe4e8caa53aadeff92477642222;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642223 .

_:807f36cf91fe4e8caa53aadeff92477642222 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477642223 rdf:first _:807f36cf91fe4e8caa53aadeff92477642224;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10808 .

_:807f36cf91fe4e8caa53aadeff92477642226 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10874-1 a owl:Class;
  rdfs:label "ELVITÉGRAVIR <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10874";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642228;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’elvitegravir par diminution de son métabolisme par l'itraconazole."@fr;
  r:conduiteATenir "Avec l’elvitegravir co-administré avec le cobicistat, surveillance clinique. Limiter la dose maximale d’itraconazole à 200 mg/j."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642234, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642228 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642229 .

_:807f36cf91fe4e8caa53aadeff92477642229 rdf:first _:807f36cf91fe4e8caa53aadeff92477642230;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642231 .

_:807f36cf91fe4e8caa53aadeff92477642230 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10321 .

_:807f36cf91fe4e8caa53aadeff92477642231 rdf:first _:807f36cf91fe4e8caa53aadeff92477642232;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477642234 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10177-2 a owl:Class;
  rdfs:label "ANTAGONISTES DES CANAUX CALCIQUES <-> ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10177";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642236;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antagoniste du calcium par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Association déconseillée avec la nimodipine"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642242, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642236 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642237 .

_:807f36cf91fe4e8caa53aadeff92477642237 rdf:first _:807f36cf91fe4e8caa53aadeff92477642238;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642239 .

_:807f36cf91fe4e8caa53aadeff92477642238 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10019 .

_:807f36cf91fe4e8caa53aadeff92477642239 rdf:first _:807f36cf91fe4e8caa53aadeff92477642240;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642240 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477642242 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11096-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> MIANSERINE"@fr;
  dct:identifier "IAM_11096";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642244;
  r:natureDuRisque "Risque d’inefficacité de la miansérine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642250, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642244 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642245 .

_:807f36cf91fe4e8caa53aadeff92477642245 rdf:first _:807f36cf91fe4e8caa53aadeff92477642246;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642247 .

_:807f36cf91fe4e8caa53aadeff92477642246 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477642247 rdf:first _:807f36cf91fe4e8caa53aadeff92477642248;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642248 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10583 .

_:807f36cf91fe4e8caa53aadeff92477642250 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11208-1 a owl:Class;
  rdfs:label "IVABRADINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11208";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642252;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l’ivabradine et de ses effets indésirables, notamment cardiaques (inhibition de son métabolisme hépatique par le vérapamil), qui s’ajoutent aux effets bradycardisants de ces substances."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642258, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642252 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642253 .

_:807f36cf91fe4e8caa53aadeff92477642253 rdf:first _:807f36cf91fe4e8caa53aadeff92477642254;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642255 .

_:807f36cf91fe4e8caa53aadeff92477642254 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:807f36cf91fe4e8caa53aadeff92477642255 rdf:first _:807f36cf91fe4e8caa53aadeff92477642256;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642256 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477642258 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11209-1 a owl:Class;
  rdfs:label "JOSAMYCINE <-> PIMOZIDE"@fr;
  dct:identifier "IAM_11209";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642260;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642266, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642260 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642261 .

_:807f36cf91fe4e8caa53aadeff92477642261 rdf:first _:807f36cf91fe4e8caa53aadeff92477642262;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642263 .

_:807f36cf91fe4e8caa53aadeff92477642262 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477642263 rdf:first _:807f36cf91fe4e8caa53aadeff92477642264;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642264 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477642266 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10017-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> CLOPIDOGREL"@fr;
  dct:identifier "IAM_10017";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642268;
  r:natureDuRisque "Majoration du risque hémorragique par addition des activités antiagrégantes plaquettaires."@fr;
  r:conduiteATenir """Association déconseillée :
- en dehors des indications validées pour cette association dans les syndromes coronariens aigus.

Précaution d'emploi :
- dans les indications validées pour cette association dans les syndromes coronariens aigus. Surveillance c"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642274, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642268 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642269 .

_:807f36cf91fe4e8caa53aadeff92477642269 rdf:first _:807f36cf91fe4e8caa53aadeff92477642270;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642271 .

_:807f36cf91fe4e8caa53aadeff92477642270 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477642271 rdf:first _:807f36cf91fe4e8caa53aadeff92477642272;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642272 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10216 .

_:807f36cf91fe4e8caa53aadeff92477642274 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10279-2 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> PEMETREXED"@fr;
  dct:identifier "IAM_10279";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642276;
  r:natureDuRisque "Risque de majoration de la toxicité du pemetrexed (diminution de sa clairance rénale par les AINS)."@fr;
  r:conduiteATenir """Association déconseillée : 
- en cas de fonction rénale faible à modérée.

Précaution d'emploi :
- en cas de fonction rénale normale. Surveillance biologique de la fonction rénale."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642282, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642276 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642277 .

_:807f36cf91fe4e8caa53aadeff92477642277 rdf:first _:807f36cf91fe4e8caa53aadeff92477642278;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642279 .

_:807f36cf91fe4e8caa53aadeff92477642278 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477642279 rdf:first _:807f36cf91fe4e8caa53aadeff92477642280;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642280 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10700 .

_:807f36cf91fe4e8caa53aadeff92477642282 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11164-2 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> QUININE"@fr;
  dct:identifier "IAM_11164";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642284;
  r:natureDuRisque "Risque de majoration des effets indésirables de la quinine, notamment troubles du rythme ventriculaire et troubles neurosensoriels (cinchonisme)."@fr;
  r:conduiteATenir """Association déconseillée : 
- avec les inhibiteurs de protéases

Précaution d’emploi : 
- avec les azolés antifongiques et certains macrolides.
Surveillance clinique et ECG. Adaptation éventuelle de la posologie de la quinine pendant le traitement par l’i"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642290, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642284 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642285 .

_:807f36cf91fe4e8caa53aadeff92477642285 rdf:first _:807f36cf91fe4e8caa53aadeff92477642286;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642287 .

_:807f36cf91fe4e8caa53aadeff92477642286 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477642287 rdf:first _:807f36cf91fe4e8caa53aadeff92477642288;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642288 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10777 .

_:807f36cf91fe4e8caa53aadeff92477642290 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10130-2 a owl:Class;
  rdfs:label "AMIODARONE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10130";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642292;
  r:natureDuRisque """Pour diltiazem voie injectable : risque de bradycardie et de bloc auriculo-ventriculaire

Pour diltiazem per os : risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez les personnes âgées."""@fr;
  r:conduiteATenir """Association déconseillée avec :
- le diltiazem IV
Si l'association ne peut être évitée, surveillance clinique et ECG continu."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642298, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642292 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642293 .

_:807f36cf91fe4e8caa53aadeff92477642293 rdf:first _:807f36cf91fe4e8caa53aadeff92477642294;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642295 .

_:807f36cf91fe4e8caa53aadeff92477642294 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477642295 rdf:first _:807f36cf91fe4e8caa53aadeff92477642296;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642296 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477642298 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10698-2 a owl:Class;
  rdfs:label "CYPROTERONE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10698";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642300;
  r:natureDuRisque "Risque de diminution de l'efficacité de la cyprotérone."@fr;
  r:conduiteATenir """Association déconseillée
- dans son utilisation comme contraceptif hormonal: utiliser de préférence une autre méthode de contraception en particulier de type mécanique, pendant la durée de l'association et un cycle suivant.

Précaution d'emploi
- dans ses"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642306, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642300 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642301 .

_:807f36cf91fe4e8caa53aadeff92477642301 rdf:first _:807f36cf91fe4e8caa53aadeff92477642302;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642303 .

_:807f36cf91fe4e8caa53aadeff92477642302 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477642303 rdf:first _:807f36cf91fe4e8caa53aadeff92477642304;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642304 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff92477642306 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10911-2 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> LAMOTRIGINE"@fr;
  dct:identifier "IAM_10911";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642308;
  r:natureDuRisque "Risque de diminution des concentrations et de l’efficacité de la lamotrigine par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir """Association déconseillée :
- éviter de mettre en route une contraception orale pendant la période d’ajustement posologique de la lamotrigine."""@fr;
  rdfs:comment """Deux publications d'une même équipe montrent que les contraceptifs oraux (COs) diminuent de près de moitié les concentrations plasmatiques de la lamotrigine. Le mécanisme passerait par une induction de la glucuronidation de la lamotrigine par les COs.
Dan"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642314, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642308 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642309 .

_:807f36cf91fe4e8caa53aadeff92477642309 rdf:first _:807f36cf91fe4e8caa53aadeff92477642310;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642311 .

_:807f36cf91fe4e8caa53aadeff92477642310 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477642311 rdf:first _:807f36cf91fe4e8caa53aadeff92477642312;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642312 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:807f36cf91fe4e8caa53aadeff92477642314 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10865-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> ERGOTAMINE"@fr;
  dct:identifier "IAM_10865";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642316;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642322, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642316 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642317 .

_:807f36cf91fe4e8caa53aadeff92477642317 rdf:first _:807f36cf91fe4e8caa53aadeff92477642318;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642319 .

_:807f36cf91fe4e8caa53aadeff92477642318 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477642319 rdf:first _:807f36cf91fe4e8caa53aadeff92477642320;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642320 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:807f36cf91fe4e8caa53aadeff92477642322 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10836-2 a owl:Class;
  rdfs:label "DOLUTÉGRAVIR <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10836";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642324;
  r:natureDuRisque "Diminution des concentrations plasmatiques de dolutégravir par augmentation de son métabolisme par l’inducteur."@fr;
  r:conduiteATenir """Association déconseillée :
- en cas de résistance à la classe des inhibiteurs d'intégrase

Précaution d'emploi :
- en l'absence de résistance à la classe des inhibiteurs d'intégrase
Adaptation de la posologie de dolutégravir à 50 mg 2 fois par jour penda"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642330, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642324 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642325 .

_:807f36cf91fe4e8caa53aadeff92477642325 rdf:first _:807f36cf91fe4e8caa53aadeff92477642326;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642327 .

_:807f36cf91fe4e8caa53aadeff92477642326 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477642327 rdf:first _:807f36cf91fe4e8caa53aadeff92477642328;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642328 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10301 .

_:807f36cf91fe4e8caa53aadeff92477642330 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10898-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10898";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642332;
  r:natureDuRisque "Surdosage en théophylline par diminution de son élimination hépatique, plus particulièrement à risque chez l'enfant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642338, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642332 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642333 .

_:807f36cf91fe4e8caa53aadeff92477642333 rdf:first _:807f36cf91fe4e8caa53aadeff92477642334;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642335 .

_:807f36cf91fe4e8caa53aadeff92477642334 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477642335 rdf:first _:807f36cf91fe4e8caa53aadeff92477642336;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642336 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477642338 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10031-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> TICAGRELOR"@fr;
  dct:identifier "IAM_10031";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642340;
  r:natureDuRisque """Majoration du risque hémorragique par addition des activités
antiagrégantes plaquettaires."""@fr;
  r:conduiteATenir """Association déconseillée :
- en dehors des indications validées pour cette association dans les syndromes coronariens aigus.

Précaution d'emploi :
- dans les indications validées pour cette association dans les syndromes coronariens aigus. Surveillance c"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642346, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642340 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642341 .

_:807f36cf91fe4e8caa53aadeff92477642341 rdf:first _:807f36cf91fe4e8caa53aadeff92477642342;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642343 .

_:807f36cf91fe4e8caa53aadeff92477642342 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477642343 rdf:first _:807f36cf91fe4e8caa53aadeff92477642344;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642344 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477642346 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10801-2 a owl:Class;
  rdfs:label "DILTIAZEM <-> ESMOLOL"@fr;
  dct:identifier "IAM_10801";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642348;
  r:natureDuRisque "Troubles de l'automatisme (bradycardie excessive, arrêt sinusal), troubles de la conduction sino-auriculaire et auriculo-ventriculaire et défaillance cardiaque."@fr;
  r:conduiteATenir """Association déconseillée :
- en cas d'altération de la fonction ventriculaire gauche."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642354, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642348 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642349 .

_:807f36cf91fe4e8caa53aadeff92477642349 rdf:first _:807f36cf91fe4e8caa53aadeff92477642350;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642351 .

_:807f36cf91fe4e8caa53aadeff92477642350 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477642351 rdf:first _:807f36cf91fe4e8caa53aadeff92477642352;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642352 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:807f36cf91fe4e8caa53aadeff92477642354 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10028-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> PEMETREXED"@fr;
  dct:identifier "IAM_10028";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642356;
  r:natureDuRisque "Risque de majoration de la toxicité du pemetrexed (diminution de sa clairance rénale par l’acide acétylsalicylique à doses anti-inflammatoires)."@fr;
  r:conduiteATenir """Association déconseillée : 
- en cas de fonction rénale faible à modérée .

Précaution d'emploi :
- en cas de fonction rénale normale. Surveillance biologique de la fonction rénale."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642362, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642356 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642357 .

_:807f36cf91fe4e8caa53aadeff92477642357 rdf:first _:807f36cf91fe4e8caa53aadeff92477642358;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642359 .

_:807f36cf91fe4e8caa53aadeff92477642358 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477642359 rdf:first _:807f36cf91fe4e8caa53aadeff92477642360;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642360 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10700 .

_:807f36cf91fe4e8caa53aadeff92477642362 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10016-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANTI-INFLAMMATOIRES NON STÉROÏDIENS"@fr;
  dct:identifier "IAM_10016";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642364;
  r:natureDuRisque "Majoration du risque ulcérogène et hémorragique digestif."@fr;
  r:conduiteATenir """Association déconseillée avec :
- des doses anti-inflammatoires d'acide acétylsalicylique (>=1g par prise et/ou >=3g par jour)
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour)"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642370, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642364 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642365 .

_:807f36cf91fe4e8caa53aadeff92477642365 rdf:first _:807f36cf91fe4e8caa53aadeff92477642366;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642367 .

_:807f36cf91fe4e8caa53aadeff92477642366 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477642367 rdf:first _:807f36cf91fe4e8caa53aadeff92477642368;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642368 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477642370 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10253-2 a owl:Class;
  rdfs:label "ANTICORPS MONOCLONAUX (HORS ANTI-TNF ALPHA) <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10253";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642372;
  r:natureDuRisque "Risque de maladie vaccinale généralisée, éventuellement mortelle."@fr;
  r:conduiteATenir """Association déconseillée avec :
- bélimumab, blinatumomab, canakinumab, obinutuzumab, ofatumumab, rituximab, tocilizumab, ustékinumab 

A prendre en compte avec :
- alemtuzumab, bevacizumab, brentuximab, cetuximab, daratumumab, dénosumab, ibritumomab, ipi"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642378, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642372 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642373 .

_:807f36cf91fe4e8caa53aadeff92477642373 rdf:first _:807f36cf91fe4e8caa53aadeff92477642374;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642375 .

_:807f36cf91fe4e8caa53aadeff92477642374 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10031 .

_:807f36cf91fe4e8caa53aadeff92477642375 rdf:first _:807f36cf91fe4e8caa53aadeff92477642376;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642376 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477642378 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10730-2 a owl:Class;
  rdfs:label "DAPOXÉTINE <-> MÉDICAMENTS À L'ORIGINE D'UNE HYPOTENSION ORTHOSTATIQUE"@fr;
  dct:identifier "IAM_10730";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642380;
  r:natureDuRisque "Risque de majoration des effets indésirables, notamment à type de vertiges ou de syncopes."@fr;
  r:conduiteATenir """Association déconseillée
- avec les inhibiteurs de la phosphodiestérase de type 5

A prendre en compte 
- avec les autres classes thérapeutiques"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642386, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642380 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642381 .

_:807f36cf91fe4e8caa53aadeff92477642381 rdf:first _:807f36cf91fe4e8caa53aadeff92477642382;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642383 .

_:807f36cf91fe4e8caa53aadeff92477642382 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10122 .

_:807f36cf91fe4e8caa53aadeff92477642383 rdf:first _:807f36cf91fe4e8caa53aadeff92477642384;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642384 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10250 .

_:807f36cf91fe4e8caa53aadeff92477642386 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10701-2 a owl:Class;
  rdfs:label "CYPROTERONE <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_10701";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642388;
  r:natureDuRisque """Dans l'indication contraception d'urgence de l'ulipristal :
Antagonisme des effets de l’ulipristal en cas de reprise d’un contraceptif hormonal moins de 5 jours après la prise de la contraception d’urgence.

Dans l’indication fibrome de l'ulipristal :
Ant"""@fr;
  r:conduiteATenir """Association déconseillée 
Dans l'utilisation à visée contraceptive de la cyprotérone

- Dans l'indication contraception d'urgence de l'ulipristal
Dans le cas où la (re)prise d’une contraception hormonale est envisagée, utiliser une contraception additionn"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642394, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642388 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642389 .

_:807f36cf91fe4e8caa53aadeff92477642389 rdf:first _:807f36cf91fe4e8caa53aadeff92477642390;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642391 .

_:807f36cf91fe4e8caa53aadeff92477642390 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff92477642391 rdf:first _:807f36cf91fe4e8caa53aadeff92477642392;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642392 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477642394 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10860-1 a owl:Class;
  rdfs:label "DULOXETINE <-> TAMOXIFENE"@fr;
  dct:identifier "IAM_10860";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642396;
  r:natureDuRisque "Risque de baisse de l'efficacité du tamoxifène, par inhibition de la formation de son métabolite actif par la duloxetine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642402, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642396 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642397 .

_:807f36cf91fe4e8caa53aadeff92477642397 rdf:first _:807f36cf91fe4e8caa53aadeff92477642398;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642399 .

_:807f36cf91fe4e8caa53aadeff92477642398 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:807f36cf91fe4e8caa53aadeff92477642399 rdf:first _:807f36cf91fe4e8caa53aadeff92477642400;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642400 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:807f36cf91fe4e8caa53aadeff92477642402 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10861-1 a owl:Class;
  rdfs:label "EBASTINE <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10861";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642404;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire chez les sujets prédisposés (syndrome du QT long congénital)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642410, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642404 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642405 .

_:807f36cf91fe4e8caa53aadeff92477642405 rdf:first _:807f36cf91fe4e8caa53aadeff92477642406;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642407 .

_:807f36cf91fe4e8caa53aadeff92477642406 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10316 .

_:807f36cf91fe4e8caa53aadeff92477642407 rdf:first _:807f36cf91fe4e8caa53aadeff92477642408;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642408 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477642410 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10862-1 a owl:Class;
  rdfs:label "EBASTINE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10862";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642412;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire chez les sujets prédisposés (syndrome du QT long congénital)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642418, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642412 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642413 .

_:807f36cf91fe4e8caa53aadeff92477642413 rdf:first _:807f36cf91fe4e8caa53aadeff92477642414;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642415 .

_:807f36cf91fe4e8caa53aadeff92477642414 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10316 .

_:807f36cf91fe4e8caa53aadeff92477642415 rdf:first _:807f36cf91fe4e8caa53aadeff92477642416;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642416 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477642418 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10147-2 a owl:Class;
  rdfs:label "AMIODARONE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10147";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642420;
  r:natureDuRisque """Pour vérapamil voie injectable :
-risque de bradycardie ou de bloc auriculo-ventriculaire.

Pour vérapamil per os :
-risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez les personnes âgées."""@fr;
  r:conduiteATenir """Association déconseillée avec :
- le vérapamil IV
Si l'association ne peut être évitée, surveillance clinique et ECG continu.

Précaution d'emploi avec :
- le vérapamil per os
Surveillance clinique et ECG."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642426, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642420 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642421 .

_:807f36cf91fe4e8caa53aadeff92477642421 rdf:first _:807f36cf91fe4e8caa53aadeff92477642422;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642423 .

_:807f36cf91fe4e8caa53aadeff92477642422 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477642423 rdf:first _:807f36cf91fe4e8caa53aadeff92477642424;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642424 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477642426 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10934-1 a owl:Class;
  rdfs:label "FER <-> PENICILLAMINE"@fr;
  dct:identifier "IAM_10934";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642428;
  r:natureDuRisque "Diminution de l'absorption digestive de la pénicillamine."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance de la pénicillamine (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642434, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642428 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642429 .

_:807f36cf91fe4e8caa53aadeff92477642429 rdf:first _:807f36cf91fe4e8caa53aadeff92477642430;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642431 .

_:807f36cf91fe4e8caa53aadeff92477642430 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477642431 rdf:first _:807f36cf91fe4e8caa53aadeff92477642432;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642432 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10702 .

_:807f36cf91fe4e8caa53aadeff92477642434 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10896-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> PRAVASTATINE"@fr;
  dct:identifier "IAM_10896";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642436;
  r:natureDuRisque "Avec l'érythromycine utilisée par voie orale : augmentation de la concentration plasmatique de la pravastatine par l' érythromycine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique pendant le traitement par l'antibiotique."@fr;
  rdfs:comment "La clarithromycine et l’érythromycine sont des inhibiteurs puissants du CYP3A4 et de la P-gp intestinale, transporteur qui intervient dans l’efflux de nombreux médicaments au niveau de la lumière intestinale et qui limite donc leur absorption digestive. L"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642442, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642436 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642437 .

_:807f36cf91fe4e8caa53aadeff92477642437 rdf:first _:807f36cf91fe4e8caa53aadeff92477642438;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642439 .

_:807f36cf91fe4e8caa53aadeff92477642438 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477642439 rdf:first _:807f36cf91fe4e8caa53aadeff92477642440;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642440 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10748 .

_:807f36cf91fe4e8caa53aadeff92477642442 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10925-1 a owl:Class;
  rdfs:label "FELBAMATE <-> PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE)"@fr;
  dct:identifier "IAM_10925";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642444;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité du felbamate et augmentation des concentrations plasmatiques du phénobarbital, avec risque de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques de phénobarbital avec adaptation de la posologie si besoin."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642450, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642444 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642445 .

_:807f36cf91fe4e8caa53aadeff92477642445 rdf:first _:807f36cf91fe4e8caa53aadeff92477642446;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642447 .

_:807f36cf91fe4e8caa53aadeff92477642446 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477642447 rdf:first _:807f36cf91fe4e8caa53aadeff92477642448;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642448 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10369 .

_:807f36cf91fe4e8caa53aadeff92477642450 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10926-1 a owl:Class;
  rdfs:label "FELBAMATE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10926";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642452;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne avec risque de surdosage, par inhibition de son métabolisme par le felbamate."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques de phénytoïne et si besoin, adaptation de sa posologie pendant le traitement par le felbamate."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642458, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642452 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642453 .

_:807f36cf91fe4e8caa53aadeff92477642453 rdf:first _:807f36cf91fe4e8caa53aadeff92477642454;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642455 .

_:807f36cf91fe4e8caa53aadeff92477642454 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477642455 rdf:first _:807f36cf91fe4e8caa53aadeff92477642456;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642456 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10369 .

_:807f36cf91fe4e8caa53aadeff92477642458 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10927-1 a owl:Class;
  rdfs:label "FELBAMATE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_10927";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642460;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'acide valproïque, avec risque de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle biologique et adaptation éventuelle de la posologie du valproate ou du valpromide pendant le traitement par le felbamate et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642466, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642460 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642461 .

_:807f36cf91fe4e8caa53aadeff92477642461 rdf:first _:807f36cf91fe4e8caa53aadeff92477642462;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642463 .

_:807f36cf91fe4e8caa53aadeff92477642462 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477642463 rdf:first _:807f36cf91fe4e8caa53aadeff92477642464;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642464 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10369 .

_:807f36cf91fe4e8caa53aadeff92477642466 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10928-1 a owl:Class;
  rdfs:label "FENTANYL <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10928";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642468;
  r:natureDuRisque "Risque d'augmentation de l’effet dépresseur respiratoire de l’analgésique opiacé par légère diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l’analgésique opiacé en cas de traitement par un inhibiteur puissant du CYP3A4."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642474, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642468 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642469 .

_:807f36cf91fe4e8caa53aadeff92477642469 rdf:first _:807f36cf91fe4e8caa53aadeff92477642470;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642471 .

_:807f36cf91fe4e8caa53aadeff92477642470 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477642471 rdf:first _:807f36cf91fe4e8caa53aadeff92477642472;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642472 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10374 .

_:807f36cf91fe4e8caa53aadeff92477642474 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10929-1 a owl:Class;
  rdfs:label "FENTANYL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10929";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642476;
  r:natureDuRisque "Diminution des concentrations plasmatiques de fentanyl par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Préférer un autre morphinique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642482, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642476 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642477 .

_:807f36cf91fe4e8caa53aadeff92477642477 rdf:first _:807f36cf91fe4e8caa53aadeff92477642478;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642479 .

_:807f36cf91fe4e8caa53aadeff92477642478 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10374 .

_:807f36cf91fe4e8caa53aadeff92477642479 rdf:first _:807f36cf91fe4e8caa53aadeff92477642480;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642480 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477642482 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10935-1 a owl:Class;
  rdfs:label "FER <-> SELS DE FER PAR VOIE INJECTABLE"@fr;
  dct:identifier "IAM_10935";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642484;
  r:natureDuRisque "Lipothymie, voire choc attribué à la libération rapide du fer de sa forme complexe et à la saturation de la sidérophiline."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642490, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642484 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642485 .

_:807f36cf91fe4e8caa53aadeff92477642485 rdf:first _:807f36cf91fe4e8caa53aadeff92477642486;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642487 .

_:807f36cf91fe4e8caa53aadeff92477642486 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10164 .

_:807f36cf91fe4e8caa53aadeff92477642487 rdf:first _:807f36cf91fe4e8caa53aadeff92477642488;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642488 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477642490 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10930-1 a owl:Class;
  rdfs:label "FER <-> FLUOROQUINOLONES"@fr;
  dct:identifier "IAM_10930";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642492;
  r:natureDuRisque "Diminution de l'absorption digestive des fluoroquinolones."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance des fluoroquinolones (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642498, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642492 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642493 .

_:807f36cf91fe4e8caa53aadeff92477642493 rdf:first _:807f36cf91fe4e8caa53aadeff92477642494;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642495 .

_:807f36cf91fe4e8caa53aadeff92477642494 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff92477642495 rdf:first _:807f36cf91fe4e8caa53aadeff92477642496;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642496 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477642498 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10931-1 a owl:Class;
  rdfs:label "FER <-> HORMONES THYROÏDIENNES"@fr;
  dct:identifier "IAM_10931";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642500;
  r:natureDuRisque "Diminution de l'absorption digestive des hormones thyroïdiennes."@fr;
  r:conduiteATenir "Prendre les hormones thyroïdiennes à distance du fer (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642506, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642500 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642501 .

_:807f36cf91fe4e8caa53aadeff92477642501 rdf:first _:807f36cf91fe4e8caa53aadeff92477642502;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642503 .

_:807f36cf91fe4e8caa53aadeff92477642502 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477642503 rdf:first _:807f36cf91fe4e8caa53aadeff92477642504;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642504 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477642506 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10923-1 a owl:Class;
  rdfs:label "EXEMESTANE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10923";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642508;
  r:natureDuRisque "Risque de diminution de l'efficacité de l'exemestane par augmentation de son métabolisme hépatique par l'inducteur enzymatique."@fr;
  rdfs:comment "L’exémestane est un inhibiteur de l’aromatase de structure stéroïdienne. Les résultats d'une étude d'interaction avec la rifampicine, un des plus puissants inducteurs enzymatiques, ont montré une diminution de plus de 40 % des concentrations de l'exémesta"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642514, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642508 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642509 .

_:807f36cf91fe4e8caa53aadeff92477642509 rdf:first _:807f36cf91fe4e8caa53aadeff92477642510;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642511 .

_:807f36cf91fe4e8caa53aadeff92477642510 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10364 .

_:807f36cf91fe4e8caa53aadeff92477642511 rdf:first _:807f36cf91fe4e8caa53aadeff92477642512;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642512 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477642514 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10933-1 a owl:Class;
  rdfs:label "FER <-> METHYLDOPA"@fr;
  dct:identifier "IAM_10933";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642516;
  r:natureDuRisque "Diminution de l'absorption digestive de la méthyldopa (formation de complexes)."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance de la méthyldopa (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642522, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642516 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642517 .

_:807f36cf91fe4e8caa53aadeff92477642517 rdf:first _:807f36cf91fe4e8caa53aadeff92477642518;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642519 .

_:807f36cf91fe4e8caa53aadeff92477642518 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477642519 rdf:first _:807f36cf91fe4e8caa53aadeff92477642520;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642520 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10572 .

_:807f36cf91fe4e8caa53aadeff92477642522 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10922-1 a owl:Class;
  rdfs:label "EVEROLIMUS <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10922";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642524;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'évérolimus par diminution de son métabolisme hépatique par le vérapamil."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l’immunosuppresseur, contrôle de la fonction rénale et adaptation de la posologie pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642530, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642524 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642525 .

_:807f36cf91fe4e8caa53aadeff92477642525 rdf:first _:807f36cf91fe4e8caa53aadeff92477642526;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642527 .

_:807f36cf91fe4e8caa53aadeff92477642526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10363 .

_:807f36cf91fe4e8caa53aadeff92477642527 rdf:first _:807f36cf91fe4e8caa53aadeff92477642528;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642528 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477642530 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10936-1 a owl:Class;
  rdfs:label "FER <-> STRONTIUM"@fr;
  dct:identifier "IAM_10936";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642532;
  r:natureDuRisque "Diminution de l'absorption digestive du strontium."@fr;
  r:conduiteATenir "Prendre le strontium à distance des sels de fer (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642538, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642532 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642533 .

_:807f36cf91fe4e8caa53aadeff92477642533 rdf:first _:807f36cf91fe4e8caa53aadeff92477642534;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642535 .

_:807f36cf91fe4e8caa53aadeff92477642534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477642535 rdf:first _:807f36cf91fe4e8caa53aadeff92477642536;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642536 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10863 .

_:807f36cf91fe4e8caa53aadeff92477642538 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10937-1 a owl:Class;
  rdfs:label "FER <-> ZINC"@fr;
  dct:identifier "IAM_10937";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642540;
  r:natureDuRisque "Diminution de l’absorption digestive du zinc par le fer."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance du zinc (plus de 2 heures si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642546, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642540 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642541 .

_:807f36cf91fe4e8caa53aadeff92477642541 rdf:first _:807f36cf91fe4e8caa53aadeff92477642542;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642543 .

_:807f36cf91fe4e8caa53aadeff92477642542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477642543 rdf:first _:807f36cf91fe4e8caa53aadeff92477642544;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642544 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11005 .

_:807f36cf91fe4e8caa53aadeff92477642546 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10938-1 a owl:Class;
  rdfs:label "FIBRATES <-> FIBRATES (AUTRES)"@fr;
  dct:identifier "IAM_10938";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642548;
  r:natureDuRisque "Risque majoré d'effets indésirables à type de rhabdomyolyse et d'antagonisme pharmacodynamique entre les deux molécules."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642550, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10074 .

_:807f36cf91fe4e8caa53aadeff92477642550 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10939-1 a owl:Class;
  rdfs:label "FIBRATES <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10939";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642552;
  r:natureDuRisque "Risque d'addition d'effets indésirables (dose-dépendants) à type de rhabdomyolyse. En outre, avec le gemfibrozil, diminution du métabolisme de la simvastatine et de la rosuvastatine, ce qui majore le risque musculaire, ainsi que la néphrotoxicité de la ro"@fr;
  r:conduiteATenir """Contre-indication 
- entre le gemfibrozil et la simvastatine
- pour des doses de rosuvastatine de 40 mg

Association déconseillée 
- entre les autres fibrates et les autres statines 
- ne pas dépasser 10 mg de simvastatine (cette restriction de doses ne"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642558, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642552 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642553 .

_:807f36cf91fe4e8caa53aadeff92477642553 rdf:first _:807f36cf91fe4e8caa53aadeff92477642554;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642555 .

_:807f36cf91fe4e8caa53aadeff92477642554 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10074 .

_:807f36cf91fe4e8caa53aadeff92477642555 rdf:first _:807f36cf91fe4e8caa53aadeff92477642556;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff92477642558 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10940-1 a owl:Class;
  rdfs:label "FIDAXOMICINE <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10940";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642560;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642566, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642560 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642561 .

_:807f36cf91fe4e8caa53aadeff92477642561 rdf:first _:807f36cf91fe4e8caa53aadeff92477642562;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642563 .

_:807f36cf91fe4e8caa53aadeff92477642562 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:807f36cf91fe4e8caa53aadeff92477642563 rdf:first _:807f36cf91fe4e8caa53aadeff92477642564;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477642566 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10941-1 a owl:Class;
  rdfs:label "FIDAXOMICINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10941";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642568;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642574, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642568 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642569 .

_:807f36cf91fe4e8caa53aadeff92477642569 rdf:first _:807f36cf91fe4e8caa53aadeff92477642570;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642571 .

_:807f36cf91fe4e8caa53aadeff92477642570 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:807f36cf91fe4e8caa53aadeff92477642571 rdf:first _:807f36cf91fe4e8caa53aadeff92477642572;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477642574 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10942-1 a owl:Class;
  rdfs:label "FLECAINIDE <-> MIRABÉGRON"@fr;
  dct:identifier "IAM_10942";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642576;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du flécaïnide par diminution de son métabolisme par le mirabégron."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie du flécaïnide pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642582, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642576 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642577 .

_:807f36cf91fe4e8caa53aadeff92477642577 rdf:first _:807f36cf91fe4e8caa53aadeff92477642578;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642579 .

_:807f36cf91fe4e8caa53aadeff92477642578 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:807f36cf91fe4e8caa53aadeff92477642579 rdf:first _:807f36cf91fe4e8caa53aadeff92477642580;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10591 .

_:807f36cf91fe4e8caa53aadeff92477642582 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10943-1 a owl:Class;
  rdfs:label "FLECAINIDE <-> TERBINAFINE"@fr;
  dct:identifier "IAM_10943";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642584;
  r:natureDuRisque "Risque d'augmentation des effets indésirables du flécaïnide, par diminution de son métabolisme hépatique par la terbinafine."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du flécaïnide pendant le traitement par la terbinafine."@fr;
  rdfs:comment """L’effet inhibiteur enzymatique de la terbinafine sur le CYP2D6 a été suggéré sur l’observation chez 12 volontaires sains d’une diminution du métabolisme hépatique de la désipramine, marqueur de l’activité de ce cytochrome.
Afin de prendre acte de cet effe"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642590, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642584 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642585 .

_:807f36cf91fe4e8caa53aadeff92477642585 rdf:first _:807f36cf91fe4e8caa53aadeff92477642586;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642587 .

_:807f36cf91fe4e8caa53aadeff92477642586 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:807f36cf91fe4e8caa53aadeff92477642587 rdf:first _:807f36cf91fe4e8caa53aadeff92477642588;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:807f36cf91fe4e8caa53aadeff92477642590 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10944-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> HALOFANTRINE"@fr;
  dct:identifier "IAM_10944";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642592;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaires, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre le fluconazole. Si l'association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642598, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642592 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642593 .

_:807f36cf91fe4e8caa53aadeff92477642593 rdf:first _:807f36cf91fe4e8caa53aadeff92477642594;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642595 .

_:807f36cf91fe4e8caa53aadeff92477642594 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477642595 rdf:first _:807f36cf91fe4e8caa53aadeff92477642596;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10425 .

_:807f36cf91fe4e8caa53aadeff92477642598 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11206-1 a owl:Class;
  rdfs:label "IVABRADINE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_11206";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642600;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l’ivabradine et de ses effets indésirables (inhibition de son métabolisme intestinal par le pamplemousse)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642606, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642600 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642601 .

_:807f36cf91fe4e8caa53aadeff92477642601 rdf:first _:807f36cf91fe4e8caa53aadeff92477642602;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642603 .

_:807f36cf91fe4e8caa53aadeff92477642602 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477642603 rdf:first _:807f36cf91fe4e8caa53aadeff92477642604;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:807f36cf91fe4e8caa53aadeff92477642606 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10932-1 a owl:Class;
  rdfs:label "FER <-> LEVODOPA"@fr;
  dct:identifier "IAM_10932";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642608;
  r:natureDuRisque "Diminution de l'absorption digestive de la lévodopa."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance de la lévodopa (plus de 2 heures si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642614, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642608 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642609 .

_:807f36cf91fe4e8caa53aadeff92477642609 rdf:first _:807f36cf91fe4e8caa53aadeff92477642610;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642611 .

_:807f36cf91fe4e8caa53aadeff92477642610 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477642611 rdf:first _:807f36cf91fe4e8caa53aadeff92477642612;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:807f36cf91fe4e8caa53aadeff92477642614 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10910-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10910";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642616;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de diminution de l'efficacité contraceptive par diminution des concentrations en contraceptif hormonal, dûe à l'augmentation de son métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique (préservatif ou stérilet), pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642622, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642616 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642617 .

_:807f36cf91fe4e8caa53aadeff92477642617 rdf:first _:807f36cf91fe4e8caa53aadeff92477642618;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642619 .

_:807f36cf91fe4e8caa53aadeff92477642618 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477642619 rdf:first _:807f36cf91fe4e8caa53aadeff92477642620;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477642622 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10899-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_10899";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642624;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642630, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642624 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642625 .

_:807f36cf91fe4e8caa53aadeff92477642625 rdf:first _:807f36cf91fe4e8caa53aadeff92477642626;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642627 .

_:807f36cf91fe4e8caa53aadeff92477642626 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477642627 rdf:first _:807f36cf91fe4e8caa53aadeff92477642628;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:807f36cf91fe4e8caa53aadeff92477642630 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10900-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10900";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642632;
  r:natureDuRisque "Bradycardie et/ou troubles de la conduction auriculo-ventriculaire, par diminution du métabolisme hépatique du vérapamil par l'érythromycine."@fr;
  r:conduiteATenir "Surveillance clinique et ECG ; s'il y a lieu, adaptation de la posologie du vérapamil pendant le traitement par l'érythromycine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642638, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642632 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642633 .

_:807f36cf91fe4e8caa53aadeff92477642633 rdf:first _:807f36cf91fe4e8caa53aadeff92477642634;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642635 .

_:807f36cf91fe4e8caa53aadeff92477642634 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477642635 rdf:first _:807f36cf91fe4e8caa53aadeff92477642636;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477642638 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10902-1 a owl:Class;
  rdfs:label "ESMOLOL <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10902";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642640;
  r:natureDuRisque "Troubles de la contractilité, de l'automatisme et de la conduction (suppression des mécanismes sympathiques compensateurs)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642646, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642640 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642641 .

_:807f36cf91fe4e8caa53aadeff92477642641 rdf:first _:807f36cf91fe4e8caa53aadeff92477642642;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642643 .

_:807f36cf91fe4e8caa53aadeff92477642642 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:807f36cf91fe4e8caa53aadeff92477642643 rdf:first _:807f36cf91fe4e8caa53aadeff92477642644;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477642646 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10903-1 a owl:Class;
  rdfs:label "ESMOLOL <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10903";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642648;
  r:natureDuRisque "Troubles de l'automatisme (bradycardie excessive, arrêt sinusal), troubles de la conduction sino-auriculaire et auriculo-ventriculaire et défaillance cardiaque."@fr;
  r:conduiteATenir """Précaution d'emploi :
- si la fonction ventriculaire gauche est normale.
Surveillance clinique et ECG."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642654, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642648 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642649 .

_:807f36cf91fe4e8caa53aadeff92477642649 rdf:first _:807f36cf91fe4e8caa53aadeff92477642650;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642651 .

_:807f36cf91fe4e8caa53aadeff92477642650 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:807f36cf91fe4e8caa53aadeff92477642651 rdf:first _:807f36cf91fe4e8caa53aadeff92477642652;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477642654 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10904-1 a owl:Class;
  rdfs:label "ESTRAMUSTINE <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10904";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642656;
  r:natureDuRisque "Risque de majoration des effets indésirables à type d'oedème angio-neurotique (angio-oedème)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642662, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642656 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642657 .

_:807f36cf91fe4e8caa53aadeff92477642657 rdf:first _:807f36cf91fe4e8caa53aadeff92477642658;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642659 .

_:807f36cf91fe4e8caa53aadeff92477642658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477642659 rdf:first _:807f36cf91fe4e8caa53aadeff92477642660;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10345 .

_:807f36cf91fe4e8caa53aadeff92477642662 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10907-1 a owl:Class;
  rdfs:label "ESTROGÈNES NON CONTRACEPTIFS <-> TELAPREVIR"@fr;
  dct:identifier "IAM_10907";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642664;
  r:natureDuRisque "Diminution de l'efficacité de l'estrogène."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du traitement hormonal pendant l'administration du télaprévir et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642670, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642664 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642665 .

_:807f36cf91fe4e8caa53aadeff92477642665 rdf:first _:807f36cf91fe4e8caa53aadeff92477642666;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642667 .

_:807f36cf91fe4e8caa53aadeff92477642666 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10072 .

_:807f36cf91fe4e8caa53aadeff92477642667 rdf:first _:807f36cf91fe4e8caa53aadeff92477642668;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642668 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477642670 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10905-1 a owl:Class;
  rdfs:label "ESTROGÈNES NON CONTRACEPTIFS <-> HORMONES THYROÏDIENNES"@fr;
  dct:identifier "IAM_10905";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642672;
  r:natureDuRisque "Risque d'hypothyroïdie clinique en cas d'estrogénothérapie substitutive."@fr;
  r:conduiteATenir "Surveillance clinique et biologique ; adaptation éventuelle des doses de l'hormone thyroïdienne chez les femmes ménopausées prenant des estrogènes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642678, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642672 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642673 .

_:807f36cf91fe4e8caa53aadeff92477642673 rdf:first _:807f36cf91fe4e8caa53aadeff92477642674;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642675 .

_:807f36cf91fe4e8caa53aadeff92477642674 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10072 .

_:807f36cf91fe4e8caa53aadeff92477642675 rdf:first _:807f36cf91fe4e8caa53aadeff92477642676;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642676 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477642678 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10906-1 a owl:Class;
  rdfs:label "ESTROGÈNES NON CONTRACEPTIFS <-> OXCARBAZEPINE"@fr;
  dct:identifier "IAM_10906";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642680;
  r:natureDuRisque "Risque de diminution de l'efficacité du traitement hormonal, par augmentation de son métabolisme hépatique par l'oxcarbazépine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du traitement hormonal pendant le traitement par l'oxcarbazépine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642686, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642680 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642681 .

_:807f36cf91fe4e8caa53aadeff92477642681 rdf:first _:807f36cf91fe4e8caa53aadeff92477642682;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642683 .

_:807f36cf91fe4e8caa53aadeff92477642682 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10072 .

_:807f36cf91fe4e8caa53aadeff92477642683 rdf:first _:807f36cf91fe4e8caa53aadeff92477642684;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642684 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10674 .

_:807f36cf91fe4e8caa53aadeff92477642686 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10915-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> TELAPREVIR"@fr;
  dct:identifier "IAM_10915";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642688;
  r:natureDuRisque "Risque de diminution de l'efficacité contraceptive par augmentation du métabolisme hépatique du contraceptif hormonal par le télaprévir."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive fiable, additionnelle ou alternative, pendant la durée de l'association et deux cycles suivants."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642694, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642688 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642689 .

_:807f36cf91fe4e8caa53aadeff92477642689 rdf:first _:807f36cf91fe4e8caa53aadeff92477642690;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642691 .

_:807f36cf91fe4e8caa53aadeff92477642690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477642691 rdf:first _:807f36cf91fe4e8caa53aadeff92477642692;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642692 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477642694 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10924-1 a owl:Class;
  rdfs:label "EZETIMIBE <-> FENOFIBRATE"@fr;
  dct:identifier "IAM_10924";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642696;
  r:natureDuRisque "Risque de lithiase biliaire par augmentation de l’excrétion biliaire du cholestérol."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642702, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642696 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642697 .

_:807f36cf91fe4e8caa53aadeff92477642697 rdf:first _:807f36cf91fe4e8caa53aadeff92477642698;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642699 .

_:807f36cf91fe4e8caa53aadeff92477642698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10365 .

_:807f36cf91fe4e8caa53aadeff92477642699 rdf:first _:807f36cf91fe4e8caa53aadeff92477642700;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642700 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10371 .

_:807f36cf91fe4e8caa53aadeff92477642702 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10909-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10909";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642704;
  r:natureDuRisque "Diminution de l'efficacité contraceptive, par augmentation du métabolisme hépatique du contraceptif hormonal par l'inducteur."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642710, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642704 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642705 .

_:807f36cf91fe4e8caa53aadeff92477642705 rdf:first _:807f36cf91fe4e8caa53aadeff92477642706;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642707 .

_:807f36cf91fe4e8caa53aadeff92477642706 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477642707 rdf:first _:807f36cf91fe4e8caa53aadeff92477642708;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642708 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477642710 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10955-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10955";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642712;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité du fluconazole par augmentation de son métabolisme par la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642718, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642712 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642713 .

_:807f36cf91fe4e8caa53aadeff92477642713 rdf:first _:807f36cf91fe4e8caa53aadeff92477642714;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642715 .

_:807f36cf91fe4e8caa53aadeff92477642714 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477642715 rdf:first _:807f36cf91fe4e8caa53aadeff92477642716;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642716 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477642718 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10911-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> LAMOTRIGINE"@fr;
  dct:identifier "IAM_10911";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642720;
  r:natureDuRisque "Risque de diminution des concentrations et de l’efficacité de la lamotrigine par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir """Précaution d'emploi :
- surveillance clinique et adaptation de la posologie de la lamotrigine lors de la mise en route d’une contraception orale et après son arrêt."""@fr;
  rdfs:comment """Deux publications d'une même équipe montrent que les contraceptifs oraux (COs) diminuent de près de moitié les concentrations plasmatiques de la lamotrigine. Le mécanisme passerait par une induction de la glucuronidation de la lamotrigine par les COs.
Dan"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642726, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642720 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642721 .

_:807f36cf91fe4e8caa53aadeff92477642721 rdf:first _:807f36cf91fe4e8caa53aadeff92477642722;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642723 .

_:807f36cf91fe4e8caa53aadeff92477642722 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477642723 rdf:first _:807f36cf91fe4e8caa53aadeff92477642724;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642724 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:807f36cf91fe4e8caa53aadeff92477642726 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10912-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10912";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642728;
  r:natureDuRisque "Diminution des concentrations plasmatiques du contraceptif hormonal, en raison de l'effet inducteur enzymatique du millepertuis, avec risque de baisse d'efficacité voire d'annulation de l'effet dont les conséquences peuvent être éventuellement graves (sur"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642734, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642728 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642729 .

_:807f36cf91fe4e8caa53aadeff92477642729 rdf:first _:807f36cf91fe4e8caa53aadeff92477642730;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642731 .

_:807f36cf91fe4e8caa53aadeff92477642730 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477642731 rdf:first _:807f36cf91fe4e8caa53aadeff92477642732;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642732 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477642734 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10913-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> MODAFINIL"@fr;
  dct:identifier "IAM_10913";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642736;
  r:natureDuRisque "Risque de diminution de l’efficacité contraceptive, pendant le traitement et un cycle après l’arrêt du traitement par le modafinil, en raison de son potentiel inducteur enzymatique."@fr;
  r:conduiteATenir "Utiliser des contraceptifs oraux normodosés ou une autre méthode contraceptive."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642742, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642736 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642737 .

_:807f36cf91fe4e8caa53aadeff92477642737 rdf:first _:807f36cf91fe4e8caa53aadeff92477642738;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642739 .

_:807f36cf91fe4e8caa53aadeff92477642738 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477642739 rdf:first _:807f36cf91fe4e8caa53aadeff92477642740;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642740 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10599 .

_:807f36cf91fe4e8caa53aadeff92477642742 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10914-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> RUFINAMIDE"@fr;
  dct:identifier "IAM_10914";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642744;
  r:natureDuRisque "Diminution modérée des concentrations d’éthinylestradiol."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642750, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642744 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642745 .

_:807f36cf91fe4e8caa53aadeff92477642745 rdf:first _:807f36cf91fe4e8caa53aadeff92477642746;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642747 .

_:807f36cf91fe4e8caa53aadeff92477642746 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477642747 rdf:first _:807f36cf91fe4e8caa53aadeff92477642748;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642748 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10818 .

_:807f36cf91fe4e8caa53aadeff92477642750 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:IAM_10916-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> TOPIRAMATE"@fr;
  dct:identifier "IAM_10916";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642752;
  r:natureDuRisque "Pour des doses de topiramate >= 200 mg/jour : Risque de diminution de l’efficacité contraceptive par diminution des concentrations en estrogène."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642758, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642752 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642753 .

_:807f36cf91fe4e8caa53aadeff92477642753 rdf:first _:807f36cf91fe4e8caa53aadeff92477642754;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642755 .

_:807f36cf91fe4e8caa53aadeff92477642754 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477642755 rdf:first _:807f36cf91fe4e8caa53aadeff92477642756;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642756 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10941 .

_:807f36cf91fe4e8caa53aadeff92477642758 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10917-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_10917";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642760;
  r:natureDuRisque "Risque d'antagonisme des effets du progestatif."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive additionnelle de type mécanique pendant quelques jours après l’arrêt de l’ulipristal."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642766, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642760 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642761 .

_:807f36cf91fe4e8caa53aadeff92477642761 rdf:first _:807f36cf91fe4e8caa53aadeff92477642762;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642763 .

_:807f36cf91fe4e8caa53aadeff92477642762 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477642763 rdf:first _:807f36cf91fe4e8caa53aadeff92477642764;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642764 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477642766 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10918-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> VÉMURAFÉNIB"@fr;
  dct:identifier "IAM_10918";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642768;
  r:natureDuRisque "Risque de diminution des concentrations des estroprogestatifs, avec pour conséquence un risque d’inefficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642774, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642768 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642769 .

_:807f36cf91fe4e8caa53aadeff92477642769 rdf:first _:807f36cf91fe4e8caa53aadeff92477642770;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642771 .

_:807f36cf91fe4e8caa53aadeff92477642770 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477642771 rdf:first _:807f36cf91fe4e8caa53aadeff92477642772;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642772 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10978 .

_:807f36cf91fe4e8caa53aadeff92477642774 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10919-1 a owl:Class;
  rdfs:label "ETHINYLESTRADIOL <-> ÉTORICOXIB"@fr;
  dct:identifier "IAM_10919";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642776;
  r:natureDuRisque "Augmentation des concentrations d’éthinylestradiol par l’étoricoxib."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642782, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642776 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642777 .

_:807f36cf91fe4e8caa53aadeff92477642777 rdf:first _:807f36cf91fe4e8caa53aadeff92477642778;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642779 .

_:807f36cf91fe4e8caa53aadeff92477642778 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10351 .

_:807f36cf91fe4e8caa53aadeff92477642779 rdf:first _:807f36cf91fe4e8caa53aadeff92477642780;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642780 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10359 .

_:807f36cf91fe4e8caa53aadeff92477642782 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10920-1 a owl:Class;
  rdfs:label "ETHINYLESTRADIOL <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10920";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642784;
  r:natureDuRisque "Augmentation de l’hépatotoxicité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642790, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642784 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642785 .

_:807f36cf91fe4e8caa53aadeff92477642785 rdf:first _:807f36cf91fe4e8caa53aadeff92477642786;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642787 .

_:807f36cf91fe4e8caa53aadeff92477642786 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477642787 rdf:first _:807f36cf91fe4e8caa53aadeff92477642788;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642788 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10351 .

_:807f36cf91fe4e8caa53aadeff92477642790 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10921-1 a owl:Class;
  rdfs:label "EVEROLIMUS <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10921";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642792;
  r:natureDuRisque "Majoration du risque d’angio-oedème"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642798, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642792 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642793 .

_:807f36cf91fe4e8caa53aadeff92477642793 rdf:first _:807f36cf91fe4e8caa53aadeff92477642794;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642795 .

_:807f36cf91fe4e8caa53aadeff92477642794 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477642795 rdf:first _:807f36cf91fe4e8caa53aadeff92477642796;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642796 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10363 .

_:807f36cf91fe4e8caa53aadeff92477642798 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10908-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> GRISEOFULVINE"@fr;
  dct:identifier "IAM_10908";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642800;
  r:natureDuRisque "Risque de diminution de l'efficacité contraceptive par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642806, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642800 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642801 .

_:807f36cf91fe4e8caa53aadeff92477642801 rdf:first _:807f36cf91fe4e8caa53aadeff92477642802;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642803 .

_:807f36cf91fe4e8caa53aadeff92477642802 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477642803 rdf:first _:807f36cf91fe4e8caa53aadeff92477642804;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642804 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10422 .

_:807f36cf91fe4e8caa53aadeff92477642806 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:PE .

this:INTERACTION_TEST-1 a owl:Class;
  rdfs:label "TEST THOMAS : ACIDE ACETYLSALICILYQUE DOSE ANTI-INF <-> HYPERKALIEMANTS (dont losartan)"@fr;
  dct:identifier "INTERACTION_TEST";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477642808;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477642814, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477642808 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477642809 .

_:807f36cf91fe4e8caa53aadeff92477642809 rdf:first _:807f36cf91fe4e8caa53aadeff92477642810;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477642811 .

_:807f36cf91fe4e8caa53aadeff92477642810 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_AASLCIQUE_3 .

_:807f36cf91fe4e8caa53aadeff92477642811 rdf:first _:807f36cf91fe4e8caa53aadeff92477642812;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477642812 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10539 .

_:807f36cf91fe4e8caa53aadeff92477642814 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .
